Abatacept_ddi|P|tnf antagonist|orencia|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 serious_RE2 infection_RE2 and_RE2 no_RE2 significant_RE2 additional_RE2 efficacy_RE2 over_RE2 use_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 alone_RE2 
Abatacept_ddi|P|orencia|tnf antagonist|concurrent_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Abatacept_ddi|P|orencia|anakinra|there_LE1 be_LE1 insufficient_LE1 experience_LE1 to_LE1 assess_LE1 the_LE1 safety_LE1 and_LE1 efficacy_LE1 of_LE1 BIOENTITY administer_BE12 concurrent_BE12 with_BE12 BIOENTITY and_RE2 therefore_RE2 such_RE2 use_RE2 be_RE2 not_RE2 recommend_RE2 
Acamprosate_ddi|P|naltrexone|acamprosate|co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY produce_RE2 NUM_RE2 increase_RE2 in_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 
Acamprosate_ddi|P|acamprosate|antidepressant|patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY much_RE2 common_RE2 report_RE2 both_RE2 weight_RE2 gain_RE2 and_RE2 weight_RE2 loss_RE2 compare_RE2 with_RE2 patient_RE2 take_RE2 either_RE2 medication_RE2 alone_RE2 
Acarbose_ddi|P|pancreatin|acarbose|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 carbohydrate-splitting_LE1 enzyme_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 concomitant_RE2 
Acarbose_ddi|P|intestinal adsorbent|acarbose|BIOENTITY -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 contain_BE12 carbohydrate-splitting_BE12 enzyme_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 concomitant_RE2 
Acarbose_ddi|P|amylase|acarbose|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 carbohydrate-splitting_LE1 enzyme_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 concomitant_RE2 
Acarbose_ddi|P|charcoal|acarbose|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 contain_BE12 carbohydrate-splitting_BE12 enzyme_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 reduce_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 concomitant_RE2 
Acarbose_ddi|P|acarbose|digoxin|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 change_BE12 the_BE12 bioavailabillty_BE12 BIOENTITY when_RE2 they_RE2 be_RE2 co-administer_RE2 which_RE2 may_RE2 require_RE2 BIOGENERAL_RE2 dose_RE2 adjustment_RE2 
Acarbose_ddi|P|acarbose|metformin|however_LE1 the_LE1 peak_LE1 plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 reduce_LE1 by_LE1 approximate_LE1 NUM_LE1 when_LE1 take_LE1 BIOENTITY due_BE12 to_BE12 slight_BE12 delay_BE12 in_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY 
Acarbose_ddi|P|metformin|acarbose|however_LE1 the_LE1 peak_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 approximate_BE12 NUM_BE12 when_BE12 take_BE12 BIOENTITY due_RE2 to_RE2 slight_RE2 delay_RE2 in_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Acebutolol_ddi|P|reserpine|beta-blocking agent|BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Acebutolol_ddi|P|catecholamine-depleting drug|beta-blocking agent|BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Acebutolol_ddi|P|acebutolol|catecholamine depletor|patient_LE1 treat_LE1 with_LE1 BIOENTITY plus_BE12 BIOENTITY shall_RE2 therefore_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 evidence_RE2 of_RE2 marked_RE2 bradycardia_RE2 or_RE2 hypotension_RE2 which_RE2 may_RE2 present_RE2 as_RE2 vertigo_RE2 syncope_RE2 or_RE2 orthostatic_RE2 change_RE2 in_RE2 blood_RE2 pressure_RE2 without_RE2 compensatory_RE2 tachycardia_RE2 
Acebutolol_ddi|P|beta-adrenergic antagonist|alpha-adrenergic stimulant|exaggerated_LE1 hypertensive_LE1 response_LE1 have_LE1 be_LE1 report_LE1 from_LE1 the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY including_RE2 those_RE2 contain_RE2 in_RE2 proprietary_RE2 cold_RE2 remedy_RE2 and_RE2 vasoconstrictive_RE2 nasal_RE2 drop_RE2 
Acebutolol_ddi|P|beta-adrenoceptor blocking agent|nonsteroidal anti-inflammatory drug|blunting_LE1 of_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Acetazolamide_ddi|P|diamox|phenytoin|BIOENTITY modify_BE12 BIOGENERAL_BE12 metabolism_BE12 with_BE12 increase_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY 
Acetazolamide_ddi|P|diamox|phenytoin|BIOENTITY modify_BE12 BIOENTITY metabolism_RE2 with_RE2 increase_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Acetazolamide_ddi|P|diamox|primidone|By_LE1 decrease_LE1 the_LE1 gastrointestinal_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 decrease_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 its_RE2 metabolite_RE2 with_RE2 consequent_RE2 possible_RE2 decrease_RE2 in_RE2 anticonvulsant_RE2 effect_RE2 
Acetazolamide_ddi|P|diamox|primidone|caution_LE1 be_LE1 advised_LE1 when_LE1 begin_LE1 discontinue_LE1 or_LE1 change_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Acetazolamide_ddi|P|acetazolamide|folic acid antagonist|BIOENTITY may_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 other_BE12 BIOENTITY 
Acetazolamide_ddi|P|acetazolamide|amphetamine|BIOENTITY decrease_BE12 urinary_BE12 excretion_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 enhance_RE2 the_RE2 magnitude_RE2 and_RE2 duration_RE2 of_RE2 their_RE2 effect_RE2 
Acetazolamide_ddi|P|acetazolamide|quinidine|BIOENTITY reduce_BE12 urinary_BE12 excretion_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 enhance_RE2 its_RE2 effect_RE2 
Acetazolamide_ddi|P|acetazolamide|methenamine|BIOENTITY may_BE12 prevent_BE12 the_BE12 urinary_BE12 antiseptic_BE12 effect_BE12 of_BE12 BIOENTITY 
Acetazolamide_ddi|P|acetazolamide|lithium|BIOENTITY increase_BE12 BIOENTITY excretion_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 decrease_RE2 
Acetazolamide_ddi|P|acetazolamide|sodium bicarbonate|BIOENTITY and_BE12 BIOENTITY use_RE2 concurrent_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 renal_RE2 calculus_RE2 formation_RE2 
Acetazolamide_ddi|P|acetazolamide|cyclosporine|BIOENTITY may_BE12 elevate_BE12 BIOENTITY level_RE2 
Aciclovir_ddi|P|probenecid|acyclovir|co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 the_RE2 mean_RE2 half-life_RE2 and_RE2 the_RE2 area_RE2 under_RE2 the_RE2 concentration-time_RE2 curve_RE2 
Acitretin_ddi|P|acitretin|ethanol|BIOGENERAL_LE1 :_LE1 clinical_LE1 evidence_LE1 have_LE1 show_LE1 that_LE1 BIOGENERAL_LE1 can_LE1 be_LE1 form_LE1 with_LE1 concurrent_LE1 ingestion_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Acitretin_ddi|P|acitretin|glibenclamide|BIOGENERAL_LE1 :_LE1 In_LE1 study_LE1 of_LE1 NUM_LE1 healthy_LE1 male_LE1 volunteer_LE1 BIOENTITY treatment_BE12 potentiate_BE12 the_BE12 blood_BE12 glucose_BE12 lowering_BE12 effect_BE12 of_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 similar_RE2 to_RE2 BIOGENERAL_RE2 -RRB-_RE2 in_RE2 NUM_RE2 of_RE2 the_RE2 NUM_RE2 subject_RE2 
Acitretin_ddi|P|acitretin|progestin|however_LE1 it_LE1 have_LE1 be_LE1 establish_LE1 that_LE1 BIOENTITY interfere_BE12 with_BE12 the_BE12 contraceptive_BE12 effect_BE12 of_BE12 microdosed_BE12 BIOENTITY minipill_RE2 preparation_RE2 
Acitretin_ddi|P|progestin|soriatane|microdosed_LE1 minipill_LE1 BIOENTITY preparation_BE12 be_BE12 not_BE12 recommend_BE12 for_BE12 use_BE12 with_BE12 BIOENTITY 
Acitretin_ddi|P|methotrexate|etretinate|BIOGENERAL_LE1 :_LE1 increase_LE1 risk_LE1 of_LE1 hepatitis_LE1 have_LE1 be_LE1 report_LE1 to_LE1 result_LE1 from_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Acitretin_ddi|P|methotrexate|acitretin|consequent_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 also_RE2 contraindicate_RE2 
Acitretin_ddi|P|acitretin|phenytoin|BIOGENERAL_LE1 :_LE1 if_LE1 BIOENTITY be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY the_RE2 protein_RE2 binding_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 reduce_RE2 
Acitretin_ddi|P|acitretin|tetracycline|BIOGENERAL_LE1 :_LE1 since_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 cause_RE2 increase_RE2 intracranial_RE2 pressure_RE2 their_RE2 combined_RE2 use_RE2 be_RE2 contraindicate_RE2 
Acitretin_ddi|P|vitamin a|acitretin|BIOGENERAL_LE1 and_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 oral_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY must_RE2 be_RE2 avoid_RE2 because_RE2 of_RE2 the_RE2 risk_RE2 of_RE2 hypervitaminosis_RE2 
Acitretin_ddi|P|retinoid|acitretin|BIOGENERAL_LE1 and_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 oral_LE1 BIOENTITY with_BE12 BIOENTITY must_RE2 be_RE2 avoid_RE2 because_RE2 of_RE2 the_RE2 risk_RE2 of_RE2 hypervitaminosis_RE2 
Adalimumab_ddi|P|anakinra|tnf-blocking agent|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 another_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 serious_RE2 infection_RE2 increase_RE2 risk_RE2 of_RE2 neutropenia_RE2 and_RE2 no_RE2 additional_RE2 benefit_RE2 compared_RE2 to_RE2 these_RE2 medicinal_RE2 product_RE2 alone_RE2 
Adalimumab_ddi|P|interleukin-1 antagonist|tnf-blocking agent|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 another_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 serious_RE2 infection_RE2 increase_RE2 risk_RE2 of_RE2 neutropenia_RE2 and_RE2 no_RE2 additional_RE2 benefit_RE2 compared_RE2 to_RE2 these_RE2 medicinal_RE2 product_RE2 alone_RE2 
Adalimumab_ddi|P|anakinra|tnf-blocking agent|therefore_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 may_RE2 also_RE2 result_RE2 similar_RE2 toxicity_RE2 
Adalimumab_ddi|P|anakinra|humira|therefore_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 similar_RE2 toxicity_RE2 
Adenosine_ddi|P|verapamil|adenocard|BIOGENERAL_LE1 and_LE1 BIOENTITY use_BE12 may_BE12 be_BE12 rare_BE12 associate_BE12 with_BE12 ventricular_BE12 fibrillation_BE12 when_BE12 combine_BE12 with_BE12 BIOENTITY 
Adenosine_ddi|P|digoxin|adenocard|BIOENTITY and_BE12 BIOGENERAL_BE12 use_BE12 may_BE12 be_BE12 rare_BE12 associate_BE12 with_BE12 ventricular_BE12 fibrillation_BE12 when_BE12 combine_BE12 with_BE12 BIOENTITY 
Adenosine_ddi|P|adenocard|digitali|the_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY may_RE2 be_RE2 rare_RE2 associate_RE2 with_RE2 ventricular_RE2 fibrillation_RE2 
Adenosine_ddi|P|adenosine|theophylline|the_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Adenosine_ddi|P|adenosine|caffeine|the_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Adenosine_ddi|P|adenosine|methylxanthine|the_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Adenosine_ddi|P|methylxanthine|adenosine|In_LE1 the_LE1 presence_LE1 of_LE1 these_LE1 BIOENTITY large_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 require_BE12 or_BE12 BIOENTITY may_RE2 not_RE2 be_RE2 effective_RE2 
Adenosine_ddi|P|methylxanthine|adenosine|In_LE1 the_LE1 presence_LE1 of_LE1 these_LE1 BIOENTITY large_BE12 dose_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 require_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 not_RE2 be_RE2 effective_RE2 
Adenosine_ddi|P|adenosine|dipyridamole|BIOENTITY effect_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY 
Adenosine_ddi|P|adenosine|dipyridamole|thus_LE1 small_LE1 dose_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 effective_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Adenosine_ddi|P|adenosine|carbamazepine|as_LE1 the_LE1 primary_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 to_BE12 decrease_BE12 conduction_BE12 through_BE12 the_BE12 a-v_BE12 node_BE12 high_BE12 degree_BE12 of_BE12 heart_BE12 block_BE12 may_BE12 be_BE12 produce_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Adinazolam_ddi|P|nafazodone|xanax|BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 consider_BE12 BIOENTITY dose_RE2 reduction_RE2 -rrb-._RE2 
Adinazolam_ddi|P|fluvoxamine|xanax|BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -LRB-_BE12 consider_BE12 BIOENTITY dose_RE2 reduction_RE2 -rrb-._RE2 
Adinazolam_ddi|P|cimetidine|xanax|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -LRB-_BE12 consider_BE12 BIOENTITY dose_RE2 reduction_RE2 -rrb-._RE2 
Albendazole_ddi|P|dexamethasone|albendazole|BIOGENERAL_LE1 :_LE1 steady-state_LE1 trough_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 about_LE1 NUM_LE1 high_LE1 when_LE1 NUM_LE1 mg_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 each_BE12 dose_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 in_RE2 eight_RE2 neurocysticercosis_RE2 patient_RE2 
Albendazole_ddi|P|praziquantel|albendazole sulfoxide|BIOGENERAL_LE1 :_LE1 In_LE1 the_LE1 fed_LE1 state_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 increase_BE12 mean_BE12 maximum_BE12 plasma_BE12 concentration_BE12 and_BE12 area_BE12 under_BE12 the_BE12 curve_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 in_RE2 healthy_RE2 subject_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 compared_RE2 with_RE2 separate_RE2 group_RE2 of_RE2 subject_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 given_RE2 BIOGENERAL_RE2 alone_RE2 
Albendazole_ddi|P|albendazole sulfoxide|cimetidine|BIOGENERAL_LE1 :_LE1 BIOENTITY concentration_BE12 in_BE12 bile_BE12 and_BE12 cystic_BE12 fluid_BE12 be_BE12 increase_BE12 -LRB-_BE12 about_BE12 NUM_BE12 -RRB-_BE12 in_BE12 hydatid_BE12 cyst_BE12 patient_BE12 treat_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 compared_RE2 with_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 alone_RE2 -LRB-_RE2 NUM_RE2 
Aldesleukin_ddi|P|aminoglycoside|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 myelotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 chemotherapy_BE12 -RRB-_BE12 cardiotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 hepatotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|methotrexate|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 myelotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 chemotherapy_LE1 -RRB-_LE1 cardiotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 hepatotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|doxorubicin|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 myelotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 chemotherapy_LE1 -RRB-_LE1 cardiotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 or_BE12 hepatotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|cytotoxic|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 myelotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY chemotherapy_BE12 -RRB-_BE12 cardiotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 hepatotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|indomethacin|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 myelotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 chemotherapy_BE12 -RRB-_BE12 cardiotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 hepatotoxic_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|asparaginase|proleukin|concurrent_LE1 administration_LE1 of_LE1 drug_LE1 possess_LE1 nephrotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 myelotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 chemotherapy_LE1 -RRB-_LE1 cardiotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 hepatotoxic_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 effect_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 toxicity_RE2 in_RE2 these_RE2 organ_RE2 system_RE2 
Aldesleukin_ddi|P|proleukin|interferon-alfa|hypersensitivity_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 combination_LE1 regimen_LE1 contain_LE1 sequential_LE1 high_LE1 dose_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 specific_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Aldesleukin_ddi|P|proleukin|antineoplastic agent|hypersensitivity_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 combination_LE1 regimen_LE1 contain_LE1 sequential_LE1 high_LE1 dose_LE1 BIOENTITY and_BE12 BIOENTITY specific_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Aldesleukin_ddi|P|proleukin|dacarbazine|hypersensitivity_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 combination_LE1 regimen_LE1 contain_LE1 sequential_LE1 high_LE1 dose_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 specific_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Aldesleukin_ddi|P|proleukin|cis-platinum|hypersensitivity_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 combination_LE1 regimen_LE1 contain_LE1 sequential_LE1 high_LE1 dose_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 specific_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Aldesleukin_ddi|P|proleukin|tamoxifen|hypersensitivity_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 combination_LE1 regimen_LE1 contain_LE1 sequential_LE1 high_LE1 dose_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 specific_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Aldesleukin_ddi|P|proleukin|interferon-alfa|myocardial_LE1 injury_LE1 including_LE1 myocardial_LE1 infarction_LE1 myocarditis_LE1 ventricular_LE1 hypokinesia_LE1 and_LE1 severe_LE1 rhabdomyolysis_LE1 appear_LE1 to_LE1 be_LE1 increase_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concurrent_RE2 
Aldesleukin_ddi|P|interferon-alfa|proleukin|exacerbation_LE1 or_LE1 the_LE1 initial_LE1 presentation_LE1 of_LE1 number_LE1 of_LE1 autoimmune_LE1 and_LE1 inflammatory_LE1 disorder_LE1 have_LE1 be_LE1 observe_LE1 following_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY including_RE2 crescentic_RE2 iga_RE2 glomerulonephritis_RE2 oculo-bulbar_RE2 myasthenia_RE2 gravis_RE2 inflammatory_RE2 arthritis_RE2 thyroiditis_RE2 bullous_RE2 pemphigoid_RE2 and_RE2 stevens-johnson_RE2 syndrome_RE2 
Aldesleukin_ddi|P|beta-blocker|proleukin|although_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 show_LE1 to_LE1 reduce_LE1 BIOGENERAL_LE1 side_LE1 effect_LE1 including_LE1 fever_LE1 renal_LE1 insufficiency_LE1 hyperbilirubinemia_LE1 confusion_LE1 and_LE1 dyspnea_LE1 concomitant_LE1 administration_LE1 of_LE1 these_LE1 agent_LE1 with_LE1 BIOGENERAL_LE1 may_LE1 reduce_LE1 the_LE1 antitumor_LE1 effectiveness_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 thus_LE1 shall_LE1 be_LE1 avoided._LE1 NUM_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypotension_BE12 see_BE12 with_BE12 BIOENTITY 
Aldesleukin_ddi|P|glucocorticoid|proleukin|although_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 reduce_BE12 BIOENTITY side_RE2 effect_RE2 including_RE2 fever_RE2 renal_RE2 insufficiency_RE2 hyperbilirubinemia_RE2 confusion_RE2 and_RE2 dyspnea_RE2 concomitant_RE2 administration_RE2 of_RE2 these_RE2 agent_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 reduce_RE2 the_RE2 antitumor_RE2 effectiveness_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 thus_RE2 shall_RE2 be_RE2 avoided._RE2 NUM_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 potentiate_RE2 the_RE2 hypotension_RE2 see_RE2 with_RE2 BIOGENERAL_RE2 
Aldesleukin_ddi|P|antihypertensive|proleukin|although_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 show_LE1 to_LE1 reduce_LE1 BIOGENERAL_LE1 side_LE1 effect_LE1 including_LE1 fever_LE1 renal_LE1 insufficiency_LE1 hyperbilirubinemia_LE1 confusion_LE1 and_LE1 dyspnea_LE1 concomitant_LE1 administration_LE1 of_LE1 these_LE1 agent_LE1 with_LE1 BIOGENERAL_LE1 may_LE1 reduce_LE1 the_LE1 antitumor_LE1 effectiveness_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 thus_LE1 shall_LE1 be_LE1 avoided._LE1 NUM_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypotension_BE12 see_BE12 with_BE12 BIOENTITY 
Aldesleukin_ddi|P|interleukin-2|radiographic iodinated contrast media|delay_LE1 adverse_LE1 reaction_LE1 to_LE1 BIOGENERAL_LE1 :_LE1 review_LE1 of_LE1 the_LE1 literature_LE1 reveal_LE1 that_LE1 NUM_LE1 -LRB-_LE1 range_LE1 NUM_LE1 -RRB-_LE1 of_LE1 NUM_LE1 patient_LE1 treat_LE1 with_LE1 various_LE1 BIOENTITY containing_BE12 regimen_BE12 who_BE12 be_BE12 subsequent_BE12 administer_BE12 BIOENTITY experience_RE2 acute_RE2 atypical_RE2 adverse_RE2 reaction_RE2 
Alendronate_ddi|P|ranitidine|alendronate|intravenous_LE1 BIOENTITY be_BE12 show_BE12 to_BE12 double_BE12 the_BE12 bioavailability_BE12 of_BE12 oral_BE12 BIOENTITY 
Alendronate_ddi|P|multivalent cation|alendronate|product_LE1 contain_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY likely_BE12 will_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Alendronate_ddi|P|calcium|alendronate|product_LE1 contain_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 likely_BE12 will_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Alfentanil_ddi|P|alfenta|cns depressant|both_LE1 the_LE1 magnitude_LE1 and_LE1 duration_LE1 of_LE1 central_LE1 nervous_LE1 system_LE1 and_LE1 cardiovascular_LE1 effect_LE1 may_LE1 be_LE1 enhance_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 inhalation_RE2 general_RE2 BIOGENERAL_RE2 
Alfentanil_ddi|P|alfenta|barbiturate|both_LE1 the_LE1 magnitude_LE1 and_LE1 duration_LE1 of_LE1 central_LE1 nervous_LE1 system_LE1 and_LE1 cardiovascular_LE1 effect_LE1 may_LE1 be_LE1 enhance_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 inhalation_RE2 general_RE2 BIOGENERAL_RE2 
Alfentanil_ddi|P|alfenta|tranquilizer|both_LE1 the_LE1 magnitude_LE1 and_LE1 duration_LE1 of_LE1 central_LE1 nervous_LE1 system_LE1 and_LE1 cardiovascular_LE1 effect_LE1 may_LE1 be_LE1 enhance_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 inhalation_RE2 general_RE2 BIOGENERAL_RE2 
Alfentanil_ddi|P|alfenta|opioid|both_LE1 the_LE1 magnitude_LE1 and_LE1 duration_LE1 of_LE1 central_LE1 nervous_LE1 system_LE1 and_LE1 cardiovascular_LE1 effect_LE1 may_LE1 be_LE1 enhance_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 inhalation_RE2 general_RE2 BIOGENERAL_RE2 
Alfentanil_ddi|P|alfenta|anesthetic|both_LE1 the_LE1 magnitude_LE1 and_LE1 duration_LE1 of_LE1 central_LE1 nervous_LE1 system_LE1 and_LE1 cardiovascular_LE1 effect_LE1 may_LE1 be_LE1 enhance_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 inhalation_BE12 general_BE12 BIOENTITY 
Alfentanil_ddi|P|erythromycin|alfenta|limited_LE1 clinical_LE1 experience_LE1 indicate_LE1 that_LE1 requirement_LE1 for_LE1 BIOGENERAL_LE1 be_LE1 reduce_LE1 by_LE1 NUM_LE1 to_LE1 NUM_LE1 for_LE1 the_LE1 first_LE1 sixty_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 minute_LE1 following_LE1 BIOGENERAL_LE1 induction_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY can_RE2 significant_RE2 inhibit_RE2 BIOGENERAL_RE2 clearance_RE2 and_RE2 may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 prolonged_RE2 or_RE2 delay_RE2 respiratory_RE2 depression_RE2 
Alfentanil_ddi|P|volatile inhalation anesthetic|alfenta|limited_LE1 clinical_LE1 experience_LE1 indicate_LE1 that_LE1 requirement_LE1 for_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 NUM_BE12 to_BE12 NUM_BE12 for_BE12 the_BE12 first_BE12 sixty_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 minute_BE12 following_BE12 BIOENTITY induction_RE2 the_RE2 concomitant_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 can_RE2 significant_RE2 inhibit_RE2 BIOGENERAL_RE2 clearance_RE2 and_RE2 may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 prolonged_RE2 or_RE2 delay_RE2 respiratory_RE2 depression_RE2 
Alfentanil_ddi|P|cimetidine|alfenta|BIOENTITY reduce_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Alfuzosin_ddi|P|uroxatral|alpha-blocker|however_LE1 interaction_LE1 may_LE1 be_LE1 expect_LE1 and_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY 
Aliskiren_ddi|P|irbesartan|aliskiren|co-administration_LE1 of_LE1 BIOENTITY reduce_BE12 BIOENTITY cmax_RE2 up_RE2 to_RE2 NUM_RE2 after_RE2 multiple_RE2 dosing_RE2 
Aliskiren_ddi|P|atorvastatin|aliskiren|co-administration_LE1 of_LE1 BIOENTITY result_BE12 in_BE12 about_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY cmax_RE2 and_RE2 auc_RE2 after_RE2 multiple_RE2 dosing_RE2 
Aliskiren_ddi|P|ketoconazole|aliskiren|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 NUM_LE1 mg_LE1 twice-daily_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Aliskiren_ddi|P|aliskiren|furosemide|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY the_RE2 auc_RE2 and_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 reduce_RE2 by_RE2 about_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Alitretinoin_ddi|P|panretin|deet|patient_LE1 who_LE1 be_LE1 apply_LE1 BIOENTITY gel_BE12 shall_BE12 not_BE12 concurrent_BE12 use_BE12 product_BE12 that_BE12 contain_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 common_RE2 component_RE2 of_RE2 insect_RE2 repellent_RE2 product_RE2 
Alitretinoin_ddi|P|panretin|n-diethyl-m-toluamide|patient_LE1 who_LE1 be_LE1 apply_LE1 BIOENTITY gel_BE12 shall_BE12 not_BE12 concurrent_BE12 use_BE12 product_BE12 that_BE12 contain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 common_RE2 component_RE2 of_RE2 insect_RE2 repellent_RE2 product_RE2 
Allopurinol_ddi|P|allopurinol|azathioprine|BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 the_BE12 enzymatic_BE12 oxidation_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY to_RE2 BIOGENERAL_RE2 
Allopurinol_ddi|P|allopurinol|mercaptopurine|BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 the_BE12 enzymatic_BE12 oxidation_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 to_RE2 BIOGENERAL_RE2 
Allopurinol_ddi|P|allopurinol|mercaptopurine|In_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY per_BE12 day_BE12 will_BE12 require_BE12 reduction_BE12 in_BE12 dose_BE12 to_BE12 approximate_BE12 one-third_BE12 to_BE12 one-fourth_BE12 of_BE12 the_BE12 usual_BE12 dose_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Allopurinol_ddi|P|allopurinol|azathioprine|In_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY per_BE12 day_BE12 will_BE12 require_BE12 reduction_BE12 in_BE12 dose_BE12 to_BE12 approximate_BE12 one-third_BE12 to_BE12 one-fourth_BE12 of_BE12 the_BE12 usual_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Allopurinol_ddi|P|allopurinol|dicumarol|BIOGENERAL_LE1 :_LE1 it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY prolong_BE12 the_BE12 half-life_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Allopurinol_ddi|P|uricosuric agent|oxipurinol|BIOGENERAL_LE1 :_LE1 since_LE1 the_LE1 excretion_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 similar_LE1 to_LE1 that_LE1 of_LE1 urate_LE1 BIOENTITY which_BE12 increase_BE12 the_BE12 excretion_BE12 of_BE12 urate_BE12 be_BE12 also_BE12 likely_BE12 to_BE12 increase_BE12 the_BE12 excretion_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 low_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 of_RE2 xanthine_RE2 oxidase_RE2 
Allopurinol_ddi|P|uricosuric agent|allopurinol|the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 decrease_RE2 in_RE2 the_RE2 excretion_RE2 of_RE2 oxypurine_RE2 -LRB-_RE2 hypoxanthine_RE2 and_RE2 xanthine_RE2 -RRB-_RE2 and_RE2 increase_RE2 in_RE2 urinary_RE2 uric_RE2 acid_RE2 excretion_RE2 compared_RE2 with_RE2 that_RE2 observe_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Allopurinol_ddi|P|allopurinol|thiazide diuretic|BIOGENERAL_LE1 :_LE1 the_LE1 report_LE1 that_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 contribute_RE2 to_RE2 the_RE2 enhancement_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 in_RE2 some_RE2 patient_RE2 have_RE2 be_RE2 review_RE2 in_RE2 attempt_RE2 to_RE2 establish_RE2 cause-and-effect_RE2 relationship_RE2 and_RE2 mechanism_RE2 of_RE2 causation_RE2 
Allopurinol_ddi|P|thiazide diuretic|allopurinol|although_LE1 causal_LE1 mechanism_LE1 and_LE1 cause-and-effect_LE1 relationship_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 current_LE1 evidence_LE1 suggest_LE1 that_LE1 renal_LE1 function_LE1 shall_LE1 be_LE1 monitor_LE1 in_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 BIOENTITY even_RE2 in_RE2 the_RE2 absence_RE2 of_RE2 renal_RE2 failure_RE2 and_RE2 dosage_RE2 level_RE2 shall_RE2 be_RE2 even_RE2 much_RE2 conservative_RE2 adjust_RE2 in_RE2 those_RE2 patient_RE2 on_RE2 such_RE2 combined_RE2 therapy_RE2 if_RE2 diminish_RE2 renal_RE2 function_RE2 be_RE2 detect_RE2 .._RE2 
Allopurinol_ddi|P|amoxicillin|allopurinol|BIOGENERAL_LE1 :_LE1 increase_LE1 in_LE1 the_LE1 frequency_LE1 of_LE1 skin_LE1 rash_LE1 have_LE1 be_LE1 report_LE1 among_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY concurrent_BE12 with_BE12 BIOENTITY compared_RE2 to_RE2 patient_RE2 who_RE2 be_RE2 not_RE2 receive_RE2 both_RE2 drug_RE2 
Allopurinol_ddi|P|ampicillin|allopurinol|BIOGENERAL_LE1 :_LE1 increase_LE1 in_LE1 the_LE1 frequency_LE1 of_LE1 skin_LE1 rash_LE1 have_LE1 be_LE1 report_LE1 among_LE1 patient_LE1 receive_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 concurrent_BE12 with_BE12 BIOENTITY compared_RE2 to_RE2 patient_RE2 who_RE2 be_RE2 not_RE2 receive_RE2 both_RE2 drug_RE2 
Allopurinol_ddi|P|cyclophosphamide|allopurinol|BIOGENERAL_LE1 :_LE1 enhance_LE1 bone_LE1 marrow_LE1 suppression_LE1 by_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 among_BE12 patient_BE12 with_BE12 neoplastic_BE12 disease_BE12 except_BE12 leukemia_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Allopurinol_ddi|P|cytotoxic agent|allopurinol|BIOGENERAL_LE1 :_LE1 enhance_LE1 bone_LE1 marrow_LE1 suppression_LE1 by_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 among_BE12 patient_BE12 with_BE12 neoplastic_BE12 disease_BE12 except_BE12 leukemia_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Allopurinol_ddi|P|chlorpropamide|allopurinol|BIOGENERAL_LE1 :_LE1 BIOENTITY plasma_BE12 half-life_BE12 may_BE12 be_BE12 prolonged_BE12 by_BE12 BIOENTITY since_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 compete_RE2 for_RE2 excretion_RE2 in_RE2 the_RE2 renal_RE2 tubule_RE2 
Allopurinol_ddi|P|allopurinol|chlorpropamide|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 plasma_LE1 half-life_LE1 may_LE1 be_LE1 prolonged_LE1 by_LE1 BIOGENERAL_LE1 since_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 compete_RE2 for_RE2 excretion_RE2 in_RE2 the_RE2 renal_RE2 tubule_RE2 
Allopurinol_ddi|P|allopurinol|chlorpropamide|the_LE1 risk_LE1 of_LE1 hypoglycemia_LE1 secondary_LE1 to_LE1 this_LE1 mechanism_LE1 may_LE1 be_LE1 increase_LE1 if_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 give_RE2 concomitant_RE2 in_RE2 the_RE2 presence_RE2 of_RE2 renal_RE2 insufficiency_RE2 
Allopurinol_ddi|P|cyclosporine|allopurinol sodium|BIOGENERAL_LE1 :_LE1 report_LE1 indicate_LE1 that_LE1 BIOENTITY level_BE12 may_BE12 be_BE12 increase_BE12 during_BE12 concomitant_BE12 treatment_BE12 with_BE12 BIOENTITY for_RE2 injection_RE2 
Almotriptan_ddi|P|methysergide|axert|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Almotriptan_ddi|P|dihydroergotamine|axert|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Almotriptan_ddi|P|ergot-type medication|axert|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Almotriptan_ddi|P|ergotamine|axert|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 
Almotriptan_ddi|P|moclobemide|almotriptan|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY result_BE12 in_BE12 NUM_BE12 decrease_BE12 in_BE12 BIOENTITY clearance_RE2 and_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 approximate_RE2 NUM_RE2 %._RE2 
Almotriptan_ddi|P|5-ht1b/1d agonist|axert|other_LE1 BIOGENERAL_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 BIOENTITY within_BE12 NUM_BE12 hour_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Almotriptan_ddi|P|sertraline|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 have_BE12 be_BE12 rare_BE12 report_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Almotriptan_ddi|P|paroxetine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 rare_BE12 report_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Almotriptan_ddi|P|fluvoxamine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 rare_BE12 report_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Almotriptan_ddi|P|fluoxetine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 rare_BE12 report_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Almotriptan_ddi|P|ssri|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 rare_BE12 report_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Almotriptan_ddi|P|axert|ssri|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Almotriptan_ddi|P|almotriptan|verapamil|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Almotriptan_ddi|P|almotriptan|ketoconazole|coadministration_LE1 of_LE1 BIOENTITY and_BE12 the_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 q.d._RE2 for_RE2 NUM_RE2 day_RE2 -RRB-_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 area_RE2 under_RE2 the_RE2 plasma_RE2 concentration-time_RE2 curve_RE2 and_RE2 maximal_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Almotriptan_ddi|P|erythromycin|almotriptan|although_LE1 the_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 potent_LE1 cyp3a4_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 increase_BE12 exposure_BE12 to_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 expect_BE12 when_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 with_RE2 these_RE2 medication_RE2 
Almotriptan_ddi|P|ritonavir|almotriptan|although_LE1 the_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 potent_LE1 cyp3a4_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 increase_BE12 exposure_BE12 to_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 expect_BE12 when_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 with_RE2 these_RE2 medication_RE2 
Almotriptan_ddi|P|itraconazole|almotriptan|although_LE1 the_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 potent_LE1 cyp3a4_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 increase_BE12 exposure_BE12 to_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 expect_BE12 when_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 with_RE2 these_RE2 medication_RE2 
Alosetron_ddi|P|fluvoxamine|alosetron|BIOENTITY increase_BE12 mean_BE12 BIOENTITY plasma_RE2 concentration_RE2 -LRB-_RE2 auc_RE2 -RRB-_RE2 approximate_RE2 NUM_RE2 and_RE2 prolong_RE2 the_RE2 half-life_RE2 by_RE2 approximate_RE2 NUM_RE2 
Alosetron_ddi|P|alosetron|fluvoxamine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Alosetron_ddi|P|alosetron|quinolone antibiotic|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 moderate_BE12 cyp1a2_BE12 inhibitor_BE12 including_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 avoid_RE2 unless_RE2 clinical_RE2 necessary_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|cimetidine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 moderate_BE12 cyp1a2_BE12 inhibitor_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 avoid_RE2 unless_RE2 clinical_RE2 necessary_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|ketoconazole|alosetron|BIOENTITY increase_BE12 mean_BE12 BIOENTITY plasma_RE2 concentration_RE2 -LRB-_RE2 auc_RE2 -RRB-_RE2 by_RE2 NUM_RE2 %._RE2 
Alosetron_ddi|P|alosetron|ketoconazole|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Alosetron_ddi|P|alosetron|clarithromycin|coadministration_LE1 of_LE1 BIOENTITY and_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|voriconazole|coadministration_LE1 of_LE1 BIOENTITY and_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|itraconazole|coadministration_LE1 of_LE1 BIOENTITY and_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|telithromycin|coadministration_LE1 of_LE1 BIOENTITY and_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|protease inhibitor|coadministration_LE1 of_LE1 BIOENTITY and_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 evaluate_RE2 but_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 because_RE2 of_RE2 similar_RE2 potential_RE2 drug_RE2 interaction_RE2 
Alosetron_ddi|P|alosetron|hydralazine|although_LE1 not_LE1 study_LE1 with_LE1 BIOENTITY inhibition_BE12 of_BE12 n-acetyltransferase_BE12 may_BE12 have_BE12 clinical_BE12 relevant_BE12 consequence_BE12 for_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Alosetron_ddi|P|alosetron|isoniazid|although_LE1 not_LE1 study_LE1 with_LE1 BIOENTITY inhibition_BE12 of_BE12 n-acetyltransferase_BE12 may_BE12 have_BE12 clinical_BE12 relevant_BE12 consequence_BE12 for_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alosetron_ddi|P|alosetron|procainamide|although_LE1 not_LE1 study_LE1 with_LE1 BIOENTITY inhibition_BE12 of_BE12 n-acetyltransferase_BE12 may_BE12 have_BE12 clinical_BE12 relevant_BE12 consequence_BE12 for_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|benzodiazepine|antihistaminic|the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|benzodiazepine|ethanol|the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|benzodiazepine|psychotropic medication|the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|benzodiazepine|anticonvulsant|the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|alprazolam|antihistaminic|the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|alprazolam|ethanol|the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|alprazolam|psychotropic medication|the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|alprazolam|anticonvulsant|the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 co-administer_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 which_RE2 themselves_RE2 produce_RE2 cns_RE2 depression_RE2 
Alprazolam_ddi|P|imipramine|alprazolam|the_LE1 steady_LE1 state_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 average_BE12 of_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY tablet_RE2 in_RE2 dose_RE2 up_RE2 to_RE2 NUM_RE2 mg_RE2 
Alprazolam_ddi|P|desipramine|alprazolam|the_LE1 steady_LE1 state_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 average_BE12 of_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY tablet_RE2 in_RE2 dose_RE2 up_RE2 to_RE2 NUM_RE2 mg_RE2 
Alprazolam_ddi|P|fluoxetine|alprazolam|drug_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 of_LE1 possible_LE1 clinical_LE1 significance_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY increase_RE2 the_RE2 maximum_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 decrease_RE2 clearance_RE2 by_RE2 NUM_RE2 increase_RE2 half-life_RE2 by_RE2 NUM_RE2 and_RE2 decrease_RE2 measure_RE2 psychomotor_RE2 performance_RE2 
Alprazolam_ddi|P|propoxyphene|alprazolam|coadministration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 maximum_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 decrease_RE2 clearance_RE2 by_RE2 NUM_RE2 and_RE2 increase_RE2 half-life_RE2 by_RE2 NUM_RE2 %._RE2 
Alprazolam_ddi|P|contraceptive|alprazolam|coadministration_LE1 of_LE1 oral_LE1 BIOENTITY increase_BE12 the_BE12 maximum_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 decrease_RE2 clearance_RE2 by_RE2 NUM_RE2 and_RE2 increase_RE2 half-life_RE2 by_RE2 NUM_RE2 %._RE2 
Alprazolam_ddi|P|alprazolam|clarithromycin|drug_LE1 and_LE1 other_LE1 substance_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 metabolize_LE1 similar_LE1 to_LE1 BIOGENERAL_LE1 or_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 available_LE1 datum_LE1 from_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 grapefruit_RE2 juice_RE2 
Alprazolam_ddi|P|alprazolam|diltiazem|drug_LE1 and_LE1 other_LE1 substance_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 metabolize_LE1 similar_LE1 to_LE1 BIOGENERAL_LE1 or_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 available_LE1 datum_LE1 from_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 grapefruit_RE2 juice_RE2 
Alprazolam_ddi|P|alprazolam|isoniazid|drug_LE1 and_LE1 other_LE1 substance_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 metabolize_LE1 similar_LE1 to_LE1 BIOGENERAL_LE1 or_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 available_LE1 datum_LE1 from_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 grapefruit_RE2 juice_RE2 
Alprazolam_ddi|P|alprazolam|macrolide antibiotic|drug_LE1 and_LE1 other_LE1 substance_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 metabolize_LE1 similar_LE1 to_LE1 BIOGENERAL_LE1 or_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 available_LE1 datum_LE1 from_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 grapefruit_RE2 juice_RE2 
Alprazolam_ddi|P|alprazolam|erythromycin|drug_LE1 and_LE1 other_LE1 substance_LE1 demonstrate_LE1 to_LE1 be_LE1 cyp_LE1 3a_LE1 inhibitor_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 clinical_LE1 study_LE1 involve_LE1 BIOGENERAL_LE1 metabolize_LE1 similar_LE1 to_LE1 BIOGENERAL_LE1 or_LE1 on_LE1 the_LE1 basis_LE1 of_LE1 in_LE1 vitro_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 caution_LE1 be_LE1 recommend_LE1 during_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 available_LE1 datum_LE1 from_LE1 clinical_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 grapefruit_RE2 juice_RE2 
Alprazolam_ddi|P|alprazolam|sertraline|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|alprazolam|paroxetine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 suggest_LE1 possible_LE1 drug_LE1 interaction_LE1 with_LE1 BIOENTITY for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Alprazolam_ddi|P|alprazolam|nifedipine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOENTITY suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Alprazolam_ddi|P|alprazolam|amiodarone|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOENTITY suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|alprazolam|nicardipine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOENTITY suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|alprazolam|ergotamine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOENTITY suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|alprazolam|cyclosporine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOGENERAL_LE1 other_LE1 than_LE1 BIOENTITY suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|benzodiazepine|ergotamine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOENTITY other_BE12 than_BE12 BIOGENERAL_BE12 suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|benzodiazepine|nicardipine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOENTITY other_BE12 than_BE12 BIOGENERAL_BE12 suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|benzodiazepine|cyclosporine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOENTITY other_BE12 than_BE12 BIOGENERAL_BE12 suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alprazolam_ddi|P|benzodiazepine|nifedipine|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOENTITY other_BE12 than_BE12 BIOGENERAL_BE12 suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Alprazolam_ddi|P|benzodiazepine|amiodarone|datum_LE1 from_LE1 in_LE1 vitro_LE1 study_LE1 of_LE1 BIOENTITY other_BE12 than_BE12 BIOGENERAL_BE12 suggest_BE12 possible_BE12 drug_BE12 interaction_BE12 for_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Alteplase_ddi|P|dipyridamole|activase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Alteplase_ddi|P|abciximab|activase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Alteplase_ddi|P|heparin|activase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Alteplase_ddi|P|vitamin k antagonist|activase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY drug_BE12 that_BE12 alter_BE12 platelet_BE12 function_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Alteplase_ddi|P|acetylsalicylic acid|activase|In_LE1 addition_LE1 to_LE1 bleeding_LE1 associate_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 drug_LE1 that_LE1 alter_LE1 platelet_LE1 function_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 if_BE12 administer_BE12 prior_BE12 to_BE12 during_BE12 or_BE12 after_BE12 BIOENTITY therapy_RE2 
Altretamine_ddi|P|cimetidine|altretamine|concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 may_LE1 cause_LE1 severe_LE1 orthostatic_LE1 BIOENTITY inhibitor_BE12 of_BE12 microsomal_BE12 drug_BE12 metabolism_BE12 increase_BE12 BIOENTITY half-life_RE2 and_RE2 toxicity_RE2 in_RE2 rat_RE2 model_RE2 
Altretamine_ddi|P|hexalen|antidepressants of the mao inhibitor clas|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 cause_RE2 severe_RE2 orthostatic_RE2 BIOGENERAL_RE2 inhibitor_RE2 of_RE2 microsomal_RE2 drug_RE2 metabolism_RE2 increase_RE2 BIOGENERAL_RE2 half-life_RE2 and_RE2 toxicity_RE2 in_RE2 rat_RE2 model_RE2 
Altretamine_ddi|P|hexalen|cisplatin|datum_LE1 from_LE1 randomized_LE1 trial_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY plus_RE2 or_RE2 minus_RE2 BIOGENERAL_RE2 in_RE2 ovarian_RE2 cancer_RE2 indicate_RE2 that_RE2 BIOGENERAL_RE2 significant_RE2 reduce_RE2 neurotoxicity_RE2 
Altretamine_ddi|P|pyridoxine|hexalen|however_LE1 it_LE1 adverse_LE1 affect_LE1 response_LE1 duration_LE1 suggest_LE1 that_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Altretamine_ddi|P|pyridoxine|cisplatin|however_LE1 it_LE1 adverse_LE1 affect_LE1 response_LE1 duration_LE1 suggest_LE1 that_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Amantadine_ddi|P|amantadine|central nervous system stimulant|careful_LE1 observation_LE1 be_LE1 require_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Amifostine_ddi|P|ethyol|antihypertensive medication|special_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 can_RE2 cause_RE2 or_RE2 potentiate_RE2 hypotension_RE2 
Amiloride_ddi|P|amiloride|angiotensin-converting enzyme inhibitor|when_LE1 BIOENTITY hcl_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY the_RE2 risk_RE2 of_RE2 hyperkalemia_RE2 may_RE2 be_RE2 increase_RE2 
Amiloride_ddi|P|lithium|diuretic|BIOENTITY general_BE12 shall_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY because_RE2 they_RE2 reduce_RE2 its_RE2 renal_RE2 clearance_RE2 and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 lithium_RE2 toxicity_RE2 
Amiloride_ddi|P|non-steroidal anti-inflammatory agent|potassium-sparing diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Amiloride_ddi|P|non-steroidal anti-inflammatory agent|thiazide diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Amiloride_ddi|P|non-steroidal anti-inflammatory agent|loop diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Amiloride_ddi|P|midamor|non-steroidal anti-inflammatory agent|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 obtain_RE2 
Amiloride_ddi|P|indomethacin|midamor|since_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY may_RE2 each_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 serum_RE2 potassium_RE2 level_RE2 the_RE2 potential_RE2 effect_RE2 on_RE2 potassium_RE2 kinetic_RE2 and_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 consider_RE2 when_RE2 these_RE2 agent_RE2 be_RE2 administer_RE2 concurrent_RE2 
Amiloride_ddi|P|indomethacin|potassium-sparing diuretic|since_LE1 BIOENTITY and_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 may_RE2 each_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 serum_RE2 potassium_RE2 level_RE2 the_RE2 potential_RE2 effect_RE2 on_RE2 potassium_RE2 kinetic_RE2 and_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 consider_RE2 when_RE2 these_RE2 agent_RE2 be_RE2 administer_RE2 concurrent_RE2 
Aminoglutethimide_ddi|P|cytadren|dexamethasone|BIOENTITY accelerate_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Aminoglutethimide_ddi|P|aminoglutethimide|coumarin|BIOENTITY diminish_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Aminoglutethimide_ddi|P|aminoglutethimide|warfarin|BIOENTITY diminish_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Aminohippurate_ddi|P|pah|thiazolesulfone|renal_LE1 clearance_LE1 measurement_LE1 of_LE1 BIOENTITY can_BE12 be_BE12 make_BE12 with_BE12 any_BE12 significant_BE12 accuracy_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Aminohippurate_ddi|P|pah|procaine|renal_LE1 clearance_LE1 measurement_LE1 of_LE1 BIOENTITY can_BE12 be_BE12 make_BE12 with_BE12 any_BE12 significant_BE12 accuracy_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Aminohippurate_ddi|P|pah|sulfonamide|renal_LE1 clearance_LE1 measurement_LE1 of_LE1 BIOENTITY can_BE12 be_BE12 make_BE12 with_BE12 any_BE12 significant_BE12 accuracy_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Aminohippurate_ddi|P|probenecid|pah|BIOENTITY depress_BE12 tubular_BE12 secretion_BE12 of_BE12 certain_BE12 weak_BE12 acid_BE12 such_BE12 as_BE12 BIOENTITY 
Aminohippurate_ddi|P|probenecid|pah|therefore_LE1 patient_LE1 receive_LE1 BIOENTITY will_BE12 have_BE12 erroneous_BE12 low_BE12 erpf_BE12 and_BE12 tm_BE12 BIOENTITY value_RE2 
Aminolevulinic acid_ddi|P|tetracycline|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|sulfonamide|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|phenothiazine|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|sulfonylurea|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|griseofulvin|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|thiazide diuretic|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminolevulinic acid_ddi|P|photosensitizing agent|levulan kerastick|it_LE1 be_LE1 however_LE1 possible_LE1 that_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 known_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 photosensitivity_BE12 reaction_BE12 of_BE12 actinic_BE12 keratose_BE12 treat_BE12 with_BE12 the_BE12 BIOENTITY for_RE2 topical_RE2 solution_RE2 
Aminosalicylic Acid_ddi|P|aminosalicylic acid|lanoxin|BIOENTITY may_BE12 decrease_BE12 the_BE12 amount_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 that_RE2 get_RE2 absorb_RE2 into_RE2 your_RE2 body_RE2 
Aminosalicylic Acid_ddi|P|aminosalicylic acid|digoxin|BIOENTITY may_BE12 decrease_BE12 the_BE12 amount_BE12 of_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 that_RE2 get_RE2 absorb_RE2 into_RE2 your_RE2 body_RE2 
Aminosalicylic Acid_ddi|P|digoxin|aminosalicylic acid|In_LE1 the_LE1 case_LE1 that_LE1 you_LE1 be_LE1 take_LE1 BIOENTITY while_BE12 take_BE12 BIOENTITY high_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 need_RE2 
Aminosalicylic Acid_ddi|P|aminosalicylic acid|vitamin b12|BIOENTITY may_BE12 also_BE12 decrease_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 lead_RE2 to_RE2 deficiency_RE2 
Aminosalicylic Acid_ddi|P|vitamin b12|aminosalicylic acid|therefore_LE1 you_LE1 may_LE1 need_LE1 to_LE1 take_LE1 BIOENTITY supplement_BE12 while_BE12 take_BE12 BIOENTITY 
Amiodarone_ddi|P|amiodarone|indinavir|case_LE1 report_LE1 of_LE1 one_LE1 patient_LE1 take_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 three_RE2 time_RE2 day_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 from_RE2 NUM_RE2 mg_RE2 to_RE2 NUM_RE2 mg_RE2 
Amiodarone_ddi|P|amiodarone|protease inhibitor|monitoring_LE1 for_LE1 BIOGENERAL_LE1 toxicity_LE1 and_LE1 serial_LE1 measurement_LE1 of_LE1 BIOENTITY serum_BE12 concentration_BE12 during_BE12 concomitant_BE12 BIOENTITY therapy_RE2 shall_RE2 be_RE2 consider_RE2 
Amiodarone_ddi|P|cimetidine|amiodarone|BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 cyp3a4_BE12 and_BE12 can_BE12 increase_BE12 serum_BE12 BIOENTITY level_RE2 
Amiodarone_ddi|P|amiodarone|digitali|On_LE1 administration_LE1 of_LE1 oral_LE1 BIOENTITY the_BE12 need_BE12 for_BE12 BIOENTITY therapy_RE2 shall_RE2 be_RE2 review_RE2 and_RE2 the_RE2 dose_RE2 reduce_RE2 by_RE2 approximate_RE2 NUM_RE2 or_RE2 discontinue_RE2 
Amitriptyline_ddi|P|ssri|tca|the_LE1 extent_LE1 to_LE1 which_LE1 BIOENTITY interaction_RE2 may_RE2 pose_RE2 clinical_RE2 problem_RE2 will_RE2 depend_RE2 on_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 and_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 involve_RE2 
Amitriptyline_ddi|P|tca|ssri|nevertheless_LE1 caution_LE1 be_LE1 indicate_LE1 in_LE1 the_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 any_BE12 of_BE12 the_BE12 BIOENTITY and_RE2 also_RE2 in_RE2 switching_RE2 from_RE2 one_RE2 class_RE2 to_RE2 the_RE2 other_RE2 
Amitriptyline_ddi|P|amitriptyline hcl|anticholinergic|hyperpyrexia_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY agent_RE2 or_RE2 with_RE2 BIOGENERAL_RE2 drug_RE2 particular_RE2 during_RE2 hot_RE2 weather_RE2 
Amitriptyline_ddi|P|tricyclic antidepressant|anticholinergic|paralytic_LE1 ileus_LE1 may_LE1 occur_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY drug_RE2 
Amitriptyline_ddi|P|cimetidine|tricyclic antidepressant|BIOENTITY be_BE12 report_BE12 to_BE12 reduce_BE12 hepatic_BE12 metabolism_BE12 of_BE12 certain_BE12 BIOENTITY thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 steady-state_RE2 concentration_RE2 of_RE2 these_RE2 BIOGENERAL_RE2 
Amitriptyline_ddi|P|tricyclic antidepressant|cimetidine|clinical_LE1 significant_LE1 effect_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 BIOENTITY when_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Amitriptyline_ddi|P|tricyclic antidepressant|cimetidine|increase_LE1 in_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY and_BE12 in_BE12 the_BE12 frequency_BE12 and_BE12 severity_BE12 of_BE12 side_BE12 effect_BE12 particular_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 when_BE12 BIOENTITY be_RE2 add_RE2 to_RE2 the_RE2 BIOGENERAL_RE2 regimen_RE2 
Amitriptyline_ddi|P|tricyclic antidepressant|cimetidine|discontinuation_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 well-controlled_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 decrease_RE2 the_RE2 plasma_RE2 level_RE2 and_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Amitriptyline_ddi|P|ethchlorvynol|amitriptyline hcl|transient_LE1 delirium_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 who_LE1 be_LE1 treat_LE1 with_LE1 one_LE1 gram_LE1 of_LE1 BIOENTITY and_BE12 NUM_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY 
Amphotericin B_ddi|P|amphotericin b|antineoplastic agent|when_LE1 administer_LE1 concurrent_LE1 the_LE1 following_LE1 drug_LE1 may_LE1 interact_LE1 with_LE1 BIOENTITY :_BE12 BIOENTITY :_RE2 may_RE2 enhance_RE2 the_RE2 potential_RE2 for_RE2 renal_RE2 toxicity_RE2 bronchospasm_RE2 and_RE2 hypotension_RE2 
Amphotericin B_ddi|P|corticosteroid|amphotericin b|BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 may_BE12 potentiate_BE12 BIOENTITY induced_RE2 hypokalemia_RE2 which_RE2 may_RE2 predispose_RE2 the_RE2 patient_RE2 to_RE2 cardiac_RE2 dysfunction_RE2 
Amphotericin B_ddi|P|acth|amphotericin b|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 :_BE12 may_BE12 potentiate_BE12 BIOENTITY induced_RE2 hypokalemia_RE2 which_RE2 may_RE2 predispose_RE2 the_RE2 patient_RE2 to_RE2 cardiac_RE2 dysfunction_RE2 
Amphotericin B_ddi|P|corticotropin|amphotericin b|BIOGENERAL_LE1 and_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 may_BE12 potentiate_BE12 BIOENTITY induced_RE2 hypokalemia_RE2 which_RE2 may_RE2 predispose_RE2 the_RE2 patient_RE2 to_RE2 cardiac_RE2 dysfunction_RE2 
Amphotericin B_ddi|P|amphotericin b|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 may_BE12 potentiate_BE12 BIOENTITY toxicity_RE2 
Amphotericin B_ddi|P|amphotericin b|flucytosine|BIOGENERAL_LE1 :_LE1 while_LE1 synergistic_LE1 relationship_LE1 with_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 concomitant_BE12 use_BE12 may_BE12 increase_BE12 the_BE12 toxicity_BE12 of_BE12 BIOENTITY by_RE2 possible_RE2 increase_RE2 its_RE2 cellular_RE2 uptake_RE2 and_RE2 impair_RE2 its_RE2 renal_RE2 excretion_RE2 
Amphotericin B_ddi|P|imidazole|amphotericin b|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 etc._LE1 -RRB-_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 animal_LE1 study_LE1 with_LE1 the_LE1 combination_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 induce_BE12 fungal_BE12 resistance_BE12 to_BE12 BIOENTITY 
Amphotericin B_ddi|P|amphotericin b|skeletal muscle relaxant|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 may_BE12 enhance_BE12 the_BE12 curariform_BE12 effect_BE12 of_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -rrb-._RE2 
Amphotericin B_ddi|P|amphotericin b|tubocurarine|BIOGENERAL_LE1 :_LE1 BIOENTITY hypokalemia_BE12 may_BE12 enhance_BE12 the_BE12 curariform_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -rrb-._RE2 
Amphotericin B_ddi|P|amphotericin b|leukocyte transfusion|BIOGENERAL_LE1 :_LE1 acute_LE1 pulmonary_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 intravenous_LE1 BIOENTITY and_BE12 BIOENTITY 
Ampicillin_ddi|P|tetracycline|penicillin|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY 
Ampicillin_ddi|P|sulfonamide|penicillin|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY 
Ampicillin_ddi|P|erythromycin|penicillin|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY 
Ampicillin_ddi|P|chloramphenicol|penicillin|BIOGENERAL_LE1 :_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY 
Ampicillin_ddi|P|probenecid|ampicillin|BIOENTITY :_BE12 may_BE12 decrease_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 blood_RE2 level_RE2 and_RE2 BIOGENERAL_RE2 toxicity_RE2 
Amprenavir_ddi|P|indinavir|amprenavir|BIOENTITY steady-state_BE12 cmax_BE12 a.c._BE12 and_BE12 cmin_BE12 be_BE12 decrease_BE12 by_BE12 NUM_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 by_BE12 concomitant_BE12 BIOENTITY 
Amprenavir_ddi|P|saquinavir|amprenavir|BIOENTITY steady-state_BE12 cmax_BE12 a.c._BE12 and_BE12 cmin_BE12 be_BE12 increase_BE12 NUM_BE12 decrease_BE12 NUM_BE12 and_BE12 decrease_BE12 NUM_BE12 respective_BE12 by_BE12 concomitant_BE12 BIOENTITY 
Amprenavir_ddi|P|nelfinavir|amprenavir|BIOENTITY steady-state_BE12 cmax_BE12 a.c._BE12 and_BE12 cmin_BE12 be_BE12 increase_BE12 by_BE12 NUM_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 by_BE12 concomitant_BE12 BIOENTITY 
Amprenavir_ddi|P|amprenavir|methadone|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 decrease_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Amprenavir_ddi|P|amprenavir|methadone|coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY as_RE2 compared_RE2 to_RE2 non-matched_RE2 historicalcontrol_RE2 group_RE2 result_RE2 in_RE2 NUM_RE2 NUM_RE2 and_RE2 NUM_RE2 decrease_RE2 in_RE2 serum_RE2 BIOGENERAL_RE2 auc_RE2 cmax_RE2 andcmin_RE2 respective_RE2 
Amprenavir_ddi|P|amprenavir|ritonavir|laboratory_LE1 test_LE1 :_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 low-dose_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 elevation_RE2 of_RE2 cholesterol_RE2 and_RE2 triglyceride_RE2 sgot_RE2 -LRB-_RE2 ast_RE2 -RRB-_RE2 and_RE2 sgpt_RE2 -LRB-_RE2 alt_RE2 -RRB-_RE2 in_RE2 some_RE2 patient_RE2 
Amprenavir_ddi|P|amprenavir|ritonavir|appropriate_LE1 laboratory_LE1 testing_LE1 shall_LE1 be_LE1 consider_LE1 prior_LE1 to_LE1 initiate_LE1 combination_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY and_RE2 at_RE2 periodic_RE2 interval_RE2 or_RE2 if_RE2 any_RE2 clinical_RE2 sign_RE2 or_RE2 symptom_RE2 of_RE2 hyperlipidemia_RE2 or_RE2 elevated_RE2 liver_RE2 function_RE2 test_RE2 occur_RE2 during_RE2 therapy_RE2 
Amyl Nitrite_ddi|P|amyl nitrite|alcohol|take_LE1 BIOENTITY after_BE12 drinking_BE12 BIOENTITY may_RE2 worsen_RE2 side_RE2 effect_RE2 and_RE2 may_RE2 cause_RE2 severe_RE2 hypotension_RE2 and_RE2 cardiovascular_RE2 collapse_RE2 
Anagrelide_ddi|P|anagrelide|aspirin|BIOENTITY alone_BE12 have_BE12 no_BE12 effect_BE12 on_BE12 platelet_BE12 aggregation_BE12 but_BE12 do_BE12 slight_BE12 enhance_BE12 the_BE12 inhibition_BE12 of_BE12 platelet_BE12 aggregation_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|fluvoxamine|anagrelide|it_LE1 be_LE1 know_LE1 that_LE1 cyp1a2_LE1 be_LE1 inhibit_LE1 by_LE1 several_LE1 medicinal_LE1 product_LE1 including_LE1 BIOENTITY and_BE12 such_BE12 medicinal_BE12 product_BE12 can_BE12 theoretical_BE12 adverse_BE12 influence_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Anagrelide_ddi|P|anagrelide|theophylline|BIOENTITY demonstrate_BE12 some_BE12 limited_BE12 inhibitory_BE12 activity_BE12 towards_BE12 cyp1a2_BE12 which_BE12 may_BE12 present_BE12 theoretical_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 other_BE12 coadministered_BE12 medicinal_BE12 product_BE12 share_BE12 that_BE12 clearance_BE12 mechanism_BE12 e.g._BE12 BIOENTITY 
Anagrelide_ddi|P|milrinone|anagrelide|the_LE1 effect_LE1 of_LE1 medicinal_LE1 product_LE1 with_LE1 similar_LE1 property_LE1 such_LE1 as_LE1 inotrope_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 exacerbated_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|enoximone|anagrelide|the_LE1 effect_LE1 of_LE1 medicinal_LE1 product_LE1 with_LE1 similar_LE1 property_LE1 such_LE1 as_LE1 inotrope_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 exacerbated_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|olprinone|anagrelide|the_LE1 effect_LE1 of_LE1 medicinal_LE1 product_LE1 with_LE1 similar_LE1 property_LE1 such_LE1 as_LE1 inotrope_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 exacerbated_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|amrinone|anagrelide|the_LE1 effect_LE1 of_LE1 medicinal_LE1 product_LE1 with_LE1 similar_LE1 property_LE1 such_LE1 as_LE1 inotrope_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 exacerbated_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|cilostazol|anagrelide|the_LE1 effect_LE1 of_LE1 medicinal_LE1 product_LE1 with_LE1 similar_LE1 property_LE1 such_LE1 as_LE1 inotrope_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 be_BE12 exacerbated_BE12 by_BE12 BIOENTITY 
Anagrelide_ddi|P|sucralfate|anagrelide|there_LE1 be_LE1 single_LE1 case_LE1 report_LE1 which_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 BIOENTITY absorption_RE2 
Anakinra_ddi|P|kineret|etanercept|In_LE1 study_LE1 in_LE1 which_LE1 patient_LE1 with_LE1 active_LE1 ra_LE1 be_LE1 treat_LE1 for_LE1 up_LE1 to_LE1 NUM_LE1 week_LE1 with_LE1 concurrent_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 NUM_RE2 rate_RE2 of_RE2 serious_RE2 infection_RE2 be_RE2 observe_RE2 which_RE2 be_RE2 high_RE2 than_RE2 that_RE2 observe_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 -LRB-_RE2 NUM_RE2 
Anakinra_ddi|P|kineret|etanercept|two_LE1 percent_LE1 of_LE1 patient_LE1 treat_LE1 concurrent_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY develop_RE2 neutropenia_RE2 -LRB-_RE2 anc_RE2 NUM_RE2 NUM_RE2 -rrb-._RE2 
Anastrozole_ddi|P|tamoxifen|anastrozole|Based_LE1 on_LE1 clinical_LE1 and_LE1 pharmacokinetic_LE1 result_LE1 from_LE1 the_LE1 atac_LE1 trial_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 with_BE12 BIOENTITY -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 drug_RE2 interaction_RE2 and_RE2 clinical_RE2 pharmacology_RE2 clinical_RE2 study_RE2 adjuvant_RE2 treatment_RE2 of_RE2 breast_RE2 cancer_RE2 in_RE2 postmenopausal_RE2 woman_RE2 subsection_RE2 -rrb-._RE2 
Anastrozole_ddi|P|anastrozole|tamoxifen|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 reduction_RE2 of_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 by_RE2 NUM_RE2 compared_RE2 with_RE2 those_RE2 achieve_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Anastrozole_ddi|P|estrogen|arimidex|BIOENTITY therapy_BE12 shall_BE12 not_BE12 be_BE12 use_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 may_RE2 diminish_RE2 its_RE2 pharmacologic_RE2 action_RE2 
Anileridine_ddi|P|anileridine|opioid|caution_LE1 shall_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 as_RE2 these_RE2 agent_RE2 may_RE2 increase_RE2 respiratory_RE2 and_RE2 circulatory_RE2 depression_RE2 
Anileridine_ddi|P|anileridine|phenothiazine|caution_LE1 shall_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 as_RE2 these_RE2 agent_RE2 may_RE2 increase_RE2 respiratory_RE2 and_RE2 circulatory_RE2 depression_RE2 
Anileridine_ddi|P|anileridine|sedative|caution_LE1 shall_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 as_RE2 these_RE2 agent_RE2 may_RE2 increase_RE2 respiratory_RE2 and_RE2 circulatory_RE2 depression_RE2 
Anileridine_ddi|P|anileridine|anesthetic|caution_LE1 shall_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY as_RE2 these_RE2 agent_RE2 may_RE2 increase_RE2 respiratory_RE2 and_RE2 circulatory_RE2 depression_RE2 
Anisindione_ddi|P|cholestyramine|anticoagulant|For_LE1 example_LE1 since_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 both_BE12 the_BE12 oral_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 the_RE2 net_RE2 effect_RE2 be_RE2 unpredictable_RE2 
Anisindione_ddi|P|cholestyramine|vitamin k|For_LE1 example_LE1 since_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 both_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY the_RE2 net_RE2 effect_RE2 be_RE2 unpredictable_RE2 
Anisindione_ddi|P|chloral hydrate|anticoagulant|BIOENTITY may_BE12 cause_BE12 increase_BE12 prothrombin_BE12 response_BE12 by_BE12 displace_BE12 the_BE12 BIOENTITY from_RE2 protein_RE2 binding_RE2 site_RE2 or_RE2 diminish_RE2 prothrombin_RE2 response_RE2 through_RE2 increase_RE2 metabolism_RE2 of_RE2 the_RE2 unbound_RE2 drug_RE2 by_RE2 hepatic_RE2 enzyme_RE2 induction_RE2 thus_RE2 lead_RE2 to_RE2 inter-patient_RE2 variation_RE2 in_RE2 ultimate_RE2 prothrombin_RE2 effect_RE2 
Anisindione_ddi|P|anticoagulant|adrenocortical steroid|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOENTITY 
Anisindione_ddi|P|anticoagulant|chlordiazepoxide|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|chloral hydrate|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|vitamin k|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|cholestyramine|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|diuretic|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|glutethimide|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|ethchlorvynol|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|warfarin sodium|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 unreliable_BE12 prothrombin_BE12 time_BE12 determination_BE12 BIOGENERAL_BE12 BIOENTITY under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|haloperidol|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|griseofulvin|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|rifampin|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|contraceptive|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|vitamin c|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 unreliable_BE12 prothrombin_BE12 time_BE12 determination_BE12 BIOENTITY BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|meprobamate|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|primidone|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|paraldehyde|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|ranitidine|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 diet_BE12 high_BE12 in_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|adrenocortical steroid|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|alcohol|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|barbiturate|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|carbamazepine|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|antacid|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|antihistamine|drug_LE1 that_LE1 have_LE1 be_LE1 report_LE1 to_LE1 diminish_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 decrease_BE12 prothrom-bin_BE12 time_BE12 response_BE12 in_BE12 man_BE12 significant_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 diet_RE2 high_RE2 in_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 under-dosage_RE2 
Anisindione_ddi|P|anticoagulant|alcohol|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 BIOENTITY 
Anisindione_ddi|P|anticoagulant|pyrazolone|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|quinidine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|quinine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|ranitidine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|salicylate|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|sulfinpyrazone|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|sulindac|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|sulfonamide|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|tolbutamide|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|thyroid drug|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|clofibrate|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|cinchophen|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|cimetidine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|trimethoprim|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|trimethoprim|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|triclofos sodium|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|warfarin sodium|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 long_BE12 act_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 unreliable_BE12 prothrombin_BE12 time_BE12 determination_BE12 BIOENTITY overdosage_RE2 
Anisindione_ddi|P|anticoagulant|diazoxide|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|diflunisal|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOENTITY BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|dextran|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|dextrothyroxine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|fenoprofen|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|disulfiram|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOENTITY drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|ethacrynic acid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|ibuprofen|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|glucagon|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|influenza virus vaccine|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|indomethacin|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|metronidazole|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|miconazole|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|anesthetic|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|mefenamic acid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|methyldopa|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|methylphenidate|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|oxyphenbutazone|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|oxolinic acid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|naproxen|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|nalidixic acid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|monoamine oxidase inhibitor|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|anabolic steroid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|antibiotic|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|aminosalicylic acid|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|amiodarone|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|alcohol|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|allopurinol|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|prolonged narcotic|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 prolonged_BE12 hot_BE12 weather_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|chlorpropamide|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|phenyramidol|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|chymotrypsin|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|phenytoin|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|bromelain|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|pentoxifylline|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|chloral hydrate|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 dietary_RE2 deficiency_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 drug_RE2 affect_RE2 blood_RE2 element_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 hepatotoxic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 inhalation_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|phenylbutazone|drug_LE1 that_LE1 reported_LE1 may_LE1 increase_LE1 oral_LE1 BIOENTITY response_BE12 ie_BE12 increase_BE12 prothrombin_BE12 response_BE12 in_BE12 man_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 dietary_BE12 deficiency_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 drug_BE12 affect_BE12 blood_BE12 element_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 hepatotoxic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 inhalation_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 prolonged_RE2 hot_RE2 weather_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 long_RE2 act_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 unreliable_RE2 prothrombin_RE2 time_RE2 determination_RE2 BIOGENERAL_RE2 overdosage_RE2 
Anisindione_ddi|P|anticoagulant|chlorpropamide|oral_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 eg_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY by_RE2 inhibit_RE2 their_RE2 metabolism_RE2 in_RE2 the_RE2 liver_RE2 
Anisindione_ddi|P|anticoagulant|tolbutamide|oral_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 eg_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 by_RE2 inhibit_RE2 their_RE2 metabolism_RE2 in_RE2 the_RE2 liver_RE2 
Anisindione_ddi|P|anticoagulant|hypoglycemic agent|oral_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY eg_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 by_RE2 inhibit_RE2 their_RE2 metabolism_RE2 in_RE2 the_RE2 liver_RE2 
Anisindione_ddi|P|anticoagulant|phenytoin|because_LE1 oral_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOENTITY toxic_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 occur_RE2 when_RE2 oral_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concurrent_RE2 
Anisindione_ddi|P|anticoagulant|phenytoin|because_LE1 oral_LE1 BIOGENERAL_LE1 may_LE1 interfere_LE1 with_LE1 the_LE1 hepatic_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 toxic_LE1 level_LE1 of_LE1 the_LE1 BIOGENERAL_LE1 may_LE1 occur_LE1 when_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concurrent_RE2 
Anisindione_ddi|P|clofibrate|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|hydrochloroquine|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|dipyridamole|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|non-steroidal anti-inflammatory drug|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|aspirin|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|antineoplastic agent|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 or_BE12 drug_BE12 which_BE12 inhibit_BE12 platelet_BE12 function_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|dextran|anticoagulant|drug_LE1 that_LE1 reduce_LE1 the_LE1 number_LE1 of_LE1 blood_LE1 platelet_LE1 by_LE1 cause_LE1 bone_LE1 marrow_LE1 depression_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 drug_LE1 which_LE1 inhibit_LE1 platelet_LE1 function_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 increase_BE12 the_BE12 bleeding_BE12 tendency_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 alter_RE2 prothrombin_RE2 time_RE2 determination_RE2 
Anisindione_ddi|P|antiplatelet medication|anticoagulant medication|the_LE1 beneficial_LE1 effect_LE1 on_LE1 arterial_LE1 thrombus_LE1 formation_LE1 from_LE1 combined_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY must_RE2 be_RE2 weigh_RE2 against_RE2 increase_RE2 risk_RE2 of_RE2 inducing_RE2 hemorrhage_RE2 
Apomorphine_ddi|P|apomorphine|5ht3 antagonist clas|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOENTITY -LRB-_RE2 include_RE2 for_RE2 example_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|ondansetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY the_RE2 concomitant_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 drug_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 for_RE2 example_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|ondansetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 for_BE12 example_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|granisetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 for_BE12 example_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|dolasetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 for_BE12 example_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|palonosetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 for_BE12 example_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|apomorphine|alosetron|BIOGENERAL_LE1 :_LE1 Based_LE1 on_LE1 report_LE1 of_LE1 profound_LE1 hypotension_LE1 and_LE1 loss_LE1 of_LE1 consciousness_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 for_BE12 example_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 be_RE2 contraindicate_RE2 
Apomorphine_ddi|P|antihypertensive medication|vasodilator|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 following_LE1 adverse_LE1 event_LE1 be_LE1 experience_LE1 much_LE1 common_LE1 in_LE1 patient_LE1 receive_LE1 concomitant_LE1 BIOENTITY or_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 compared_RE2 to_RE2 patient_RE2 not_RE2 receive_RE2 these_RE2 concomitant_RE2 drug_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 :_RE2 hypotension_RE2 NUM_RE2 vs_RE2 NUM_RE2 myocardial_RE2 infarction_RE2 NUM_RE2 vs_RE2 NUM_RE2 serious_RE2 pneumonia_RE2 NUM_RE2 vs_RE2 NUM_RE2 serious_RE2 fall_RE2 NUM_RE2 vs_RE2 NUM_RE2 and_RE2 bone_RE2 and_RE2 joint_RE2 injury_RE2 NUM_RE2 vs_RE2 NUM_RE2 %._RE2 
Apomorphine_ddi|P|dopamine antagonist|metoclopramide|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOENTITY such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOENTITY may_RE2 diminish_RE2 the_RE2 effectiveness_RE2 of_RE2 BIOGENERAL_RE2 
Apomorphine_ddi|P|phenothiazine|apokyn|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Apomorphine_ddi|P|butyrophenone|apokyn|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Apomorphine_ddi|P|thioxanthene|apokyn|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Apomorphine_ddi|P|metoclopramide|apokyn|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 be_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 possible_LE1 that_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 the_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 effectiveness_BE12 of_BE12 BIOENTITY 
Apomorphine_ddi|P|neuroleptic|dopamine agonist|patient_LE1 with_LE1 major_LE1 psychotic_LE1 disorder_LE1 treat_LE1 with_LE1 BIOENTITY shall_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY only_RE2 if_RE2 the_RE2 potential_RE2 benefit_RE2 outweigh_RE2 the_RE2 risk_RE2 
Apraclonidine_ddi|P|apraclonidine|mao inhibitor|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY .._RE2 
Apraclonidine_ddi|P|iopidine|opiate|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|iopidine|barbiturate|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|iopidine|alcohol|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|iopidine|cns depressant|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|iopidine|sedative|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|iopidine|anesthetic|although_LE1 no_LE1 specific_LE1 drug_LE1 interaction_LE1 with_LE1 topical_LE1 glaucoma_LE1 drug_LE1 or_LE1 systemic_LE1 medication_LE1 be_LE1 identify_LE1 in_LE1 clinical_LE1 study_LE1 of_LE1 BIOENTITY NUM_BE12 ophthalmic_BE12 solution_BE12 the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Apraclonidine_ddi|P|tricyclic antidepressant|clonidine|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 blunt_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 systemic_BE12 BIOENTITY 
Apraclonidine_ddi|P|clonidine|neuroleptic|additive_LE1 hypotensive_LE1 effect_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 combination_LE1 of_LE1 systemic_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 
Apraclonidine_ddi|P|apraclonidine|cardiac glycoside|since_LE1 BIOENTITY may_BE12 reduce_BE12 pulse_BE12 and_BE12 blood_BE12 pressure_BE12 caution_BE12 in_BE12 use_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 ophthalmic_BE12 and_BE12 systemic_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY be_RE2 advised_RE2 
Apraclonidine_ddi|P|apraclonidine|antihypertensive|since_LE1 BIOENTITY may_BE12 reduce_BE12 pulse_BE12 and_BE12 blood_BE12 pressure_BE12 caution_BE12 in_BE12 use_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 ophthalmic_BE12 and_BE12 systemic_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 be_RE2 advised_RE2 
Apraclonidine_ddi|P|apraclonidine|beta-blocker|since_LE1 BIOENTITY may_BE12 reduce_BE12 pulse_BE12 and_BE12 blood_BE12 pressure_BE12 caution_BE12 in_BE12 use_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 ophthalmic_RE2 and_RE2 systemic_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 advised_RE2 
Aprepitant_ddi|P|aprepitant|s(-) warfarin|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 induce_BE12 the_BE12 metabolism_BE12 of_BE12 -LRB-_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 metabolize_RE2 through_RE2 cyp2c9_RE2 
Aprepitant_ddi|P|aprepitant|tolbutamide|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 induce_BE12 the_BE12 metabolism_BE12 of_BE12 -LRB-_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY which_RE2 be_RE2 metabolize_RE2 through_RE2 cyp2c9_RE2 
Aprepitant_ddi|P|aprepitant|phenytoin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 these_BE12 drug_BE12 or_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2c9_BE12 such_BE12 as_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 low_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 drug_RE2 
Aprepitant_ddi|P|aprepitant|dexamethasone|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY when_BE12 give_BE12 as_BE12 regimen_BE12 of_BE12 125mg_BE12 with_BE12 BIOENTITY coadminister_RE2 oral_RE2 as_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 BIOGENERAL_RE2 when_RE2 give_RE2 as_RE2 NUM_RE2 mg_RE2 with_RE2 BIOGENERAL_RE2 coadminister_RE2 oral_RE2 as_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 through_RE2 NUM_RE2 increase_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 cyp3a4_RE2 substrate_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|dexamethasone|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 when_LE1 give_LE1 as_LE1 regimen_LE1 of_LE1 125mg_LE1 with_LE1 BIOGENERAL_LE1 coadminister_LE1 oral_LE1 as_LE1 NUM_LE1 mg_LE1 on_LE1 day_LE1 NUM_LE1 and_LE1 BIOENTITY when_BE12 give_BE12 as_BE12 NUM_BE12 mg_BE12 with_BE12 BIOENTITY coadminister_RE2 oral_RE2 as_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 through_RE2 NUM_RE2 increase_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 cyp3a4_RE2 substrate_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 
Aprepitant_ddi|P|dexamethasone|aprepitant|the_LE1 oral_LE1 BIOENTITY dose_BE12 shall_BE12 be_BE12 reduce_BE12 by_BE12 approximate_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY to_RE2 achieve_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 similar_RE2 to_RE2 those_RE2 obtain_RE2 when_RE2 it_RE2 be_RE2 give_RE2 without_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|dexamethasone|aprepitant|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY administer_BE12 in_BE12 clinical_BE12 study_BE12 with_BE12 BIOENTITY reflect_RE2 approximate_RE2 NUM_RE2 reduction_RE2 of_RE2 the_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|aprepitant|methylprednisolone|BIOENTITY when_BE12 give_BE12 as_BE12 regimen_BE12 of_BE12 NUM_BE12 mg_BE12 on_BE12 day_BE12 NUM_BE12 and_BE12 NUM_BE12 mg_BE12 on_BE12 day_BE12 NUM_BE12 and_BE12 NUM_BE12 increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY cyp3a4_RE2 substrate_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 coadminister_RE2 intravenous_RE2 as_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 oral_RE2 as_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 
Aprepitant_ddi|P|methylprednisolone|aprepitant|the_LE1 iv_LE1 BIOGENERAL_LE1 dose_LE1 shall_LE1 be_LE1 reduce_LE1 by_LE1 approximate_LE1 NUM_LE1 and_LE1 the_LE1 oral_LE1 BIOENTITY dose_BE12 shall_BE12 be_BE12 reduce_BE12 by_BE12 approximate_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY to_RE2 achieve_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 similar_RE2 to_RE2 those_RE2 obtain_RE2 when_RE2 it_RE2 be_RE2 give_RE2 without_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|methylprednisolone|aprepitant|the_LE1 iv_LE1 BIOENTITY dose_BE12 shall_BE12 be_BE12 reduce_BE12 by_BE12 approximate_BE12 NUM_BE12 and_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 dose_BE12 shall_BE12 be_BE12 reduce_BE12 by_BE12 approximate_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY to_RE2 achieve_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 similar_RE2 to_RE2 those_RE2 obtain_RE2 when_RE2 it_RE2 be_RE2 give_RE2 without_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|s(-)warfarin|aprepitant|although_LE1 there_LE1 be_LE1 no_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 on_LE1 the_LE1 plasma_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 -RRB-_LE1 or_LE1 -LRB-_LE1 -RRB-_LE1 BIOGENERAL_LE1 determine_LE1 on_LE1 day_LE1 NUM_LE1 there_LE1 be_LE1 NUM_LE1 decrease_LE1 in_LE1 BIOENTITY -LRB-_BE12 -RRB-_BE12 -LRB-_BE12 cyp2c9_BE12 substrate_BE12 -RRB-_BE12 trough_BE12 concentration_BE12 accompany_BE12 by_BE12 NUM_BE12 decrease_BE12 in_BE12 the_BE12 prothrombin_BE12 time_BE12 -LRB-_BE12 report_BE12 as_BE12 international_BE12 normalize_BE12 ratio_BE12 or_BE12 inr_BE12 -RRB-_BE12 NUM_BE12 day_BE12 after_BE12 completion_BE12 of_BE12 dosing_BE12 with_BE12 BIOENTITY 
Aprepitant_ddi|P|warfarin|aprepitant|In_LE1 patient_LE1 on_LE1 chronic_LE1 BIOENTITY therapy_BE12 the_BE12 prothrombin_BE12 time_BE12 -LRB-_BE12 inr_BE12 -RRB-_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 in_BE12 the_BE12 NUM_BE12 period_BE12 particular_BE12 at_BE12 NUM_BE12 to_BE12 NUM_BE12 day_BE12 following_BE12 initiation_BE12 of_BE12 the_BE12 NUM_BE12 regimen_BE12 of_BE12 BIOENTITY with_RE2 each_RE2 chemotherapy_RE2 cycle_RE2 
Aprepitant_ddi|P|tolbutamide|aprepitant|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 when_LE1 give_LE1 as_LE1 NUM_LE1 mg_LE1 on_LE1 day_LE1 NUM_LE1 and_LE1 NUM_LE1 mg_LE1 on_LE1 day_LE1 NUM_LE1 and_LE1 NUM_LE1 decrease_LE1 the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 cyp2c9_LE1 substrate_LE1 -RRB-_LE1 by_LE1 NUM_LE1 on_LE1 day_LE1 NUM_LE1 NUM_LE1 on_LE1 day_LE1 NUM_LE1 and_LE1 NUM_LE1 on_LE1 day_LE1 NUM_LE1 when_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 be_BE12 adminus_BE12 stered_BE12 oral_BE12 prior_BE12 to_BE12 the_BE12 administration_BE12 of_BE12 the_BE12 NUM_BE12 regimen_BE12 of_BE12 BIOENTITY and_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|norethindrone|oral_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY when_BE12 give_BE12 once_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 as_BE12 NUM_BE12 capsule_BE12 with_BE12 oral_BE12 BIOGENERAL_BE12 contain_BE12 NUM_BE12 mcg_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 and_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 %;_RE2 
Aprepitant_ddi|P|aprepitant|ethinyl estradiol|oral_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY when_BE12 give_BE12 once_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 as_BE12 NUM_BE12 capsule_BE12 with_BE12 oral_BE12 BIOGENERAL_BE12 contain_BE12 NUM_BE12 mcg_BE12 of_BE12 BIOENTITY and_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 and_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 %;_RE2 
Aprepitant_ddi|P|contraceptive|aprepitant|therefore_LE1 the_LE1 efficacy_LE1 of_LE1 oral_LE1 BIOENTITY during_BE12 administration_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 reduce_RE2 
Aprepitant_ddi|P|aprepitant|contraceptive|although_LE1 NUM_LE1 regimen_LE1 of_LE1 BIOENTITY give_BE12 concomitant_BE12 with_BE12 oral_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 study_RE2 alternative_RE2 or_RE2 back-up_RE2 method_RE2 of_RE2 contraception_RE2 shall_RE2 be_RE2 use_RE2 
Aprepitant_ddi|P|aprepitant|midazolam|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY sensitive_RE2 cyp3a4_RE2 substrate_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 when_RE2 single_RE2 oral_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 be_RE2 coadminister_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 day_RE2 NUM_RE2 of_RE2 regimen_RE2 of_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 NUM_RE2 mg_RE2 on_RE2 day_RE2 NUM_RE2 through_RE2 NUM_RE2 
Aprepitant_ddi|P|midazolam|aprepitant|the_LE1 potential_LE1 effect_LE1 of_LE1 increase_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY or_BE12 other_BE12 BIOGENERAL_BE12 metabolize_BE12 via_BE12 cyp3a4_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 consider_BE12 when_BE12 coadminister_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Aprepitant_ddi|P|benzodiazepine|aprepitant|the_LE1 potential_LE1 effect_LE1 of_LE1 increase_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOENTITY metabolize_BE12 via_BE12 cyp3a4_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 consider_BE12 when_BE12 coadminister_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Aprepitant_ddi|P|alprazolam|aprepitant|the_LE1 potential_LE1 effect_LE1 of_LE1 increase_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 metabolize_LE1 via_LE1 cyp3a4_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 consider_BE12 when_BE12 coadminister_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Aprepitant_ddi|P|triazolam|aprepitant|the_LE1 potential_LE1 effect_LE1 of_LE1 increase_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 metabolize_LE1 via_LE1 cyp3a4_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 shall_BE12 be_BE12 consider_BE12 when_BE12 coadminister_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Aprepitant_ddi|P|aprepitant|midazolam|BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 and_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 relative_RE2 to_RE2 the_RE2 dosing_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 day_RE2 NUM_RE2 through_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|midazolam|BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOGENERAL_BE12 by_BE12 NUM_BE12 on_BE12 day_BE12 NUM_BE12 and_BE12 decrease_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 on_RE2 day_RE2 NUM_RE2 relative_RE2 to_RE2 the_RE2 dosing_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 day_RE2 NUM_RE2 through_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|nefazodone|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|troleandomycin|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|ketoconazole|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|itraconazole|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|nelfinavir|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|ritonavir|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|clarithromycin|consequent_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|diltiazem|aprepitant|because_LE1 moderate_LE1 cyp3a4_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 result_BE12 in_BE12 NUM_BE12 increase_BE12 in_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY concomitant_RE2 administration_RE2 shall_RE2 also_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Aprepitant_ddi|P|aprepitant|rifampin|therefore_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 strong_BE12 induce_BE12 cyp3a4_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 reduce_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 that_RE2 may_RE2 result_RE2 in_RE2 decrease_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|aprepitant|phenytoin|therefore_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 strong_BE12 induce_BE12 cyp3a4_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 may_RE2 result_RE2 in_RE2 reduce_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 that_RE2 may_RE2 result_RE2 in_RE2 decrease_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|aprepitant|aprepitant|therefore_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 strong_BE12 induce_BE12 cyp3a4_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 result_BE12 in_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY that_RE2 may_RE2 result_RE2 in_RE2 decrease_RE2 efficacy_RE2 of_RE2 BIOGENERAL_RE2 
Aprepitant_ddi|P|aprepitant|ketoconazole|BIOGENERAL_LE1 :_LE1 when_LE1 single_LE1 NUM_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 administer_BE12 on_BE12 day5_BE12 of_BE12 NUM_BE12 regimen_BE12 of_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY strong_RE2 cyp3a4_RE2 inhibitor_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 increase_RE2 approximate_RE2 NUM_RE2 and_RE2 the_RE2 mean_RE2 terminal_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 increase_RE2 approximate_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|rifampin|BIOGENERAL_LE1 :_LE1 when_LE1 single_LE1 NUM_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 administer_BE12 on_BE12 day9_BE12 of_BE12 NUM_BE12 regimen_BE12 of_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY strong_RE2 cyp3a4_RE2 inducer_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 decrease_RE2 approximate_RE2 NUM_RE2 and_RE2 the_RE2 mean_RE2 terminal_RE2 half-life_RE2 decrease_RE2 approximate_RE2 NUM_RE2 
Aprepitant_ddi|P|aprepitant|diltiazem|BIOGENERAL_LE1 :_LE1 In_LE1 patient_LE1 with_LE1 mild_LE1 to_LE1 moderate_LE1 hypertension_LE1 administration_LE1 of_LE1 BIOENTITY once_BE12 daily_BE12 as_BE12 tablet_BE12 formulation_BE12 comparable_BE12 to_BE12 NUM_BE12 mg_BE12 of_BE12 the_BE12 capsule_BE12 formulation_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 NUM_RE2 time_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 of_RE2 BIOGENERAL_RE2 auc_RE2 and_RE2 simultaneous_RE2 NUM_RE2 increase_RE2 of_RE2 BIOGENERAL_RE2 auc_RE2 
Aprepitant_ddi|P|aprepitant|paroxetine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 once_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY as_BE12 tablet_BE12 formulation_BE12 comparable_BE12 to_BE12 NUM_BE12 mg_BE12 or_BE12 NUM_BE12 mg_BE12 of_BE12 the_BE12 capsule_BE12 formulation_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 once_RE2 daily_RE2 result_RE2 in_RE2 decrease_RE2 in_RE2 auc_RE2 by_RE2 approximate_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 approximate_RE2 NUM_RE2 of_RE2 both_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Arbutamine_ddi|P|beta-adrenergic blocking agent|arbutamine|BIOENTITY shall_BE12 be_BE12 withdraw_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 before_BE12 conduct_BE12 BIOENTITY stress_RE2 test_RE2 
Ardeparin_ddi|P|anticoagulant|ardeparin|BIOENTITY including_BE12 coumarin_BE12 derivative_BE12 indandione_BE12 derivative_BE12 and_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Ardeparin_ddi|P|nsaid|ardeparin|BIOGENERAL_LE1 including_LE1 coumarin_LE1 derivative_LE1 indandione_LE1 derivative_LE1 and_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Ardeparin_ddi|P|aspirin|ardeparin|BIOGENERAL_LE1 including_LE1 coumarin_LE1 derivative_LE1 indandione_LE1 derivative_LE1 and_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Ardeparin_ddi|P|platelet aggregation inhibitor|ardeparin|BIOGENERAL_LE1 including_LE1 coumarin_LE1 derivative_LE1 indandione_LE1 derivative_LE1 and_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Ardeparin_ddi|P|nonsteroidal anti-inflammatory drug|ardeparin|BIOGENERAL_LE1 including_LE1 coumarin_LE1 derivative_LE1 indandione_LE1 derivative_LE1 and_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 bleeding_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Arformoterol_ddi|P|adrenergic drug|brovana|if_LE1 additional_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 administer_BE12 by_BE12 any_BE12 route_BE12 they_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 because_BE12 the_BE12 pharmacological_BE12 predictable_BE12 sympathetic_BE12 effect_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 potentiate_RE2 
Arformoterol_ddi|P|diuretic|adrenergic agonist|concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY may_BE12 potentiate_BE12 any_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Arformoterol_ddi|P|methylxanthine|adrenergic agonist|concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 any_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Arformoterol_ddi|P|aminophylline|adrenergic agonist|concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 any_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Arformoterol_ddi|P|theophylline|adrenergic agonist|concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 any_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Arformoterol_ddi|P|steroid|adrenergic agonist|concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 any_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Arformoterol_ddi|P|non-potassium sparing diuretic|beta-agonist|the_LE1 ecg_LE1 change_LE1 and_LE1 hypokalemia_LE1 that_LE1 may_LE1 result_LE1 from_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 can_BE12 be_BE12 acute_BE12 worsen_BE12 by_BE12 BIOENTITY especial_RE2 when_RE2 the_RE2 recommend_RE2 dose_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 exceed_RE2 
Arformoterol_ddi|P|loop diuretic|beta-agonist|the_LE1 ecg_LE1 change_LE1 and_LE1 hypokalemia_LE1 that_LE1 may_LE1 result_LE1 from_LE1 the_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 can_BE12 be_BE12 acute_BE12 worsen_BE12 by_BE12 BIOENTITY especial_RE2 when_RE2 the_RE2 recommend_RE2 dose_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 exceed_RE2 
Arformoterol_ddi|P|thiazide diuretic|beta-agonist|the_LE1 ecg_LE1 change_LE1 and_LE1 hypokalemia_LE1 that_LE1 may_LE1 result_LE1 from_LE1 the_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 can_BE12 be_BE12 acute_BE12 worsen_BE12 by_BE12 BIOENTITY especial_RE2 when_RE2 the_RE2 recommend_RE2 dose_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 exceed_RE2 
Arformoterol_ddi|P|beta-agonist|non-potassium sparing diuretic|although_LE1 the_LE1 clinical_LE1 significance_LE1 of_LE1 these_LE1 effect_LE1 be_LE1 not_LE1 know_LE1 caution_LE1 be_LE1 advise_LE1 in_LE1 the_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY 
Arformoterol_ddi|P|monoamine oxidase inhibitor|adrenergic agonist|BIOGENERAL_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 administer_LE1 with_LE1 extreme_LE1 caution_LE1 to_LE1 patient_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qtc_BE12 interval_BE12 because_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|beta2-agonist|tricyclic antidepressant|BIOGENERAL_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 drug_RE2 know_RE2 to_RE2 prolong_RE2 the_RE2 qtc_RE2 interval_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|tricyclic antidepressant|adrenergic agonist|BIOGENERAL_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 administer_LE1 with_LE1 extreme_LE1 caution_LE1 to_LE1 patient_LE1 be_LE1 treat_LE1 with_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qtc_BE12 interval_BE12 because_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|brovana|monoamine oxidase inhibitor|BIOENTITY as_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 drug_RE2 know_RE2 to_RE2 prolong_RE2 the_RE2 qtc_RE2 interval_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|beta2-agonist|monoamine oxidase inhibitor|BIOGENERAL_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 drug_RE2 know_RE2 to_RE2 prolong_RE2 the_RE2 qtc_RE2 interval_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|brovana|tricyclic antidepressant|BIOENTITY as_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 drug_RE2 know_RE2 to_RE2 prolong_RE2 the_RE2 qtc_RE2 interval_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Arformoterol_ddi|P|beta-blocker|brovana|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY may_RE2 interfere_RE2 with_RE2 the_RE2 effect_RE2 of_RE2 each_RE2 other_RE2 when_RE2 administer_RE2 concurrent_RE2 
Arformoterol_ddi|P|beta-adrenergic receptor antagonist|brovana|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY may_RE2 interfere_RE2 with_RE2 the_RE2 effect_RE2 of_RE2 each_RE2 other_RE2 when_RE2 administer_RE2 concurrent_RE2 
Arformoterol_ddi|P|beta-blocker|beta-agonist|BIOENTITY not_BE12 only_BE12 block_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY but_RE2 may_RE2 produce_RE2 severe_RE2 bronchospasm_RE2 in_RE2 copd_RE2 patient_RE2 
Argatroban_ddi|P|argatroban|warfarin|however_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 initial_RE2 oral_RE2 dose_RE2 follow_RE2 by_RE2 NUM_RE2 mg_RE2 oral_RE2 for_RE2 NUM_RE2 day_RE2 -RRB-_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 the_RE2 prothrombin_RE2 time_RE2 -LRB-_RE2 pt_RE2 -RRB-_RE2 and_RE2 international_RE2 normalize_RE2 ratio_RE2 -LRB-_RE2 inr-rrb-._RE2 
Argatroban_ddi|P|argatroban|antiplatelet agent|co-administration_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Argatroban_ddi|P|argatroban|thrombolytic|co-administration_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Argatroban_ddi|P|argatroban|anticoagulant|co-administration_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Aripiprazole_ddi|P|abilify|centrally acting drug|drug-drug_LE1 interaction_LE1 Given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Aripiprazole_ddi|P|abilify|alcohol|drug-drug_LE1 interaction_LE1 Given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Aripiprazole_ddi|P|aripiprazole|antihypertensive agent|NUM_LE1 adrenergic_LE1 receptor_LE1 antagonism_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 certain_BE12 BIOENTITY 
Aripiprazole_ddi|P|carbamazepine|aripiprazole|agent_LE1 that_LE1 induce_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 can_BE12 cause_BE12 increase_BE12 in_BE12 BIOENTITY clearance_RE2 and_RE2 low_RE2 blood_RE2 level_RE2 
Aripiprazole_ddi|P|paroxetine|aripiprazole|inhibitor_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 cyp2d6_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 can_BE12 inhibit_BE12 BIOENTITY elimination_RE2 and_RE2 cause_RE2 increase_RE2 blood_RE2 level_RE2 
Aripiprazole_ddi|P|quinidine|aripiprazole|inhibitor_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 cyp2d6_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 can_BE12 inhibit_BE12 BIOENTITY elimination_RE2 and_RE2 cause_RE2 increase_RE2 blood_RE2 level_RE2 
Aripiprazole_ddi|P|fluoxetine|aripiprazole|inhibitor_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 or_LE1 cyp2d6_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 can_BE12 inhibit_BE12 BIOENTITY elimination_RE2 and_RE2 cause_RE2 increase_RE2 blood_RE2 level_RE2 
Aripiprazole_ddi|P|ketoconazole|aripiprazole|inhibitor_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 or_BE12 cyp2d6_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 can_BE12 inhibit_BE12 BIOENTITY elimination_RE2 and_RE2 cause_RE2 increase_RE2 blood_RE2 level_RE2 
Aripiprazole_ddi|P|ketoconazole|aripiprazole|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 with_BE12 NUM_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY increase_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 active_RE2 metabolite_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Aripiprazole_ddi|P|ketoconazole|aripiprazole|when_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY occur_RE2 BIOGENERAL_RE2 dose_RE2 shall_RE2 be_RE2 reduce_RE2 to_RE2 one-half_RE2 of_RE2 its_RE2 normal_RE2 dose_RE2 
Aripiprazole_ddi|P|aripiprazole|quinidine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 NUM_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 for_RE2 NUM_RE2 day_RE2 -RRB-_RE2 potent_RE2 inhibitor_RE2 of_RE2 cyp2d6_RE2 increase_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 but_RE2 decrease_RE2 the_RE2 auc_RE2 of_RE2 its_RE2 active_RE2 metabolite_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 %._RE2 
Aripiprazole_ddi|P|quinidine|aripiprazole|BIOGENERAL_LE1 dose_LE1 shall_LE1 be_LE1 reduce_LE1 to_LE1 one-half_LE1 of_LE1 its_LE1 normal_LE1 dose_LE1 when_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY occur_RE2 
Aripiprazole_ddi|P|carbamazepine|aripiprazole|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 -RRB-_BE12 potent_BE12 cyp3a4_BE12 inducer_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 cmax_RE2 and_RE2 auc_RE2 value_RE2 of_RE2 both_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 active_RE2 metabolite_RE2 BIOGENERAL_RE2 
Aripiprazole_ddi|P|carbamazepine|aripiprazole|when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 BIOENTITY therapy_RE2 BIOGENERAL_RE2 dose_RE2 shall_RE2 be_RE2 double_RE2 
Aripiprazole_ddi|P|carbamazepine|aripiprazole|when_LE1 BIOENTITY be_BE12 withdraw_BE12 from_BE12 the_BE12 combination_BE12 therapy_BE12 BIOENTITY dose_RE2 shall_RE2 then_RE2 be_RE2 reduce_RE2 
Aripiprazole_ddi|P|alcohol|abilify|as_LE1 with_LE1 many_LE1 psychoactive_LE1 medication_LE1 patient_LE1 shall_LE1 be_LE1 advise_LE1 to_LE1 avoid_LE1 BIOENTITY while_BE12 take_BE12 BIOENTITY 
Arsenic trioxide_ddi|P|trisenox|amphotericin b|caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 medication_BE12 that_BE12 can_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 -LRB-_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 lead_BE12 to_BE12 electrolyte_BE12 abnormality_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -rrb-._RE2 
Arsenic trioxide_ddi|P|trisenox|diuretic|caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 medication_BE12 that_BE12 can_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 -LRB-_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 lead_BE12 to_BE12 electrolyte_BE12 abnormality_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Arsenic trioxide_ddi|P|trisenox|thioridazine|caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 medication_BE12 that_BE12 can_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 -LRB-_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 or_RE2 lead_RE2 to_RE2 electrolyte_RE2 abnormality_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Arsenic trioxide_ddi|P|trisenox|antiarrhythmic|caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 other_BE12 medication_BE12 that_BE12 can_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 -LRB-_BE12 e.g._BE12 certain_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 lead_RE2 to_RE2 electrolyte_RE2 abnormality_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Asparaginase_ddi|P|elspar|methotrexate|tissue_LE1 culture_LE1 and_LE1 animal_LE1 study_LE1 indicate_LE1 that_LE1 BIOENTITY can_BE12 diminish_BE12 or_BE12 abolish_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY on_RE2 malignant_RE2 NUM_RE2 this_RE2 effect_RE2 on_RE2 BIOGENERAL_RE2 activity_RE2 persist_RE2 as_RE2 long_RE2 as_RE2 plasma_RE2 asparagine_RE2 level_RE2 be_RE2 suppress_RE2 
Asparaginase_ddi|P|methotrexate|elspar|these_LE1 result_LE1 will_LE1 seem_LE1 to_LE1 dictate_LE1 against_LE1 the_LE1 clinical_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 during_RE2 the_RE2 period_RE2 following_RE2 BIOGENERAL_RE2 therapy_RE2 when_RE2 plasma_RE2 asparagine_RE2 level_RE2 be_RE2 below_RE2 normal_RE2 
Aspirin_ddi|P|aspirin|probenecid|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Aspirin_ddi|P|aspirin|sulfinpyrazone|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Aspirin_ddi|P|aspirin|phenylbutazone|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Aspirin_ddi|P|alcohol|aspirin|BIOENTITY :_BE12 have_BE12 synergistic_BE12 effect_BE12 with_BE12 BIOENTITY in_RE2 cause_RE2 gastrointestinal_RE2 bleeding_RE2 
Aspirin_ddi|P|corticosteroid|aspirin|BIOENTITY :_BE12 concomitant_BE12 administration_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 ulceration_RE2 and_RE2 may_RE2 reduce_RE2 serum_RE2 salicylate_RE2 level_RE2 
Aspirin_ddi|P|oxyphenbutazone|aspirin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 possible_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 concomitant_BE12 administration_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 ulceration_RE2 
Aspirin_ddi|P|phenylbutazone|aspirin|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 possible_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 concomitant_BE12 administration_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 ulceration_RE2 
Aspirin_ddi|P|pyrazolone derivative|aspirin|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 possible_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 concomitant_BE12 administration_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 ulceration_RE2 
Aspirin_ddi|P|dipyrone|aspirin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 possible_LE1 BIOENTITY -RRB-_BE12 :_BE12 concomitant_BE12 administration_BE12 with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 ulceration_RE2 
Aspirin_ddi|P|aspirin|nonsteroidal anti-inflammatory|BIOGENERAL_LE1 agent_LE1 :_LE1 BIOENTITY be_BE12 contraindicate_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 hypersensitive_BE12 to_BE12 BIOENTITY agent_RE2 
Aspirin_ddi|P|phenobarbital|aspirin|BIOENTITY :_BE12 decrease_BE12 BIOENTITY effectiveness_RE2 by_RE2 enzyme_RE2 induction_RE2 
Aspirin_ddi|P|phenytoin|aspirin|BIOGENERAL_LE1 :_LE1 serum_LE1 BIOENTITY level_BE12 may_BE12 be_BE12 increase_BE12 by_BE12 BIOENTITY 
Aspirin_ddi|P|propranolol|aspirin|BIOENTITY :_BE12 may_BE12 decrease_BE12 BIOENTITY anti-inflammatory_RE2 action_RE2 by_RE2 compete_RE2 for_RE2 the_RE2 same_RE2 receptor_RE2 
Aspirin_ddi|P|aspirin|antacid|BIOGENERAL_LE1 :_LE1 enteric_LE1 coated_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY since_RE2 increase_RE2 in_RE2 the_RE2 ph_RE2 of_RE2 the_RE2 stomach_RE2 may_RE2 effect_RE2 the_RE2 enteric_RE2 coating_RE2 of_RE2 the_RE2 tablet_RE2 
Atenolol_ddi|P|reserpine|beta-blocking agent|catecholamine-depleting_LE1 drug_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Atenolol_ddi|P|calcium channel blocker|tenormin|BIOENTITY may_BE12 also_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Atenolol_ddi|P|beta blocker|clonidine|BIOENTITY may_BE12 exacerbate_BE12 the_BE12 rebound_BE12 hypertension_BE12 which_BE12 can_BE12 follow_BE12 the_BE12 withdrawal_BE12 of_BE12 BIOENTITY 
Atenolol_ddi|P|beta blocker|clonidine|if_LE1 the_LE1 two_LE1 drug_LE1 be_LE1 coadminister_LE1 the_LE1 BIOENTITY shall_BE12 be_BE12 withdraw_BE12 several_BE12 day_BE12 before_BE12 the_BE12 gradual_BE12 withdrawal_BE12 of_BE12 BIOENTITY 
Atenolol_ddi|P|beta blocker|clonidine|if_LE1 replace_LE1 BIOGENERAL_LE1 by_LE1 BIOGENERAL_LE1 therapy_LE1 the_LE1 introduction_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 delay_BE12 for_BE12 several_BE12 day_BE12 after_BE12 BIOENTITY administration_RE2 have_RE2 stop_RE2 
Atenolol_ddi|P|indomethacin|beta blocker|concomitant_LE1 use_LE1 of_LE1 prostaglandin_LE1 synthase_LE1 inhibiting_LE1 drug_LE1 eg_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Atomoxetine_ddi|P|strattera|albuterol|drug-drug_LE1 interaction_LE1 BIOGENERAL_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 systemically-administered_BE12 -LRB-_BE12 oral_BE12 or_BE12 intravenous_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 -RRB-_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 can_RE2 be_RE2 potentiate_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 heart_RE2 rate_RE2 and_RE2 blood_RE2 pressure_RE2 
Atomoxetine_ddi|P|strattera|fluoxetine|dosage_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 necessary_BE12 when_BE12 coadminister_BE12 with_BE12 cyp2d6_BE12 inhibitor_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Atomoxetine_ddi|P|strattera|paroxetine|dosage_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 necessary_BE12 when_BE12 coadminister_BE12 with_BE12 cyp2d6_BE12 inhibitor_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atomoxetine_ddi|P|strattera|quinidine|dosage_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 necessary_BE12 when_BE12 coadminister_BE12 with_BE12 cyp2d6_BE12 inhibitor_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Atomoxetine_ddi|P|paroxetine|atomoxetine|In_LE1 em_LE1 individual_LE1 treat_LE1 with_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY be_RE2 approximate_RE2 NUM_RE2 to_RE2 NUM_RE2 and_RE2 css_RE2 max_RE2 be_RE2 about_RE2 NUM_RE2 to_RE2 NUM_RE2 great_RE2 than_RE2 BIOGENERAL_RE2 alone_RE2 
Atomoxetine_ddi|P|fluoxetine|atomoxetine|In_LE1 em_LE1 individual_LE1 treat_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY the_BE12 auc_BE12 of_BE12 BIOENTITY be_RE2 approximate_RE2 NUM_RE2 to_RE2 NUM_RE2 and_RE2 css_RE2 max_RE2 be_RE2 about_RE2 NUM_RE2 to_RE2 NUM_RE2 great_RE2 than_RE2 BIOGENERAL_RE2 alone_RE2 
Atorvastatin_ddi|P|atorvastatin|maalox tc|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY suspension_RE2 be_RE2 coadminister_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 decrease_RE2 approximate_RE2 NUM_RE2 %._RE2 
Atorvastatin_ddi|P|colestipol|atorvastatin|BIOGENERAL_LE1 :_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 decrease_LE1 approximate_LE1 NUM_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Atorvastatin_ddi|P|atorvastatin|colestipol|however_LE1 ldl-c_LE1 reduction_LE1 be_LE1 great_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 than_RE2 when_RE2 either_RE2 drug_RE2 be_RE2 give_RE2 alone_RE2 
Atorvastatin_ddi|P|atorvastatin|digoxin|BIOGENERAL_LE1 :_LE1 when_LE1 multiple_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 steady-state_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 increase_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Atorvastatin_ddi|P|atorvastatin|erythromycin|BIOGENERAL_LE1 :_LE1 In_LE1 healthy_LE1 individual_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 increase_LE1 approximate_LE1 NUM_LE1 with_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY known_RE2 inhibitor_RE2 of_RE2 cytochrome_RE2 p450_RE2 3a4_RE2 
Atorvastatin_ddi|P|atorvastatin|ethinyl estradiol|oral_LE1 BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 oral_BE12 BIOGENERAL_BE12 increase_BE12 auc_BE12 value_BE12 for_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY by_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 %._RE2 
Atorvastatin_ddi|P|atorvastatin|norethindrone|oral_LE1 BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 oral_BE12 BIOGENERAL_BE12 increase_BE12 auc_BE12 value_BE12 for_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 by_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 %._RE2 
Atorvastatin_ddi|P|atorvastatin|contraceptive|oral_LE1 BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY increase_RE2 auc_RE2 value_RE2 for_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 by_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 %._RE2 
Atorvastatin_ddi|P|contraceptive|atorvastatin|these_LE1 increase_LE1 shall_LE1 be_LE1 consider_LE1 when_LE1 select_LE1 oral_LE1 BIOENTITY for_BE12 woman_BE12 take_BE12 BIOENTITY 
Atorvastatin_ddi|P|hmg-coa reductase inhibitor|spironolactone|caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 may_BE12 decrease_BE12 the_BE12 level_BE12 or_BE12 activity_BE12 of_BE12 endogenous_BE12 steroid_BE12 hormone_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Atorvastatin_ddi|P|hmg-coa reductase inhibitor|ketoconazole|caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 may_BE12 decrease_BE12 the_BE12 level_BE12 or_BE12 activity_BE12 of_BE12 endogenous_BE12 steroid_BE12 hormone_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atorvastatin_ddi|P|hmg-coa reductase inhibitor|cimetidine|caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 may_BE12 decrease_BE12 the_BE12 level_BE12 or_BE12 activity_BE12 of_BE12 endogenous_BE12 steroid_BE12 hormone_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Atovaquone_ddi|P|rifampin|mepron|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY suspension_RE2 result_RE2 in_RE2 significant_RE2 decrease_RE2 in_RE2 average_RE2 steady-_RE2 state_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 
Atovaquone_ddi|P|rifampin|mepron|alternative_LE1 to_LE1 BIOENTITY shall_BE12 be_BE12 consider_BE12 during_BE12 the_BE12 course_BE12 of_BE12 pcp_BE12 treatment_BE12 with_BE12 BIOENTITY 
Atracurium_ddi|P|tracrium|enflurane|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOENTITY 
Atracurium_ddi|P|tracrium|quinidine|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Atracurium_ddi|P|tracrium|procainamide|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|magnesium|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|polymyxin|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|lithium|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|antibiotic|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY especial_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|aminoglycoside|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 especial_BE12 the_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|isoflurane|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 especial_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|halothane|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 especial_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|tracrium|enflurane|drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY include_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 especial_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Atracurium_ddi|P|succinylcholine|tracrium|the_LE1 prior_LE1 administration_LE1 of_LE1 BIOENTITY do_BE12 not_BE12 enhance_BE12 the_BE12 duration_BE12 but_BE12 quicken_BE12 the_BE12 onset_BE12 and_BE12 may_BE12 increase_BE12 the_BE12 depth_BE12 of_BE12 neuromuscular_BE12 block_BE12 induce_BE12 by_BE12 BIOENTITY 
Atracurium_ddi|P|tracrium|succinylcholine|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 until_BE12 patient_BE12 have_BE12 recover_BE12 from_BE12 BIOENTITY neuromuscular_RE2 block_RE2 
Atropine_ddi|P|atropine|pralidoxime|when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 together_RE2 the_RE2 sign_RE2 of_RE2 atropinization_RE2 -LRB-_RE2 flush_RE2 mydriasis_RE2 tachycardia_RE2 dryness_RE2 of_RE2 the_RE2 mouth_RE2 and_RE2 nose_RE2 -RRB-_RE2 may_RE2 occur_RE2 early_RE2 than_RE2 may_RE2 be_RE2 expect_RE2 than_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 alone_RE2 because_RE2 BIOGENERAL_RE2 may_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Atropine_ddi|P|pralidoxime|atropine|when_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 together_LE1 the_LE1 sign_LE1 of_LE1 atropinization_LE1 -LRB-_LE1 flush_LE1 mydriasis_LE1 tachycardia_LE1 dryness_LE1 of_LE1 the_LE1 mouth_LE1 and_LE1 nose_LE1 -RRB-_LE1 may_LE1 occur_LE1 early_LE1 than_LE1 may_LE1 be_LE1 expect_LE1 than_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 alone_LE1 because_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Atropine_ddi|P|atropine|pralidoxime|the_LE1 following_LE1 precaution_LE1 shall_LE1 be_LE1 keep_LE1 in_LE1 mind_LE1 in_LE1 the_LE1 treatment_LE1 of_LE1 anticholinesterase_LE1 poisoning_LE1 although_LE1 they_LE1 do_LE1 not_LE1 bear_LE1 direct_LE1 on_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Atropine_ddi|P|barbiturate|anticholinesterase|since_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 the_BE12 BIOENTITY they_RE2 shall_RE2 be_RE2 use_RE2 cautious_RE2 in_RE2 the_RE2 treatment_RE2 of_RE2 convulsion_RE2 
Auranofin_ddi|P|auranofin|solganal|BIOENTITY shall_BE12 be_BE12 avoid_BE12 by_BE12 patient_BE12 with_BE12 history_BE12 of_BE12 serious_BE12 reaction_BE12 to_BE12 any_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Auranofin_ddi|P|auranofin|myochrysine|BIOENTITY shall_BE12 be_BE12 avoid_BE12 by_BE12 patient_BE12 with_BE12 history_BE12 of_BE12 serious_BE12 reaction_BE12 to_BE12 any_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Auranofin_ddi|P|auranofin|gold medication|BIOENTITY shall_BE12 be_BE12 avoid_BE12 by_BE12 patient_BE12 with_BE12 history_BE12 of_BE12 serious_BE12 reaction_BE12 to_BE12 any_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Auranofin_ddi|P|auranofin|cuprimine|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 together_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 another_RE2 arthritis_RE2 medication_RE2 
Auranofin_ddi|P|auranofin|depen|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 together_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 another_RE2 arthritis_RE2 medication_RE2 
Auranofin_ddi|P|auranofin|penicillamine|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 together_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 another_RE2 arthritis_RE2 medication_RE2 
Azatadine_ddi|P|mao inhibitor|antihistamine|BIOENTITY prolong_BE12 and_BE12 intensify_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Azatadine_ddi|P|antihistamine|central nervous system depressant|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY may_RE2 have_RE2 additive_RE2 effect_RE2 
Azatadine_ddi|P|antihistamine|barbiturate|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Azatadine_ddi|P|antihistamine|tricyclic antidepressant|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Azatadine_ddi|P|antihistamine|alcohol|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 
Azatadine_ddi|P|sympathomimetic drug|monoamine oxidase inhibitor|when_LE1 BIOENTITY be_BE12 give_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY hypertensive_RE2 reaction_RE2 including_RE2 hypertensive_RE2 crisis_RE2 may_RE2 occur_RE2 
Azatadine_ddi|P|mecamylamine|sympathomimetic|the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Azatadine_ddi|P|methyldopa|sympathomimetic|the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Azatadine_ddi|P|reserpine|sympathomimetic|the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Azatadine_ddi|P|veratrum alkaloid|sympathomimetic|the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Azatadine_ddi|P|beta-adrenergic blocking agent|sympathomimetic|BIOENTITY may_BE12 also_BE12 interact_BE12 with_BE12 BIOENTITY 
Azatadine_ddi|P|pseudoephedrine|digitali|increase_LE1 ectopic_LE1 pacemaker_LE1 activity_LE1 can_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Azatadine_ddi|P|pseudoephedrine|kaolin|BIOGENERAL_LE1 increase_LE1 the_LE1 rate_LE1 of_LE1 absorption_LE1 of_LE1 BIOENTITY while_BE12 BIOENTITY decrease_RE2 it_RE2 
Azatadine_ddi|P|antacid|pseudoephedrine|BIOENTITY increase_BE12 the_BE12 rate_BE12 of_BE12 absorption_BE12 of_BE12 BIOENTITY while_RE2 BIOGENERAL_RE2 decrease_RE2 it_RE2 
Azathioprine_ddi|P|azathioprine|allopurinol|use_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 principal_LE1 pathway_LE1 for_LE1 detoxification_LE1 of_LE1 BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Azathioprine_ddi|P|azathioprine|allopurinol|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 shall_RE2 have_RE2 dose_RE2 reduction_RE2 of_RE2 BIOGENERAL_RE2 to_RE2 approximate_RE2 NUM_RE2 to_RE2 NUM_RE2 the_RE2 usual_RE2 dose_RE2 
Azathioprine_ddi|P|angiotensin converting enzyme inhibitor|azathioprine|use_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY to_BE12 control_BE12 hypertension_BE12 in_BE12 patient_BE12 on_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 induce_RE2 severe_RE2 leukopenia_RE2 
Azithromycin_ddi|P|nelfinavir|azithromycin|co-administration_LE1 of_LE1 BIOENTITY at_BE12 steady-state_BE12 with_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 NUM_RE2 mg_RE2 tablet_RE2 -RRB-_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 serum_RE2 concentration_RE2 
Azithromycin_ddi|P|azithromycin|nelfinavir|although_LE1 dose_LE1 adjustment_LE1 of_LE1 BIOENTITY be_BE12 not_BE12 recommend_BE12 when_BE12 administer_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY close_RE2 monitoring_RE2 for_RE2 known_RE2 side_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 liver_RE2 enzyme_RE2 abnormality_RE2 and_RE2 hearing_RE2 impairment_RE2 be_RE2 warrant_RE2 
Azithromycin_ddi|P|azithromycin|warfarin|however_LE1 prudent_LE1 medical_LE1 practice_LE1 dictate_LE1 careful_LE1 monitoring_LE1 of_LE1 prothrombin_LE1 time_LE1 in_LE1 all_LE1 patient_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 
Azithromycin_ddi|P|macrolide|warfarin|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 clinical_RE2 practice_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 anticoagulant_RE2 effect_RE2 
Azithromycin_ddi|P|azithromycin|triazolam|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 intravenous_BE12 and_BE12 oral_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|trimethoprim|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 intravenous_BE12 and_BE12 oral_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|trimethoprim|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 intravenous_BE12 and_BE12 oral_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|rifabutin|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|zidovudine|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 intravenous_BE12 and_BE12 oral_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Azithromycin_ddi|P|azithromycin|sildenafil|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|indinavir|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|midazolam|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|efavirenz|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|fluconazole|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|theophylline|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|carbamazepine|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|atorvastatin|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|didanosine|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|azithromycin|cetirizine|when_LE1 use_LE1 in_LE1 therapeutic_LE1 dose_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 intravenous_RE2 and_RE2 oral_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azithromycin_ddi|P|efavirenz|azithromycin|co-administration_LE1 with_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOENTITY 
Azithromycin_ddi|P|fluconazole|azithromycin|co-administration_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY have_BE12 modest_BE12 effect_BE12 on_BE12 the_BE12 pharmacokinetic_BE12 of_BE12 BIOENTITY 
Azlocillin_ddi|P|azlocillin|netilmicin|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Azlocillin_ddi|P|azlocillin|gentamicin|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azlocillin_ddi|P|azlocillin|tobramycin|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Azlocillin_ddi|P|azlocillin|ciprofloxacin|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Azlocillin_ddi|P|azlocillin|amikacin|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Baclofen_ddi|P|baclofen|morphine|interaction_LE1 attribute_LE1 to_LE1 the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY injection_BE12 and_BE12 epidural_BE12 BIOENTITY include_RE2 hypotension_RE2 and_RE2 dyspnea_RE2 
Basiliximab_ddi|P|simulect|azathioprine|total_LE1 body_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 average_BE12 NUM_BE12 and_BE12 NUM_BE12 when_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 respective_RE2 be_RE2 add_RE2 to_RE2 regimen_RE2 consist_RE2 of_RE2 BIOGENERAL_RE2 usp_RE2 -LRB-_RE2 modified_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Basiliximab_ddi|P|simulect|mycophenolate mofetil|total_LE1 body_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 average_BE12 NUM_BE12 and_BE12 NUM_BE12 when_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY respective_RE2 be_RE2 add_RE2 to_RE2 regimen_RE2 consist_RE2 of_RE2 BIOGENERAL_RE2 usp_RE2 -LRB-_RE2 modified_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Benazepril_ddi|P|diuretic|lotensin|BIOGENERAL_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY especial_BE12 those_BE12 in_BE12 who_BE12 diuretic_BE12 therapy_BE12 be_BE12 recent_BE12 institute_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Benazepril_ddi|P|diuretic|lotensin|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 with_LE1 BIOGENERAL_LE1 can_LE1 be_LE1 minimize_LE1 by_LE1 either_LE1 discontinue_LE1 the_LE1 BIOENTITY or_BE12 increase_BE12 the_BE12 salt_BE12 intake_BE12 prior_BE12 to_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Benazepril_ddi|P|potassium-sparing diuretic|thiazide diuretic|BIOGENERAL_LE1 supplement_LE1 and_LE1 BIOENTITY lotensin_BE12 can_BE12 attenuate_BE12 potassium_BE12 loss_BE12 cause_BE12 by_BE12 BIOENTITY 
Benazepril_ddi|P|ace inhibitor|lithium|BIOGENERAL_LE1 :_LE1 increase_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 symptom_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY during_BE12 therapy_BE12 with_BE12 BIOENTITY 
Benazepril_ddi|P|diuretic|lithium|if_LE1 BIOENTITY be_BE12 also_BE12 use_BE12 the_BE12 risk_BE12 of_BE12 BIOENTITY toxicity_RE2 may_RE2 be_RE2 increase_RE2 
Benazepril_ddi|P|ace inhibitor|beta-adrenergic blocker|BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY have_BE12 have_BE12 little_BE12 than_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY presumable_RE2 because_RE2 both_RE2 drug_RE2 low_RE2 blood_RE2 pressure_RE2 by_RE2 inhibit_RE2 part_RE2 of_RE2 the_RE2 renin-angiotensin_RE2 system_RE2 
Benazepril_ddi|P|benazepril|beta-adrenergic blocker|BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 have_BE12 little_BE12 than_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY presumable_RE2 because_RE2 both_RE2 drug_RE2 low_RE2 blood_RE2 pressure_RE2 by_RE2 inhibit_RE2 part_RE2 of_RE2 the_RE2 renin-angiotensin_RE2 system_RE2 
Bendroflumethiazide_ddi|P|cholestyramine|thiazide diuretic|may_LE1 interact_LE1 with_LE1 the_LE1 following_LE1 :_LE1 BIOENTITY BIOGENERAL_BE12 -LRB-_BE12 use_BE12 with_BE12 BIOENTITY may_RE2 prevent_RE2 the_RE2 BIOGENERAL_RE2 from_RE2 working_RE2 proper_RE2 
Bendroflumethiazide_ddi|P|colestipol|thiazide diuretic|may_LE1 interact_LE1 with_LE1 the_LE1 following_LE1 :_LE1 BIOGENERAL_LE1 BIOENTITY -LRB-_BE12 use_BE12 with_BE12 BIOENTITY may_RE2 prevent_RE2 the_RE2 BIOGENERAL_RE2 from_RE2 working_RE2 proper_RE2 
Bentiromide_ddi|P|bentiromide|thiazide diuretic|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -containing_BE12 preparation_BE12 -LRB-_BE12 e.g._BE12 sunscreen_BE12 and_BE12 some_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 sulfa_BE12 medicine_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|para-aminobenzoic acid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|lidocaine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|multivitamin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -containing_BE12 preparation_BE12 -LRB-_BE12 e.g._BE12 sunscreen_BE12 and_BE12 some_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|paba|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|sulfonamide|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -containing_BE12 preparation_BE12 -LRB-_BE12 e.g._BE12 sunscreen_BE12 and_BE12 some_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|pronestyl|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -containing_BE12 preparation_BE12 -LRB-_BE12 e.g._BE12 sunscreen_BE12 and_BE12 some_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|procainamide|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -containing_BE12 preparation_BE12 -LRB-_BE12 e.g._BE12 sunscreen_BE12 and_BE12 some_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|tylenol|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 local_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|acetaminophen|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 local_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|chloromycetin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 local_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|chloramphenicol|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 local_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|benzocaine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Bentiromide_ddi|P|bentiromide|anesthetic|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 local_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 -containing_RE2 preparation_RE2 -LRB-_RE2 e.g._RE2 sunscreen_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 sulfa_RE2 medicine_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 use_RE2 of_RE2 these_RE2 medicine_RE2 during_RE2 the_RE2 test_RE2 period_RE2 will_RE2 affect_RE2 the_RE2 test_RE2 result_RE2 -RRB-_RE2 and_RE2 pancreatic_RE2 supplement_RE2 -LRB-_RE2 use_RE2 of_RE2 pancreatic_RE2 supplement_RE2 may_RE2 give_RE2 false_RE2 test_RE2 result_RE2 -rrb-._RE2 
Benzphetamine_ddi|P|sympathomimetic amine|monoamine oxidase inhibitor|hypertensive_LE1 crisis_LE1 have_LE1 result_LE1 when_LE1 BIOENTITY have_BE12 be_BE12 use_BE12 concomitant_BE12 within14_BE12 day_BE12 following_BE12 use_BE12 of_BE12 BIOENTITY 
Benzphetamine_ddi|P|didrex|cns stimulant|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 other_BE12 BIOENTITY 
Benzphetamine_ddi|P|amphetamine|antihypertensive|BIOENTITY may_BE12 decrease_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Benzphetamine_ddi|P|amphetamine|tricyclic antidepressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Benzphetamine_ddi|P|urinary acidifying|amphetamine|BIOENTITY agent_BE12 decrease_BE12 blood_BE12 level_BE12 and_BE12 increase_BE12 excretion_BE12 of_BE12 BIOENTITY 
Benzthiazide_ddi|P|benzthiazide|alcohol|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 allergy_RE2 cold_RE2 and_RE2 sinus_RE2 medicine_RE2 -RRB-_RE2 diabetic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|norepinephrine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 allergy_BE12 cold_BE12 and_BE12 sinus_BE12 medicine_BE12 -RRB-_BE12 diabetic_BE12 drug_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|lithium|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 allergy_BE12 cold_BE12 and_BE12 sinus_BE12 medicine_BE12 -RRB-_BE12 diabetic_BE12 drug_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|decongestant drug|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 allergy_RE2 cold_RE2 and_RE2 sinus_RE2 medicine_RE2 -RRB-_RE2 diabetic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|blood thinner|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 allergy_RE2 cold_RE2 and_RE2 sinus_RE2 medicine_RE2 -RRB-_RE2 diabetic_RE2 drug_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|ibuprofen|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 allergy_BE12 cold_BE12 and_BE12 sinus_BE12 medicine_BE12 -RRB-_BE12 diabetic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|aleve|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 allergy_BE12 cold_BE12 and_BE12 sinus_BE12 medicine_BE12 -RRB-_BE12 diabetic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 like_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Benzthiazide_ddi|P|benzthiazide|nsaid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 allergy_BE12 cold_BE12 and_BE12 sinus_BE12 medicine_BE12 -RRB-_BE12 diabetic_BE12 drug_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY like_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 high_RE2 pressure_RE2 medication_RE2 
Bepridil_ddi|P|bepridil hydrochloride|digoxin|BIOGENERAL_LE1 :_LE1 In_LE1 controlled_LE1 study_LE1 in_LE1 healthy_LE1 volunteer_LE1 BIOENTITY either_BE12 have_BE12 no_BE12 effect_BE12 -LRB-_BE12 one_BE12 study_BE12 -RRB-_BE12 or_BE12 be_BE12 associate_BE12 with_BE12 modest_BE12 increase_BE12 about_BE12 NUM_BE12 -LRB-_BE12 two_BE12 study_BE12 -RRB-_BE12 in_BE12 steady-state_BE12 serum_BE12 BIOENTITY concentration_RE2 
Bepridil_ddi|P|tricyclic anti-depressant|bepridil hydrochloride|BIOGENERAL_LE1 and_LE1 BIOENTITY can_BE12 exaggerate_BE12 the_BE12 prolongation_BE12 of_BE12 the_BE12 qt_BE12 interval_BE12 observe_BE12 with_BE12 BIOENTITY 
Bepridil_ddi|P|anti-arrhythmic|bepridil hydrochloride|BIOENTITY and_BE12 BIOGENERAL_BE12 can_BE12 exaggerate_BE12 the_BE12 prolongation_BE12 of_BE12 the_BE12 qt_BE12 interval_BE12 observe_BE12 with_BE12 BIOENTITY 
Bepridil_ddi|P|cardiac glycoside|bepridil hydrochloride|BIOENTITY can_BE12 exaggerate_BE12 the_BE12 depression_BE12 of_BE12 av_BE12 nodal_BE12 conduction_BE12 observe_BE12 with_BE12 BIOENTITY 
Betaxolol_ddi|P|reserpine|beta-blocking|catecholamine-depleting_LE1 drug_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY agent_RE2 
Betaxolol_ddi|P|beta-blocker|clonidine|shall_LE1 it_LE1 be_LE1 decide_LE1 to_LE1 discontinue_LE1 therapy_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concurrent_RE2 the_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 discontinue_RE2 slow_RE2 over_RE2 several_RE2 day_RE2 before_RE2 the_RE2 gradual_RE2 withdrawal_RE2 of_RE2 BIOGENERAL_RE2 
Betaxolol_ddi|P|beta-blocker|clonidine|shall_LE1 it_LE1 be_LE1 decide_LE1 to_LE1 discontinue_LE1 therapy_LE1 in_LE1 patient_LE1 receive_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 concurrent_LE1 the_LE1 BIOENTITY shall_BE12 be_BE12 discontinue_BE12 slow_BE12 over_BE12 several_BE12 day_BE12 before_BE12 the_BE12 gradual_BE12 withdrawal_BE12 of_BE12 BIOENTITY 
Betaxolol_ddi|P|calcium antagonist|beta-adrenergic blocking agent|literature_LE1 report_LE1 suggest_LE1 that_LE1 oral_LE1 BIOENTITY may_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY when_RE2 heart_RE2 function_RE2 be_RE2 normal_RE2 but_RE2 shall_RE2 be_RE2 avoid_RE2 in_RE2 patient_RE2 with_RE2 impaired_RE2 cardiac_RE2 function_RE2 
Betaxolol_ddi|P|beta-adrenergic blocking agent|calcium antagonist|hypotension_LE1 av_LE1 conduction_LE1 disturbance_LE1 and_LE1 left_LE1 ventricular_LE1 failure_LE1 have_LE1 be_LE1 report_LE1 in_LE1 some_LE1 patient_LE1 receive_LE1 BIOENTITY when_BE12 oral_BE12 BIOENTITY be_RE2 add_RE2 to_RE2 the_RE2 treatment_RE2 regimen_RE2 
Betaxolol_ddi|P|beta-blocker|epinephrine|risk_LE1 of_LE1 anaphylactic_LE1 reaction_LE1 :_LE1 although_LE1 it_LE1 be_LE1 know_LE1 that_LE1 patient_LE1 on_LE1 BIOENTITY may_BE12 be_BE12 refractory_BE12 to_BE12 BIOENTITY in_RE2 the_RE2 treatment_RE2 of_RE2 anaphylactic_RE2 shock_RE2 BIOGENERAL_RE2 can_RE2 in_RE2 addition_RE2 interfere_RE2 with_RE2 the_RE2 modulation_RE2 of_RE2 allergic_RE2 reaction_RE2 and_RE2 lead_RE2 to_RE2 increase_RE2 severity_RE2 and_RE2 frequency_RE2 of_RE2 attack_RE2 
Bexarotene_ddi|P|ketoconazole|bexarotene|on_LE1 the_LE1 basis_LE1 of_LE1 the_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 and_BE12 other_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 lead_BE12 to_BE12 increase_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|itraconazole|bexarotene|on_LE1 the_LE1 basis_LE1 of_LE1 the_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 and_BE12 other_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 lead_BE12 to_BE12 increase_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|erythromycin|bexarotene|on_LE1 the_LE1 basis_LE1 of_LE1 the_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 and_BE12 other_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 lead_BE12 to_BE12 increase_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|gemfibrozil|bexarotene|on_LE1 the_LE1 basis_LE1 of_LE1 the_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 by_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY grapefruit_BE12 juice_BE12 and_BE12 other_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 lead_BE12 to_BE12 increase_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|rifampin|bexarotene|furthermore_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 inducer_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 may_BE12 cause_BE12 reduction_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|phenobarbital|bexarotene|furthermore_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 other_BE12 inducer_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 may_BE12 cause_BE12 reduction_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|phenytoin|bexarotene|furthermore_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 other_BE12 inducer_BE12 of_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 may_BE12 cause_BE12 reduction_BE12 in_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Bexarotene_ddi|P|targretin|gemfibrozil|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY capsule_BE12 and_BE12 BIOENTITY result_RE2 in_RE2 substantial_RE2 increase_RE2 in_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 probable_RE2 at_RE2 little_RE2 partial_RE2 related_RE2 to_RE2 cytochrome_RE2 p450_RE2 3a4_RE2 inhibition_RE2 by_RE2 BIOGENERAL_RE2 
Bexarotene_ddi|P|gemfibrozil|targretin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY capsule_RE2 be_RE2 not_RE2 recommend_RE2 
Bezafibrate_ddi|P|bezalip retard|anticoagulants of the coumarin type|when_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 at_LE1 the_LE1 same_LE1 time_LE1 as_LE1 other_LE1 medicine_LE1 or_LE1 substance_LE1 the_LE1 follow_LE1 interaction_LE1 must_LE1 be_LE1 take_LE1 into_LE1 account_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Bezafibrate_ddi|P|bezalip|anticoagulants of the coumarin type|when_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 at_LE1 the_LE1 same_LE1 time_LE1 as_LE1 other_LE1 medicine_LE1 or_LE1 substance_LE1 the_LE1 follow_LE1 interaction_LE1 must_LE1 be_LE1 take_LE1 into_LE1 account_LE1 :_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Bezafibrate_ddi|P|anticoagulant|bezalip|For_LE1 this_LE1 reason_LE1 the_LE1 dose_LE1 of_LE1 the_LE1 BIOENTITY shall_BE12 be_BE12 reduce_BE12 by_BE12 NUM_BE12 NUM_BE12 at_BE12 the_BE12 start_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 retard_RE2 and_RE2 then_RE2 titrate_RE2 according_RE2 to_RE2 the_RE2 blood_RE2 clotting_RE2 parameter_RE2 
Bezafibrate_ddi|P|anticoagulant|bezalip|For_LE1 this_LE1 reason_LE1 the_LE1 dose_LE1 of_LE1 the_LE1 BIOENTITY shall_BE12 be_BE12 reduce_BE12 by_BE12 NUM_BE12 NUM_BE12 at_BE12 the_BE12 start_BE12 of_BE12 treatment_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY retard_RE2 and_RE2 then_RE2 titrate_RE2 according_RE2 to_RE2 the_RE2 blood_RE2 clotting_RE2 parameter_RE2 
Bezafibrate_ddi|P|sulphonylurea|bezalip retard|the_LE1 action_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 enhance_BE12 by_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bezafibrate_ddi|P|sulphonylurea|bezalip|the_LE1 action_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Bezafibrate_ddi|P|insulin|bezalip retard|the_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bezafibrate_ddi|P|insulin|bezalip|the_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Bezafibrate_ddi|P|immuno-suppressant|bezafibrate|In_LE1 isolate_LE1 case_LE1 pronounced_LE1 though_LE1 reversible_LE1 impairment_LE1 of_LE1 renal_LE1 function_LE1 -LRB-_LE1 accompany_LE1 by_LE1 corresponding_LE1 increase_LE1 in_LE1 the_LE1 serum_LE1 creatinine_LE1 level_LE1 -RRB-_LE1 have_LE1 be_LE1 report_LE1 in_LE1 organ_LE1 transplant_LE1 patient_LE1 receive_LE1 BIOENTITY therapy_BE12 and_BE12 concomitant_BE12 BIOENTITY 
Bezafibrate_ddi|P|bezalip|anion-exchange resin|when_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 interval_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 shall_RE2 be_RE2 maintain_RE2 between_RE2 the_RE2 two_RE2 medicine_RE2 since_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 be_RE2 impair_RE2 
Bezafibrate_ddi|P|bezalip|cholestryramine|when_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 interval_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 shall_RE2 be_RE2 maintain_RE2 between_RE2 the_RE2 two_RE2 medicine_RE2 since_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 be_RE2 impair_RE2 
Bezafibrate_ddi|P|bezalip retard|anion-exchange resin|when_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 interval_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 shall_RE2 be_RE2 maintain_RE2 between_RE2 the_RE2 two_RE2 medicine_RE2 since_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 be_RE2 impair_RE2 
Bezafibrate_ddi|P|bezalip retard|cholestryramine|when_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 interval_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 shall_RE2 be_RE2 maintain_RE2 between_RE2 the_RE2 two_RE2 medicine_RE2 since_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 be_RE2 impair_RE2 
Bezafibrate_ddi|P|perhexiline hydrogen maleate|bezalip|BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 with_BE12 hepatotoxic_BE12 potential_BE12 -RRB-_BE12 must_BE12 not_BE12 be_BE12 administer_BE12 together_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Bezafibrate_ddi|P|perhexiline hydrogen maleate|bezalip retard|BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 with_BE12 hepatotoxic_BE12 potential_BE12 -RRB-_BE12 must_BE12 not_BE12 be_BE12 administer_BE12 together_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bezafibrate_ddi|P|mao-inhibitor|bezalip|BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 with_BE12 hepatotoxic_BE12 potential_BE12 -RRB-_BE12 must_BE12 not_BE12 be_BE12 administer_BE12 together_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Bezafibrate_ddi|P|mao-inhibitor|bezalip retard|BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 with_BE12 hepatotoxic_BE12 potential_BE12 -RRB-_BE12 must_BE12 not_BE12 be_BE12 administer_BE12 together_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bicalutamide_ddi|P|casodex|coumarin anticoagulant|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 BIOENTITY can_BE12 displace_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 from_RE2 their_RE2 protein-binding_RE2 site_RE2 
Bicalutamide_ddi|P|coumarin anticoagulant|warfarin|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 BIOGENERAL_LE1 can_LE1 displace_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY from_RE2 their_RE2 protein-binding_RE2 site_RE2 
Bicalutamide_ddi|P|casodex|anticoagulant|it_LE1 be_LE1 recommend_LE1 that_LE1 if_LE1 BIOENTITY be_BE12 start_BE12 in_BE12 patient_BE12 already_BE12 receive_BE12 BIOGENERAL_BE12 prothrombin_BE12 time_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 and_BE12 adjustment_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 may_RE2 be_RE2 necessary_RE2 
Bicalutamide_ddi|P|casodex|coumarin anticoagulant|it_LE1 be_LE1 recommend_LE1 that_LE1 if_LE1 BIOENTITY be_BE12 start_BE12 in_BE12 patient_BE12 already_BE12 receive_BE12 BIOENTITY prothrombin_RE2 time_RE2 shall_RE2 be_RE2 close_RE2 monitor_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 dose_RE2 may_RE2 be_RE2 necessary_RE2 
Biperiden_ddi|P|akineton|narcotic analgesic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|meperidine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY the_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|quinidine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 the_BE12 BIOENTITY salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|antihistamine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 salt_BE12 and_BE12 BIOENTITY 
Biperiden_ddi|P|anticholinergic|tricyclic antidepressant|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|antiarrhythmic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|phenothiazine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|antipsychotic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|antipsychotic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|tricyclic antidepressant|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|phenothiazine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|antihistamine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 salt_BE12 and_BE12 BIOENTITY 
Biperiden_ddi|P|akineton|antiarrhythmic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|akineton|quinidine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOGENERAL_LE1 syndrome_LE1 can_LE1 occur_LE1 when_LE1 anticholinergic_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 the_BE12 BIOENTITY salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|meperidine|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY the_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Biperiden_ddi|P|anticholinergic|narcotic analgesic|drug_LE1 interaction_LE1 :_LE1 the_LE1 central_LE1 BIOENTITY syndrome_BE12 can_BE12 occur_BE12 when_BE12 anticholinergic_BE12 agent_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 drug_BE12 that_BE12 have_BE12 secondary_BE12 anticholinergic_BE12 action_BE12 e.g._BE12 certain_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 the_RE2 BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 
Bisoprolol_ddi|P|zebeta|beta-blocking agent|BIOENTITY shall_BE12 not_BE12 be_BE12 combine_BE12 with_BE12 other_BE12 BIOENTITY 
Bisoprolol_ddi|P|guanethidine|zebeta|patient_LE1 receive_LE1 catecholamine-depleting_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY shall_BE12 be_BE12 close_BE12 monitor_BE12 because_BE12 the_BE12 add_BE12 beta-adrenergic_BE12 block_BE12 action_BE12 of_BE12 BIOENTITY may_RE2 produce_RE2 excessive_RE2 reduction_RE2 of_RE2 sympathetic_RE2 activity_RE2 
Bisoprolol_ddi|P|reserpine|zebeta|patient_LE1 receive_LE1 catecholamine-depleting_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 because_BE12 the_BE12 add_BE12 beta-adrenergic_BE12 block_BE12 action_BE12 of_BE12 BIOENTITY may_RE2 produce_RE2 excessive_RE2 reduction_RE2 of_RE2 sympathetic_RE2 activity_RE2 
Bisoprolol_ddi|P|zebeta|clonidine|In_LE1 patient_LE1 receive_LE1 concurrent_LE1 therapy_LE1 with_LE1 BIOGENERAL_LE1 if_LE1 therapy_LE1 be_LE1 to_LE1 be_LE1 discontinue_LE1 it_LE1 be_LE1 suggest_LE1 that_LE1 BIOENTITY be_BE12 discontinue_BE12 for_BE12 several_BE12 day_BE12 before_BE12 the_BE12 withdrawal_BE12 of_BE12 BIOENTITY 
Bisoprolol_ddi|P|zebeta|disopyramide|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 class_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|myocardial depressant|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOENTITY or_RE2 inhibitor_RE2 of_RE2 av_RE2 conduction_RE2 such_RE2 as_RE2 certain_RE2 BIOGENERAL_RE2 -LRB-_RE2 particular_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|phenylalkylamine|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOENTITY BIOGENERAL_RE2 -rsb-_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|calcium antagonist|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOENTITY -LRB-_RE2 particular_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|benzothiazepine|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|verapamil|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY -rsb-_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|antiarrhythmic agent|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 class_BE12 -RRB-_BE12 or_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|zebeta|diltiazem|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 care_BE12 when_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 av_BE12 conduction_BE12 such_BE12 as_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 particular_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY -rsb-_RE2 class_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concurrent_RE2 
Bisoprolol_ddi|P|rifampin|zebeta|concurrent_LE1 use_LE1 of_LE1 BIOENTITY increase_BE12 the_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 shorten_RE2 elimination_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 
Bitolterol_ddi|P|bitolterol|steroid|if_LE1 you_LE1 be_LE1 also_LE1 use_LE1 BIOGENERAL_LE1 inhaler_LE1 take_LE1 BIOENTITY first_BE12 and_BE12 then_BE12 wait_BE12 about_BE12 NUM_BE12 minute_BE12 before_BE12 use_BE12 the_BE12 BIOENTITY inhaler_RE2 
Bitolterol_ddi|P|steroid|bitolterol|if_LE1 you_LE1 be_LE1 also_LE1 use_LE1 BIOENTITY inhaler_BE12 take_BE12 BIOENTITY first_RE2 and_RE2 then_RE2 wait_RE2 about_RE2 NUM_RE2 minute_RE2 before_RE2 use_RE2 the_RE2 BIOGENERAL_RE2 inhaler_RE2 
Bitolterol_ddi|P|bitolterol|steroid|this_LE1 allow_LE1 BIOENTITY to_BE12 open_BE12 air_BE12 passage_BE12 increase_BE12 the_BE12 effectiveness_BE12 of_BE12 the_BE12 BIOENTITY 
Bivalirudin_ddi|P|angiomax|thrombolytic|In_LE1 clinical_LE1 trial_LE1 in_LE1 patient_LE1 undergo_LE1 ptca_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 glycoprotein_RE2 iib_RE2 inhibitor_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 major_RE2 bleeding_RE2 event_RE2 compared_RE2 to_RE2 patient_RE2 not_RE2 receive_RE2 these_RE2 concomitant_RE2 medication_RE2 
Bivalirudin_ddi|P|angiomax|heparin|In_LE1 clinical_LE1 trial_LE1 in_LE1 patient_LE1 undergo_LE1 ptca_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 glycoprotein_RE2 iib_RE2 inhibitor_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 major_RE2 bleeding_RE2 event_RE2 compared_RE2 to_RE2 patient_RE2 not_RE2 receive_RE2 these_RE2 concomitant_RE2 medication_RE2 
Bivalirudin_ddi|P|angiomax|warfarin|In_LE1 clinical_LE1 trial_LE1 in_LE1 patient_LE1 undergo_LE1 ptca_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 glycoprotein_RE2 iib_RE2 inhibitor_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 major_RE2 bleeding_RE2 event_RE2 compared_RE2 to_RE2 patient_RE2 not_RE2 receive_RE2 these_RE2 concomitant_RE2 medication_RE2 
Bortezomib_ddi|P|antidiabetic agent|velcade|patient_LE1 on_LE1 oral_LE1 BIOENTITY receive_BE12 BIOENTITY treatment_RE2 may_RE2 require_RE2 close_RE2 monitoring_RE2 of_RE2 their_RE2 blood_RE2 glucose_RE2 level_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 dose_RE2 of_RE2 their_RE2 BIOGENERAL_RE2 
Bosentan_ddi|P|bosentan|ortho-novum|BIOGENERAL_LE1 Including_LE1 oral_LE1 injectable_LE1 transdermal_LE1 and_LE1 implantable_LE1 BIOGENERAL_LE1 :_LE1 interaction_LE1 study_LE1 demonstrate_LE1 that_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY produce_RE2 average_RE2 decrease_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 level_RE2 of_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Bosentan_ddi|P|hormonal contraceptive|tracleer|therefore_LE1 BIOENTITY including_BE12 oral_BE12 injectable_BE12 transdermal_BE12 and_BE12 implantable_BE12 form_BE12 may_BE12 not_BE12 be_BE12 reliable_BE12 when_BE12 BIOENTITY be_RE2 co-administered_RE2 
Bosentan_ddi|P|bosentan|cyclosporine a|steady-state_LE1 BIOENTITY plasma_BE12 concentration_BE12 be_BE12 NUM_BE12 to_BE12 NUM_BE12 high_BE12 than_BE12 in_BE12 the_BE12 absence_BE12 of_BE12 BIOENTITY 
Bosentan_ddi|P|bosentan|cyclosporine a|the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Bosentan_ddi|P|bosentan|cyclosporine a|co-administration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY -LRB-_RE2 cyp3a4_RE2 substrate_RE2 -RRB-_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Bosentan_ddi|P|tacrolimu|bosentan|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 marked_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 animal_RE2 
Bosentan_ddi|P|tacrolimu|bosentan|caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 together_RE2 
Bosentan_ddi|P|tracleer|glyburide|therefore_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 and_RE2 alternative_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Bosentan_ddi|P|bosentan|glyburide|co-administration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Bosentan_ddi|P|bosentan|hypoglycemic agent|BIOENTITY be_BE12 also_BE12 expect_BE12 to_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 other_BE12 oral_BE12 BIOENTITY that_RE2 be_RE2 predominant_RE2 metabolize_RE2 by_RE2 cyp2c9_RE2 or_RE2 cyp3a4_RE2 
Bosentan_ddi|P|bosentan|ketoconazole|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 b.i.d._BE12 and_BE12 BIOENTITY potent_RE2 cyp3a4_RE2 inhibitor_RE2 increase_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 approximate_RE2 NUM_RE2 
Bosentan_ddi|P|bosentan|simvastatin|BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY -LRB-_RE2 cyp3a4_RE2 substrate_RE2 -RRB-_RE2 and_RE2 its_RE2 active_RE2 -hydroxy_RE2 acid_RE2 metabolite_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Bosentan_ddi|P|bosentan|atorvastatin|BIOENTITY be_BE12 also_BE12 expect_BE12 to_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 that_BE12 have_BE12 significant_BE12 metabolism_BE12 by_BE12 cyp3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Bosentan_ddi|P|bosentan|lovastatin|BIOENTITY be_BE12 also_BE12 expect_BE12 to_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 that_BE12 have_BE12 significant_BE12 metabolism_BE12 by_BE12 cyp3a4_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Bosentan_ddi|P|bosentan|statin|BIOENTITY be_BE12 also_BE12 expect_BE12 to_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 other_BE12 BIOENTITY that_RE2 have_RE2 significant_RE2 metabolism_RE2 by_RE2 cyp3a4_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Bosentan_ddi|P|statin|tracleer|patient_LE1 use_LE1 cyp3a4_LE1 metabolized_LE1 BIOENTITY shall_BE12 have_BE12 cholesterol_BE12 level_BE12 monitor_BE12 after_BE12 BIOENTITY be_RE2 initiate_RE2 to_RE2 see_RE2 whether_RE2 the_RE2 BIOGENERAL_RE2 dose_RE2 need_RE2 adjustment_RE2 
Bosentan_ddi|P|bosentan|r-warfarin|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 b.i.d._BE12 for_BE12 NUM_BE12 day_BE12 decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 both_BE12 BIOGENERAL_BE12 -LRB-_BE12 cyp2c9_BE12 substrate_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 cyp3a4_RE2 substrate_RE2 -RRB-_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Bosentan_ddi|P|bosentan|s-warfarin|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 b.i.d._BE12 for_BE12 NUM_BE12 day_BE12 decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 both_BE12 BIOENTITY -LRB-_RE2 cyp2c9_RE2 substrate_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 cyp3a4_RE2 substrate_RE2 -RRB-_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Botulinum Toxin Type A_ddi|P|botox|curare-like compound|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 agent_BE12 interfere_BE12 with_BE12 neuromuscular_BE12 transmission_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 shall_RE2 only_RE2 be_RE2 perform_RE2 with_RE2 caution_RE2 as_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 potentiate_RE2 
Botulinum Toxin Type A_ddi|P|botox|aminoglycoside|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY or_RE2 other_RE2 agent_RE2 interfere_RE2 with_RE2 neuromuscular_RE2 transmission_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 only_RE2 be_RE2 perform_RE2 with_RE2 caution_RE2 as_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 potentiate_RE2 
Botulinum Toxin Type A_ddi|P|botulinum toxin|botulinum toxin|excessive_LE1 neuromuscular_LE1 weakness_LE1 may_LE1 be_LE1 exacerbated_LE1 by_LE1 administration_LE1 of_LE1 another_LE1 BIOENTITY prior_BE12 to_BE12 the_BE12 resolution_BE12 of_BE12 the_BE12 effect_BE12 of_BE12 previous_BE12 administer_BE12 BIOENTITY 
Botulinum Toxin Type B_ddi|P|myobloc|aminoglycoside|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY or_RE2 other_RE2 agent_RE2 interfere_RE2 with_RE2 neuromuscular_RE2 transmission_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 only_RE2 be_RE2 perform_RE2 with_RE2 caution_RE2 as_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 potentiate_RE2 
Botulinum Toxin Type B_ddi|P|myobloc|curare-like compound|co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 agent_BE12 interfere_BE12 with_BE12 neuromuscular_BE12 transmission_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 shall_RE2 only_RE2 be_RE2 perform_RE2 with_RE2 caution_RE2 as_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 potentiate_RE2 
Bretylium_ddi|P|digitali|bretylium tosylate|BIOENTITY toxicity_BE12 may_BE12 be_BE12 aggravate_BE12 by_BE12 the_BE12 initial_BE12 release_BE12 of_BE12 norepinephrine_BE12 cause_BE12 by_BE12 BIOENTITY injection_RE2 
Bretylium_ddi|P|catecholamine|bretylium tosylate|the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY 
Bretylium_ddi|P|dopamine|bretylium tosylate|the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY 
Bretylium_ddi|P|norepinephrine|bretylium tosylate|the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 enhance_BE12 by_BE12 BIOENTITY 
Brimonidine_ddi|P|alphagan p|cns depressant|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|alphagan p|barbiturate|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|alphagan p|alcohol|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|alphagan p|sedative|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|alphagan p|opiate|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|alphagan p|anesthetic|although_LE1 specific_LE1 drug_LE1 interaction_LE1 study_LE1 have_LE1 not_LE1 be_LE1 conduct_LE1 with_LE1 BIOENTITY the_BE12 possibility_BE12 of_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 consider_RE2 
Brimonidine_ddi|P|tricyclic antidepressant|clonidine|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 blunt_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 systemic_BE12 BIOENTITY be_RE2 not_RE2 know_RE2 whether_RE2 the_RE2 concurrent_RE2 use_RE2 of_RE2 these_RE2 agent_RE2 with_RE2 BIOGENERAL_RE2 in_RE2 human_RE2 can_RE2 lead_RE2 to_RE2 result_RE2 interference_RE2 with_RE2 the_RE2 iop_RE2 lowering_RE2 effect_RE2 
Brinzolamide_ddi|P|carbonic anhydrase inhibitor|salicylate|however_LE1 in_LE1 patient_LE1 treat_LE1 with_LE1 oral_LE1 BIOENTITY rare_BE12 instance_BE12 of_BE12 drug_BE12 interaction_BE12 have_BE12 occur_BE12 with_BE12 high-dose_BE12 BIOENTITY therapy_RE2 
Bromocriptine_ddi|P|alcohol|bromocriptine mesylate|the_LE1 risk_LE1 of_LE1 use_LE1 BIOGENERAL_LE1 in_LE1 combination_LE1 with_LE1 other_LE1 drug_LE1 have_LE1 not_LE1 be_LE1 systematic_LE1 evaluate_LE1 but_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 side_BE12 effect_BE12 of_BE12 BIOENTITY 
Bromocriptine_ddi|P|bromocriptine mesylate|dopamine antagonist|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 certain_RE2 other_RE2 agent_RE2 
Bromocriptine_ddi|P|bromocriptine mesylate|butyrophenone|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 certain_RE2 other_RE2 agent_RE2 
Bromocriptine_ddi|P|bromocriptine mesylate|haloperidol|compound_LE1 in_LE1 these_LE1 category_LE1 result_LE1 in_LE1 decrease_LE1 efficacy_LE1 of_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Bromocriptine_ddi|P|bromocriptine mesylate|phenothiazine|compound_LE1 in_LE1 these_LE1 category_LE1 result_LE1 in_LE1 decrease_LE1 efficacy_LE1 of_LE1 BIOENTITY :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Bromocriptine_ddi|P|bromocriptine mesylate|pimozide|compound_LE1 in_LE1 these_LE1 category_LE1 result_LE1 in_LE1 decrease_LE1 efficacy_LE1 of_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Bromocriptine_ddi|P|bromocriptine mesylate|metoclopramide|compound_LE1 in_LE1 these_LE1 category_LE1 result_LE1 in_LE1 decrease_LE1 efficacy_LE1 of_LE1 BIOENTITY :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Bromocriptine_ddi|P|bromocriptine mesylate|ergot alkaloid|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Brompheniramine_ddi|P|dexbrompheniramine|monoamine oxidase (mao) inhibitor|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 potentiate_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 either_BE12 these_BE12 medication_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 -LRB-_BE12 anticholinergic_BE12 effect_BE12 may_BE12 be_BE12 potentiate_BE12 when_BE12 these_BE12 medication_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Brompheniramine_ddi|P|dexbrompheniramine|anticholinergic|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 potentiate_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 either_BE12 these_BE12 medication_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Brompheniramine_ddi|P|dexbrompheniramine|cns depressant|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY -LRB-_RE2 may_RE2 potentiate_RE2 the_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 either_RE2 these_RE2 medication_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Brompheniramine_ddi|P|dexbrompheniramine|alcohol|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 potentiate_RE2 the_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 either_RE2 these_RE2 medication_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Budesonide_ddi|P|ketoconazole|budesonide|concomitant_LE1 oral_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 known_BE12 inhibitor_BE12 of_BE12 cyp3a4_BE12 activity_BE12 in_BE12 the_BE12 liver_BE12 and_BE12 in_BE12 the_BE12 intestinal_BE12 mucosa_BE12 -RRB-_BE12 cause_BE12 eight-fold_BE12 increase_BE12 of_BE12 the_BE12 systemic_BE12 exposure_BE12 to_BE12 oral_BE12 BIOENTITY 
Budesonide_ddi|P|indinavir|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Budesonide_ddi|P|saquinavir|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Budesonide_ddi|P|erythromycin|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Budesonide_ddi|P|ketoconazole|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Budesonide_ddi|P|intraconazole|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Budesonide_ddi|P|ritonavir|budesonide|if_LE1 treatment_LE1 with_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 be_BE12 indicate_BE12 reduction_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 shall_RE2 be_RE2 consider_RE2 
Bumetanide_ddi|P|bumetanide|aminoglycoside antibiotic|drug_LE1 with_LE1 ototoxic_LE1 potential_LE1 :_LE1 especial_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 impaired_LE1 renal_LE1 function_LE1 the_LE1 use_LE1 of_LE1 parenteral_LE1 administer_LE1 BIOENTITY in_BE12 patient_BE12 to_BE12 who_BE12 BIOENTITY be_RE2 also_RE2 be_RE2 give_RE2 shall_RE2 be_RE2 avoid_RE2 except_RE2 in_RE2 life-threatening_RE2 condition_RE2 
Bumetanide_ddi|P|lithium|diuretic|BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 general_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -RRB-_RE2 because_RE2 they_RE2 reduce_RE2 its_RE2 renal_RE2 clearance_RE2 and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Bumetanide_ddi|P|lithium|bumetanide|BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 general_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY -RRB-_RE2 because_RE2 they_RE2 reduce_RE2 its_RE2 renal_RE2 clearance_RE2 and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Bumetanide_ddi|P|probenecid|bumetanide|BIOGENERAL_LE1 :_LE1 pretreatment_LE1 with_LE1 BIOENTITY reduce_BE12 both_BE12 the_BE12 natriuresis_BE12 and_BE12 hyperreninemia_BE12 produce_BE12 by_BE12 BIOENTITY 
Bumetanide_ddi|P|probenecid|bumetanide|this_LE1 antagonistic_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 BIOENTITY natriuresis_RE2 be_RE2 not_RE2 due_RE2 to_RE2 direct_RE2 action_RE2 on_RE2 sodium_RE2 excretion_RE2 but_RE2 be_RE2 probable_RE2 secondary_RE2 to_RE2 its_RE2 inhibitory_RE2 effect_RE2 on_RE2 renal_RE2 tubular_RE2 secretion_RE2 of_RE2 BIOGENERAL_RE2 
Bumetanide_ddi|P|probenecid|bumetanide|thus_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Bumetanide_ddi|P|indomethacin|bumetanide|BIOGENERAL_LE1 :_LE1 BIOENTITY blunt_BE12 the_BE12 increase_BE12 in_BE12 urine_BE12 volume_BE12 and_BE12 sodium_BE12 excretion_BE12 see_BE12 during_BE12 BIOENTITY treatment_RE2 and_RE2 inhibit_RE2 the_RE2 BIOGENERAL_RE2 increase_RE2 in_RE2 plasma_RE2 renin_RE2 activity_RE2 
Bumetanide_ddi|P|indomethacin|bumetanide|BIOGENERAL_LE1 :_LE1 BIOENTITY blunt_BE12 the_BE12 increase_BE12 in_BE12 urine_BE12 volume_BE12 and_BE12 sodium_BE12 excretion_BE12 see_BE12 during_BE12 BIOGENERAL_BE12 treatment_BE12 and_BE12 inhibit_BE12 the_BE12 BIOENTITY increase_RE2 in_RE2 plasma_RE2 renin_RE2 activity_RE2 
Bumetanide_ddi|P|bumetanide|antihypertensive drug|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 various_BE12 BIOENTITY necessitate_RE2 reduction_RE2 in_RE2 the_RE2 dosage_RE2 of_RE2 these_RE2 drug_RE2 
Bupivacaine_ddi|P|epinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Bupivacaine_ddi|P|epinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Bupivacaine_ddi|P|norepinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Bupivacaine_ddi|P|norepinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Bupivacaine_ddi|P|butyrophenone|epinephrine|BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 reduce_BE12 or_BE12 reverse_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY 
Bupivacaine_ddi|P|phenothiazine|epinephrine|BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 or_BE12 reverse_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY 
Buprenorphine_ddi|P|buprenorphine|benzodiazepine|Based_LE1 on_LE1 anecdotal_LE1 report_LE1 there_LE1 may_LE1 be_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY 
Buprenorphine_ddi|P|buprenorphine|benzodiazepine|there_LE1 have_LE1 be_LE1 number_LE1 of_LE1 report_LE1 in_LE1 the_LE1 post-marketing_LE1 experience_LE1 of_LE1 coma_LE1 and_LE1 death_LE1 associate_LE1 with_LE1 the_LE1 concomitant_LE1 intravenous_LE1 misuse_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY by_RE2 addict_RE2 
Buprenorphine_ddi|P|subutex|benzodiazepine|BIOENTITY and_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 prescribe_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 on_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 act_RE2 on_RE2 the_RE2 central_RE2 nervous_RE2 system_RE2 regardless_RE2 of_RE2 whether_RE2 these_RE2 drug_RE2 be_RE2 take_RE2 on_RE2 the_RE2 advice_RE2 of_RE2 physician_RE2 or_RE2 be_RE2 take_RE2 as_RE2 drug_RE2 of_RE2 abuse_RE2 
Buprenorphine_ddi|P|suboxone|benzodiazepine|BIOGENERAL_LE1 and_LE1 BIOENTITY shall_BE12 be_BE12 prescribe_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 on_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 act_RE2 on_RE2 the_RE2 central_RE2 nervous_RE2 system_RE2 regardless_RE2 of_RE2 whether_RE2 these_RE2 drug_RE2 be_RE2 take_RE2 on_RE2 the_RE2 advice_RE2 of_RE2 physician_RE2 or_RE2 be_RE2 take_RE2 as_RE2 drug_RE2 of_RE2 abuse_RE2 
Buprenorphine_ddi|P|benzodiazepine|suboxone|patient_LE1 shall_LE1 be_LE1 warn_LE1 of_LE1 the_LE1 potential_LE1 danger_LE1 of_LE1 the_LE1 intravenous_LE1 self-administration_LE1 of_LE1 BIOENTITY while_BE12 under_BE12 treatment_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Buprenorphine_ddi|P|benzodiazepine|subutex|patient_LE1 shall_LE1 be_LE1 warn_LE1 of_LE1 the_LE1 potential_LE1 danger_LE1 of_LE1 the_LE1 intravenous_LE1 self-administration_LE1 of_LE1 BIOENTITY while_BE12 under_BE12 treatment_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bupropion_ddi|P|wellbutrin|orphenadrine|therefore_LE1 the_LE1 potential_LE1 exist_LE1 for_LE1 drug_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 affect_BE12 the_BE12 cyp2b6_BE12 isoenzyme_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Bupropion_ddi|P|wellbutrin|cyclophosphamide|therefore_LE1 the_LE1 potential_LE1 exist_LE1 for_LE1 drug_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 affect_BE12 the_BE12 cyp2b6_BE12 isoenzyme_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -rrb-._RE2 
Bupropion_ddi|P|bupropion|carbamazepine|while_LE1 not_LE1 systematic_LE1 study_LE1 certain_LE1 drug_LE1 may_LE1 induce_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Bupropion_ddi|P|bupropion|phenobarbital|while_LE1 not_LE1 systematic_LE1 study_LE1 certain_LE1 drug_LE1 may_LE1 induce_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Bupropion_ddi|P|bupropion|phenytoin|while_LE1 not_LE1 systematic_LE1 study_LE1 certain_LE1 drug_LE1 may_LE1 induce_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
Bupropion_ddi|P|bupropion|desipramine|In_LE1 study_LE1 of_LE1 NUM_LE1 male_LE1 subject_LE1 -LRB-_LE1 age_LE1 NUM_LE1 to_LE1 NUM_LE1 year_LE1 -RRB-_LE1 who_LE1 be_LE1 extensive_LE1 metabolizer_LE1 of_LE1 the_LE1 cyp2d6_LE1 isoenzyme_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY give_BE12 as_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 follow_BE12 by_BE12 single_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 BIOENTITY increase_RE2 the_RE2 cmax_RE2 auc_RE2 and_RE2 t1_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 average_RE2 of_RE2 approximate_RE2 NUM_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Bupropion_ddi|P|bupropion|flecainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|type 1c antiarrhythmic|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|propafenone|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|beta-blocker|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|metoprolol|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|imipramine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|desipramine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|antidepressant|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|thioridazine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|nortriptyline|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|sertraline|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|antipsychotic|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|paroxetine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|fluoxetine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|haloperidol|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|risperidone|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 isoenzyme_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 and_RE2 shall_RE2 be_RE2 initiate_RE2 at_RE2 the_RE2 low_RE2 end_RE2 of_RE2 the_RE2 dose_RE2 range_RE2 of_RE2 the_RE2 concomitant_RE2 medication_RE2 
Bupropion_ddi|P|bupropion|phenelzine|BIOGENERAL_LE1 :_LE1 study_LE1 in_LE1 animal_LE1 demonstrate_LE1 that_LE1 the_LE1 acute_LE1 toxicity_LE1 of_LE1 BIOENTITY be_BE12 enhance_BE12 by_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Bupropion_ddi|P|bupropion|levodopa|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 limited_LE1 clinical_LE1 datum_LE1 suggest_LE1 high_LE1 incidence_LE1 of_LE1 adverse_LE1 experience_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concurrent_BE12 with_BE12 either_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Bupropion_ddi|P|bupropion|amantadine|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 limited_LE1 clinical_LE1 datum_LE1 suggest_LE1 high_LE1 incidence_LE1 of_LE1 adverse_LE1 experience_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concurrent_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Bupropion_ddi|P|wellbutrin|levodopa|administration_LE1 of_LE1 BIOENTITY tablet_BE12 to_BE12 patient_BE12 receive_BE12 either_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 concurrent_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 use_RE2 small_RE2 initial_RE2 dose_RE2 and_RE2 small_RE2 gradual_RE2 dose_RE2 increase_RE2 
Bupropion_ddi|P|wellbutrin|amantadine|administration_LE1 of_LE1 BIOENTITY tablet_BE12 to_BE12 patient_BE12 receive_BE12 either_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY concurrent_RE2 shall_RE2 be_RE2 undertake_RE2 with_RE2 caution_RE2 use_RE2 small_RE2 initial_RE2 dose_RE2 and_RE2 small_RE2 gradual_RE2 dose_RE2 increase_RE2 
Bupropion_ddi|P|wellbutrin|steroid|drug_LE1 that_LE1 low_LE1 seizure_LE1 threshold_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 systemic_BE12 BIOENTITY etc._RE2 -RRB-_RE2 that_RE2 low_RE2 seizure_RE2 threshold_RE2 shall_RE2 be_RE2 undertake_RE2 only_RE2 with_RE2 extreme_RE2 caution_RE2 
Bupropion_ddi|P|wellbutrin|theophylline|drug_LE1 that_LE1 low_LE1 seizure_LE1 threshold_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY systemic_RE2 BIOGENERAL_RE2 etc._RE2 -RRB-_RE2 that_RE2 low_RE2 seizure_RE2 threshold_RE2 shall_RE2 be_RE2 undertake_RE2 only_RE2 with_RE2 extreme_RE2 caution_RE2 
Bupropion_ddi|P|wellbutrin|antidepressant|drug_LE1 that_LE1 low_LE1 seizure_LE1 threshold_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 systemic_RE2 BIOGENERAL_RE2 etc._RE2 -RRB-_RE2 that_RE2 low_RE2 seizure_RE2 threshold_RE2 shall_RE2 be_RE2 undertake_RE2 only_RE2 with_RE2 extreme_RE2 caution_RE2 
Bupropion_ddi|P|wellbutrin|antipsychotic|drug_LE1 that_LE1 low_LE1 seizure_LE1 threshold_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 systemic_RE2 BIOGENERAL_RE2 etc._RE2 -RRB-_RE2 that_RE2 low_RE2 seizure_RE2 threshold_RE2 shall_RE2 be_RE2 undertake_RE2 only_RE2 with_RE2 extreme_RE2 caution_RE2 
Bupropion_ddi|P|alcohol|wellbutrin|BIOGENERAL_LE1 :_LE1 In_LE1 post-marketing_LE1 experience_LE1 there_LE1 have_LE1 be_LE1 rare_LE1 report_LE1 of_LE1 adverse_LE1 neuropsychiatric_LE1 event_LE1 or_LE1 reduce_LE1 BIOGENERAL_LE1 tolerance_LE1 in_LE1 patient_LE1 who_LE1 be_LE1 drinking_LE1 BIOENTITY during_BE12 treatment_BE12 with_BE12 BIOENTITY 
Bupropion_ddi|P|alcohol|wellbutrin|the_LE1 consumption_LE1 of_LE1 BIOENTITY during_BE12 treatment_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 minimize_RE2 or_RE2 avoid_RE2 -LRB-_RE2 also_RE2 see_RE2 href=_RE2 bupropz_od.htm_RE2 ci_RE2 contraindication_RE2 -RRB-_RE2 
Buspirone_ddi|P|buspirone hydrochloride|mao inhibitor|it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY because_RE2 the_RE2 effect_RE2 of_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 many_RE2 other_RE2 BIOGENERAL_RE2 have_RE2 not_RE2 be_RE2 study_RE2 the_RE2 concomitant_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 other_RE2 cns-active_RE2 drug_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Buspirone_ddi|P|trazodone hydrochloride|buspirone hcl|there_LE1 be_LE1 one_LE1 report_LE1 suggest_LE1 that_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY may_RE2 have_RE2 cause_RE2 NUM_RE2 to_RE2 NUM_RE2 elevation_RE2 on_RE2 sgpt_RE2 -LRB-_RE2 alt_RE2 -RRB-_RE2 in_RE2 few_RE2 patient_RE2 
Buspirone_ddi|P|desyrel|buspirone hcl|there_LE1 be_LE1 one_LE1 report_LE1 suggest_LE1 that_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY may_RE2 have_RE2 cause_RE2 NUM_RE2 to_RE2 NUM_RE2 elevation_RE2 on_RE2 sgpt_RE2 -LRB-_RE2 alt_RE2 -RRB-_RE2 in_RE2 few_RE2 patient_RE2 
Buspirone_ddi|P|buspirone hcl|haloperidol|In_LE1 study_LE1 in_LE1 normal_LE1 volunteer_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 serum_RE2 BIOGENERAL_RE2 concentration_RE2 
Buspirone_ddi|P|buspirone|warfarin|however_LE1 there_LE1 have_LE1 be_LE1 one_LE1 report_LE1 of_LE1 prolonged_LE1 prothrombin_LE1 time_LE1 when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 the_BE12 regimen_BE12 of_BE12 patient_BE12 treat_BE12 with_BE12 BIOENTITY 
Buspirone_ddi|P|buspirone|digoxin|in_LE1 vitro_LE1 BIOENTITY may_BE12 displace_BE12 little_BE12 firm_BE12 bind_BE12 drug_BE12 like_BE12 BIOENTITY 
Busulfan_ddi|P|itraconazole|busulfan|BIOENTITY decrease_BE12 BIOENTITY clearance_RE2 by_RE2 up_RE2 to_RE2 NUM_RE2 and_RE2 may_RE2 produce_RE2 auc_RE2 NUM_RE2 min_RE2 in_RE2 some_RE2 patient_RE2 
Busulfan_ddi|P|phenytoin|busulfan|BIOENTITY increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 or_RE2 many_RE2 possible_RE2 due_RE2 to_RE2 the_RE2 induction_RE2 of_RE2 glutathione-s-transferase_RE2 
Busulfan_ddi|P|busulfex|phenytoin|since_LE1 the_LE1 pharmacokinetic_LE1 of_LE1 BIOENTITY be_BE12 study_BE12 in_BE12 patient_BE12 treat_BE12 with_BE12 BIOENTITY the_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 at_RE2 the_RE2 recommend_RE2 dose_RE2 may_RE2 be_RE2 low_RE2 and_RE2 exposure_RE2 -LRB-_RE2 auc_RE2 -RRB-_RE2 high_RE2 in_RE2 patient_RE2 not_RE2 treat_RE2 with_RE2 BIOGENERAL_RE2 
Busulfan_ddi|P|acetaminophen|busulfex|because_LE1 BIOGENERAL_LE1 be_LE1 eliminate_LE1 from_LE1 the_LE1 body_LE1 via_LE1 conjugation_LE1 with_LE1 glutathione_LE1 use_LE1 of_LE1 BIOENTITY prior_BE12 to_BE12 -LRB-_BE12 NUM_BE12 hour_BE12 -RRB-_BE12 or_BE12 concurrent_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 reduce_RE2 BIOGENERAL_RE2 clearance_RE2 base_RE2 upon_RE2 the_RE2 known_RE2 property_RE2 of_RE2 BIOGENERAL_RE2 to_RE2 decrease_RE2 glutathione_RE2 level_RE2 in_RE2 the_RE2 blood_RE2 and_RE2 tissue_RE2 
Butabarbital_ddi|P|barbiturate|contraceptive|interaction_LE1 may_LE1 occur_LE1 with_LE1 the_LE1 following_LE1 :_LE1 adrenocorticoid_LE1 -LRB-_LE1 cortisone-like_LE1 medicine_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 may_LE1 decrease_LE1 the_LE1 effect_LE1 of_LE1 these_LE1 medicine_LE1 -RRB-_LE1 -LRB-_LE1 cns_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 use_LE1 these_LE1 medicine_LE1 with_LE1 BIOGENERAL_LE1 may_LE1 result_LE1 in_LE1 increase_LE1 cns_LE1 depressant_LE1 effect_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -LRB-_LE1 use_LE1 these_LE1 medicine_LE1 with_LE1 BIOGENERAL_LE1 may_LE1 change_LE1 the_LE1 amount_LE1 of_LE1 either_LE1 medicine_LE1 that_LE1 you_LE1 need_LE1 to_LE1 take_LE1 -RRB-_LE1 and_LE1 oral_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 these_BE12 oral_BE12 BIOENTITY and_RE2 you_RE2 may_RE2 need_RE2 to_RE2 change_RE2 to_RE2 different_RE2 type_RE2 of_RE2 birth_RE2 control_RE2 -rrb-._RE2 
Butalbital_ddi|P|butalbital|monoamine oxidase (mao) inhibitor|the_LE1 cns_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOENTITY 
Butalbital_ddi|P|acetaminophen|anesthetic|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|narcotic analgesic|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|alcohol|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|alcohol|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|anesthetic|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|tranquilizer|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|narcotic analgesic|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|chlordiazepoxide|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|sedative-hypnotic|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|cns depressant|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|tranquilizer|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|cns depressant|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|butalbital|chlordiazepoxide|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|alcohol|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|narcotic analgesic|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|cns depressant|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|acetaminophen|sedative-hypnotic|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|sedative-hypnotic|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|chlordiazepoxide|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|tranquilizer|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butalbital_ddi|P|caffeine|anesthetic|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 :_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 cns_RE2 depression_RE2 
Butorphanol_ddi|P|butorphanol|antihistamine|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 effect_RE2 
Butorphanol_ddi|P|butorphanol|tranquilizer|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 effect_RE2 
Butorphanol_ddi|P|butorphanol|central nervous system depressant|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 effect_RE2 
Butorphanol_ddi|P|butorphanol|alcohol|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 effect_RE2 
Butorphanol_ddi|P|butorphanol|barbiturate|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 effect_RE2 
Butorphanol_ddi|P|stadol n|sumatriptan|however_LE1 in_LE1 another_LE1 study_LE1 in_LE1 healthy_LE1 volunteer_LE1 the_LE1 pharmacokinetic_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 significant_LE1 alter_LE1 -LRB-_LE1 NUM_LE1 decrease_LE1 in_LE1 auc_LE1 and_LE1 NUM_LE1 decrease_LE1 in_LE1 cmax_LE1 -RRB-_LE1 when_LE1 NUM_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 administer_BE12 NUM_BE12 minute_BE12 after_BE12 NUM_BE12 dose_BE12 of_BE12 BIOENTITY nasal_RE2 spray_RE2 
Butorphanol_ddi|P|stadol n|sumatriptan|when_LE1 the_LE1 BIOENTITY be_BE12 administer_BE12 NUM_BE12 minute_BE12 after_BE12 the_BE12 BIOENTITY nasal_RE2 spray_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 increase_RE2 NUM_RE2 and_RE2 cmax_RE2 decrease_RE2 NUM_RE2 %._RE2 
Butorphanol_ddi|P|stadol n|sumatriptan|these_LE1 result_LE1 suggest_LE1 that_LE1 the_LE1 analgesic_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 diminish_BE12 when_BE12 it_BE12 be_BE12 administer_BE12 short_BE12 after_BE12 BIOENTITY nasal_RE2 spray_RE2 but_RE2 by_RE2 NUM_RE2 minute_RE2 any_RE2 such_RE2 reduction_RE2 in_RE2 effect_RE2 shall_RE2 be_RE2 minimal_RE2 
Butorphanol_ddi|P|butorphanol|erythromycin|it_LE1 be_LE1 not_LE1 know_LE1 if_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 alter_BE12 by_BE12 concomitant_BE12 medication_BE12 that_BE12 affect_BE12 hepatic_BE12 metabolism_BE12 of_BE12 drug_BE12 -LRB-_BE12 BIOENTITY etc._RE2 -RRB-_RE2 but_RE2 physician_RE2 shall_RE2 be_RE2 alert_RE2 to_RE2 the_RE2 possibility_RE2 that_RE2 small_RE2 initial_RE2 dose_RE2 and_RE2 long_RE2 interval_RE2 between_RE2 dose_RE2 may_RE2 be_RE2 need_RE2 
Butorphanol_ddi|P|stadol n|nasal vasoconstrictor|therefore_LE1 slow_LE1 onset_LE1 can_LE1 be_LE1 anticipate_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 immediate_BE12 follow_BE12 BIOENTITY 
Cabergoline_ddi|P|dostinex|metoclopramide|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 d2-antagonist_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Cabergoline_ddi|P|dostinex|butyrophenone|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 d2-antagonist_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Cabergoline_ddi|P|dostinex|thioxanthine|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 d2-antagonist_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Cabergoline_ddi|P|dostinex|phenothiazine|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 d2-antagonist_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Caffeine_ddi|P|caffeine|phenobarbital|Based_LE1 on_LE1 adult_LE1 datum_LE1 low_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 need_LE1 following_LE1 coadministration_LE1 of_LE1 drug_LE1 which_LE1 be_LE1 report_LE1 to_LE1 decrease_LE1 BIOGENERAL_LE1 elimination_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 high_LE1 BIOENTITY dose_BE12 may_BE12 be_BE12 need_BE12 following_BE12 coadministration_BE12 of_BE12 drug_BE12 that_BE12 increase_BE12 BIOGENERAL_BE12 elimination_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Caffeine_ddi|P|caffeine|ketoconazole|Based_LE1 on_LE1 adult_LE1 datum_LE1 low_LE1 dose_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 need_BE12 following_BE12 coadministration_BE12 of_BE12 drug_BE12 which_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 BIOGENERAL_BE12 elimination_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 and_RE2 high_RE2 BIOGENERAL_RE2 dose_RE2 may_RE2 be_RE2 need_RE2 following_RE2 coadministration_RE2 of_RE2 drug_RE2 that_RE2 increase_RE2 BIOGENERAL_RE2 elimination_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Caffeine_ddi|P|caffeine|phenytoin|Based_LE1 on_LE1 adult_LE1 datum_LE1 low_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 need_LE1 following_LE1 coadministration_LE1 of_LE1 drug_LE1 which_LE1 be_LE1 report_LE1 to_LE1 decrease_LE1 BIOGENERAL_LE1 elimination_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 high_LE1 BIOENTITY dose_BE12 may_BE12 be_BE12 need_BE12 following_BE12 coadministration_BE12 of_BE12 drug_BE12 that_BE12 increase_BE12 BIOGENERAL_BE12 elimination_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -rrb-._RE2 
Caffeine_ddi|P|caffeine|cimetidine|Based_LE1 on_LE1 adult_LE1 datum_LE1 low_LE1 dose_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 need_BE12 following_BE12 coadministration_BE12 of_BE12 drug_BE12 which_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 BIOGENERAL_BE12 elimination_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 high_RE2 BIOGENERAL_RE2 dose_RE2 may_RE2 be_RE2 need_RE2 following_RE2 coadministration_RE2 of_RE2 drug_RE2 that_RE2 increase_RE2 BIOGENERAL_RE2 elimination_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Caffeine_ddi|P|caffeine|ketoprofen|BIOENTITY administer_BE12 concurrent_BE12 with_BE12 BIOENTITY reduce_RE2 the_RE2 urine_RE2 volume_RE2 in_RE2 NUM_RE2 healthy_RE2 volunteer_RE2 
Calcidiol_ddi|P|cholestyramine|fat soluble vitamin|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Calcidiol_ddi|P|phenobarbital|calcitriol|BIOGENERAL_LE1 :_LE1 the_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY will_BE12 not_BE12 affect_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 but_BE12 may_BE12 reduce_BE12 endogenous_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY by_RE2 accelerate_RE2 metabolism_RE2 
Calcidiol_ddi|P|phenytoin|calcitriol|BIOGENERAL_LE1 :_LE1 the_LE1 coadministration_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 will_BE12 not_BE12 affect_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 but_BE12 may_BE12 reduce_BE12 endogenous_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY by_RE2 accelerate_RE2 metabolism_RE2 
Calcidiol_ddi|P|thiazide|vitamin d|some_LE1 report_LE1 have_LE1 show_LE1 that_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY cause_RE2 hypercalcemia_RE2 
Calcidiol_ddi|P|vitamin d|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY dosage_BE12 must_BE12 be_BE12 determine_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 undergo_BE12 treatment_BE12 with_BE12 BIOENTITY as_RE2 hypercalcemia_RE2 in_RE2 such_RE2 patient_RE2 may_RE2 precipitate_RE2 cardiac_RE2 arrhythmia_RE2 
Calcidiol_ddi|P|ketoconazole|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 inhibit_BE12 both_BE12 synthetic_BE12 and_BE12 catabolic_BE12 enzyme_BE12 of_BE12 BIOENTITY 
Calcidiol_ddi|P|vitamin d analogue|corticosteroid|BIOGENERAL_LE1 :_LE1 relationship_LE1 of_LE1 functional_LE1 antagonism_LE1 exist_LE1 between_LE1 BIOENTITY which_BE12 promote_BE12 calcium_BE12 absorption_BE12 and_BE12 BIOENTITY which_RE2 inhibit_RE2 calcium_RE2 absorption_RE2 
Calcidiol_ddi|P|magnesium|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY preparation_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Calcidiol_ddi|P|antacid|vitamin d|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 preparation_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Calcitriol_ddi|P|cholestyramine|fat soluble vitamin|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Calcitriol_ddi|P|phenytoin|calcitriol|BIOGENERAL_LE1 :_LE1 the_LE1 coadministration_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 will_BE12 not_BE12 affect_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 but_BE12 may_BE12 reduce_BE12 endogenous_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY by_RE2 accelerate_RE2 metabolism_RE2 
Calcitriol_ddi|P|phenobarbital|calcitriol|BIOGENERAL_LE1 :_LE1 the_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY will_BE12 not_BE12 affect_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 but_BE12 may_BE12 reduce_BE12 endogenous_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY by_RE2 accelerate_RE2 metabolism_RE2 
Calcitriol_ddi|P|thiazide|vitamin d|some_LE1 report_LE1 have_LE1 show_LE1 that_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY cause_RE2 hypercalcemia_RE2 
Calcitriol_ddi|P|vitamin d|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY dosage_BE12 must_BE12 be_BE12 determine_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 undergo_BE12 treatment_BE12 with_BE12 BIOENTITY as_RE2 hypercalcemia_RE2 in_RE2 such_RE2 patient_RE2 may_RE2 precipitate_RE2 cardiac_RE2 arrhythmia_RE2 
Calcitriol_ddi|P|ketoconazole|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 inhibit_BE12 both_BE12 synthetic_BE12 and_BE12 catabolic_BE12 enzyme_BE12 of_BE12 BIOENTITY 
Calcitriol_ddi|P|vitamin d analogue|corticosteroid|BIOGENERAL_LE1 :_LE1 relationship_LE1 of_LE1 functional_LE1 antagonism_LE1 exist_LE1 between_LE1 BIOENTITY which_BE12 promote_BE12 calcium_BE12 absorption_BE12 and_BE12 BIOENTITY which_RE2 inhibit_RE2 calcium_RE2 absorption_RE2 
Calcitriol_ddi|P|magnesium|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY preparation_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Calcitriol_ddi|P|antacid|vitamin d|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 preparation_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Calcium Acetate_ddi|P|calcium acetate|digitalis glycoside|use_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 heart_RE2 medicine_RE2 -RRB-_RE2 may_RE2 cause_RE2 hypercalcemia_RE2 -LRB-_RE2 too_RE2 much_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 blood_RE2 -RRB-_RE2 which_RE2 can_RE2 increase_RE2 the_RE2 chance_RE2 of_RE2 develop_RE2 irregular_RE2 heartbeat_RE2 
Candesartan_ddi|P|lithium|angiotensin ii receptor antagonist|BIOGENERAL_LE1 reversible_LE1 increase_LE1 in_LE1 serum_LE1 BIOGENERAL_LE1 concentration_LE1 and_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 with_BE12 some_BE12 BIOENTITY 
Candesartan_ddi|P|lithium|ace inhibitor|BIOGENERAL_LE1 reversible_LE1 increase_LE1 in_LE1 serum_LE1 BIOGENERAL_LE1 concentration_LE1 and_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 with_RE2 some_RE2 BIOGENERAL_RE2 
Candesartan_ddi|P|lithium|atacand|increase_LE1 in_LE1 serum_LE1 BIOGENERAL_LE1 concentration_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY so_RE2 careful_RE2 monitoring_RE2 of_RE2 serum_RE2 BIOGENERAL_RE2 level_RE2 be_RE2 recommend_RE2 during_RE2 concomitant_RE2 use_RE2 
Capecitabine_ddi|P|capecitabine|phenprocoumon|BIOGENERAL_LE1 altered_LE1 coagulation_LE1 parameter_LE1 and_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Capecitabine_ddi|P|capecitabine|coumarin-derivative anticoagulant|BIOGENERAL_LE1 altered_LE1 coagulation_LE1 parameter_LE1 and_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Capecitabine_ddi|P|coumarin-derivative anticoagulant|capecitabine|patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 regular_RE2 for_RE2 alteration_RE2 in_RE2 their_RE2 coagulation_RE2 parameter_RE2 -LRB-_RE2 pt_RE2 or_RE2 inr_RE2 -rrb-._RE2 
Capecitabine_ddi|P|5-fluorouracil|leucovorin|BIOGENERAL_LE1 :_LE1 the_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 and_BE12 its_BE12 toxicity_BE12 may_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY 
Capecitabine_ddi|P|leucovorin|fluorouracil|death_LE1 from_LE1 severe_LE1 enterocolitis_LE1 diarrhea_LE1 and_LE1 dehydration_LE1 have_LE1 be_LE1 report_LE1 in_LE1 elderly_LE1 patient_LE1 receive_LE1 weekly_LE1 BIOENTITY and_BE12 BIOENTITY 
Captopril_ddi|P|diuretic|captopril|hypotension_LE1 patient_LE1 on_LE1 BIOGENERAL_LE1 therapy_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 especial_BE12 those_BE12 in_BE12 who_BE12 BIOGENERAL_BE12 therapy_BE12 be_BE12 recent_BE12 institute_BE12 as_BE12 well_BE12 as_BE12 those_BE12 on_BE12 severe_BE12 dietary_BE12 salt_BE12 restriction_BE12 or_BE12 dialysis_BE12 may_BE12 occasional_BE12 experience_BE12 precipitous_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 usual_BE12 within_BE12 the_BE12 first_BE12 hour_BE12 after_BE12 receive_BE12 the_BE12 initial_BE12 dose_BE12 of_BE12 BIOENTITY 
Captopril_ddi|P|captopril|diuretic|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 with_LE1 BIOENTITY can_BE12 be_BE12 minimize_BE12 by_BE12 either_BE12 discontinue_BE12 the_BE12 BIOENTITY or_RE2 increase_RE2 the_RE2 salt_RE2 intake_RE2 approximate_RE2 one_RE2 week_RE2 prior_RE2 to_RE2 initiation_RE2 of_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 tablet_RE2 usp_RE2 -RRB-_RE2 or_RE2 initiate_RE2 therapy_RE2 with_RE2 small_RE2 dose_RE2 -LRB-_RE2 NUM_RE2 or_RE2 NUM_RE2 mg_RE2 -rrb-._RE2 
Captopril_ddi|P|nitrate|captopril|therefore_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOENTITY -LRB-_BE12 as_BE12 use_BE12 for_BE12 management_BE12 of_BE12 angina_BE12 -RRB-_BE12 or_BE12 other_BE12 drug_BE12 have_BE12 vasodilator_BE12 activity_BE12 shall_BE12 if_BE12 possible_BE12 be_BE12 discontinue_BE12 before_BE12 start_BE12 BIOENTITY 
Captopril_ddi|P|nitroglycerin|captopril|therefore_LE1 BIOENTITY or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 as_BE12 use_BE12 for_BE12 management_BE12 of_BE12 angina_BE12 -RRB-_BE12 or_BE12 other_BE12 drug_BE12 have_BE12 vasodilator_BE12 activity_BE12 shall_BE12 if_BE12 possible_BE12 be_BE12 discontinue_BE12 before_BE12 start_BE12 BIOENTITY 
Captopril_ddi|P|captopril|antihypertensive agent|agent_LE1 cause_LE1 renin_LE1 release_LE1 BIOENTITY 's_BE12 effect_BE12 will_BE12 be_BE12 augment_BE12 by_BE12 BIOENTITY that_RE2 cause_RE2 renin_RE2 release_RE2 
Captopril_ddi|P|beta-adrenergic blocking drug|captopril|BIOENTITY add_BE12 some_BE12 further_BE12 antihypertensive_BE12 effect_BE12 to_BE12 BIOENTITY but_RE2 the_RE2 overall_RE2 response_RE2 be_RE2 little_RE2 than_RE2 additive_RE2 
Captopril_ddi|P|indomethacin|captopril|inhibitor_LE1 Of_LE1 endogenous_LE1 prostaglandin_LE1 synthesis_LE1 it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY especial_RE2 in_RE2 case_RE2 of_RE2 low_RE2 renin_RE2 hypertension_RE2 
Captopril_ddi|P|lithium|ace inhibitor|BIOGENERAL_LE1 :_LE1 increase_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 symptom_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 
Captopril_ddi|P|diuretic|lithium|if_LE1 BIOENTITY be_BE12 also_BE12 use_BE12 it_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 BIOENTITY toxicity_RE2 
Carbamazepine_ddi|P|equetrotm|nicotinamide|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|protease inhibitor|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|nefazodone|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|niacinamide|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|propoxyphene|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|fluvoxamine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|ketoconazole|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|loratadine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|isoniazid|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|itraconazole|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|acetazolamide|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|azole antifungal|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|cimetidine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|clarithromycin|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|diltiazem|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|delavirdine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|danazol|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|dalfopristin|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|fluoxetine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|erythromycin|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 grapefruit_RE2 juice_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|quinine|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|quinupristin|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|troleandomycin|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|valproate|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|verapamil|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|zileuton|agent_LE1 that_LE1 be_LE1 cyp3a4_LE1 inhibitor_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 increase_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 follow_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY 
Carbamazepine_ddi|P|equetrotm|theophylline|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|rifampin|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|felbamate|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|doxorubicin hcl|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|cisplatin|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|methsuximide|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|primidone|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|phenytoin|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|phenobarbital|agent_LE1 that_LE1 be_LE1 cyp_LE1 inducer_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 decrease_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 BIOGENERAL_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 treatment_RE2 with_RE2 one_RE2 of_RE2 these_RE2 cyp3a4_RE2 inducer_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 increase_RE2 for_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|ziprasidone|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|amitriptyline|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|warfarin|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|bupropion|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|valproate|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|acetaminophen|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|triazolam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|alprazolam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|zonisamide|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbamazepine_ddi|P|equetrotm|methadone|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|midazolam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|clozapine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|levothyroxine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|cyclosporin|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|lorazepam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|clobazam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|itraconazole|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|clonazepam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|lamotrigine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|buspirone|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|citalopram|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|contraceptive|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|olanzapine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|nortriptyline|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|mirtazapine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|protease inhibitor|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|quetiapine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|risperidone|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|theophylline|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|delavirdine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|desipramine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|oxcarbazepine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|diazepam|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|phenytoin|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|dicumarol|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|praziquantel|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|doxycycline|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|felbamate|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|ethosuximide|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|glucocorticoid|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|felodipine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|tiagabine|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|topiramate|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|haloperidol|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|tramadol|agent_LE1 that_LE1 have_LE1 be_LE1 find_LE1 or_LE1 be_LE1 expect_LE1 to_LE1 have_LE1 decrease_LE1 plasma_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY due_BE12 to_BE12 induction_BE12 of_BE12 cyp_BE12 enzyme_BE12 be_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbamazepine_ddi|P|equetrotm|primidone|agent_LE1 with_LE1 increase_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 plasma_BE12 level_BE12 of_BE12 the_BE12 following_BE12 agent_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 BIOENTITY thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 one_RE2 of_RE2 the_RE2 agent_RE2 in_RE2 this_RE2 category_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 the_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 decrease_RE2 for_RE2 the_RE2 concomitant_RE2 agent_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|phenytoin|agent_LE1 with_LE1 increase_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 plasma_BE12 level_BE12 of_BE12 the_BE12 following_BE12 agent_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 one_RE2 of_RE2 the_RE2 agent_RE2 in_RE2 this_RE2 category_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 the_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 decrease_RE2 for_RE2 the_RE2 concomitant_RE2 agent_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|equetrotm|clomipramine hcl|agent_LE1 with_LE1 increase_LE1 level_LE1 in_LE1 the_LE1 presence_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 plasma_BE12 level_BE12 of_BE12 the_BE12 following_BE12 agent_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 thus_RE2 if_RE2 patient_RE2 have_RE2 be_RE2 titrate_RE2 to_RE2 stable_RE2 dosage_RE2 on_RE2 one_RE2 of_RE2 the_RE2 agent_RE2 in_RE2 this_RE2 category_RE2 and_RE2 then_RE2 begin_RE2 course_RE2 of_RE2 the_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 it_RE2 be_RE2 reasonable_RE2 to_RE2 expect_RE2 that_RE2 dose_RE2 decrease_RE2 for_RE2 the_RE2 concomitant_RE2 agent_RE2 may_RE2 be_RE2 necessary_RE2 
Carbamazepine_ddi|P|carbamazepine|lithium|pharmacological_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 neurotoxic_RE2 side_RE2 effect_RE2 
Carbamazepine_ddi|P|chloroquine|carbamazepine|additional_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 antagonize_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Carbamazepine_ddi|P|mefloquine|carbamazepine|additional_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 antagonize_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Carbamazepine_ddi|P|anti-malarial drug|carbamazepine|additional_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 antagonize_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Carbamazepine_ddi|P|equetrotm|alcohol|Because_LE1 of_LE1 its_LE1 primary_LE1 cns_LE1 effect_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbamazepine_ddi|P|equetrotm|centrally acting drug|Because_LE1 of_LE1 its_LE1 primary_LE1 cns_LE1 effect_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 with_BE12 other_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carbenicillin_ddi|P|carbenicillin indanyl sodium|probenecid|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 blood_BE12 level_BE12 may_BE12 be_BE12 increase_BE12 and_BE12 prolong_BE12 by_BE12 concurrent_BE12 administration_BE12 of_BE12 BIOENTITY 
Carbenicillin_ddi|P|geocillin|probenecid|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 blood_BE12 level_BE12 may_BE12 be_BE12 increase_BE12 and_BE12 prolong_BE12 by_BE12 concurrent_BE12 administration_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|risperidone|levodopa|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|butyrophenone|levodopa|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|isoniazid|levodopa|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|phenothiazine|levodopa|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|dopamine d2 receptor antagonist|levodopa|BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbidopa_ddi|P|levodopa|phenytoin|In_LE1 addition_LE1 the_LE1 beneficial_LE1 effect_LE1 of_LE1 BIOENTITY in_BE12 parkinsons_BE12 disease_BE12 have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 reverse_BE12 by_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carbidopa_ddi|P|levodopa|papaverine|In_LE1 addition_LE1 the_LE1 beneficial_LE1 effect_LE1 of_LE1 BIOENTITY in_BE12 parkinsons_BE12 disease_BE12 have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 reverse_BE12 by_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbidopa_ddi|P|iron|carbidopa|BIOENTITY salt_BE12 may_BE12 reduce_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carbidopa_ddi|P|iron|levodopa|BIOENTITY salt_BE12 may_BE12 reduce_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbidopa_ddi|P|metoclopramide|levodopa|although_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOENTITY by_RE2 increase_RE2 gastric_RE2 emptying_RE2 BIOGENERAL_RE2 may_RE2 also_RE2 adverse_RE2 affect_RE2 disease_RE2 control_RE2 by_RE2 its_RE2 dopamine_RE2 receptor_RE2 antagonistic_RE2 property_RE2 
Carbimazole_ddi|P|iodine|carbimazole|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 excess_LE1 may_LE1 decrease_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY deficiency_BE12 can_BE12 increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbimazole_ddi|P|iodine|carbimazole|BIOENTITY or_BE12 BIOGENERAL_BE12 excess_BE12 may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 deficiency_RE2 can_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Carbimazole_ddi|P|digoxin|antithyroid agent|serum_LE1 concentration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 when_BE12 patient_BE12 take_BE12 BIOENTITY 
Carbimazole_ddi|P|digitoxin|antithyroid agent|serum_LE1 concentration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 when_BE12 patient_BE12 take_BE12 BIOENTITY 
Carbimazole_ddi|P|antithyroid agent|sodium iodide i131|BIOENTITY may_BE12 decrease_BE12 thyroidal_BE12 uptake_BE12 of_BE12 BIOENTITY rebound_RE2 in_RE2 uptake_RE2 may_RE2 occur_RE2 up_RE2 to_RE2 NUM_RE2 day_RE2 after_RE2 sudden_RE2 withdrawal_RE2 of_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|antihistamine|cns depressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Carbinoxamine_ddi|P|antihistamine|tricyclic antidepressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|antihistamine|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|antihistamine|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|mao inhibitor|antihistamine|BIOENTITY prolong_BE12 and_BE12 intensify_BE12 the_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Carbinoxamine_ddi|P|sympathomimetic amine|reserpine|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|sympathomimetic amine|veratrum alkaloid|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|sympathomimetic amine|methyldopa|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carbinoxamine_ddi|P|sympathomimetic amine|mecamylamine|BIOENTITY may_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbinoxamine_ddi|P|sympathomimetic|beta adrenergic blocker|effect_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Carbinoxamine_ddi|P|sympathomimetic|mao inhibitor|effect_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Carboprost Tromethamine_ddi|P|hemabate|oxytocic agent|BIOENTITY may_BE12 augment_BE12 the_BE12 activity_BE12 of_BE12 other_BE12 BIOENTITY 
Carteolol_ddi|P|ocupres|beta-adrenergic blocking agent|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 BIOENTITY oral_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 for_RE2 additive_RE2 effect_RE2 on_RE2 systemic_RE2 beta-blockade_RE2 
Carteolol_ddi|P|beta-blocker|reserpine|close_LE1 observation_LE1 of_LE1 the_LE1 patient_LE1 be_LE1 recommend_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 to_BE12 patient_BE12 receive_BE12 catecholamine-depleting_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY because_RE2 of_RE2 possible_RE2 additive_RE2 effect_RE2 and_RE2 the_RE2 production_RE2 of_RE2 hypotension_RE2 and_RE2 marked_RE2 bradycardia_RE2 which_RE2 may_RE2 produce_RE2 vertigo_RE2 syncope_RE2 or_RE2 postural_RE2 hypotension_RE2 
Carvedilol_ddi|P|paroxetine|carvedilol|poor_LE1 metabolizer_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 interaction_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 strong_LE1 inhibitor_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 but_BE12 these_BE12 drug_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 blood_BE12 level_BE12 of_BE12 the_BE12 -LRB-_BE12 -RRB-_BE12 enantiomer_BE12 of_BE12 BIOENTITY 
Carvedilol_ddi|P|fluoxetine|carvedilol|poor_LE1 metabolizer_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 interaction_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 strong_LE1 inhibitor_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 but_BE12 these_BE12 drug_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 blood_BE12 level_BE12 of_BE12 the_BE12 -LRB-_BE12 -RRB-_BE12 enantiomer_BE12 of_BE12 BIOENTITY 
Carvedilol_ddi|P|quinidine|carvedilol|poor_LE1 metabolizer_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 interaction_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 strong_LE1 inhibitor_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 but_BE12 these_BE12 drug_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 blood_BE12 level_BE12 of_BE12 the_BE12 -LRB-_BE12 -RRB-_BE12 enantiomer_BE12 of_BE12 BIOENTITY 
Carvedilol_ddi|P|propafenone|carvedilol|poor_LE1 metabolizer_LE1 of_LE1 BIOGENERAL_LE1 :_LE1 interaction_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 strong_LE1 inhibitor_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 have_BE12 not_BE12 be_BE12 study_BE12 but_BE12 these_BE12 drug_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 blood_BE12 level_BE12 of_BE12 the_BE12 -LRB-_BE12 -RRB-_BE12 enantiomer_BE12 of_BE12 BIOENTITY 
Carvedilol_ddi|P|agents with b-blocking propertie|reserpine|catecholamine-depleting_LE1 agent_LE1 :_LE1 patient_LE1 take_LE1 both_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 can_BE12 deplete_BE12 catecholamine_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 sign_RE2 of_RE2 hypotension_RE2 and_RE2 severe_RE2 bradycardia_RE2 
Carvedilol_ddi|P|agents with b-blocking propertie|monoamine oxidase inhibitor|catecholamine-depleting_LE1 agent_LE1 :_LE1 patient_LE1 take_LE1 both_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 can_BE12 deplete_BE12 catecholamine_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 sign_RE2 of_RE2 hypotension_RE2 and_RE2 severe_RE2 bradycardia_RE2 
Carvedilol_ddi|P|clonidine|agents with b-blocking propertie|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 potentiate_RE2 blood-pressure-_RE2 and_RE2 heart-rate-lowering_RE2 effect_RE2 
Carvedilol_ddi|P|agents with b-blocking propertie|clonidine|when_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 to_RE2 be_RE2 terminate_RE2 the_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 discontinue_RE2 first_RE2 
Carvedilol_ddi|P|cyclosporine|carvedilol|BIOGENERAL_LE1 :_LE1 modest_LE1 increase_LE1 in_LE1 mean_LE1 trough_LE1 BIOENTITY concentration_BE12 be_BE12 observe_BE12 following_BE12 initiation_BE12 of_BE12 BIOENTITY treatment_RE2 in_RE2 NUM_RE2 renal_RE2 transplant_RE2 patient_RE2 suffer_RE2 from_RE2 chronic_RE2 vascular_RE2 rejection_RE2 
Carvedilol_ddi|P|carvedilol|cyclosporine|Due_LE1 to_LE1 wide_LE1 interindividual_LE1 variability_LE1 in_LE1 the_LE1 dose_LE1 adjustment_LE1 require_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOGENERAL_LE1 concentration_LE1 be_LE1 monitor_LE1 close_LE1 after_LE1 initiation_LE1 of_LE1 BIOENTITY therapy_BE12 and_BE12 that_BE12 the_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 adjust_RE2 as_RE2 appropriate_RE2 
Carvedilol_ddi|P|cyclosporine|carvedilol|Due_LE1 to_LE1 wide_LE1 interindividual_LE1 variability_LE1 in_LE1 the_LE1 dose_LE1 adjustment_LE1 require_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY concentration_BE12 be_BE12 monitor_BE12 close_BE12 after_BE12 initiation_BE12 of_BE12 BIOENTITY therapy_RE2 and_RE2 that_RE2 the_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 adjust_RE2 as_RE2 appropriate_RE2 
Carvedilol_ddi|P|digoxin|carvedilol|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 concentration_LE1 be_LE1 increase_LE1 by_LE1 about_LE1 NUM_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Carvedilol_ddi|P|digoxin|coreg|both_LE1 BIOENTITY and_BE12 BIOENTITY slow_RE2 av_RE2 conduction_RE2 
Carvedilol_ddi|P|digoxin|coreg|therefore_LE1 increase_LE1 monitoring_LE1 of_LE1 BIOENTITY be_BE12 recommend_BE12 when_BE12 initiate_BE12 adjust_BE12 or_BE12 discontinue_BE12 BIOENTITY 
Carvedilol_ddi|P|rifampin|carvedilol|inducer_LE1 and_LE1 inhibitor_LE1 of_LE1 hepatic_LE1 metabolism_LE1 :_LE1 BIOENTITY reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 about_RE2 NUM_RE2 %._RE2 
Carvedilol_ddi|P|coreg|diltiazem|BIOGENERAL_LE1 :_LE1 isolate_LE1 case_LE1 of_LE1 conduction_LE1 disturbance_LE1 -LRB-_LE1 rare_LE1 with_LE1 hemodynamic_LE1 compromise_LE1 -RRB-_LE1 have_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY 
Carvedilol_ddi|P|coreg|diltiazem|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 administer_BE12 oral_BE12 with_BE12 BIOGENERAL_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY type_RE2 it_RE2 be_RE2 recommend_RE2 that_RE2 ecg_RE2 and_RE2 blood_RE2 pressure_RE2 be_RE2 monitor_RE2 
Carvedilol_ddi|P|coreg|verapamil|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 administer_BE12 oral_BE12 with_BE12 BIOGENERAL_BE12 of_BE12 the_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 type_RE2 it_RE2 be_RE2 recommend_RE2 that_RE2 ecg_RE2 and_RE2 blood_RE2 pressure_RE2 be_RE2 monitor_RE2 
Carvedilol_ddi|P|agents with b-blocking propertie|hypoglycemic|BIOGENERAL_LE1 or_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 blood-sugar-reducing_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 oral_BE12 BIOENTITY 
Carvedilol_ddi|P|agents with b-blocking propertie|insulin|BIOGENERAL_LE1 or_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 blood-sugar-reducing_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 oral_RE2 BIOGENERAL_RE2 
Caspofungin_ddi|P|cancida|tacrolimu|BIOENTITY reduce_BE12 the_BE12 blood_BE12 NUM_BE12 of_BE12 BIOENTITY by_RE2 approximate_RE2 NUM_RE2 peak_RE2 blood_RE2 concentration_RE2 -LRB-_RE2 cmax_RE2 -RRB-_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 blood_RE2 concentration_RE2 -LRB-_RE2 c12hr_RE2 -RRB-_RE2 by_RE2 NUM_RE2 in_RE2 healthy_RE2 subject_RE2 when_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 NUM_RE2 hour_RE2 apart_RE2 -RRB-_RE2 be_RE2 administer_RE2 on_RE2 the_RE2 10th_RE2 day_RE2 of_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 daily_RE2 as_RE2 compare_RE2 to_RE2 result_RE2 from_RE2 control_RE2 period_RE2 in_RE2 which_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 alone_RE2 
Caspofungin_ddi|P|cyclosporine|caspofungin|In_LE1 two_LE1 clinical_LE1 study_LE1 BIOENTITY -LRB-_BE12 one_BE12 NUM_BE12 mg_BE12 dose_BE12 or_BE12 two_BE12 NUM_BE12 mg_BE12 dose_BE12 -RRB-_BE12 increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Caspofungin_ddi|P|cancida|cyclosporine|there_LE1 be_LE1 transient_LE1 increase_LE1 in_LE1 liver_LE1 alt_LE1 and_LE1 ast_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 co-administer_RE2 
Caspofungin_ddi|P|rifampin|caspofungin|drug-drug_LE1 interaction_LE1 study_LE1 with_LE1 BIOENTITY in_BE12 healthy_BE12 volunteer_BE12 have_BE12 show_BE12 NUM_BE12 decrease_BE12 in_BE12 BIOENTITY trough_RE2 concentration_RE2 
Caspofungin_ddi|P|rifampin|cancida|patient_LE1 on_LE1 BIOENTITY shall_BE12 receive_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY daily_RE2 
Caspofungin_ddi|P|carbamazepine|cancida|In_LE1 addition_LE1 result_LE1 from_LE1 regression_LE1 analysis_LE1 of_LE1 patient_LE1 pharmacokinetic_LE1 datum_LE1 suggest_LE1 that_LE1 co-administration_LE1 of_LE1 other_LE1 inducer_LE1 of_LE1 drug_LE1 clearance_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 clinical_RE2 meaningful_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 
Caspofungin_ddi|P|phenytoin|cancida|In_LE1 addition_LE1 result_LE1 from_LE1 regression_LE1 analysis_LE1 of_LE1 patient_LE1 pharmacokinetic_LE1 datum_LE1 suggest_LE1 that_LE1 co-administration_LE1 of_LE1 other_LE1 inducer_LE1 of_LE1 drug_LE1 clearance_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 clinical_RE2 meaningful_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 
Caspofungin_ddi|P|dexamethasone|cancida|In_LE1 addition_LE1 result_LE1 from_LE1 regression_LE1 analysis_LE1 of_LE1 patient_LE1 pharmacokinetic_LE1 datum_LE1 suggest_LE1 that_LE1 co-administration_LE1 of_LE1 other_LE1 inducer_LE1 of_LE1 drug_LE1 clearance_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 clinical_RE2 meaningful_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 
Caspofungin_ddi|P|efavirenz|cancida|In_LE1 addition_LE1 result_LE1 from_LE1 regression_LE1 analysis_LE1 of_LE1 patient_LE1 pharmacokinetic_LE1 datum_LE1 suggest_LE1 that_LE1 co-administration_LE1 of_LE1 other_LE1 inducer_LE1 of_LE1 drug_LE1 clearance_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 clinical_RE2 meaningful_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 
Caspofungin_ddi|P|nevirapine|cancida|In_LE1 addition_LE1 result_LE1 from_LE1 regression_LE1 analysis_LE1 of_LE1 patient_LE1 pharmacokinetic_LE1 datum_LE1 suggest_LE1 that_LE1 co-administration_LE1 of_LE1 other_LE1 inducer_LE1 of_LE1 drug_LE1 clearance_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 clinical_RE2 meaningful_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 concentration_RE2 
Caspofungin_ddi|P|cancida|nevirapine|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 inducer_BE12 of_BE12 drug_BE12 clearance_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 use_RE2 of_RE2 daily_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Caspofungin_ddi|P|cancida|efavirenz|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 inducer_BE12 of_BE12 drug_BE12 clearance_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 use_RE2 of_RE2 daily_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Caspofungin_ddi|P|cancida|dexamethasone|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 inducer_BE12 of_BE12 drug_BE12 clearance_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 use_RE2 of_RE2 daily_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Caspofungin_ddi|P|cancida|phenytoin|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 inducer_BE12 of_BE12 drug_BE12 clearance_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 use_RE2 of_RE2 daily_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Caspofungin_ddi|P|cancida|carbamazepine|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 inducer_BE12 of_BE12 drug_BE12 clearance_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY use_RE2 of_RE2 daily_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 consider_RE2 
Cefazolin_ddi|P|probenecid|cephalosporin|BIOENTITY may_BE12 decrease_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY when_RE2 use_RE2 concurrent_RE2 result_RE2 in_RE2 increase_RE2 and_RE2 much_RE2 prolonged_RE2 BIOGENERAL_RE2 blood_RE2 level_RE2 
Cefdinir_ddi|P|cefdinir|maalox tc|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 NUM_LE1 BIOENTITY capsule_BE12 with_BE12 NUM_BE12 ml_BE12 BIOENTITY suspension_RE2 reduce_RE2 the_RE2 rate_RE2 -LRB-_RE2 cmax_RE2 -RRB-_RE2 and_RE2 extent_RE2 -LRB-_RE2 auc_RE2 -RRB-_RE2 of_RE2 absorption_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Cefdinir_ddi|P|omnicef|antacid|if_LE1 BIOGENERAL_LE1 be_LE1 require_LE1 during_LE1 BIOGENERAL_LE1 therapy_LE1 BIOENTITY shall_BE12 be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 after_BE12 the_BE12 BIOENTITY 
Cefdinir_ddi|P|probenecid|cefdinir|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 BIOENTITY inhibit_BE12 the_BE12 renal_BE12 excretion_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 approximate_RE2 doubling_RE2 in_RE2 a.c._RE2 NUM_RE2 increase_RE2 in_RE2 peak_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 and_RE2 NUM_RE2 prolongation_RE2 in_RE2 the_RE2 apparent_RE2 elimination_RE2 half-life_RE2 
Cefdinir_ddi|P|b-lactam antibiotic|cefdinir|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY BIOGENERAL_BE12 inhibit_BE12 the_BE12 renal_BE12 excretion_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 approximate_RE2 doubling_RE2 in_RE2 a.c._RE2 NUM_RE2 increase_RE2 in_RE2 peak_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 and_RE2 NUM_RE2 prolongation_RE2 in_RE2 the_RE2 apparent_RE2 elimination_RE2 half-life_RE2 
Cefdinir_ddi|P|cefdinir|iron|BIOGENERAL_LE1 and_LE1 food_LE1 fortify_LE1 With_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 therapeutic_BE12 BIOGENERAL_BE12 contain_BE12 NUM_BE12 mg_BE12 of_BE12 elemental_BE12 BIOGENERAL_BE12 -LRB-_BE12 as_BE12 feso4_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 supplement_BE12 with_BE12 NUM_BE12 mg_BE12 of_BE12 elemental_BE12 BIOENTITY reduce_RE2 extent_RE2 of_RE2 absorption_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Cefdinir_ddi|P|cefdinir|iron|BIOGENERAL_LE1 and_LE1 food_LE1 fortify_LE1 With_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 therapeutic_BE12 BIOGENERAL_BE12 contain_BE12 NUM_BE12 mg_BE12 of_BE12 elemental_BE12 BIOENTITY -LRB-_RE2 as_RE2 feso4_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 supplement_RE2 with_RE2 NUM_RE2 mg_RE2 of_RE2 elemental_RE2 BIOGENERAL_RE2 reduce_RE2 extent_RE2 of_RE2 absorption_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Cefdinir_ddi|P|iron supplement|omnicef|if_LE1 BIOENTITY be_BE12 require_BE12 during_BE12 BIOGENERAL_BE12 therapy_BE12 BIOENTITY shall_RE2 be_RE2 take_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 before_RE2 or_RE2 after_RE2 the_RE2 supplement_RE2 
Cefdinir_ddi|P|cefdinir|iron|the_LE1 reddish_LE1 color_LE1 be_LE1 due_LE1 to_LE1 the_LE1 formation_LE1 of_LE1 nonabsorbable_LE1 complex_LE1 between_LE1 BIOENTITY or_BE12 its_BE12 breakdown_BE12 product_BE12 and_BE12 BIOENTITY in_RE2 the_RE2 gastrointestinal_RE2 tract_RE2 
Cefditoren_ddi|P|cefditoren pivoxil|antacid|although_LE1 the_LE1 clinical_LE1 significance_LE1 be_LE1 not_LE1 know_LE1 it_LE1 be_LE1 not_LE1 recommend_LE1 that_LE1 BIOENTITY be_BE12 take_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Cefditoren_ddi|P|famotidine|cefditoren pivoxil|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 intravenous_LE1 administer_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 reduce_BE12 the_BE12 oral_BE12 absorption_BE12 of_BE12 single_BE12 NUM_BE12 mg_BE12 dose_BE12 of_BE12 BIOENTITY administer_RE2 following_RE2 meal_RE2 as_RE2 evidence_RE2 by_RE2 NUM_RE2 decrease_RE2 in_RE2 mean_RE2 cmax_RE2 and_RE2 NUM_RE2 decrease_RE2 in_RE2 mean_RE2 auc_RE2 
Cefditoren_ddi|P|b-lactam antibiotic|cefditoren pivoxil|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY co-administration_BE12 of_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 in_RE2 the_RE2 plasma_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 NUM_RE2 increase_RE2 in_RE2 mean_RE2 cmax_RE2 NUM_RE2 increase_RE2 in_RE2 mean_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 half-life_RE2 
Cefditoren_ddi|P|probenecid|cefditoren pivoxil|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 in_RE2 the_RE2 plasma_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 with_RE2 NUM_RE2 increase_RE2 in_RE2 mean_RE2 cmax_RE2 NUM_RE2 increase_RE2 in_RE2 mean_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 half-life_RE2 
Cefepime_ddi|P|aminoglycoside|maxipime|renal_LE1 function_LE1 shall_LE1 be_LE1 monitor_LE1 careful_LE1 if_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 administer_BE12 with_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 increase_RE2 potential_RE2 of_RE2 nephrotoxicity_RE2 and_RE2 ototoxicity_RE2 of_RE2 BIOGENERAL_RE2 
Cefepime_ddi|P|cephalosporin|furosemide|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 other_LE1 BIOENTITY with_BE12 potent_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Cefepime_ddi|P|cephalosporin|diuretic|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 other_LE1 BIOENTITY with_BE12 potent_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 
Cefixime_ddi|P|carbamazepine|suprax|BIOGENERAL_LE1 :_LE1 elevated_LE1 BIOENTITY level_BE12 have_BE12 be_BE12 report_BE12 in_BE12 postmarketing_BE12 experience_BE12 when_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Cefixime_ddi|P|anticoagulant|cefixime|BIOGENERAL_LE1 and_LE1 BIOENTITY :_BE12 increase_BE12 prothrombin_BE12 time_BE12 with_BE12 or_BE12 without_BE12 clinical_BE12 bleeding_BE12 have_BE12 be_BE12 report_BE12 when_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Cefixime_ddi|P|warfarin|cefixime|BIOENTITY and_BE12 BIOGENERAL_BE12 :_BE12 increase_BE12 prothrombin_BE12 time_BE12 with_BE12 or_BE12 without_BE12 clinical_BE12 bleeding_BE12 have_BE12 be_BE12 report_BE12 when_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Cefotaxime_ddi|P|cephalosporin|aminoglycoside antibiotic|increase_LE1 nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Cefotetan_ddi|P|cefotan|aminoglycoside|if_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 because_RE2 nephrotoxicity_RE2 may_RE2 be_RE2 potentiate_RE2 
Cefoxitin_ddi|P|cephalosporin|aminoglycoside antibiotic|increase_LE1 nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Cefprozil_ddi|P|aminoglycoside antibiotic|cephalosporin antibiotic|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Cefprozil_ddi|P|probenecid|cefprozil|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY double_BE12 the_BE12 auc_BE12 for_BE12 BIOENTITY 
Ceftazidime_ddi|P|cephalosporin|aminoglycoside antibiotic|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 potent_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 
Ceftazidime_ddi|P|cephalosporin|diuretic|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 potent_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 
Ceftazidime_ddi|P|cephalosporin|furosemide|nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 potent_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Ceftazidime_ddi|P|chloramphenicol|beta-lactam antibiotic|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 be_BE12 antagonistic_BE12 to_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 base_RE2 on_RE2 in_RE2 vitro_RE2 study_RE2 and_RE2 time_RE2 kill_RE2 curve_RE2 with_RE2 enteric_RE2 gram-negative_RE2 bacillus_RE2 
Ceftazidime_ddi|P|chloramphenicol|ceftazidime|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 be_BE12 antagonistic_BE12 to_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY base_RE2 on_RE2 in_RE2 vitro_RE2 study_RE2 and_RE2 time_RE2 kill_RE2 curve_RE2 with_RE2 enteric_RE2 gram-negative_RE2 bacillus_RE2 
Ceftibuten_ddi|P|ranitidine|ceftibuten|however_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY q12h_BE12 for_BE12 NUM_BE12 day_BE12 increase_BE12 the_BE12 BIOGENERAL_BE12 max_BE12 by_BE12 NUM_BE12 and_BE12 BIOENTITY auc_RE2 by_RE2 NUM_RE2 %._RE2 
Ceftibuten_ddi|P|ranitidine|ceftibuten|however_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY q12h_BE12 for_BE12 NUM_BE12 day_BE12 increase_BE12 the_BE12 BIOENTITY max_RE2 by_RE2 NUM_RE2 and_RE2 BIOGENERAL_RE2 auc_RE2 by_RE2 NUM_RE2 %._RE2 
Ceftizoxime_ddi|P|cephalosporin|aminoglycoside|although_LE1 the_LE1 occurrence_LE1 have_LE1 not_LE1 be_LE1 report_LE1 with_LE1 BIOGENERAL_LE1 nephrotoxicity_LE1 have_LE1 be_LE1 report_LE1 following_LE1 concomitant_LE1 administration_LE1 of_LE1 other_LE1 BIOENTITY and_BE12 BIOENTITY 
Celecoxib_ddi|P|celecoxib|lithium|clinical_LE1 study_LE1 with_LE1 BIOENTITY have_BE12 identify_BE12 potential_BE12 significant_BE12 interaction_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Celecoxib_ddi|P|celecoxib|fluconazole|clinical_LE1 study_LE1 with_LE1 BIOENTITY have_BE12 identify_BE12 potential_BE12 significant_BE12 interaction_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Celecoxib_ddi|P|nonsteroidal anti-inflammatory drug|ace inhibitor|experience_LE1 with_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 suggest_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Celecoxib_ddi|P|nonsteroidal anti-inflammatory drug|furosemide|experience_LE1 with_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 suggest_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Celecoxib_ddi|P|nsaid|furosemide|experience_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 suggest_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Celecoxib_ddi|P|nsaid|ace inhibitor|experience_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 suggest_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Celecoxib_ddi|P|nsaid|angiotensin converting enzyme (ace) inhibitor|BIOGENERAL_LE1 :_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 -LRB-_BE12 ace_BE12 -RRB-_BE12 BIOENTITY 
Celecoxib_ddi|P|celebrex|ace-inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Celecoxib_ddi|P|nsaid|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post_LE1 marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Celecoxib_ddi|P|nsaid|thiazide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post_LE1 marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Celecoxib_ddi|P|celebrex|aspirin|BIOGENERAL_LE1 :_LE1 BIOENTITY can_BE12 be_BE12 use_BE12 with_BE12 low_BE12 dose_BE12 BIOENTITY 
Celecoxib_ddi|P|aspirin|celebrex|however_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 rate_RE2 of_RE2 gi_RE2 ulceration_RE2 or_RE2 other_RE2 complication_RE2 compared_RE2 to_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 alone_RE2 
Celecoxib_ddi|P|fluconazole|celecoxib|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 qd_BE12 result_BE12 in_BE12 twofold_BE12 increase_BE12 in_BE12 BIOENTITY plasma_RE2 concentration_RE2 
Celecoxib_ddi|P|celecoxib|fluconazole|this_LE1 increase_LE1 be_LE1 due_LE1 to_LE1 the_LE1 inhibition_LE1 of_LE1 BIOENTITY metabolism_BE12 via_BE12 p450_BE12 2c9_BE12 by_BE12 BIOENTITY -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 pharmacokinetic_RE2 :_RE2 metabolism_RE2 -rrb-._RE2 
Celecoxib_ddi|P|celebrex|fluconazole|BIOENTITY shall_BE12 be_BE12 introduce_BE12 at_BE12 the_BE12 low_BE12 recommend_BE12 dose_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Celecoxib_ddi|P|lithium|celebrex|BIOGENERAL_LE1 :_LE1 In_LE1 study_LE1 conduct_LE1 in_LE1 healthy_LE1 subject_LE1 mean_LE1 steady-state_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 increase_LE1 approximate_LE1 NUM_LE1 in_LE1 subject_LE1 receive_LE1 BIOENTITY NUM_BE12 mg_BE12 bid_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 bid_RE2 as_RE2 compared_RE2 to_RE2 subject_RE2 receive_RE2 BIOGENERAL_RE2 alone_RE2 
Celecoxib_ddi|P|lithium|celebrex|patient_LE1 on_LE1 BIOENTITY treatment_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 when_BE12 BIOENTITY be_RE2 introduce_RE2 or_RE2 withdraw_RE2 
Celecoxib_ddi|P|celebrex|warfarin|however_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY since_RE2 these_RE2 patient_RE2 be_RE2 at_RE2 increase_RE2 risk_RE2 of_RE2 bleeding_RE2 complication_RE2 
Cephalexin_ddi|P|cephalexin|metformin|BIOGENERAL_LE1 :_LE1 In_LE1 healthy_LE1 subject_LE1 give_LE1 single_LE1 NUM_LE1 mg_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY plasma_RE2 BIOGENERAL_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 increase_RE2 by_RE2 average_RE2 of_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 and_RE2 BIOGENERAL_RE2 mean_RE2 renal_RE2 clearance_RE2 decrease_RE2 by_RE2 NUM_RE2 %._RE2 
Cephalexin_ddi|P|cephalexin|metformin|although_LE1 not_LE1 observe_LE1 in_LE1 this_LE1 study_LE1 adverse_LE1 effect_LE1 can_LE1 potential_LE1 arise_LE1 from_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY by_RE2 inhibition_RE2 of_RE2 tubular_RE2 secretion_RE2 via_RE2 organic_RE2 cationic_RE2 transporter_RE2 system_RE2 
Cephalexin_ddi|P|cephalexin|metformin|according_LE1 careful_LE1 patient_LE1 monitoring_LE1 and_LE1 dose_LE1 adjustment_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 recommend_LE1 in_LE1 patient_LE1 concomitant_LE1 take_LE1 BIOENTITY and_BE12 BIOENTITY 
Cephalexin_ddi|P|cephalexin|probenecid|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 the_LE1 renal_LE1 excretion_LE1 of_LE1 BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Cerivastatin_ddi|P|cerivastatin sodium|cholestyramine|In_LE1 the_LE1 first_LE1 study_LE1 concomitant_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 BIOENTITY and_BE12 NUM_BE12 BIOENTITY result_RE2 in_RE2 decrease_RE2 of_RE2 many_RE2 than_RE2 NUM_RE2 for_RE2 auc_RE2 and_RE2 NUM_RE2 for_RE2 cmax_RE2 when_RE2 compare_RE2 to_RE2 dosing_RE2 BIOGENERAL_RE2 alone_RE2 
Cerivastatin_ddi|P|cholestyramine|cerivastatin sodium|however_LE1 in_LE1 the_LE1 second_LE1 study_LE1 administration_LE1 of_LE1 NUM_LE1 BIOENTITY NUM_BE12 hour_BE12 before_BE12 the_BE12 evening_BE12 meal_BE12 and_BE12 NUM_BE12 mg_BE12 BIOENTITY approximate_RE2 NUM_RE2 hour_RE2 after_RE2 the_RE2 same_RE2 evening_RE2 meal_RE2 result_RE2 in_RE2 decrease_RE2 in_RE2 the_RE2 BIOGENERAL_RE2 auc_RE2 of_RE2 little_RE2 than_RE2 NUM_RE2 and_RE2 decrease_RE2 in_RE2 cmax_RE2 of_RE2 about_RE2 NUM_RE2 when_RE2 compare_RE2 to_RE2 dosing_RE2 BIOGENERAL_RE2 alone_RE2 
Cerivastatin_ddi|P|cerivastatin|erythromycin|BIOGENERAL_LE1 :_LE1 In_LE1 hypercholesterolemic_LE1 patient_LE1 steady-state_LE1 BIOENTITY auc_BE12 and_BE12 cmax_BE12 increase_BE12 approximate_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 after_BE12 NUM_BE12 day_BE12 with_BE12 co-administration_BE12 of_BE12 BIOENTITY known_RE2 inhibitor_RE2 of_RE2 cytochrome_RE2 p450_RE2 3a4_RE2 
Cetirizine_ddi|P|theophylline|cetirizine|In_LE1 multiple_LE1 dose_LE1 study_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 once_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 -RRB-_RE2 NUM_RE2 decrease_RE2 in_RE2 the_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 observe_RE2 
Cetirizine_ddi|P|cetirizine|theophylline|there_LE1 be_LE1 small_LE1 decrease_LE1 in_LE1 the_LE1 clearance_LE1 of_LE1 BIOENTITY cause_BE12 by_BE12 NUM_BE12 dose_BE12 of_BE12 BIOENTITY 
Cevimeline_ddi|P|cevimeline|beta adrenergic antagonist|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 take_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 possibility_RE2 of_RE2 conduction_RE2 disturbance_RE2 
Chlordiazepoxide_ddi|P|anticoagulant|chlordiazepoxide|although_LE1 clinical_LE1 study_LE1 have_LE1 not_LE1 establish_LE1 cause_LE1 and_LE1 effect_LE1 relationship_LE1 physician_LE1 shall_LE1 be_LE1 aware_LE1 that_LE1 variable_LE1 effect_LE1 blood_LE1 coagulation_LE1 have_LE1 be_LE1 report_LE1 very_LE1 rare_LE1 in_LE1 patient_LE1 receive_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY 
Chloroprocaine_ddi|P|norepinephrine|phenothiazine|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|epinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|epinephrine|phenothiazine|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|norepinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|norepinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|anesthetic solution|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOENTITY contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|anesthetic solution|phenothiazine|the_LE1 administration_LE1 of_LE1 local_LE1 BIOENTITY contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|epinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypotension_RE2 or_RE2 hypertension_RE2 
Chloroprocaine_ddi|P|vasopressor drug|ergot-type oxytocic drug|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 for_BE12 the_BE12 treatment_BE12 of_BE12 hypotension_BE12 related_BE12 to_BE12 obstetric_BE12 block_BE12 -RRB-_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 severe_RE2 persistent_RE2 hypertension_RE2 or_RE2 cerebrovascular_RE2 accident_RE2 
Chloroprocaine_ddi|P|chloroprocaine|sulfonamide drug|therefore_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 any_BE12 condition_BE12 in_BE12 which_BE12 BIOENTITY be_RE2 be_RE2 employ_RE2 
Chloroquine_ddi|P|antacid|chloroquine|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 can_BE12 reduce_BE12 absorption_BE12 of_BE12 BIOENTITY 
Chloroquine_ddi|P|kaolin|chloroquine|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY can_BE12 reduce_BE12 absorption_BE12 of_BE12 BIOENTITY 
Chloroquine_ddi|P|cimetidine|chloroquine|BIOGENERAL_LE1 :_LE1 BIOENTITY can_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY increase_RE2 its_RE2 plasma_RE2 level_RE2 
Chloroquine_ddi|P|chloroquine|ampicillin|BIOGENERAL_LE1 :_LE1 In_LE1 study_LE1 of_LE1 healthy_LE1 volunteer_LE1 BIOENTITY significant_BE12 reduce_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOENTITY 
Chloroquine_ddi|P|chloroquine|cyclosporin|BIOGENERAL_LE1 :_LE1 After_LE1 introduction_LE1 of_LE1 BIOENTITY -LRB-_BE12 oral_BE12 form_BE12 -RRB-_BE12 sudden_BE12 increase_BE12 in_BE12 serum_BE12 BIOENTITY level_RE2 have_RE2 be_RE2 report_RE2 
Chlorothiazide_ddi|P|cholestytamine|thiazide diuretic|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 have_BE12 the_BE12 potential_BE12 of_BE12 binding_BE12 BIOENTITY and_RE2 reduce_RE2 BIOGENERAL_RE2 absorption_RE2 from_RE2 the_RE2 gastrointestinal_RE2 tract_RE2 
Chlorothiazide_ddi|P|colestipol|thiazide diuretic|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY BIOGENERAL_BE12 have_BE12 the_BE12 potential_BE12 of_BE12 binding_BE12 BIOENTITY and_RE2 reduce_RE2 BIOGENERAL_RE2 absorption_RE2 from_RE2 the_RE2 gastrointestinal_RE2 tract_RE2 
Chlorothiazide_ddi|P|lithium|diuretic|BIOENTITY :_BE12 general_BE12 shall_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY 
Chlorothiazide_ddi|P|diuretic agent|lithium|BIOENTITY reduce_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Chlorothiazide_ddi|P|diuretic agent|lithium|BIOENTITY reduce_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 add_BE12 high_BE12 risk_BE12 of_BE12 BIOENTITY toxicity_RE2 
Chlorothiazide_ddi|P|lithium|chlorothiazide|refer_LE1 to_LE1 the_LE1 package_LE1 insert_LE1 for_LE1 BIOENTITY preparation_BE12 before_BE12 use_BE12 of_BE12 such_BE12 preparation_BE12 with_BE12 BIOENTITY 
Chlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|loop diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|thiazide diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Chlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|potassium-sparing diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Chlorothiazide_ddi|P|chlorothiazide|non-steroidal anti-inflammatory agent|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 obtain_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|nicotine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|aspirin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|barbiturate|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|bromocriptine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|calcium|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|corticosteroid|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|corticotropin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|cyclosporine|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|dantrolene|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|antidepressant|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 supplement_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|warfarin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Chlorotrianisene_ddi|P|chlorotrianisene|somatropin|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorotrianisene_ddi|P|chlorotrianisene|tamoxifen|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 supplement_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Chlorpromazine_ddi|P|antipsychotic drug|antiparkinsonian drug|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|chlorpromazine|amitriptyline|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|chlorpromazine|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|chlorpromazine|trihexyphenidyl|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|chlorpromazine|antiparkinsonian drug|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antipsychotic drug|amitriptyline|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antiparkinsonian drug|amitriptyline|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|trihexyphenidyl|amitriptyline|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antiparkinsonian drug|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antiparkinsonian drug|amitriptyline|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antipsychotic drug|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|antipsychotic drug|trihexyphenidyl|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|trihexyphenidyl|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpromazine_ddi|P|trihexyphenidyl|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 two_LE1 or_LE1 many_LE1 drug_LE1 with_LE1 anticholinergic_LE1 activity--such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 --common_RE2 result_RE2 in_RE2 excessive_RE2 anticholinergic_RE2 effect_RE2 including_RE2 dry_RE2 mouth_RE2 and_RE2 associate_RE2 dental_RE2 complication_RE2 blurred_RE2 vision_RE2 and_RE2 in_RE2 patient_RE2 expose_RE2 to_RE2 high_RE2 temperature_RE2 and_RE2 humidity_RE2 hyperpyrexia_RE2 
Chlorpropamide_ddi|P|sulfonylurea|coumarin|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|probenecid|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|beta adrenergic blocking agent|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Chlorpropamide_ddi|P|sulfonylurea|monoamine oxidase inhibitor|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|nonsteroidal anti-inflammatory agent|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 high_RE2 protein_RE2 bind_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|salicylate|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|sulfonamide|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|sulfonylurea|chloramphenicol|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Chlorpropamide_ddi|P|barbiturate|chlorpropamide|since_LE1 animal_LE1 study_LE1 suggest_LE1 that_LE1 the_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 prolonged_BE12 by_BE12 therapy_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 shall_RE2 be_RE2 employ_RE2 with_RE2 caution_RE2 
Chlorpropamide_ddi|P|miconazole|hypoglycemic agent|potential_LE1 interaction_LE1 between_LE1 oral_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY lead_RE2 to_RE2 severe_RE2 hypoglycemia_RE2 have_RE2 be_RE2 report_RE2 
Chlorprothixene_ddi|P|chlorprothixene|lithium|BIOENTITY may_BE12 increase_BE12 the_BE12 plasma-level_BE12 of_BE12 concomitant_BE12 give_BE12 BIOENTITY 
Chlorprothixene_ddi|P|chlorprothixene|opioid|if_LE1 BIOENTITY be_BE12 give_BE12 concomitant_BE12 with_BE12 BIOENTITY the_RE2 BIOGENERAL_RE2 dose_RE2 shall_RE2 be_RE2 reduce_RE2 -LRB-_RE2 by_RE2 approx._RE2 NUM_RE2 -RRB-_RE2 because_RE2 BIOGENERAL_RE2 amplify_RE2 the_RE2 therapeutic_RE2 action_RE2 and_RE2 side-effect_RE2 of_RE2 BIOGENERAL_RE2 massive_RE2 
Chlorprothixene_ddi|P|chlorprothixene|opioid|if_LE1 BIOGENERAL_LE1 be_LE1 give_LE1 concomitant_LE1 with_LE1 BIOGENERAL_LE1 the_LE1 BIOGENERAL_LE1 dose_LE1 shall_LE1 be_LE1 reduce_LE1 -LRB-_LE1 by_LE1 approx._LE1 NUM_LE1 -RRB-_LE1 because_LE1 BIOENTITY amplify_BE12 the_BE12 therapeutic_BE12 action_BE12 and_BE12 side-effect_BE12 of_BE12 BIOENTITY massive_RE2 
Chlorprothixene_ddi|P|chlorprothixene|tramadol|avoid_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Chlorprothixene_ddi|P|chlorprothixene|ultram|avoid_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Chlorprothixene_ddi|P|chlorprothixene|benzodiazepine|consider_LE1 additive_LE1 sedative_LE1 effect_LE1 and_LE1 confusional_LE1 state_LE1 to_LE1 emerge_LE1 if_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Chlorprothixene_ddi|P|chlorprothixene|barbituate|consider_LE1 additive_LE1 sedative_LE1 effect_LE1 and_LE1 confusional_LE1 state_LE1 to_LE1 emerge_LE1 if_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Chlorprothixene_ddi|P|chlorprothixene|antiparkinsonian agent|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Chlorprothixene_ddi|P|chlorprothixene|anticholinergic drug|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Chlorprothixene_ddi|P|chlorprothixene|tricyclic antidepressant|exert_LE1 particular_LE1 caution_LE1 in_LE1 combine_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 :_RE2 particular_RE2 the_RE2 elderly_RE2 may_RE2 develop_RE2 delirium_RE2 high_RE2 fever_RE2 severe_RE2 obstipation_RE2 even_RE2 ileus_RE2 and_RE2 glaucoma_RE2 
Chlorthalidone_ddi|P|chlorthalidone|antihypertensive drug|BIOENTITY may_BE12 add_BE12 to_BE12 or_BE12 potentiate_BE12 the_BE12 action_BE12 of_BE12 other_BE12 BIOENTITY 
Chlorthalidone_ddi|P|chlorthalidone|tubocurarine|BIOENTITY and_BE12 related_BE12 drug_BE12 may_BE12 increase_BE12 the_BE12 responsiveness_BE12 to_BE12 BIOENTITY 
Chlorthalidone_ddi|P|chlorthalidone|norepinephrine|BIOENTITY and_BE12 related_BE12 drug_BE12 may_BE12 decrease_BE12 arterial_BE12 responsiveness_BE12 to_BE12 BIOENTITY 
Cholecalciferol_ddi|P|cholestyramine|fat soluble vitamin|interaction_LE1 for_LE1 BIOGENERAL_LE1 analogue_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Cholecalciferol_ddi|P|thiazide|vitamin d|some_LE1 report_LE1 have_LE1 show_LE1 that_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY cause_RE2 hypercalcemia_RE2 
Cholecalciferol_ddi|P|vitamin d|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY dosage_BE12 must_BE12 be_BE12 determine_BE12 with_BE12 care_BE12 in_BE12 patient_BE12 undergo_BE12 treatment_BE12 with_BE12 BIOENTITY as_RE2 hypercalcemia_RE2 in_RE2 such_RE2 patient_RE2 may_RE2 precipitate_RE2 cardiac_RE2 arrhythmia_RE2 
Cholecalciferol_ddi|P|ketoconazole|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 inhibit_BE12 both_BE12 synthetic_BE12 and_BE12 catabolic_BE12 enzyme_BE12 of_BE12 BIOENTITY 
Cholecalciferol_ddi|P|vitamin d|corticosteroid|BIOGENERAL_LE1 :_LE1 relationship_LE1 of_LE1 functional_LE1 antagonism_LE1 exist_LE1 between_LE1 BIOENTITY analogue_BE12 which_BE12 promote_BE12 calcium_BE12 absorption_BE12 and_BE12 BIOENTITY which_RE2 inhibit_RE2 calcium_RE2 absorption_RE2 
Cholecalciferol_ddi|P|antacid|vitamin d|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 preparation_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Cholecalciferol_ddi|P|magnesium|vitamin d|BIOGENERAL_LE1 :_LE1 BIOENTITY preparation_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 cause_BE12 hypermagnesemia_BE12 and_BE12 shall_BE12 therefore_BE12 not_BE12 be_BE12 take_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY by_RE2 patient_RE2 on_RE2 chronic_RE2 renal_RE2 dialysis_RE2 
Cholestyramine_ddi|P|cholestyramine|warfarin|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 acidic_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 basic_RE2 -RRB-_RE2 as_RE2 well_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|phenylbutazone|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 acidic_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 basic_RE2 -RRB-_RE2 as_RE2 well_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|digitali|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 thyroid_BE12 and_BE12 BIOGENERAL_BE12 preparation_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Cholestyramine_ddi|P|cholestyramine|estrogen|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 thyroid_BE12 and_BE12 BIOGENERAL_BE12 preparation_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|progestin|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 thyroid_BE12 and_BE12 BIOGENERAL_BE12 preparation_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|phenobarbital|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|thyroxine|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 thyroid_BE12 and_BE12 BIOENTITY preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|tetracycline|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|penicillin g|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 basic_BE12 -RRB-_BE12 as_BE12 well_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|thiazide diuretic|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 acidic_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 basic_RE2 -RRB-_RE2 as_RE2 well_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|propranolol|BIOENTITY BIOGENERAL_BE12 may_BE12 delay_BE12 or_BE12 reduce_BE12 the_BE12 absorption_BE12 of_BE12 concomitant_BE12 oral_BE12 medication_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 acidic_BE12 -RRB-_BE12 or_BE12 BIOENTITY -LRB-_RE2 basic_RE2 -RRB-_RE2 as_RE2 well_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 thyroid_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cholestyramine_ddi|P|cholestyramine|digitali|BIOGENERAL_LE1 BIOGENERAL_LE1 may_LE1 interfere_LE1 with_LE1 the_LE1 pharmacokinetic_LE1 of_LE1 drug_LE1 that_LE1 undergo_LE1 enterohepatic_LE1 circulation_LE1 the_LE1 discontinuance_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 can_BE12 pose_BE12 hazard_BE12 to_BE12 health_BE12 if_BE12 potential_BE12 toxic_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY have_RE2 be_RE2 filtrate_RE2 to_RE2 maintenance_RE2 level_RE2 while_RE2 the_RE2 patient_RE2 be_RE2 take_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Ciclesonide_ddi|P|ciclesonide|ketoconazole|In_LE1 another_LE1 drug_LE1 interaction_LE1 study_LE1 co-administration_LE1 of_LE1 oral_LE1 inhale_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY potent_RE2 inhibitor_RE2 of_RE2 cytochrome_RE2 p450_RE2 3a4_RE2 increase_RE2 the_RE2 exposure_RE2 -LRB-_RE2 auc_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 approximate_RE2 NUM_RE2 at_RE2 steady_RE2 state_RE2 while_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 remain_RE2 unchanged_RE2 
Ciclesonide_ddi|P|ketoconazole|ciclesonide|therefore_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 with_BE12 intranasal_BE12 BIOENTITY 
Cidofovir_ddi|P|probenecid|clofibrate|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|methotrexate|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|famotidine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|aminosalicylic acid|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|barbiturate|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|benzodiazepine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|bumetanide|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|acetaminophen|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|acyclovir|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|angiotensin-converting enzyme inhibitor|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|theophylline|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 agent_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|zidovudine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 agent_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -rrb-._RE2 
Cidofovir_ddi|P|probenecid|furosemide|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|probenecid|nonsteroidal anti-inflammatory|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 interact_BE12 with_BE12 the_BE12 metabolism_BE12 or_BE12 renal_BE12 tubular_BE12 excretion_BE12 of_BE12 many_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY agent_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Cidofovir_ddi|P|zidovudine|probenecid|BIOENTITY shall_BE12 either_BE12 be_BE12 temporary_BE12 discontinue_BE12 or_BE12 decrease_BE12 by_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY on_RE2 the_RE2 day_RE2 of_RE2 BIOGENERAL_RE2 infusion_RE2 
Cidofovir_ddi|P|vistide|non-steroidal anti-inflammatory agent|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 intravenous_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|vancomycin|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 intravenous_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|pentamidine|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 intravenous_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|foscarnet|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|amphotericin b|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|amikacin|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|gentamicin|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|tobramycin|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cidofovir_ddi|P|vistide|aminoglycoside|nephrotoxic_LE1 agent_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 agent_BE12 with_BE12 nephrotoxic_BE12 potential_BE12 -lsb-e.g._BE12 intravenous_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 intravenous_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -rsb-_RE2 be_RE2 contraindicate_RE2 
Cilostazol_ddi|P|pletal|omeprazole|since_LE1 BIOGENERAL_LE1 be_LE1 extensive_LE1 metabolize_LE1 by_LE1 cytochrome_LE1 NUM_LE1 isoenzyme_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 inhibitor_BE12 of_BE12 c.p.a._BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 or_BE12 inhibitor_BE12 of_BE12 cyp2c19_BE12 such_BE12 as_BE12 BIOENTITY 
Cilostazol_ddi|P|pletal|erythromycin|since_LE1 BIOGENERAL_LE1 be_LE1 extensive_LE1 metabolize_LE1 by_LE1 cytochrome_LE1 NUM_LE1 isoenzyme_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 inhibitor_BE12 of_BE12 c.p.a._BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY or_RE2 inhibitor_RE2 of_RE2 cyp2c19_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 
Cilostazol_ddi|P|pletal|ketoconazole|since_LE1 BIOGENERAL_LE1 be_LE1 extensive_LE1 metabolize_LE1 by_LE1 cytochrome_LE1 NUM_LE1 isoenzyme_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 inhibitor_BE12 of_BE12 c.p.a._BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 or_RE2 inhibitor_RE2 of_RE2 cyp2c19_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 
Cilostazol_ddi|P|omeprazole|cilostazol|pharmacokinetic_LE1 study_LE1 have_LE1 demonstrate_LE1 that_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 significant_BE12 increase_BE12 the_BE12 systemic_BE12 exposure_BE12 of_BE12 BIOENTITY and_RE2 its_RE2 major_RE2 metabolite_RE2 
Cilostazol_ddi|P|erythromycin|cilostazol|pharmacokinetic_LE1 study_LE1 have_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY significant_BE12 increase_BE12 the_BE12 systemic_BE12 exposure_BE12 of_BE12 BIOENTITY and_RE2 its_RE2 major_RE2 metabolite_RE2 
Cilostazol_ddi|P|cilostazol|diltiazem|population_LE1 pharmacokinetic_LE1 study_LE1 show_LE1 high_LE1 concentration_LE1 of_LE1 BIOENTITY among_BE12 patient_BE12 concurrent_BE12 treat_BE12 with_BE12 BIOENTITY inhibitor_RE2 of_RE2 c.p.a._RE2 
Cimetidine_ddi|P|tagamet|metronidazole|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|theophylline|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|lidocaine|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|tricyclic antidepressant|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|diazepam|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|chlordiazepoxide|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|nifedipine|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|propranolol|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|phenytoin|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|tagamet|warfarin-type anticoagulant|BIOENTITY apparent_BE12 through_BE12 effect_BE12 on_BE12 certain_BE12 microsomal_BE12 enzyme_BE12 system_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 thereby_RE2 delay_RE2 elimination_RE2 and_RE2 increase_RE2 blood_RE2 level_RE2 of_RE2 these_RE2 drug_RE2 
Cimetidine_ddi|P|anticoagulant|tagamet|therefore_LE1 close_LE1 monitoring_LE1 of_LE1 prothrombin_LE1 time_LE1 be_LE1 recommend_LE1 and_LE1 adjustment_LE1 of_LE1 the_LE1 BIOENTITY dose_BE12 may_BE12 be_BE12 necessary_BE12 when_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Cimetidine_ddi|P|tagamet|theo-dur|however_LE1 crossover_LE1 study_LE1 in_LE1 healthy_LE1 subject_LE1 receive_LE1 either_LE1 BIOENTITY NUM_BE12 mg_BE12 q.i.d._BE12 or_BE12 NUM_BE12 mg_BE12 h.s._BE12 concomitant_BE12 with_BE12 NUM_BE12 mg_BE12 b.i.d._BE12 dosage_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY key_RE2 pharmaceuticals_RE2 inc._RE2 -RRB-_RE2 demonstrate_RE2 little_RE2 alteration_RE2 in_RE2 steady-state_RE2 BIOGENERAL_RE2 peak_RE2 serum_RE2 level_RE2 with_RE2 the_RE2 NUM_RE2 mg_RE2 h.s._RE2 regimen_RE2 particular_RE2 in_RE2 subject_RE2 aged_RE2 NUM_RE2 year_RE2 and_RE2 old_RE2 
Cimetidine_ddi|P|tagamet|theophylline|however_LE1 crossover_LE1 study_LE1 in_LE1 healthy_LE1 subject_LE1 receive_LE1 either_LE1 BIOENTITY NUM_BE12 mg_BE12 q.i.d._BE12 or_BE12 NUM_BE12 mg_BE12 h.s._BE12 concomitant_BE12 with_BE12 NUM_BE12 mg_BE12 b.i.d._BE12 dosage_BE12 of_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 key_RE2 pharmaceuticals_RE2 inc._RE2 -RRB-_RE2 demonstrate_RE2 little_RE2 alteration_RE2 in_RE2 steady-state_RE2 BIOGENERAL_RE2 peak_RE2 serum_RE2 level_RE2 with_RE2 the_RE2 NUM_RE2 mg_RE2 h.s._RE2 regimen_RE2 particular_RE2 in_RE2 subject_RE2 aged_RE2 NUM_RE2 year_RE2 and_RE2 old_RE2 
Cinacalcet_ddi|P|cinacalcet|amitriptyline|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 or_LE1 NUM_LE1 mg_LE1 BIOENTITY with_BE12 NUM_BE12 mg_BE12 BIOENTITY increase_RE2 BIOGENERAL_RE2 exposure_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 active_RE2 metabolite_RE2 -RRB-_RE2 exposure_RE2 by_RE2 approximate_RE2 NUM_RE2 in_RE2 cyp2d6_RE2 extensive_RE2 metabolizer_RE2 
Cinacalcet_ddi|P|ketoconazole|cinacalcet|co-administration_LE1 of_LE1 BIOENTITY strong_BE12 inhibitor_BE12 of_BE12 cyp3a4_BE12 increase_BE12 BIOENTITY exposure_RE2 following_RE2 single_RE2 NUM_RE2 mg_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 fold_RE2 
Cinacalcet_ddi|P|sensipar|ketoconazole|dose_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 require_BE12 and_BE12 pth_BE12 and_BE12 serum_BE12 calcium_BE12 concentration_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 if_BE12 patient_BE12 initiate_BE12 or_BE12 discontinues_BE12 therapy_BE12 with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Cinacalcet_ddi|P|sensipar|erythromycin|dose_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 require_BE12 and_BE12 pth_BE12 and_BE12 serum_BE12 calcium_BE12 concentration_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 if_BE12 patient_BE12 initiate_BE12 or_BE12 discontinues_BE12 therapy_BE12 with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Cinacalcet_ddi|P|sensipar|itraconazole|dose_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 require_BE12 and_BE12 pth_BE12 and_BE12 serum_BE12 calcium_BE12 concentration_BE12 shall_BE12 be_BE12 close_BE12 monitor_BE12 if_BE12 patient_BE12 initiate_BE12 or_BE12 discontinues_BE12 therapy_BE12 with_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Cinoxacin_ddi|P|theophylline|quinolone|elevated_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 with_BE12 concomitant_BE12 use_BE12 of_BE12 some_BE12 BIOENTITY 
Cinoxacin_ddi|P|theophylline|quinolone|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 BIOGENERAL_LE1 side-effect_LE1 in_LE1 patient_LE1 on_LE1 concomitant_LE1 BIOENTITY therapy_RE2 
Cinoxacin_ddi|P|quinolone|caffeine|BIOENTITY have_BE12 also_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Cinoxacin_ddi|P|cinoxacin|caffeine|although_LE1 this_LE1 interaction_LE1 have_LE1 not_LE1 be_LE1 report_LE1 with_LE1 BIOGENERAL_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 concomitant_BE12 with_BE12 BIOENTITY product_RE2 
Cinoxacin_ddi|P|sucralfate|quinolone|BIOGENERAL_LE1 or_LE1 BIOENTITY substantial_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 some_BE12 BIOENTITY result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|antacid|quinolone|BIOENTITY or_BE12 BIOGENERAL_BE12 substantial_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 some_BE12 BIOENTITY result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|quinolone|iron|also_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 product_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 containing_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|quinolone|videx|also_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 containing_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|quinolone|zinc|also_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 containing_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|quinolone|didanosine|also_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 containing_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 result_RE2 in_RE2 low_RE2 urine_RE2 level_RE2 
Cinoxacin_ddi|P|cinoxacin|warfarin|BIOGENERAL_LE1 including_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Cinoxacin_ddi|P|cinoxacin|anticoagulant|BIOGENERAL_LE1 including_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 
Cinoxacin_ddi|P|quinolone|warfarin|BIOENTITY including_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Cinoxacin_ddi|P|quinolone|anticoagulant|BIOENTITY including_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 
Cinoxacin_ddi|P|quinolone class antimicrobial|nonsteroidal anti-inflammatory drug|seizure_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 another_LE1 BIOENTITY and_BE12 the_BE12 BIOENTITY BIOGENERAL_RE2 concurrent_RE2 
Cinoxacin_ddi|P|quinolone class antimicrobial|fenbufen|seizure_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 another_LE1 BIOENTITY and_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY concurrent_RE2 
Cinoxacin_ddi|P|cinoxacin|nonsteroidal anti-inflammatory agent|physician_LE1 be_LE1 provide_LE1 this_LE1 information_LE1 to_LE1 increase_LE1 awareness_LE1 of_LE1 the_LE1 potential_LE1 for_LE1 serious_LE1 interaction_LE1 when_LE1 BIOENTITY and_BE12 certain_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Cinoxacin_ddi|P|quinolone|cyclosporine|elevated_LE1 BIOGENERAL_LE1 serum_LE1 level_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Ciprofloxacin_ddi|P|ciprofloxacin|caffeine|some_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY have_BE12 also_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Ciprofloxacin_ddi|P|quinolone|caffeine|some_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 have_BE12 also_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Ciprofloxacin_ddi|P|quinolone|cyclosporine|some_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 associate_BE12 with_BE12 transient_BE12 elevation_BE12 in_BE12 serum_BE12 creatinine_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY concomitant_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|cyclosporine|some_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY have_BE12 be_BE12 associate_BE12 with_BE12 transient_BE12 elevation_BE12 in_BE12 serum_BE12 creatinine_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY concomitant_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|sulfonylurea|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 the_BE12 BIOENTITY BIOGENERAL_RE2 have_RE2 on_RE2 rare_RE2 occasion_RE2 result_RE2 in_RE2 severe_RE2 hypoglycemia_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|glyburide|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY have_RE2 on_RE2 rare_RE2 occasion_RE2 result_RE2 in_RE2 severe_RE2 hypoglycemia_RE2 
Ciprofloxacin_ddi|P|methotrexate|ciprofloxacin|BIOGENERAL_LE1 renal_LE1 tubular_LE1 transport_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 inhibit_BE12 by_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY potential_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Ciprofloxacin_ddi|P|methotrexate|ciprofloxacin|therefore_LE1 patient_LE1 under_LE1 BIOENTITY therapy_BE12 shall_BE12 be_BE12 careful_BE12 monitor_BE12 when_BE12 concomitant_BE12 BIOENTITY therapy_RE2 be_RE2 indicate_RE2 
Ciprofloxacin_ddi|P|quinolone|magnesium|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|aluminum|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|antacid|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|sucralfate|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|videx|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|calcium|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|ciprofloxacin|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 substantial_BE12 decrease_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|iron|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|zinc|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|quinolone|zinc|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY include_BE12 BIOGENERAL_BE12 with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|iron|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|magnesium|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|aluminum|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|videx|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|calcium|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 chewable_BE12 tablet_BE12 or_BE12 pediatric_BE12 powder_BE12 or_BE12 product_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|antacid|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|sucralfate|multivalent_LE1 cation-containing_LE1 product_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 include_LE1 BIOENTITY with_BE12 multivalent_BE12 cation-containing_BE12 product_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 chewable_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 or_RE2 product_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 substantial_RE2 decrease_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|antacid|this_LE1 time_LE1 window_LE1 be_LE1 different_LE1 than_LE1 for_LE1 other_LE1 oral_LE1 formulation_LE1 of_LE1 BIOENTITY which_BE12 be_BE12 usual_BE12 administer_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Ciprofloxacin_ddi|P|phenytoin|ciprofloxacin|BIOGENERAL_LE1 :_LE1 altered_LE1 serum_LE1 level_LE1 of_LE1 BIOENTITY -LRB-_BE12 increase_BE12 and_BE12 decrease_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 in_BE12 patient_BE12 receive_BE12 concomitant_BE12 BIOENTITY 
Ciprofloxacin_ddi|P|probenecid|ciprofloxacin|BIOGENERAL_LE1 :_LE1 BIOENTITY interfere_BE12 with_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY and_RE2 produce_RE2 increase_RE2 in_RE2 the_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 serum_RE2 
Ciprofloxacin_ddi|P|probenecid|ciprofloxacin|BIOGENERAL_LE1 :_LE1 BIOENTITY interfere_BE12 with_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 produce_BE12 increase_BE12 in_BE12 the_BE12 level_BE12 of_BE12 BIOENTITY in_RE2 serum_RE2 
Ciprofloxacin_ddi|P|quinolone|theophylline|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 some_LE1 other_LE1 BIOENTITY concurrent_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY may_RE2 lead_RE2 to_RE2 elevated_RE2 serum_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 prolongation_RE2 of_RE2 its_RE2 elimination_RE2 half-life_RE2 
Ciprofloxacin_ddi|P|ciprofloxacin|theophylline|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 some_LE1 other_LE1 BIOGENERAL_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 lead_RE2 to_RE2 elevated_RE2 serum_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 prolongation_RE2 of_RE2 its_RE2 elimination_RE2 half-life_RE2 
Ciprofloxacin_ddi|P|quinolone|warfarin|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Cisapride_ddi|P|clarithromycin|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 show_LE1 that_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|troleandomycin|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 show_LE1 that_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|erythromycin|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 show_LE1 that_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|anticholinergic compound|cisapride|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 certain_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 compromise_BE12 the_BE12 beneficial_BE12 effect_BE12 of_BE12 BIOENTITY 
Cisapride_ddi|P|belladonna alkaloid|cisapride|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 certain_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 compromise_BE12 the_BE12 beneficial_BE12 effect_BE12 of_BE12 BIOENTITY 
Cisapride_ddi|P|dicyclomine|cisapride|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 certain_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY will_BE12 be_BE12 expect_BE12 to_BE12 compromise_BE12 the_BE12 beneficial_BE12 effect_BE12 of_BE12 BIOENTITY 
Cisapride_ddi|P|cisapride|anticoagulant|it_LE1 be_LE1 advisable_LE1 to_LE1 check_LE1 coagulation_LE1 time_LE1 within_LE1 the_LE1 first_LE1 few_LE1 day_LE1 after_LE1 the_LE1 start_LE1 and_LE1 discontinuation_LE1 of_LE1 BIOENTITY therapy_BE12 with_BE12 appropriate_BE12 adjustment_BE12 of_BE12 the_BE12 BIOENTITY dose_RE2 if_RE2 necessary_RE2 
Cisapride_ddi|P|nefazodone|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 datum_LE1 indicate_LE1 that_LE1 BIOENTITY inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|itraconazole|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 indicate_LE1 that_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 oral_BE12 BIOGENERAL_BE12 marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|fluconazole|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 indicate_LE1 that_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 oral_BE12 BIOGENERAL_BE12 marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|ketoconazole|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 and_LE1 in_LE1 vivo_LE1 datum_LE1 indicate_LE1 that_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 oral_LE1 BIOENTITY marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|ketoconazole|cisapride|human_LE1 pharmacokinetic_LE1 datum_LE1 indicate_LE1 that_LE1 oral_LE1 BIOENTITY marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 mean_RE2 eight-fold_RE2 increase_RE2 in_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Cisapride_ddi|P|cisapride|ketoconazole|study_LE1 in_LE1 NUM_LE1 normal_LE1 male_LE1 and_LE1 female_LE1 volunteer_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|cimetidine|cisapride|BIOGENERAL_LE1 :_LE1 BIOENTITY coadministration_BE12 lead_BE12 to_BE12 increase_BE12 peak_BE12 plasma_BE12 concentration_BE12 and_BE12 auc_BE12 of_BE12 BIOENTITY there_RE2 be_RE2 no_RE2 effect_RE2 on_RE2 BIOGENERAL_RE2 absorption_RE2 when_RE2 it_RE2 be_RE2 coadminister_RE2 with_RE2 BIOGENERAL_RE2 
Cisapride_ddi|P|cimetidine|cisapride|the_LE1 gastrointestinal_LE1 absorption_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 accelerate_BE12 when_BE12 they_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Cisapride_ddi|P|ranitidine|cisapride|the_LE1 gastrointestinal_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 accelerate_BE12 when_BE12 they_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Cisapride_ddi|P|indinavir|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 datum_LE1 indicate_LE1 that_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|ritonavir|cisapride|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 datum_LE1 indicate_LE1 that_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY marked_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY which_RE2 can_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Cisapride_ddi|P|cisapride|sotalol|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 :_BE12 certain_BE12 BIOGENERAL_BE12 including_BE12 those_BE12 of_BE12 class_BE12 ia_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 class_BE12 iii_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY -rrb-;_RE2 
Cisapride_ddi|P|cisapride|procainamide|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 :_BE12 certain_BE12 BIOGENERAL_BE12 including_BE12 those_BE12 of_BE12 class_BE12 ia_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 and_RE2 class_RE2 iii_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -rrb-;_RE2 
Cisapride_ddi|P|cisapride|quinidine|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 :_BE12 certain_BE12 BIOGENERAL_BE12 including_BE12 those_BE12 of_BE12 class_BE12 ia_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 class_RE2 iii_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -rrb-;_RE2 
Cisapride_ddi|P|cisapride|antiarrhythmic|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 prolong_BE12 the_BE12 qt_BE12 interval_BE12 :_BE12 certain_BE12 BIOENTITY including_RE2 those_RE2 of_RE2 class_RE2 ia_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 class_RE2 iii_RE2 -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -rrb-;_RE2 
Cisatracurium Besylate_ddi|P|nimbex|succinylcholine|administration_LE1 of_LE1 NUM_LE1 -LRB-_LE1 NUM_LE1 ed95_LE1 -RRB-_LE1 BIOENTITY at_BE12 NUM_BE12 or_BE12 NUM_BE12 recovery_BE12 following_BE12 intubating_BE12 dose_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 produce_RE2 NUM_RE2 neuromuscular_RE2 block_RE2 
Cisatracurium Besylate_ddi|P|nimbex|succinylcholine|the_LE1 time_LE1 to_LE1 onset_LE1 of_LE1 maximum_LE1 block_LE1 following_LE1 BIOENTITY be_BE12 approximate_BE12 NUM_BE12 minute_BE12 fast_BE12 with_BE12 prior_BE12 administration_BE12 of_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|succinylcholine|nimbex|infusion_LE1 requirement_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 patient_LE1 administer_LE1 BIOENTITY prior_BE12 to_BE12 infusion_BE12 of_BE12 BIOENTITY be_RE2 comparable_RE2 to_RE2 or_RE2 slight_RE2 great_RE2 than_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 administer_RE2 
Cisatracurium Besylate_ddi|P|nitrous oxide|nimbex|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 administer_LE1 with_LE1 BIOENTITY to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 decrease_BE12 the_BE12 required_BE12 infusion_BE12 rate_BE12 of_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|enflurane|nimbex|BIOGENERAL_LE1 or_LE1 BIOENTITY administer_BE12 with_BE12 BIOGENERAL_BE12 to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 decrease_BE12 the_BE12 required_BE12 infusion_BE12 rate_BE12 of_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|isoflurane|nimbex|BIOENTITY or_BE12 BIOGENERAL_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 decrease_BE12 the_BE12 required_BE12 infusion_BE12 rate_BE12 of_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|nitrous oxide|nimbex|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 administer_LE1 with_LE1 BIOENTITY to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOENTITY and_RE2 decrease_RE2 the_RE2 required_RE2 infusion_RE2 rate_RE2 of_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|enflurane|nimbex|BIOGENERAL_LE1 or_LE1 BIOENTITY administer_BE12 with_BE12 BIOGENERAL_BE12 to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOENTITY and_RE2 decrease_RE2 the_RE2 required_RE2 infusion_RE2 rate_RE2 of_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|isoflurane|nimbex|BIOENTITY or_BE12 BIOGENERAL_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 to_BE12 achieve_BE12 NUM_BE12 mac_BE12 -lsb-minimum_BE12 alveolar_BE12 concentration_BE12 -rsb-_BE12 may_BE12 prolong_BE12 the_BE12 clinical_BE12 effective_BE12 duration_BE12 of_BE12 action_BE12 of_BE12 initial_BE12 and_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOENTITY and_RE2 decrease_RE2 the_RE2 required_RE2 infusion_RE2 rate_RE2 of_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|enflurane|nimbex|In_LE1 long_LE1 surgical_LE1 procedure_LE1 during_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 anesthesia_BE12 little_BE12 frequent_BE12 maintenance_BE12 dosing_BE12 low_BE12 maintenance_BE12 dose_BE12 or_BE12 reduce_BE12 infusion_BE12 rate_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 necessary_RE2 
Cisatracurium Besylate_ddi|P|isoflurane|nimbex|In_LE1 long_LE1 surgical_LE1 procedure_LE1 during_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY anesthesia_BE12 little_BE12 frequent_BE12 maintenance_BE12 dosing_BE12 low_BE12 maintenance_BE12 dose_BE12 or_BE12 reduce_BE12 infusion_BE12 rate_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 necessary_RE2 
Cisatracurium Besylate_ddi|P|nimbex|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|sodium colistemethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|nimbex|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|sodium colistemethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|nimbex|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY include_RE2 certain_RE2 BIOGENERAL_RE2 -LRB-_RE2 e._RE2 g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing agent|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e._RE2 g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e._RE2 g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nimbex|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|nondepolarizing neuromuscular blocking agent|carbamazepine|resistance_LE1 to_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 demonstrate_BE12 in_BE12 patient_BE12 chronic_BE12 administer_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Cisatracurium Besylate_ddi|P|nondepolarizing neuromuscular blocking agent|phenytoin|resistance_LE1 to_LE1 the_LE1 neuromuscular_LE1 block_LE1 action_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 demonstrate_BE12 in_BE12 patient_BE12 chronic_BE12 administer_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Cisatracurium Besylate_ddi|P|carbamazepine|nimbex|while_LE1 the_LE1 effect_LE1 of_LE1 chronic_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY therapy_BE12 on_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY be_RE2 unknown_RE2 slight_RE2 short_RE2 duration_RE2 of_RE2 neuromuscular_RE2 block_RE2 may_RE2 be_RE2 anticipate_RE2 and_RE2 infusion_RE2 rate_RE2 requirement_RE2 may_RE2 be_RE2 high_RE2 
Cisatracurium Besylate_ddi|P|phenytoin|nimbex|while_LE1 the_LE1 effect_LE1 of_LE1 chronic_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 therapy_BE12 on_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY be_RE2 unknown_RE2 slight_RE2 short_RE2 duration_RE2 of_RE2 neuromuscular_RE2 block_RE2 may_RE2 be_RE2 anticipate_RE2 and_RE2 infusion_RE2 rate_RE2 requirement_RE2 may_RE2 be_RE2 high_RE2 
Cisplatin_ddi|P|anticonvulsant agent|cisplatin|plasma_LE1 level_LE1 of_LE1 BIOENTITY may_BE12 become_BE12 subtherapeutic_BE12 during_BE12 BIOENTITY therapy_RE2 
Clavulanate_ddi|P|allopurinol|ampicillin|the_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY increase_RE2 substantial_RE2 the_RE2 incidence_RE2 of_RE2 rash_RE2 in_RE2 patient_RE2 receive_RE2 both_RE2 drug_RE2 as_RE2 compare_RE2 to_RE2 patient_RE2 receive_RE2 BIOGENERAL_RE2 alone_RE2 
Clavulanate_ddi|P|ampicillin|allopurinol|it_LE1 be_LE1 not_LE1 know_LE1 whether_LE1 this_LE1 potentiation_LE1 of_LE1 BIOENTITY rash_BE12 be_BE12 due_BE12 to_BE12 BIOENTITY or_RE2 the_RE2 hyperuricemia_RE2 present_RE2 in_RE2 these_RE2 patient_RE2 
Clavulanate_ddi|P|augmentin xr|contraceptive|In_LE1 common_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 efficacy_BE12 of_BE12 oral_BE12 BIOENTITY 
Clavulanate_ddi|P|broad-spectrum antibiotic|contraceptive|In_LE1 common_LE1 with_LE1 other_LE1 BIOENTITY BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 efficacy_BE12 of_BE12 oral_BE12 BIOENTITY 
Clemastine_ddi|P|antihistamine|alcohol|additive_LE1 cns_LE1 depression_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Clemastine_ddi|P|antihistamine|cns depressant|additive_LE1 cns_LE1 depression_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Clemastine_ddi|P|antihistamine|barbiturate|additive_LE1 cns_LE1 depression_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Clemastine_ddi|P|antihistamine|tranquilizer|additive_LE1 cns_LE1 depression_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Clemastine_ddi|P|antihistamine|cns depressant drug|patient_LE1 receive_LE1 BIOENTITY shall_BE12 be_BE12 advise_BE12 against_BE12 the_BE12 concurrent_BE12 use_BE12 of_BE12 other_BE12 BIOENTITY 
Clemastine_ddi|P|monoamine oxidase (mao) inhibitor|antihistamine|-LRB-_LE1 mao_LE1 -RRB-_LE1 BIOENTITY prolong_BE12 and_BE12 intensify_BE12 the_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Clidinium_ddi|P|tricyclic antidepressant|clidinium|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Clidinium_ddi|P|amantadine|clidinium|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Clidinium_ddi|P|maoi|clidinium|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Clidinium_ddi|P|clidinium|phenothiazine|BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Clidinium_ddi|P|clidinium|levodopa|BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Clidinium_ddi|P|clidinium|ketoconazole|BIOENTITY may_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Clindamycin_ddi|P|clindamycin|neuromuscular blocking agent|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 neuromuscular_BE12 blocking_BE12 property_BE12 that_BE12 may_BE12 enhance_BE12 the_BE12 action_BE12 of_BE12 other_BE12 BIOENTITY 
Clindamycin_ddi|P|clindamycin|erythromycin|antagonism_LE1 have_LE1 be_LE1 demonstrate_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 vitro_RE2 
Clofazimine_ddi|P|dapsone|lamprene|preliminary_LE1 datum_LE1 which_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 anti-inflammatory_BE12 activity_BE12 of_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 confirm_RE2 
Clofazimine_ddi|P|dapsone|clofazimine|if_LE1 leprosy-associated_LE1 inflammatory_LE1 reaction_LE1 develop_LE1 in_LE1 patient_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY it_RE2 be_RE2 still_RE2 advisable_RE2 to_RE2 continue_RE2 treatment_RE2 with_RE2 both_RE2 drug_RE2 
Clofibrate_ddi|P|anticoagulant|atromid-|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY 
Clofibrate_ddi|P|atromid-|tolbutamide|BIOENTITY may_BE12 displace_BE12 acidic_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY from_RE2 their_RE2 bind_RE2 site_RE2 
Clofibrate_ddi|P|atromid-|phenytoin|BIOENTITY may_BE12 displace_BE12 acidic_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 from_RE2 their_RE2 bind_RE2 site_RE2 
Clofibrate_ddi|P|tolbutamide|atromid-|the_LE1 hypoglycemic_LE1 effect_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 when_BE12 BIOENTITY be_RE2 give_RE2 concurrent_RE2 
Clofibrate_ddi|P|fibrate|lovastatin|fulminant_LE1 rhabdomyolysis_LE1 have_LE1 be_LE1 see_LE1 as_LE1 early_LE1 as_LE1 three_LE1 week_LE1 after_LE1 initiation_LE1 of_LE1 combined_LE1 therapy_LE1 with_LE1 another_LE1 BIOENTITY and_BE12 BIOENTITY but_RE2 may_RE2 be_RE2 see_RE2 after_RE2 several_RE2 month_RE2 
Clofibrate_ddi|P|lovastatin|fibrate|For_LE1 these_LE1 reason_LE1 it_LE1 be_LE1 feel_LE1 that_LE1 in_LE1 many_LE1 subject_LE1 who_LE1 have_LE1 have_LE1 unsatisfactory_LE1 lipid_LE1 response_LE1 to_LE1 either_LE1 drug_LE1 alone_LE1 the_LE1 possible_LE1 benefit_LE1 of_LE1 combined_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY do_RE2 not_RE2 outweigh_RE2 the_RE2 risk_RE2 of_RE2 severe_RE2 myopathy_RE2 rhabdomyolysis_RE2 and_RE2 acute_RE2 renal_RE2 failure_RE2 
Clofibrate_ddi|P|lovastatin|fibrate|therefore_LE1 the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY shall_RE2 general_RE2 be_RE2 avoid_RE2 
Clomipramine_ddi|P|anafranil|mao inhibitor|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 with_BE12 BIOENTITY 
Clomipramine_ddi|P|anafranil|sympathomimetic drug|close_LE1 supervision_LE1 and_LE1 careful_LE1 adjustment_LE1 of_LE1 dosage_LE1 be_LE1 require_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Clomipramine_ddi|P|anafranil|anticholinergic|close_LE1 supervision_LE1 and_LE1 careful_LE1 adjustment_LE1 of_LE1 dosage_LE1 be_LE1 require_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|guanethidine|several_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 block_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 similar_RE2 agent_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 because_RE2 of_RE2 its_RE2 structural_RE2 similarity_RE2 to_RE2 other_RE2 BIOGENERAL_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|clonidine|several_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 block_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 similar_RE2 agent_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 because_RE2 of_RE2 its_RE2 structural_RE2 similarity_RE2 to_RE2 other_RE2 BIOGENERAL_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|cmi|several_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 block_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 similar_BE12 agent_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY because_RE2 of_RE2 its_RE2 structural_RE2 similarity_RE2 to_RE2 other_RE2 BIOGENERAL_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|tricyclic antidepressant|several_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 block_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 similar_BE12 agent_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOGENERAL_BE12 because_BE12 of_BE12 its_BE12 structural_BE12 similarity_BE12 to_BE12 other_BE12 BIOENTITY 
Clomipramine_ddi|P|cmi|haloperidol|the_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY 
Clomipramine_ddi|P|fluoxetine|cmi|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 increase_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 hepatic_LE1 enzyme_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY as_RE2 well_RE2 
Clomipramine_ddi|P|cimetidine|cmi|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 increase_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 hepatic_LE1 enzyme_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY as_RE2 well_RE2 
Clomipramine_ddi|P|phenytoin|cmi|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 increase_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 hepatic_LE1 enzyme_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 decrease_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 hepatic_LE1 enzyme_LE1 inducer_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY as_RE2 well_RE2 
Clomipramine_ddi|P|barbiturate|cmi|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 increase_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 hepatic_LE1 enzyme_LE1 inhibitor_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 decrease_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 hepatic_LE1 enzyme_LE1 inducer_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY as_RE2 well_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|methylphenidate|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY or_RE2 hepatic_RE2 enzyme_RE2 inhibitor_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 decrease_RE2 by_RE2 the_RE2 concomitant_RE2 administration_RE2 of_RE2 hepatic_RE2 enzyme_RE2 inducer_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 as_RE2 well_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|cimetidine|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 decrease_RE2 by_RE2 the_RE2 concomitant_RE2 administration_RE2 of_RE2 hepatic_RE2 enzyme_RE2 inducer_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 as_RE2 well_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|fluoxetine|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 decrease_RE2 by_RE2 the_RE2 concomitant_RE2 administration_RE2 of_RE2 hepatic_RE2 enzyme_RE2 inducer_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 as_RE2 well_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|barbiturate|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 as_RE2 well_RE2 
Clomipramine_ddi|P|tricyclic antidepressant|phenytoin|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 be_BE12 increase_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 such_RE2 effect_RE2 may_RE2 be_RE2 anticipate_RE2 with_RE2 BIOGENERAL_RE2 as_RE2 well_RE2 
Clomipramine_ddi|P|methylphenidate|cmi|plasma_LE1 level_LE1 of_LE1 several_LE1 close_LE1 related_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 increase_LE1 by_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY or_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 such_BE12 effect_BE12 may_BE12 be_BE12 anticipate_BE12 with_BE12 BIOENTITY as_RE2 well_RE2 
Clomipramine_ddi|P|cmi|phenobarbital|administration_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 the_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY if_RE2 give_RE2 concomitant_RE2 
Clomipramine_ddi|P|fluvoxamine|tca|BIOENTITY have_BE12 also_BE12 be_BE12 show_BE12 to_BE12 inhibit_BE12 p450_BE12 1a2_BE12 isoform_BE12 also_BE12 involve_BE12 in_BE12 BIOENTITY 
Clomipramine_ddi|P|ssri|tcainteraction|the_LE1 extent_LE1 to_LE1 which_LE1 BIOENTITY may_RE2 pose_RE2 clinical_RE2 problem_RE2 will_RE2 depend_RE2 on_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 and_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 involve_RE2 
Clomipramine_ddi|P|tca|ssri|nevertheless_LE1 caution_LE1 be_LE1 indicate_LE1 in_LE1 the_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 any_BE12 of_BE12 the_BE12 BIOENTITY and_RE2 also_RE2 in_RE2 switching_RE2 from_RE2 one_RE2 class_RE2 to_RE2 the_RE2 other_RE2 
Clomipramine_ddi|P|tca|fluoxetine|Of_LE1 particular_LE1 importance_LE1 sufficient_LE1 time_LE1 must_LE1 elapse_LE1 before_LE1 initiate_LE1 BIOENTITY in_BE12 patient_BE12 be_BE12 withdrawn_BE12 from_BE12 BIOENTITY given_RE2 the_RE2 long_RE2 half-life_RE2 of_RE2 the_RE2 parent_RE2 and_RE2 active_RE2 metabolite_RE2 -LRB-_RE2 at_RE2 little_RE2 NUM_RE2 week_RE2 may_RE2 be_RE2 necessary_RE2 -rrb-._RE2 
Clomipramine_ddi|P|anafranil|digoxin|because_LE1 BIOGENERAL_LE1 be_LE1 high_LE1 bind_LE1 to_LE1 serum_LE1 protein_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 bind_BE12 to_BE12 protein_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 may_RE2 cause_RE2 increase_RE2 in_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 drug_RE2 potential_RE2 result_RE2 in_RE2 adverse_RE2 effect_RE2 
Clomipramine_ddi|P|anafranil|warfarin|because_LE1 BIOGENERAL_LE1 be_LE1 high_LE1 bind_LE1 to_LE1 serum_LE1 protein_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 take_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 bind_BE12 to_BE12 protein_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 may_RE2 cause_RE2 increase_RE2 in_RE2 plasma_RE2 concentration_RE2 of_RE2 these_RE2 drug_RE2 potential_RE2 result_RE2 in_RE2 adverse_RE2 effect_RE2 
Clonazepam_ddi|P|clonazepam|propantheline|In_LE1 study_LE1 in_LE1 which_LE1 the_LE1 NUM_LE1 mg_LE1 BIOGENERAL_LE1 oral_LE1 disintegrate_LE1 tablet_LE1 be_LE1 administer_LE1 with_LE1 and_LE1 without_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 with_LE1 multiple_LE1 effect_LE1 on_LE1 the_LE1 gi_LE1 tract_LE1 -RRB-_LE1 to_LE1 healthy_LE1 volunteer_LE1 the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 NUM_LE1 low_LE1 and_LE1 the_LE1 cmax_LE1 of_LE1 BIOENTITY be_BE12 NUM_BE12 low_BE12 when_BE12 the_BE12 oral_BE12 disintegrating_BE12 tablet_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY compared_RE2 to_RE2 when_RE2 it_RE2 be_RE2 give_RE2 alone_RE2 
Clonazepam_ddi|P|clonazepam|propantheline|In_LE1 study_LE1 in_LE1 which_LE1 the_LE1 NUM_LE1 mg_LE1 BIOENTITY oral_BE12 disintegrate_BE12 tablet_BE12 be_BE12 administer_BE12 with_BE12 and_BE12 without_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 with_RE2 multiple_RE2 effect_RE2 on_RE2 the_RE2 gi_RE2 tract_RE2 -RRB-_RE2 to_RE2 healthy_RE2 volunteer_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 NUM_RE2 low_RE2 and_RE2 the_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 NUM_RE2 low_RE2 when_RE2 the_RE2 oral_RE2 disintegrating_RE2 tablet_RE2 be_RE2 give_RE2 with_RE2 BIOGENERAL_RE2 compared_RE2 to_RE2 when_RE2 it_RE2 be_RE2 give_RE2 alone_RE2 
Clonazepam_ddi|P|phenobarbital|clonazepam|cytochrome_LE1 NUM_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY induce_BE12 BIOENTITY metabolism_RE2 cause_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Clonazepam_ddi|P|carbamazepine|clonazepam|cytochrome_LE1 NUM_LE1 inducer_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 induce_BE12 BIOENTITY metabolism_RE2 cause_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Clonazepam_ddi|P|phenytoin|clonazepam|cytochrome_LE1 NUM_LE1 inducer_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 induce_BE12 BIOENTITY metabolism_RE2 cause_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Clonazepam_ddi|P|antifungal agent|clonazepam|although_LE1 clinical_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 based_LE1 on_LE1 the_LE1 involvement_LE1 of_LE1 the_LE1 cytochrome_LE1 NUM_LE1 3a_LE1 family_LE1 in_LE1 BIOGENERAL_LE1 metabolism_LE1 inhibitor_LE1 of_LE1 this_LE1 enzyme_LE1 system_LE1 notable_LE1 oral_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Clonazepam_ddi|P|benzodiazepine clas|anticonvulsant drug|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 the_BE12 BIOGENERAL_BE12 and_BE12 by_BE12 other_BE12 BIOENTITY 
Clonazepam_ddi|P|benzodiazepine clas|alcohol|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|narcotic|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|barbiturate|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|nonbarbiturate hypnotic|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|antianxiety agent|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|phenothiazines classes of antipsychotic agent|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|thioxanthene classes of antipsychotic agent|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|butyrophenone classes of antipsychotic agent|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|monoamine oxidase inhibitor|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonazepam_ddi|P|benzodiazepine clas|tricyclic antidepressant|pharmacodynamic_LE1 interaction_LE1 :_LE1 the_LE1 cns-depressant_LE1 action_LE1 the_LE1 BIOENTITY drug_BE12 may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 the_BE12 BIOENTITY and_RE2 by_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|clonidine hydrochloride|tricyclic antidepressant|tablet_LE1 If_LE1 patient_LE1 receive_LE1 BIOENTITY be_BE12 also_BE12 take_BE12 BIOENTITY the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 reduce_RE2 thus_RE2 necessitate_RE2 increase_RE2 in_RE2 dosage_RE2 
Clonidine_ddi|P|clonidine hydrochloride|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|clonidine hydrochloride|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|clonidine hydrochloride|sedative|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY 
Clonidine_ddi|P|clonidine|alcohol|BIOGENERAL_LE1 in_LE1 combination_LE1 with_LE1 BIOGENERAL_LE1 enhance_LE1 the_LE1 manifestation_LE1 of_LE1 corneal_LE1 lesion_LE1 in_LE1 rat_LE1 epidural_LE1 injection_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|clonidine|barbiturate|BIOGENERAL_LE1 in_LE1 combination_LE1 with_LE1 BIOGENERAL_LE1 enhance_LE1 the_LE1 manifestation_LE1 of_LE1 corneal_LE1 lesion_LE1 in_LE1 rat_LE1 epidural_LE1 injection_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|clonidine|sedating drug|BIOGENERAL_LE1 in_LE1 combination_LE1 with_LE1 BIOGENERAL_LE1 enhance_LE1 the_LE1 manifestation_LE1 of_LE1 corneal_LE1 lesion_LE1 in_LE1 rat_LE1 epidural_LE1 injection_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 cns-depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY 
Clonidine_ddi|P|amitriptyline|clonidine|BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY enhance_RE2 the_RE2 manifestation_RE2 of_RE2 corneal_RE2 lesion_RE2 in_RE2 rat_RE2 epidural_RE2 injection_RE2 BIOGENERAL_RE2 may_RE2 potentiate_RE2 the_RE2 cns-depressive_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clonidine_ddi|P|narcotic analgesic|clonidine|BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Clonidine_ddi|P|tricyclic antidepressant|clonidine|BIOENTITY may_BE12 antagonize_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Clonidine_ddi|P|beta blocker|clonidine|BIOENTITY may_BE12 exacerbate_BE12 the_BE12 hypertensive_BE12 response_BE12 see_BE12 with_BE12 BIOENTITY withdrawl_RE2 
Clonidine_ddi|P|clonidine|digitali|also_LE1 due_LE1 to_LE1 the_LE1 potential_LE1 for_LE1 additive_LE1 effect_LE1 such_LE1 as_LE1 bradycardia_LE1 and_LE1 av_LE1 block_LE1 caution_LE1 be_LE1 warrant_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY with_BE12 agent_BE12 know_BE12 to_BE12 affect_BE12 sinus_BE12 node_BE12 function_BE12 or_BE12 av_BE12 nodal_BE12 conduction_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 .-rrb-_RE2 
Clonidine_ddi|P|clonidine|calcium channel blocker|also_LE1 due_LE1 to_LE1 the_LE1 potential_LE1 for_LE1 additive_LE1 effect_LE1 such_LE1 as_LE1 bradycardia_LE1 and_LE1 av_LE1 block_LE1 caution_LE1 be_LE1 warrant_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY with_BE12 agent_BE12 know_BE12 to_BE12 affect_BE12 sinus_BE12 node_BE12 function_BE12 or_BE12 av_BE12 nodal_BE12 conduction_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 .-rrb-_RE2 
Clonidine_ddi|P|clonidine|beta-blocker|also_LE1 due_LE1 to_LE1 the_LE1 potential_LE1 for_LE1 additive_LE1 effect_LE1 such_LE1 as_LE1 bradycardia_LE1 and_LE1 av_LE1 block_LE1 caution_LE1 be_LE1 warrant_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY with_BE12 agent_BE12 know_BE12 to_BE12 affect_BE12 sinus_BE12 node_BE12 function_BE12 or_BE12 av_BE12 nodal_BE12 conduction_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY .-rrb-_RE2 
Clonidine_ddi|P|fluphenazine|clonidine|there_LE1 be_LE1 one_LE1 report_LE1 case_LE1 of_LE1 patient_LE1 with_LE1 acute_LE1 delirium_LE1 associate_LE1 with_LE1 the_LE1 simultaneous_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY 
Clonidine_ddi|P|clonidine|anesthetic|epidural_LE1 BIOENTITY may_BE12 prolong_BE12 the_BE12 duration_BE12 of_BE12 pharmacologic_BE12 effect_BE12 of_BE12 epidural_BE12 local_BE12 BIOENTITY including_RE2 both_RE2 sensory_RE2 and_RE2 motor_RE2 blockade_RE2 
Clorazepate_ddi|P|clorazepate dipotassium|ethyl alcohol|animal_LE1 experience_LE1 indicate_LE1 that_LE1 BIOENTITY prolong_BE12 the_BE12 sleeping_BE12 time_BE12 after_BE12 BIOGENERAL_BE12 or_BE12 after_BE12 BIOENTITY increase_RE2 the_RE2 inhibitory_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 do_RE2 not_RE2 exhibit_RE2 monoamine_RE2 oxidase_RE2 inhibition_RE2 
Clorazepate_ddi|P|clorazepate dipotassium|chlorpromazine|animal_LE1 experience_LE1 indicate_LE1 that_LE1 BIOENTITY prolong_BE12 the_BE12 sleeping_BE12 time_BE12 after_BE12 BIOGENERAL_BE12 or_BE12 after_BE12 BIOGENERAL_BE12 increase_BE12 the_BE12 inhibitory_BE12 effect_BE12 of_BE12 BIOENTITY but_RE2 do_RE2 not_RE2 exhibit_RE2 monoamine_RE2 oxidase_RE2 inhibition_RE2 
Clorazepate_ddi|P|clorazepate dipotassium|hexobarbital|animal_LE1 experience_LE1 indicate_LE1 that_LE1 BIOENTITY prolong_BE12 the_BE12 sleeping_BE12 time_BE12 after_BE12 BIOENTITY or_RE2 after_RE2 BIOGENERAL_RE2 increase_RE2 the_RE2 inhibitory_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 do_RE2 not_RE2 exhibit_RE2 monoamine_RE2 oxidase_RE2 inhibition_RE2 
Clorazepate_ddi|P|benzodiazepine|narcotic|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clorazepate_ddi|P|benzodiazepine|phenothiazine|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clorazepate_ddi|P|benzodiazepine|monoamine oxidase inhibitor|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 
Clorazepate_ddi|P|benzodiazepine|antidepressant|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY 
Clorazepate_ddi|P|benzodiazepine|barbiturate|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Clozapine_ddi|P|clozapine|alcohol|Given_LE1 the_LE1 primary_LE1 cns_LE1 effect_LE1 of_LE1 BIOENTITY caution_BE12 be_BE12 advise_BE12 in_BE12 use_BE12 it_BE12 concomitant_BE12 with_BE12 other_BE12 cns-active_BE12 drug_BE12 or_BE12 BIOENTITY 
Clozapine_ddi|P|clozapine|benzodiazepine|although_LE1 it_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 that_LE1 there_LE1 be_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 initiate_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY or_RE2 any_RE2 other_RE2 BIOGENERAL_RE2 
Clozapine_ddi|P|clozapine|psychotropic drug|although_LE1 it_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 that_LE1 there_LE1 be_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 caution_LE1 be_LE1 advise_LE1 when_LE1 BIOENTITY be_BE12 initiate_BE12 in_BE12 patient_BE12 take_BE12 BIOGENERAL_BE12 or_BE12 any_BE12 other_BE12 BIOENTITY 
Clozapine_ddi|P|clozapine|atropine|BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 the_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY drug_RE2 
Clozapine_ddi|P|clozapine|antihypertensive drug|BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 the_RE2 anticholinergic_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 drug_RE2 
Clozapine_ddi|P|rifampin|clozapine|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 decrease_BE12 BIOENTITY plasma_RE2 level_RE2 result_RE2 in_RE2 decrease_RE2 in_RE2 effectiveness_RE2 of_RE2 previous_RE2 effective_RE2 BIOGENERAL_RE2 dose_RE2 
Clozapine_ddi|P|nicotine|clozapine|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 decrease_BE12 BIOENTITY plasma_RE2 level_RE2 result_RE2 in_RE2 decrease_RE2 in_RE2 effectiveness_RE2 of_RE2 previous_RE2 effective_RE2 BIOGENERAL_RE2 dose_RE2 
Clozapine_ddi|P|phenytoin|clozapine|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 decrease_BE12 BIOENTITY plasma_RE2 level_RE2 result_RE2 in_RE2 decrease_RE2 in_RE2 effectiveness_RE2 of_RE2 previous_RE2 effective_RE2 BIOGENERAL_RE2 dose_RE2 
Clozapine_ddi|P|erythromycin|clozapine|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY potential_RE2 result_RE2 in_RE2 adverse_RE2 effect_RE2 
Clozapine_ddi|P|caffeine|clozapine|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY potential_RE2 result_RE2 in_RE2 adverse_RE2 effect_RE2 
Clozapine_ddi|P|cimetidine|clozapine|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY potential_RE2 result_RE2 in_RE2 adverse_RE2 effect_RE2 
Clozapine_ddi|P|clozapine|carbamazepine|although_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 it_RE2 shall_RE2 be_RE2 note_RE2 that_RE2 discontinuation_RE2 of_RE2 concomitant_RE2 BIOGENERAL_RE2 administration_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 
Clozapine_ddi|P|carbamazepine|clozapine|although_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 it_LE1 shall_LE1 be_LE1 note_LE1 that_LE1 discontinuation_LE1 of_LE1 concomitant_LE1 BIOENTITY administration_BE12 may_BE12 result_BE12 in_BE12 increase_BE12 in_BE12 BIOENTITY plasma_RE2 level_RE2 
Clozapine_ddi|P|paroxetine|clozapine|BIOENTITY produce_BE12 only_BE12 minor_BE12 change_BE12 in_BE12 the_BE12 level_BE12 of_BE12 BIOENTITY and_RE2 its_RE2 metabolite_RE2 
Clozapine_ddi|P|clozapine|paroxetine|however_LE1 other_LE1 publish_LE1 report_LE1 describe_LE1 modest_LE1 elevation_LE1 -LRB-_LE1 little_LE1 than_LE1 twofold_LE1 -RRB-_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 metabolite_LE1 concentration_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Clozapine_ddi|P|clozapine|sertraline|however_LE1 other_LE1 publish_LE1 report_LE1 describe_LE1 modest_LE1 elevation_LE1 -LRB-_LE1 little_LE1 than_LE1 twofold_LE1 -RRB-_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 metabolite_LE1 concentration_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Clozapine_ddi|P|clozapine|fluoxetine|however_LE1 other_LE1 publish_LE1 report_LE1 describe_LE1 modest_LE1 elevation_LE1 -LRB-_LE1 little_LE1 than_LE1 twofold_LE1 -RRB-_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 metabolite_LE1 concentration_LE1 when_LE1 BIOENTITY be_BE12 take_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Clozapine_ddi|P|clozapine|fluvoxamine|therefore_LE1 such_LE1 combined_LE1 treatment_LE1 shall_LE1 be_LE1 approach_LE1 with_LE1 caution_LE1 and_LE1 patient_LE1 shall_LE1 be_LE1 monitor_LE1 close_LE1 when_LE1 BIOENTITY be_BE12 combine_BE12 with_BE12 these_BE12 drug_BE12 particular_BE12 with_BE12 BIOENTITY 
Clozapine_ddi|P|clozapine|encainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|quinidine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 that_BE12 inhibit_BE12 this_BE12 enzyme_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|antidepressant|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|phenothiazine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|propafenone|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|flecainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|carbamazepine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Clozapine_ddi|P|clozapine|type 1c antiarrhythmic|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Codeine_ddi|P|codeine|narcotic analgesic|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|tranquilizer|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|sedative-hypnotic|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|anesthetic|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|phenothiazine|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|alcohol|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOENTITY -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Codeine_ddi|P|codeine|cns depressant|BIOENTITY in_BE12 combination_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY -LRB-_RE2 include_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 additive_RE2 depressant_RE2 effect_RE2 
Colchicine_ddi|P|colchicine|acidifying agent|BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Colchicine_ddi|P|colchicine|alkalinizing agent|the_LE1 action_LE1 of_LE1 BIOENTITY be_BE12 potentiate_BE12 by_BE12 BIOENTITY 
Colchicine_ddi|P|colchicine|cns depressant|BIOENTITY may_BE12 increase_BE12 sensitivity_BE12 to_BE12 the_BE12 BIOENTITY 
Colchicine_ddi|P|sympathomimetic agent|colchicine|response_LE1 to_LE1 BIOENTITY may_BE12 be_BE12 enhance_BE12 by_BE12 BIOENTITY 
Colesevelam_ddi|P|welchol|verapamil|BIOENTITY decrease_BE12 the_BE12 cmax_BE12 and_BE12 auc_BE12 of_BE12 sustained-release_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 by_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Colesevelam_ddi|P|welchol|calan sr|BIOENTITY decrease_BE12 the_BE12 cmax_BE12 and_BE12 auc_BE12 of_BE12 sustained-release_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 by_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Colestipol_ddi|P|colestipol hydrochloride|propranolol|repeated_LE1 dose_LE1 of_LE1 BIOENTITY give_BE12 prior_BE12 to_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY in_RE2 human_RE2 trial_RE2 have_RE2 be_RE2 report_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 absorption_RE2 
Colestipol_ddi|P|propranolol|colestid|therefore_LE1 patient_LE1 on_LE1 BIOENTITY shall_BE12 be_BE12 observe_BE12 when_BE12 BIOENTITY tablet_RE2 be_RE2 either_RE2 add_RE2 or_RE2 delete_RE2 from_RE2 therapeutic_RE2 regimen_RE2 
Colestipol_ddi|P|chlorothiazide|colestipol hydrochloride|study_LE1 in_LE1 human_LE1 show_LE1 that_LE1 the_LE1 absorption_LE1 of_LE1 BIOENTITY as_BE12 reflect_BE12 in_BE12 urinary_BE12 excretion_BE12 be_BE12 marked_BE12 decrease_BE12 even_BE12 when_BE12 administer_BE12 one_BE12 hour_BE12 before_BE12 BIOENTITY 
Colestipol_ddi|P|tetracycline|colestipol hydrochloride|the_LE1 absorption_LE1 of_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 decrease_BE12 when_BE12 give_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Colestipol_ddi|P|hydrochlorothiazide|colestipol hydrochloride|the_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 decrease_BE12 when_BE12 give_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Colestipol_ddi|P|gemfibrozil|colestipol hydrochloride|the_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 significant_BE12 decrease_BE12 when_BE12 give_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Colestipol_ddi|P|furosemide|colestipol hydrochloride|the_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 decrease_BE12 when_BE12 give_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Colestipol_ddi|P|penicillin g|colestipol hydrochloride|the_LE1 absorption_LE1 of_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 significant_BE12 decrease_BE12 when_BE12 give_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Colestipol_ddi|P|colestipol hydrochloride|digitoxin|particular_LE1 caution_LE1 shall_LE1 be_LE1 observe_LE1 with_LE1 BIOGENERAL_LE1 since_LE1 there_LE1 be_LE1 conflict_LE1 result_LE1 for_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 availability_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Colestipol_ddi|P|colestipol hydrochloride|digoxin|particular_LE1 caution_LE1 shall_LE1 be_LE1 observe_LE1 with_LE1 BIOGENERAL_LE1 since_LE1 there_LE1 be_LE1 conflict_LE1 result_LE1 for_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 availability_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Colestipol_ddi|P|digitalis preparation|colestipol hydrochloride|particular_LE1 caution_LE1 shall_LE1 be_LE1 observe_LE1 with_LE1 BIOENTITY since_BE12 there_BE12 be_BE12 conflict_BE12 result_BE12 for_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY on_RE2 the_RE2 availability_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Colestipol_ddi|P|bile acid binding resin|hydrocortisone|BIOENTITY may_BE12 also_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 supplement_BE12 and_BE12 BIOENTITY 
Colestipol_ddi|P|bile acid binding resin|phosphate|BIOENTITY may_BE12 also_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 oral_BE12 BIOENTITY supplement_RE2 and_RE2 BIOGENERAL_RE2 
Colistimethate_ddi|P|sodium citrate|coly-mycin m|BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 other_LE1 drug_LE1 including_LE1 ether_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|decamethonium|coly-mycin m|BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 other_LE1 drug_LE1 including_LE1 ether_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|tubocurarine|coly-mycin m|BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY -RRB-_BE12 and_BE12 other_BE12 drug_BE12 including_BE12 ether_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|curariform muscle relaxant|coly-mycin m|BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 other_BE12 drug_BE12 including_BE12 ether_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|gallamine|coly-mycin m|BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 other_LE1 drug_LE1 including_LE1 ether_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|succinylcholine|coly-mycin m|BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 other_LE1 drug_LE1 including_LE1 ether_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 potentiate_BE12 the_BE12 neuromuscular_BE12 blocking_BE12 effect_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|sodium cephalothin|coly-mycin m|BIOENTITY may_BE12 enhance_BE12 the_BE12 nephrotoxicity_BE12 of_BE12 BIOENTITY parenteral_RE2 
Colistimethate_ddi|P|sodium cephalothin|coly-mycin m|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY parenteral_RE2 shall_RE2 be_RE2 avoid_RE2 
Conivaptan_ddi|P|digoxin|conivaptan|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY p-glycoprotein_BE12 substrate_BE12 with_BE12 oral_BE12 BIOENTITY result_RE2 in_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 cmax_RE2 and_RE2 auc_RE2 value_RE2 
Conivaptan_ddi|P|digoxin|vaprisol|therefore_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY the_RE2 clinician_RE2 shall_RE2 be_RE2 alert_RE2 to_RE2 the_RE2 possibility_RE2 of_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 level_RE2 
Corticotropin_ddi|P|corticotropin|diuretic|BIOENTITY may_BE12 accentuate_BE12 the_BE12 electrolyte_BE12 loss_BE12 associate_BE12 with_BE12 BIOENTITY therapy_RE2 
Cortisone acetate_ddi|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 require_BE12 increase_BE12 in_BE12 BIOENTITY dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|phenytoin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|rifampin|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|phenobarbital|corticosteroid|drug_LE1 that_LE1 induce_LE1 hepatic_LE1 enzyme_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dose_RE2 to_RE2 achieve_RE2 the_RE2 desired_RE2 response_RE2 
Cortisone acetate_ddi|P|troleandomycin|corticosteroid|drug_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 their_RE2 clearance_RE2 
Cortisone acetate_ddi|P|ketoconazole|corticosteroid|drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 decrease_RE2 their_RE2 clearance_RE2 
Cortisone acetate_ddi|P|corticosteroid|aspirin|BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 chronic_BE12 high_BE12 dose_BE12 BIOENTITY 
Cortisone acetate_ddi|P|salicylate|corticosteroid|this_LE1 can_LE1 lead_LE1 to_LE1 decrease_LE1 BIOGENERAL_LE1 serum_LE1 level_LE1 or_LE1 increase_LE1 the_LE1 risk_LE1 of_LE1 BIOENTITY toxicity_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Cortisone acetate_ddi|P|aspirin|cortico-steroid|BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY in_RE2 patient_RE2 suffer_RE2 from_RE2 hypopro-thrombinemia_RE2 
Cortisone acetate_ddi|P|corticosteroid|anticoagulant|the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 oral_BE12 BIOENTITY be_RE2 variable_RE2 
Cortisone acetate_ddi|P|anticoagulant|corticosteroid|there_LE1 be_LE1 report_LE1 of_LE1 enhance_LE1 as_LE1 well_LE1 as_LE1 diminish_LE1 effect_LE1 of_LE1 BIOENTITY when_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Cosyntropin_ddi|P|corticotropin|diuretic|BIOENTITY may_BE12 accentuate_BE12 the_BE12 electrolyte_BE12 loss_BE12 associate_BE12 with_BE12 BIOENTITY therapy_RE2 
Cromoglicate_ddi|P|cromolyn sodium|isoproterenol|the_LE1 addition_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY -LRB-_BE12 approximate_BE12 NUM_BE12 time_BE12 the_BE12 maximum_BE12 recommend_BE12 daily_BE12 inhalation_BE12 dose_BE12 in_BE12 adult_BE12 on_BE12 mg_BE12 basis_BE12 -RRB-_BE12 to_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY -LRB-_RE2 approximate_RE2 NUM_RE2 time_RE2 the_RE2 maximum_RE2 recommend_RE2 daily_RE2 inhalation_RE2 dose_RE2 in_RE2 adult_RE2 on_RE2 mg_RE2 basis_RE2 -RRB-_RE2 appear_RE2 to_RE2 have_RE2 increase_RE2 the_RE2 incidence_RE2 of_RE2 both_RE2 resorption_RE2 and_RE2 malformation_RE2 
Cyanocobalamin_ddi|P|colchicine|vitamin b12|BIOENTITY BIOGENERAL_BE12 and_BE12 heavy_BE12 BIOGENERAL_BE12 intake_BE12 for_BE12 long_BE12 than_BE12 NUM_BE12 week_BE12 may_BE12 produce_BE12 malabsorption_BE12 of_BE12 BIOENTITY 
Cyanocobalamin_ddi|P|para-aminosalicylic acid|vitamin b12|BIOGENERAL_LE1 BIOENTITY and_BE12 heavy_BE12 BIOGENERAL_BE12 intake_BE12 for_BE12 long_BE12 than_BE12 NUM_BE12 week_BE12 may_BE12 produce_BE12 malabsorption_BE12 of_BE12 BIOENTITY 
Cyanocobalamin_ddi|P|alcohol|vitamin b12|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 heavy_LE1 BIOENTITY intake_BE12 for_BE12 long_BE12 than_BE12 NUM_BE12 week_BE12 may_BE12 produce_BE12 malabsorption_BE12 of_BE12 BIOENTITY 
Cyclobenzaprine_ddi|P|flexeril|mao inhibitor|BIOENTITY may_BE12 have_BE12 life-threatening_BE12 interaction_BE12 with_BE12 BIOENTITY 
Cyclobenzaprine_ddi|P|flexeril|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Cyclobenzaprine_ddi|P|flexeril|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 
Cyclobenzaprine_ddi|P|flexeril|cns depressant|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Cyclobenzaprine_ddi|P|tricyclic antidepressant|guanethidine|BIOENTITY may_BE12 block_BE12 the_BE12 antihypertensive_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 similar_RE2 acting_RE2 compound_RE2 
Cyclobenzaprine_ddi|P|tricyclic antidepressant|tramadol|BIOENTITY may_BE12 enhance_BE12 the_BE12 seizure_BE12 risk_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY 
Cyclopentolate_ddi|P|cyclopentolate|carbachol|BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 anti-glaucoma_BE12 action_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Cyclopentolate_ddi|P|cyclopentolate|pilocarpine|BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 anti-glaucoma_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Cyclophosphamide_ddi|P|cyclophosphamide|phenobarbital|the_LE1 rate_LE1 of_LE1 metabolism_LE1 and_LE1 the_LE1 leukopenic_LE1 activity_LE1 of_LE1 BIOENTITY reported_BE12 be_BE12 increase_BE12 by_BE12 chronic_BE12 administration_BE12 of_BE12 high_BE12 dose_BE12 of_BE12 BIOENTITY 
Cyclophosphamide_ddi|P|cyclophosphamide|succinylcholine chloride|BIOENTITY treatment_BE12 which_BE12 cause_BE12 marked_BE12 and_BE12 persistent_BE12 inhibition_BE12 of_BE12 cholinesterase_BE12 activity_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Cyproheptadine_ddi|P|mao inhibitor|antihistamine|BIOENTITY prolong_BE12 and_BE12 intensify_BE12 the_BE12 anticholinergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Cyproheptadine_ddi|P|antihistamine|antianxiety agent|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Cyproheptadine_ddi|P|antihistamine|sedative|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Cyproheptadine_ddi|P|antihistamine|tranquilizer|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Cyproheptadine_ddi|P|antihistamine|cns depressant|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Cyproheptadine_ddi|P|antihistamine|hypnotic|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Cyproheptadine_ddi|P|antihistamine|alcohol|BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Dantrolene_ddi|P|dantrolene sodium|calcium channel blocker|it_LE1 be_LE1 recommend_LE1 that_LE1 the_LE1 combination_LE1 of_LE1 intravenous_LE1 BIOENTITY and_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 not_RE2 be_RE2 use_RE2 together_RE2 during_RE2 the_RE2 management_RE2 of_RE2 malignant_RE2 hyperthermia_RE2 crisis_RE2 until_RE2 the_RE2 relevance_RE2 of_RE2 these_RE2 finding_RE2 to_RE2 human_RE2 be_RE2 establish_RE2 
Dantrolene_ddi|P|dantrolene sodium|verapamil|it_LE1 be_LE1 recommend_LE1 that_LE1 the_LE1 combination_LE1 of_LE1 intravenous_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY not_RE2 be_RE2 use_RE2 together_RE2 during_RE2 the_RE2 management_RE2 of_RE2 malignant_RE2 hyperthermia_RE2 crisis_RE2 until_RE2 the_RE2 relevance_RE2 of_RE2 these_RE2 finding_RE2 to_RE2 human_RE2 be_RE2 establish_RE2 
Dantrolene_ddi|P|dantrolene|vecuronium|administration_LE1 of_LE1 BIOENTITY may_BE12 potentiate_BE12 BIOENTITY neuromuscular_RE2 block_RE2 
Dapsone_ddi|P|dapsone|folic acid antagonist|With_LE1 oral_LE1 BIOENTITY treatment_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 note_RE2 to_RE2 possible_RE2 increase_RE2 the_RE2 likelihood_RE2 of_RE2 hematologic_RE2 reaction_RE2 
Dapsone_ddi|P|dapsone|pyrimethamine|With_LE1 oral_LE1 BIOENTITY treatment_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY have_RE2 be_RE2 note_RE2 to_RE2 possible_RE2 increase_RE2 the_RE2 likelihood_RE2 of_RE2 hematologic_RE2 reaction_RE2 
Daptomycin_ddi|P|hmg-coa reductase inhibitor|fentanyl|experience_LE1 with_LE1 co-administration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 in_LE1 patient_LE1 be_LE1 limit_LE1 therefore_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 temporary_LE1 suspending_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Darifenacin_ddi|P|enablex|ketoconazole|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 exceed_BE12 NUM_BE12 mg_BE12 when_BE12 coadminister_BE12 with_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 -RRB-_RE2 
Darifenacin_ddi|P|enablex|ritonavir|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 exceed_BE12 NUM_BE12 mg_BE12 when_BE12 coadminister_BE12 with_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 -RRB-_RE2 
Darifenacin_ddi|P|enablex|itraconazole|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 exceed_BE12 NUM_BE12 mg_BE12 when_BE12 coadminister_BE12 with_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 -RRB-_RE2 
Darifenacin_ddi|P|enablex|clarithromycin|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 exceed_BE12 NUM_BE12 mg_BE12 when_BE12 coadminister_BE12 with_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 nefazadone_RE2 -RRB-_RE2 
Darifenacin_ddi|P|enablex|nelfinavir|the_LE1 daily_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 exceed_BE12 NUM_BE12 mg_BE12 when_BE12 coadminister_BE12 with_BE12 potent_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 nefazadone_RE2 -RRB-_RE2 
Darifenacin_ddi|P|enablex|tricyclic antidepressant|caution_LE1 shall_LE1 be_LE1 take_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 medication_BE12 that_BE12 be_BE12 predominant_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 window_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 -rrb-._RE2 
Darifenacin_ddi|P|enablex|flecainide|caution_LE1 shall_LE1 be_LE1 take_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 medication_BE12 that_BE12 be_BE12 predominant_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 window_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 -rrb-._RE2 
Darifenacin_ddi|P|enablex|thioridazine|caution_LE1 shall_LE1 be_LE1 take_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 medication_BE12 that_BE12 be_BE12 predominant_BE12 metabolize_BE12 by_BE12 cyp2d6_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 window_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 see_RE2 clinical_RE2 pharmacology_RE2 -rrb-._RE2 
Darifenacin_ddi|P|enablex|anticholinergic agent|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 frequency_RE2 and_RE2 severity_RE2 of_RE2 dry_RE2 mouth_RE2 constipation_RE2 blurred_RE2 vision_RE2 and_RE2 other_RE2 anticholinergic_RE2 pharmacological_RE2 effect_RE2 
Dasatinib_ddi|P|sprycel|ritonavir|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|atazanavir|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|indinavir|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|nefazodone|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|ketoconazole|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|itraconazole|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|erythromycin|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|telithromycin|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|clarithromycin|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|saquinavir|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|nelfinavir|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 inhibit_BE12 cyp3a4_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 increase_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 and_RE2 shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|sprycel|antacid|simultaneous_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 
Dasatinib_ddi|P|antacid|sprycel|if_LE1 BIOENTITY therapy_BE12 be_BE12 need_BE12 the_BE12 antacid_BE12 dose_BE12 shall_BE12 be_BE12 administer_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 the_BE12 dose_BE12 of_BE12 BIOENTITY 
Dasatinib_ddi|P|h2 blocker|dasatinib|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 long-term_LE1 suppression_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 by_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 reduce_BE12 BIOENTITY exposure_RE2 
Dasatinib_ddi|P|omeprazole|dasatinib|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 long-term_LE1 suppression_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 by_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 be_BE12 likely_BE12 to_BE12 reduce_BE12 BIOENTITY exposure_RE2 
Dasatinib_ddi|P|famotidine|dasatinib|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 long-term_LE1 suppression_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 by_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 reduce_BE12 BIOENTITY exposure_RE2 
Dasatinib_ddi|P|proton pump inhibitor|dasatinib|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 long-term_LE1 suppression_LE1 of_LE1 gastric_LE1 acid_LE1 secretion_LE1 by_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 reduce_BE12 BIOENTITY exposure_RE2 
Dasatinib_ddi|P|h2 blocker|sprycel|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Dasatinib_ddi|P|proton pump inhibitor|sprycel|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Dasatinib_ddi|P|h2 blocker|sprycel|the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 consider_LE1 in_LE1 place_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY therapy_RE2 
Dasatinib_ddi|P|proton pump inhibitor|sprycel|the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 consider_LE1 in_LE1 place_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY therapy_RE2 
Dasatinib_ddi|P|ergot alkaloid|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|ergotamine|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|dihydroergotamine|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|alfentanil|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|terfenadine|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|astemizole|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|cyclosporine|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|cisapride|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|pimozide|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|fentanyl|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|sirolimu|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|quinidine|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Dasatinib_ddi|P|tacrolimu|sprycel|therefore_LE1 cyp3a4_LE1 substrate_LE1 know_LE1 to_LE1 have_LE1 narrow_LE1 therapeutic_LE1 index_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Daunorubicin_ddi|P|cerubidine|doxorubicin|use_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 who_BE12 have_BE12 previous_BE12 receive_BE12 BIOENTITY increase_RE2 the_RE2 risk_RE2 of_RE2 cardiotoxicity_RE2 
Daunorubicin_ddi|P|cerubidine|doxorubicin|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 patient_BE12 who_BE12 have_BE12 previous_BE12 receive_BE12 the_BE12 recommend_BE12 maximum_BE12 cumulative_BE12 dose_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Daunorubicin_ddi|P|cyclophosphamide|cerubidine|BIOENTITY use_BE12 concurrent_BE12 with_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 in_RE2 increase_RE2 cardiotoxicity_RE2 
Deferasirox_ddi|P|exjade|aluminum|although_LE1 BIOGENERAL_LE1 have_LE1 low_LE1 affinity_LE1 for_LE1 BIOGENERAL_LE1 than_LE1 for_LE1 BIOGENERAL_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 take_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 
Demecarium bromide_ddi|P|humorsol|succinylcholine|possible_LE1 drug_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 with_RE2 other_RE2 BIOGENERAL_RE2 
Demecarium bromide_ddi|P|humorsol|anticholinesterase agent|possible_LE1 drug_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 other_BE12 BIOENTITY 
Demeclocycline_ddi|P|tetracycline|anticoagulant|because_LE1 the_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 depress_BE12 plasma_BE12 prothrombin_BE12 activity_BE12 patient_BE12 who_BE12 be_BE12 on_BE12 BIOENTITY therapy_RE2 may_RE2 require_RE2 downward_RE2 adjustment_RE2 of_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 
Demeclocycline_ddi|P|tetracycline clas|penicillin|since_LE1 bacteriostatic_LE1 drug_LE1 such_LE1 as_LE1 the_LE1 BIOENTITY of_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 the_BE12 bactericidal_BE12 action_BE12 of_BE12 BIOENTITY it_RE2 be_RE2 not_RE2 advisable_RE2 to_RE2 administer_RE2 these_RE2 drug_RE2 concomitant_RE2 
Demeclocycline_ddi|P|tetracycline|contraceptive|concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY may_RE2 render_RE2 oral_RE2 BIOGENERAL_RE2 little_RE2 effective_RE2 
Deserpidine_ddi|P|rauwolfia alkaloid|mao inhibitor|take_LE1 BIOENTITY while_BE12 you_BE12 be_BE12 take_BE12 or_BE12 within_BE12 NUM_BE12 week_BE12 of_BE12 take_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 central_RE2 nervous_RE2 system_RE2 depression_RE2 or_RE2 may_RE2 cause_RE2 severe_RE2 high_RE2 blood_RE2 pressure_RE2 reaction_RE2 
Desipramine_ddi|P|ssri|tca|the_LE1 extent_LE1 to_LE1 which_LE1 BIOENTITY interaction_RE2 may_RE2 pose_RE2 clinical_RE2 problem_RE2 will_RE2 depend_RE2 on_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 and_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 involve_RE2 
Desipramine_ddi|P|t.a.|ssri|nevertheless_LE1 caution_LE1 be_LE1 indicate_LE1 in_LE1 the_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 any_BE12 of_BE12 the_BE12 BIOENTITY and_RE2 also_RE2 in_RE2 switching_RE2 from_RE2 one_RE2 class_RE2 to_RE2 the_RE2 other_RE2 
Desipramine_ddi|P|desipramine|diazepam|if_LE1 BIOGENERAL_LE1 be_LE1 to_LE1 be_LE1 combine_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 careful_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 the_LE1 pharmacology_LE1 of_LE1 the_LE1 agent_LE1 employ_LE1 since_LE1 the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine|chlordiazepoxide|if_LE1 BIOGENERAL_LE1 be_LE1 to_LE1 be_LE1 combine_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 careful_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 the_LE1 pharmacology_LE1 of_LE1 the_LE1 agent_LE1 employ_LE1 since_LE1 the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine|benzodiazepine|if_LE1 BIOGENERAL_LE1 be_LE1 to_LE1 be_LE1 combine_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 careful_LE1 consideration_LE1 shall_LE1 be_LE1 give_LE1 to_LE1 the_LE1 pharmacology_LE1 of_LE1 the_LE1 agent_LE1 employ_LE1 since_LE1 the_LE1 sedative_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine hydrochloride|hypnotic|if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 combine_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY careful_RE2 consideration_RE2 shall_RE2 be_RE2 give_RE2 to_RE2 the_RE2 pharmacology_RE2 of_RE2 the_RE2 agent_RE2 employ_RE2 since_RE2 the_RE2 sedative_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine hydrochloride|hypnotic|if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 combine_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY careful_RE2 consideration_RE2 shall_RE2 be_RE2 give_RE2 to_RE2 the_RE2 pharmacology_RE2 of_RE2 the_RE2 agent_RE2 employ_RE2 since_RE2 the_RE2 sedative_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine hydrochloride|tranquilizer|if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 combine_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 careful_RE2 consideration_RE2 shall_RE2 be_RE2 give_RE2 to_RE2 the_RE2 pharmacology_RE2 of_RE2 the_RE2 agent_RE2 employ_RE2 since_RE2 the_RE2 sedative_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|desipramine hydrochloride|psychotropic agent|if_LE1 BIOENTITY be_BE12 to_BE12 be_BE12 combine_BE12 with_BE12 other_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 careful_RE2 consideration_RE2 shall_RE2 be_RE2 give_RE2 to_RE2 the_RE2 pharmacology_RE2 of_RE2 the_RE2 agent_RE2 employ_RE2 since_RE2 the_RE2 sedative_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 additive_RE2 
Desipramine_ddi|P|major tranquilizer|desipramine|both_LE1 the_LE1 sedative_LE1 and_LE1 anticholinergic_LE1 effect_LE1 of_LE1 the_LE1 BIOENTITY be_BE12 also_BE12 additive_BE12 to_BE12 those_BE12 of_BE12 BIOENTITY 
Desipramine_ddi|P|cimetidine|tricyclic antidepressant|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 produce_RE2 clinical_RE2 significant_RE2 increase_RE2 in_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Desipramine_ddi|P|tricyclic antidepressant|cimetidine|converse_LE1 decrease_LE1 in_LE1 plasma_LE1 level_LE1 of_LE1 the_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 upon_BE12 discontinuation_BE12 of_BE12 BIOENTITY which_RE2 may_RE2 result_RE2 in_RE2 the_RE2 loss_RE2 of_RE2 the_RE2 therapeutic_RE2 efficacy_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 NUM_RE2 
Desipramine_ddi|P|tricyclic antidepressant|fluoxetine|there_LE1 have_LE1 be_LE1 great_LE1 than_LE1 twofold_LE1 increase_LE1 of_LE1 previous_LE1 stable_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY when_BE12 BIOENTITY have_RE2 be_RE2 administer_RE2 in_RE2 combination_RE2 with_RE2 these_RE2 agent_RE2 
Dexamethasone_ddi|P|aminoglutethimide|corticosteroid|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 diminish_BE12 adrenal_BE12 suppression_BE12 by_BE12 BIOENTITY 
Dexamethasone_ddi|P|corticosteroid|diuretic|BIOGENERAL_LE1 injection_LE1 and_LE1 potassium-depleting_LE1 agent_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 potassium-depleting_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 development_RE2 of_RE2 hypokalemia_RE2 
Dexamethasone_ddi|P|corticosteroid|amphotericin b|BIOGENERAL_LE1 injection_LE1 and_LE1 potassium-depleting_LE1 agent_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 potassium-depleting_BE12 agent_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 development_RE2 of_RE2 hypokalemia_RE2 
Dexamethasone_ddi|P|amphotericin b|hydrocortisone|In_LE1 addition_LE1 there_LE1 have_LE1 be_LE1 case_LE1 report_LE1 in_LE1 which_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 follow_RE2 by_RE2 cardiac_RE2 enlargement_RE2 and_RE2 congestive_RE2 heart_RE2 failure_RE2 
Dexamethasone_ddi|P|macrolide antibiotic|corticosteroid|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 cause_BE12 significant_BE12 decrease_BE12 in_BE12 BIOENTITY clearance_RE2 
Dexamethasone_ddi|P|anticholinesterase agent|corticosteroid|BIOGENERAL_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 weakness_RE2 in_RE2 patient_RE2 with_RE2 myasthenia_RE2 gravis_RE2 
Dexamethasone_ddi|P|anticholinesterase agent|corticosteroid|if_LE1 possible_LE1 BIOENTITY shall_BE12 be_BE12 withdraw_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 before_BE12 initiate_BE12 BIOENTITY therapy_RE2 
Dexamethasone_ddi|P|corticosteroid|warfarin|BIOGENERAL_LE1 oral_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY usual_RE2 result_RE2 in_RE2 inhibition_RE2 of_RE2 response_RE2 to_RE2 BIOGENERAL_RE2 although_RE2 there_RE2 have_RE2 be_RE2 some_RE2 conflict_RE2 report_RE2 
Dexamethasone_ddi|P|corticosteroid|antidiabetic agent|BIOGENERAL_LE1 :_LE1 because_LE1 BIOENTITY may_BE12 increase_BE12 blood_BE12 glucose_BE12 concentration_BE12 dosage_BE12 adjustment_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 require_RE2 
Dexamethasone_ddi|P|cholestyramine|corticosteroid|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Dexamethasone_ddi|P|cyclosporine|corticosteroid|BIOGENERAL_LE1 :_LE1 increase_LE1 activity_LE1 of_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 occur_RE2 when_RE2 the_RE2 two_RE2 be_RE2 use_RE2 concurrent_RE2 
Dexamethasone_ddi|P|ephedrine|corticosteroid|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 decrease_RE2 blood_RE2 level_RE2 and_RE2 lessened_RE2 physiologic_RE2 activity_RE2 thus_RE2 require_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 dosage_RE2 
Dexamethasone_ddi|P|estrogen|corticosteroid|BIOGENERAL_LE1 include_LE1 oral_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 hepatic_BE12 metabolism_BE12 of_BE12 certain_BE12 BIOENTITY thereby_RE2 increase_RE2 their_RE2 effect_RE2 
Dexamethasone_ddi|P|carbamazepine|corticosteroid|hepatic_LE1 enzyme_LE1 inducer_LE1 inhibitor_LE1 and_LE1 substrate_LE1 :_LE1 drug_LE1 which_LE1 induce_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 -LRB-_LE1 cyp_LE1 3a4_LE1 -RRB-_LE1 enzyme_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 require_RE2 that_RE2 the_RE2 dosage_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 
Dexamethasone_ddi|P|rifampin|corticosteroid|hepatic_LE1 enzyme_LE1 inducer_LE1 inhibitor_LE1 and_LE1 substrate_LE1 :_LE1 drug_LE1 which_LE1 induce_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 -LRB-_LE1 cyp_LE1 3a4_LE1 -RRB-_LE1 enzyme_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 enhance_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 require_RE2 that_RE2 the_RE2 dosage_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 
Dexamethasone_ddi|P|phenytoin|corticosteroid|hepatic_LE1 enzyme_LE1 inducer_LE1 inhibitor_LE1 and_LE1 substrate_LE1 :_LE1 drug_LE1 which_LE1 induce_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 -LRB-_LE1 cyp_LE1 3a4_LE1 -RRB-_LE1 enzyme_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 require_RE2 that_RE2 the_RE2 dosage_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 
Dexamethasone_ddi|P|barbiturate|corticosteroid|hepatic_LE1 enzyme_LE1 inducer_LE1 inhibitor_LE1 and_LE1 substrate_LE1 :_LE1 drug_LE1 which_LE1 induce_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 -LRB-_LE1 cyp_LE1 3a4_LE1 -RRB-_LE1 enzyme_LE1 activity_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 enhance_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 require_RE2 that_RE2 the_RE2 dosage_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 
Dexamethasone_ddi|P|ketoconazole|corticosteroid|drug_LE1 which_LE1 inhibit_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 the_BE12 potential_BE12 to_BE12 result_BE12 in_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Dexamethasone_ddi|P|macrolide antibiotic|corticosteroid|drug_LE1 which_LE1 inhibit_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 the_BE12 potential_BE12 to_BE12 result_BE12 in_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Dexamethasone_ddi|P|erythromycin|corticosteroid|drug_LE1 which_LE1 inhibit_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 have_BE12 the_BE12 potential_BE12 to_BE12 result_BE12 in_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Dexamethasone_ddi|P|ketoconazole|corticosteroid|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 metabolism_BE12 of_BE12 certain_BE12 BIOENTITY by_RE2 up_RE2 to_RE2 NUM_RE2 lead_RE2 to_RE2 increase_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 side_RE2 effect_RE2 
Dexamethasone_ddi|P|ketoconazole|corticosteroid|In_LE1 addition_LE1 BIOENTITY alone_BE12 can_BE12 inhibit_BE12 adrenal_BE12 BIOENTITY synthesis_RE2 and_RE2 may_RE2 cause_RE2 adrenal_RE2 insufficiency_RE2 during_RE2 corticosteroid_RE2 withdrawal_RE2 
Dexamethasone_ddi|P|aspirin|corticosteroid|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 side_RE2 effect_RE2 
Dexamethasone_ddi|P|nonsteroidal antiinflammatory agent|corticosteroid|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 or_LE1 other_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY increase_RE2 the_RE2 risk_RE2 of_RE2 gastrointestinal_RE2 side_RE2 effect_RE2 
Dexamethasone_ddi|P|aspirin|corticosteroid|BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY in_RE2 hypoprothrombinemia_RE2 
Dexamethasone_ddi|P|salicylate|corticosteroid|the_LE1 clearance_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 increase_BE12 with_BE12 concurrent_BE12 use_BE12 of_BE12 BIOENTITY 
Dexamethasone_ddi|P|phenytoin|dexamethasone|BIOGENERAL_LE1 :_LE1 In_LE1 post-marketing_LE1 experience_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 both_LE1 increase_LE1 and_LE1 decrease_LE1 in_LE1 BIOENTITY level_BE12 with_BE12 BIOENTITY co-administration_RE2 lead_RE2 to_RE2 alteration_RE2 in_RE2 seizure_RE2 control_RE2 
Dexamethasone_ddi|P|corticosteroid|live vaccine|BIOGENERAL_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY therapy_BE12 may_BE12 exhibit_BE12 diminish_BE12 response_BE12 to_BE12 toxoid_BE12 and_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 due_RE2 to_RE2 inhibition_RE2 of_RE2 antibody_RE2 response_RE2 
Dexamethasone_ddi|P|corticosteroid|inactivated vaccine|BIOGENERAL_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY therapy_BE12 may_BE12 exhibit_BE12 diminish_BE12 response_BE12 to_BE12 toxoid_BE12 and_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY due_RE2 to_RE2 inhibition_RE2 of_RE2 antibody_RE2 response_RE2 
Dexamethasone_ddi|P|corticosteroid|live attenuated vaccine|BIOENTITY may_BE12 also_BE12 potentiate_BE12 the_BE12 replication_BE12 of_BE12 some_BE12 organism_BE12 contain_BE12 in_BE12 BIOENTITY 
Dexamethasone_ddi|P|vaccine|corticosteroid|routine_LE1 administration_LE1 of_LE1 BIOENTITY or_BE12 toxoid_BE12 shall_BE12 be_BE12 defer_BE12 until_BE12 BIOENTITY therapy_RE2 be_RE2 discontinue_RE2 if_RE2 possible_RE2 
Dexbrompheniramine_ddi|P|dexbrompheniramine|anticholinergic|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 potentiate_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 either_BE12 these_BE12 medication_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Dexbrompheniramine_ddi|P|dexbrompheniramine|cns depressant|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY -LRB-_RE2 may_RE2 potentiate_RE2 the_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 either_RE2 these_RE2 medication_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Dexbrompheniramine_ddi|P|dexbrompheniramine|alcohol|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 may_RE2 potentiate_RE2 the_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 either_RE2 these_RE2 medication_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 -LRB-_RE2 anticholinergic_RE2 effect_RE2 may_RE2 be_RE2 potentiate_RE2 when_RE2 these_RE2 medication_RE2 be_RE2 use_RE2 concurrent_RE2 with_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Dexbrompheniramine_ddi|P|dexbrompheniramine|monoamine oxidase (mao) inhibitor|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 may_BE12 potentiate_BE12 the_BE12 cns_BE12 depressant_BE12 effect_BE12 of_BE12 either_BE12 these_BE12 medication_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 -LRB-_BE12 anticholinergic_BE12 effect_BE12 may_BE12 be_BE12 potentiate_BE12 when_BE12 these_BE12 medication_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 concurrent_RE2 use_RE2 with_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 and_RE2 intensify_RE2 the_RE2 anticholinergic_RE2 and_RE2 cns_RE2 depressant_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|fluoxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|serotoninergic agent|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|fluvoxamine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|fluvoxamine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|fluoxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|paroxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|sertraline|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|serotoninergic agent|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|paroxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|fluoxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|sertraline|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|sertraline|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|venlafaxine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|fluvoxamine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|serotoninergic agent|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|monoamine oxidase inhibitor|paroxetine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|maoi|venlafaxine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|selegiline hydrochloride|venlafaxine|In_LE1 patient_LE1 receive_LE1 nonselective_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 
Dexfenfluramine_ddi|P|dexfenfluramine|mao inhibitor|because_LE1 BIOGENERAL_LE1 be_LE1 serotonin_LE1 releaser_LE1 and_LE1 reuptake_LE1 inhibitor_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Dexfenfluramine_ddi|P|mao inhibitor|dexfenfluramine|at_LE1 little_LE1 NUM_LE1 day_LE1 shall_LE1 elapse_LE1 between_LE1 discontinuation_LE1 of_LE1 BIOENTITY and_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Dexfenfluramine_ddi|P|dexfenfluramine|mao inhibitor|at_LE1 little_LE1 NUM_LE1 week_LE1 shall_LE1 elapse_LE1 between_LE1 discontinuation_LE1 of_LE1 BIOENTITY and_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Dexfenfluramine_ddi|P|selective serotonin reuptake inhibitor|imitrex|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Dexfenfluramine_ddi|P|selective serotonin reuptake inhibitor|sumatriptan succinate|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Dexfenfluramine_ddi|P|ssri|sumatriptan succinate|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Dexfenfluramine_ddi|P|ssri|dihydroergotamine|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY 
Dexfenfluramine_ddi|P|selective serotonin reuptake inhibitor|dihydroergotamine|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY 
Dexfenfluramine_ddi|P|ssri|imitrex|rare_LE1 but_LE1 serious_LE1 constellation_LE1 of_LE1 symptom_LE1 term_LE1 serotonin_LE1 syndrome_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 agent_BE12 for_BE12 migraine_BE12 therapy_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Dexfenfluramine_ddi|P|dexfenfluramine|serotoninergic agent|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 with_BE12 other_BE12 BIOENTITY 
Dexmedetomidine_ddi|P|precedex|sedative|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 likely_RE2 to_RE2 lead_RE2 to_RE2 enhancement_RE2 of_RE2 effect_RE2 
Dexmedetomidine_ddi|P|precedex|hypnotic|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 be_RE2 likely_RE2 to_RE2 lead_RE2 to_RE2 enhancement_RE2 of_RE2 effect_RE2 
Dexmedetomidine_ddi|P|precedex|opioid|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY be_RE2 likely_RE2 to_RE2 lead_RE2 to_RE2 enhancement_RE2 of_RE2 effect_RE2 
Dexmedetomidine_ddi|P|precedex|anesthetic|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 likely_RE2 to_RE2 lead_RE2 to_RE2 enhancement_RE2 of_RE2 effect_RE2 
Dexmedetomidine_ddi|P|precedex|sedative|however_LE1 due_LE1 to_LE1 possible_LE1 pharmacodynamic_LE1 interaction_LE1 when_LE1 co-administer_LE1 with_LE1 BIOGENERAL_LE1 reduction_LE1 in_LE1 dosage_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 concomitant_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 require_RE2 
Dexmedetomidine_ddi|P|precedex|anesthetic|however_LE1 due_LE1 to_LE1 possible_LE1 pharmacodynamic_LE1 interaction_LE1 when_LE1 co-administer_LE1 with_LE1 BIOGENERAL_LE1 reduction_LE1 in_LE1 dosage_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 concomitant_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 require_RE2 
Dexmedetomidine_ddi|P|precedex|opioid|however_LE1 due_LE1 to_LE1 possible_LE1 pharmacodynamic_LE1 interaction_LE1 when_LE1 co-administer_LE1 with_LE1 BIOGENERAL_LE1 reduction_LE1 in_LE1 dosage_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 concomitant_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 be_RE2 require_RE2 
Dexmedetomidine_ddi|P|precedex|hypnotic|however_LE1 due_LE1 to_LE1 possible_LE1 pharmacodynamic_LE1 interaction_LE1 when_LE1 co-administer_LE1 with_LE1 BIOGENERAL_LE1 reduction_LE1 in_LE1 dosage_LE1 of_LE1 BIOENTITY on_BE12 the_BE12 concomitant_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 require_RE2 
Dextroamphetamine_ddi|P|ascorbic acid|amphetamine|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY fruit_BE12 juice_BE12 etc._BE12 -RRB-_BE12 low_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|reserpine|amphetamine|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 fruit_BE12 juice_BE12 etc._BE12 -RRB-_BE12 low_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|glutamic acid hcl|amphetamine|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 fruit_BE12 juice_BE12 etc._BE12 -RRB-_BE12 low_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|guanethidine|amphetamine|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 fruit_BE12 juice_BE12 etc._BE12 -RRB-_BE12 low_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|gastrointestinal acidifying agent|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 fruit_BE12 juice_BE12 etc._BE12 -RRB-_BE12 low_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|urinary acidifying agent|amphetamine|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 ionize_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 increase_RE2 urinary_RE2 excretion_RE2 
Dextroamphetamine_ddi|P|sodium acid phosphate|amphetamine|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY etc._BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 ionize_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 increase_RE2 urinary_RE2 excretion_RE2 
Dextroamphetamine_ddi|P|ammonium chloride|amphetamine|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 ionize_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 increase_RE2 urinary_RE2 excretion_RE2 
Dextroamphetamine_ddi|P|adrenergic blocker|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|sodium bicarbonate|amphetamine|alkalinizing_LE1 agent_LE1 :_LE1 gastrointestinal_LE1 alkalinizing_LE1 agent_LE1 -LRB-_LE1 BIOENTITY etc._BE12 -RRB-_BE12 increase_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|thiazide|amphetamine|urinary_LE1 alkalinizing_LE1 agent_LE1 -LRB-_LE1 BIOGENERAL_LE1 some_LE1 BIOENTITY -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 non-ionized_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 decrease_RE2 urinary_RE2 excretion_RE2 
Dextroamphetamine_ddi|P|acetazolamide|amphetamine|urinary_LE1 alkalinizing_LE1 agent_LE1 -LRB-_LE1 BIOENTITY some_BE12 BIOGENERAL_BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 non-ionized_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 decrease_RE2 urinary_RE2 excretion_RE2 
Dextroamphetamine_ddi|P|amphetamine|sympathomimetic agent|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 activity_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|tricyclic|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Dextroamphetamine_ddi|P|d-amphetamine|protriptyline|BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 possible_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Dextroamphetamine_ddi|P|d-amphetamine|desipramine|BIOENTITY with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Dextroamphetamine_ddi|P|d-amphetamine|tricyclic|BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 and_BE12 possible_BE12 other_BE12 BIOENTITY cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Dextroamphetamine_ddi|P|maoi antidepressant|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY as_BE12 well_BE12 as_BE12 metabolite_BE12 of_BE12 BIOGENERAL_BE12 slow_BE12 BIOENTITY metabolism_RE2 
Dextroamphetamine_ddi|P|furazolidone|amphetamine|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 as_LE1 well_LE1 as_LE1 metabolite_LE1 of_LE1 BIOENTITY slow_BE12 BIOENTITY metabolism_RE2 
Dextroamphetamine_ddi|P|amphetamine|antihistamine|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 counteract_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|antihypertensive|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 antagonize_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|chlorpromazine|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY block_BE12 dopamine_BE12 and_BE12 norepinephrine_BE12 reuptake_BE12 thus_BE12 inhibit_BE12 the_BE12 central_BE12 stimulant_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 can_RE2 be_RE2 use_RE2 to_RE2 treat_RE2 BIOGENERAL_RE2 poisoning_RE2 
Dextroamphetamine_ddi|P|amphetamine|ethosuximide|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|haloperidol|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY block_BE12 dopamine_BE12 and_BE12 norepinephrine_BE12 reuptake_BE12 thus_BE12 inhibit_BE12 the_BE12 central_BE12 stimulant_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|lithium carbonate|BIOGENERAL_LE1 :_LE1 the_LE1 stimulatory_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|meperidine|BIOGENERAL_LE1 :_LE1 BIOENTITY potentiate_BE12 the_BE12 analgesic_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|acidifying agent|BIOGENERAL_LE1 therapy_LE1 :_LE1 urinary_LE1 excretion_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 and_BE12 efficacy_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY use_RE2 in_RE2 BIOGENERAL_RE2 therapy_RE2 
Dextroamphetamine_ddi|P|amphetamine|norepinephrine|BIOGENERAL_LE1 :_LE1 BIOENTITY enhance_BE12 the_BE12 adrenergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|phenobarbital|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|phenytoin|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|propoxyphene|amphetamine|BIOGENERAL_LE1 :_LE1 In_LE1 case_LE1 of_LE1 BIOENTITY overdosage_BE12 BIOENTITY cns_RE2 stimulation_RE2 be_RE2 potentiate_RE2 and_RE2 fatal_RE2 convulsion_RE2 can_RE2 occur_RE2 
Dextroamphetamine_ddi|P|amphetamine|veratrum alkaloid|BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Dextroamphetamine_ddi|P|amphetamine|corticosteroid|drug_LE1 test_LE1 interaction_LE1 :_LE1 BIOENTITY can_BE12 cause_BE12 significant_BE12 elevation_BE12 in_BE12 plasma_BE12 BIOENTITY level_RE2 
Dichlorphenamide_ddi|P|aspirin|carbonic anhydrase inhibitor|caution_LE1 be_LE1 advise_LE1 in_LE1 patient_LE1 receive_LE1 concomitant_LE1 high-dose_LE1 BIOENTITY and_BE12 BIOENTITY as_RE2 anorexia_RE2 tachypnea_RE2 lethargy_RE2 and_RE2 coma_RE2 have_RE2 be_RE2 rare_RE2 report_RE2 due_RE2 to_RE2 possible_RE2 drug_RE2 interaction_RE2 
Diclofenac_ddi|P|diclofenac|aspirin|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 because_RE2 BIOGENERAL_RE2 be_RE2 displace_RE2 from_RE2 its_RE2 binding_RE2 site_RE2 during_RE2 the_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 low_RE2 plasma_RE2 concentration_RE2 peak_RE2 plasma_RE2 level_RE2 and_RE2 auc_RE2 value_RE2 
Diclofenac_ddi|P|diclofenac|aspirin|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 because_LE1 BIOENTITY be_BE12 displace_BE12 from_BE12 its_BE12 binding_BE12 site_BE12 during_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 low_RE2 plasma_RE2 concentration_RE2 peak_RE2 plasma_RE2 level_RE2 and_RE2 auc_RE2 value_RE2 
Diclofenac_ddi|P|diclofenac|nsaid|BIOGENERAL_LE1 :_LE1 while_LE1 study_LE1 have_LE1 not_LE1 show_LE1 BIOENTITY to_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 caution_BE12 shall_BE12 be_BE12 exercise_BE12 nonetheless_BE12 since_BE12 interaction_BE12 have_BE12 be_BE12 see_BE12 with_BE12 other_BE12 BIOENTITY 
Diclofenac_ddi|P|nsaid|warfarin|because_LE1 prostaglandin_LE1 play_LE1 important_LE1 role_LE1 in_LE1 hemostasis_LE1 and_LE1 BIOGENERAL_LE1 affect_LE1 platelet_LE1 function_LE1 as_LE1 well_LE1 concurrent_LE1 therapy_LE1 with_LE1 all_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY require_RE2 close_RE2 monitoring_RE2 of_RE2 patient_RE2 to_RE2 be_RE2 certain_RE2 that_RE2 no_RE2 change_RE2 in_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 be_RE2 require_RE2 
Diclofenac_ddi|P|diclofenac|warfarin|because_LE1 prostaglandin_LE1 play_LE1 important_LE1 role_LE1 in_LE1 hemostasis_LE1 and_LE1 BIOGENERAL_LE1 affect_LE1 platelet_LE1 function_LE1 as_LE1 well_LE1 concurrent_LE1 therapy_LE1 with_LE1 all_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY and_BE12 BIOENTITY require_RE2 close_RE2 monitoring_RE2 of_RE2 patient_RE2 to_RE2 be_RE2 certain_RE2 that_RE2 no_RE2 change_RE2 in_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 be_RE2 require_RE2 
Diclofenac_ddi|P|diclofenac|digoxin|ingestion_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 nephrotoxicity_RE2 
Diclofenac_ddi|P|diclofenac|methotrexate|ingestion_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 serum_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 increase_RE2 BIOGENERAL_RE2 nephrotoxicity_RE2 
Diclofenac_ddi|P|diclofenac|cyclosporine|ingestion_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 serum_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 increase_BE12 BIOENTITY nephrotoxicity_RE2 
Diclofenac_ddi|P|nsaid|cyclosporine|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOGENERAL_LE1 or_LE1 who_LE1 increase_LE1 their_LE1 BIOGENERAL_LE1 dose_LE1 or_LE1 any_LE1 other_LE1 BIOENTITY while_BE12 take_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|diclofenac|digoxin|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOENTITY or_BE12 who_BE12 increase_BE12 their_BE12 BIOGENERAL_BE12 dose_BE12 or_BE12 any_BE12 other_BE12 BIOGENERAL_BE12 while_BE12 take_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|diclofenac|methotrexate|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOENTITY or_BE12 who_BE12 increase_BE12 their_BE12 BIOGENERAL_BE12 dose_BE12 or_BE12 any_BE12 other_BE12 BIOGENERAL_BE12 while_BE12 take_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|diclofenac|cyclosporine|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOENTITY or_BE12 who_BE12 increase_BE12 their_BE12 BIOGENERAL_BE12 dose_BE12 or_BE12 any_BE12 other_BE12 BIOGENERAL_BE12 while_BE12 take_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|nsaid|digoxin|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOGENERAL_LE1 or_LE1 who_LE1 increase_LE1 their_LE1 BIOGENERAL_LE1 dose_LE1 or_LE1 any_LE1 other_LE1 BIOENTITY while_BE12 take_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|nsaid|methotrexate|patient_LE1 who_LE1 begin_LE1 take_LE1 BIOGENERAL_LE1 or_LE1 who_LE1 increase_LE1 their_LE1 BIOGENERAL_LE1 dose_LE1 or_LE1 any_LE1 other_LE1 BIOENTITY while_BE12 take_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 develop_RE2 toxicity_RE2 characteristic_RE2 for_RE2 these_RE2 drug_RE2 
Diclofenac_ddi|P|diclofenac|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY decrease_BE12 BIOENTITY renal_RE2 clearance_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 
Diclofenac_ddi|P|diclofenac|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY decrease_BE12 BIOGENERAL_BE12 renal_BE12 clearance_BE12 and_BE12 increase_BE12 BIOENTITY plasma_RE2 level_RE2 
Diclofenac_ddi|P|diclofenac|lithium|In_LE1 patient_LE1 take_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 BIOGENERAL_RE2 toxicity_RE2 may_RE2 develop_RE2 
Diclofenac_ddi|P|insulin|diclofenac|there_LE1 be_LE1 rare_LE1 report_LE1 however_LE1 from_LE1 marketing_LE1 experience_LE1 of_LE1 change_LE1 in_LE1 effect_LE1 of_LE1 BIOENTITY or_BE12 oral_BE12 BIOGENERAL_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY that_RE2 necessitate_RE2 change_RE2 in_RE2 the_RE2 dose_RE2 of_RE2 such_RE2 agent_RE2 
Diclofenac_ddi|P|hypoglycemic agent|diclofenac|there_LE1 be_LE1 rare_LE1 report_LE1 however_LE1 from_LE1 marketing_LE1 experience_LE1 of_LE1 change_LE1 in_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 oral_LE1 BIOENTITY in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY that_RE2 necessitate_RE2 change_RE2 in_RE2 the_RE2 dose_RE2 of_RE2 such_RE2 agent_RE2 
Diclofenac_ddi|P|diclofenac|insulin|direct_LE1 causal_LE1 relationship_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 but_LE1 physician_LE1 shall_LE1 consider_LE1 the_LE1 possibility_LE1 that_LE1 BIOENTITY may_BE12 alter_BE12 diabetic_BE12 patient_BE12 response_BE12 to_BE12 BIOENTITY or_RE2 oral_RE2 BIOGENERAL_RE2 
Diclofenac_ddi|P|diclofenac|hypoglycemic agent|direct_LE1 causal_LE1 relationship_LE1 have_LE1 not_LE1 be_LE1 establish_LE1 but_LE1 physician_LE1 shall_LE1 consider_LE1 the_LE1 possibility_LE1 that_LE1 BIOENTITY may_BE12 alter_BE12 diabetic_BE12 patient_BE12 response_BE12 to_BE12 BIOGENERAL_BE12 or_BE12 oral_BE12 BIOENTITY 
Diclofenac_ddi|P|nsaid|diuretic|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY can_BE12 inhibit_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Diclofenac_ddi|P|diclofenac|diuretic|BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY 
Diclofenac_ddi|P|phenobarbital|diclofenac|BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 to_LE1 have_LE1 occur_LE1 in_LE1 patient_LE1 on_LE1 chronic_LE1 BIOENTITY treatment_BE12 following_BE12 the_BE12 initiation_BE12 of_BE12 BIOENTITY therapy_RE2 
Diclofenac_ddi|P|diclofenac|salicylic acid|protein_LE1 binding_LE1 in_LE1 vitro_LE1 BIOENTITY interfere_BE12 minimal_BE12 or_BE12 not_BE12 at_BE12 all_BE12 with_BE12 the_BE12 protein_BE12 binding_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 decrease_RE2 in_RE2 binding_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 decrease_RE2 in_RE2 binding_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 
Diclofenac_ddi|P|diclofenac|prednisolone|protein_LE1 binding_LE1 in_LE1 vitro_LE1 BIOENTITY interfere_BE12 minimal_BE12 or_BE12 not_BE12 at_BE12 all_BE12 with_BE12 the_BE12 protein_BE12 binding_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 decrease_BE12 in_BE12 binding_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 decrease_RE2 in_RE2 binding_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 
Diclofenac_ddi|P|diclofenac|tolbutamide|protein_LE1 binding_LE1 in_LE1 vitro_LE1 BIOENTITY interfere_BE12 minimal_BE12 or_BE12 not_BE12 at_BE12 all_BE12 with_BE12 the_BE12 protein_BE12 binding_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 decrease_BE12 in_BE12 binding_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 decrease_RE2 in_RE2 binding_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 
Diclofenac_ddi|P|diclofenac|warfarin|protein_LE1 binding_LE1 in_LE1 vitro_LE1 BIOENTITY interfere_BE12 minimal_BE12 or_BE12 not_BE12 at_BE12 all_BE12 with_BE12 the_BE12 protein_BE12 binding_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 decrease_BE12 in_BE12 binding_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 decrease_BE12 in_BE12 binding_BE12 -RRB-_BE12 or_BE12 BIOENTITY 
Dicloxacillin_ddi|P|tetracycline|penicillin|BIOENTITY BIOGENERAL_BE12 may_BE12 antagonize_BE12 the_BE12 bactercidal_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 concurrent_RE2 use_RE2 of_RE2 these_RE2 drug_RE2 shall_RE2 be_RE2 avoid_RE2 
Dicyclomine_ddi|P|anticholinergic agent|digoxin|BIOENTITY may_BE12 affect_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 various_BE12 drug_BE12 such_BE12 as_BE12 slow_BE12 dissolve_BE12 dosage_BE12 form_BE12 of_BE12 BIOENTITY 
Dicyclomine_ddi|P|anticholinergic drug|metoclopramide|BIOENTITY may_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 drug_BE12 that_BE12 alter_BE12 gastrointestinal_BE12 motility_BE12 such_BE12 as_BE12 BIOENTITY 
Dicyclomine_ddi|P|antacid|anticholinergic agent|because_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY simultaneous_RE2 use_RE2 of_RE2 these_RE2 drug_RE2 shall_RE2 be_RE2 avoid_RE2 
Didanosine_ddi|P|allopurinol|videx|BIOGENERAL_LE1 :_LE1 the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 increase_LE1 about_LE1 NUM_LE1 when_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 be_BE12 coadminister_BE12 with_BE12 single_BE12 NUM_BE12 dose_BE12 of_BE12 BIOENTITY to_RE2 two_RE2 patient_RE2 with_RE2 renal_RE2 impairment_RE2 -LRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 ml_RE2 -rrb-._RE2 
Didanosine_ddi|P|magnesium|videx|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY chewable_RE2 buffered_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 potentiate_RE2 adverse_RE2 event_RE2 associate_RE2 with_RE2 the_RE2 BIOGENERAL_RE2 component_RE2 
Didanosine_ddi|P|antacid|videx|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY chewable_RE2 buffered_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 potentiate_RE2 adverse_RE2 event_RE2 associate_RE2 with_RE2 the_RE2 BIOGENERAL_RE2 component_RE2 
Didanosine_ddi|P|aluminum|videx|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY with_BE12 BIOENTITY chewable_RE2 buffered_RE2 tablet_RE2 or_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 potentiate_RE2 adverse_RE2 event_RE2 associate_RE2 with_RE2 the_RE2 BIOGENERAL_RE2 component_RE2 
Didanosine_ddi|P|itraconazole|videx|drug_LE1 Whose_LE1 absorption_LE1 can_LE1 be_LE1 affect_LE1 by_LE1 the_LE1 level_LE1 of_LE1 acidity_LE1 in_LE1 the_LE1 stomach_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 dosing_BE12 with_BE12 BIOENTITY 
Didanosine_ddi|P|ketoconazole|videx|drug_LE1 Whose_LE1 absorption_LE1 can_LE1 be_LE1 affect_LE1 by_LE1 the_LE1 level_LE1 of_LE1 acidity_LE1 in_LE1 the_LE1 stomach_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 administer_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 dosing_BE12 with_BE12 BIOENTITY 
Didanosine_ddi|P|videx|ganciclovir|BIOGENERAL_LE1 :_LE1 administration_LE1 of_LE1 BIOENTITY NUM_BE12 hour_BE12 prior_BE12 to_BE12 or_BE12 concurrent_BE12 with_BE12 oral_BE12 BIOENTITY be_RE2 associate_RE2 with_RE2 NUM_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 increase_RE2 in_RE2 the_RE2 steady-state_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -rrb-._RE2 
Didanosine_ddi|P|videx|ganciclovir|NUM_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 decrease_LE1 in_LE1 the_LE1 steady-state_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 observe_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 BIOENTITY but_RE2 not_RE2 when_RE2 the_RE2 two_RE2 drug_RE2 be_RE2 administer_RE2 simultaneous_RE2 -LRB-_RE2 NUM_RE2 -rrb-._RE2 
Didanosine_ddi|P|ciprofloxacin|calcium|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 administer_LE1 at_LE1 little_LE1 NUM_LE1 hour_LE1 after_LE1 or_LE1 NUM_LE1 hour_LE1 before_LE1 dosing_LE1 with_LE1 BIOGENERAL_LE1 because_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Didanosine_ddi|P|ciprofloxacin|aluminum|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 administer_LE1 at_LE1 little_LE1 NUM_LE1 hour_LE1 after_LE1 or_LE1 NUM_LE1 hour_LE1 before_LE1 dosing_LE1 with_LE1 BIOGENERAL_LE1 because_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Didanosine_ddi|P|videx|ciprofloxacin|BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 after_BE12 or_BE12 NUM_BE12 hour_BE12 before_BE12 dosing_BE12 with_BE12 BIOENTITY because_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 decrease_RE2 when_RE2 administer_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Didanosine_ddi|P|ciprofloxacin|magnesium|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 administer_LE1 at_LE1 little_LE1 NUM_LE1 hour_LE1 after_LE1 or_LE1 NUM_LE1 hour_LE1 before_LE1 dosing_LE1 with_LE1 BIOGENERAL_LE1 because_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Didanosine_ddi|P|ciprofloxacin|videx|In_LE1 eight_LE1 hiv-infected_LE1 patient_LE1 the_LE1 steady-state_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 decrease_LE1 average_LE1 of_LE1 NUM_LE1 -LRB-_LE1 NUM_LE1 ci_LE1 NUM_LE1 NUM_LE1 -RRB-_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 market_BE12 chewable_BE12 tablet_BE12 formulation_BE12 of_BE12 BIOENTITY 
Didanosine_ddi|P|ciprofloxacin|didanosine|the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 decrease_LE1 average_LE1 of_LE1 NUM_LE1 in_LE1 NUM_LE1 healthy_LE1 subject_LE1 given_LE1 BIOENTITY and_BE12 BIOENTITY tablet_RE2 concurrent_RE2 
Didanosine_ddi|P|ciprofloxacin|didanosine|In_LE1 single_LE1 subject_LE1 give_LE1 one_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 hour_BE12 after_BE12 dose_BE12 of_BE12 BIOENTITY tablet_RE2 great_RE2 than_RE2 NUM_RE2 reduction_RE2 in_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 observe_RE2 
Didanosine_ddi|P|quinolone antibiotic|calcium|plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Didanosine_ddi|P|quinolone antibiotic|aluminum|plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Didanosine_ddi|P|quinolone antibiotic|magnesium|plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 decrease_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Didanosine_ddi|P|delavirdine|videx|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 significant_LE1 decrease_LE1 in_LE1 the_LE1 auc_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 occur_BE12 following_BE12 simultaneous_BE12 administration_BE12 of_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Didanosine_ddi|P|indinavir|videx|interaction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 significant_LE1 decrease_LE1 in_LE1 the_LE1 auc_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 and_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 -RRB-_BE12 occur_BE12 following_BE12 simultaneous_BE12 administration_BE12 of_BE12 these_BE12 agent_BE12 with_BE12 BIOENTITY 
Didanosine_ddi|P|delavirdine|videx|to_LE1 avoid_LE1 this_LE1 interaction_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 given_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 dosing_BE12 with_BE12 BIOENTITY 
Didanosine_ddi|P|indinavir|videx|to_LE1 avoid_LE1 this_LE1 interaction_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY shall_BE12 be_BE12 given_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 dosing_BE12 with_BE12 BIOENTITY 
Diethylpropion_ddi|P|diethylpropion|guanethidine|converse_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 i.e._BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Diethylpropion_ddi|P|diethylpropion|antihypertensive drug|converse_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 BIOENTITY -LRB-_RE2 i.e._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Diethylpropion_ddi|P|diethylpropion|a-methyldopa|converse_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 i.e._BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
Diethylpropion_ddi|P|phenothiazine|diethylpropion|concurrent_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 antagonize_BE12 the_BE12 anorectic_BE12 effect_BE12 of_BE12 BIOENTITY 
Diflunisal_ddi|P|diflunisal|warfarin|oral_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 normal_LE1 volunteer_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 prothrombin_RE2 time_RE2 
Diflunisal_ddi|P|diflunisal|acenocoumarol|oral_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 normal_LE1 volunteer_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 prothrombin_RE2 time_RE2 
Diflunisal_ddi|P|diflunisal|phenprocoumon|oral_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 normal_LE1 volunteer_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY result_RE2 in_RE2 prolongation_RE2 of_RE2 prothrombin_RE2 time_RE2 
Diflunisal_ddi|P|diflunisal|coumarin|this_LE1 may_LE1 occur_LE1 because_LE1 BIOENTITY competitive_BE12 displace_BE12 BIOENTITY from_RE2 protein_RE2 binding_RE2 site_RE2 
Diflunisal_ddi|P|diflunisal|anticoagulant|according_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 oral_BE12 BIOENTITY the_RE2 prothrombin_RE2 time_RE2 shall_RE2 be_RE2 close_RE2 monitor_RE2 during_RE2 and_RE2 for_RE2 several_RE2 day_RE2 after_RE2 concomitant_RE2 drug_RE2 administration_RE2 
Diflunisal_ddi|P|diflunisal|hydrochlorothiazide|BIOGENERAL_LE1 :_LE1 In_LE1 normal_LE1 volunteer_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 significant_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Diflunisal_ddi|P|diflunisal|hydrochlorothiazide|BIOENTITY decrease_BE12 the_BE12 hyperuricemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Diflunisal_ddi|P|diflunisal|furosemide|BIOENTITY decrease_BE12 the_BE12 hyperuricemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Diflunisal_ddi|P|antacid|diflunisal|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY may_BE12 reduce_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Diflunisal_ddi|P|diflunisal|acetaminophen|BIOGENERAL_LE1 :_LE1 In_LE1 normal_LE1 volunteer_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Diflunisal_ddi|P|diflunisal|acetaminophen|since_LE1 BIOGENERAL_LE1 in_LE1 high_LE1 dose_LE1 have_LE1 be_LE1 associate_LE1 with_LE1 hepatotoxicity_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 use_RE2 cautious_RE2 with_RE2 careful_RE2 monitoring_RE2 of_RE2 patient_RE2 
Diflunisal_ddi|P|diflunisal|acetaminophen|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 dog_RE2 but_RE2 not_RE2 in_RE2 rat_RE2 at_RE2 approximate_RE2 NUM_RE2 time_RE2 the_RE2 recommend_RE2 maximum_RE2 human_RE2 therapeutic_RE2 dose_RE2 of_RE2 each_RE2 -LRB-_RE2 NUM_RE2 to_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 -RRB-_RE2 result_RE2 in_RE2 great_RE2 gastrointestinal_RE2 toxicity_RE2 than_RE2 when_RE2 either_RE2 drug_RE2 be_RE2 administer_RE2 alone_RE2 
Diflunisal_ddi|P|diflunisal|methotrexate|BIOGENERAL_LE1 :_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Diflunisal_ddi|P|nonsteroidal anti-inflammatory drug|methotrexate|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY and_RE2 to_RE2 potentiate_RE2 its_RE2 toxicity_RE2 
Diflunisal_ddi|P|nonsteroial anti-inflammatory drug|cyclosporine|BIOGENERAL_LE1 :_LE1 administration_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 toxicity_RE2 possible_RE2 due_RE2 to_RE2 decrease_RE2 synthesis_RE2 of_RE2 renal_RE2 prostacyclin_RE2 
Diflunisal_ddi|P|nsaid|cyclosporine|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY and_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Diflunisal_ddi|P|diflunisal|indomethacin|BIOGENERAL_LE1 :_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY to_BE12 normal_BE12 volunteer_BE12 receive_BE12 BIOENTITY decrease_RE2 the_RE2 renal_RE2 clearance_RE2 and_RE2 significant_RE2 increase_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Diflunisal_ddi|P|indomethacin|diflunisal|In_LE1 some_LE1 patient_LE1 the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 fatal_RE2 gastrointestinal_RE2 hemorrhage_RE2 
Diflunisal_ddi|P|indomethacin|diflunisal|therefore_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 use_RE2 concomitant_RE2 
Diflunisal_ddi|P|diflunisal|nsaid|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY tablet_BE12 and_BE12 other_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 due_RE2 to_RE2 the_RE2 increase_RE2 possibility_RE2 of_RE2 gastrointestinal_RE2 toxicity_RE2 with_RE2 little_RE2 or_RE2 no_RE2 increase_RE2 in_RE2 efficacy_RE2 
Diflunisal_ddi|P|diflunisal|aspirin|BIOGENERAL_LE1 :_LE1 In_LE1 normal_LE1 volunteer_LE1 small_LE1 decrease_LE1 in_LE1 BIOGENERAL_LE1 level_LE1 be_LE1 observe_LE1 when_LE1 multiple_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Diflunisal_ddi|P|diflunisal|sulindac|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 normal_RE2 volunteer_RE2 result_RE2 in_RE2 lowering_RE2 of_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 active_RE2 sulindac_RE2 sulfide_RE2 metabolite_RE2 by_RE2 approximate_RE2 one-third_RE2 
Diflunisal_ddi|P|diflunisal|naproxen|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 normal_RE2 volunteer_RE2 have_RE2 no_RE2 effect_RE2 on_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 significant_RE2 decrease_RE2 the_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 glucuronide_RE2 metabolite_RE2 
Digoxin_ddi|P|potassium-depleting diuretic|digitali|BIOENTITY be_BE12 major_BE12 contribute_BE12 factor_BE12 to_BE12 BIOENTITY toxicity_RE2 
Digoxin_ddi|P|alprazolam|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|spironolactone|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|indomethacin|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|itraconazole|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|amiodarone|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|propafenone|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|quinidine|digoxin|BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|verapamil|digoxin|BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 raise_BE12 the_BE12 serum_BE12 BIOENTITY concentration_RE2 due_RE2 to_RE2 reduction_RE2 in_RE2 clearance_RE2 and_RE2 in_RE2 volume_RE2 of_RE2 distribution_RE2 of_RE2 the_RE2 drug_RE2 with_RE2 the_RE2 implication_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|erythromycin|digoxin|BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 and_BE12 possible_BE12 other_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 BIOENTITY absorption_RE2 in_RE2 patient_RE2 who_RE2 inactivate_RE2 BIOGENERAL_RE2 by_RE2 bacterial_RE2 metabolism_RE2 in_RE2 the_RE2 low_RE2 intestine_RE2 so_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|clarithromycin|digoxin|BIOGENERAL_LE1 and_LE1 BIOENTITY -LRB-_BE12 and_BE12 possible_BE12 other_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 BIOENTITY absorption_RE2 in_RE2 patient_RE2 who_RE2 inactivate_RE2 BIOGENERAL_RE2 by_RE2 bacterial_RE2 metabolism_RE2 in_RE2 the_RE2 low_RE2 intestine_RE2 so_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|macrolide antibiotic|digoxin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 and_LE1 possible_LE1 other_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 BIOENTITY absorption_RE2 in_RE2 patient_RE2 who_RE2 inactivate_RE2 BIOGENERAL_RE2 by_RE2 bacterial_RE2 metabolism_RE2 in_RE2 the_RE2 low_RE2 intestine_RE2 so_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|tetracycline|digoxin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 and_LE1 possible_LE1 other_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 BIOENTITY absorption_RE2 in_RE2 patient_RE2 who_RE2 inactivate_RE2 BIOGENERAL_RE2 by_RE2 bacterial_RE2 metabolism_RE2 in_RE2 the_RE2 low_RE2 intestine_RE2 so_RE2 that_RE2 BIOGENERAL_RE2 intoxication_RE2 may_RE2 result_RE2 
Digoxin_ddi|P|propantheline|digoxin|BIOENTITY and_BE12 BIOGENERAL_BE12 by_BE12 decrease_BE12 gut_BE12 motility_BE12 may_BE12 increase_BE12 BIOENTITY absorption_RE2 
Digoxin_ddi|P|diphenoxylate|digoxin|BIOGENERAL_LE1 and_LE1 BIOENTITY by_BE12 decrease_BE12 gut_BE12 motility_BE12 may_BE12 increase_BE12 BIOENTITY absorption_RE2 
Digoxin_ddi|P|sulfasalazine|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 anticancer_BE12 drug_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|neomycin|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 certain_BE12 anticancer_BE12 drug_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|cholestyramine|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY certain_BE12 anticancer_BE12 drug_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|metoclopramide|digoxin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 certain_LE1 anticancer_LE1 drug_LE1 and_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|antacid|digoxin|BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 anticancer_BE12 drug_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|kaolin|digoxin|BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 anticancer_BE12 drug_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 interfere_BE12 with_BE12 intestinal_BE12 BIOENTITY absorption_RE2 result_RE2 in_RE2 unexpected_RE2 low_RE2 serum_RE2 concentration_RE2 
Digoxin_ddi|P|rifampin|digoxin|BIOENTITY may_BE12 decrease_BE12 serum_BE12 BIOENTITY concentration_RE2 especial_RE2 in_RE2 patient_RE2 with_RE2 renal_RE2 dysfunction_RE2 by_RE2 increase_RE2 the_RE2 non-renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Digoxin_ddi|P|thyroid|digoxin|BIOENTITY administration_BE12 to_BE12 digitalized_BE12 hypothyroid_BE12 patient_BE12 may_BE12 increase_BE12 the_BE12 dose_BE12 requirement_BE12 of_BE12 BIOENTITY 
Digoxin_ddi|P|digoxin|sympathomimetic|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY increase_RE2 the_RE2 risk_RE2 of_RE2 cardiac_RE2 arrhythmia_RE2 
Digoxin_ddi|P|calcium channel blocker|digoxin|although_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 be_RE2 useful_RE2 in_RE2 combination_RE2 to_RE2 control_RE2 atrial_RE2 fibrillation_RE2 their_RE2 additive_RE2 effect_RE2 on_RE2 av_RE2 node_RE2 conduction_RE2 can_RE2 result_RE2 in_RE2 advanced_RE2 or_RE2 complete_RE2 heart_RE2 block_RE2 
Digoxin_ddi|P|beta-adrenergic blocker|digoxin|although_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 be_RE2 useful_RE2 in_RE2 combination_RE2 to_RE2 control_RE2 atrial_RE2 fibrillation_RE2 their_RE2 additive_RE2 effect_RE2 on_RE2 av_RE2 node_RE2 conduction_RE2 can_RE2 result_RE2 in_RE2 advanced_RE2 or_RE2 complete_RE2 heart_RE2 block_RE2 
Dihydroergotamine_ddi|P|d.h.e. 45|peripheral vasoconstrictor|BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 injection_BE12 usp_BE12 shall_BE12 not_BE12 be_BE12 use_BE12 with_BE12 BIOENTITY because_RE2 the_RE2 combination_RE2 may_RE2 cause_RE2 synergistic_RE2 elevation_RE2 of_RE2 blood_RE2 pressure_RE2 
Dihydroergotamine_ddi|P|dihydroergotamine mesylate|peripheral vasoconstrictor|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 injection_BE12 usp_BE12 shall_BE12 not_BE12 be_BE12 use_BE12 with_BE12 BIOENTITY because_RE2 the_RE2 combination_RE2 may_RE2 cause_RE2 synergistic_RE2 elevation_RE2 of_RE2 blood_RE2 pressure_RE2 
Dihydroergotamine_ddi|P|sumatriptan|d.h.e. 45|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 cause_BE12 coronary_BE12 artery_BE12 vasospasm_BE12 and_BE12 its_BE12 effect_BE12 can_BE12 be_BE12 additive_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 injection_RE2 usp_RE2 
Dihydroergotamine_ddi|P|sumatriptan|dihydroergotamine mesylate|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 cause_BE12 coronary_BE12 artery_BE12 vasospasm_BE12 and_BE12 its_BE12 effect_BE12 can_BE12 be_BE12 additive_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 injection_RE2 usp_RE2 
Dihydroergotamine_ddi|P|sumatriptan|d.h.e. 45|BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 injection_RE2 usp_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 .._RE2 
Dihydroergotamine_ddi|P|sumatriptan|dihydroergotamine mesylate|BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 injection_RE2 usp_RE2 shall_RE2 not_RE2 be_RE2 take_RE2 within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 .._RE2 
Dihydroergotamine_ddi|P|propranolol|ergotamine|BIOGENERAL_LE1 :_LE1 although_LE1 the_LE1 result_LE1 of_LE1 clinical_LE1 study_LE1 do_LE1 not_LE1 indicate_LE1 safe_LE1 problem_LE1 associate_LE1 with_LE1 the_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 injection_LE1 usp_LE1 to_LE1 subject_LE1 already_LE1 receive_LE1 BIOGENERAL_LE1 there_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 vasoconstrictive_BE12 action_BE12 of_BE12 BIOENTITY by_RE2 block_RE2 the_RE2 vasodilating_RE2 property_RE2 of_RE2 epinephrine_RE2 
Dihydroergotamine_ddi|P|nicotine|ergot|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 provoke_BE12 vasoconstriction_BE12 in_BE12 some_BE12 patient_BE12 predispose_BE12 to_BE12 great_BE12 ischemic_BE12 response_BE12 to_BE12 BIOENTITY therapy_RE2 
Dihydroergotamine_ddi|P|ergot alkaloid clas|macrolide clas|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 agent_LE1 of_LE1 the_LE1 BIOENTITY of_BE12 which_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 injection_BE12 usp_BE12 be_BE12 member_BE12 have_BE12 be_BE12 show_BE12 to_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 of_BE12 the_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 unchanged_RE2 alkaloid_RE2 and_RE2 peripheral_RE2 vasoconstriction_RE2 
Dihydroergotamine_ddi|P|dihydroergotamine mesylate|macrolide clas|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 agent_LE1 of_LE1 the_LE1 BIOGENERAL_LE1 of_LE1 which_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 injection_BE12 usp_BE12 be_BE12 member_BE12 have_BE12 be_BE12 show_BE12 to_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 of_BE12 the_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 unchanged_RE2 alkaloid_RE2 and_RE2 peripheral_RE2 vasoconstriction_RE2 
Dihydroergotamine_ddi|P|d.h.e. 45|macrolide clas|BIOGENERAL_LE1 -LRB-_LE1 e._LE1 g._LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 agent_LE1 of_LE1 the_LE1 BIOGENERAL_LE1 of_LE1 which_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 injection_BE12 usp_BE12 be_BE12 member_BE12 have_BE12 be_BE12 show_BE12 to_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 of_BE12 the_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 level_RE2 of_RE2 unchanged_RE2 alkaloid_RE2 and_RE2 peripheral_RE2 vasoconstriction_RE2 
Dihydroergotamine_ddi|P|ergotamine|antibiotic|vasospastic_LE1 reaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 therapeutic_LE1 dose_LE1 of_LE1 BIOENTITY drug_BE12 when_BE12 co-administer_BE12 with_BE12 these_BE12 BIOENTITY 
Dihydroergotamine_ddi|P|5-ht1 agonist|ssri|BIOGENERAL_LE1 :_LE1 weakness_LE1 hyperreflexia_LE1 and_LE1 incoordination_LE1 have_LE1 be_LE1 report_LE1 rare_LE1 when_LE1 BIOENTITY have_BE12 be_BE12 co-administer_BE12 with_BE12 BIOENTITY -LRB-_RE2 e._RE2 
Dihydrotachysterol_ddi|P|thiazide diuretic|dihydrotachysterol|administration_LE1 of_LE1 BIOENTITY to_BE12 hypoparathyroid_BE12 patient_BE12 who_BE12 be_BE12 concurrent_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY may_RE2 cause_RE2 hypercalcemia_RE2 
Diltiazem_ddi|P|beta-blocker|tiazac|pharmacologic_LE1 study_LE1 indicate_LE1 that_LE1 there_LE1 may_LE1 be_LE1 additive_LE1 effect_LE1 in_LE1 prolong_LE1 av_LE1 conduction_LE1 when_LE1 use_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Diltiazem_ddi|P|digitali|tiazac|pharmacologic_LE1 study_LE1 indicate_LE1 that_LE1 there_LE1 may_LE1 be_LE1 additive_LE1 effect_LE1 in_LE1 prolong_LE1 av_LE1 conduction_LE1 when_LE1 use_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Diltiazem_ddi|P|diltiazem hydrochloride|propranolol|administration_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY in_RE2 five_RE2 normal_RE2 volunteer_RE2 result_RE2 in_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 in_RE2 all_RE2 subject_RE2 and_RE2 bioavailability_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 increase_RE2 approximate_RE2 NUM_RE2 %._RE2 
Diltiazem_ddi|P|propranolol|diltiazem|in_LE1 vitro_LE1 BIOENTITY appear_BE12 to_BE12 be_BE12 displace_BE12 from_BE12 its_BE12 binding_BE12 site_BE12 by_BE12 BIOENTITY 
Diltiazem_ddi|P|cimetidine|diltiazem|study_LE1 in_LE1 six_LE1 healthy_LE1 volunteer_LE1 have_LE1 show_LE1 significant_LE1 increase_LE1 in_LE1 peak_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 and_LE1 auc_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 after_LE1 NUM_LE1 course_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY 60mg_RE2 
Diltiazem_ddi|P|cimetidine|diltiazem|the_LE1 effect_LE1 may_LE1 be_LE1 mediate_LE1 by_LE1 BIOENTITY known_BE12 inhibition_BE12 of_BE12 hepatic_BE12 cytochrome_BE12 NUM_BE12 the_BE12 enzyme_BE12 system_BE12 responsible_BE12 for_BE12 the_BE12 first-pass_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Diltiazem_ddi|P|diltiazem|cimetidine|patient_LE1 current_LE1 receive_LE1 BIOENTITY therapy_BE12 shall_BE12 be_BE12 careful_BE12 monitor_BE12 for_BE12 change_BE12 in_BE12 pharmacological_BE12 effect_BE12 when_BE12 initiate_BE12 and_BE12 discontinue_BE12 therapy_BE12 with_BE12 BIOENTITY 
Diltiazem_ddi|P|diltiazem hydrochloride|digoxin|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY in_RE2 NUM_RE2 healthy_RE2 male_RE2 subject_RE2 increase_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 approximate_RE2 NUM_RE2 %._RE2 
Diltiazem_ddi|P|digoxin|diltiazem hydrochloride|since_LE1 there_LE1 have_LE1 be_LE1 conflict_LE1 result_LE1 regarding_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 level_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY level_BE12 be_BE12 monitor_BE12 when_BE12 initiate_BE12 adjust_BE12 and_BE12 discontinue_BE12 BIOENTITY therapy_RE2 to_RE2 avoid_RE2 possible_RE2 over-_RE2 or_RE2 under-digitalization_RE2 
Diltiazem_ddi|P|anesthetic|calcium channel blocker|the_LE1 depression_LE1 of_LE1 cardiac_LE1 contractility_LE1 conductivity_LE1 and_LE1 automaticity_LE1 as_LE1 well_LE1 as_LE1 the_LE1 vascular_LE1 dilation_LE1 associate_LE1 with_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY 
Diltiazem_ddi|P|anesthetic|calcium channel blocker|when_LE1 use_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 titrate_RE2 careful_RE2 
Diltiazem_ddi|P|diltiazem|cyclosporine|pharmacokinetic_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 observe_RE2 during_RE2 study_RE2 involve_RE2 renal_RE2 and_RE2 cardiac_RE2 transplant_RE2 patient_RE2 
Diltiazem_ddi|P|cyclosporine|diltiazem|In_LE1 renal_LE1 and_LE1 cardiac_LE1 transplant_LE1 recipient_LE1 reduction_LE1 of_LE1 BIOENTITY dose_BE12 range_BE12 from_BE12 NUM_BE12 to_BE12 NUM_BE12 be_BE12 necessary_BE12 to_BE12 maintain_BE12 BIOGENERAL_BE12 trough_BE12 concentration_BE12 similar_BE12 to_BE12 those_BE12 see_BE12 prior_BE12 to_BE12 the_BE12 addition_BE12 of_BE12 BIOENTITY 
Diltiazem_ddi|P|cyclosporine|diltiazem|if_LE1 these_LE1 agent_LE1 be_LE1 to_LE1 be_LE1 administer_LE1 concurrent_LE1 BIOENTITY concentration_BE12 shall_BE12 be_BE12 monitor_BE12 especial_BE12 when_BE12 BIOENTITY therapy_RE2 be_RE2 initiate_RE2 adjust_RE2 or_RE2 discontinue_RE2 
Diltiazem_ddi|P|diltiazem|carbamazepine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 elevated_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 result_RE2 in_RE2 toxicity_RE2 in_RE2 some_RE2 case_RE2 
Diltiazem_ddi|P|diltiazem|triazolam|study_LE1 show_LE1 that_LE1 BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY by_RE2 NUM_RE2 fold_RE2 and_RE2 the_RE2 cmax_RE2 by_RE2 NUM_RE2 compare_RE2 to_RE2 placebo_RE2 
Diltiazem_ddi|P|diltiazem|midazolam|study_LE1 show_LE1 that_LE1 BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 fold_RE2 and_RE2 the_RE2 cmax_RE2 by_RE2 NUM_RE2 compare_RE2 to_RE2 placebo_RE2 
Diltiazem_ddi|P|midazolam|diltiazem|the_LE1 elimination_LE1 half_LE1 life_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 also_BE12 increase_BE12 -LRB-_BE12 NUM_BE12 fold_BE12 -RRB-_BE12 during_BE12 coadministration_BE12 with_BE12 BIOENTITY 
Diltiazem_ddi|P|triazolam|diltiazem|the_LE1 elimination_LE1 half_LE1 life_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY also_BE12 increase_BE12 -LRB-_BE12 NUM_BE12 fold_BE12 -RRB-_BE12 during_BE12 coadministration_BE12 with_BE12 BIOENTITY 
Diltiazem_ddi|P|diltiazem|midazolam|these_LE1 pharmacokinetic_LE1 effect_LE1 see_LE1 during_LE1 BIOENTITY coadministration_BE12 can_BE12 result_BE12 in_BE12 increase_BE12 clinical_BE12 effect_BE12 -LRB-_BE12 e.g._BE12 prolonged_BE12 sodation_BE12 -RRB-_BE12 of_BE12 both_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Diltiazem_ddi|P|diltiazem|triazolam|these_LE1 pharmacokinetic_LE1 effect_LE1 see_LE1 during_LE1 BIOENTITY coadministration_BE12 can_BE12 result_BE12 in_BE12 increase_BE12 clinical_BE12 effect_BE12 -LRB-_BE12 e.g._BE12 prolonged_BE12 sodation_BE12 -RRB-_BE12 of_BE12 both_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Diltiazem_ddi|P|diltiazem|lovastatin|In_LE1 ten-subject_LE1 study_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 -RRB-_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 time_RE2 increase_RE2 in_RE2 mean_RE2 BIOGENERAL_RE2 auc_RE2 and_RE2 cmax_RE2 vs._RE2 BIOGENERAL_RE2 alone_RE2 
Diltiazem_ddi|P|rifampin|diltiazem|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY lower_RE2 the_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 to_RE2 undetectable_RE2 level_RE2 
Diltiazem_ddi|P|diltiazem|rifampin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 any_RE2 known_RE2 cyp3a4_RE2 inducer_RE2 shall_RE2 be_RE2 avoid_RE2 when_RE2 possible_RE2 and_RE2 alternative_RE2 therapy_RE2 consider_RE2 
Dimenhydrinate_ddi|P|dimenhydrinate|apomorphine|BIOENTITY may_BE12 decrease_BE12 BIOGENERAL_BE12 response_BE12 to_BE12 BIOENTITY 
Dinoprost Tromethamine_ddi|P|oxytocin|dinoprost|BIOENTITY or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 concurrent_BE12 use_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 uterine_RE2 hypertonus_RE2 possible_RE2 cause_RE2 uterine_RE2 rupture_RE2 or_RE2 cervical_RE2 laceration_RE2 especial_RE2 in_RE2 the_RE2 absence_RE2 of_RE2 adequate_RE2 cervical_RE2 dilatation_RE2 
Dinoprost Tromethamine_ddi|P|oxytocic|dinoprost|BIOGENERAL_LE1 or_LE1 other_LE1 BIOENTITY -LRB-_BE12 concurrent_BE12 use_BE12 with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 uterine_RE2 hypertonus_RE2 possible_RE2 cause_RE2 uterine_RE2 rupture_RE2 or_RE2 cervical_RE2 laceration_RE2 especial_RE2 in_RE2 the_RE2 absence_RE2 of_RE2 adequate_RE2 cervical_RE2 dilatation_RE2 
Dinoprostone_ddi|P|prostin e2|oxytocic drug|BIOENTITY may_BE12 augment_BE12 the_BE12 activity_BE12 of_BE12 other_BE12 BIOENTITY 
Diphenhydramine_ddi|P|diphenhydramine hydrochloride|tranquilizer|BIOENTITY have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY etc_RE2 -rrb-._RE2 
Diphenhydramine_ddi|P|diphenhydramine hydrochloride|sedative|BIOENTITY have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 etc_RE2 -rrb-._RE2 
Diphenhydramine_ddi|P|diphenhydramine hydrochloride|hypnotic|BIOENTITY have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 -rrb-._RE2 
Diphenhydramine_ddi|P|diphenhydramine hydrochloride|cns depressant|BIOENTITY have_BE12 additive_BE12 effect_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 -rrb-._RE2 
Diphenhydramine_ddi|P|diphenhydramine hydrochloride|alcohol|BIOENTITY have_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 etc_RE2 -rrb-._RE2 
Diphenhydramine_ddi|P|mao inhibitor|antihistamine|BIOENTITY prolong_BE12 and_BE12 intensify_BE12 the_BE12 anticholinergic_BE12 -LRB-_BE12 drying_BE12 -RRB-_BE12 effect_BE12 of_BE12 BIOENTITY 
Diphenidol_ddi|P|diphenidol|apomorphine|BIOGENERAL_LE1 prior_LE1 ingestion_LE1 of_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 BIOGENERAL_BE12 response_BE12 to_BE12 BIOENTITY in_RE2 the_RE2 treatment_RE2 of_RE2 poisoning_RE2 
Diphenoxylate_ddi|P|atropine sulfate|mao inhibitor|BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY In_RE2 study_RE2 with_RE2 male_RE2 rat_RE2 BIOGENERAL_RE2 be_RE2 find_RE2 to_RE2 inhibit_RE2 the_RE2 hepatic_RE2 microsomal_RE2 enzyme_RE2 system_RE2 at_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 
Diphenoxylate_ddi|P|diphenoxylate hcl|mao inhibitor|BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 interact_BE12 with_BE12 BIOENTITY In_RE2 study_RE2 with_RE2 male_RE2 rat_RE2 BIOGENERAL_RE2 be_RE2 find_RE2 to_RE2 inhibit_RE2 the_RE2 hepatic_RE2 microsomal_RE2 enzyme_RE2 system_RE2 at_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 
Dipyridamole_ddi|P|dipyridamole|adenosine|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 the_BE12 plasma_BE12 level_BE12 and_BE12 cardiovascular_BE12 effect_BE12 of_BE12 BIOENTITY 
Dipyridamole_ddi|P|dipyridamole|cholinesterase inhibitor|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 counteract_BE12 the_BE12 anticholinesterase_BE12 effect_BE12 of_BE12 BIOENTITY thereby_RE2 potential_RE2 aggravate_RE2 myasthenia_RE2 gravis_RE2 
Dirithromycin_ddi|P|terfenadine|dirithromycin|in_LE1 one_LE1 man_LE1 the_LE1 max_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 NUM_LE1 ng_LE1 with_LE1 BIOGENERAL_LE1 alone_LE1 and_LE1 NUM_LE1 ng_LE1 with_LE1 BIOENTITY plus_BE12 BIOENTITY 
Dirithromycin_ddi|P|terfenadine|dirithromycin|the_LE1 mean_LE1 qt_LE1 interval_LE1 -LRB-_LE1 msec_LE1 -RRB-_LE1 be_LE1 NUM_LE1 with_LE1 BIOGENERAL_LE1 alone_LE1 and_LE1 NUM_LE1 with_LE1 BIOENTITY plus_BE12 BIOENTITY 
Dirithromycin_ddi|P|erythromycin|terfenadine|thus_LE1 the_LE1 interaction_LE1 observe_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 expect_RE2 for_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|terfenadine|macrolide antibiotic|serious_LE1 cardiac_LE1 dysrhythmia_LE1 some_LE1 result_LE1 in_LE1 death_LE1 have_LE1 occur_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concomitant_BE12 with_BE12 other_BE12 BIOENTITY 
Dirithromycin_ddi|P|macrolide|terfenadine|In_LE1 addition_LE1 many_LE1 BIOENTITY be_BE12 contraindicate_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY therapy_RE2 who_RE2 have_RE2 pre-existing_RE2 cardiac_RE2 abnormality_RE2 -LRB-_RE2 arrhythmia_RE2 bradycardia_RE2 qt_RE2 interval_RE2 prolongation_RE2 ischemic_RE2 heart_RE2 disease_RE2 congestive_RE2 heart_RE2 failure_RE2 etc._RE2 -RRB-_RE2 or_RE2 electrolyte_RE2 disturbance_RE2 
Dirithromycin_ddi|P|dirithromycin|antacid|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 immediate_BE12 following_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 slight_RE2 enhance_RE2 
Dirithromycin_ddi|P|dirithromycin|h 2 -receptor antagonist|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 immediate_BE12 following_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 slight_RE2 enhance_RE2 
Dirithromycin_ddi|P|erythromycin|triazolam|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 thus_BE12 may_BE12 increase_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 BIOENTITY 
Dirithromycin_ddi|P|erythromycin|triazolam|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 thus_RE2 may_RE2 increase_RE2 the_RE2 pharmacologic_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|digoxin|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 elevated_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 
Dirithromycin_ddi|P|erythromycin|anticoagulant|BIOGENERAL_LE1 :_LE1 there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 increase_LE1 anticoagulant_LE1 effect_LE1 when_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 
Dirithromycin_ddi|P|erythromycin|ergotamine|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 associate_RE2 in_RE2 some_RE2 patient_RE2 with_RE2 acute_RE2 ergot_RE2 toxicity_RE2 characterize_RE2 by_RE2 severe_RE2 peripheral_RE2 vasospasm_RE2 and_RE2 dysesthesia_RE2 
Dirithromycin_ddi|P|erythromycin|dihydroergotamine|BIOGENERAL_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 in_RE2 some_RE2 patient_RE2 with_RE2 acute_RE2 ergot_RE2 toxicity_RE2 characterize_RE2 by_RE2 severe_RE2 peripheral_RE2 vasospasm_RE2 and_RE2 dysesthesia_RE2 
Dirithromycin_ddi|P|erythromycin|alfentanil|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|carbamazepine|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|hexobarbital|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|cyclosporine|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|lovastatin|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Dirithromycin_ddi|P|erythromycin|astemizole|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|valproate|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|bromocriptine|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|phenytoin|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dirithromycin_ddi|P|erythromycin|disopyramide|other_LE1 drug_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 medication_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Disopyramide_ddi|P|phenytoin|norpace cr|if_LE1 BIOENTITY or_BE12 other_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 be_BE12 take_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY low_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 occur_RE2 
Disopyramide_ddi|P|phenytoin|norpace|if_LE1 BIOENTITY or_BE12 other_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 be_BE12 take_BE12 concurrent_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 low_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 occur_RE2 
Disopyramide_ddi|P|norpace|quinidine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 slight_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 slight_RE2 decrease_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 
Disopyramide_ddi|P|disopyramide phosphate|erythromycin|patient_LE1 take_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 may_RE2 develop_RE2 increase_RE2 serum_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 excessive_RE2 widening_RE2 of_RE2 the_RE2 qrs_RE2 complex_RE2 and_RE2 prolongation_RE2 of_RE2 the_RE2 q-t_RE2 interval_RE2 
Disopyramide_ddi|P|disopyramide|verapamil|until_LE1 datum_LE1 on_LE1 possible_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 obtain_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY administration_RE2 
Disulfiram_ddi|P|disulfiram|phenytoin|BIOENTITY shall_BE12 be_BE12 use_BE12 WITH_BE12 caution_BE12 IN_BE12 those_BE12 patient_BE12 reveive_BE12 BIOENTITY AND_RE2 its_RE2 congener_RE2 
Disulfiram_ddi|P|disulfiram|phenytoin|since_LE1 the_LE1 concomitant_LE1 administration_LE1 OF_LE1 these_LE1 two_LE1 drug_LE1 can_LE1 lead_LE1 TO_LE1 BIOGENERAL_LE1 intoxication_LE1 PRIOR_LE1 TO_LE1 administer_LE1 BIOENTITY TO_BE12 patient_BE12 ON_BE12 BIOENTITY therapy_RE2 baseline_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 shall_RE2 be_RE2 obtain_RE2 
Disulfiram_ddi|P|anticoagulant|disulfiram|it_LE1 may_LE1 be_LE1 necessary_LE1 to_LE1 adjust_LE1 the_LE1 dosage_LE1 of_LE1 oral_LE1 BIOENTITY upon_BE12 beginning_BE12 or_BE12 stopping_BE12 BIOENTITY since_RE2 BIOGENERAL_RE2 may_RE2 prolong_RE2 prothrombin_RE2 time_RE2 
Disulfiram_ddi|P|isoniazid|disulfiram|patient_LE1 take_LE1 BIOENTITY when_BE12 BIOENTITY be_RE2 give_RE2 shall_RE2 be_RE2 observe_RE2 for_RE2 the_RE2 appearance_RE2 of_RE2 unsteady_RE2 gait_RE2 or_RE2 marked_RE2 change_RE2 in_RE2 mental_RE2 status_RE2 
Disulfiram_ddi|P|disulfiram|nitrite|In_LE1 rat_LE1 simultaneous_LE1 ingestion_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 in_LE1 the_LE1 diet_LE1 for_LE1 NUM_LE1 week_LE1 have_LE1 be_LE1 report_LE1 to_LE1 cause_LE1 tumor_LE1 and_LE1 it_LE1 have_LE1 be_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 react_BE12 with_BE12 BIOENTITY in_RE2 the_RE2 rat_RE2 stomach_RE2 to_RE2 form_RE2 nitrosamine_RE2 which_RE2 be_RE2 tumorigenic_RE2 
Disulfiram_ddi|P|disulfiram|nitrite|In_LE1 rat_LE1 simultaneous_LE1 ingestion_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 the_RE2 diet_RE2 for_RE2 NUM_RE2 week_RE2 have_RE2 be_RE2 report_RE2 to_RE2 cause_RE2 tumor_RE2 and_RE2 it_RE2 have_RE2 be_RE2 suggest_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 react_RE2 with_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 rat_RE2 stomach_RE2 to_RE2 form_RE2 nitrosamine_RE2 which_RE2 be_RE2 tumorigenic_RE2 
Dobutamine_ddi|P|dobutamine|b-blocking drug|animal_LE1 study_LE1 indicate_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 ineffective_BE12 if_BE12 the_BE12 patient_BE12 have_BE12 recent_BE12 receive_BE12 BIOENTITY 
Dobutamine_ddi|P|dobutamine|nitroprusside|preliminary_LE1 study_LE1 indicate_LE1 that_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 high_RE2 cardiac_RE2 output_RE2 and_RE2 usual_RE2 low_RE2 pulmonary_RE2 wedge_RE2 pressure_RE2 than_RE2 when_RE2 either_RE2 drug_RE2 be_RE2 use_RE2 alone_RE2 
Docetaxel_ddi|P|docetaxel|cyclosporine|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 modify_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 compound_BE12 that_BE12 induce_BE12 inhibit_BE12 or_BE12 be_BE12 metabolize_BE12 by_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Docetaxel_ddi|P|docetaxel|terfenadine|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 modify_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 compound_BE12 that_BE12 induce_BE12 inhibit_BE12 or_BE12 be_BE12 metabolize_BE12 by_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Docetaxel_ddi|P|docetaxel|ketoconazole|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 modify_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 compound_BE12 that_BE12 induce_BE12 inhibit_BE12 or_BE12 be_BE12 metabolize_BE12 by_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Docetaxel_ddi|P|docetaxel|erythromycin|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 modify_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 compound_BE12 that_BE12 induce_BE12 inhibit_BE12 or_BE12 be_BE12 metabolize_BE12 by_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Docetaxel_ddi|P|docetaxel|troleandomycin|in_LE1 vitro_LE1 study_LE1 have_LE1 show_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 modify_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 compound_BE12 that_BE12 induce_BE12 inhibit_BE12 or_BE12 be_BE12 metabolize_BE12 by_BE12 cytochrome_BE12 p450_BE12 3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Dofetilide_ddi|P|cimetidine|tikosyn|BIOENTITY at_BE12 NUM_BE12 mg_BE12 bid_BE12 -LRB-_BE12 the_BE12 usual_BE12 prescription_BE12 dose_BE12 -RRB-_BE12 co-administer_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mcg_RE2 bid_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 by_RE2 NUM_RE2 %._RE2 
Dofetilide_ddi|P|cimetidine|dofetilide|BIOENTITY at_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 bid_BE12 -LRB-_BE12 otc_BE12 dose_BE12 -RRB-_BE12 result_BE12 in_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY plasma_RE2 level_RE2 -LRB-_RE2 NUM_RE2 mcg_RE2 single_RE2 dose_RE2 -rrb-._RE2 
Dofetilide_ddi|P|tikosyn|cimetidine|if_LE1 patient_LE1 require_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 therapy_BE12 it_BE12 be_BE12 suggest_BE12 that_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 use_BE12 as_BE12 alternative_BE12 to_BE12 BIOENTITY as_RE2 these_RE2 agent_RE2 have_RE2 no_RE2 effect_RE2 on_RE2 the_RE2 pharmacokinetic_RE2 profile_RE2 of_RE2 BIOGENERAL_RE2 
Dofetilide_ddi|P|tikosyn|verapamil|co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 peak_RE2 plasma_RE2 level_RE2 of_RE2 NUM_RE2 although_RE2 overall_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 significant_RE2 increase_RE2 
Dofetilide_ddi|P|verapamil|dofetilide|In_LE1 analysis_LE1 of_LE1 the_LE1 supraventricular_LE1 arrhythmia_LE1 and_LE1 diamond_LE1 patient_LE1 population_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 associate_RE2 with_RE2 high_RE2 occurrence_RE2 of_RE2 torsade_RE2 de_RE2 pointe_RE2 
Dofetilide_ddi|P|ketoconazole|tikosyn|BIOENTITY at_BE12 NUM_BE12 mg_BE12 daily_BE12 -LRB-_BE12 the_BE12 maximum_BE12 approved_BE12 prescription_BE12 dose_BE12 -RRB-_BE12 co-administer_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mcg_RE2 bid_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 BIOGENERAL_RE2 cmax_RE2 by_RE2 NUM_RE2 in_RE2 male_RE2 and_RE2 NUM_RE2 in_RE2 female_RE2 and_RE2 auc_RE2 by_RE2 NUM_RE2 in_RE2 male_RE2 and_RE2 NUM_RE2 in_RE2 female_RE2 
Dofetilide_ddi|P|hctz|dofetilide|in_LE1 patient_LE1 receive_LE1 BIOENTITY alone_BE12 BIOENTITY auc_RE2 increase_RE2 by_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 NUM_RE2 %._RE2 
Dofetilide_ddi|P|triamterene|dofetilide|In_LE1 addition_LE1 drug_LE1 that_LE1 be_LE1 active_LE1 secrete_LE1 via_LE1 this_LE1 route_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 co-administer_BE12 with_BE12 care_BE12 as_BE12 they_BE12 may_BE12 increase_BE12 BIOENTITY level_RE2 
Dofetilide_ddi|P|metformin|dofetilide|In_LE1 addition_LE1 drug_LE1 that_LE1 be_LE1 active_LE1 secrete_LE1 via_LE1 this_LE1 route_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 co-administer_BE12 with_BE12 care_BE12 as_BE12 they_BE12 may_BE12 increase_BE12 BIOENTITY level_RE2 
Dofetilide_ddi|P|amiloride|dofetilide|In_LE1 addition_LE1 drug_LE1 that_LE1 be_LE1 active_LE1 secrete_LE1 via_LE1 this_LE1 route_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 shall_BE12 be_BE12 co-administer_BE12 with_BE12 care_BE12 as_BE12 they_BE12 may_BE12 increase_BE12 BIOENTITY level_RE2 
Dofetilide_ddi|P|macrolide antibiotic|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|azole antifungal agent|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|protease inhibitor|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|serotonin reuptake inhibitor|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|amiodarone|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|zafirlukast|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 grapefruit_LE1 juice_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|cannabinoid|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|diltiazem|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY grapefruit_BE12 juice_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|nefazadone|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 grapefruit_LE1 juice_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|norfloxacin|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 grapefruit_LE1 juice_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|quinine|tikosyn|inhibitor_LE1 of_LE1 this_LE1 isoenzyme_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 grapefruit_LE1 juice_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 be_BE12 cautious_BE12 coadminister_BE12 with_BE12 BIOENTITY as_RE2 they_RE2 can_RE2 potential_RE2 increase_RE2 BIOGENERAL_RE2 level_RE2 
Dofetilide_ddi|P|digoxin|dofetilide|In_LE1 patient_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 associate_RE2 with_RE2 high_RE2 occurrence_RE2 of_RE2 torsade_RE2 de_RE2 pointe_RE2 
Dofetilide_ddi|P|dofetilide|thiazide diuretic|the_LE1 mean_LE1 clearance_LE1 of_LE1 BIOENTITY be_BE12 NUM_BE12 and_BE12 NUM_BE12 low_BE12 in_BE12 patient_BE12 on_BE12 BIOENTITY and_RE2 inhibitor_RE2 of_RE2 tubular_RE2 organic_RE2 cation_RE2 transport_RE2 respective_RE2 
Dolasetron_ddi|P|dolasetron|rifampin|blood_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 increase_LE1 NUM_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 nonselective_BE12 inhibitor_BE12 of_BE12 cytochrome_BE12 NUM_BE12 -RRB-_BE12 for_BE12 NUM_BE12 day_BE12 and_BE12 decrease_BE12 NUM_BE12 with_BE12 coadministration_BE12 of_BE12 BIOENTITY -LRB-_RE2 potent_RE2 inducer_RE2 of_RE2 cytochrome_RE2 NUM_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 
Dolasetron_ddi|P|dolasetron|cimetidine|blood_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 increase_LE1 NUM_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY -LRB-_RE2 nonselective_RE2 inhibitor_RE2 of_RE2 cytochrome_RE2 NUM_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 and_RE2 decrease_RE2 NUM_RE2 with_RE2 coadministration_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 potent_RE2 inducer_RE2 of_RE2 cytochrome_RE2 NUM_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 
Dolasetron_ddi|P|dolasetron mesylate|atenolol|clearance_LE1 of_LE1 BIOGENERAL_LE1 decrease_LE1 by_LE1 about_LE1 NUM_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 intravenous_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Dopamine_ddi|P|mao inhibitor|dopamine hcl|patient_LE1 who_LE1 have_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY within_BE12 two_BE12 to_BE12 three_BE12 week_BE12 prior_BE12 to_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY shall_RE2 receive_RE2 initial_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 not_RE2 great_RE2 than_RE2 one-tenth_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 of_RE2 the_RE2 usual_RE2 dose_RE2 
Dopamine_ddi|P|dopamine hcl|diuretic agent|concurrent_LE1 administration_LE1 of_LE1 low-dose_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 produce_RE2 additive_RE2 or_RE2 potentiating_RE2 effect_RE2 on_RE2 urine_RE2 flow_RE2 
Dopamine_ddi|P|dopamine|beta-adrenergic blocking agent|cardiac_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Dopamine_ddi|P|dopamine|metoprolol|cardiac_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Dopamine_ddi|P|dopamine|propranolol|cardiac_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Dopamine_ddi|P|dopamine hcl|alpha-adrenergic blocking agent|the_LE1 peripheral_LE1 vasoconstriction_LE1 cause_LE1 by_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 antagonize_BE12 by_BE12 BIOENTITY 
Dopamine_ddi|P|butyrophenone|dopamine|BIOENTITY -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 can_BE12 suppress_BE12 the_BE12 BIOENTITY renal_RE2 and_RE2 mesenteric_RE2 vasodilation_RE2 induce_RE2 with_RE2 low_RE2 dose_RE2 dopamine_RE2 infusion_RE2 
Dopamine_ddi|P|haloperidol|dopamine|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOGENERAL_BE12 can_BE12 suppress_BE12 the_BE12 BIOENTITY renal_RE2 and_RE2 mesenteric_RE2 vasodilation_RE2 induce_RE2 with_RE2 low_RE2 dose_RE2 dopamine_RE2 infusion_RE2 
Dopamine_ddi|P|phenothiazine|dopamine|BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -RRB-_LE1 and_LE1 BIOENTITY can_BE12 suppress_BE12 the_BE12 BIOENTITY renal_RE2 and_RE2 mesenteric_RE2 vasodilation_RE2 induce_RE2 with_RE2 low_RE2 dose_RE2 dopamine_RE2 infusion_RE2 
Dopamine_ddi|P|cyclopropane|catecholamine|BIOENTITY or_BE12 BIOGENERAL_BE12 increase_BE12 cardiac_BE12 autonomic_BE12 irritability_BE12 and_BE12 may_BE12 sensitize_BE12 the_BE12 myocardium_BE12 to_BE12 the_BE12 action_BE12 of_BE12 certain_BE12 intravenous_BE12 administer_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 
Dopamine_ddi|P|halogenated hydrocarbon anesthetic|dopamine|BIOGENERAL_LE1 or_LE1 BIOENTITY increase_BE12 cardiac_BE12 autonomic_BE12 irritability_BE12 and_BE12 may_BE12 sensitize_BE12 the_BE12 myocardium_BE12 to_BE12 the_BE12 action_BE12 of_BE12 certain_BE12 intravenous_BE12 administer_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Dopamine_ddi|P|halogenated hydrocarbon anesthetic|catecholamine|BIOGENERAL_LE1 or_LE1 BIOENTITY increase_BE12 cardiac_BE12 autonomic_BE12 irritability_BE12 and_BE12 may_BE12 sensitize_BE12 the_BE12 myocardium_BE12 to_BE12 the_BE12 action_BE12 of_BE12 certain_BE12 intravenous_BE12 administer_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 
Dopamine_ddi|P|cyclopropane|dopamine|BIOENTITY or_BE12 BIOGENERAL_BE12 increase_BE12 cardiac_BE12 autonomic_BE12 irritability_BE12 and_BE12 may_BE12 sensitize_BE12 the_BE12 myocardium_BE12 to_BE12 the_BE12 action_BE12 of_BE12 certain_BE12 intravenous_BE12 administer_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Dopamine_ddi|P|dopamine hcl|halogenated hydrocarbon anesthetic|therefore_LE1 extreme_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Dopamine_ddi|P|dopamine hcl|cyclopropane|therefore_LE1 extreme_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Dopamine_ddi|P|dopamine|propranolol|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 result_LE1 of_LE1 study_LE1 in_LE1 animal_LE1 indicate_LE1 that_LE1 BIOENTITY ventricular_BE12 arrhythmia_BE12 during_BE12 anesthesia_BE12 can_BE12 be_BE12 reverse_BE12 by_BE12 BIOENTITY 
Dopamine_ddi|P|vasopressor|oxytocic drug|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY vasoconstrict_BE12 agent_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 some_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 severe_RE2 hypertension_RE2 
Dopamine_ddi|P|ergonovine|oxytocic drug|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 vasoconstrict_LE1 agent_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY -RRB-_BE12 and_BE12 some_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 severe_RE2 hypertension_RE2 
Dopamine_ddi|P|phenytoin|dopamine hcl|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 lead_RE2 to_RE2 hypotension_RE2 and_RE2 bradycardia_RE2 
Dopamine_ddi|P|dopamine hcl|phenytoin|it_LE1 be_LE1 suggest_LE1 that_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY alternative_BE12 to_BE12 BIOENTITY shall_RE2 be_RE2 use_RE2 if_RE2 BIOGENERAL_RE2 therapy_RE2 be_RE2 need_RE2 
Dorzolamide_ddi|P|dorzolamide|carbonic anhydrase inhibitor|although_LE1 acid-base_LE1 and_LE1 electrolyte_LE1 disturbance_LE1 be_LE1 not_LE1 report_LE1 in_LE1 the_LE1 clinical_LE1 trial_LE1 with_LE1 BIOENTITY these_BE12 disturbance_BE12 have_BE12 be_BE12 report_BE12 with_BE12 oral_BE12 BIOENTITY and_RE2 have_RE2 in_RE2 some_RE2 instance_RE2 result_RE2 in_RE2 drug_RE2 interaction_RE2 -LRB-_RE2 e.g._RE2 toxicity_RE2 associate_RE2 with_RE2 high-dose_RE2 BIOGENERAL_RE2 therapy_RE2 -rrb-._RE2 
Doxacurium chloride_ddi|P|enflurane|nuromax|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 ed50_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 to_RE2 NUM_RE2 %._RE2 
Doxacurium chloride_ddi|P|halothane|nuromax|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY decrease_BE12 the_BE12 ed50_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 to_RE2 NUM_RE2 %._RE2 
Doxacurium chloride_ddi|P|isoflurane|nuromax|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 ed50_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 to_RE2 NUM_RE2 %._RE2 
Doxacurium chloride_ddi|P|nuromax|clindamycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|lincomycin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|sodium colistimethate|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|colistin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|tetracycline|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|aminoglycoside|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|polymyxin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|bacitracin|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|lithium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|anesthetic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|antibiotic|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOENTITY -LRB-_RE2 e._RE2 g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|procainamide|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|quinidine|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 salt_BE12 BIOGENERAL_BE12 local_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Doxacurium chloride_ddi|P|nuromax|magnesium|other_LE1 drug_LE1 which_LE1 may_LE1 enhance_LE1 the_LE1 neuromuscular_LE1 blocking_LE1 action_LE1 of_LE1 nondepolarizing_LE1 agent_LE1 such_LE1 as_LE1 BIOENTITY include_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 e._BE12 g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 local_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nondepolarizing neuromuscular blocking agent|phenytoin|as_LE1 with_LE1 some_LE1 other_LE1 BIOENTITY the_BE12 time_BE12 of_BE12 onset_BE12 of_BE12 neuromuscular_BE12 block_BE12 induce_BE12 by_BE12 BIOGENERAL_BE12 be_BE12 lengthen_BE12 and_BE12 the_BE12 duration_BE12 of_BE12 block_BE12 be_BE12 shorten_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nondepolarizing neuromuscular blocking agent|carbamazepine|as_LE1 with_LE1 some_LE1 other_LE1 BIOENTITY the_BE12 time_BE12 of_BE12 onset_BE12 of_BE12 neuromuscular_BE12 block_BE12 induce_BE12 by_BE12 BIOGENERAL_BE12 be_BE12 lengthen_BE12 and_BE12 the_BE12 duration_BE12 of_BE12 block_BE12 be_BE12 shorten_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Doxacurium chloride_ddi|P|nuromax|phenytoin|as_LE1 with_LE1 some_LE1 other_LE1 BIOGENERAL_LE1 the_LE1 time_LE1 of_LE1 onset_LE1 of_LE1 neuromuscular_LE1 block_LE1 induce_LE1 by_LE1 BIOENTITY be_BE12 lengthen_BE12 and_BE12 the_BE12 duration_BE12 of_BE12 block_BE12 be_BE12 shorten_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Doxacurium chloride_ddi|P|nuromax|carbamazepine|as_LE1 with_LE1 some_LE1 other_LE1 BIOGENERAL_LE1 the_LE1 time_LE1 of_LE1 onset_LE1 of_LE1 neuromuscular_LE1 block_LE1 induce_LE1 by_LE1 BIOENTITY be_BE12 lengthen_BE12 and_BE12 the_BE12 duration_BE12 of_BE12 block_BE12 be_BE12 shorten_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Doxapram_ddi|P|doxapram|monoamine oxidase inhibiting drug|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 additive_RE2 pressor_RE2 effect_RE2 
Doxapram_ddi|P|doxapram|sympathomimetic|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 pressor_RE2 effect_RE2 
Doxapram_ddi|P|doxapram|muscle relaxant drug|In_LE1 patient_LE1 who_LE1 have_LE1 receive_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 temporary_BE12 mask_BE12 the_BE12 residual_BE12 effect_BE12 of_BE12 BIOENTITY 
Doxazosin_ddi|P|doxazosin|cimetidine|In_LE1 placebo-controlled_LE1 trial_LE1 in_LE1 normal_LE1 volunteer_LE1 the_LE1 administration_LE1 of_LE1 single_LE1 NUM_LE1 mg_LE1 dose_LE1 of_LE1 BIOENTITY on_BE12 day_BE12 NUM_BE12 of_BE12 four-day_BE12 regimen_BE12 of_BE12 oral_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 twice_RE2 daily_RE2 -RRB-_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 mean_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 slight_RE2 but_RE2 not_RE2 statistical_RE2 significant_RE2 increase_RE2 in_RE2 mean_RE2 cmax_RE2 and_RE2 mean_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 
Doxepin_ddi|P|ssri|tca|the_LE1 extent_LE1 to_LE1 which_LE1 BIOENTITY interaction_RE2 may_RE2 pose_RE2 clinical_RE2 problem_RE2 will_RE2 depend_RE2 on_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 and_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 involve_RE2 
Doxepin_ddi|P|tca|ssri|nevertheless_LE1 caution_LE1 be_LE1 indicate_LE1 in_LE1 the_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 any_BE12 of_BE12 the_BE12 BIOENTITY and_RE2 also_RE2 in_RE2 switching_RE2 from_RE2 one_RE2 class_RE2 to_RE2 the_RE2 other_RE2 
Doxepin_ddi|P|selective serotonin reuptake inhibitor|doxepin|inhibitor_LE1 or_LE1 substrate_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -rsb-_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY when_RE2 administer_RE2 concomitant_RE2 
Doxepin_ddi|P|ssri|doxepin|inhibitor_LE1 or_LE1 substrate_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 i.e._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -rsb-_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY when_RE2 administer_RE2 concomitant_RE2 
Doxepin_ddi|P|quinidine|doxepin|inhibitor_LE1 or_LE1 substrate_LE1 of_LE1 cyp2d6_LE1 -LRB-_LE1 i.e._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 -RRB-_BE12 may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY when_RE2 administer_RE2 concomitant_RE2 
Doxepin_ddi|P|mao inhibitor|sinequan|therefore_LE1 BIOENTITY shall_BE12 be_BE12 discontinue_BE12 at_BE12 little_BE12 two_BE12 week_BE12 prior_BE12 to_BE12 the_BE12 cautious_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Doxepin_ddi|P|cimetidine|tricyclic antidepressant|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 produce_BE12 clinical_BE12 significant_BE12 fluctuation_BE12 in_BE12 steady-state_BE12 serum_BE12 concentration_BE12 of_BE12 various_BE12 BIOENTITY 
Doxepin_ddi|P|tricyclic antidepressant|cimetidine|serious_LE1 anticholinergic_LE1 symptom_LE1 -LRB-_LE1 i.e._LE1 severe_LE1 dry_LE1 mouth_LE1 urinary_LE1 retention_LE1 and_LE1 blurred_LE1 vision_LE1 -RRB-_LE1 have_LE1 be_LE1 associate_LE1 with_LE1 elevation_LE1 in_LE1 the_LE1 serum_LE1 level_LE1 of_LE1 BIOENTITY when_BE12 BIOENTITY therapy_RE2 be_RE2 initiate_RE2 
Doxepin_ddi|P|tricyclic antidepressant|cimetidine|additional_LE1 high_LE1 than_LE1 expect_LE1 BIOENTITY level_BE12 have_BE12 be_BE12 observe_BE12 when_BE12 they_BE12 be_BE12 begin_BE12 in_BE12 patient_BE12 already_BE12 take_BE12 BIOENTITY 
Doxepin_ddi|P|cimetidine|tricyclic antidepressant|In_LE1 patient_LE1 who_LE1 have_LE1 be_LE1 report_LE1 to_LE1 be_LE1 well_LE1 control_LE1 on_LE1 BIOGENERAL_LE1 receive_LE1 concurrent_LE1 BIOGENERAL_LE1 therapy_LE1 discontinuation_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 established_BE12 steady-state_BE12 serum_BE12 BIOENTITY level_RE2 and_RE2 compromise_RE2 their_RE2 therapeutic_RE2 effect_RE2 
Doxepin_ddi|P|alcohol|sinequan|BIOGENERAL_LE1 :_LE1 it_LE1 shall_LE1 be_LE1 bear_LE1 in_LE1 mind_LE1 that_LE1 BIOENTITY ingestion_BE12 may_BE12 increase_BE12 the_BE12 danger_BE12 inherent_BE12 in_BE12 any_BE12 intentional_BE12 or_BE12 unintentional_BE12 BIOENTITY overdosage_RE2 
Doxepin_ddi|P|tolazamide|doxepin|BIOGENERAL_LE1 :_LE1 case_LE1 of_LE1 severe_LE1 hypoglycemia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 type_LE1 ii_LE1 diabetic_LE1 patient_LE1 maintain_LE1 on_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 gm_BE12 -RRB-_BE12 NUM_BE12 day_BE12 after_BE12 the_BE12 addition_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -rrb-._RE2 
Doxycycline_ddi|P|tetracycline|anticoagulant|because_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 depress_BE12 plasma_BE12 prothrombin_BE12 activity_BE12 patient_BE12 who_BE12 be_BE12 on_BE12 BIOENTITY therapy_RE2 may_RE2 require_RE2 downward_RE2 adjustment_RE2 of_RE2 their_RE2 BIOGENERAL_RE2 dosage_RE2 
Doxycycline_ddi|P|tetracycline|penicillin|since_LE1 bacteriostatic_LE1 drug_LE1 may_LE1 interfere_LE1 with_LE1 the_LE1 bactericidal_LE1 action_LE1 of_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 advisable_LE1 to_LE1 avoid_LE1 giving_LE1 BIOENTITY in_BE12 conjunction_BE12 with_BE12 BIOENTITY 
Doxycycline_ddi|P|tetracycline|magnesium|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 preparation_RE2 
Doxycycline_ddi|P|tetracycline|iron|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY preparation_RE2 
Doxycycline_ddi|P|tetracycline|aluminum|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 
Doxycycline_ddi|P|tetracycline|calcium|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 preparation_RE2 
Doxycycline_ddi|P|tetracycline|bismuth subsalicylate|absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 by_BE12 BIOENTITY 
Doxycycline_ddi|P|carbamazepine|doxycycline|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 half-life_BE12 of_BE12 BIOENTITY 
Doxycycline_ddi|P|barbiturate|doxycycline|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 half-life_BE12 of_BE12 BIOENTITY 
Doxycycline_ddi|P|phenytoin|doxycycline|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY decrease_BE12 the_BE12 half-life_BE12 of_BE12 BIOENTITY 
Doxycycline_ddi|P|tetracycline|methoxyflurane|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 fatal_RE2 renal_RE2 toxicity_RE2 
Doxycycline_ddi|P|tetracycline|penthrane|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 fatal_RE2 renal_RE2 toxicity_RE2 
Doxycycline_ddi|P|tetracycline|contraceptive|concurrent_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 render_BE12 oral_BE12 BIOENTITY little_RE2 effective_RE2 
Doxylamine_ddi|P|doxylamine|cns depressant drug|potential_LE1 drug_LE1 interaction_LE1 for_LE1 BIOGENERAL_LE1 include_LE1 increase_LE1 sedation_LE1 if_LE1 BIOENTITY be_BE12 combine_BE12 with_BE12 other_BE12 BIOENTITY 
Doxylamine_ddi|P|antihistamine|heparin|BIOENTITY may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulation_BE12 effect_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Doxylamine_ddi|P|antihistamine|warfarin|BIOENTITY may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulation_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Doxylamine_ddi|P|doxylamine|epinephrine|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Dromostanolone_ddi|P|oxyphenbutazone|androgen|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 elevated_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Dromostanolone_ddi|P|androgen|insulin|In_LE1 diabetic_LE1 patient_LE1 the_LE1 metabolic_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 decrease_BE12 blood_BE12 glucose_BE12 and_BE12 therefore_BE12 BIOENTITY requirement_RE2 
Droperidol_ddi|P|barbiturate|inapsine|other_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 general_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY 
Droperidol_ddi|P|cns depressant drug|inapsine|other_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 general_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY 
Droperidol_ddi|P|opioid|inapsine|other_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 general_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY 
Droperidol_ddi|P|tranquilizer|inapsine|other_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 general_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY 
Droperidol_ddi|P|anesthetic|inapsine|other_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 general_LE1 BIOENTITY -RRB-_BE12 have_BE12 additive_BE12 or_BE12 potentiating_BE12 effect_BE12 with_BE12 BIOENTITY 
Droperidol_ddi|P|inapsine|cns depressant drug|Following_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY the_BE12 dose_BE12 of_BE12 other_BE12 BIOENTITY shall_RE2 be_RE2 reduce_RE2 
Duloxetine_ddi|P|duloxetine|fluvoxamine|inhibitor_LE1 of_LE1 cyp1a2_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY inhibitor_RE2 of_RE2 cyp1a2_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 auc_RE2 and_RE2 about_RE2 NUM_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 
Duloxetine_ddi|P|paroxetine|duloxetine|BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 qd_BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 by_RE2 about_RE2 NUM_RE2 and_RE2 great_RE2 degree_RE2 of_RE2 inhibition_RE2 be_RE2 expect_RE2 with_RE2 high_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 
Duloxetine_ddi|P|duloxetine|desipramine|when_LE1 BIOENTITY be_BE12 administer_BE12 -LRB-_BE12 at_BE12 dose_BE12 of_BE12 NUM_BE12 mg_BE12 bid_BE12 -RRB-_BE12 in_BE12 conjunction_BE12 with_BE12 single_BE12 NUM_BE12 dose_BE12 of_BE12 BIOENTITY cyp2d6_RE2 substrate_RE2 the_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 increase_RE2 NUM_RE2 
Duloxetine_ddi|P|duloxetine|antidepressant|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rsb-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|tca|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY -rsb-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|tricyclic antidepressant|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 -rsb-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|amitriptyline|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|nortriptyline|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|phenothiazine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|imipramine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|type 1c antiarrhythmic|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|propafenone|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|duloxetine|flecainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 extensive_BE12 metabolize_BE12 by_BE12 this_BE12 isozyme_BE12 and_BE12 which_BE12 have_BE12 narrow_BE12 therapeutic_BE12 index_BE12 including_BE12 certain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -rsb-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Duloxetine_ddi|P|tca|duloxetine|plasma_LE1 BIOGENERAL_LE1 concentration_LE1 may_LE1 need_LE1 to_LE1 be_LE1 monitor_LE1 and_LE1 the_LE1 dose_LE1 of_LE1 the_LE1 BIOGENERAL_LE1 may_LE1 need_LE1 to_LE1 be_LE1 reduce_LE1 if_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY 
Duloxetine_ddi|P|duloxetine|thioridazine|Because_LE1 of_LE1 the_LE1 risk_LE1 of_LE1 serious_LE1 ventricular_LE1 arrhythmia_LE1 and_LE1 sudden_LE1 death_LE1 potential_LE1 associate_LE1 with_LE1 elevated_LE1 plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 co-administer_RE2 
Dyphylline_ddi|P|theophylline|sympathomimetic bronchodilator|synergism_LE1 between_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Dyphylline_ddi|P|ephedrine|sympathomimetic bronchodilator|synergism_LE1 between_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY and_BE12 other_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Dyphylline_ddi|P|xanthine bronchodilator|sympathomimetic bronchodilator|synergism_LE1 between_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Dyphylline_ddi|P|dyphylline|probenecid|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY which_RE2 compete_RE2 for_RE2 tubular_RE2 secretion_RE2 have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 the_RE2 plasma_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 
Echothiophate Iodide_ddi|P|phospholine iodide|carbamate insecticide|BIOENTITY potentiate_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Echothiophate Iodide_ddi|P|phospholine iodide|organophosphate insecticide|BIOENTITY potentiate_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Echothiophate Iodide_ddi|P|phospholine iodide|succinylcholine|BIOENTITY potentiate_BE12 other_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Echothiophate Iodide_ddi|P|phospholine iodide|cholinesterase inhibitor|BIOENTITY potentiate_BE12 other_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Edetic Acid_ddi|P|edetate calcium disodium|zinc insulin|BIOGENERAL_LE1 enhance_LE1 the_LE1 renal_LE1 toxicity_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 animals._LE1 NUM_LE1 BIOENTITY interfere_BE12 with_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY preparation_RE2 by_RE2 chelating_RE2 the_RE2 BIOGENERAL_RE2 NUM_RE2 
Edetic Acid_ddi|P|steroid|edetate calcium disodium|BIOENTITY enhance_BE12 the_BE12 renal_BE12 toxicity_BE12 of_BE12 BIOENTITY in_RE2 animals._RE2 NUM_RE2 BIOGENERAL_RE2 interfere_RE2 with_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 preparation_RE2 by_RE2 chelating_RE2 the_RE2 BIOGENERAL_RE2 NUM_RE2 
Efalizumab_ddi|P|raptiva|immunosuppressive drug|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 with_BE12 other_BE12 BIOENTITY 
Efalizumab_ddi|P|live-attenuated vaccine|raptiva|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 during_BE12 BIOENTITY treatment_RE2 
Efalizumab_ddi|P|live vaccine|raptiva|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 during_BE12 BIOENTITY treatment_RE2 
Efalizumab_ddi|P|acellular vaccine|raptiva|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 during_BE12 BIOENTITY treatment_RE2 
Efavirenz_ddi|P|rifabutin|efavirenz|drug_LE1 which_LE1 induce_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 lowered_RE2 plasma_RE2 concentration_RE2 
Efavirenz_ddi|P|rifampin|efavirenz|drug_LE1 which_LE1 induce_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 lowered_RE2 plasma_RE2 concentration_RE2 
Efavirenz_ddi|P|phenobarbital|efavirenz|drug_LE1 which_LE1 induce_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 lowered_RE2 plasma_RE2 concentration_RE2 
Efavirenz_ddi|P|sustiva|clarithromycin|In_LE1 uninfected_LE1 volunteer_LE1 NUM_LE1 develop_LE1 rash_LE1 while_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY 
Efavirenz_ddi|P|indinavir|sustiva|increase_LE1 the_LE1 BIOGENERAL_LE1 dose_LE1 to_LE1 NUM_LE1 mg_LE1 every_LE1 NUM_LE1 hour_LE1 do_LE1 not_LE1 compensate_LE1 for_LE1 the_LE1 increase_LE1 BIOENTITY metabolism_BE12 due_BE12 to_BE12 BIOENTITY 
Efavirenz_ddi|P|indinavir|sustiva|when_LE1 BIOENTITY at_BE12 increase_BE12 dose_BE12 -LRB-_BE12 NUM_BE12 mg_BE12 every_BE12 NUM_BE12 hour_BE12 -RRB-_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 once_RE2 daily_RE2 -RRB-_RE2 the_RE2 BIOGENERAL_RE2 auc_RE2 and_RE2 cmin_RE2 be_RE2 decrease_RE2 on_RE2 average_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 compared_RE2 to_RE2 when_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 every_RE2 NUM_RE2 hour_RE2 -RRB-_RE2 be_RE2 give_RE2 alone_RE2 
Efavirenz_ddi|P|ritonavir|sustiva|dose_LE1 increase_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 -LRB-_BE12 NUM_BE12 capsule_BE12 or_BE12 NUM_BE12 ml_BE12 -RRB-_BE12 twice_BE12 daily_BE12 take_BE12 with_BE12 food_BE12 be_BE12 recommend_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Efavirenz_ddi|P|ritonavir|sustiva|dose_LE1 increase_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 -LRB-_BE12 NUM_BE12 capsule_BE12 or_BE12 NUM_BE12 ml_BE12 -RRB-_BE12 twice_BE12 daily_BE12 take_BE12 with_BE12 food_BE12 be_BE12 recommend_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Efavirenz_ddi|P|efavirenz|contraceptive|because_LE1 the_LE1 potential_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY have_RE2 not_RE2 be_RE2 full_RE2 characterize_RE2 reliable_RE2 method_RE2 of_RE2 barrier_RE2 contraception_RE2 shall_RE2 be_RE2 use_RE2 in_RE2 addition_RE2 to_RE2 oral_RE2 BIOGENERAL_RE2 
Efavirenz_ddi|P|sustiva|ritonavir|monitoring_LE1 of_LE1 liver_LE1 enzyme_LE1 be_LE1 recommend_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Efavirenz_ddi|P|anticonvulsant|efavirenz|potential_LE1 for_LE1 reduction_LE1 in_LE1 BIOENTITY and_BE12 BIOENTITY plasma_RE2 level_RE2 
Efavirenz_ddi|P|sustiva|ketoconazole|BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 decrease_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Efavirenz_ddi|P|sustiva|itraconazole|BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 decrease_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Enalapril_ddi|P|diuretic|enalapril|hypotension_LE1 :_LE1 patient_LE1 on_LE1 diuretic_LE1 therapy_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 especial_BE12 those_BE12 in_BE12 who_BE12 diuretic_BE12 therapy_BE12 be_BE12 recent_BE12 institute_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Enalapril_ddi|P|diuretic|enalaprilat|hypotension_LE1 :_LE1 patient_LE1 on_LE1 diuretic_LE1 therapy_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 especial_BE12 those_BE12 in_BE12 who_BE12 diuretic_BE12 therapy_BE12 be_BE12 recent_BE12 institute_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Enalapril_ddi|P|enalapril|diuretic|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 with_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 can_BE12 be_BE12 minimize_BE12 by_BE12 either_BE12 discontinue_BE12 the_BE12 BIOENTITY or_RE2 increase_RE2 the_RE2 salt_RE2 intake_RE2 prior_RE2 to_RE2 initiation_RE2 of_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Enalapril_ddi|P|enalaprilat|diuretic|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY can_BE12 be_BE12 minimize_BE12 by_BE12 either_BE12 discontinue_BE12 the_BE12 BIOENTITY or_RE2 increase_RE2 the_RE2 salt_RE2 intake_RE2 prior_RE2 to_RE2 initiation_RE2 of_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Enalapril_ddi|P|enalapril|antihypertensive agent|agent_LE1 cause_LE1 renin_LE1 release_LE1 :_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY iv_BE12 be_BE12 augment_BE12 by_BE12 BIOENTITY that_RE2 cause_RE2 renin_RE2 release_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -rrb-._RE2 
Enalapril_ddi|P|enalapril|diuretic|agent_LE1 cause_LE1 renin_LE1 release_LE1 :_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY iv_BE12 be_BE12 augment_BE12 by_BE12 BIOGENERAL_BE12 that_BE12 cause_BE12 renin_BE12 release_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -rrb-._RE2 
Enalapril_ddi|P|enalapril|diuretic|agent_LE1 cause_LE1 renin_LE1 release_LE1 :_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 iv_BE12 be_BE12 augment_BE12 by_BE12 BIOGENERAL_BE12 that_BE12 cause_BE12 renin_BE12 release_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -rrb-._RE2 
Enalapril_ddi|P|enalapril|antihypertensive agent|agent_LE1 cause_LE1 renin_LE1 release_LE1 :_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 iv_BE12 be_BE12 augment_BE12 by_BE12 BIOENTITY that_RE2 cause_RE2 renin_RE2 release_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -rrb-._RE2 
Enalapril_ddi|P|nonsteroidal anti-inflammatory drug|enalapril|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 with_LE1 compromise_LE1 renal_LE1 function_LE1 who_LE1 be_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY the_BE12 co-administration_BE12 of_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 further_RE2 deterioration_RE2 of_RE2 renal_RE2 function_RE2 
Enalapril_ddi|P|nsaid|ace inhibitor|however_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Enalapril_ddi|P|nsaid|ace inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Enalapril_ddi|P|enalapril|thiazide-type diuretic|agent_LE1 Increasing_LE1 serum_LE1 potassium_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY iv_BE12 attenuate_BE12 potassium_BE12 loss_BE12 cause_BE12 by_BE12 BIOENTITY 
Enalapril_ddi|P|enalapril|thiazide-type diuretic|agent_LE1 Increasing_LE1 serum_LE1 potassium_LE1 :_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 iv_BE12 attenuate_BE12 potassium_BE12 loss_BE12 cause_BE12 by_BE12 BIOENTITY 
Enalapril_ddi|P|lithium|ace inhibitor|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concomitant_BE12 with_BE12 drug_BE12 which_BE12 cause_BE12 elimination_BE12 of_BE12 sodium_BE12 including_BE12 BIOENTITY 
Enalapril_ddi|P|enalapril|lithium|it_LE1 be_LE1 recommend_LE1 that_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 be_LE1 monitor_LE1 frequent_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Enoxacin_ddi|P|bismuth subsalicylate|enoxacin|BIOGENERAL_LE1 :_LE1 BIOENTITY give_BE12 concomitant_BE12 with_BE12 BIOENTITY or_RE2 NUM_RE2 minute_RE2 following_RE2 BIOGENERAL_RE2 administration_RE2 decrease_RE2 BIOGENERAL_RE2 bioavailability_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Enoxacin_ddi|P|enoxacin|bismuth subsalicylate|thus_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 
Enoxacin_ddi|P|enoxacin|methylxanthine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 potent_BE12 inhibitor_BE12 of_BE12 the_BE12 cytochrome_BE12 NUM_BE12 isozyme_BE12 responsible_BE12 for_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Enoxacin_ddi|P|enoxacin|caffeine|In_LE1 multiple-dose_LE1 study_LE1 BIOENTITY cause_BE12 dose-related_BE12 increase_BE12 in_BE12 the_BE12 mean_BE12 elimination_BE12 half-life_BE12 of_BE12 BIOENTITY thereby_RE2 decrease_RE2 the_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 up_RE2 to_RE2 NUM_RE2 and_RE2 lead_RE2 to_RE2 fivefold_RE2 increase_RE2 in_RE2 the_RE2 auc_RE2 and_RE2 the_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 
Enoxacin_ddi|P|caffeine|enoxacin|trough_LE1 plasma_LE1 BIOGENERAL_LE1 level_LE1 be_LE1 also_LE1 NUM_LE1 high_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Enoxacin_ddi|P|caffeine|enoxacin|BIOGENERAL_LE1 adverse_LE1 effect_LE1 have_LE1 occur_LE1 in_LE1 patient_LE1 consume_LE1 BIOENTITY while_BE12 on_BE12 therapy_BE12 with_BE12 BIOENTITY 
Enoxacin_ddi|P|cyclosporine|quinolone clas|BIOGENERAL_LE1 :_LE1 elevated_LE1 serum_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 member_BE12 of_BE12 the_BE12 BIOENTITY 
Enoxacin_ddi|P|enoxacin|digoxin|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 raise_BE12 serum_BE12 BIOENTITY level_RE2 in_RE2 some_RE2 individual_RE2 
Enoxacin_ddi|P|enoxacin|digoxin|if_LE1 sign_LE1 and_LE1 symptom_LE1 suggestive_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 occur_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 give_RE2 concomitant_RE2 physician_RE2 be_RE2 advise_RE2 to_RE2 obtain_RE2 serum_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 adjust_RE2 BIOGENERAL_RE2 dose_RE2 appropriate_RE2 
Enoxacin_ddi|P|enoxacin|fenbufen|BIOGENERAL_LE1 :_LE1 seizure_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Enoxacin_ddi|P|zinc|quinolone|or_LE1 with_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY may_BE12 substantial_BE12 interfere_BE12 with_BE12 drug_BE12 absorption_BE12 and_BE12 result_BE12 in_BE12 insufficient_BE12 plasma_BE12 and_BE12 tissue_BE12 BIOENTITY concentration_RE2 
Enoxacin_ddi|P|magnesium hydroxide|enoxacin|BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY reduce_BE12 the_BE12 oral_BE12 absorption_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Enoxacin_ddi|P|aluminum hydroxide|enoxacin|BIOGENERAL_LE1 contain_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 reduce_BE12 the_BE12 oral_BE12 absorption_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Enoxacin_ddi|P|enoxacin|ranitidine|the_LE1 oral_LE1 bioavailability_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 by_BE12 NUM_BE12 with_BE12 coadministration_BE12 of_BE12 BIOENTITY 
Enoxacin_ddi|P|enoxacin|methylxanthine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 potent_BE12 inhibitor_BE12 of_BE12 the_BE12 cytochrome_BE12 NUM_BE12 isozyme_BE12 responsible_BE12 for_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Enoxacin_ddi|P|enoxacin|theophylline|BIOENTITY interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 to_RE2 NUM_RE2 dose-related_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 clearance_RE2 and_RE2 subsequent_RE2 NUM_RE2 to_RE2 NUM_RE2 increase_RE2 in_RE2 serum_RE2 theophylline_RE2 level_RE2 
Enoxacin_ddi|P|theophylline|enoxacin|BIOGENERAL_LE1 adverse_LE1 effect_LE1 have_LE1 occur_LE1 in_LE1 patient_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Enoxacin_ddi|P|enoxacin|r-warfarin|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY the_RE2 little_RE2 active_RE2 isomer_RE2 of_RE2 racemic_RE2 BIOGENERAL_RE2 
Enoxacin_ddi|P|quinolone|r-warfarin|BIOGENERAL_LE1 :_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY the_RE2 little_RE2 active_RE2 isomer_RE2 of_RE2 racemic_RE2 BIOGENERAL_RE2 
Enoxacin_ddi|P|warfarin|enoxacin|nevertheless_LE1 the_LE1 prothrombin_LE1 time_LE1 or_LE1 other_LE1 suitable_LE1 coagulation_LE1 test_LE1 shall_LE1 be_LE1 monitor_LE1 when_LE1 BIOENTITY or_BE12 its_BE12 derivative_BE12 and_BE12 BIOENTITY be_RE2 give_RE2 concomitant_RE2 
Epinephrine_ddi|P|vasopressor|monoamine oxidase (mao) inhibitor|all_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 patient_BE12 take_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOENTITY 
Epinephrine_ddi|P|epinephrine|sympathomimetic drug|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOENTITY -LRB-_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -RRB-_RE2 because_RE2 of_RE2 possible_RE2 additive_RE2 effect_RE2 and_RE2 increase_RE2 toxicity_RE2 
Epinephrine_ddi|P|epinephrine|isoproterenol|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY -RRB-_RE2 because_RE2 of_RE2 possible_RE2 additive_RE2 effect_RE2 and_RE2 increase_RE2 toxicity_RE2 
Epinephrine_ddi|P|epinephrine|halogenated hydrocarbon general anesthetic|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 which_RE2 sensitize_RE2 the_RE2 myocardium_RE2 may_RE2 induce_RE2 cardiac_RE2 arrhythmia_RE2 .._RE2 
Epinephrine_ddi|P|epinephrine|halothane|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY which_RE2 sensitize_RE2 the_RE2 myocardium_RE2 may_RE2 induce_RE2 cardiac_RE2 arrhythmia_RE2 .._RE2 
Epinephrine_ddi|P|epinephrine|cyclopropane|administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 which_RE2 sensitize_RE2 the_RE2 myocardium_RE2 may_RE2 induce_RE2 cardiac_RE2 arrhythmia_RE2 .._RE2 
Epinephrine_ddi|P|epinephrine|glycoside|BIOENTITY also_BE12 shall_BE12 be_BE12 use_BE12 cautious_BE12 with_BE12 other_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 that_RE2 sensitize_RE2 the_RE2 myocardium_RE2 to_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 
Epinephrine_ddi|P|epinephrine|digitali|BIOENTITY also_BE12 shall_BE12 be_BE12 use_BE12 cautious_BE12 with_BE12 other_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 that_RE2 sensitize_RE2 the_RE2 myocardium_RE2 to_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 
Epinephrine_ddi|P|diuretic agent|epinephrine|BIOENTITY may_BE12 decrease_BE12 vascular_BE12 response_BE12 to_BE12 pressor_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY 
Epinephrine_ddi|P|epinephrine|guanethidine|BIOENTITY may_BE12 antagonize_BE12 the_BE12 neuron_BE12 blockade_BE12 produce_BE12 by_BE12 BIOENTITY result_RE2 in_RE2 decrease_RE2 antihypertensive_RE2 effect_RE2 and_RE2 require_RE2 increase_RE2 dosage_RE2 of_RE2 the_RE2 latter_RE2 
Epirubicin_ddi|P|ellence|calcium channel blocker|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 cardioactive_BE12 compound_BE12 that_BE12 can_BE12 cause_BE12 heart_BE12 failure_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 require_RE2 close_RE2 monitoring_RE2 of_RE2 cardiac_RE2 function_RE2 throughout_RE2 treatment_RE2 
Epirubicin_ddi|P|cimetidine|epirubicin|BIOENTITY increase_BE12 the_BE12 auc_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 %._RE2 
Epirubicin_ddi|P|cimetidine|ellence|BIOENTITY treatment_BE12 shall_BE12 be_BE12 stop_BE12 during_BE12 treatment_BE12 with_BE12 BIOENTITY 
Eplerenone_ddi|P|inspra|ketoconazole|pharmacokinetic_LE1 study_LE1 evaluate_LE1 the_LE1 administration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 bid_RE2 potent_RE2 inhibitor_RE2 of_RE2 the_RE2 cyp3a4_RE2 pathway_RE2 show_RE2 NUM_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Eplerenone_ddi|P|eplerenone|fluconazole|administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 bid_BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 qd_BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 tid_BE12 BIOENTITY NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 range_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 and_RE2 auc_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 
Eplerenone_ddi|P|eplerenone|saquinavir|administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 bid_BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 qd_BE12 BIOENTITY NUM_RE2 mg_RE2 tid_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 range_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 and_RE2 auc_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 
Eplerenone_ddi|P|eplerenone|verapamil|administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 NUM_BE12 mg_BE12 bid_BE12 BIOENTITY NUM_RE2 mg_RE2 qd_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 tid_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 range_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 and_RE2 auc_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 
Eplerenone_ddi|P|eplerenone|erythromycin|administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY NUM_RE2 mg_RE2 bid_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 qd_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 tid_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 range_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 and_RE2 auc_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 fold_RE2 
Eplerenone_ddi|P|inspra|ace inhibitor|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 hypertension_LE1 -RRB-_LE1 In_LE1 clinical_LE1 study_LE1 of_LE1 patient_LE1 with_LE1 hypertension_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY NUM_BE12 to_BE12 NUM_BE12 mg_BE12 to_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 increase_RE2 mean_RE2 serum_RE2 potassium_RE2 slight_RE2 -LRB-_RE2 about_RE2 NUM_RE2 meq_RE2 -rrb-._RE2 
Eplerenone_ddi|P|inspra|angiotensin ii receptor antagonist|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 hypertension_LE1 -RRB-_LE1 In_LE1 clinical_LE1 study_LE1 of_LE1 patient_LE1 with_LE1 hypertension_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY NUM_BE12 to_BE12 NUM_BE12 mg_BE12 to_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY increase_RE2 mean_RE2 serum_RE2 potassium_RE2 slight_RE2 -LRB-_RE2 about_RE2 NUM_RE2 meq_RE2 -rrb-._RE2 
Eplerenone_ddi|P|inspra|enalapril|In_LE1 study_LE1 in_LE1 diabetic_LE1 with_LE1 microalbuminuria_LE1 BIOENTITY NUM_BE12 mg_BE12 combine_BE12 with_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY NUM_RE2 mg_RE2 increase_RE2 the_RE2 frequency_RE2 of_RE2 hyperkalemia_RE2 -LRB-_RE2 serum_RE2 potassium_RE2 NUM_RE2 meq_RE2 -RRB-_RE2 from_RE2 NUM_RE2 on_RE2 BIOGENERAL_RE2 alone_RE2 to_RE2 NUM_RE2 %._RE2 
Eplerenone_ddi|P|inspra|lithium|serum_LE1 BIOGENERAL_LE1 level_LE1 shall_LE1 be_LE1 monitor_LE1 frequent_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Eplerenone_ddi|P|potassium-sparing antihypertensive|nsaid|the_LE1 administration_LE1 of_LE1 other_LE1 BIOENTITY with_BE12 BIOENTITY have_RE2 be_RE2 show_RE2 to_RE2 reduce_RE2 the_RE2 antihypertensive_RE2 effect_RE2 in_RE2 some_RE2 patient_RE2 and_RE2 result_RE2 in_RE2 severe_RE2 hyperkalemia_RE2 in_RE2 patient_RE2 with_RE2 impaired_RE2 renal_RE2 function_RE2 
Eplerenone_ddi|P|inspra|nsaid|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 to_RE2 determine_RE2 whether_RE2 the_RE2 desired_RE2 effect_RE2 on_RE2 blood_RE2 pressure_RE2 be_RE2 obtain_RE2 
Epoprostenol_ddi|P|flolan|vasodilator|additional_LE1 reduction_LE1 in_LE1 blood_LE1 pressure_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY 
Epoprostenol_ddi|P|flolan|diuretic|additional_LE1 reduction_LE1 in_LE1 blood_LE1 pressure_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 
Epoprostenol_ddi|P|flolan|antihypertensive agent|additional_LE1 reduction_LE1 in_LE1 blood_LE1 pressure_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 
Epoprostenol_ddi|P|anticoagulant|flolan|when_LE1 other_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 there_BE12 be_BE12 the_BE12 potential_BE12 for_BE12 BIOENTITY to_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Epoprostenol_ddi|P|antiplatelet agent|flolan|when_LE1 other_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 concomitant_BE12 there_BE12 be_BE12 the_BE12 potential_BE12 for_BE12 BIOENTITY to_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Epoprostenol_ddi|P|furosemide|flolan|In_LE1 clinical_LE1 trial_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 oral_LE1 BIOGENERAL_LE1 and_LE1 supplemental_LE1 BIOGENERAL_LE1 pharmacokinetic_LE1 substudy_LE1 in_LE1 patient_LE1 with_LE1 congestive_LE1 heart_LE1 failure_LE1 receive_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 in_BE12 who_BE12 therapy_BE12 with_BE12 BIOENTITY be_RE2 initiate_RE2 apparent_RE2 oral_RE2 clearance_RE2 value_RE2 for_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 be_RE2 decrease_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 on_RE2 the_RE2 second_RE2 day_RE2 of_RE2 therapy_RE2 and_RE2 have_RE2 return_RE2 to_RE2 baseline_RE2 value_RE2 by_RE2 day_RE2 NUM_RE2 
Epoprostenol_ddi|P|digoxin|flolan|In_LE1 clinical_LE1 trial_LE1 BIOGENERAL_LE1 be_LE1 use_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 oral_LE1 BIOGENERAL_LE1 and_LE1 supplemental_LE1 BIOGENERAL_LE1 pharmacokinetic_LE1 substudy_LE1 in_LE1 patient_LE1 with_LE1 congestive_LE1 heart_LE1 failure_LE1 receive_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY in_BE12 who_BE12 therapy_BE12 with_BE12 BIOENTITY be_RE2 initiate_RE2 apparent_RE2 oral_RE2 clearance_RE2 value_RE2 for_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 be_RE2 decrease_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 on_RE2 the_RE2 second_RE2 day_RE2 of_RE2 therapy_RE2 and_RE2 have_RE2 return_RE2 to_RE2 baseline_RE2 value_RE2 by_RE2 day_RE2 NUM_RE2 
Epoprostenol_ddi|P|digoxin|flolan|however_LE1 patient_LE1 on_LE1 BIOENTITY may_BE12 show_BE12 elevation_BE12 of_BE12 BIOGENERAL_BE12 concentration_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY which_RE2 may_RE2 be_RE2 clinical_RE2 significant_RE2 in_RE2 patient_RE2 prone_RE2 to_RE2 BIOGENERAL_RE2 toxicity_RE2 
Ergocalciferol_ddi|P|mineral oil|fat-soluble vitamin|BIOENTITY interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 
Ergocalciferol_ddi|P|mineral oil|vitamin d preparation|BIOENTITY interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY 
Ergocalciferol_ddi|P|thiazide diuretic|ergocalciferol|administration_LE1 of_LE1 BIOENTITY to_BE12 hypoparathyroid_BE12 patient_BE12 who_BE12 be_BE12 concurrent_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY may_RE2 cause_RE2 hypercalcemia_RE2 
Ergotamine_ddi|P|triacetyloleandomycin|ergotamine|the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 potentiate_LE1 by_LE1 BIOENTITY which_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Ergotamine_ddi|P|ergomar|triacetyloleandomycin|the_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY which_RE2 inhibit_RE2 the_RE2 metabolism_RE2 of_RE2 BIOGENERAL_RE2 
Ergotamine_ddi|P|ergomar|vasoconstrictor drug|the_LE1 pressor_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOENTITY can_RE2 combine_RE2 to_RE2 cause_RE2 dangerous_RE2 hypertension_RE2 
Erlotinib_ddi|P|ketoconazole|erlotinib|co-treatment_LE1 with_LE1 the_LE1 potent_LE1 cyp3a4_LE1 inhibitor_LE1 BIOENTITY increase_BE12 BIOENTITY auc_RE2 by_RE2 NUM_RE2 
Erlotinib_ddi|P|tarceva|atazanavir|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|tao|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|clarithromycin|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|troleandomycin|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|ketoconazole|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 other_RE2 strong_RE2 cyp3a4_RE2 inhibitor_RE2 such_RE2 as_RE2 but_RE2 not_RE2 limited_RE2 to_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|voriconazole|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY 
Erlotinib_ddi|P|tarceva|telithromycin|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|saquinavir|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|ritonavir|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|nelfinavir|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|nefazodone|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|itraconazole|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|tarceva|indinavir|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 or_LE1 take_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 strong_BE12 cyp3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Erlotinib_ddi|P|rifampicin|erlotinib|pre-treatment_LE1 with_LE1 the_LE1 cyp3a4_LE1 inducer_LE1 BIOENTITY decrease_BE12 BIOENTITY auc_RE2 by_RE2 about_RE2 NUM_RE2 
Erlotinib_ddi|P|tarceva|rifampicin|if_LE1 the_LE1 BIOENTITY dose_BE12 be_BE12 adjust_BE12 upward_BE12 the_BE12 dose_BE12 will_BE12 need_BE12 to_BE12 be_BE12 reduce_BE12 upon_BE12 discontinuation_BE12 of_BE12 BIOENTITY or_RE2 other_RE2 inducer_RE2 
Ertapenem_ddi|P|probenecid|ertapenem|when_LE1 BIOGENERAL_LE1 be_LE1 co-administer_LE1 with_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 p.o._LE1 every_LE1 NUM_LE1 hour_LE1 -RRB-_LE1 BIOENTITY compete_BE12 for_BE12 active_BE12 tubular_BE12 secretion_BE12 and_BE12 reduce_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY 
Ertapenem_ddi|P|ertapenem|probenecid|Based_LE1 on_LE1 total_LE1 BIOENTITY concentration_BE12 BIOENTITY increase_RE2 the_RE2 auc_RE2 by_RE2 NUM_RE2 and_RE2 reduce_RE2 the_RE2 plasma_RE2 and_RE2 renal_RE2 clearance_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Ertapenem_ddi|P|probenecid|ertapenem|Because_LE1 of_LE1 the_LE1 small_LE1 effect_LE1 on_LE1 half-life_LE1 the_LE1 coadministration_LE1 with_LE1 BIOENTITY to_BE12 extend_BE12 the_BE12 half-life_BE12 of_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Erythromycin_ddi|P|erythromycin|theophylline|BIOENTITY use_BE12 in_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 high_BE12 dose_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 in_RE2 serum_RE2 BIOGENERAL_RE2 level_RE2 and_RE2 potential_RE2 BIOGENERAL_RE2 toxicity_RE2 
Erythromycin_ddi|P|theophylline|erythromycin|In_LE1 case_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 and_LE1 elevated_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 reduce_BE12 while_BE12 the_BE12 patient_BE12 be_BE12 receive_BE12 concomitant_BE12 BIOENTITY therapy_RE2 
Erythromycin_ddi|P|erythromycin|digoxin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 result_RE2 in_RE2 elevated_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 
Erythromycin_ddi|P|erythromycin|anticoagulant|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 increase_LE1 anticoagulant_LE1 effect_LE1 when_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 
Erythromycin_ddi|P|erythromycin|dihydroergotamine|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 in_RE2 some_RE2 patient_RE2 with_RE2 acute_RE2 ergot_RE2 toxicity_RE2 characterize_RE2 by_RE2 severe_RE2 peripheral_RE2 vasospasm_RE2 and_RE2 dysesthesia_RE2 
Erythromycin_ddi|P|erythromycin|ergotamine|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 associate_RE2 in_RE2 some_RE2 patient_RE2 with_RE2 acute_RE2 ergot_RE2 toxicity_RE2 characterize_RE2 by_RE2 severe_RE2 peripheral_RE2 vasospasm_RE2 and_RE2 dysesthesia_RE2 
Erythromycin_ddi|P|erythromycin|benzodiazepine|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 thus_BE12 may_BE12 increase_BE12 the_BE12 pharmacologic_BE12 effect_BE12 of_BE12 these_BE12 BIOENTITY 
Erythromycin_ddi|P|erythromycin|midazolam|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 thus_RE2 may_RE2 increase_RE2 the_RE2 pharmacologic_RE2 effect_RE2 of_RE2 these_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|triazolam|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 thus_RE2 may_RE2 increase_RE2 the_RE2 pharmacologic_RE2 effect_RE2 of_RE2 these_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|bromocriptine|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|lovastatin|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|disopyramide|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|cisapride|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|alfentanil|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|phenytoin|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|hexobarbital|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|tacrolimu|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|cyclosporine|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|carbamazepine|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|astemizole|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Erythromycin_ddi|P|erythromycin|terfenadine|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|valproate|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|erythromycin|astemizole|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 significant_BE12 alter_BE12 the_BE12 metabolism_BE12 of_BE12 nonsedating_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY when_RE2 take_RE2 concomitant_RE2 
Erythromycin_ddi|P|erythromycin|terfenadine|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 significant_BE12 alter_BE12 the_BE12 metabolism_BE12 of_BE12 nonsedating_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 when_RE2 take_RE2 concomitant_RE2 
Erythromycin_ddi|P|terfenadine|erythromycin|In_LE1 addition_LE1 death_LE1 have_LE1 be_LE1 report_LE1 rare_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Erythromycin_ddi|P|cisapride|erythromycin|there_LE1 have_LE1 be_LE1 postmarketing_LE1 report_LE1 of_LE1 drug_LE1 interaction_LE1 when_LE1 BIOGENERAL_LE1 be_LE1 coadminister_LE1 with_LE1 BIOGENERAL_LE1 result_LE1 in_LE1 qt_LE1 prolongation_LE1 cardiac_LE1 arrythmias_LE1 ventricular_LE1 tachycardia_LE1 ventricular_LE1 fibrulation_LE1 and_LE1 torsade_LE1 de_LE1 pointes_LE1 much_LE1 like_LE1 due_LE1 to_LE1 inhibition_LE1 of_LE1 hepatic_LE1 metabolism_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY 
Erythromycin_ddi|P|erythromycin|cisapride|there_LE1 have_LE1 be_LE1 postmarketing_LE1 report_LE1 of_LE1 drug_LE1 interaction_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 qt_RE2 prolongation_RE2 cardiac_RE2 arrythmias_RE2 ventricular_RE2 tachycardia_RE2 ventricular_RE2 fibrulation_RE2 and_RE2 torsade_RE2 de_RE2 pointes_RE2 much_RE2 like_RE2 due_RE2 to_RE2 inhibition_RE2 of_RE2 hepatic_RE2 metabolism_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 BIOGENERAL_RE2 
Erythromycin_ddi|P|lovastatin|erythromycin|patient_LE1 receive_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Escitalopram_ddi|P|psychotropic medication|lexapro|BIOGENERAL_LE1 although_LE1 BIOGENERAL_LE1 do_LE1 not_LE1 potentiate_LE1 the_LE1 cognitive_LE1 and_LE1 motor_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 clinical_LE1 trial_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY the_BE12 use_BE12 of_BE12 BIOGENERAL_BE12 by_BE12 patient_BE12 take_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Escitalopram_ddi|P|alcohol|lexapro|BIOGENERAL_LE1 although_LE1 BIOGENERAL_LE1 do_LE1 not_LE1 potentiate_LE1 the_LE1 cognitive_LE1 and_LE1 motor_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 clinical_LE1 trial_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY by_BE12 patient_BE12 take_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Escitalopram_ddi|P|psychotropic drug|aspirin|epidemiological_LE1 study_LE1 of_LE1 the_LE1 case-control_LE1 and_LE1 cohort_LE1 design_LE1 that_LE1 have_LE1 demonstrate_LE1 association_LE1 between_LE1 use_LE1 of_LE1 BIOENTITY that_BE12 interfere_BE12 with_BE12 serotonin_BE12 reuptake_BE12 and_BE12 the_BE12 occurrence_BE12 of_BE12 upper_BE12 gastrointestinal_BE12 bleeding_BE12 have_BE12 also_BE12 show_BE12 that_BE12 concurrent_BE12 use_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY potentiate_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Escitalopram_ddi|P|psychotropic drug|nsaid|epidemiological_LE1 study_LE1 of_LE1 the_LE1 case-control_LE1 and_LE1 cohort_LE1 design_LE1 that_LE1 have_LE1 demonstrate_LE1 association_LE1 between_LE1 use_LE1 of_LE1 BIOENTITY that_BE12 interfere_BE12 with_BE12 serotonin_BE12 reuptake_BE12 and_BE12 the_BE12 occurrence_BE12 of_BE12 upper_BE12 gastrointestinal_BE12 bleeding_BE12 have_BE12 also_BE12 show_BE12 that_BE12 concurrent_BE12 use_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 potentiate_RE2 the_RE2 risk_RE2 of_RE2 bleeding_RE2 
Escitalopram_ddi|P|citalopram|cimetidine|BIOGENERAL_LE1 In_LE1 subject_LE1 who_LE1 have_LE1 receive_LE1 NUM_LE1 day_LE1 of_LE1 NUM_LE1 mg_LE1 racemic_LE1 BIOENTITY combined_BE12 administration_BE12 of_BE12 NUM_BE12 mg_BE12 BIOENTITY for_RE2 NUM_RE2 day_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 and_RE2 cmax_RE2 of_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Escitalopram_ddi|P|lexapro|lithium|because_LE1 BIOGENERAL_LE1 may_LE1 enhance_LE1 the_LE1 serotonergic_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Escitalopram_ddi|P|lithium|escitalopram|because_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 serotonergic_BE12 effect_BE12 of_BE12 BIOENTITY caution_RE2 shall_RE2 be_RE2 exercise_RE2 when_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 coadminister_RE2 
Escitalopram_ddi|P|pimozide|citalopram|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 In_LE1 controlled_LE1 study_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 co-administer_BE12 with_BE12 racemic_BE12 BIOENTITY NUM_RE2 mg_RE2 give_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 be_RE2 associate_RE2 with_RE2 mean_RE2 increase_RE2 in_RE2 qtc_RE2 value_RE2 of_RE2 approximate_RE2 NUM_RE2 msec_RE2 compare_RE2 to_RE2 BIOGENERAL_RE2 give_RE2 alone_RE2 
Escitalopram_ddi|P|selective serotonin reuptake inhibitor|sumatriptan|BIOGENERAL_LE1 there_LE1 have_LE1 be_LE1 rare_LE1 postmarketing_LE1 report_LE1 describe_LE1 patient_LE1 with_LE1 weakness_LE1 hyperreflexia_LE1 and_LE1 incoordination_LE1 following_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY 
Escitalopram_ddi|P|ssri|sumatriptan|BIOGENERAL_LE1 there_LE1 have_LE1 be_LE1 rare_LE1 postmarketing_LE1 report_LE1 describe_LE1 patient_LE1 with_LE1 weakness_LE1 hyperreflexia_LE1 and_LE1 incoordination_LE1 following_LE1 the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY 
Escitalopram_ddi|P|sumatriptan|paroxetine|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|fluvoxamine|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|citalopram|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|sertraline|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|escitalopram|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|ssri|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|sumatriptan|fluoxetine|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Escitalopram_ddi|P|carbamazepine|escitalopram|although_LE1 trough_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 be_LE1 unaffected_LE1 given_LE1 the_LE1 enzyme-inducing_LE1 property_LE1 of_LE1 BIOGENERAL_LE1 the_LE1 possibility_LE1 that_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY shall_RE2 be_RE2 consider_RE2 if_RE2 the_RE2 two_RE2 drug_RE2 be_RE2 coadminister_RE2 
Escitalopram_ddi|P|citalopram|ketoconazole|BIOGENERAL_LE1 combined_LE1 administration_LE1 of_LE1 racemic_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 decrease_RE2 the_RE2 cmax_RE2 and_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 and_RE2 do_RE2 not_RE2 significant_RE2 affect_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 
Escitalopram_ddi|P|escitalopram|desipramine|however_LE1 there_LE1 be_LE1 limited_LE1 in_LE1 vivo_LE1 datum_LE1 suggest_LE1 modest_LE1 cyp2d6_LE1 inhibitory_LE1 effect_LE1 for_LE1 BIOGENERAL_LE1 i.e._LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 with_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 single_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 substrate_RE2 for_RE2 cyp2d6_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 cmax_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Escitalopram_ddi|P|lexapro|metoprolol|BIOGENERAL_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 BIOENTITY for_BE12 NUM_BE12 day_BE12 in_BE12 healthy_BE12 volunteer_BE12 result_BE12 in_BE12 NUM_BE12 increase_BE12 in_BE12 cmax_BE12 and_BE12 NUM_BE12 increase_BE12 in_BE12 auc_BE12 of_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 give_RE2 in_RE2 single_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 -rrb-._RE2 
Escitalopram_ddi|P|escitalopram|citalopram|concomitant_LE1 administration_LE1 with_LE1 racemic_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 since_LE1 BIOENTITY be_BE12 the_BE12 active_BE12 isomer_BE12 of_BE12 racemic_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 the_RE2 two_RE2 agent_RE2 shall_RE2 not_RE2 be_RE2 coadminister_RE2 
Escitalopram_ddi|P|escitalopram|celexa|concomitant_LE1 administration_LE1 with_LE1 racemic_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 since_LE1 BIOENTITY be_BE12 the_BE12 active_BE12 isomer_BE12 of_BE12 racemic_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 the_RE2 two_RE2 agent_RE2 shall_RE2 not_RE2 be_RE2 coadminister_RE2 
Esmolol_ddi|P|reserpine|beta blocking agent|catecholamine-depleting_LE1 drug_LE1 e.g._LE1 BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Esmolol_ddi|P|brevibloc|warfarin|BIOENTITY concentration_BE12 be_BE12 equivocal_BE12 high_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY but_RE2 this_RE2 be_RE2 not_RE2 likely_RE2 to_RE2 be_RE2 clinical_RE2 important_RE2 
Esmolol_ddi|P|digoxin|brevibloc|when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 concomitant_RE2 administer_RE2 intravenous_RE2 to_RE2 normal_RE2 volunteer_RE2 there_RE2 be_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 blood_RE2 level_RE2 at_RE2 some_RE2 time_RE2 point_RE2 
Esmolol_ddi|P|brevibloc|morphine|when_LE1 intravenous_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 concomitant_LE1 administer_LE1 in_LE1 normal_LE1 subject_LE1 no_LE1 effect_LE1 on_LE1 BIOGENERAL_LE1 blood_LE1 level_LE1 be_LE1 see_LE1 but_LE1 BIOENTITY steady-state_BE12 blood_BE12 level_BE12 be_BE12 increase_BE12 by_BE12 NUM_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Esmolol_ddi|P|succinylcholine|brevibloc|the_LE1 onset_LE1 of_LE1 neuromuscular_LE1 blockade_LE1 by_LE1 BIOENTITY be_BE12 unaffect_BE12 by_BE12 BIOENTITY but_RE2 the_RE2 duration_RE2 of_RE2 neuromuscular_RE2 blockade_RE2 be_RE2 prolong_RE2 from_RE2 NUM_RE2 minute_RE2 to_RE2 NUM_RE2 minute_RE2 
Esmolol_ddi|P|brevibloc|warfarin|although_LE1 the_LE1 interaction_LE1 observe_LE1 in_LE1 these_LE1 study_LE1 do_LE1 not_LE1 appear_LE1 to_LE1 be_LE1 of_LE1 major_LE1 clinical_LE1 importance_LE1 BIOENTITY shall_BE12 be_BE12 titrate_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Esmolol_ddi|P|brevibloc|succinylcholine|although_LE1 the_LE1 interaction_LE1 observe_LE1 in_LE1 these_LE1 study_LE1 do_LE1 not_LE1 appear_LE1 to_LE1 be_LE1 of_LE1 major_LE1 clinical_LE1 importance_LE1 BIOENTITY shall_BE12 be_BE12 titrate_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Esmolol_ddi|P|brevibloc|morphine|although_LE1 the_LE1 interaction_LE1 observe_LE1 in_LE1 these_LE1 study_LE1 do_LE1 not_LE1 appear_LE1 to_LE1 be_LE1 of_LE1 major_LE1 clinical_LE1 importance_LE1 BIOENTITY shall_BE12 be_BE12 titrate_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Esmolol_ddi|P|brevibloc|digoxin|although_LE1 the_LE1 interaction_LE1 observe_LE1 in_LE1 these_LE1 study_LE1 do_LE1 not_LE1 appear_LE1 to_LE1 be_LE1 of_LE1 major_LE1 clinical_LE1 importance_LE1 BIOENTITY shall_BE12 be_BE12 titrate_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 concurrent_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Esmolol_ddi|P|brevibloc|verapamil|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 consider_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 patient_RE2 with_RE2 depressed_RE2 myocardial_RE2 function_RE2 
Esmolol_ddi|P|brevibloc|norepinephrine|additional_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 to_BE12 control_BE12 supraventricular_BE12 tachycardia_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 agent_BE12 which_BE12 be_BE12 vasoconstrictive_BE12 and_BE12 inotropic_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 danger_RE2 of_RE2 block_RE2 cardiac_RE2 contractility_RE2 when_RE2 systemic_RE2 vascular_RE2 resistance_RE2 be_RE2 high_RE2 
Esmolol_ddi|P|brevibloc|epinephrine|additional_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 to_BE12 control_BE12 supraventricular_BE12 tachycardia_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 agent_BE12 which_BE12 be_BE12 vasoconstrictive_BE12 and_BE12 inotropic_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 because_RE2 of_RE2 the_RE2 danger_RE2 of_RE2 block_RE2 cardiac_RE2 contractility_RE2 when_RE2 systemic_RE2 vascular_RE2 resistance_RE2 be_RE2 high_RE2 
Esmolol_ddi|P|brevibloc|dopamine|additional_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 to_BE12 control_BE12 supraventricular_BE12 tachycardia_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 agent_BE12 which_BE12 be_BE12 vasoconstrictive_BE12 and_BE12 inotropic_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 because_RE2 of_RE2 the_RE2 danger_RE2 of_RE2 block_RE2 cardiac_RE2 contractility_RE2 when_RE2 systemic_RE2 vascular_RE2 resistance_RE2 be_RE2 high_RE2 
Esomeprazole_ddi|P|warfarin|esomeprazole|post-marketing_LE1 report_LE1 of_LE1 change_LE1 in_LE1 prothrombin_LE1 measure_LE1 have_LE1 be_LE1 receive_LE1 among_LE1 patient_LE1 on_LE1 concomitant_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 
Esomeprazole_ddi|P|proton pump inhibitor|warfarin|patient_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 may_RE2 need_RE2 to_RE2 be_RE2 monitor_RE2 for_RE2 increase_RE2 in_RE2 inr_RE2 and_RE2 prothrombin_RE2 time_RE2 
Esomeprazole_ddi|P|esomeprazole|diazepam|coadministration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY cyp2c19_RE2 substrate_RE2 result_RE2 in_RE2 NUM_RE2 decrease_RE2 in_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Esomeprazole_ddi|P|esomeprazole|ketoconazole|therefore_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 salt_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Esomeprazole_ddi|P|esomeprazole|iron|therefore_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY salt_RE2 and_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Esomeprazole_ddi|P|esomeprazole|digoxin|therefore_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 salt_BE12 and_BE12 BIOENTITY -rrb-._RE2 
Esomeprazole_ddi|P|clarithromycin|pimozide|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Estazolam_ddi|P|benzodiazepine|alcohol|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|barbiturate|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|anticonvulsant|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|antihistamine|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|phenothiazine|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|psychotropic medication|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|monoamine oxidase inhibitor|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|benzodiazepine|narcotic|the_LE1 action_LE1 of_LE1 the_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Estazolam_ddi|P|estazolam|rifampin|while_LE1 no_LE1 in_LE1 vivo_LE1 drug-drug_LE1 interaction_LE1 study_LE1 be_LE1 conduct_LE1 between_LE1 BIOENTITY and_BE12 inducer_BE12 of_BE12 cyp3a_BE12 compound_BE12 that_BE12 be_BE12 potent_BE12 cyp3a_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 will_RE2 be_RE2 expect_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Estazolam_ddi|P|estazolam|phenytoin|while_LE1 no_LE1 in_LE1 vivo_LE1 drug-drug_LE1 interaction_LE1 study_LE1 be_LE1 conduct_LE1 between_LE1 BIOENTITY and_BE12 inducer_BE12 of_BE12 cyp3a_BE12 compound_BE12 that_BE12 be_BE12 potent_BE12 cyp3a_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 will_RE2 be_RE2 expect_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Estazolam_ddi|P|estazolam|carbamazepine|while_LE1 no_LE1 in_LE1 vivo_LE1 drug-drug_LE1 interaction_LE1 study_LE1 be_LE1 conduct_LE1 between_LE1 BIOENTITY and_BE12 inducer_BE12 of_BE12 cyp3a_BE12 compound_BE12 that_BE12 be_BE12 potent_BE12 cyp3a_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 will_RE2 be_RE2 expect_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Estazolam_ddi|P|estazolam|barbiturate|while_LE1 no_LE1 in_LE1 vivo_LE1 drug-drug_LE1 interaction_LE1 study_LE1 be_LE1 conduct_LE1 between_LE1 BIOENTITY and_BE12 inducer_BE12 of_BE12 cyp3a_BE12 compound_BE12 that_BE12 be_BE12 potent_BE12 cyp3a_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 will_RE2 be_RE2 expect_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 concentration_RE2 
Estazolam_ddi|P|estazolam|estazolam|while_LE1 no_LE1 in_LE1 vivo_LE1 drug-drug_LE1 interaction_LE1 study_LE1 be_LE1 conduct_LE1 between_LE1 BIOENTITY and_BE12 inducer_BE12 of_BE12 cyp3a_BE12 compound_BE12 that_BE12 be_BE12 potent_BE12 cyp3a_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 decrease_BE12 BIOENTITY concentration_RE2 
Estazolam_ddi|P|estazolam|itraconazole|consequent_LE1 BIOENTITY shall_BE12 be_BE12 avoid_BE12 in_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY which_RE2 be_RE2 very_RE2 potent_RE2 inhibitor_RE2 of_RE2 cyp3a_RE2 
Estazolam_ddi|P|estazolam|ketoconazole|consequent_LE1 BIOENTITY shall_BE12 be_BE12 avoid_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 very_RE2 potent_RE2 inhibitor_RE2 of_RE2 cyp3a_RE2 
Estazolam_ddi|P|benzodiazepine|macrolide antibiotic|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY 
Estazolam_ddi|P|benzodiazepine|isoniazide|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 
Estazolam_ddi|P|benzodiazepine|diltiazem|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 
Estazolam_ddi|P|benzodiazepine|cimetidine|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 
Estazolam_ddi|P|benzodiazepine|fluvoxamine|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 
Estazolam_ddi|P|benzodiazepine|nefazodone|the_LE1 following_LE1 be_LE1 example_LE1 of_LE1 drug_LE1 know_LE1 to_LE1 inhibit_LE1 the_LE1 metabolism_LE1 of_LE1 other_LE1 related_LE1 BIOENTITY presumable_BE12 through_BE12 inhibition_BE12 of_BE12 cyp3a_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 some_RE2 BIOGENERAL_RE2 
Estramustine_ddi|P|calcium|emcyt|milk_LE1 milk_LE1 product_LE1 and_LE1 BIOENTITY food_BE12 or_BE12 drug_BE12 may_BE12 impair_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY 
Eszopiclone_ddi|P|eszopiclone|ethanol|cns-active_LE1 drug_LE1 BIOGENERAL_LE1 additive_LE1 effect_LE1 on_LE1 psychomotor_LE1 performance_LE1 be_LE1 see_LE1 with_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY NUM_RE2 for_RE2 up_RE2 to_RE2 NUM_RE2 hour_RE2 after_RE2 BIOGENERAL_RE2 administration_RE2 
Eszopiclone_ddi|P|eszopiclone|olanzapine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 produce_RE2 decrease_RE2 in_RE2 dsst_RE2 score_RE2 
Eszopiclone_ddi|P|eszopiclone|ketoconazole|the_LE1 auc_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 NUM_BE12 by_BE12 coadministration_BE12 of_BE12 BIOENTITY potent_RE2 inhibitor_RE2 of_RE2 cyp3a4_RE2 NUM_RE2 mg_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 
Eszopiclone_ddi|P|zopiclone|rifampicin|drug_LE1 That_LE1 induce_LE1 cyp3a4_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 racemic_LE1 BIOENTITY exposure_BE12 be_BE12 decrease_BE12 NUM_BE12 by_BE12 concomitant_BE12 useof_BE12 BIOENTITY potent_RE2 inducer_RE2 of_RE2 cyp3a4_RE2 
Etanercept_ddi|P|enbrel|anakinra|In_LE1 study_LE1 in_LE1 which_LE1 patient_LE1 with_LE1 active_LE1 ra_LE1 be_LE1 treat_LE1 for_LE1 up_LE1 to_LE1 NUM_LE1 week_LE1 with_LE1 concurrent_LE1 BIOENTITY and_BE12 BIOENTITY therapy_RE2 NUM_RE2 rate_RE2 of_RE2 serious_RE2 infection_RE2 be_RE2 observe_RE2 which_RE2 be_RE2 high_RE2 than_RE2 that_RE2 observe_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 -LRB-_RE2 NUM_RE2 
Etanercept_ddi|P|enbrel|anakinra|two_LE1 percent_LE1 of_LE1 patient_LE1 treat_LE1 concurrent_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY develop_RE2 neutropenia_RE2 -LRB-_RE2 anc_RE2 NUM_RE2 NUM_RE2 -rrb-._RE2 
Etanercept_ddi|P|sulfasalazine|enbrel|patient_LE1 in_LE1 clinical_LE1 study_LE1 who_LE1 be_LE1 on_LE1 established_LE1 therapy_LE1 with_LE1 BIOENTITY to_BE12 which_BE12 BIOENTITY be_RE2 add_RE2 be_RE2 note_RE2 to_RE2 develop_RE2 mild_RE2 decrease_RE2 in_RE2 mean_RE2 neutrophil_RE2 count_RE2 in_RE2 comparison_RE2 to_RE2 group_RE2 treat_RE2 with_RE2 either_RE2 BIOGENERAL_RE2 ci_RE2 or_RE2 BIOGENERAL_RE2 alone_RE2 
Ethacrynic acid_ddi|P|lithium|diuretic|BIOENTITY general_BE12 shall_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY because_RE2 they_RE2 reduce_RE2 its_RE2 renal_RE2 clearance_RE2 and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Ethacrynic acid_ddi|P|edecrin|cephalosporin antibiotic|BIOENTITY may_BE12 increase_BE12 the_BE12 ototoxic_BE12 potential_BE12 of_BE12 other_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY 
Ethacrynic acid_ddi|P|edecrin|aminoglycoside|BIOENTITY may_BE12 increase_BE12 the_BE12 ototoxic_BE12 potential_BE12 of_BE12 other_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 
Ethacrynic acid_ddi|P|ethacrynic acid|warfarin|number_LE1 of_LE1 drug_LE1 including_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 displace_BE12 BIOENTITY from_RE2 plasma_RE2 protein_RE2 
Ethacrynic acid_ddi|P|non- steroidal antiinflammatory agent|potassium- sparing diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Ethacrynic acid_ddi|P|non- steroidal antiinflammatory agent|loop diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Ethacrynic acid_ddi|P|non- steroidal antiinflammatory agent|thiazide diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Ethacrynic acid_ddi|P|edecrin|non- steroidal anti- inflammatory agent|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 obtain_RE2 
Ethambutol_ddi|P|ethambutol|aluminum hydroxide|the_LE1 result_LE1 of_LE1 study_LE1 of_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 with_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 to_RE2 NUM_RE2 patient_RE2 with_RE2 tuberculosis_RE2 show_RE2 reduction_RE2 of_RE2 mean_RE2 serum_RE2 concentration_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 of_RE2 approximate_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 suggest_RE2 that_RE2 the_RE2 oral_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 be_RE2 reduce_RE2 by_RE2 these_RE2 BIOGENERAL_RE2 
Ethambutol_ddi|P|ethambutol|aluminum hydroxide|it_LE1 be_LE1 recommend_LE1 to_LE1 avoid_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 for_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 following_RE2 BIOGENERAL_RE2 administration_RE2 
Ethchlorvynol_ddi|P|alcohol|ethchlorvynol|other_LE1 depressasnt_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 cns_BE12 depression_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY 
Ethchlorvynol_ddi|P|barbiturate|ethchlorvynol|other_LE1 depressasnt_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 cns_BE12 depression_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY 
Ethchlorvynol_ddi|P|maoi|ethchlorvynol|other_LE1 depressasnt_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 enhance_BE12 cns_BE12 depression_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY 
Ethionamide_ddi|P|trecator|isoniazid|BIOENTITY have_BE12 be_BE12 find_BE12 to_BE12 temporary_BE12 raise_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY 
Ethionamide_ddi|P|trecator|antituberculous drug|BIOENTITY may_BE12 potentiate_BE12 the_BE12 adverse_BE12 effect_BE12 of_BE12 other_BE12 BIOENTITY administer_RE2 concomitant_RE2 
Ethionamide_ddi|P|ethionamide|cycloserine|In_LE1 particular_LE1 convulsion_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY and_RE2 special_RE2 care_RE2 shall_RE2 be_RE2 take_RE2 when_RE2 the_RE2 treatment_RE2 regimen_RE2 include_RE2 both_RE2 of_RE2 these_RE2 drug_RE2 
Ethopropazine_ddi|P|ethopropazine|cns depressant|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY cause_RE2 increase_RE2 sedative_RE2 effect_RE2 
Ethopropazine_ddi|P|ethopropazine|alcohol|BIOENTITY may_BE12 interact_BE12 with_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 increase_RE2 sedative_RE2 effect_RE2 
Ethopropazine_ddi|P|ethopropazine|chlorpromazine|BIOENTITY can_BE12 interact_BE12 with_BE12 BIOENTITY increase_RE2 the_RE2 metabolism_RE2 of_RE2 BIOGENERAL_RE2 
Ethosuximide_ddi|P|ethosuximide|antiepileptic drug|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 may_BE12 interact_BE12 with_BE12 concurrent_BE12 administer_BE12 BIOENTITY periodic_RE2 serum_RE2 level_RE2 determination_RE2 of_RE2 these_RE2 drug_RE2 may_RE2 be_RE2 necessary_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 may_RE2 elevate_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 to_RE2 both_RE2 increase_RE2 and_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -rrb-._RE2 
Ethosuximide_ddi|P|zarontin|antiepileptic drug|since_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 interact_BE12 with_BE12 concurrent_BE12 administer_BE12 BIOENTITY periodic_RE2 serum_RE2 level_RE2 determination_RE2 of_RE2 these_RE2 drug_RE2 may_RE2 be_RE2 necessary_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 may_RE2 elevate_RE2 BIOGENERAL_RE2 serum_RE2 level_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 to_RE2 both_RE2 increase_RE2 and_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -rrb-._RE2 
Ethosuximide_ddi|P|valproic acid|ethosuximide|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 interact_LE1 with_LE1 concurrent_LE1 administer_LE1 BIOGENERAL_LE1 periodic_LE1 serum_LE1 level_LE1 determination_LE1 of_LE1 these_LE1 drug_LE1 may_LE1 be_LE1 necessary_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 may_LE1 elevate_LE1 BIOGENERAL_LE1 serum_LE1 level_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 both_BE12 increase_BE12 and_BE12 decrease_BE12 BIOENTITY level_RE2 -rrb-._RE2 
Ethosuximide_ddi|P|ethosuximide|phenytoin|since_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 interact_LE1 with_LE1 concurrent_LE1 administer_LE1 BIOGENERAL_LE1 periodic_LE1 serum_LE1 level_LE1 determination_LE1 of_LE1 these_LE1 drug_LE1 may_LE1 be_LE1 necessary_LE1 -LRB-_LE1 eg_LE1 BIOENTITY may_BE12 elevate_BE12 BIOENTITY serum_RE2 level_RE2 and_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 to_RE2 both_RE2 increase_RE2 and_RE2 decrease_RE2 BIOGENERAL_RE2 level_RE2 -rrb-._RE2 
Ethotoin_ddi|P|peganone|phenacemide|considerable_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 since_RE2 paranoid_RE2 symptom_RE2 have_RE2 be_RE2 report_RE2 during_RE2 therapy_RE2 with_RE2 this_RE2 combination_RE2 
Ethotoin_ddi|P|peganone|phenurone|considerable_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 since_RE2 paranoid_RE2 symptom_RE2 have_RE2 be_RE2 report_RE2 during_RE2 therapy_RE2 with_RE2 this_RE2 combination_RE2 
Ethotoin_ddi|P|hydantoin antiepileptic|phenytoin|two-way_LE1 interaction_LE1 between_LE1 the_LE1 BIOENTITY BIOENTITY and_RE2 the_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 suggest_RE2 
Ethotoin_ddi|P|hydantoin antiepileptic|coumarin anticoagulant|two-way_LE1 interaction_LE1 between_LE1 the_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 the_BE12 BIOENTITY have_RE2 be_RE2 suggest_RE2 
Ethotoin_ddi|P|phenytoin|coumarin|presumable_LE1 BIOENTITY act_BE12 as_BE12 stimulator_BE12 of_BE12 BIOENTITY metabolism_RE2 and_RE2 have_RE2 be_RE2 report_RE2 to_RE2 cause_RE2 decrease_RE2 serum_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 prothrombin-proconvertin_RE2 concentration_RE2 
Ethotoin_ddi|P|phenytoin|coumarin anticoagulant|presumable_LE1 BIOENTITY act_BE12 as_BE12 stimulator_BE12 of_BE12 BIOGENERAL_BE12 metabolism_BE12 and_BE12 have_BE12 be_BE12 report_BE12 to_BE12 cause_BE12 decrease_BE12 serum_BE12 level_BE12 of_BE12 the_BE12 BIOENTITY and_RE2 increase_RE2 prothrombin-proconvertin_RE2 concentration_RE2 
Ethotoin_ddi|P|coumarin anticoagulant|phenytoin|converse_LE1 the_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 the_BE12 serum_BE12 level_BE12 and_BE12 prolong_BE12 the_BE12 serum_BE12 half-life_BE12 of_BE12 BIOENTITY by_RE2 inhibit_RE2 its_RE2 metabolism_RE2 
Ethotoin_ddi|P|peganone|coumarin anticoagulant|caution_LE1 be_LE1 therefore_LE1 advise_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY 
Ethoxzolamide_ddi|P|ethoxzolamide|quinidine|BIOENTITY may_BE12 increase_BE12 the_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Ethoxzolamide_ddi|P|ethoxzolamide|amphetamine|BIOENTITY may_BE12 increase_BE12 the_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Ethoxzolamide_ddi|P|ethoxzolamide|procainamide|BIOENTITY may_BE12 increase_BE12 the_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Ethoxzolamide_ddi|P|ethoxzolamide|tricyclic|BIOENTITY may_BE12 increase_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Ethoxzolamide_ddi|P|ethoxzolamide|amphotericin b|coadministration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 hypokalemia_RE2 
Ethoxzolamide_ddi|P|ethoxzolamide|corticosteroid|coadministration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 hypokalemia_RE2 
Ethoxzolamide_ddi|P|ethoxzolamide|diuretic|coadministration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 hypokalemia_RE2 
Ethynodiol Diacetate_ddi|P|acetaminophen|synthetic estrogen|BIOENTITY :_BE12 may_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY possible_RE2 by_RE2 inhibit_RE2 conjugation_RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|acetaminophen|combination_LE1 BIOENTITY may_BE12 also_BE12 decrease_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|acitretin|progestin|BIOENTITY :_BE12 interfere_BE12 with_BE12 the_BE12 contraceptive_BE12 effect_BE12 of_BE12 microdosed_BE12 BIOENTITY minipill_RE2 preparation_RE2 
Ethynodiol Diacetate_ddi|P|aminoglutethimide|progestin|BIOENTITY :_BE12 may_BE12 increase_BE12 cyp_BE12 metabolism_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|coumarin derivative|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 increase_BE12 or_BE12 decrease_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|topiramate|ethinyl estradiol|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|anticonvulsant|progestin|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|phenobarbital|ethinyl estradiol|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|phenytoin|ethinyl estradiol|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|carbamazepine|ethinyl estradiol|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|felbamate|ethinyl estradiol|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|phenytoin|progestin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|topiramate|progestin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|anticonvulsant|ethinyl estradiol|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|felbamate|progestin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|carbamazepine|progestin|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|phenobarbital|progestin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY lead_RE2 to_RE2 possible_RE2 decrease_RE2 in_RE2 contraceptive_RE2 effectiveness_RE2 
Ethynodiol Diacetate_ddi|P|ascorbic acid|synthetic estrogen|BIOGENERAL_LE1 :_LE1 dose_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 NUM_BE12 have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 possible_RE2 by_RE2 inhibit_RE2 conjugation_RE2 
Ethynodiol Diacetate_ddi|P|vitamin c|synthetic estrogen|BIOGENERAL_LE1 :_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 NUM_BE12 have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 possible_RE2 by_RE2 inhibit_RE2 conjugation_RE2 
Ethynodiol Diacetate_ddi|P|atorvastatin|norethindrone|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 auc_BE12 for_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Ethynodiol Diacetate_ddi|P|atorvastatin|ethinyl estradiol|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 auc_BE12 for_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|temazepam|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 other_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|oxazepam|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 other_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|lorazepam|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 other_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|diazepam|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 increase_RE2 the_RE2 clearance_RE2 of_RE2 other_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|chlordiazepoxide|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 increase_RE2 the_RE2 clearance_RE2 of_RE2 other_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|alprazolam|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 increase_RE2 the_RE2 clearance_RE2 of_RE2 other_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|benzodiazepine|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 clearance_BE12 of_BE12 some_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 increase_RE2 the_RE2 clearance_RE2 of_RE2 other_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|clofibric acid|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|cyclosporine|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 
Ethynodiol Diacetate_ddi|P|griseofulvin|combination hormonal contraceptive|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 induce_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY cause_RE2 menstrual_RE2 change_RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|morphine|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|nevirapine|combination hormonal contraceptive|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOENTITY may_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|ethinyl estradiol|prednisolone|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 
Ethynodiol Diacetate_ddi|P|ritonavir|combination hormonal contraceptive|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|lopinavir|combination hormonal contraceptive|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 show_BE12 to_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|nelfinavir|combination hormonal contraceptive|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 show_BE12 to_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|amprenavir|combination hormonal contraceptive|BIOGENERAL_LE1 :_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 show_BE12 to_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|indinavir|combination hormonal contraceptive|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 increase_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|rifampin|ethinyl estradiol|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 some_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 result_RE2 in_RE2 decrease_RE2 contraceptive_RE2 effectiveness_RE2 and_RE2 increase_RE2 menstrual_RE2 irregularity_RE2 
Ethynodiol Diacetate_ddi|P|rifampin|norethindrone|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 result_RE2 in_RE2 decrease_RE2 contraceptive_RE2 effectiveness_RE2 and_RE2 increase_RE2 menstrual_RE2 irregularity_RE2 
Ethynodiol Diacetate_ddi|P|rifampin|progestin|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 some_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 result_RE2 in_RE2 decrease_RE2 contraceptive_RE2 effectiveness_RE2 and_RE2 increase_RE2 menstrual_RE2 irregularity_RE2 
Ethynodiol Diacetate_ddi|P|hormonal contraceptive|salicylic acid|BIOGENERAL_LE1 :_LE1 combination_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|combination hormonal contraceptive|selegiline|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY 
Ethynodiol Diacetate_ddi|P|ethinyl estradiol|theophylline|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 
Ethynodiol Diacetate_ddi|P|amitriptyline|combination hormonal contraceptive|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 metabolism_BE12 may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Ethynodiol Diacetate_ddi|P|imipramine|combination hormonal contraceptive|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 :_BE12 metabolism_BE12 may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Ethynodiol Diacetate_ddi|P|tricyclic antidepressant|combination hormonal contraceptive|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 :_BE12 metabolism_BE12 may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Ethynodiol Diacetate_ddi|P|nortriptyline|combination hormonal contraceptive|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 :_BE12 metabolism_BE12 may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY increase_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Ethynodiol Diacetate_ddi|P|combination hormonal contraceptive|caffeine|BIOGENERAL_LE1 nutrition_LE1 herb_LE1 interaction_LE1 :_LE1 food_LE1 :_LE1 cns_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 enhance_LE1 if_LE1 BIOENTITY be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Etidronic acid_ddi|P|etidronate|warfarin|there_LE1 have_LE1 be_LE1 isolate_LE1 report_LE1 of_LE1 patient_LE1 experience_LE1 increase_LE1 in_LE1 their_LE1 prothrombin_LE1 time_LE1 when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 BIOENTITY therapy_RE2 
Etodolac_ddi|P|nsaid|ace-inhibitor|BIOGENERAL_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Etodolac_ddi|P|nsaid|ace-inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Etodolac_ddi|P|lodine|aspirin|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY its_RE2 protein_RE2 binding_RE2 be_RE2 reduce_RE2 although_RE2 the_RE2 clearance_RE2 of_RE2 free_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 alter_RE2 
Etodolac_ddi|P|lodine|aspirin|however_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 general_RE2 recommend_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 of_RE2 increase_RE2 adverse_RE2 effect_RE2 
Etodolac_ddi|P|lodine|cyclosporine|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|lodine|digoxin|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|lodine|methotrexate|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|nsaid|cyclosporine|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|nsaid|methotrexate|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|nsaid|digoxin|cyclosporine_LE1 digoxin_LE1 methotrexate_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY through_BE12 effect_BE12 on_BE12 renal_BE12 prostaglandin_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 these_BE12 drug_BE12 lead_BE12 to_BE12 elevated_BE12 serum_BE12 level_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 increase_RE2 toxicity_RE2 
Etodolac_ddi|P|lodine|furosemide|nevertheless_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 postmarket_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Etodolac_ddi|P|lodine|thiazide|nevertheless_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 postmarket_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Etodolac_ddi|P|nsaid|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY level_RE2 and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 
Etodolac_ddi|P|nsaid|lithium|thus_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concurrent_RE2 subject_RE2 shall_RE2 be_RE2 observe_RE2 careful_RE2 for_RE2 sign_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Etodolac_ddi|P|phenylbutazone|etodolac|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 increase_BE12 -LRB-_BE12 by_BE12 about_BE12 NUM_BE12 -RRB-_BE12 in_BE12 the_BE12 free_BE12 fraction_BE12 of_BE12 BIOENTITY 
Etodolac_ddi|P|etodolac|phenylbutazone|although_LE1 in_LE1 vivo_LE1 study_LE1 have_LE1 not_LE1 be_LE1 do_LE1 to_LE1 see_LE1 if_LE1 BIOENTITY clearance_BE12 be_BE12 change_BE12 by_BE12 coadministration_BE12 of_BE12 BIOENTITY it_RE2 be_RE2 not_RE2 recommend_RE2 that_RE2 they_RE2 be_RE2 coadminister_RE2 
Etodolac_ddi|P|warfarin|nsaid|BIOGENERAL_LE1 :_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY on_RE2 gi_RE2 bleeding_RE2 be_RE2 synergistic_RE2 such_RE2 that_RE2 user_RE2 of_RE2 both_RE2 drug_RE2 together_RE2 have_RE2 risk_RE2 of_RE2 serious_RE2 gi_RE2 bleeding_RE2 high_RE2 than_RE2 that_RE2 of_RE2 user_RE2 of_RE2 either_RE2 drug_RE2 alone_RE2 
Etodolac_ddi|P|warfarin|etodolac|short-term_LE1 pharmacokinetic_LE1 study_LE1 have_LE1 demonstrate_LE1 that_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY capsule_RE2 and_RE2 tablet_RE2 -RRB-_RE2 result_RE2 in_RE2 reduce_RE2 protein_RE2 binding_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 there_RE2 be_RE2 no_RE2 change_RE2 in_RE2 the_RE2 clearance_RE2 of_RE2 free_RE2 BIOGENERAL_RE2 
Etodolac_ddi|P|warfarin|lodine|short-term_LE1 pharmacokinetic_LE1 study_LE1 have_LE1 demonstrate_LE1 that_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 capsule_RE2 and_RE2 tablet_RE2 -RRB-_RE2 result_RE2 in_RE2 reduce_RE2 protein_RE2 binding_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 there_RE2 be_RE2 no_RE2 change_RE2 in_RE2 the_RE2 clearance_RE2 of_RE2 free_RE2 BIOGENERAL_RE2 
Etodolac_ddi|P|etodolac|warfarin|however_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 because_LE1 there_LE1 have_LE1 be_LE1 few_LE1 spontaneous_LE1 report_LE1 of_LE1 prolonged_LE1 prothrombin_LE1 time_LE1 with_LE1 or_LE1 without_LE1 bleeding_LE1 in_LE1 BIOENTITY patient_BE12 receive_BE12 concomitant_BE12 BIOENTITY therapy_RE2 
Etonogestrel_ddi|P|etonogestrel|rifadin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|rifampin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|prednisolone|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|prelone|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|ms contin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|phenylbutazone|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|astramorph|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|kadian|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|viracept|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|morphine|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|sandimmune|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|neoral|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|cyclosporine|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|norvir|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|kaletra|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|invirase|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|fortovase|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|crixivan|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|agenerase|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|protease inhibitor|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|phenobarbital|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|tegretol|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|trileptal|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|theophylline|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 st._BE12 john_BE12 wort_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|theo-dur|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 st._BE12 john_BE12 wort_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|vitamin c|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 st._BE12 john_BE12 wort_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY 
Etonogestrel_ddi|P|etonogestrel|temazepam|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 hiv_BE12 drug_BE12 classify_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 st._BE12 john_BE12 wort_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|felbatol|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|topamax|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|acetaminophen|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|lipitor|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|atorvastatin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|antibiotic|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|atromid-|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|tylenol|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|clofibrate|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|tetracycline|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|gris-peg|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|antifungal|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|ampicillin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|dilantin|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|sporanox|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|anticonvulsant|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etonogestrel_ddi|P|etonogestrel|nizoral|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 follow_BE12 medication_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 hiv_RE2 drug_RE2 classify_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 st._RE2 john_RE2 wort_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 
Etoposide_ddi|P|etopopho|levamisole hydrochloride|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 drug_BE12 that_BE12 be_BE12 know_BE12 to_BE12 inhibit_BE12 phosphatase_BE12 activity_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -rrb-._RE2 
Etoposide_ddi|P|cyclosporin a|etoposide|high-dose_LE1 BIOENTITY result_BE12 in_BE12 concentration_BE12 above_BE12 NUM_BE12 ng_BE12 administer_BE12 with_BE12 oral_BE12 BIOENTITY have_RE2 lead_RE2 to_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 exposure_RE2 with_RE2 NUM_RE2 decrease_RE2 in_RE2 total_RE2 body_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 alone_RE2 
Exemestane_ddi|P|rifampicin|exemestane|co-medication_LE1 that_LE1 induce_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 st._BE12 john_BE12 wort_BE12 -RRB-_BE12 may_BE12 significant_BE12 decrease_BE12 exposure_BE12 to_BE12 BIOENTITY 
Exemestane_ddi|P|carbamazepine|exemestane|co-medication_LE1 that_LE1 induce_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 st._BE12 john_BE12 wort_BE12 -RRB-_BE12 may_BE12 significant_BE12 decrease_BE12 exposure_BE12 to_BE12 BIOENTITY 
Exemestane_ddi|P|phenytoin|exemestane|co-medication_LE1 that_LE1 induce_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 st._BE12 john_BE12 wort_BE12 -RRB-_BE12 may_BE12 significant_BE12 decrease_BE12 exposure_BE12 to_BE12 BIOENTITY 
Exemestane_ddi|P|phenobarbital|exemestane|co-medication_LE1 that_LE1 induce_LE1 cyp_LE1 3a4_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 st._BE12 john_BE12 wort_BE12 -RRB-_BE12 may_BE12 significant_BE12 decrease_BE12 exposure_BE12 to_BE12 BIOENTITY 
Famciclovir_ddi|P|probenecid|penciclovir|concurrent_LE1 use_LE1 with_LE1 BIOENTITY or_BE12 other_BE12 drug_BE12 significant_BE12 eliminate_BE12 by_BE12 active_BE12 renal_BE12 tubular_BE12 secretion_BE12 may_BE12 result_BE12 in_BE12 increase_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY 
Felbamate_ddi|P|felbatol|antiepileptic drug|use_LE1 in_LE1 conjunction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY to_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 affect_RE2 the_RE2 steady-state_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Felbamate_ddi|P|felbatol|aed|use_LE1 in_LE1 conjunction_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY to_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 affect_RE2 the_RE2 steady-state_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Felbamate_ddi|P|felbatol|phenytoin|specific_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 on_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 increase_BE12 in_BE12 steady-state_BE12 BIOENTITY plasma_RE2 concentration_RE2 
Felbamate_ddi|P|felbamate|phenytoin|increase_LE1 the_LE1 BIOENTITY dose_BE12 to_BE12 NUM_BE12 mg_BE12 in_BE12 six_BE12 of_BE12 these_BE12 subject_BE12 increase_BE12 the_BE12 steady-state_BE12 BIOENTITY cmin_RE2 to_RE2 NUM_RE2 NUM_RE2 micrograms_RE2 
Felbamate_ddi|P|felbamate|phenytoin|in_LE1 order_LE1 to_LE1 maintain_LE1 BIOGENERAL_LE1 level_LE1 limit_LE1 adverse_LE1 experience_LE1 and_LE1 achieve_LE1 the_LE1 BIOENTITY dose_BE12 of_BE12 NUM_BE12 mg_BE12 BIOENTITY dose_RE2 reduction_RE2 of_RE2 approximate_RE2 NUM_RE2 be_RE2 necessary_RE2 for_RE2 eight_RE2 of_RE2 these_RE2 NUM_RE2 subject_RE2 
Felbamate_ddi|P|felbatol|carbamazepine|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 decrease_BE12 in_BE12 the_BE12 steady-state_BE12 BIOENTITY plasma_RE2 concentration_RE2 and_RE2 increase_RE2 in_RE2 the_RE2 steady-state_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Felbamate_ddi|P|carbamazepine|felbamate|the_LE1 BIOENTITY steady-state_BE12 cmin_BE12 decrease_BE12 NUM_BE12 to_BE12 NUM_BE12 NUM_BE12 micrograms_BE12 when_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 divide_RE2 into_RE2 three_RE2 dose_RE2 -RRB-_RE2 be_RE2 coadminister_RE2 
Felbamate_ddi|P|felbatol|valproate|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 increase_BE12 in_BE12 steady-state_BE12 BIOENTITY concentration_RE2 
Felbamate_ddi|P|felbamate|valproate|increase_LE1 the_LE1 BIOENTITY dose_BE12 to_BE12 NUM_BE12 mg_BE12 increase_BE12 the_BE12 steadystate_BE12 BIOENTITY cmin_RE2 to_RE2 NUM_RE2 NUM_RE2 micrograms_RE2 
Felbamate_ddi|P|felbamate|phenobarbital|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY cause_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 In_RE2 NUM_RE2 otherwise_RE2 healthy_RE2 male_RE2 volunteer_RE2 ingest_RE2 BIOGENERAL_RE2 the_RE2 steady-state_RE2 trough_RE2 -LRB-_RE2 cmin_RE2 -RRB-_RE2 BIOGENERAL_RE2 concentration_RE2 be_RE2 NUM_RE2 micrograms_RE2 
Felbamate_ddi|P|phenytoin|felbatol|effect_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 on_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 approximate_BE12 doubling_BE12 of_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 at_RE2 steady_RE2 state_RE2 and_RE2 therefore_RE2 the_RE2 addition_RE2 of_RE2 BIOGENERAL_RE2 cause_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 the_RE2 steady-state_RE2 trough_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 to_RE2 the_RE2 same_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 give_RE2 as_RE2 monotherapy_RE2 
Felbamate_ddi|P|phenytoin|felbamate|effect_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 on_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 approximate_BE12 doubling_BE12 of_BE12 the_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 at_RE2 steady_RE2 state_RE2 and_RE2 therefore_RE2 the_RE2 addition_RE2 of_RE2 BIOGENERAL_RE2 cause_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 the_RE2 steady-state_RE2 trough_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 to_RE2 the_RE2 same_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 give_RE2 as_RE2 monotherapy_RE2 
Felbamate_ddi|P|phenytoin|felbatol|effect_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 on_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 cause_LE1 approximate_LE1 doubling_LE1 of_LE1 the_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 at_LE1 steady_LE1 state_LE1 and_LE1 therefore_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY cause_BE12 approximate_BE12 NUM_BE12 decrease_BE12 in_BE12 the_BE12 steady-state_BE12 trough_BE12 concentration_BE12 of_BE12 BIOENTITY as_RE2 compare_RE2 to_RE2 the_RE2 same_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 give_RE2 as_RE2 monotherapy_RE2 
Felbamate_ddi|P|carbamazepine|felbatol|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 cause_LE1 approximate_LE1 NUM_LE1 increase_LE1 in_LE1 the_LE1 clearance_LE1 of_LE1 BIOGENERAL_LE1 at_LE1 steady_LE1 state_LE1 and_LE1 therefore_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY result_BE12 in_BE12 approximate_BE12 NUM_BE12 decrease_BE12 in_BE12 the_BE12 steady-state_BE12 trough_BE12 concentration_BE12 of_BE12 BIOENTITY as_RE2 compare_RE2 to_RE2 the_RE2 same_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 give_RE2 as_RE2 monotherapy_RE2 
Felbamate_ddi|P|carbamazepine|felbatol|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 approximate_BE12 NUM_BE12 increase_BE12 in_BE12 the_BE12 clearance_BE12 of_BE12 BIOENTITY at_RE2 steady_RE2 state_RE2 and_RE2 therefore_RE2 the_RE2 addition_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 the_RE2 steady-state_RE2 trough_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 to_RE2 the_RE2 same_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 give_RE2 as_RE2 monotherapy_RE2 
Felbamate_ddi|P|phenobarbital|felbamate|BIOGENERAL_LE1 :_LE1 it_LE1 appear_LE1 that_LE1 BIOENTITY may_BE12 reduce_BE12 plasma_BE12 BIOENTITY concentration_RE2 
Felbamate_ddi|P|felbamate|gestodene|BIOENTITY treatment_BE12 result_BE12 in_BE12 NUM_BE12 decrease_BE12 in_BE12 the_BE12 BIOENTITY auc_RE2 NUM_RE2 but_RE2 no_RE2 clinical_RE2 relevant_RE2 effect_RE2 be_RE2 observe_RE2 on_RE2 the_RE2 pharmacokinetic_RE2 parameter_RE2 of_RE2 BIOGENERAL_RE2 
Felodipine_ddi|P|felodipine|anticonvulsant|BIOGENERAL_LE1 :_LE1 In_LE1 pharmacokinetic_LE1 study_LE1 maximum_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 considerable_BE12 low_BE12 in_BE12 epileptic_BE12 patient_BE12 on_BE12 long-term_BE12 BIOENTITY therapy_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 than_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Felodipine_ddi|P|felodipine|phenytoin|BIOGENERAL_LE1 :_LE1 In_LE1 pharmacokinetic_LE1 study_LE1 maximum_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 considerable_BE12 low_BE12 in_BE12 epileptic_BE12 patient_BE12 on_BE12 long-term_BE12 BIOGENERAL_BE12 therapy_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 than_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Felodipine_ddi|P|felodipine|carbamazepine|BIOGENERAL_LE1 :_LE1 In_LE1 pharmacokinetic_LE1 study_LE1 maximum_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 considerable_BE12 low_BE12 in_BE12 epileptic_BE12 patient_BE12 on_BE12 long-term_BE12 BIOGENERAL_BE12 therapy_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 than_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Felodipine_ddi|P|felodipine|phenobarbital|BIOGENERAL_LE1 :_LE1 In_LE1 pharmacokinetic_LE1 study_LE1 maximum_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 considerable_BE12 low_BE12 in_BE12 epileptic_BE12 patient_BE12 on_BE12 long-term_BE12 BIOGENERAL_BE12 therapy_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 than_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Fenfluramine_ddi|P|fenfluramine|reserpine|BIOENTITY may_BE12 increase_BE12 slight_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Fenfluramine_ddi|P|fenfluramine|methyldopa|BIOENTITY may_BE12 increase_BE12 slight_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Fenfluramine_ddi|P|fenfluramine|antihypertensive drug|BIOENTITY may_BE12 increase_BE12 slight_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fenfluramine_ddi|P|fenfluramine|guanethidine|BIOENTITY may_BE12 increase_BE12 slight_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Fenfluramine_ddi|P|cns depressant drug|fenfluramine|other_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY since_RE2 the_RE2 effect_RE2 may_RE2 be_RE2 additive_RE2 
Fenofibrate_ddi|P|coumarin anticoagulant|tricor|oral_LE1 BIOGENERAL_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 IN_BE12 conjunction_BE12 WITH_BE12 BIOENTITY 
Fenofibrate_ddi|P|tricor|hmg-coa reductase inhibitor|BIOGENERAL_LE1 :_LE1 the_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 unless_RE2 the_RE2 benefit_RE2 of_RE2 further_RE2 alteration_RE2 in_RE2 lipid_RE2 level_RE2 be_RE2 likely_RE2 to_RE2 outweigh_RE2 the_RE2 increase_RE2 risk_RE2 of_RE2 this_RE2 drug_RE2 combination_RE2 
Fenofibrate_ddi|P|tricor|bile acid binding resin|BIOGENERAL_LE1 :_LE1 since_LE1 BIOGENERAL_LE1 may_LE1 bind_LE1 other_LE1 drug_LE1 give_LE1 concurrent_LE1 patient_LE1 shall_LE1 take_LE1 BIOENTITY at_BE12 little_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY to_RE2 avoid_RE2 impede_RE2 its_RE2 absorption_RE2 
Fenofibrate_ddi|P|cyclosporine|tricor|BIOGENERAL_LE1 :_LE1 because_LE1 BIOENTITY can_BE12 produce_BE12 nephrotoxicity_BE12 with_BE12 decrease_BE12 in_BE12 creatinine_BE12 clearance_BE12 and_BE12 rise_BE12 in_BE12 serum_BE12 creatinine_BE12 and_BE12 because_BE12 renal_BE12 excretion_BE12 be_BE12 the_BE12 primary_BE12 elimination_BE12 route_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY there_RE2 be_RE2 risk_RE2 that_RE2 interaction_RE2 will_RE2 lead_RE2 to_RE2 deterioration_RE2 
Fenofibrate_ddi|P|cyclosporine|fibrate drug|BIOGENERAL_LE1 :_LE1 because_LE1 BIOENTITY can_BE12 produce_BE12 nephrotoxicity_BE12 with_BE12 decrease_BE12 in_BE12 creatinine_BE12 clearance_BE12 and_BE12 rise_BE12 in_BE12 serum_BE12 creatinine_BE12 and_BE12 because_BE12 renal_BE12 excretion_BE12 be_BE12 the_BE12 primary_BE12 elimination_BE12 route_BE12 of_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 there_RE2 be_RE2 risk_RE2 that_RE2 interaction_RE2 will_RE2 lead_RE2 to_RE2 deterioration_RE2 
Fenofibrate_ddi|P|tricor|immunosuppressant|the_LE1 benefit_LE1 and_LE1 risk_LE1 of_LE1 use_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 other_RE2 potential_RE2 nephrotoxic_RE2 agent_RE2 shall_RE2 be_RE2 careful_RE2 consider_RE2 and_RE2 the_RE2 low_RE2 effective_RE2 dose_RE2 employ_RE2 
Fenofibrate_ddi|P|fenofibrate|bile acid binding resin|therefore_LE1 BIOENTITY shall_BE12 be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY to_RE2 avoid_RE2 impede_RE2 its_RE2 absorption_RE2 
Fenofibrate_ddi|P|fenofibrate|pravastatin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 equivalent_BE12 to_BE12 145mg_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 the_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 value_RE2 for_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 and_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 respective_RE2 and_RE2 for_RE2 NUM_RE2 -hydroxy-iso-pravastatin_RE2 by_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 and_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 respective_RE2 in_RE2 NUM_RE2 healthy_RE2 adult_RE2 
Fenofibrate_ddi|P|tricor|pravastatin|concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 equivalent_LE1 to_LE1 145mg_LE1 BIOENTITY -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 have_RE2 be_RE2 show_RE2 to_RE2 increase_RE2 the_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 value_RE2 for_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 and_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 respective_RE2 and_RE2 for_RE2 NUM_RE2 -hydroxy-iso-pravastatin_RE2 by_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 and_RE2 NUM_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 respective_RE2 in_RE2 NUM_RE2 healthy_RE2 adult_RE2 
Fenofibrate_ddi|P|tricor|atorvastatin|concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 equivalent_LE1 to_LE1 NUM_LE1 mg_LE1 BIOENTITY -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 decrease_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 value_RE2 in_RE2 NUM_RE2 healthy_RE2 male_RE2 
Fenofibrate_ddi|P|fenofibrate|atorvastatin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 equivalent_BE12 to_BE12 NUM_BE12 mg_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 once_RE2 daily_RE2 for_RE2 NUM_RE2 day_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 decrease_RE2 -LRB-_RE2 range_RE2 from_RE2 NUM_RE2 decrease_RE2 to_RE2 NUM_RE2 increase_RE2 -RRB-_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 value_RE2 in_RE2 NUM_RE2 healthy_RE2 male_RE2 
Fenoldopam_ddi|P|fenoldopam|beta-blocker|drug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 
Fenoprofen_ddi|P|aspirin|fenoprofen|the_LE1 coadministration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 biologic_BE12 half-life_BE12 of_BE12 BIOENTITY because_RE2 of_RE2 increase_RE2 in_RE2 metabolic_RE2 clearance_RE2 that_RE2 result_RE2 in_RE2 great_RE2 amount_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 urine_RE2 
Fenoprofen_ddi|P|fenoprofen|aspirin|although_LE1 the_LE1 mechanism_LE1 of_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 total_RE2 know_RE2 enzyme_RE2 induction_RE2 and_RE2 displacement_RE2 of_RE2 BIOGENERAL_RE2 from_RE2 plasma_RE2 albumin_RE2 binding_RE2 site_RE2 be_RE2 possibility_RE2 
Fenoprofen_ddi|P|nalfon|salicylate|because_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 show_LE1 to_LE1 produce_LE1 any_LE1 additional_LE1 effect_LE1 beyond_LE1 that_LE1 obtain_LE1 with_LE1 BIOGENERAL_LE1 alone_LE1 and_LE1 because_LE1 BIOGENERAL_LE1 increase_LE1 the_LE1 rate_LE1 of_LE1 excretion_LE1 of_LE1 BIOGENERAL_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Fenoprofen_ddi|P|aspirin|nalfon|because_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 show_LE1 to_LE1 produce_LE1 any_LE1 additional_LE1 effect_LE1 beyond_LE1 that_LE1 obtain_LE1 with_LE1 BIOGENERAL_LE1 alone_LE1 and_LE1 because_LE1 BIOENTITY increase_BE12 the_BE12 rate_BE12 of_BE12 excretion_BE12 of_BE12 BIOENTITY the_RE2 concomitant_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 be_RE2 not_RE2 recommend_RE2 
Fenoprofen_ddi|P|phenobarbital|fenoprofen|chronic_LE1 administration_LE1 of_LE1 BIOENTITY known_BE12 enzyme_BE12 inducer_BE12 may_BE12 be_BE12 associate_BE12 with_BE12 decrease_BE12 in_BE12 the_BE12 plasma_BE12 half-life_BE12 of_BE12 BIOENTITY 
Fenoprofen_ddi|P|phenobarbital|nalfon|when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 or_BE12 withdraw_BE12 from_BE12 treatment_BE12 dosage_BE12 adjustment_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 require_RE2 
Fenoprofen_ddi|P|coumarin-type anticoagulant|nalfon|In_LE1 patient_LE1 receive_LE1 BIOENTITY the_BE12 addition_BE12 of_BE12 BIOENTITY to_RE2 therapy_RE2 can_RE2 prolong_RE2 the_RE2 prothrombin_RE2 time_RE2 
Fenoprofen_ddi|P|nalfon|loop diuretic|patient_LE1 treat_LE1 with_LE1 BIOENTITY may_BE12 be_BE12 resistant_BE12 to_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Fenoprofen_ddi|P|nalfon|steroid|In_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concomitant_RE2 any_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 dosage_RE2 shall_RE2 be_RE2 gradual_RE2 in_RE2 order_RE2 to_RE2 avoid_RE2 the_RE2 possible_RE2 complication_RE2 of_RE2 sudden_RE2 BIOGENERAL_RE2 withdrawal_RE2 
Fentanyl_ddi|P|fentanyl|itraconazole|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 potent_BE12 3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|fentanyl|ketoconazole|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 potent_BE12 3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|fentanyl|ritonavir|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 other_RE2 potent_RE2 3a4_RE2 inhibitor_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|fentanyl|nelfinavir|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 potent_BE12 3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|fentanyl|clarithromycin|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 potent_BE12 3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|fentanyl|troleandomycin|the_LE1 concomitant_LE1 use_LE1 of_LE1 transdermal_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 potent_BE12 3a4_BE12 inhibitor_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 nefazadone_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Fentanyl_ddi|P|erythromycin|fentanyl|the_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 cyp3a4_LE1 inhibitor_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY with_BE12 transdermal_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 which_RE2 can_RE2 increase_RE2 or_RE2 prolong_RE2 adverse_RE2 drug_RE2 effect_RE2 and_RE2 may_RE2 cause_RE2 serious_RE2 respiratory_RE2 depression_RE2 
Fentanyl_ddi|P|diltiazem|fentanyl|the_LE1 concomitant_LE1 use_LE1 of_LE1 other_LE1 cyp3a4_LE1 inhibitor_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 with_BE12 transdermal_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 which_RE2 can_RE2 increase_RE2 or_RE2 prolong_RE2 adverse_RE2 drug_RE2 effect_RE2 and_RE2 may_RE2 cause_RE2 serious_RE2 respiratory_RE2 depression_RE2 
Fentanyl_ddi|P|duragesic|sedative|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|hypnotic|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|tranquilizer|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|benzodiazepine|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|alcohol|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|anesthetic|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|phenothiazine|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|phenothiazine|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|skeletal muscle relaxant|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|skeletal muscle relaxant|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|alcohol|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|benzodiazepine|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|anesthetic|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 -RRB-_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|hypnotic|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|tranquilizer|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|opioid|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|sedative|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|fentanyl|central nervous system depressant|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOENTITY including_RE2 but_RE2 not_RE2 limited_RE2 to_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|opioid|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 but_BE12 not_BE12 limited_BE12 to_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|central nervous system depressant|BIOGENERAL_LE1 :_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 transdermal_BE12 system_BE12 -RRB-_BE12 with_BE12 other_BE12 BIOENTITY including_RE2 but_RE2 not_RE2 limited_RE2 to_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 may_RE2 cause_RE2 respiratory_RE2 depression_RE2 hypotension_RE2 and_RE2 profound_RE2 sedation_RE2 or_RE2 potential_RE2 result_RE2 in_RE2 coma_RE2 or_RE2 death_RE2 
Fentanyl_ddi|P|duragesic|maoi|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 not_BE12 recommend_BE12 for_BE12 use_BE12 in_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 BIOENTITY within_RE2 NUM_RE2 day_RE2 because_RE2 severe_RE2 and_RE2 unpredictable_RE2 potentiation_RE2 by_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 with_RE2 BIOGENERAL_RE2 
Fentanyl_ddi|P|mao inhibitor|opioid analgesic|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 for_LE1 use_LE1 in_LE1 patient_LE1 who_LE1 have_LE1 receive_LE1 BIOGENERAL_LE1 within_LE1 NUM_LE1 day_LE1 because_LE1 severe_LE1 and_LE1 unpredictable_LE1 potentiation_LE1 by_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 with_BE12 BIOENTITY 
Fexofenadine_ddi|P|fexofenadine hydrochloride|erythromycin|however_LE1 co_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 either_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Fexofenadine_ddi|P|fexofenadine hydrochloride|ketoconazole|however_LE1 co_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 either_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Fexofenadine_ddi|P|erythromycin|fexofenadine|these_LE1 study_LE1 indicate_LE1 that_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY co-administration_BE12 enhance_BE12 BIOENTITY gastrointestinal_RE2 absorption_RE2 
Fexofenadine_ddi|P|ketoconazole|fexofenadine|these_LE1 study_LE1 indicate_LE1 that_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 co-administration_BE12 enhance_BE12 BIOENTITY gastrointestinal_RE2 absorption_RE2 
Fexofenadine_ddi|P|ketoconazole|fexofenadine|this_LE1 observe_LE1 increase_LE1 in_LE1 the_LE1 bioavailability_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 due_LE1 to_LE1 transport-related_LE1 effect_LE1 such_LE1 as_LE1 p-glycoprotein._LE1 in_LE1 vivo_LE1 animal_LE1 study_LE1 also_LE1 suggest_LE1 that_LE1 in_LE1 addition_LE1 to_LE1 enhance_LE1 absorption_LE1 BIOENTITY decrease_BE12 BIOENTITY gastrointestinal_RE2 secretion_RE2 while_RE2 BIOGENERAL_RE2 may_RE2 also_RE2 decrease_RE2 biliary_RE2 excretion_RE2 
Fexofenadine_ddi|P|fexofenadine hydrochloride|aluminum|drug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 NUM_BE12 mg_BE12 capsule_BE12 -RRB-_BE12 within_BE12 NUM_BE12 minute_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 decrease_RE2 BIOGENERAL_RE2 auc_RE2 by_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 NUM_RE2 %._RE2 
Fexofenadine_ddi|P|fexofenadine hydrochloride|maalox|drug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 NUM_BE12 mg_BE12 capsule_BE12 -RRB-_BE12 within_BE12 NUM_BE12 minute_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 decrease_RE2 BIOGENERAL_RE2 auc_RE2 by_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 NUM_RE2 %._RE2 
Fexofenadine_ddi|P|fexofenadine hydrochloride|magnesium|drug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 NUM_BE12 mg_BE12 capsule_BE12 -RRB-_BE12 within_BE12 NUM_BE12 minute_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 decrease_RE2 BIOGENERAL_RE2 auc_RE2 by_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 NUM_RE2 %._RE2 
Fexofenadine_ddi|P|fexofenadine hydrochloride|antacid|drug_LE1 interaction_LE1 with_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 NUM_BE12 mg_BE12 capsule_BE12 -RRB-_BE12 within_BE12 NUM_BE12 minute_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 decrease_RE2 BIOGENERAL_RE2 auc_RE2 by_RE2 NUM_RE2 and_RE2 cmax_RE2 by_RE2 NUM_RE2 %._RE2 
Fexofenadine_ddi|P|allegra|magnesium|BIOENTITY shall_BE12 not_BE12 be_BE12 take_BE12 close_BE12 in_BE12 time_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 
Fexofenadine_ddi|P|allegra|aluminum|BIOENTITY shall_BE12 not_BE12 be_BE12 take_BE12 close_BE12 in_BE12 time_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 
Flecainide_ddi|P|tambocor|digoxin|During_LE1 administration_LE1 of_LE1 multiple_LE1 oral_LE1 dose_LE1 of_LE1 BIOENTITY to_BE12 healthy_BE12 subject_BE12 stabilise_BE12 on_BE12 maintenance_BE12 dose_BE12 of_BE12 BIOENTITY NUM_RE2 NUM_RE2 increase_RE2 in_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 occur_RE2 at_RE2 six_RE2 hour_RE2 postdose_RE2 
Flecainide_ddi|P|tambocor|propranolol|In_LE1 study_LE1 involve_LE1 healthy_LE1 subject_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY concurrent_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 be_RE2 increase_RE2 about_RE2 NUM_RE2 and_RE2 BIOGENERAL_RE2 level_RE2 be_RE2 increase_RE2 about_RE2 NUM_RE2 compared_RE2 to_RE2 control_RE2 value_RE2 
Flecainide_ddi|P|tambocor|propranolol|the_LE1 effect_LE1 of_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY on_RE2 the_RE2 pr_RE2 interval_RE2 be_RE2 little_RE2 than_RE2 additive_RE2 
Flecainide_ddi|P|beta blocker|flecainide|nevertheless_LE1 the_LE1 possibility_LE1 of_LE1 additive_LE1 negative_LE1 inotropic_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 recognize_RE2 
Flecainide_ddi|P|carbamazepine|flecainide|limited_LE1 datum_LE1 in_LE1 patient_LE1 receive_LE1 known_LE1 enzyme_LE1 inducer_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 indicate_BE12 only_BE12 NUM_BE12 increase_BE12 in_BE12 the_BE12 rate_BE12 of_BE12 BIOENTITY elimination_RE2 
Flecainide_ddi|P|phenobarbital|flecainide|limited_LE1 datum_LE1 in_LE1 patient_LE1 receive_LE1 known_LE1 enzyme_LE1 inducer_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 indicate_BE12 only_BE12 NUM_BE12 increase_BE12 in_BE12 the_BE12 rate_BE12 of_BE12 BIOENTITY elimination_RE2 
Flecainide_ddi|P|phenytoin|flecainide|limited_LE1 datum_LE1 in_LE1 patient_LE1 receive_LE1 known_LE1 enzyme_LE1 inducer_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 indicate_BE12 only_BE12 NUM_BE12 increase_BE12 in_BE12 the_BE12 rate_BE12 of_BE12 BIOENTITY elimination_RE2 
Flecainide_ddi|P|cimetidine|flecainide|In_LE1 healthy_LE1 subject_LE1 receive_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 gm_BE12 daily_BE12 -RRB-_BE12 for_BE12 one_BE12 week_BE12 plasma_BE12 BIOENTITY level_RE2 increase_RE2 by_RE2 about_RE2 NUM_RE2 and_RE2 half-life_RE2 increase_RE2 by_RE2 about_RE2 NUM_RE2 %._RE2 
Flecainide_ddi|P|amiodarone|flecainide|when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 BIOENTITY therapy_RE2 plasma_RE2 BIOGENERAL_RE2 level_RE2 may_RE2 increase_RE2 two-fold_RE2 or_RE2 much_RE2 in_RE2 some_RE2 patient_RE2 if_RE2 BIOGENERAL_RE2 dosage_RE2 be_RE2 not_RE2 reduce_RE2 
Flecainide_ddi|P|quinidine|flecainide|drug_LE1 that_LE1 inhibit_LE1 cytochrome_LE1 p450iid6_LE1 such_LE1 as_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY in_RE2 patient_RE2 that_RE2 be_RE2 on_RE2 chronic_RE2 BIOGENERAL_RE2 therapy_RE2 
Flecainide_ddi|P|disopyramide|tambocor|because_LE1 both_LE1 of_LE1 these_LE1 drug_LE1 have_LE1 negative_LE1 inotropic_LE1 property_LE1 and_LE1 the_LE1 effect_LE1 of_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 be_LE1 unknown_LE1 neither_LE1 BIOENTITY nor_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY unless_RE2 in_RE2 the_RE2 judgment_RE2 of_RE2 the_RE2 physician_RE2 the_RE2 benefit_RE2 of_RE2 this_RE2 combination_RE2 outweigh_RE2 the_RE2 risk_RE2 
Flecainide_ddi|P|verapamil|tambocor|because_LE1 both_LE1 of_LE1 these_LE1 drug_LE1 have_LE1 negative_LE1 inotropic_LE1 property_LE1 and_LE1 the_LE1 effect_LE1 of_LE1 coadministration_LE1 with_LE1 BIOGENERAL_LE1 be_LE1 unknown_LE1 neither_LE1 BIOGENERAL_LE1 nor_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY unless_RE2 in_RE2 the_RE2 judgment_RE2 of_RE2 the_RE2 physician_RE2 the_RE2 benefit_RE2 of_RE2 this_RE2 combination_RE2 outweigh_RE2 the_RE2 risk_RE2 
Flucytosine_ddi|P|cytosine arabinoside|flucytosine|BIOENTITY BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 inactivate_BE12 the_BE12 antifungal_BE12 activity_BE12 of_BE12 BIOENTITY by_RE2 competitive_RE2 inhibition_RE2 
Fludarabine_ddi|P|fludara|pentostatin|the_LE1 use_LE1 of_LE1 BIOENTITY FOR_BE12 injection_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 due_RE2 to_RE2 the_RE2 risk_RE2 of_RE2 severe_RE2 pulmonary_RE2 toxicity_RE2 
Fludrocortisone_ddi|P|steroid|aspirin|rare_LE1 BIOGENERAL_LE1 toxicity_LE1 may_LE1 occur_LE1 in_LE1 patient_LE1 who_LE1 discontinue_LE1 BIOENTITY after_BE12 concurrent_BE12 high-dose_BE12 BIOENTITY therapy_RE2 
Fludrocortisone_ddi|P|rifampin|fludrocortisone acetate|BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY increase_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 induction_RE2 of_RE2 hepatic_RE2 enzyme_RE2 
Fludrocortisone_ddi|P|phenytoin|fludrocortisone acetate|BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 increase_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 induction_RE2 of_RE2 hepatic_RE2 enzyme_RE2 
Fludrocortisone_ddi|P|barbiturate|fludrocortisone acetate|BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 increase_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 induction_RE2 of_RE2 hepatic_RE2 enzyme_RE2 
Flumazenil_ddi|P|romazicon|cyclic antidepressant|particular_LE1 caution_LE1 be_LE1 necessary_LE1 when_LE1 use_LE1 BIOENTITY in_BE12 case_BE12 of_BE12 mixed_BE12 drug_BE12 overdosage_BE12 since_BE12 the_BE12 toxic_BE12 effect_BE12 -LRB-_BE12 such_BE12 as_BE12 convulsion_BE12 and_BE12 cardiac_BE12 dysrhythmia_BE12 -RRB-_BE12 of_BE12 other_BE12 drug_BE12 take_BE12 in_BE12 overdose_BE12 -LRB-_BE12 especial_BE12 BIOENTITY -RRB-_RE2 may_RE2 emerge_RE2 with_RE2 the_RE2 reversal_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 effect_RE2 by_RE2 BIOGENERAL_RE2 
Flumazenil_ddi|P|romazicon|benzodiazepine|although_LE1 BIOENTITY exert_BE12 slight_BE12 intrinsic_BE12 anticonvulsant_BE12 effect_BE12 its_BE12 abrupt_BE12 suppression_BE12 of_BE12 the_BE12 protective_BE12 effect_BE12 of_BE12 BIOENTITY agonist_RE2 can_RE2 give_RE2 rise_RE2 to_RE2 convulsion_RE2 in_RE2 epileptic_RE2 patient_RE2 
Flumazenil_ddi|P|romazicon|benzodiazepine|BIOENTITY block_BE12 the_BE12 central_BE12 effect_BE12 of_BE12 BIOENTITY by_RE2 competitive_RE2 interaction_RE2 at_RE2 the_RE2 receptor_RE2 level_RE2 
Flumazenil_ddi|P|zopiclone|romazicon|the_LE1 effect_LE1 of_LE1 nonbenzodiazepine_LE1 agonist_LE1 at_LE1 benzodiazepine_LE1 receptor_LE1 such_LE1 as_LE1 BIOENTITY triazolopyridazines_BE12 and_BE12 other_BE12 be_BE12 also_BE12 block_BE12 by_BE12 BIOENTITY 
Fluoxetine_ddi|P|escitalopram|non-selective mao inhibitor|wait_LE1 NUM_LE1 week_LE1 after_LE1 stop_LE1 BIOENTITY before_BE12 start_BE12 BIOENTITY 
Fluoxetine_ddi|P|mao inhibitor|escitalopram|wait_LE1 NUM_LE1 week_LE1 after_LE1 stop_LE1 BIOENTITY before_BE12 start_BE12 BIOENTITY 
Fluoxymesterone_ddi|P|oxyphenbutazone|androgen|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 elevated_RE2 serum_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Fluoxymesterone_ddi|P|androgen|insulin|In_LE1 diabetic_LE1 patient_LE1 the_LE1 metabolic_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 decrease_BE12 blood_BE12 glucose_BE12 and_BE12 therefore_BE12 BIOENTITY requirement_RE2 
Flupenthixol_ddi|P|flupenthixol|monoamine oxidase inhibitor|drug_LE1 interaction_LE1 :_LE1 BIOENTITY may_BE12 interact_BE12 with_BE12 some_BE12 drug_BE12 like_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 :_RE2 BIOGENERAL_RE2 can_RE2 theoretical_RE2 affect_RE2 BIOGENERAL_RE2 pharmacodynamic_RE2 BIOGENERAL_RE2 eproxindine_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 cause_RE2 additive_RE2 cns_RE2 depression_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Flupenthixol_ddi|P|maoi|flupenthixol|drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 may_LE1 interact_LE1 with_LE1 some_LE1 drug_LE1 like_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOENTITY can_BE12 theoretical_BE12 affect_BE12 BIOENTITY pharmacodynamic_RE2 BIOGENERAL_RE2 eproxindine_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 cause_RE2 additive_RE2 cns_RE2 depression_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Flupenthixol_ddi|P|flupenthixol|maoi|drug_LE1 interaction_LE1 :_LE1 BIOENTITY may_BE12 interact_BE12 with_BE12 some_BE12 drug_BE12 like_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 :_RE2 BIOGENERAL_RE2 can_RE2 theoretical_RE2 affect_RE2 BIOGENERAL_RE2 pharmacodynamic_RE2 BIOGENERAL_RE2 eproxindine_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 cause_RE2 additive_RE2 cns_RE2 depression_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Flupenthixol_ddi|P|flupenthixol|tricyclic antidepressant|drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 may_LE1 interact_LE1 with_LE1 some_LE1 drug_LE1 like_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 can_LE1 theoretical_LE1 affect_LE1 BIOGENERAL_LE1 pharmacodynamic_LE1 BIOGENERAL_LE1 eproxindine_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 cause_LE1 additive_LE1 cns_LE1 depression_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Flupenthixol_ddi|P|flupenthixol|ethanol|drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 may_LE1 interact_LE1 with_LE1 some_LE1 drug_LE1 like_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 can_LE1 theoretical_LE1 affect_LE1 BIOGENERAL_LE1 pharmacodynamic_LE1 BIOGENERAL_LE1 eproxindine_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 BIOENTITY cause_RE2 additive_RE2 cns_RE2 depression_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Flurbiprofen_ddi|P|flurbiprofen|anti-coagulant|BIOGENERAL_LE1 :_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 show_BE12 to_BE12 affect_BE12 bleeding_BE12 parameter_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY and_RE2 serious_RE2 clinical_RE2 bleeding_RE2 have_RE2 be_RE2 report_RE2 
Flurbiprofen_ddi|P|nonsteroidal anti-inflammatory drug|anti-coagulant|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 affect_BE12 bleeding_BE12 parameter_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY and_RE2 serious_RE2 clinical_RE2 bleeding_RE2 have_RE2 be_RE2 report_RE2 
Flurbiprofen_ddi|P|flurbiprofen|anticoagulant|the_LE1 physician_LE1 shall_LE1 be_LE1 cautious_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 take_BE12 BIOENTITY 
Flurbiprofen_ddi|P|aspirin|flurbiprofen|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 low_RE2 serum_RE2 BIOGENERAL_RE2 concentration_RE2 
Flurbiprofen_ddi|P|flurbiprofen|aspirin|concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 therefore_RE2 not_RE2 recommend_RE2 
Flurbiprofen_ddi|P|flurbiprofen|propranolol|BIOENTITY pretreatment_BE12 attenuate_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY but_RE2 not_RE2 BIOGENERAL_RE2 
Flurbiprofen_ddi|P|flurbiprofen|propranolol|BIOENTITY do_BE12 not_BE12 affect_BE12 the_BE12 pharmacokinetic_BE12 profile_BE12 of_BE12 either_BE12 drug_BE12 and_BE12 the_BE12 mechanism_BE12 under_BE12 lie_BE12 the_BE12 interference_BE12 with_BE12 BIOENTITY hypotensive_RE2 effect_RE2 be_RE2 unknown_RE2 
Flurbiprofen_ddi|P|flurbiprofen|beta-blocker|patient_LE1 take_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 to_RE2 ensure_RE2 that_RE2 satisfactory_RE2 hypotensive_RE2 effect_RE2 be_RE2 achieve_RE2 
Flurbiprofen_ddi|P|flurbiprofen|cimetidine|BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 In_LE1 normal_LE1 volunteer_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 pretreatment_LE1 with_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 do_LE1 not_LE1 affect_LE1 BIOGENERAL_LE1 pharmacokinetic_LE1 except_LE1 that_LE1 small_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 but_LE1 statistical_LE1 significant_LE1 increase_LE1 in_LE1 the_LE1 area_LE1 under_LE1 the_LE1 serum_LE1 concentration_LE1 curve_LE1 of_LE1 BIOENTITY result_BE12 with_BE12 BIOENTITY 
Flurbiprofen_ddi|P|flurbiprofen|furosemide|BIOGENERAL_LE1 :_LE1 study_LE1 in_LE1 normal_LE1 volunteer_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 can_BE12 interfere_BE12 with_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Flurbiprofen_ddi|P|nonsteroidal anti-inflammatory drug|furosemide|BIOGENERAL_LE1 :_LE1 study_LE1 in_LE1 normal_LE1 volunteer_LE1 have_LE1 show_LE1 that_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY can_BE12 interfere_BE12 with_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Flurbiprofen_ddi|P|nonsteroidal anti-inflammatory drug|thiazide diuretic|other_LE1 BIOENTITY that_BE12 inhibit_BE12 prostaglandin_BE12 synthesis_BE12 have_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 BIOENTITY in_RE2 some_RE2 study_RE2 and_RE2 with_RE2 BIOGENERAL_RE2 
Flurbiprofen_ddi|P|nonsteroidal anti-inflammatory drug|potassium-sparing diuretic|other_LE1 BIOENTITY that_BE12 inhibit_BE12 prostaglandin_BE12 synthesis_BE12 have_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 BIOGENERAL_BE12 in_BE12 some_BE12 study_BE12 and_BE12 with_BE12 BIOENTITY 
Flurbiprofen_ddi|P|flurbiprofen|furosemide|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY or_RE2 other_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 be_RE2 obtain_RE2 
Flurbiprofen_ddi|P|flurbiprofen|diuretic|patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOENTITY shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 be_RE2 obtain_RE2 
Flurbiprofen_ddi|P|flurbiprofen|hypoglycemic agent|although_LE1 there_LE1 be_LE1 slight_LE1 reduction_LE1 in_LE1 blood_LE1 sugar_LE1 concentration_LE1 during_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY there_RE2 be_RE2 no_RE2 sign_RE2 or_RE2 symptom_RE2 of_RE2 hypoglycemia_RE2 
Flutamide_ddi|P|warfarin|flutamide|increase_LE1 in_LE1 prothrombin_LE1 time_LE1 have_LE1 be_LE1 note_LE1 in_LE1 patient_LE1 receive_LE1 long-_LE1 term_LE1 BIOENTITY therapy_BE12 after_BE12 BIOENTITY be_RE2 initiate_RE2 
Flutamide_ddi|P|eulexin|warfarin|therefore_LE1 close_LE1 monitoring_LE1 of_LE1 prothrombin_LE1 time_LE1 be_LE1 recommend_LE1 and_LE1 adjustment_LE1 of_LE1 the_LE1 BIOGENERAL_LE1 dose_LE1 may_LE1 be_LE1 necessary_LE1 when_LE1 BIOENTITY capsule_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Fluvoxamine_ddi|P|serotonin reuptake inhibitor drug|monoamine oxidase inhibitor|In_LE1 patient_LE1 receive_LE1 another_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 including_RE2 hyperthermia_RE2 rigidity_RE2 myoclonus_RE2 autonomic_RE2 instability_RE2 with_RE2 possible_RE2 rapid_RE2 fluctuation_RE2 of_RE2 vital_RE2 sign_RE2 and_RE2 mental_RE2 status_RE2 change_RE2 that_RE2 include_RE2 extreme_RE2 agitation_RE2 progress_RE2 to_RE2 delirium_RE2 and_RE2 coma_RE2 
Fluvoxamine_ddi|P|serotonin reuptake inhibitor drug|maoi|In_LE1 patient_LE1 receive_LE1 another_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 there_RE2 have_RE2 be_RE2 report_RE2 of_RE2 serious_RE2 sometimes_RE2 fatal_RE2 reaction_RE2 including_RE2 hyperthermia_RE2 rigidity_RE2 myoclonus_RE2 autonomic_RE2 instability_RE2 with_RE2 possible_RE2 rapid_RE2 fluctuation_RE2 of_RE2 vital_RE2 sign_RE2 and_RE2 mental_RE2 status_RE2 change_RE2 that_RE2 include_RE2 extreme_RE2 agitation_RE2 progress_RE2 to_RE2 delirium_RE2 and_RE2 coma_RE2 
Fluvoxamine_ddi|P|fluvoxamine|maoi|therefore_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY tablet_BE12 not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 within_BE12 NUM_BE12 day_BE12 of_BE12 discontinuing_BE12 treatment_BE12 with_BE12 BIOENTITY 
Fluvoxamine_ddi|P|fluvoxamine|maoi|therefore_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY tablet_BE12 not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY or_RE2 within_RE2 NUM_RE2 day_RE2 of_RE2 discontinuing_RE2 treatment_RE2 with_RE2 BIOGENERAL_RE2 
Fluvoxamine_ddi|P|fluvoxamine|maoi|After_LE1 stop_LE1 BIOENTITY tablet_BE12 at_BE12 little_BE12 NUM_BE12 week_BE12 shall_BE12 be_BE12 allow_BE12 before_BE12 start_BE12 BIOENTITY 
Fluvoxamine_ddi|P|cisapride|ketoconazole|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 all_BE12 metabolize_BE12 by_BE12 the_BE12 cytochrome_BE12 p450iiia4_BE12 isozyme_BE12 and_BE12 it_BE12 have_BE12 be_BE12 demonstrate_BE12 that_BE12 BIOENTITY potent_RE2 inhibitor_RE2 of_RE2 iiia4_RE2 block_RE2 the_RE2 metabolism_RE2 of_RE2 these_RE2 drug_RE2 result_RE2 in_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 parent_RE2 drug_RE2 
Fluvoxamine_ddi|P|astemizole|ketoconazole|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 all_BE12 metabolize_BE12 by_BE12 the_BE12 cytochrome_BE12 p450iiia4_BE12 isozyme_BE12 and_BE12 it_BE12 have_BE12 be_BE12 demonstrate_BE12 that_BE12 BIOENTITY potent_RE2 inhibitor_RE2 of_RE2 iiia4_RE2 block_RE2 the_RE2 metabolism_RE2 of_RE2 these_RE2 drug_RE2 result_RE2 in_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 parent_RE2 drug_RE2 
Fluvoxamine_ddi|P|terfenadine|ketoconazole|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 be_BE12 all_BE12 metabolize_BE12 by_BE12 the_BE12 cytochrome_BE12 p450iiia4_BE12 isozyme_BE12 and_BE12 it_BE12 have_BE12 be_BE12 demonstrate_BE12 that_BE12 BIOENTITY potent_RE2 inhibitor_RE2 of_RE2 iiia4_RE2 block_RE2 the_RE2 metabolism_RE2 of_RE2 these_RE2 drug_RE2 result_RE2 in_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 parent_RE2 drug_RE2 
Fluvoxamine_ddi|P|fluvoxamine|alprazolam|although_LE1 it_LE1 have_LE1 not_LE1 be_LE1 definitive_LE1 demonstrate_LE1 that_LE1 BIOGENERAL_LE1 be_LE1 potent_LE1 iiia4_LE1 inhibitor_LE1 it_LE1 be_LE1 likely_LE1 to_LE1 be_LE1 given_LE1 the_LE1 substantial_LE1 interaction_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY 
Fluvoxamine_ddi|P|fluvoxamine|cisapride|consequent_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Fluvoxamine_ddi|P|fluvoxamine|terbinafine|consequent_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 either_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Fluvoxamine_ddi|P|fluvoxamine|astemizole|consequent_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY not_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Fluvoxamine_ddi|P|benzodiazepine|fluvoxamine|other_LE1 potential_LE1 important_LE1 drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY metabolize_BE12 by_BE12 hepatic_BE12 oxidation_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 elc._BE12 -RRB-_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 because_BE12 the_BE12 clearance_BE12 of_BE12 these_BE12 drug_BE12 be_BE12 likely_BE12 to_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Fluvoxamine_ddi|P|triazolam|fluvoxamine|other_LE1 potential_LE1 important_LE1 drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 metabolize_LE1 by_LE1 hepatic_LE1 oxidation_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY elc._BE12 -RRB-_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 because_BE12 the_BE12 clearance_BE12 of_BE12 these_BE12 drug_BE12 be_BE12 likely_BE12 to_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Fluvoxamine_ddi|P|alprazolam|fluvoxamine|other_LE1 potential_LE1 important_LE1 drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 metabolize_LE1 by_LE1 hepatic_LE1 oxidation_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 elc._BE12 -RRB-_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 because_BE12 the_BE12 clearance_BE12 of_BE12 these_BE12 drug_BE12 be_BE12 likely_BE12 to_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Fluvoxamine_ddi|P|midazolam|fluvoxamine|other_LE1 potential_LE1 important_LE1 drug_LE1 interaction_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 metabolize_LE1 by_LE1 hepatic_LE1 oxidation_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 elc._BE12 -RRB-_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 because_BE12 the_BE12 clearance_BE12 of_BE12 these_BE12 drug_BE12 be_BE12 likely_BE12 to_BE12 be_BE12 reduce_BE12 by_BE12 BIOENTITY 
Fluvoxamine_ddi|P|fluvoxamine maleate|alprazolam|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 qd_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 q.d._RE2 be_RE2 co-administer_RE2 to_RE2 steady_RE2 state_RE2 plasma_RE2 concentration_RE2 and_RE2 other_RE2 pharmacokinetic_RE2 parameter_RE2 -LRB-_RE2 auc_RE2 cmax_RE2 t1_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 approximate_RE2 twice_RE2 those_RE2 observe_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 alone_RE2 
Fluvoxamine_ddi|P|alprazolam|fluvoxamine|this_LE1 interaction_LE1 which_LE1 have_LE1 not_LE1 be_LE1 investigate_LE1 use_LE1 high_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 may_LE1 be_LE1 much_LE1 pronounced_LE1 if_LE1 NUM_LE1 mg_LE1 daily_LE1 dose_LE1 be_LE1 co-administer_LE1 particular_LE1 since_LE1 BIOGENERAL_LE1 exhibit_LE1 non-linear_LE1 pharmacokinetic_LE1 over_LE1 the_LE1 dosage_LE1 range_LE1 NUM_LE1 mg._LE1 if_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY tablet_RE2 the_RE2 initial_RE2 BIOGENERAL_RE2 dosage_RE2 shall_RE2 be_RE2 at_RE2 little_RE2 halve_RE2 and_RE2 titration_RE2 to_RE2 the_RE2 low_RE2 effective_RE2 dose_RE2 be_RE2 recommend_RE2 
Fluvoxamine_ddi|P|fluvoxamine|diazepam|BIOGENERAL_LE1 :_LE1 the_LE1 co-administration_LE1 of_LE1 BIOENTITY tablet_BE12 and_BE12 BIOENTITY be_RE2 general_RE2 not_RE2 advisable_RE2 
Fluvoxamine_ddi|P|fluvoxamine|n-desmethyldiazepam|because_LE1 BIOENTITY reduce_BE12 the_BE12 clearance_BE12 of_BE12 both_BE12 BIOGENERAL_BE12 and_BE12 its_BE12 active_BE12 metabolite_BE12 BIOENTITY there_RE2 be_RE2 strong_RE2 likelihood_RE2 of_RE2 substantial_RE2 accumulation_RE2 of_RE2 both_RE2 specie_RE2 during_RE2 chronic_RE2 co-administration_RE2 
Fluvoxamine_ddi|P|fluvoxamine|diazepam|because_LE1 BIOENTITY reduce_BE12 the_BE12 clearance_BE12 of_BE12 both_BE12 BIOENTITY and_RE2 its_RE2 active_RE2 metabolite_RE2 BIOGENERAL_RE2 there_RE2 be_RE2 strong_RE2 likelihood_RE2 of_RE2 substantial_RE2 accumulation_RE2 of_RE2 both_RE2 specie_RE2 during_RE2 chronic_RE2 co-administration_RE2 
Fluvoxamine_ddi|P|fluvoxamine|diazepam|evidence_LE1 support_LE1 the_LE1 conclusion_LE1 that_LE1 it_LE1 be_LE1 inadvisable_LE1 to_LE1 co-administer_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 derive_RE2 from_RE2 study_RE2 in_RE2 which_RE2 healthy_RE2 volunteer_RE2 take_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 single_RE2 oral_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 
Fluvoxamine_ddi|P|alprazolam|fluvoxamine|moreover_LE1 as_LE1 note_LE1 with_LE1 BIOENTITY the_BE12 effect_BE12 of_BE12 BIOENTITY may_RE2 even_RE2 be_RE2 much_RE2 pronounced_RE2 when_RE2 it_RE2 be_RE2 administer_RE2 at_RE2 high_RE2 dose_RE2 
Fluvoxamine_ddi|P|diazepam|fluvoxamine|according_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 ordinary_RE2 be_RE2 co-administer_RE2 
Fluvoxamine_ddi|P|theophylline|fluvoxamine maleate|therefore_LE1 if_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY its_RE2 dose_RE2 shall_RE2 be_RE2 reduce_RE2 to_RE2 one_RE2 third_RE2 of_RE2 the_RE2 usual_RE2 daily_RE2 maintenance_RE2 dose_RE2 and_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 to_RE2 monitor_RE2 
Fluvoxamine_ddi|P|fluvoxamine maleate|warfarin|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 tid_BE12 -RRB-_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY for_RE2 two_RE2 week_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 increase_RE2 by_RE2 NUM_RE2 and_RE2 prothrombin_RE2 time_RE2 be_RE2 prolonged_RE2 
Fluvoxamine_ddi|P|anticoagulant|fluvoxamine|thus_LE1 patient_LE1 receive_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY tablet_RE2 shall_RE2 have_RE2 their_RE2 prothrombin_RE2 time_RE2 monitor_RE2 and_RE2 their_RE2 BIOGENERAL_RE2 dose_RE2 adjust_RE2 according_RE2 
Folic Acid_ddi|P|vitamin b12|folic acid|medication_LE1 can_LE1 interfere_LE1 with_LE1 folate_LE1 utilization_LE1 include_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 sometimes_LE1 prescribe_LE1 to_LE1 control_LE1 blood_LE1 sugar_LE1 in_LE1 type_LE1 NUM_LE1 diabetes_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 use_LE1 to_LE1 control_LE1 inflammation_LE1 associate_LE1 with_LE1 crohns_LE1 disease_LE1 and_LE1 ulcerative_LE1 colitis_LE1 -RRB-_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 there_LE1 have_LE1 be_LE1 concern_LE1 about_LE1 the_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY 
Fomepizole_ddi|P|antizol|ethanol|oral_LE1 dose_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 via_BE12 alcohol_BE12 dehydrogenase_BE12 inhibition_BE12 significant_BE12 reduce_BE12 the_BE12 rate_BE12 of_BE12 elimination_BE12 of_BE12 BIOENTITY -LRB-_RE2 by_RE2 approximate_RE2 NUM_RE2 -RRB-_RE2 give_RE2 to_RE2 healthy_RE2 volunteer_RE2 in_RE2 moderate_RE2 dose_RE2 
Fomepizole_ddi|P|ethanol|antizol|similar_LE1 BIOENTITY decrease_BE12 the_BE12 rate_BE12 of_BE12 elimination_BE12 of_BE12 BIOENTITY -LRB-_RE2 by_RE2 approximate_RE2 NUM_RE2 -RRB-_RE2 by_RE2 the_RE2 same_RE2 mechanism_RE2 
Fomepizole_ddi|P|antizol|ketoconazole|reciprocal_LE1 interaction_LE1 may_LE1 occur_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 increase_BE12 or_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 p450_BE12 system_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 though_RE2 this_RE2 have_RE2 not_RE2 be_RE2 study_RE2 
Fomepizole_ddi|P|antizol|carbamazepine|reciprocal_LE1 interaction_LE1 may_LE1 occur_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 increase_BE12 or_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 p450_BE12 system_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 though_RE2 this_RE2 have_RE2 not_RE2 be_RE2 study_RE2 
Fomepizole_ddi|P|antizol|cimetidine|reciprocal_LE1 interaction_LE1 may_LE1 occur_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 increase_BE12 or_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 p450_BE12 system_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 though_RE2 this_RE2 have_RE2 not_RE2 be_RE2 study_RE2 
Fomepizole_ddi|P|antizol|phenytoin|reciprocal_LE1 interaction_LE1 may_LE1 occur_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 drug_BE12 that_BE12 increase_BE12 or_BE12 inhibit_BE12 the_BE12 cytochrome_BE12 p450_BE12 system_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 though_RE2 this_RE2 have_RE2 not_RE2 be_RE2 study_RE2 
Fondaparinux sodium_ddi|P|coumarin|fondaparinux|In_LE1 in_LE1 vitro_LE1 study_LE1 in_LE1 human_LE1 liver_LE1 microsome_LE1 inhibition_LE1 of_LE1 cyp2a6_LE1 hydroxylation_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 i.e._RE2 NUM_RE2 mg_RE2 -RRB-_RE2 be_RE2 NUM_RE2 %._RE2 
Formoterol_ddi|P|sympathomimetic agent|foradil|concomitant_LE1 administration_LE1 of_LE1 other_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 undesirable_BE12 effect_BE12 of_BE12 BIOENTITY 
Formoterol_ddi|P|foradil|tricyclic antidepressant|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Formoterol_ddi|P|foradil|monoamine oxidase inhibitor|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 extreme_BE12 caution_BE12 in_BE12 patient_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 because_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 the_RE2 cardiovascular_RE2 system_RE2 may_RE2 be_RE2 potentiate_RE2 by_RE2 these_RE2 agent_RE2 
Formoterol_ddi|P|xanthine derivative|beta2-agonists.|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 possible_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Formoterol_ddi|P|steroid|beta2-agonists.|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 possible_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Formoterol_ddi|P|diuretic|beta2-agonists.|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY may_BE12 potentiate_BE12 possible_BE12 hypokalemic_BE12 effect_BE12 of_BE12 BIOENTITY 
Foscarnet_ddi|P|foscavir|pentamidine|possible_LE1 drug_LE1 interaction_LE1 of_LE1 BIOENTITY and_BE12 intravenous_BE12 BIOENTITY have_RE2 be_RE2 describe_RE2 
Foscarnet_ddi|P|foscavir|pentamidine|concomitant_LE1 treatment_LE1 of_LE1 four_LE1 patient_LE1 in_LE1 the_LE1 unite_LE1 kingdom_LE1 with_LE1 BIOENTITY and_BE12 intravenous_BE12 BIOENTITY may_RE2 have_RE2 cause_RE2 hypocalcemia_RE2 
Foscarnet_ddi|P|foscavir|amphotericin b|Because_LE1 of_LE1 BIOGENERAL_LE1 tendency_LE1 to_LE1 cause_LE1 renal_LE1 impairment_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 avoid_BE12 in_BE12 combination_BE12 with_BE12 potential_BE12 nephrotoxic_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 intravenous_RE2 BIOGENERAL_RE2 unless_RE2 the_RE2 potential_RE2 benefit_RE2 outweigh_RE2 the_RE2 risk_RE2 to_RE2 the_RE2 patient_RE2 
Foscarnet_ddi|P|foscavir|aminoglycoside|Because_LE1 of_LE1 BIOGENERAL_LE1 tendency_LE1 to_LE1 cause_LE1 renal_LE1 impairment_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 avoid_BE12 in_BE12 combination_BE12 with_BE12 potential_BE12 nephrotoxic_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 intravenous_RE2 BIOGENERAL_RE2 unless_RE2 the_RE2 potential_RE2 benefit_RE2 outweigh_RE2 the_RE2 risk_RE2 to_RE2 the_RE2 patient_RE2 
Foscarnet_ddi|P|foscavir|pentamidine|Because_LE1 of_LE1 BIOGENERAL_LE1 tendency_LE1 to_LE1 cause_LE1 renal_LE1 impairment_LE1 the_LE1 use_LE1 of_LE1 BIOENTITY shall_BE12 be_BE12 avoid_BE12 in_BE12 combination_BE12 with_BE12 potential_BE12 nephrotoxic_BE12 drug_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 intravenous_BE12 BIOENTITY unless_RE2 the_RE2 potential_RE2 benefit_RE2 outweigh_RE2 the_RE2 risk_RE2 to_RE2 the_RE2 patient_RE2 
Fosfomycin_ddi|P|monurol|metoclopramide|BIOGENERAL_LE1 :_LE1 when_LE1 coadminister_LE1 with_LE1 BIOENTITY BIOENTITY drug_RE2 which_RE2 increase_RE2 gastrointestinal_RE2 motility_RE2 lower_RE2 the_RE2 serum_RE2 concentration_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 
Fosinopril_ddi|P|diuretic|fosinopril sodium|BIOGENERAL_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY especial_BE12 those_BE12 with_BE12 intravascular_BE12 volume_BE12 depletion_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Fosinopril_ddi|P|diuretic|fosinopril sodium|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 can_LE1 be_LE1 minimize_LE1 by_LE1 either_LE1 discontinue_LE1 the_LE1 BIOENTITY or_BE12 increase_BE12 salt_BE12 intake_BE12 prior_BE12 to_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Fosinopril_ddi|P|fosinopril sodium|thiazide diuretic|BIOGENERAL_LE1 supplement_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY can_BE12 attenuate_BE12 potassium_BE12 loss_BE12 cause_BE12 by_BE12 BIOENTITY 
Fosinopril_ddi|P|ace inhibitor|lithium|BIOGENERAL_LE1 :_LE1 increase_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 symptom_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY during_BE12 therapy_BE12 with_BE12 BIOENTITY 
Fosinopril_ddi|P|magnesium hydroxide|fosinopril|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 pharmacology_LE1 study_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY reduce_RE2 serum_RE2 level_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 with_RE2 BIOGENERAL_RE2 administer_RE2 alone_RE2 suggest_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 impair_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Fosinopril_ddi|P|simethicone|fosinopril|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 pharmacology_LE1 study_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 with_BE12 BIOENTITY reduce_RE2 serum_RE2 level_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 with_RE2 BIOGENERAL_RE2 administer_RE2 alone_RE2 suggest_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 impair_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Fosinopril_ddi|P|antacid|fosinopril|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 pharmacology_LE1 study_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY reduce_RE2 serum_RE2 level_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 with_RE2 BIOGENERAL_RE2 administer_RE2 alone_RE2 suggest_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 impair_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Fosinopril_ddi|P|aluminum hydroxide|fosinopril|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 pharmacology_LE1 study_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 with_BE12 BIOENTITY reduce_RE2 serum_RE2 level_RE2 and_RE2 urinary_RE2 excretion_RE2 of_RE2 BIOGENERAL_RE2 as_RE2 compare_RE2 with_RE2 BIOGENERAL_RE2 administer_RE2 alone_RE2 suggest_RE2 that_RE2 BIOGENERAL_RE2 may_RE2 impair_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Fosinopril_ddi|P|antacid|fosinopril|BIOGENERAL_LE1 :_LE1 In_LE1 clinical_LE1 pharmacology_LE1 study_LE1 coadministration_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 with_LE1 BIOGENERAL_LE1 reduce_LE1 serum_LE1 level_LE1 and_LE1 urinary_LE1 excretion_LE1 of_LE1 BIOGENERAL_LE1 as_LE1 compare_LE1 with_LE1 BIOGENERAL_LE1 administer_LE1 alone_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 impair_BE12 absorption_BE12 of_BE12 BIOENTITY 
Fosphenytoin_ddi|P|phenytoin|trazodone|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Fosphenytoin_ddi|P|phenytoin|h2-antagonist|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|isoniazid|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|halothane|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|phenothiazine|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|methylphenidate|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|fluoxetine|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|ethosuximide|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|dicumarol|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|diazepam|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|estrogen|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|disulfiram|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|phenylbutazone|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|amiodarone|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOENTITY chboramphenicol_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|salicylate|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|alcohol|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOENTITY intake_RE2 BIOGENERAL_RE2 chboramphenicol_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|succinimide|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|cimetidine|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|sulfonamide|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|chlordiazepoxide|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|tolbutamide|the_LE1 much_LE1 common_LE1 occur_LE1 drug_LE1 interaction_LE1 be_LE1 list_LE1 below_LE1 :_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 acute_BE12 BIOGENERAL_BE12 intake_BE12 BIOGENERAL_BE12 chboramphenicol_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|reserpine|drug_LE1 that_LE1 may_LE1 decrease_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 chronic_BE12 BIOGENERAL_BE12 abuse_BE12 BIOENTITY 
Fosphenytoin_ddi|P|phenytoin|carbamazepine|drug_LE1 that_LE1 may_LE1 decrease_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 BIOENTITY chronic_RE2 BIOGENERAL_RE2 abuse_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|alcohol|drug_LE1 that_LE1 may_LE1 decrease_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 chronic_BE12 BIOENTITY abuse_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|sodium valproate|drug_LE1 that_LE1 may_LE1 either_LE1 increase_LE1 or_LE1 decrease_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 BIOGENERAL_BE12 vaiproic_BE12 acid_BE12 and_BE12 BIOENTITY 
Fosphenytoin_ddi|P|phenytoin|phenobarbital|drug_LE1 that_LE1 may_LE1 either_LE1 increase_LE1 or_LE1 decrease_LE1 plasma_LE1 BIOENTITY concentration_BE12 include_BE12 :_BE12 BIOENTITY vaiproic_RE2 acid_RE2 and_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|phenobarbital|similar_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 sodium_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 be_RE2 unpredictable_RE2 
Fosphenytoin_ddi|P|phenytoin|valproate|similar_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 sodium_BE12 plasma_BE12 BIOENTITY concentration_RE2 be_RE2 unpredictable_RE2 
Fosphenytoin_ddi|P|phenytoin|valproic acid|similar_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 sodium_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 be_RE2 unpredictable_RE2 
Fosphenytoin_ddi|P|tricyclic antidepressant|cerebyx|although_LE1 not_LE1 true_LE1 drug_LE1 interaction_LE1 BIOENTITY may_BE12 precipitate_BE12 seizure_BE12 in_BE12 susceptible_BE12 patient_BE12 and_BE12 BIOENTITY dosage_RE2 may_RE2 need_RE2 to_RE2 be_RE2 adjust_RE2 
Fosphenytoin_ddi|P|phenytoin|quinidine|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|vitamin d|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Fosphenytoin_ddi|P|phenytoin|theophylline|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|furosemide|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|estrogen|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|rifampin|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|contraceptive|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|digitoxin|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|doxycycline|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|corticosteroid|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|coumarin|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Fosphenytoin_ddi|P|phenytoin|anticoagulant|drug_LE1 whose_LE1 efficacy_LE1 be_LE1 impair_LE1 by_LE1 BIOENTITY include_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Frovatriptan_ddi|P|methysergide|frova|Due_LE1 to_LE1 theoretical_LE1 risk_LE1 of_LE1 pharmacodynamic_LE1 interaction_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 -LRB-_RE2 see_RE2 href=_RE2 frova_od.htm_RE2 ci_RE2 contraindication_RE2 -rrb-._RE2 
Frovatriptan_ddi|P|dihydroergotamine|frova|Due_LE1 to_LE1 theoretical_LE1 risk_LE1 of_LE1 pharmacodynamic_LE1 interaction_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 -LRB-_RE2 see_RE2 href=_RE2 frova_od.htm_RE2 ci_RE2 contraindication_RE2 -rrb-._RE2 
Frovatriptan_ddi|P|ergot-type medication|frova|Due_LE1 to_LE1 theoretical_LE1 risk_LE1 of_LE1 pharmacodynamic_LE1 interaction_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 -LRB-_RE2 see_RE2 href=_RE2 frova_od.htm_RE2 ci_RE2 contraindication_RE2 -rrb-._RE2 
Frovatriptan_ddi|P|ergotamine|frova|Due_LE1 to_LE1 theoretical_LE1 risk_LE1 of_LE1 pharmacodynamic_LE1 interaction_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 shall_RE2 be_RE2 avoid_RE2 -LRB-_RE2 see_RE2 href=_RE2 frova_od.htm_RE2 ci_RE2 contraindication_RE2 -rrb-._RE2 
Frovatriptan_ddi|P|sertraline|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|paroxetine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|fluvoxamine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|fluoxetine|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|selective serotonin reuptake inhibitor|5-ht1 agonist|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|ssri|5-ht1 agonist|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 rare_BE12 to_BE12 cause_BE12 weakness_BE12 hyperreflexia_BE12 and_BE12 incoordination_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Frovatriptan_ddi|P|frovatriptan|ssri|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Furosemide_ddi|P|furosemide|aminoglycoside antibiotic|BIOENTITY may_BE12 increase_BE12 the_BE12 ototoxic_BE12 potential_BE12 of_BE12 BIOENTITY especial_RE2 in_RE2 the_RE2 presence_RE2 of_RE2 impaired_RE2 renal_RE2 function_RE2 
Furosemide_ddi|P|furosemide|ethacrynic acid|BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 possibility_RE2 of_RE2 ototoxicity_RE2 
Furosemide_ddi|P|salicylate|furosemide|patient_LE1 receive_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY as_RE2 in_RE2 rheumatic_RE2 disease_RE2 may_RE2 experience_RE2 BIOGENERAL_RE2 toxicity_RE2 at_RE2 low_RE2 dose_RE2 because_RE2 of_RE2 competitive_RE2 renal_RE2 excretory_RE2 site_RE2 
Furosemide_ddi|P|furosemide|succinylcholine|BIOENTITY have_BE12 tendency_BE12 to_BE12 antagonize_BE12 the_BE12 skeletal_BE12 muscle_BE12 relaxing_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 may_BE12 potentiate_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Furosemide_ddi|P|furosemide|tubocurarine|BIOENTITY have_BE12 tendency_BE12 to_BE12 antagonize_BE12 the_BE12 skeletal_BE12 muscle_BE12 relaxing_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 may_RE2 potentiate_RE2 the_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 
Furosemide_ddi|P|lithium|diuretic|BIOENTITY general_BE12 shall_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY because_RE2 they_RE2 reduce_RE2 BIOGENERAL_RE2 renal_RE2 clearance_RE2 and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Furosemide_ddi|P|furosemide|antihypertensive drug|BIOENTITY may_BE12 add_BE12 to_BE12 or_BE12 potentiate_BE12 the_BE12 therapeutic_BE12 effect_BE12 of_BE12 other_BE12 BIOENTITY 
Furosemide_ddi|P|furosemide|norepinephrine|BIOENTITY may_BE12 decrease_BE12 arterial_BE12 responsiveness_BE12 to_BE12 BIOENTITY 
Furosemide_ddi|P|sucralfate|furosemide|tablet_LE1 simultaneous_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY tablet_RE2 may_RE2 reduce_RE2 the_RE2 natriuretic_RE2 and_RE2 antihypertensive_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Furosemide_ddi|P|furosemide|sucralfate|the_LE1 intake_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 separate_RE2 by_RE2 at_RE2 little_RE2 two_RE2 hour_RE2 
Furosemide_ddi|P|furosemide|acetylsalicylic acid|tablet_LE1 injection_LE1 and_LE1 oral_LE1 solution_LE1 one_LE1 study_LE1 in_LE1 six_LE1 subject_LE1 demonstrate_LE1 that_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY temporary_RE2 reduce_RE2 creatinine_RE2 clearance_RE2 in_RE2 patient_RE2 with_RE2 chronic_RE2 renal_RE2 insufficiency_RE2 
Furosemide_ddi|P|furosemide|nsaid|there_LE1 be_LE1 case_LE1 report_LE1 of_LE1 patient_LE1 who_LE1 develop_LE1 increase_LE1 bun_LE1 serum_LE1 creatinine_LE1 and_LE1 serum_LE1 potassium_LE1 level_LE1 and_LE1 weight_LE1 gain_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 conjunction_BE12 with_BE12 BIOENTITY 
Furosemide_ddi|P|indomethacin|furosemide|literature_LE1 report_LE1 indicate_LE1 that_LE1 coadministration_LE1 of_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 by_RE2 inhibit_RE2 prostaglandin_RE2 synthesis_RE2 
Furosemide_ddi|P|indomethacin|furosemide|patient_LE1 receive_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 diuretic_RE2 and_RE2 antihypertensive_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 achieve_RE2 
Gabapentin_ddi|P|naproxen sodium|neurontin|BIOGENERAL_LE1 :_LE1 coadministration_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 of_LE1 BIOENTITY capsule_BE12 -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 appear_RE2 to_RE2 increase_RE2 the_RE2 amount_RE2 of_RE2 BIOGENERAL_RE2 absorb_RE2 by_RE2 NUM_RE2 to_RE2 NUM_RE2 %._RE2 
Gabapentin_ddi|P|hydrocodone|gabapentin|BIOENTITY increase_BE12 BIOENTITY auc_RE2 value_RE2 by_RE2 NUM_RE2 %._RE2 
Gabapentin_ddi|P|morphine|neurontin|BIOGENERAL_LE1 :_LE1 literature_LE1 article_LE1 report_LE1 that_LE1 when_LE1 NUM_LE1 controlled-release_LE1 BIOENTITY capsule_BE12 be_BE12 administer_BE12 NUM_BE12 hour_BE12 prior_BE12 to_BE12 NUM_BE12 BIOENTITY capsule_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 mean_RE2 BIOGENERAL_RE2 auc_RE2 increase_RE2 by_RE2 NUM_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 administer_RE2 without_RE2 BIOGENERAL_RE2 
Gabapentin_ddi|P|cimetidine|gabapentin|BIOGENERAL_LE1 :_LE1 In_LE1 the_LE1 presence_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 qid_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 the_BE12 mean_BE12 apparent_BE12 oral_BE12 clearance_BE12 of_BE12 BIOENTITY fell_RE2 by_RE2 NUM_RE2 and_RE2 creatinine_RE2 clearance_RE2 fall_RE2 by_RE2 NUM_RE2 %._RE2 
Gabapentin_ddi|P|cimetidine|gabapentin|thus_LE1 BIOENTITY appear_BE12 to_BE12 alter_BE12 the_BE12 renal_BE12 excretion_BE12 of_BE12 both_BE12 BIOENTITY and_RE2 creatinine_RE2 endogenous_RE2 marker_RE2 of_RE2 renal_RE2 function_RE2 
Gabapentin_ddi|P|gabapentin|cimetidine|this_LE1 small_LE1 decrease_LE1 in_LE1 excretion_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY be_RE2 not_RE2 expect_RE2 to_RE2 be_RE2 of_RE2 clinical_RE2 importance_RE2 
Gabapentin_ddi|P|norethindrone|gabapentin|the_LE1 cmax_LE1 of_LE1 BIOENTITY be_BE12 NUM_BE12 high_BE12 when_BE12 it_BE12 be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Gabapentin_ddi|P|maalox|gabapentin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOENTITY reduce_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 by_RE2 about_RE2 NUM_RE2 %._RE2 
Gabapentin_ddi|P|gabapentin|maalox|this_LE1 decrease_LE1 in_LE1 bioavailability_LE1 be_LE1 about_LE1 NUM_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gabapentin_ddi|P|gabapentin|maalox|it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 hour_BE12 following_BE12 BIOENTITY administration_RE2 
Gefitinib_ddi|P|warfarin|iressa|international_LE1 normalize_LE1 ratio_LE1 -LRB-_LE1 inr_LE1 -RRB-_LE1 elevation_LE1 and_LE1 bleeding_LE1 event_LE1 have_LE1 be_LE1 report_LE1 in_LE1 some_LE1 patient_LE1 take_LE1 BIOENTITY while_BE12 on_BE12 BIOENTITY therapy_RE2 
Gefitinib_ddi|P|ketoconazole|gefitinib|substance_LE1 that_LE1 be_LE1 potent_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 BIOENTITY metabolism_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Gefitinib_ddi|P|itraconazole|gefitinib|substance_LE1 that_LE1 be_LE1 potent_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 decrease_BE12 BIOENTITY metabolism_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Gefitinib_ddi|P|itraconazole|gefitinib|substance_LE1 that_LE1 be_LE1 potent_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 decrease_BE12 BIOGENERAL_BE12 metabolism_BE12 and_BE12 increase_BE12 BIOENTITY plasma_RE2 concentration_RE2 
Gefitinib_ddi|P|ketoconazole|gefitinib|substance_LE1 that_LE1 be_LE1 potent_LE1 inhibitor_LE1 of_LE1 cyp3a4_LE1 activity_LE1 -LRB-_LE1 eg_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 decrease_BE12 BIOGENERAL_BE12 metabolism_BE12 and_BE12 increase_BE12 BIOENTITY plasma_RE2 concentration_RE2 
Gefitinib_ddi|P|histamine h2-receptor antagonist|iressa|drug_LE1 that_LE1 cause_LE1 significant_LE1 sustained_LE1 elevation_LE1 in_LE1 gastric_LE1 ph_LE1 -LRB-_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 therefore_RE2 potential_RE2 may_RE2 reduce_RE2 efficacy_RE2 
Gefitinib_ddi|P|cimetidine|iressa|drug_LE1 that_LE1 cause_LE1 significant_LE1 sustained_LE1 elevation_LE1 in_LE1 gastric_LE1 ph_LE1 -LRB-_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 may_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 therefore_RE2 potential_RE2 may_RE2 reduce_RE2 efficacy_RE2 
Gefitinib_ddi|P|ranitidine|iressa|drug_LE1 that_LE1 cause_LE1 significant_LE1 sustained_LE1 elevation_LE1 in_LE1 gastric_LE1 ph_LE1 -LRB-_LE1 BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 reduce_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 therefore_RE2 potential_RE2 may_RE2 reduce_RE2 efficacy_RE2 
Gefitinib_ddi|P|iressa|vinorelbine|phase_LE1 ii_LE1 clinical_LE1 trial_LE1 datum_LE1 where_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 use_LE1 concomitant_LE1 indicate_LE1 that_LE1 BIOENTITY may_BE12 exacerbate_BE12 the_BE12 neutropenic_BE12 effect_BE12 of_BE12 BIOENTITY 
Gemifloxacin_ddi|P|factive|calcium carbonate|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|cimetidine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|estrogen|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|omeprazole|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|contraceptive|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|estrogen|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 produce_RE2 minor_RE2 change_RE2 in_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 BIOGENERAL_RE2 which_RE2 be_RE2 consider_RE2 to_RE2 be_RE2 without_RE2 clinical_RE2 significance_RE2 
Gemifloxacin_ddi|P|factive|probenecid|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 systemic_RE2 exposure_RE2 to_RE2 BIOGENERAL_RE2 
Gemifloxacin_ddi|P|quinolone antimicrobial|warfarin|however_LE1 because_LE1 some_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 enhance_LE1 the_LE1 anticoagulant_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 its_LE1 derivative_LE1 in_LE1 patient_LE1 the_LE1 prothrombin_LE1 time_LE1 or_LE1 other_LE1 suitable_LE1 coagulation_LE1 test_LE1 shall_LE1 be_LE1 close_LE1 monitor_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Gemifloxacin_ddi|P|quinolone|warfarin|however_LE1 because_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 enhance_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 in_RE2 patient_RE2 the_RE2 prothrombin_RE2 time_RE2 or_RE2 other_RE2 suitable_RE2 coagulation_RE2 test_RE2 shall_RE2 be_RE2 close_RE2 monitor_RE2 if_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 concomitant_RE2 with_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 
Gemifloxacin_ddi|P|gemifloxacin|aluminum|the_LE1 absorption_LE1 of_LE1 oral_LE1 BIOENTITY be_BE12 significant_BE12 reduce_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Gemifloxacin_ddi|P|gemifloxacin|magnesium|the_LE1 absorption_LE1 of_LE1 oral_LE1 BIOENTITY be_BE12 significant_BE12 reduce_BE12 by_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Gemifloxacin_ddi|P|ferrous sulfate|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|iron|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|magnesium|factive|BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|aluminum|factive|BIOGENERAL_LE1 and_LE1 BIOENTITY BIOGENERAL_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|videx|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 metal_LE1 cation_LE1 or_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|didanosine|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 metal_LE1 cation_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|multivitamin preparation|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY contain_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|zinc|factive|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 other_BE12 metal_BE12 cation_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 before_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY 
Gemifloxacin_ddi|P|sucralfate|factive|BIOENTITY shall_BE12 not_BE12 be_BE12 take_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 BIOENTITY 
Glibenclamide_ddi|P|sulfonylurea|beta adrenergic blocking agent|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Glibenclamide_ddi|P|sulfonylurea|monoamine oxidase inhibitor|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|coumarin|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|chloramphenicol|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|probenecid|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|salicylate|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|sulfonamide|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|sulfonylurea|nonsteroidal anti-inflammatory agent|the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 high_RE2 protein_RE2 bind_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|glyburide|ciprofloxacin|possible_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 result_RE2 in_RE2 potentiation_RE2 of_RE2 the_RE2 hypoglycemic_RE2 action_RE2 of_RE2 BIOGENERAL_RE2 
Glibenclamide_ddi|P|miconazole|hypoglycemic agent|potential_LE1 interaction_LE1 between_LE1 oral_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY lead_RE2 to_RE2 severe_RE2 hypoglycemia_RE2 have_RE2 be_RE2 report_RE2 
Glimepiride_ddi|P|glimepiride|magan|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|bismuth subsalicylate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|magnesium salicylate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|pepto-bismol|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Glimepiride_ddi|P|glimepiride|arthropan|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|choline salicylate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 other_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|disalcid|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|salsalate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|magnesium/choline salicylate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|trilisate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|aspirin|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOENTITY or_RE2 another_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glimepiride_ddi|P|glimepiride|salicylate|Before_LE1 take_LE1 BIOENTITY tell_BE12 your_BE12 doctor_BE12 if_BE12 you_BE12 be_BE12 take_BE12 any_BE12 of_BE12 the_BE12 following_BE12 medicine_BE12 :_BE12 BIOGENERAL_BE12 or_BE12 another_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 other_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|monoamine oxidase inhibitor|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|coumarin|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|beta adrenergic blocking agent|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Glipizide_ddi|P|sulfonylurea|sulfonamide|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|salicylate|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|probenecid|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|chloramphenicol|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 high_BE12 protein_BE12 bind_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|nonsteroidal anti-inflammatory agent|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOENTITY some_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 high_RE2 protein_RE2 bind_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|sulfonylurea|azole|immediate_LE1 and_LE1 extended_LE1 release_LE1 tablet_LE1 the_LE1 hypoglycemic_LE1 action_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 potentiate_BE12 by_BE12 certain_BE12 drug_BE12 including_BE12 BIOGENERAL_BE12 some_BE12 BIOENTITY and_RE2 other_RE2 drug_RE2 that_RE2 be_RE2 high_RE2 protein_RE2 bind_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Glipizide_ddi|P|miconazole|hypoglycemic agent|potential_LE1 interaction_LE1 between_LE1 oral_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY lead_RE2 to_RE2 severe_RE2 hypoglycemia_RE2 have_RE2 be_RE2 report_RE2 
Glipizide_ddi|P|fluconazole|glipizide|the_LE1 effect_LE1 of_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 demonstrate_RE2 in_RE2 placebo-controlled_RE2 crossover_RE2 study_RE2 in_RE2 normal_RE2 volunteer_RE2 
Glipizide_ddi|P|glipizide|fluconazole|the_LE1 mean_LE1 percentage_LE1 increase_LE1 in_LE1 the_LE1 BIOENTITY auc_BE12 after_BE12 BIOENTITY administration_RE2 be_RE2 NUM_RE2 -LRB-_RE2 range_RE2 :_RE2 NUM_RE2 to_RE2 NUM_RE2 -rrb-._RE2 
Glycopyrrolate_ddi|P|robinul|anticholinergic|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY injection_BE12 with_BE12 other_BE12 BIOENTITY or_RE2 medication_RE2 with_RE2 anticholinergic_RE2 activity_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 intensify_RE2 the_RE2 antimuscarinic_RE2 effect_RE2 and_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 anticholinergic_RE2 side_RE2 effect_RE2 
Glycopyrrolate_ddi|P|robinul|antiparkinson drug|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY injection_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 intensify_RE2 the_RE2 antimuscarinic_RE2 effect_RE2 and_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 anticholinergic_RE2 side_RE2 effect_RE2 
Glycopyrrolate_ddi|P|robinul|phenothiazine|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY injection_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 may_RE2 intensify_RE2 the_RE2 antimuscarinic_RE2 effect_RE2 and_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 anticholinergic_RE2 side_RE2 effect_RE2 
Glycopyrrolate_ddi|P|robinul|tricyclic antidepressant|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY injection_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 medication_BE12 with_BE12 anticholinergic_BE12 activity_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 intensify_RE2 the_RE2 antimuscarinic_RE2 effect_RE2 and_RE2 may_RE2 result_RE2 in_RE2 increase_RE2 in_RE2 anticholinergic_RE2 side_RE2 effect_RE2 
Glycopyrrolate_ddi|P|robinul|potassium chloride|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY injection_BE12 and_BE12 BIOENTITY in_RE2 wax_RE2 matrix_RE2 may_RE2 increase_RE2 the_RE2 severity_RE2 of_RE2 potassium_RE2 chloride-induced_RE2 gastrointestinal_RE2 lesion_RE2 as_RE2 result_RE2 of_RE2 slow_RE2 gastrointestinal_RE2 transit_RE2 time_RE2 
Gonadorelin_ddi|P|factrel|dopamine antagonist|the_LE1 response_LE1 to_LE1 BIOENTITY may_BE12 be_BE12 blunt_BE12 by_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY which_RE2 cause_RE2 rise_RE2 in_RE2 prolactin_RE2 
Gonadorelin_ddi|P|factrel|phenothiazine|the_LE1 response_LE1 to_LE1 BIOENTITY may_BE12 be_BE12 blunt_BE12 by_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 which_RE2 cause_RE2 rise_RE2 in_RE2 prolactin_RE2 
Grepafloxacin_ddi|P|quinolone|calcium|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY with_RE2 BIOGENERAL_RE2 with_RE2 metal_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|magnesium|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 with_RE2 metal_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|aluminum|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 with_RE2 BIOGENERAL_RE2 with_RE2 metal_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|didanosine|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 formulation_BE12 contain_BE12 divalent_BE12 and_BE12 trivalent_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|videx|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 formulation_BE12 contain_BE12 divalent_BE12 and_BE12 trivalent_BE12 cation_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|zinc|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|iron|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 BIOGENERAL_BE12 contain_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|multivitamin|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 with_BE12 BIOENTITY contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|iron|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOGENERAL_BE12 with_BE12 metal_BE12 cation_BE12 such_BE12 as_BE12 BIOENTITY or_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|quinolone|sucralfate|administration_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY with_RE2 metal_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 or_RE2 with_RE2 formulation_RE2 contain_RE2 divalent_RE2 and_RE2 trivalent_RE2 cation_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 chewable_RE2 tablet_RE2 or_RE2 the_RE2 pediatric_RE2 powder_RE2 for_RE2 oral_RE2 solution_RE2 may_RE2 substantial_RE2 interfere_RE2 with_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 systemic_RE2 concentration_RE2 considerable_RE2 low_RE2 than_RE2 desired_RE2 
Grepafloxacin_ddi|P|grepafloxacin|caffeine|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Grepafloxacin_ddi|P|quinolone|theobromine|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Grepafloxacin_ddi|P|quinolone|caffeine|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Grepafloxacin_ddi|P|grepafloxacin|theobromine|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Grepafloxacin_ddi|P|grepafloxacin|theophylline|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 competitive_BE12 inhibitor_BE12 of_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Grepafloxacin_ddi|P|grepafloxacin|theophylline|serum_LE1 BIOGENERAL_LE1 concentration_LE1 increase_LE1 when_LE1 BIOENTITY be_BE12 initiate_BE12 in_BE12 patient_BE12 maintain_BE12 on_BE12 BIOENTITY 
Grepafloxacin_ddi|P|theophylline|grepafloxacin|when_LE1 initiate_LE1 multi-day_LE1 course_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 patient_LE1 maintain_LE1 on_LE1 BIOGENERAL_LE1 the_LE1 BIOENTITY maintenance_BE12 dose_BE12 shall_BE12 be_BE12 halve_BE12 for_BE12 the_BE12 period_BE12 of_BE12 concurrent_BE12 use_BE12 of_BE12 BIOENTITY and_RE2 monitoring_RE2 of_RE2 serum_RE2 BIOGENERAL_RE2 concentration_RE2 shall_RE2 be_RE2 initiate_RE2 as_RE2 guide_RE2 to_RE2 further_RE2 dosage_RE2 adjustment_RE2 
Grepafloxacin_ddi|P|quinolone|warfarin|however_LE1 because_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 prothrombin_RE2 time_RE2 or_RE2 other_RE2 suitable_RE2 anticoagulation_RE2 test_RE2 shall_RE2 be_RE2 monitor_RE2 close_RE2 if_RE2 BIOGENERAL_RE2 be_RE2 administer_RE2 with_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 
Grepafloxacin_ddi|P|quinolone antimicrobial|warfarin|however_LE1 because_LE1 some_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 to_LE1 enhance_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 its_LE1 derivative_LE1 prothrombin_LE1 time_LE1 or_LE1 other_LE1 suitable_LE1 anticoagulation_LE1 test_LE1 shall_LE1 be_LE1 monitor_LE1 close_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Grepafloxacin_ddi|P|grepafloxacin|theophylline|drug_LE1 metabolize_LE1 by_LE1 cytochrome_LE1 p450_LE1 enzyme_LE1 the_LE1 drug_LE1 interaction_LE1 study_LE1 evaluate_LE1 the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 on_LE1 BIOGENERAL_LE1 indicate_LE1 that_LE1 BIOENTITY inhibit_BE12 BIOENTITY metabolism_RE2 which_RE2 be_RE2 mediate_RE2 by_RE2 cyp1a2_RE2 
Grepafloxacin_ddi|P|quinolone|cyclosporine|In_LE1 addition_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 cyp3a4-mediated_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Grepafloxacin_ddi|P|nonsteroidal anti inflammatory drug|quinolone|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 cns_RE2 stimulation_RE2 and_RE2 convulsion_RE2 
Grepafloxacin_ddi|P|quinolone|antidiabetic agent|BIOGENERAL_LE1 :_LE1 disturbance_LE1 of_LE1 blood_LE1 glucose_LE1 including_LE1 hyperglycemia_LE1 and_LE1 hypoglycemia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 treat_LE1 concomitant_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY 
Griseofulvin_ddi|P|warfarin-type anticoagulant|griseofulvin|patient_LE1 on_LE1 BIOENTITY therapy_BE12 may_BE12 require_BE12 dosage_BE12 adjustment_BE12 of_BE12 the_BE12 anticoagulant_BE12 during_BE12 and_BE12 after_BE12 BIOENTITY therapy_RE2 
Griseofulvin_ddi|P|barbiturate|griseofulvin|concomitant_LE1 use_LE1 of_LE1 BIOENTITY usual_BE12 depress_BE12 BIOENTITY activity_RE2 and_RE2 may_RE2 necessitate_RE2 raise_RE2 the_RE2 dosage_RE2 
Griseofulvin_ddi|P|griseofulvin|contraceptive|the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 efficacy_BE12 of_BE12 oral_BE12 BIOENTITY and_RE2 to_RE2 increase_RE2 the_RE2 incidence_RE2 of_RE2 breakthrough_RE2 bleeding_RE2 
Guaifenesin_ddi|P|codeine|antihistamine|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guaifenesin_ddi|P|codeine|psychotropic|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guaifenesin_ddi|P|codeine|alcohol|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guaifenesin_ddi|P|dextromethorphan|maoi|serious_LE1 toxicity_LE1 may_LE1 result_LE1 if_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY 
Guaifenesin_ddi|P|dextromethorphan|monoamine oxidase inhibitor|serious_LE1 toxicity_LE1 may_LE1 result_LE1 if_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 
Guaifenesin_ddi|P|dextromethorphan hydrobromide|antihistamine|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guaifenesin_ddi|P|dextromethorphan hydrobromide|psychotropic|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guaifenesin_ddi|P|dextromethorphan hydrobromide|alcohol|the_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 result_BE12 in_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 drug_RE2 that_RE2 produce_RE2 cns_RE2 depression_RE2 
Guanfacine_ddi|P|guanfacine|cns-depressant drug|the_LE1 potential_LE1 for_LE1 increase_LE1 sedation_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 other_BE12 BIOENTITY shall_RE2 be_RE2 appreciate_RE2 
Guanfacine_ddi|P|guanfacine|phenytoin|the_LE1 administration_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 known_BE12 microsomal_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 to_RE2 two_RE2 patient_RE2 with_RE2 renal_RE2 impairment_RE2 reported_RE2 result_RE2 in_RE2 significant_RE2 reduction_RE2 in_RE2 elimination_RE2 half-life_RE2 and_RE2 plasma_RE2 concentration_RE2 
Guanfacine_ddi|P|guanfacine|phenobarbital|the_LE1 administration_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 known_BE12 microsomal_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 to_RE2 two_RE2 patient_RE2 with_RE2 renal_RE2 impairment_RE2 reported_RE2 result_RE2 in_RE2 significant_RE2 reduction_RE2 in_RE2 elimination_RE2 half-life_RE2 and_RE2 plasma_RE2 concentration_RE2 
Guanfacine_ddi|P|tca|guanfacine|BIOENTITY decrease_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Guanfacine_ddi|P|timolol|guanfacine|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 porpranolol_LE1 BIOENTITY -RRB-_BE12 may_BE12 exacerbate_BE12 rebound_BE12 hypertension_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Guanfacine_ddi|P|nadolol|guanfacine|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY porpranolol_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 exacerbate_BE12 rebound_BE12 hypertension_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Guanfacine_ddi|P|noncardioselective beta-blocker|guanfacine|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 porpranolol_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 exacerbate_BE12 rebound_BE12 hypertension_BE12 when_BE12 BIOENTITY be_RE2 withdraw_RE2 
Haloperidol_ddi|P|lithium|haldol|encephalopathic_LE1 syndrome_LE1 -LRB-_LE1 characterize_LE1 by_LE1 weakness_LE1 lethargy_LE1 fever_LE1 tremulousness_LE1 and_LE1 confusion_LE1 extrapyramidal_LE1 symptom_LE1 leukocytosis_LE1 elevated_LE1 serum_LE1 enzyme_LE1 bun_LE1 and_LE1 fbs_LE1 -RRB-_LE1 follow_LE1 by_LE1 irreversible_LE1 brain_LE1 damage_LE1 have_LE1 occur_LE1 in_LE1 few_LE1 patient_LE1 treat_LE1 with_LE1 BIOENTITY plus_BE12 BIOENTITY 
Haloperidol_ddi|P|haldol|cns depressant|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 it_LE1 shall_LE1 be_LE1 note_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|antipsychotic agent|alcohol|as_LE1 with_LE1 other_LE1 BIOENTITY it_BE12 shall_BE12 be_BE12 note_BE12 that_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Haloperidol_ddi|P|haldol|opiate|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 it_LE1 shall_LE1 be_LE1 note_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|haldol|anesthetic|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 it_LE1 shall_LE1 be_LE1 note_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|haldol|alcohol|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 it_LE1 shall_LE1 be_LE1 note_LE1 that_LE1 BIOENTITY may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Haloperidol_ddi|P|antipsychotic agent|cns depressant|as_LE1 with_LE1 other_LE1 BIOENTITY it_BE12 shall_BE12 be_BE12 note_BE12 that_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|antipsychotic agent|opiate|as_LE1 with_LE1 other_LE1 BIOENTITY it_BE12 shall_BE12 be_BE12 note_BE12 that_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|antipsychotic agent|anesthetic|as_LE1 with_LE1 other_LE1 BIOENTITY it_BE12 shall_BE12 be_BE12 note_BE12 that_BE12 BIOGENERAL_BE12 may_BE12 be_BE12 capable_BE12 of_BE12 potentiating_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Haloperidol_ddi|P|haloperidol|rifampin|In_LE1 study_LE1 of_LE1 NUM_LE1 schizophrenic_LE1 patient_LE1 coadministered_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY plasma_RE2 BIOGENERAL_RE2 level_RE2 be_RE2 decrease_RE2 by_RE2 mean_RE2 of_RE2 NUM_RE2 and_RE2 mean_RE2 score_RE2 on_RE2 the_RE2 brief_RE2 psychiatric_RE2 rating_RE2 scale_RE2 be_RE2 increase_RE2 from_RE2 baseline_RE2 
Haloperidol_ddi|P|rifampin|haloperidol|In_LE1 NUM_LE1 other_LE1 schizophrenic_LE1 patient_LE1 treat_LE1 with_LE1 oral_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 discontinuation_LE1 of_LE1 BIOENTITY produce_BE12 mean_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY concentration_RE2 
Haloperidol_ddi|P|rifampin|haloperidol|thus_LE1 careful_LE1 monitoring_LE1 of_LE1 clinical_LE1 status_LE1 be_LE1 warrant_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 or_BE12 discontinue_BE12 in_BE12 BIOENTITY patient_RE2 
Halothane_ddi|P|fluothane|non-depolarising muscle relaxant|BIOENTITY augment_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Halothane_ddi|P|fluothane|aminoglycoside|BIOENTITY augment_BE12 the_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Halothane_ddi|P|fluothane|tubocurarine|BIOENTITY may_BE12 augment_BE12 the_BE12 hypotension_BE12 cause_BE12 by_BE12 the_BE12 ganglionic-blocking_BE12 effect_BE12 of_BE12 BIOENTITY 
Halothane_ddi|P|adrenaline|fluothane|caution_LE1 shall_LE1 be_LE1 exercise_LE1 during_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 anaesthetised_BE12 with_BE12 BIOENTITY as_RE2 arrhythmia_RE2 may_RE2 be_RE2 precipitated_RE2 
Heparin_ddi|P|heparin sodium|dicumarol|therefore_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 period_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 after_RE2 the_RE2 last_RE2 intravenous_RE2 dose_RE2 or_RE2 NUM_RE2 hour_RE2 after_RE2 the_RE2 last_RE2 subcutaneous_RE2 dose_RE2 shall_RE2 elapse_RE2 before_RE2 blood_RE2 be_RE2 draw_RE2 if_RE2 valid_RE2 prothrombin_RE2 time_RE2 be_RE2 to_RE2 be_RE2 obtain_RE2 
Heparin_ddi|P|heparin sodium|warfarin sodium|therefore_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY period_RE2 of_RE2 at_RE2 little_RE2 NUM_RE2 hour_RE2 after_RE2 the_RE2 last_RE2 intravenous_RE2 dose_RE2 or_RE2 NUM_RE2 hour_RE2 after_RE2 the_RE2 last_RE2 subcutaneous_RE2 dose_RE2 shall_RE2 elapse_RE2 before_RE2 blood_RE2 be_RE2 draw_RE2 if_RE2 valid_RE2 prothrombin_RE2 time_RE2 be_RE2 to_RE2 be_RE2 obtain_RE2 
Heparin_ddi|P|acetylsalicylic acid|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|ibuprofen|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|indomethacin|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|dextran|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|phenylbutazone|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|hydroxychloroquine|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|dipyridamole|heparin sodium|BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 other_BE12 that_BE12 interfere_BE12 with_BE12 platelet-aggregation_BE12 reaction_BE12 -LRB-_BE12 the_BE12 main_BE12 hemostatic_BE12 defense_BE12 of_BE12 heparinized_BE12 patient_BE12 -RRB-_BE12 may_BE12 induce_BE12 bleeding_BE12 and_BE12 shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Heparin_ddi|P|heparin|antithrombin iii|the_LE1 anticoagulant_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 enhance_BE12 by_BE12 concurrent_BE12 treatment_BE12 with_BE12 BIOENTITY -LRB-_RE2 human_RE2 -RRB-_RE2 in_RE2 patient_RE2 with_RE2 hereditary_RE2 antithrombin_RE2 iii_RE2 deficiency_RE2 
Heparin_ddi|P|heparin|antithrombin iii|thus_LE1 in_LE1 order_LE1 to_LE1 avoid_LE1 bleeding_LE1 reduce_LE1 dosage_LE1 of_LE1 BIOENTITY be_BE12 recommend_BE12 during_BE12 treatment_BE12 with_BE12 BIOENTITY -LRB-_RE2 human-rrb-._RE2 
Heparin_ddi|P|digitali|heparin sodium|drug_LE1 Decreasing_LE1 BIOGENERAL_LE1 effect_LE1 :_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulant_BE12 action_BE12 of_BE12 BIOENTITY 
Heparin_ddi|P|tetracycline|heparin sodium|drug_LE1 Decreasing_LE1 BIOGENERAL_LE1 effect_LE1 :_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulant_BE12 action_BE12 of_BE12 BIOENTITY 
Heparin_ddi|P|nicotine|heparin sodium|drug_LE1 Decreasing_LE1 BIOGENERAL_LE1 effect_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulant_BE12 action_BE12 of_BE12 BIOENTITY 
Heparin_ddi|P|antihistamine|heparin sodium|drug_LE1 Decreasing_LE1 BIOGENERAL_LE1 effect_LE1 :_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY may_BE12 partial_BE12 counteract_BE12 the_BE12 anticoagulant_BE12 action_BE12 of_BE12 BIOENTITY 
Heroin_ddi|P|central nervous system depressant|heroin|In_LE1 combination_LE1 with_LE1 other_LE1 BIOENTITY BIOENTITY may_RE2 still_RE2 kill_RE2 even_RE2 experience_RE2 user_RE2 particular_RE2 if_RE2 their_RE2 tolerance_RE2 to_RE2 the_RE2 drug_RE2 have_RE2 reduce_RE2 or_RE2 the_RE2 strength_RE2 of_RE2 their_RE2 usual_RE2 dose_RE2 have_RE2 increase_RE2 
Heroin_ddi|P|heroin|methadone|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 to_BE12 rising_BE12 degree_BE12 BIOENTITY 
Heroin_ddi|P|heroin|benzodiazepine|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 to_RE2 rising_RE2 degree_RE2 BIOGENERAL_RE2 
Heroin_ddi|P|heroin|alcohol|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 to_RE2 rising_RE2 degree_RE2 BIOGENERAL_RE2 
Heroin_ddi|P|heroin|valium|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 and_RE2 to_RE2 rising_RE2 degree_RE2 BIOGENERAL_RE2 
Heroin_ddi|P|heroin|diazepam|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 to_RE2 rising_RE2 degree_RE2 BIOGENERAL_RE2 
Heroin_ddi|P|heroin|central nervous system depressant|toxicology_LE1 study_LE1 of_LE1 BIOENTITY death_BE12 reveal_BE12 frequent_BE12 involvement_BE12 of_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 to_RE2 rising_RE2 degree_RE2 BIOGENERAL_RE2 
Heroin_ddi|P|cocaine|heroin|BIOENTITY sometimes_BE12 prove_BE12 to_BE12 be_BE12 fatal_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Hexobarbital_ddi|P|barbiturate|contraceptive|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hexobarbital_ddi|P|barbiturate|quinidine|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hexobarbital_ddi|P|barbiturate|antibiotic|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hexobarbital_ddi|P|barbiturate|corticosteroid|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hexobarbital_ddi|P|barbiturate|theophylline|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hexobarbital_ddi|P|barbiturate|beta blocker|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Hexobarbital_ddi|P|barbiturate|anticoagulant|BIOENTITY may_BE12 decrease_BE12 the_BE12 effectiveness_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 certain_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Hydralazine_ddi|P|mao inhibitor|hydralazine|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Hydralazine_ddi|P|antihypertensive drug|hydralazine|when_LE1 other_LE1 potent_LE1 parental_LE1 BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY patient_RE2 shall_RE2 be_RE2 continuous_RE2 observe_RE2 for_RE2 several_RE2 hour_RE2 for_RE2 any_RE2 excessive_RE2 fall_RE2 in_RE2 blood_RE2 pressure_RE2 
Hydralazine_ddi|P|antihypertensive drug|diazoxide|when_LE1 other_LE1 potent_LE1 parental_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY be_RE2 use_RE2 in_RE2 combination_RE2 with_RE2 BIOGENERAL_RE2 patient_RE2 shall_RE2 be_RE2 continuous_RE2 observe_RE2 for_RE2 several_RE2 hour_RE2 for_RE2 any_RE2 excessive_RE2 fall_RE2 in_RE2 blood_RE2 pressure_RE2 
Hydralazine_ddi|P|diazoxide|hydralazine|profound_LE1 hypotensive_LE1 episode_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY infection_BE12 and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 
Hydralazine_ddi|P|propranolol|hydralazine|BIOENTITY increase_BE12 BIOENTITY serum_RE2 concentration_RE2 
Hydralazine_ddi|P|nsaid|hydralazine|BIOENTITY may_BE12 decrease_BE12 the_BE12 hemodynamic_BE12 effect_BE12 of_BE12 BIOENTITY 
Hydrochlorothiazide_ddi|P|hydrochlorothiazide|anionic exchange resin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 :_LE1 absorption_LE1 of_LE1 BIOENTITY be_BE12 impair_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Hydrochlorothiazide_ddi|P|cholestyramine|hydrochlorothiazide|single_LE1 dose_LE1 of_LE1 either_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 bind_BE12 the_BE12 BIOENTITY and_RE2 reduce_RE2 its_RE2 absorption_RE2 from_RE2 the_RE2 gastrointestinal_RE2 tract_RE2 by_RE2 up_RE2 to_RE2 NUM_RE2 and_RE2 NUM_RE2 percent_RE2 respective_RE2 
Hydrochlorothiazide_ddi|P|colestipol|hydrochlorothiazide|single_LE1 dose_LE1 of_LE1 either_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY BIOGENERAL_BE12 bind_BE12 the_BE12 BIOENTITY and_RE2 reduce_RE2 its_RE2 absorption_RE2 from_RE2 the_RE2 gastrointestinal_RE2 tract_RE2 by_RE2 up_RE2 to_RE2 NUM_RE2 and_RE2 NUM_RE2 percent_RE2 respective_RE2 
Hydrochlorothiazide_ddi|P|lithium|diuretic|BIOENTITY :_BE12 general_BE12 shall_BE12 not_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY 
Hydrochlorothiazide_ddi|P|diuretic agent|lithium|BIOENTITY reduce_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY and_RE2 add_RE2 high_RE2 risk_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Hydrochlorothiazide_ddi|P|diuretic agent|lithium|BIOENTITY reduce_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 add_BE12 high_BE12 risk_BE12 of_BE12 BIOENTITY toxicity_RE2 
Hydrochlorothiazide_ddi|P|lithium|hydrochlorothiazide|refer_LE1 to_LE1 the_LE1 package_LE1 insert_LE1 for_LE1 BIOENTITY preparation_BE12 before_BE12 use_BE12 of_BE12 such_BE12 preparation_BE12 with_BE12 BIOENTITY 
Hydrochlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|thiazide diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Hydrochlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|potassium-sparing diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Hydrochlorothiazide_ddi|P|non-steroidal anti-inflammatory agent|loop diuretic|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hydrochlorothiazide_ddi|P|hydrochlorothiazide|non-steroidal anti-inflammatory agent|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 obtain_RE2 
Hydrocodone_ddi|P|cns depressant|hydrocodone|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOENTITY -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 tablet_RE2 may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydrocodone_ddi|P|alcohol|hydrocodone|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOENTITY -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 tablet_RE2 may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydrocodone_ddi|P|antipsychotic|hydrocodone|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 tablet_RE2 may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydrocodone_ddi|P|antianxiety agent|hydrocodone|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 tablet_RE2 may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydrocodone_ddi|P|narcotic analgesic|hydrocodone|patient_LE1 receive_LE1 other_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 tablet_RE2 may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydrocodone_ddi|P|tricyclic antidepressant|hydrocodone|the_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY with_BE12 BIOENTITY preparation_RE2 may_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 either_RE2 the_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Hydrocodone_ddi|P|mao inhibitor|hydrocodone|the_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY preparation_RE2 may_RE2 increase_RE2 the_RE2 effect_RE2 of_RE2 either_RE2 the_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Hydrocodone_ddi|P|anticholinergic|hydrocodone|the_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 produce_RE2 paralytic_RE2 ileus_RE2 
Hydroflumethiazide_ddi|P|thiazide diuretic|digitali|-LRB-_LE1 concurrent_LE1 use_LE1 with_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 possibility_BE12 of_BE12 BIOENTITY toxicity_RE2 associate_RE2 with_RE2 hypokalemia_RE2 .-rrb-_RE2 
Hydroflumethiazide_ddi|P|hypoglycemic medication|thiazide diuretic|for_LE1 adult-onset_LE1 diabetic_LE1 dosage_LE1 adjustment_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 necessary_BE12 during_BE12 and_BE12 after_BE12 BIOENTITY therapy_RE2 
Hydroflumethiazide_ddi|P|steroidal anti-inflammatory agent|thiazide diuretic|-LRB-_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Hydroflumethiazide_ddi|P|steroidal anti-inflammatory agent|potassium sparing diuretic|-LRB-_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Hydroflumethiazide_ddi|P|steroidal anti-inflammatory agent|loop diuretic|-LRB-_LE1 In_LE1 some_LE1 patient_LE1 the_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Hydroflumethiazide_ddi|P|hydroflumethiazide|nonsteroidal anti-inflammatory agent|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 to_RE2 determine_RE2 if_RE2 the_RE2 desired_RE2 effect_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 be_RE2 obtain_RE2 .-rrb-_RE2 
Hydroflumethiazide_ddi|P|thiazide|norepinephrine|-LRB-_LE1 BIOENTITY may_BE12 decrease_BE12 arterial_BE12 responsiveness_BE12 to_BE12 BIOENTITY 
Hydroflumethiazide_ddi|P|thiazide drug|tubocurarine|-LRB-_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 responsiveness_BE12 to_BE12 BIOENTITY .-rrb-_RE2 
Hydromorphone_ddi|P|alcohol|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOENTITY -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|narcotic analgesic|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOENTITY general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|phenothiazine|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|anesthetic|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|sedative-hypnotic|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|tranquilizer|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|cns depressant|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 other_LE1 BIOENTITY -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydromorphone_ddi|P|tricyclic antidepressant|dilaudid|patient_LE1 receive_LE1 other_LE1 BIOGENERAL_LE1 general_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 other_BE12 BIOGENERAL_BE12 -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 exhibit_RE2 additive_RE2 cns_RE2 depression_RE2 
Hydroxyurea_ddi|P|hydroxyurea|uricosuric medication|since_LE1 BIOENTITY may_BE12 raise_BE12 the_BE12 serum_BE12 uric_BE12 acid_BE12 level_BE12 dosage_BE12 adjustment_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 necessary_RE2 
Hydroxyzine_ddi|P|hydroxyzine|non-narcotic analgesic|the_LE1 potentiating_LE1 action_LE1 OF_LE1 BIOENTITY must_BE12 be_BE12 consider_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 use_BE12 IN_BE12 conjunction_BE12 WITH_BE12 BIOGENERAL_BE12 SUCH_BE12 AS_BE12 BIOGENERAL_BE12 BIOENTITY AND_RE2 BIOGENERAL_RE2 
Hydroxyzine_ddi|P|hydroxyzine|barbiturate|the_LE1 potentiating_LE1 action_LE1 OF_LE1 BIOENTITY must_BE12 be_BE12 consider_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 use_BE12 IN_BE12 conjunction_BE12 WITH_BE12 BIOGENERAL_BE12 SUCH_BE12 AS_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 AND_BE12 BIOENTITY 
Hydroxyzine_ddi|P|hydroxyzine|central nervous system depressant|the_LE1 potentiating_LE1 action_LE1 OF_LE1 BIOENTITY must_BE12 be_BE12 consider_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 use_BE12 IN_BE12 conjunction_BE12 WITH_BE12 BIOENTITY SUCH_RE2 AS_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 AND_RE2 BIOGENERAL_RE2 
Hydroxyzine_ddi|P|hydroxyzine|narcotic|the_LE1 potentiating_LE1 action_LE1 OF_LE1 BIOENTITY must_BE12 be_BE12 consider_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 use_BE12 IN_BE12 conjunction_BE12 WITH_BE12 BIOGENERAL_BE12 SUCH_BE12 AS_BE12 BIOENTITY BIOGENERAL_RE2 AND_RE2 BIOGENERAL_RE2 
Hydroxyzine_ddi|P|central nervous system depressant|hydroxyzine|therefore_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY their_RE2 dosage_RE2 shall_RE2 be_RE2 reduce_RE2 
Hyoscyamine_ddi|P|levsin|antihistamine|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 some_BE12 BIOENTITY 
Hyoscyamine_ddi|P|levsin|monoamine oxidase (mao) inhibitor|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|levsin|tricyclic antidepressant|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -LRB-_BE12 mao_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|levsin|haloperidol|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|levsin|phenothiazine|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|levsin|antimuscarinic|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|levsin|amantadine|additive_LE1 adverse_LE1 effect_LE1 result_LE1 from_LE1 cholinergic_LE1 blockade_LE1 may_LE1 occur_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -LRB-_RE2 mao_RE2 -RRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 some_RE2 BIOGENERAL_RE2 
Hyoscyamine_ddi|P|antacid|levsin|BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY 
Ibandronate_ddi|P|aluminum|ibandronate|product_LE1 contain_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 multivalent_LE1 cation_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Ibandronate_ddi|P|calcium|ibandronate|product_LE1 contain_LE1 BIOENTITY and_BE12 other_BE12 multivalent_BE12 cation_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Ibandronate_ddi|P|iron|ibandronate|product_LE1 contain_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 multivalent_LE1 cation_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 be_BE12 likely_BE12 to_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Ibandronate_ddi|P|magnesium|ibandronate|product_LE1 contain_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 multivalent_LE1 cation_LE1 -LRB-_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 be_BE12 likely_BE12 to_BE12 interfere_BE12 with_BE12 absorption_BE12 of_BE12 BIOENTITY 
Ibandronate_ddi|P|ibandronate|antacid|BIOENTITY shall_BE12 be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 minute_BE12 before_BE12 any_BE12 oral_BE12 medication_BE12 contain_BE12 multivalent_BE12 cation_BE12 -LRB-_BE12 including_BE12 BIOENTITY supplement_RE2 or_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ibandronate_ddi|P|ibandronate|vitamin|BIOENTITY shall_BE12 be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 minute_BE12 before_BE12 any_BE12 oral_BE12 medication_BE12 contain_BE12 multivalent_BE12 cation_BE12 -LRB-_BE12 including_BE12 BIOGENERAL_BE12 supplement_BE12 or_BE12 BIOENTITY -rrb-._RE2 
Ibandronate_ddi|P|aspirin|ibandronate|however_LE1 since_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 all_LE1 associate_LE1 with_LE1 gastrointestinal_LE1 irritation_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 in_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY 
Ibandronate_ddi|P|nsaid|ibandronate|however_LE1 since_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 all_LE1 associate_LE1 with_LE1 gastrointestinal_LE1 irritation_LE1 caution_LE1 shall_LE1 be_LE1 exercise_LE1 in_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY with_BE12 BIOENTITY 
Ibuprofen_ddi|P|nonsteroidal anti-inflammatory agent|coumarin-type anticoagulant|however_LE1 because_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 on_BE12 BIOENTITY the_RE2 physician_RE2 shall_RE2 be_RE2 cautious_RE2 when_RE2 administer_RE2 BIOGENERAL_RE2 to_RE2 patient_RE2 on_RE2 BIOGENERAL_RE2 
Ibuprofen_ddi|P|ibuprofen|coumarin-type anticoagulant|however_LE1 because_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 on_BE12 BIOENTITY the_RE2 physician_RE2 shall_RE2 be_RE2 cautious_RE2 when_RE2 administer_RE2 BIOGENERAL_RE2 to_RE2 patient_RE2 on_RE2 BIOGENERAL_RE2 
Ibuprofen_ddi|P|ibuprofen|anticoagulant|however_LE1 because_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 administer_LE1 to_LE1 patient_LE1 on_LE1 BIOGENERAL_LE1 the_LE1 physician_LE1 shall_LE1 be_LE1 cautious_LE1 when_LE1 administer_LE1 BIOENTITY to_BE12 patient_BE12 on_BE12 BIOENTITY 
Ibuprofen_ddi|P|aspirin|ibuprofen|BIOGENERAL_LE1 :_LE1 animal_LE1 study_LE1 wshow_LE1 that_LE1 BIOENTITY give_BE12 with_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY yield_RE2 net_RE2 decrease_RE2 in_RE2 anti-inflammatory_RE2 activity_RE2 with_RE2 lowered_RE2 blood_RE2 level_RE2 of_RE2 the_RE2 non-aspirin_RE2 drug_RE2 
Ibuprofen_ddi|P|aspirin|nonsteroidal anti-inflammatory agent|BIOGENERAL_LE1 :_LE1 animal_LE1 study_LE1 wshow_LE1 that_LE1 BIOENTITY give_BE12 with_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 yield_RE2 net_RE2 decrease_RE2 in_RE2 anti-inflammatory_RE2 activity_RE2 with_RE2 lowered_RE2 blood_RE2 level_RE2 of_RE2 the_RE2 non-aspirin_RE2 drug_RE2 
Ibuprofen_ddi|P|ibuprofen|methotrexate|BIOGENERAL_LE1 :_LE1 BIOENTITY as_BE12 well_BE12 as_BE12 other_BE12 BIOGENERAL_BE12 probable_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY base_RE2 on_RE2 in_RE2 vitro_RE2 study_RE2 in_RE2 rabbit_RE2 kidney_RE2 slice_RE2 
Ibuprofen_ddi|P|nonsteroidal anti-inflammatory drug|methotrexate|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 as_LE1 well_LE1 as_LE1 other_LE1 BIOENTITY probable_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY base_RE2 on_RE2 in_RE2 vitro_RE2 study_RE2 in_RE2 rabbit_RE2 kidney_RE2 slice_RE2 
Ibuprofen_ddi|P|ibuprofen|methotrexate|this_LE1 may_LE1 indicate_LE1 that_LE1 BIOENTITY can_BE12 enhance_BE12 the_BE12 toxicity_BE12 of_BE12 BIOENTITY 
Ibuprofen_ddi|P|ibuprofen|methotrexate|caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Ibuprofen_ddi|P|ibuprofen|thiazide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 random_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Ibuprofen_ddi|P|ibuprofen|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 random_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Ibuprofen_ddi|P|ibuprofen|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY level_RE2 and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 in_RE2 study_RE2 of_RE2 eleven_RE2 normal_RE2 volunteer_RE2 
Ibuprofen_ddi|P|ibuprofen|lithium|thus_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concurrent_RE2 subject_RE2 shall_RE2 be_RE2 observe_RE2 careful_RE2 for_RE2 sign_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Icodextrin_ddi|P|extraneal|insulin|however_LE1 appropriate_LE1 monitoring_LE1 of_LE1 blood_LE1 glucose_LE1 shall_LE1 be_LE1 perform_LE1 when_LE1 initiate_LE1 BIOENTITY in_BE12 diabetic_BE12 patient_BE12 and_BE12 BIOENTITY dosage_RE2 shall_RE2 be_RE2 adjust_RE2 if_RE2 need_RE2 
Icosapent_ddi|P|epa|aspirin|interaction_LE1 may_LE1 occur_LE1 between_LE1 BIOENTITY supplement_BE12 and_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 and_RE2 herb_RE2 such_RE2 as_RE2 garlic_RE2 -LRB-_RE2 allium_RE2 sativum_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Icosapent_ddi|P|epa|ginkgo biloba|interaction_LE1 may_LE1 occur_LE1 between_LE1 BIOENTITY supplement_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 herb_BE12 such_BE12 as_BE12 garlic_BE12 -LRB-_BE12 allium_BE12 sativum_BE12 -RRB-_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -rrb-._RE2 
Icosapent_ddi|P|epa|ginkgo|interaction_LE1 may_LE1 occur_LE1 between_LE1 BIOENTITY supplement_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 and_BE12 herb_BE12 such_BE12 as_BE12 garlic_BE12 -LRB-_BE12 allium_BE12 sativum_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Icosapent_ddi|P|epa|non-steroidal anti-inflammatory drug|interaction_LE1 may_LE1 occur_LE1 between_LE1 BIOENTITY supplement_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY and_RE2 herb_RE2 such_RE2 as_RE2 garlic_RE2 -LRB-_RE2 allium_RE2 sativum_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Idoxuridine_ddi|P|idoxuridine|boric acid|when_LE1 you_LE1 be_LE1 use_LE1 BIOENTITY it_BE12 be_BE12 especial_BE12 important_BE12 that_BE12 your_BE12 health_BE12 care_BE12 professional_BE12 know_BE12 if_BE12 you_BE12 be_BE12 use_BE12 the_BE12 following_BE12 :_BE12 eye_BE12 product_BE12 contain_BE12 BIOENTITY 
Idoxuridine_ddi|P|boric acid|idoxuridine|BIOENTITY may_BE12 interact_BE12 with_BE12 the_BE12 BIOENTITY preparation_RE2 cause_RE2 gritty_RE2 substance_RE2 to_RE2 form_RE2 or_RE2 may_RE2 interact_RE2 with_RE2 the_RE2 preservative_RE2 in_RE2 the_RE2 BIOGENERAL_RE2 preparation_RE2 cause_RE2 toxic_RE2 effect_RE2 in_RE2 the_RE2 eye_RE2 
Iloprost_ddi|P|iloprost|antihypertensive agent|however_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 increase_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Iloprost_ddi|P|iloprost|vasodilator|however_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 to_BE12 increase_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Iloprost_ddi|P|iloprost|anticoagulant|since_LE1 BIOENTITY inhibit_BE12 platelet_BE12 function_BE12 there_BE12 be_BE12 potential_BE12 for_BE12 increase_BE12 risk_BE12 of_BE12 bleeding_BE12 particular_BE12 in_BE12 patient_BE12 maintain_BE12 on_BE12 BIOENTITY 
Imatinib_ddi|P|gleevec|erythromycin|drug_LE1 that_LE1 may_LE1 alter_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 :_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 inhibitor_BE12 of_BE12 the_BE12 cyp3a4_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Imatinib_ddi|P|gleevec|clarithromycin|drug_LE1 that_LE1 may_LE1 alter_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 :_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 inhibitor_BE12 of_BE12 the_BE12 cyp3a4_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
Imatinib_ddi|P|gleevec|itraconazole|drug_LE1 that_LE1 may_LE1 alter_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 :_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 inhibitor_BE12 of_BE12 the_BE12 cyp3a4_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Imatinib_ddi|P|gleevec|ketoconazole|drug_LE1 that_LE1 may_LE1 alter_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 drug_LE1 that_LE1 may_LE1 increase_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 :_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 inhibitor_BE12 of_BE12 the_BE12 cyp3a4_BE12 family_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Imatinib_ddi|P|gleevec|ketoconazole|there_LE1 be_LE1 significant_LE1 increase_LE1 in_LE1 exposure_LE1 to_LE1 BIOGENERAL_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY -LRB-_RE2 cyp3a4_RE2 inhibitor_RE2 -rrb-._RE2 
Imatinib_ddi|P|rifampin|gleevec|pretreatment_LE1 of_LE1 healthy_LE1 volunteer_LE1 with_LE1 multiple_LE1 dose_LE1 of_LE1 BIOENTITY followed_BE12 by_BE12 single_BE12 dose_BE12 of_BE12 BIOENTITY increase_RE2 BIOGENERAL_RE2 oral-dose_RE2 clearance_RE2 by_RE2 NUM_RE2 which_RE2 significant_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 decrease_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 NUM_RE2 
Imatinib_ddi|P|gleevec|simvastatin|drug_LE1 that_LE1 may_LE1 have_LE1 their_LE1 plasma_LE1 concentration_LE1 altered_LE1 by_LE1 BIOGENERAL_LE1 BIOENTITY increase_BE12 the_BE12 mean_BE12 cmax_BE12 and_BE12 auc_BE12 of_BE12 BIOENTITY -LRB-_RE2 cyp3a4_RE2 substrate_RE2 -RRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 suggest_RE2 inhibition_RE2 of_RE2 the_RE2 cyp3a4_RE2 by_RE2 BIOGENERAL_RE2 
Imatinib_ddi|P|gleevec|cyclosporine|particular_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 cyp3a4_BE12 substrate_BE12 that_BE12 have_BE12 narrow_BE12 therapeutic_BE12 window_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Imatinib_ddi|P|gleevec|pimozide|particular_LE1 caution_LE1 be_LE1 recommend_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 cyp3a4_BE12 substrate_BE12 that_BE12 have_BE12 narrow_BE12 therapeutic_BE12 window_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -rrb-._RE2 
Imatinib_ddi|P|gleevec|benzodiazepine|BIOENTITY will_BE12 increase_BE12 plasmaconcentration_BE12 of_BE12 other_BE12 cyp3a4_BE12 metabolized_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 certain_RE2 BIOGENERAL_RE2 etc_RE2 .-rrb-._RE2 
Imatinib_ddi|P|gleevec|dihydropyridine calcium channel blocker|BIOENTITY will_BE12 increase_BE12 plasmaconcentration_BE12 of_BE12 other_BE12 cyp3a4_BE12 metabolized_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY certain_RE2 BIOGENERAL_RE2 etc_RE2 .-rrb-._RE2 
Imatinib_ddi|P|gleevec|hmg-coa reductase inhibitor|BIOENTITY will_BE12 increase_BE12 plasmaconcentration_BE12 of_BE12 other_BE12 cyp3a4_BE12 metabolized_BE12 drug_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 certain_BE12 BIOENTITY etc_RE2 .-rrb-._RE2 
Imatinib_ddi|P|acetaminophen|gleevec|systemic_LE1 exposure_LE1 to_LE1 BIOENTITY be_BE12 expect_BE12 to_BE12 be_BE12 increase_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Imipramine_ddi|P|sympathomimetic amine|tricyclic antidepressant|avoid_LE1 the_LE1 use_LE1 of_LE1 preparation_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 local_LE1 BIOGENERAL_LE1 which_LE1 contain_LE1 any_LE1 BIOENTITY -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 since_BE12 it_BE12 have_BE12 be_BE12 report_BE12 that_BE12 BIOENTITY can_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 catecholamine_RE2 
Imipramine_ddi|P|anesthetic|tricyclic antidepressant|avoid_LE1 the_LE1 use_LE1 of_LE1 preparation_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 local_LE1 BIOENTITY which_BE12 contain_BE12 any_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 since_BE12 it_BE12 have_BE12 be_BE12 report_BE12 that_BE12 BIOENTITY can_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 catecholamine_RE2 
Imipramine_ddi|P|norepinephrine|tricyclic antidepressant|avoid_LE1 the_LE1 use_LE1 of_LE1 preparation_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 local_LE1 BIOGENERAL_LE1 which_LE1 contain_LE1 any_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 since_BE12 it_BE12 have_BE12 be_BE12 report_BE12 that_BE12 BIOENTITY can_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 catecholamine_RE2 
Imipramine_ddi|P|epinephrine|tricyclic antidepressant|avoid_LE1 the_LE1 use_LE1 of_LE1 preparation_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 local_LE1 BIOGENERAL_LE1 which_LE1 contain_LE1 any_LE1 BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 since_BE12 it_BE12 have_BE12 be_BE12 report_BE12 that_BE12 BIOENTITY can_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 catecholamine_RE2 
Imipramine_ddi|P|decongestant|tricyclic antidepressant|avoid_LE1 the_LE1 use_LE1 of_LE1 preparation_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 local_BE12 BIOGENERAL_BE12 which_BE12 contain_BE12 any_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 since_BE12 it_BE12 have_BE12 be_BE12 report_BE12 that_BE12 BIOENTITY can_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 catecholamine_RE2 
Imipramine_ddi|P|imipramine hydrochloride|cns depressant drug|BIOENTITY may_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Imipramine_ddi|P|imipramine|fluoxetine|the_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 give_BE12 concomitant_BE12 with_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 decrease_RE2 by_RE2 concomitant_RE2 administration_RE2 of_RE2 hepatic_RE2 enzyme_RE2 inducer_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 therefore_RE2 be_RE2 necessary_RE2 
Imipramine_ddi|P|imipramine|cimetidine|the_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 give_BE12 concomitant_BE12 with_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 decrease_RE2 by_RE2 concomitant_RE2 administration_RE2 of_RE2 hepatic_RE2 enzyme_RE2 inducer_RE2 -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 therefore_RE2 be_RE2 necessary_RE2 
Imipramine_ddi|P|imipramine|phenytoin|the_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 give_BE12 concomitant_BE12 with_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 therefore_RE2 be_RE2 necessary_RE2 
Imipramine_ddi|P|imipramine|barbiturate|the_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY may_BE12 increase_BE12 when_BE12 the_BE12 drug_BE12 be_BE12 give_BE12 concomitant_BE12 with_BE12 hepatic_BE12 enzyme_BE12 inhibitor_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 decrease_BE12 by_BE12 concomitant_BE12 administration_BE12 of_BE12 hepatic_BE12 enzyme_BE12 inducer_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 and_RE2 adjustment_RE2 of_RE2 the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 may_RE2 therefore_RE2 be_RE2 necessary_RE2 
Imipramine_ddi|P|ssri|tca|the_LE1 extent_LE1 to_LE1 which_LE1 BIOENTITY interaction_RE2 may_RE2 pose_RE2 clinical_RE2 problem_RE2 will_RE2 depend_RE2 on_RE2 the_RE2 degree_RE2 of_RE2 inhibition_RE2 and_RE2 the_RE2 pharmacokinetic_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 involve_RE2 
Indinavir_ddi|P|crixivan|atazanavir|combination_LE1 of_LE1 these_LE1 drug_LE1 have_LE1 not_LE1 be_LE1 study_LE1 and_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Indinavir_ddi|P|crixivan|delavirdine|dose_LE1 reduction_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 every_BE12 NUM_BE12 hour_BE12 shall_BE12 be_BE12 consider_BE12 when_BE12 take_BE12 BIOENTITY NUM_RE2 mg_RE2 three_RE2 time_RE2 day_RE2 
Indinavir_ddi|P|indinavir|didanosine|BIOENTITY and_BE12 BIOENTITY formulation_RE2 contain_RE2 buffer_RE2 shall_RE2 be_RE2 administer_RE2 at_RE2 little_RE2 one_RE2 hour_RE2 apart_RE2 on_RE2 empty_RE2 stomach_RE2 
Indinavir_ddi|P|indinavir|efavirenz|increase_LE1 the_LE1 BIOGENERAL_LE1 dose_LE1 to_LE1 NUM_LE1 mg_LE1 every_LE1 NUM_LE1 hour_LE1 do_LE1 not_LE1 compensate_LE1 for_LE1 the_LE1 increase_LE1 BIOENTITY metabolism_BE12 due_BE12 to_BE12 BIOENTITY 
Indinavir_ddi|P|indinavir|nevirapine|BIOENTITY concentration_BE12 may_BE12 be_BE12 decrease_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Indinavir_ddi|P|indinavir|ritonavir|preliminary_LE1 clinical_LE1 datum_LE1 suggest_LE1 that_LE1 the_LE1 incidence_LE1 of_LE1 nephrolithiasis_LE1 be_LE1 high_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY than_RE2 those_RE2 receive_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 q8h_RE2 
Indinavir_ddi|P|antiarrhythmic|crixivan|caution_LE1 be_LE1 warrant_LE1 and_LE1 therapeutic_LE1 concentration_LE1 monitoring_LE1 be_LE1 recommend_LE1 for_LE1 BIOENTITY when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Indinavir_ddi|P|crixivan|indinavir|BIOENTITY may_BE12 not_BE12 be_BE12 effective_BE12 due_BE12 to_BE12 decrease_BE12 BIOENTITY concentration_RE2 in_RE2 patient_RE2 take_RE2 these_RE2 agent_RE2 concomitant_RE2 
Indinavir_ddi|P|hmg-coa reductase inhibitor|crixivan|use_LE1 low_LE1 possible_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 careful_LE1 monitoring_LE1 or_LE1 consider_LE1 BIOENTITY that_BE12 be_BE12 not_BE12 primary_BE12 metabolize_BE12 by_BE12 cyp3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Indinavir_ddi|P|atorvastatin|crixivan|use_LE1 low_LE1 possible_LE1 dose_LE1 of_LE1 BIOENTITY with_BE12 careful_BE12 monitoring_BE12 or_BE12 consider_BE12 BIOGENERAL_BE12 that_BE12 be_BE12 not_BE12 primary_BE12 metabolize_BE12 by_BE12 cyp3a4_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Indinavir_ddi|P|crixivan|itraconazole|dose_LE1 reduction_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 every_BE12 NUM_BE12 hour_BE12 be_BE12 recommend_BE12 when_BE12 administer_BE12 BIOENTITY concurrent_RE2 
Indinavir_ddi|P|rifabutin|crixivan|dose_LE1 reduction_LE1 of_LE1 BIOGENERAL_LE1 to_LE1 half_LE1 the_LE1 standard_LE1 dose_LE1 and_LE1 dose_LE1 increase_LE1 of_LE1 BIOGENERAL_LE1 to_LE1 NUM_LE1 mg_LE1 -LRB-_LE1 three_LE1 NUM_LE1 capsule_LE1 -RRB-_LE1 every_LE1 NUM_LE1 hour_LE1 be_LE1 recommend_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Indinavir_ddi|P|sildenafil|indinavir|BIOENTITY dose_BE12 shall_BE12 not_BE12 exceed_BE12 maximum_BE12 of_BE12 NUM_BE12 mg_BE12 in_BE12 NUM_BE12 hour_BE12 period_BE12 in_BE12 patient_BE12 receive_BE12 concomitant_BE12 BIOENTITY therapy_RE2 
Indinavir_ddi|P|tadalafil|indinavir|BIOENTITY dose_BE12 shall_BE12 not_BE12 exceed_BE12 maximum_BE12 of_BE12 NUM_BE12 mg_BE12 in_BE12 NUM_BE12 hour_BE12 period_BE12 in_BE12 patient_BE12 receive_BE12 concomitant_BE12 BIOENTITY therapy_RE2 
Indinavir_ddi|P|vardenafil|indinavir|BIOENTITY dose_BE12 shall_BE12 not_BE12 exceed_BE12 maximum_BE12 of_BE12 NUM_BE12 mg_BE12 in_BE12 NUM_BE12 period_BE12 in_BE12 patient_BE12 receive_BE12 concomitant_BE12 BIOENTITY therapy_RE2 
Indomethacin_ddi|P|diflunisal|indomethacin|In_LE1 normal_LE1 volunteer_LE1 receive_LE1 BIOGENERAL_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY decrease_BE12 the_BE12 renal_BE12 clearance_BE12 and_BE12 significant_BE12 increase_BE12 the_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Indomethacin_ddi|P|indocin|diflunisal|In_LE1 some_LE1 patient_LE1 combined_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 fatal_RE2 gastrointestinal_RE2 hemorrhage_RE2 
Indomethacin_ddi|P|diflunisal|indocin|therefore_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 use_RE2 concomitant_RE2 
Indomethacin_ddi|P|aspirin|indomethacin|In_LE1 study_LE1 in_LE1 normal_LE1 volunteer_LE1 it_LE1 be_LE1 find_LE1 that_LE1 chronic_LE1 concurrent_LE1 administration_LE1 of_LE1 NUM_LE1 of_LE1 BIOENTITY per_BE12 day_BE12 decrease_BE12 BIOENTITY blood_RE2 level_RE2 approximate_RE2 NUM_RE2 %._RE2 
Indomethacin_ddi|P|indocin|nsaid|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 due_RE2 to_RE2 the_RE2 increase_RE2 possibility_RE2 of_RE2 gastrointestinal_RE2 toxicity_RE2 with_RE2 little_RE2 or_RE2 no_RE2 increase_RE2 in_RE2 efficacy_RE2 
Indomethacin_ddi|P|indocin|anticoagulant|however_LE1 when_LE1 any_LE1 additional_LE1 drug_LE1 including_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 the_BE12 treatment_BE12 of_BE12 patient_BE12 on_BE12 BIOENTITY therapy_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 for_RE2 alteration_RE2 of_RE2 the_RE2 prothrombin_RE2 time_RE2 
Indomethacin_ddi|P|anticoagulant|indocin|In_LE1 post-marketing_LE1 experience_LE1 bleeding_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 on_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY 
Indomethacin_ddi|P|indocin|anticoagulant|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Indomethacin_ddi|P|indocin|probenecid|when_LE1 BIOENTITY be_BE12 give_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY the_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 likely_RE2 to_RE2 be_RE2 increase_RE2 
Indomethacin_ddi|P|indocin|methotrexate|caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 simultaneous_BE12 with_BE12 BIOENTITY 
Indomethacin_ddi|P|indocin|methotrexate|BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 decrease_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY and_RE2 to_RE2 potentiate_RE2 its_RE2 toxicity_RE2 
Indomethacin_ddi|P|non-steroidal anti-inflammatory drug|cyclosporine|administration_LE1 of_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 toxicity_RE2 possible_RE2 due_RE2 to_RE2 decrease_RE2 synthesis_RE2 of_RE2 renal_RE2 prostacyclin_RE2 
Indomethacin_ddi|P|nsaid|cyclosporine|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY and_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 
Indomethacin_ddi|P|indocin|lithium|capsule_LE1 BIOENTITY NUM_BE12 mg_BE12 t.i.d._BE12 produce_BE12 clinical_BE12 relevant_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 in_RE2 psychiatric_RE2 patient_RE2 and_RE2 normal_RE2 subject_RE2 with_RE2 steady_RE2 state_RE2 plasma_RE2 BIOGENERAL_RE2 concentration_RE2 
Indomethacin_ddi|P|indocin|lithium|As_LE1 consequence_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 give_RE2 concomitant_RE2 the_RE2 patient_RE2 shall_RE2 be_RE2 careful_RE2 observe_RE2 for_RE2 sign_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Indomethacin_ddi|P|indocin|digoxin|BIOENTITY give_BE12 concomitant_BE12 with_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 increase_RE2 the_RE2 serum_RE2 concentration_RE2 and_RE2 prolong_RE2 the_RE2 half-life_RE2 of_RE2 BIOGENERAL_RE2 
Indomethacin_ddi|P|indocin|digoxin|therefore_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 concomitant_RE2 serum_RE2 BIOGENERAL_RE2 level_RE2 shall_RE2 be_RE2 close_RE2 monitor_RE2 
Indomethacin_ddi|P|indocin|loop diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Indomethacin_ddi|P|indocin|potassium-sparing diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Indomethacin_ddi|P|indocin|thiazide diuretic|In_LE1 some_LE1 patient_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 diuretic_BE12 natriuretic_BE12 and_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Indomethacin_ddi|P|triamterene|indocin|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 the_LE1 addition_LE1 of_LE1 BIOENTITY to_BE12 maintenance_BE12 schedule_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 reversible_RE2 acute_RE2 renal_RE2 failure_RE2 in_RE2 two_RE2 of_RE2 four_RE2 healthy_RE2 volunteer_RE2 
Indomethacin_ddi|P|indocin|triamterene|BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 administer_RE2 together_RE2 
Indomethacin_ddi|P|indocin|potassium-sparing diuretic|the_LE1 potential_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY on_RE2 potassium_RE2 kinetic_RE2 and_RE2 renal_RE2 function_RE2 shall_RE2 be_RE2 consider_RE2 when_RE2 these_RE2 agent_RE2 be_RE2 administer_RE2 concurrent_RE2 
Indomethacin_ddi|P|diuretic|indocin|many_LE1 of_LE1 the_LE1 above_LE1 effect_LE1 concern_LE1 BIOENTITY have_BE12 be_BE12 attribute_BE12 at_BE12 little_BE12 in_BE12 part_BE12 to_BE12 mechanism_BE12 involve_BE12 inhibition_BE12 of_BE12 prostaglandin_BE12 synthesis_BE12 by_BE12 BIOENTITY 
Indomethacin_ddi|P|beta-adrenoceptor blocking agent|non-steroidal antiinflammatory drug|blunting_LE1 of_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 have_RE2 be_RE2 report_RE2 
Indomethacin_ddi|P|beta-adrenoceptor blocking agent|indocin|blunting_LE1 of_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY by_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Indomethacin_ddi|P|indocin|captopril|BIOENTITY can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Indomethacin_ddi|P|indocin|losartan|BIOENTITY can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Infliximab_ddi|P|etanercept|anakinra|concurrent_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 another_BE12 tnf_BE12 -blocking_BE12 agent_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 increase_RE2 risk_RE2 of_RE2 serious_RE2 infection_RE2 and_RE2 increase_RE2 risk_RE2 of_RE2 neutropenia_RE2 and_RE2 no_RE2 additional_RE2 benefit_RE2 compare_RE2 to_RE2 these_RE2 medicinal_RE2 product_RE2 alone_RE2 
Infliximab_ddi|P|tnfa-blocking agent|anakinra|other_LE1 BIOENTITY -LRB-_BE12 include_BE12 BIOGENERAL_BE12 -RRB-_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 in_RE2 similar_RE2 toxicity_RE2 
Infliximab_ddi|P|remicade|anakinra|other_LE1 BIOGENERAL_LE1 -LRB-_LE1 include_LE1 BIOENTITY -RRB-_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY may_RE2 also_RE2 result_RE2 in_RE2 similar_RE2 toxicity_RE2 
Insulin Glargine recombinant_ddi|P|alcohol|insulin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 salt_LE1 and_LE1 BIOENTITY may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin Glargine recombinant_ddi|P|lithium|insulin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin Glargine recombinant_ddi|P|clonidine|insulin|BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin Glargine recombinant_ddi|P|beta-blocker|insulin|BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin recombinant_ddi|P|alcohol|insulin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 salt_LE1 and_LE1 BIOENTITY may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin recombinant_ddi|P|lithium|insulin|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin recombinant_ddi|P|clonidine|insulin|BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Insulin recombinant_ddi|P|beta-blocker|insulin|BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 salt_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 either_BE12 potentiate_BE12 or_BE12 weaken_BE12 the_BE12 blood-glucose-lowering_BE12 effect_BE12 of_BE12 BIOENTITY 
Interferon beta-1b_ddi|P|betaseron|antipyrine|BIOENTITY administration_BE12 to_BE12 three_BE12 cancer_BE12 patient_BE12 over_BE12 dose_BE12 range_BE12 of_BE12 NUM_BE12 mg_BE12 to_BE12 NUM_BE12 mg_BE12 lead_BE12 to_BE12 dose-dependent_BE12 inhibition_BE12 of_BE12 BIOENTITY NUM_RE2 the_RE2 effect_RE2 of_RE2 alternate-day_RE2 administration_RE2 of_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 on_RE2 drug_RE2 metabolism_RE2 in_RE2 ms_RE2 patient_RE2 be_RE2 unknown_RE2 
Ipratropium_ddi|P|ipratropium bromide|anticholinergic medication|BIOGENERAL_LE1 :_LE1 although_LE1 BIOENTITY be_BE12 minimal_BE12 absorb_BE12 into_BE12 the_BE12 systemic_BE12 circulation_BE12 there_BE12 be_BE12 some_BE12 potential_BE12 for_BE12 additive_BE12 interaction_BE12 with_BE12 concomitant_BE12 use_BE12 BIOENTITY 
Ipratropium_ddi|P|atrovent|anticholinergic|caution_LE1 be_LE1 therefore_LE1 advise_LE1 in_LE1 the_LE1 coadministration_LE1 of_LE1 BIOENTITY inhalation_BE12 aerosol_BE12 with_BE12 other_BE12 BIOENTITY drug_RE2 
Irinotecan_ddi|P|camptosar|antineoplastic agent|the_LE1 adverse_LE1 effect_LE1 of_LE1 BIOENTITY such_BE12 as_BE12 myelosuppression_BE12 and_BE12 diarrhea_BE12 will_BE12 be_BE12 expect_BE12 to_BE12 be_BE12 exacerbated_BE12 by_BE12 other_BE12 BIOENTITY have_RE2 similar_RE2 adverse_RE2 effect_RE2 
Irinotecan_ddi|P|camptosar|dexamethasone|lymphocytopenia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 it_BE12 be_BE12 possible_BE12 that_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY as_RE2 antiemetic_RE2 prophylaxis_RE2 may_RE2 have_RE2 enhance_RE2 the_RE2 likelihood_RE2 of_RE2 this_RE2 effect_RE2 
Irinotecan_ddi|P|prochlorperazine|camptosar|the_LE1 incidence_LE1 of_LE1 akathisia_LE1 in_LE1 clinical_LE1 trial_LE1 of_LE1 the_LE1 weekly_LE1 dosage_LE1 schedule_LE1 be_LE1 great_LE1 -LRB-_LE1 NUM_LE1 NUM_LE1 patient_LE1 -RRB-_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 on_BE12 the_BE12 same_BE12 day_BE12 as_BE12 BIOENTITY than_RE2 when_RE2 these_RE2 drug_RE2 be_RE2 give_RE2 on_RE2 separate_RE2 day_RE2 -LRB-_RE2 NUM_RE2 NUM_RE2 patient_RE2 -rrb-._RE2 
Irinotecan_ddi|P|laxative|camptosar|it_LE1 will_LE1 be_LE1 expect_LE1 that_LE1 BIOENTITY use_BE12 during_BE12 therapy_BE12 with_BE12 BIOENTITY will_RE2 worsen_RE2 the_RE2 incidence_RE2 or_RE2 severity_RE2 of_RE2 diarrhea_RE2 but_RE2 this_RE2 have_RE2 not_RE2 be_RE2 study_RE2 
Irinotecan_ddi|P|diuretic|camptosar|In_LE1 view_LE1 of_LE1 the_LE1 potential_LE1 risk_LE1 of_LE1 dehydration_LE1 secondary_LE1 to_LE1 vomiting_LE1 and_LE1 diarrhea_LE1 induce_LE1 by_LE1 BIOGENERAL_LE1 the_LE1 physician_LE1 may_LE1 wish_LE1 to_LE1 withhold_LE1 BIOENTITY during_BE12 dosing_BE12 with_BE12 BIOENTITY and_RE2 certain_RE2 during_RE2 period_RE2 of_RE2 active_RE2 vomiting_RE2 or_RE2 diarrhea_RE2 
Isocarboxazid_ddi|P|isocarboxazid|disulfiram|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY wyeth-ayerst_RE2 laboratory_RE2 -rrb-._RE2 
Isocarboxazid_ddi|P|isocarboxazid|antabuse|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 wyeth-ayerst_RE2 laboratory_RE2 -rrb-._RE2 
Isocarboxazid_ddi|P|mao inhibitor|disulfiram|In_LE1 single_LE1 study_LE1 rat_LE1 give_LE1 high_LE1 intraperitoneal_LE1 dose_LE1 of_LE1 BIOENTITY plus_BE12 BIOENTITY experience_RE2 severe_RE2 toxicity_RE2 including_RE2 convulsion_RE2 and_RE2 death_RE2 
Isocarboxazid_ddi|P|isocarboxazid|psychotropic agent|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOENTITY be_RE2 general_RE2 not_RE2 recommend_RE2 because_RE2 of_RE2 possible_RE2 potentiating_RE2 effect_RE2 
Isoflurane_ddi|P|isoflurane|muscle relaxant|BIOENTITY potentiate_BE12 the_BE12 muscle_BE12 relaxant_BE12 effect_BE12 of_BE12 all_BE12 BIOENTITY much_RE2 notable_RE2 BIOGENERAL_RE2 and_RE2 mac_RE2 -LRB-_RE2 minimum_RE2 alveolar_RE2 concentration_RE2 -RRB-_RE2 be_RE2 reduce_RE2 by_RE2 concomitant_RE2 administration_RE2 of_RE2 2o_RE2 
Isoflurane_ddi|P|isoflurane|nondepolarizing muscle relaxant|BIOENTITY potentiate_BE12 the_BE12 muscle_BE12 relaxant_BE12 effect_BE12 of_BE12 all_BE12 BIOGENERAL_BE12 much_BE12 notable_BE12 BIOENTITY and_RE2 mac_RE2 -LRB-_RE2 minimum_RE2 alveolar_RE2 concentration_RE2 -RRB-_RE2 be_RE2 reduce_RE2 by_RE2 concomitant_RE2 administration_RE2 of_RE2 2o_RE2 
Isoniazid_ddi|P|acetaminophen|isoniazid|BIOGENERAL_LE1 :_LE1 report_LE1 of_LE1 severe_LE1 BIOENTITY toxicity_BE12 be_BE12 report_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Isoniazid_ddi|P|isoniazid|acetaminophen|it_LE1 be_LE1 believe_LE1 that_LE1 the_LE1 toxicity_LE1 may_LE1 have_LE1 result_LE1 from_LE1 previous_LE1 unrecognized_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY and_RE2 molecular_RE2 basis_RE2 for_RE2 this_RE2 interaction_RE2 have_RE2 be_RE2 propose_RE2 
Isoniazid_ddi|P|isoniazid|acetaminophen|furthermore_LE1 it_LE1 have_LE1 be_LE1 propose_LE1 that_LE1 BIOENTITY result_BE12 In_BE12 induction_BE12 of_BE12 p-450iie1_BE12 in_BE12 the_BE12 patient_BE12 liver_BE12 which_BE12 in_BE12 turn_BE12 result_BE12 in_BE12 great_BE12 proportion_BE12 of_BE12 the_BE12 ingest_BE12 BIOENTITY be_RE2 convert_RE2 to_RE2 the_RE2 toxic_RE2 metabolite_RE2 
Isoniazid_ddi|P|isoniazid|carbamazepine|BIOGENERAL_LE1 :_LE1 BIOENTITY be_BE12 know_BE12 to_BE12 slow_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 increase_RE2 its_RE2 serum_RE2 level_RE2 BIOGENERAL_RE2 level_RE2 shall_RE2 be_RE2 determine_RE2 prior_RE2 to_RE2 concurrent_RE2 administration_RE2 with_RE2 BIOGENERAL_RE2 sign_RE2 and_RE2 symptom_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 shall_RE2 be_RE2 monitor_RE2 close_RE2 and_RE2 appropriate_RE2 dosage_RE2 adjustment_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 make_RE2 
Isoniazid_ddi|P|carbamazepine|isoniazid|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 be_LE1 know_LE1 to_LE1 slow_LE1 the_LE1 metabolism_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 increase_LE1 its_LE1 serum_LE1 level_LE1 BIOENTITY level_BE12 shall_BE12 be_BE12 determine_BE12 prior_BE12 to_BE12 concurrent_BE12 administration_BE12 with_BE12 BIOENTITY sign_RE2 and_RE2 symptom_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 shall_RE2 be_RE2 monitor_RE2 close_RE2 and_RE2 appropriate_RE2 dosage_RE2 adjustment_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 make_RE2 
Isoniazid_ddi|P|ketoconazole|isoniazid|BIOGENERAL_LE1 :_LE1 potential_LE1 interaction_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 exist_RE2 
Isoniazid_ddi|P|isoniazid|phenytoin|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 increase_BE12 serum_BE12 level_BE12 of_BE12 BIOENTITY 
Isoniazid_ddi|P|isoniazid|theophylline|therophylline_LE1 :_LE1 recent_LE1 study_LE1 have_LE1 show_LE1 that_LE1 concomitan_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 cause_RE2 elevated_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 in_RE2 some_RE2 instance_RE2 slight_RE2 decrease_RE2 in_RE2 the_RE2 elimination_RE2 of_RE2 BIOGENERAL_RE2 
Isoniazid_ddi|P|valproate|isoniazid|BIOGENERAL_LE1 :_LE1 recent_LE1 case_LE1 study_LE1 have_LE1 show_LE1 possible_LE1 increase_LE1 in_LE1 the_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY when_BE12 co_BE12 administer_BE12 with_BE12 BIOENTITY 
Isoniazid_ddi|P|isoniazid|valproate|plasma_LE1 BIOGENERAL_LE1 concentration_LE1 shall_LE1 be_LE1 monitor_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 co_RE2 administer_RE2 and_RE2 appropriate_RE2 dosage_RE2 adjustment_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 make_RE2 
Isoproterenol_ddi|P|isoproterenol hydrochloride|epinephrine|BIOENTITY injection_BE12 and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 administer_RE2 simultaneous_RE2 because_RE2 both_RE2 drug_RE2 be_RE2 direct_RE2 cardiac_RE2 stimulant_RE2 and_RE2 their_RE2 combined_RE2 effect_RE2 may_RE2 induce_RE2 serious_RE2 arrhythmia_RE2 
Isoproterenol_ddi|P|isuprel|halothane|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 if_BE12 at_BE12 all_BE12 when_BE12 potent_BE12 inhalational_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY be_RE2 employ_RE2 because_RE2 of_RE2 potential_RE2 to_RE2 sensitize_RE2 the_RE2 myocardium_RE2 to_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Isoproterenol_ddi|P|isuprel|anesthetic|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 if_BE12 at_BE12 all_BE12 when_BE12 potent_BE12 inhalational_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 be_RE2 employ_RE2 because_RE2 of_RE2 potential_RE2 to_RE2 sensitize_RE2 the_RE2 myocardium_RE2 to_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Isosorbide Dinitrate_ddi|P|isosorbide dinitrate|vasodilator|the_LE1 vasodilating_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 additive_BE12 with_BE12 those_BE12 of_BE12 other_BE12 BIOENTITY 
Isosorbide Mononitrate_ddi|P|isosorbide mononitrate|vasodilator|the_LE1 vasodilating_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 additive_BE12 with_BE12 those_BE12 of_BE12 other_BE12 BIOENTITY 
Isosorbide Mononitrate_ddi|P|calcium channel blocker|organic nitrate|marked_LE1 symptomatic_LE1 orthostatic_LE1 hypotension_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 in_RE2 combination_RE2 
Isotretinoin_ddi|P|accutane|vitamin a|BIOGENERAL_LE1 :_LE1 Because_LE1 of_LE1 the_LE1 relationship_LE1 of_LE1 BIOENTITY to_BE12 BIOENTITY patient_RE2 shall_RE2 be_RE2 advise_RE2 against_RE2 take_RE2 BIOGENERAL_RE2 contain_RE2 BIOGENERAL_RE2 to_RE2 avoid_RE2 additive_RE2 toxic_RE2 effect_RE2 
Isotretinoin_ddi|P|accutane|tetracycline|BIOGENERAL_LE1 :_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 avoid_LE1 because_LE1 BIOENTITY use_BE12 have_BE12 be_BE12 associate_BE12 with_BE12 number_BE12 of_BE12 case_BE12 of_BE12 pseudotumor_BE12 cerebri_BE12 -LRB-_BE12 benign_BE12 intracranial_BE12 hypertension_BE12 -RRB-_BE12 some_BE12 of_BE12 which_BE12 involve_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY 
Isotretinoin_ddi|P|accutane|tetracycline|BIOGENERAL_LE1 :_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY shall_RE2 be_RE2 avoid_RE2 because_RE2 BIOGENERAL_RE2 use_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 number_RE2 of_RE2 case_RE2 of_RE2 pseudotumor_RE2 cerebri_RE2 -LRB-_RE2 benign_RE2 intracranial_RE2 hypertension_RE2 -RRB-_RE2 some_RE2 of_RE2 which_RE2 involve_RE2 concomitant_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 
Isotretinoin_ddi|P|progesterone|accutane|micro-dosed_LE1 BIOGENERAL_LE1 preparation_LE1 :_LE1 micro-dosed_LE1 BIOENTITY preparation_BE12 -LRB-_BE12 minipill_BE12 that_BE12 do_BE12 not_BE12 contain_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 be_BE12 inadequate_BE12 method_BE12 of_BE12 contraception_BE12 during_BE12 BIOENTITY therapy_RE2 
Isradipine_ddi|P|cimetidine|isradipine|BIOGENERAL_LE1 :_LE1 In_LE1 study_LE1 in_LE1 healthy_LE1 volunteer_LE1 one-week_LE1 course_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 b.i.d._BE12 with_BE12 single_BE12 NUM_BE12 mg_BE12 dose_BE12 of_BE12 BIOENTITY on_RE2 the_RE2 sixth_RE2 day_RE2 show_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 mean_RE2 peak_RE2 plasma_RE2 concentration_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 significant_RE2 increase_RE2 in_RE2 area_RE2 under_RE2 the_RE2 curve_RE2 -LRB-_RE2 NUM_RE2 
Isradipine_ddi|P|isradipine|cimetidine|if_LE1 BIOENTITY therapy_BE12 be_BE12 initiate_BE12 in_BE12 patient_BE12 current_BE12 receive_BE12 BIOENTITY careful_RE2 monitoring_RE2 for_RE2 adverse_RE2 reaction_RE2 be_RE2 advised_RE2 and_RE2 downward_RE2 dose_RE2 adjustment_RE2 may_RE2 be_RE2 require_RE2 
Isradipine_ddi|P|rifampicin|isradipine|BIOGENERAL_LE1 :_LE1 In_LE1 study_LE1 in_LE1 healthy_LE1 volunteer_LE1 six-day_LE1 course_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 follow_BE12 by_BE12 single_BE12 NUM_BE12 mg_BE12 dose_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 level_RE2 to_RE2 below_RE2 detectable_RE2 limit_RE2 
Isradipine_ddi|P|rifampicin|isradipine|if_LE1 BIOENTITY therapy_BE12 be_BE12 require_BE12 BIOENTITY concentration_RE2 and_RE2 therapeutic_RE2 effect_RE2 be_RE2 likely_RE2 to_RE2 be_RE2 marked_RE2 reduce_RE2 or_RE2 abolish_RE2 as_RE2 consequence_RE2 of_RE2 increase_RE2 metabolism_RE2 and_RE2 high_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 
Isradipine_ddi|P|fentanyl|calcium channel blocker|BIOGENERAL_LE1 anesthesia_LE1 :_LE1 severe_LE1 hypotension_LE1 have_LE1 be_LE1 report_LE1 during_LE1 BIOENTITY anesthesia_BE12 with_BE12 concomitant_BE12 use_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Isradipine_ddi|P|fentanyl|beta blocker|BIOGENERAL_LE1 anesthesia_LE1 :_LE1 severe_LE1 hypotension_LE1 have_LE1 be_LE1 report_LE1 during_LE1 BIOENTITY anesthesia_BE12 with_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Itraconazole_ddi|P|terfenadine|itraconazole|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY have_RE2 lead_RE2 to_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 rare_RE2 instance_RE2 of_RE2 life-_RE2 threaten_RE2 cardiac_RE2 dysrhythmia_RE2 and_RE2 one_RE2 death_RE2 
Itraconazole_ddi|P|ketoconazole|astemizole|another_LE1 oral_LE1 BIOGENERAL_LE1 BIOENTITY inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 active_RE2 metabolite_RE2 BIOGENERAL_RE2 which_RE2 may_RE2 prolong_RE2 qt_RE2 interval_RE2 
Itraconazole_ddi|P|itraconazole|astemizole|in_LE1 vitro_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY when_BE12 compare_BE12 to_BE12 BIOGENERAL_BE12 have_BE12 little_BE12 pronounced_BE12 effect_BE12 on_BE12 the_BE12 biotransformation_BE12 system_BE12 responsible_BE12 for_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Itraconazole_ddi|P|astemizole|itraconazole|Based_LE1 on_LE1 the_LE1 chemical_LE1 resemblance_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Itraconazole_ddi|P|ketoconazole|cisapride|human_LE1 pharmacokinetic_LE1 datum_LE1 indicate_LE1 that_LE1 oral_LE1 BIOENTITY potent_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 eight-fold_RE2 increase_RE2 in_RE2 the_RE2 mean_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Itraconazole_ddi|P|ketoconazole|cisapride|datum_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Itraconazole_ddi|P|itraconazole|cisapride|in_LE1 vitro_LE1 datum_LE1 suggest_LE1 that_LE1 BIOENTITY also_BE12 marked_BE12 inhibit_BE12 the_BE12 biotransformation_BE12 system_BE12 main_BE12 responsible_BE12 for_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|cisapride|therefore_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Itraconazole_ddi|P|itraconazole|midazolam|coadministration_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 have_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 two_RE2 drug_RE2 
Itraconazole_ddi|P|itraconazole|triazolam|coadministration_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY have_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 two_RE2 drug_RE2 
Itraconazole_ddi|P|itraconazole|tacrolimu|coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 have_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 three_RE2 drug_RE2 
Itraconazole_ddi|P|itraconazole|digoxin|coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY have_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 three_RE2 drug_RE2 
Itraconazole_ddi|P|itraconazole|cyclosporine|coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 have_RE2 lead_RE2 to_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 three_RE2 drug_RE2 
Itraconazole_ddi|P|cyclosporine|itraconazole|BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 concentration_BE12 shall_BE12 be_BE12 monitor_BE12 at_BE12 the_BE12 initiation_BE12 of_BE12 BIOENTITY therapy_RE2 and_RE2 frequent_RE2 thereafter_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 these_RE2 three_RE2 drug_RE2 product_RE2 adjust_RE2 appropriate_RE2 
Itraconazole_ddi|P|tacrolimu|itraconazole|BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 concentration_BE12 shall_BE12 be_BE12 monitor_BE12 at_BE12 the_BE12 initiation_BE12 of_BE12 BIOENTITY therapy_RE2 and_RE2 frequent_RE2 thereafter_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 these_RE2 three_RE2 drug_RE2 product_RE2 adjust_RE2 appropriate_RE2 
Itraconazole_ddi|P|digoxin|itraconazole|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY concentration_BE12 shall_BE12 be_BE12 monitor_BE12 at_BE12 the_BE12 initiation_BE12 of_BE12 BIOENTITY therapy_RE2 and_RE2 frequent_RE2 thereafter_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 these_RE2 three_RE2 drug_RE2 product_RE2 adjust_RE2 appropriate_RE2 
Itraconazole_ddi|P|hmg-coa reductase inhibitor|immunosuppressive drug|rhabdomyolysis_LE1 have_LE1 be_LE1 observe_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY administer_BE12 alone_BE12 -LRB-_BE12 at_BE12 recommend_BE12 dosage_BE12 -RRB-_BE12 or_BE12 concomitant_BE12 with_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 
Itraconazole_ddi|P|hmg-coa reductase inhibitor|cyclosporine|rhabdomyolysis_LE1 have_LE1 be_LE1 observe_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY administer_BE12 alone_BE12 -LRB-_BE12 at_BE12 recommend_BE12 dosage_BE12 -RRB-_BE12 or_BE12 concomitant_BE12 with_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|rifampin|when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 h2antagonists_RE2 reduce_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 report_RE2 
Itraconazole_ddi|P|itraconazole|phenytoin|when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 h2antagonists_RE2 reduce_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 report_RE2 
Itraconazole_ddi|P|itraconazole|phenytoin|although_LE1 no_LE1 study_LE1 have_LE1 be_LE1 conduct_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 alter_RE2 the_RE2 metabolism_RE2 of_RE2 BIOGENERAL_RE2 
Itraconazole_ddi|P|phenytoin|itraconazole|therefore_LE1 plasma_LE1 concentration_LE1 of_LE1 BIOENTITY shall_BE12 also_BE12 be_BE12 monitor_BE12 when_BE12 it_BE12 be_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|coumarin|it_LE1 have_LE1 be_LE1 report_LE1 that_LE1 BIOENTITY enhance_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOENTITY drug_RE2 
Itraconazole_ddi|P|itraconazole|coumarin|therefore_LE1 prothrombin_LE1 time_LE1 shall_LE1 be_LE1 careful_LE1 monitor_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY drug_RE2 simultaneous_RE2 
Itraconazole_ddi|P|azole antifungal agent|isoniazid|plasma_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 when_BE12 give_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|isoniazid|BIOGENERAL_LE1 plasma_LE1 concentration_LE1 shall_LE1 be_LE1 monitor_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Itraconazole_ddi|P|azole antifungal agent|hypoglycemic agent|severe_LE1 hypoglycemia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 concomitant_LE1 receive_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|hypoglycemic agent|blood_LE1 glucose_LE1 concentration_LE1 shall_LE1 be_LE1 careful_LE1 monitor_LE1 when_LE1 BIOENTITY and_BE12 oral_BE12 BIOENTITY be_RE2 coadminister_RE2 
Itraconazole_ddi|P|itraconazole|quinidine|tinnitus_LE1 and_LE1 decrease_LE1 hearing_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 concomitant_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY 
Itraconazole_ddi|P|itraconazole|dihydropyridine calcium channel blocker|edema_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 concomitant_LE1 receive_LE1 BIOENTITY and_BE12 BIOENTITY 
Kanamycin_ddi|P|aminoglycoside|penicillin|in_LE1 vitro_LE1 mixing_LE1 of_LE1 BIOENTITY with_BE12 beta-lactamtype_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 significant_RE2 mutual_RE2 inactivation_RE2 
Kanamycin_ddi|P|aminoglycoside|cephalosporin|in_LE1 vitro_LE1 mixing_LE1 of_LE1 BIOENTITY with_BE12 beta-lactamtype_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 may_RE2 result_RE2 in_RE2 significant_RE2 mutual_RE2 inactivation_RE2 
Kanamycin_ddi|P|aminoglycoside|antibiotic|in_LE1 vitro_LE1 mixing_LE1 of_LE1 BIOENTITY with_BE12 beta-lactamtype_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 significant_RE2 mutual_RE2 inactivation_RE2 
Kanamycin_ddi|P|aminoglycoside|penicillin|even_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY drug_RE2 be_RE2 administer_RE2 separate_RE2 by_RE2 different_RE2 route_RE2 reduction_RE2 in_RE2 BIOGENERAL_RE2 serum_RE2 half-life_RE2 or_RE2 serum_RE2 level_RE2 have_RE2 be_RE2 report_RE2 in_RE2 patient_RE2 with_RE2 impaired_RE2 renal_RE2 function_RE2 and_RE2 in_RE2 some_RE2 patient_RE2 with_RE2 normal_RE2 renal_RE2 function_RE2 
Ketamine_ddi|P|barbiturate|ketamine|prolonged_LE1 recovery_LE1 time_LE1 may_LE1 occur_LE1 if_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Ketamine_ddi|P|narcotic|ketamine|prolonged_LE1 recovery_LE1 time_LE1 may_LE1 occur_LE1 if_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY be_BE12 use_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Ketoconazole_ddi|P|ketoconazole|terfenadine|the_LE1 following_LE1 drug_LE1 interaction_LE1 have_LE1 be_LE1 identify_LE1 involve_LE1 BIOGENERAL_LE1 tablet_LE1 and_LE1 other_LE1 drug_LE1 metabolize_LE1 by_LE1 the_LE1 cytochrome_LE1 p450_LE1 3a4_LE1 enzyme_LE1 system_LE1 :_LE1 BIOENTITY tablet_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 increase_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 delay_RE2 in_RE2 the_RE2 elimination_RE2 of_RE2 its_RE2 acid_RE2 metabolite_RE2 
Ketoconazole_ddi|P|ketoconazole|astemizole|pharmacokinetic_LE1 datum_LE1 indicate_LE1 that_LE1 oral_LE1 BIOENTITY inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 elevated_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 active_RE2 metabolite_RE2 BIOGENERAL_RE2 which_RE2 may_RE2 prolong_RE2 qt_RE2 interval_RE2 
Ketoconazole_ddi|P|astemizole|ketoconazole|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY tablet_RE2 be_RE2 therefore_RE2 contraindicate_RE2 
Ketoconazole_ddi|P|ketoconazole|cisapride|human_LE1 pharmacokinetic_LE1 datum_LE1 indicate_LE1 that_LE1 oral_LE1 BIOENTITY potent_BE12 inhibit_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 mean_RE2 eight-fold_RE2 increase_RE2 in_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
Ketoconazole_ddi|P|ketoconazole|cisapride|datum_LE1 suggest_LE1 that_LE1 coadministration_LE1 of_LE1 oral_LE1 BIOENTITY and_BE12 BIOENTITY can_RE2 result_RE2 in_RE2 prolongation_RE2 of_RE2 the_RE2 qt_RE2 interval_RE2 on_RE2 the_RE2 ecg_RE2 
Ketoconazole_ddi|P|ketoconazole|cisapride|therefore_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY tablet_BE12 with_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Ketoconazole_ddi|P|ketoconazole|cyclosporine|BIOENTITY tablet_BE12 may_BE12 alter_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 drug_RE2 
Ketoconazole_ddi|P|ketoconazole|methylprednisolone|BIOENTITY tablet_BE12 may_BE12 alter_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 drug_RE2 
Ketoconazole_ddi|P|ketoconazole|tacrolimu|BIOENTITY tablet_BE12 may_BE12 alter_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 drug_RE2 
Ketoconazole_ddi|P|nizoral|midazolam|coadministration_LE1 of_LE1 BIOENTITY tablet_BE12 with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 have_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 two_RE2 drug_RE2 
Ketoconazole_ddi|P|nizoral|triazolam|coadministration_LE1 of_LE1 BIOENTITY tablet_BE12 with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY have_RE2 result_RE2 in_RE2 elevated_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 latter_RE2 two_RE2 drug_RE2 
Ketoconazole_ddi|P|digoxin|ketoconazole|it_LE1 be_LE1 therefore_LE1 advisable_LE1 to_LE1 monitor_LE1 BIOENTITY concentration_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Ketoconazole_ddi|P|ketoconazole|coumarin|when_LE1 take_LE1 oral_LE1 BIOGENERAL_LE1 like_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOENTITY drug_RE2 
Ketoconazole_ddi|P|imidazole compound|coumarin|when_LE1 take_LE1 oral_LE1 BIOENTITY like_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 anticoagulant_BE12 effect_BE12 of_BE12 BIOENTITY drug_RE2 
Ketoconazole_ddi|P|imidazole drug|coumarin drug|In_LE1 simultaneous_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY the_RE2 anticoagulant_RE2 effect_RE2 shall_RE2 be_RE2 careful_RE2 titrate_RE2 and_RE2 monitor_RE2 
Ketoconazole_ddi|P|miconazole|hypoglycemic agent|because_LE1 severe_LE1 hypoglycemia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 concomitant_LE1 receive_LE1 oral_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 oral_BE12 BIOENTITY such_RE2 potential_RE2 interaction_RE2 involve_RE2 the_RE2 latter_RE2 agent_RE2 when_RE2 use_RE2 concomitant_RE2 with_RE2 BIOGENERAL_RE2 tablet_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 can_RE2 not_RE2 be_RE2 rule_RE2 out_RE2 
Ketoconazole_ddi|P|ketoconazole|phenytoin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY tablet_BE12 with_BE12 BIOENTITY may_RE2 alter_RE2 the_RE2 metabolism_RE2 of_RE2 one_RE2 or_RE2 both_RE2 of_RE2 the_RE2 drug_RE2 
Ketoconazole_ddi|P|ketoconazole|phenytoin|it_LE1 be_LE1 suggest_LE1 to_LE1 monitor_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY 
Ketoconazole_ddi|P|rifampin|ketoconazole|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY tablet_RE2 reduce_RE2 the_RE2 blood_RE2 level_RE2 of_RE2 the_RE2 latter_RE2 
Ketoconazole_ddi|P|isoniazid|ketoconazole|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 be_BE12 also_BE12 report_BE12 to_BE12 affect_BE12 BIOENTITY concentration_RE2 adverse_RE2 
Ketoconazole_ddi|P|inh|ketoconazole|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 be_BE12 also_BE12 report_BE12 to_BE12 affect_BE12 BIOENTITY concentration_RE2 adverse_RE2 
Ketoconazole_ddi|P|ketoconazole|loratadine|After_LE1 the_LE1 coadministration_LE1 of_LE1 NUM_LE1 mg_LE1 oral_LE1 BIOENTITY twice_BE12 daily_BE12 and_BE12 one_BE12 NUM_BE12 mg_BE12 dose_BE12 of_BE12 BIOENTITY to_RE2 NUM_RE2 subject_RE2 the_RE2 auc_RE2 and_RE2 cmax_RE2 of_RE2 BIOGENERAL_RE2 average_RE2 NUM_RE2 -LRB-_RE2 NUM_RE2 s.d._RE2 -RRB-_RE2 and_RE2 NUM_RE2 -LRB-_RE2 NUM_RE2 s.d._RE2 -RRB-_RE2 respective_RE2 of_RE2 those_RE2 obtain_RE2 after_RE2 co-treatment_RE2 with_RE2 placebo_RE2 
Ketoprofen_ddi|P|aspirin|ketoprofen|however_LE1 in_LE1 study_LE1 of_LE1 NUM_LE1 normal_LE1 subject_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY decrease_BE12 BIOENTITY protein_RE2 binding_RE2 and_RE2 increase_RE2 BIOGENERAL_RE2 plasma_RE2 clearance_RE2 from_RE2 NUM_RE2 without_RE2 BIOGENERAL_RE2 to_RE2 NUM_RE2 with_RE2 BIOGENERAL_RE2 
Ketoprofen_ddi|P|aspirin|ketoprofen|however_LE1 in_LE1 study_LE1 of_LE1 NUM_LE1 normal_LE1 subject_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY decrease_BE12 BIOGENERAL_BE12 protein_BE12 binding_BE12 and_BE12 increase_BE12 BIOENTITY plasma_RE2 clearance_RE2 from_RE2 NUM_RE2 without_RE2 BIOGENERAL_RE2 to_RE2 NUM_RE2 with_RE2 BIOGENERAL_RE2 
Ketoprofen_ddi|P|aspirin|ketoprofen|therefore_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Ketoprofen_ddi|P|hydrochlorothiazide|ketoprofen|BIOGENERAL_LE1 :_LE1 BIOENTITY give_BE12 concomitant_BE12 with_BE12 BIOENTITY produce_RE2 reduction_RE2 in_RE2 urinary_RE2 potassium_RE2 and_RE2 chloride_RE2 excretion_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 alone_RE2 
Ketoprofen_ddi|P|ketoprofen|warfarin|because_LE1 prostaglandinum_LE1 play_LE1 important_LE1 role_LE1 in_LE1 hemostasis_LE1 and_LE1 BIOGENERAL_LE1 have_LE1 effect_LE1 on_LE1 platelet_LE1 function_LE1 as_LE1 well_LE1 concurent_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY require_RE2 close_RE2 monitoring_RE2 of_RE2 patient_RE2 on_RE2 both_RE2 drug_RE2 
Ketoprofen_ddi|P|probenecid|ketoprofen|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 both_BE12 free_BE12 and_BE12 bind_BE12 BIOENTITY by_RE2 reduce_RE2 the_RE2 plasma_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 to_RE2 about_RE2 one-third_RE2 as_RE2 well_RE2 as_RE2 decrease_RE2 its_RE2 protein_RE2 binding_RE2 
Ketoprofen_ddi|P|ketoprofen|probenecid|therefore_LE1 the_LE1 combination_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Ketoprofen_ddi|P|ketoprofen|methotrexate|BIOGENERAL_LE1 :_LE1 BIOENTITY like_BE12 other_BE12 BIOGENERAL_BE12 may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 elevated_RE2 serum_RE2 level_RE2 of_RE2 the_RE2 drug_RE2 and_RE2 increase_RE2 toxicity_RE2 
Ketoprofen_ddi|P|nsaid|methotrexate|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 like_LE1 other_LE1 BIOENTITY may_BE12 cause_BE12 change_BE12 in_BE12 the_BE12 elimination_BE12 of_BE12 BIOENTITY lead_RE2 to_RE2 elevated_RE2 serum_RE2 level_RE2 of_RE2 the_RE2 drug_RE2 and_RE2 increase_RE2 toxicity_RE2 
Ketoprofen_ddi|P|nonsteroidal anti-inflammatory agent|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 increase_BE12 steadystate_BE12 plasma_BE12 BIOENTITY level_RE2 
Ketoprofen_ddi|P|ketoprofen|lithium|it_LE1 be_LE1 recommend_LE1 that_LE1 plasma_LE1 BIOGENERAL_LE1 level_LE1 be_LE1 monitor_LE1 when_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Ketorolac_ddi|P|warfarin|ketorolac tromethamine|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 the_LE1 in_LE1 vitro_LE1 binding_LE1 of_LE1 BIOENTITY to_BE12 plasma_BE12 protein_BE12 be_BE12 only_BE12 slight_BE12 reduce_BE12 by_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 control_RE2 vs_RE2 NUM_RE2 -RRB-_RE2 when_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 reach_RE2 NUM_RE2 to10_RE2 
Ketorolac_ddi|P|salicylate|ketorolac|in_LE1 vitro_LE1 study_LE1 indicate_LE1 that_LE1 at_LE1 therapeutic_LE1 concentration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 -RRB-_BE12 the_BE12 binding_BE12 of_BE12 BIOENTITY be_RE2 reduce_RE2 from_RE2 approximate_RE2 NUM_RE2 to_RE2 NUM_RE2 represent_RE2 potential_RE2 twofold_RE2 increase_RE2 in_RE2 unbound_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 
Ketorolac_ddi|P|toradol|anticoagulant|although_LE1 these_LE1 result_LE1 do_LE1 not_LE1 indicate_LE1 significant_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 the_LE1 administration_LE1 of_LE1 BIOENTITY to_BE12 patient_BE12 take_BE12 BIOENTITY shall_RE2 be_RE2 do_RE2 extreme_RE2 cautious_RE2 and_RE2 patient_RE2 shall_RE2 be_RE2 close_RE2 monitor_RE2 
Ketorolac_ddi|P|toradol|furosemide|BIOGENERAL_LE1 :_LE1 BIOENTITY iv_BE12 reduce_BE12 the_BE12 BIOGENERAL_BE12 response_BE12 to_BE12 BIOENTITY in_RE2 normovolemic_RE2 healthy_RE2 subject_RE2 by_RE2 approximate_RE2 NUM_RE2 -LRB-_RE2 mean_RE2 sodium_RE2 and_RE2 urinary_RE2 output_RE2 decrease_RE2 NUM_RE2 %-rrb-._RE2 
Ketorolac_ddi|P|toradol|probenecid|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY oral_BE12 and_BE12 BIOENTITY result_RE2 in_RE2 decrease_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 significant_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 -LRB-_RE2 total_RE2 auc_RE2 increase_RE2 approximate_RE2 threefold_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 -RRB-_RE2 and_RE2 terminal_RE2 half-life_RE2 increase_RE2 approximate_RE2 twofold_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 hour_RE2 
Ketorolac_ddi|P|toradol|probenecid|therefore_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Ketorolac_ddi|P|lithium|toradol|the_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 on_LE1 plasma_LE1 BIOGENERAL_LE1 have_LE1 not_LE1 be_LE1 study_LE1 but_LE1 case_LE1 of_LE1 increase_LE1 BIOENTITY plasma_BE12 level_BE12 during_BE12 BIOENTITY therapy_RE2 have_RE2 be_RE2 report_RE2 
Ketorolac_ddi|P|methotrexate|nsaid|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 some_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 to_RE2 reduce_RE2 the_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 enhance_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Ketorolac_ddi|P|toradol|antiepileptic drug|BIOGENERAL_LE1 :_LE1 sporadic_LE1 case_LE1 of_LE1 seizure_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ketorolac_ddi|P|toradol|phenytoin|BIOGENERAL_LE1 :_LE1 sporadic_LE1 case_LE1 of_LE1 seizure_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Ketorolac_ddi|P|toradol|carbamazepine|BIOGENERAL_LE1 :_LE1 sporadic_LE1 case_LE1 of_LE1 seizure_LE1 have_LE1 be_LE1 report_LE1 during_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
Ketorolac_ddi|P|toradol|psychoactive drug|BIOGENERAL_LE1 :_LE1 hallucination_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ketorolac_ddi|P|toradol|fluoxetine|BIOGENERAL_LE1 :_LE1 hallucination_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 patient_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Ketorolac_ddi|P|toradol|thiothixene|BIOGENERAL_LE1 :_LE1 hallucination_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 patient_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -rrb-._RE2 
Ketorolac_ddi|P|toradol|alprazolam|BIOGENERAL_LE1 :_LE1 hallucination_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 in_BE12 patient_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -rrb-._RE2 
L-Arginine_ddi|P|l-arginine|cyclosporin|BIOGENERAL_LE1 BIOENTITY may_BE12 counteract_BE12 the_BE12 antinaturetic_BE12 effect_BE12 of_BE12 BIOENTITY 
L-Arginine_ddi|P|l-arginine|ibuprofen|BIOGENERAL_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY if_RE2 take_RE2 concomitant_RE2 
L-Arginine_ddi|P|l-arginine|nitrate|organic_LE1 BIOGENERAL_LE1 BIOENTITY supplement_BE12 theoretical_BE12 may_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 organic_BE12 BIOENTITY if_RE2 take_RE2 concomitant_RE2 
L-Arginine_ddi|P|l-arginine|sildenafil citrate|BIOGENERAL_LE1 theoretical_LE1 BIOENTITY supplement_BE12 take_BE12 concomitant_BE12 with_BE12 BIOENTITY may_RE2 potentiate_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 drug_RE2 
L-Glutamine_ddi|P|l-glutamine|human growth hormone|BIOGENERAL_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 enhance_RE2 nutrient_RE2 absorption_RE2 in_RE2 those_RE2 with_RE2 severe_RE2 short_RE2 bowel_RE2 syndrome_RE2 
L-Glutamine_ddi|P|l-glutamine|indomethacin|BIOGENERAL_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 ameliorate_RE2 increase_RE2 intestinal_RE2 permeability_RE2 cause_RE2 by_RE2 BIOGENERAL_RE2 
L-Glutamine_ddi|P|methotrexate|l-glutamine|BIOGENERAL_LE1 there_LE1 be_LE1 one_LE1 report_LE1 that_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 possible_BE12 effectiveness_BE12 of_BE12 supplemental_BE12 BIOENTITY for_RE2 chemotherapy-induced_RE2 mucositis_RE2 
L-Glutamine_ddi|P|methotrexate|l-glutamine|In_LE1 another_LE1 report_LE1 nine_LE1 patient_LE1 with_LE1 breast_LE1 cancer_LE1 be_LE1 report_LE1 to_LE1 have_LE1 decrease_LE1 symptom_LE1 of_LE1 BIOENTITY toxicity_BE12 when_BE12 give_BE12 supplemental_BE12 BIOENTITY at_RE2 dose_RE2 of_RE2 NUM_RE2 gram_RE2 
L-Glutamine_ddi|P|l-glutamine|paclitaxel|BIOGENERAL_LE1 In_LE1 one_LE1 report_LE1 BIOENTITY at_BE12 dose_BE12 of_BE12 NUM_BE12 gram_BE12 three_BE12 time_BE12 daily_BE12 give_BE12 NUM_BE12 hour_BE12 after_BE12 receive_BE12 BIOENTITY appear_RE2 to_RE2 prevent_RE2 the_RE2 development_RE2 of_RE2 myalgia_RE2 and_RE2 arthralgia_RE2 adverse_RE2 reaction_RE2 of_RE2 BIOGENERAL_RE2 
L-Histidine_ddi|P|l-histidine|medroxyprogesterone acetate|BIOGENERAL_LE1 BIOENTITY be_BE12 observe_BE12 to_BE12 enhance_BE12 -LRB-_BE12 in_BE12 tissue_BE12 culture_BE12 -RRB-_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY in_RE2 reduce_RE2 the_RE2 number_RE2 of_RE2 human_RE2 breast_RE2 cancer_RE2 cell_RE2 that_RE2 be_RE2 in_RE2 the_RE2 phase_RE2 
L-Histidine_ddi|P|l-histidine|h1 blocker|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 although_LE1 not_LE1 report_LE1 BIOENTITY via_BE12 its_BE12 metabolism_BE12 to_BE12 histamine_BE12 may_BE12 decrease_BE12 the_BE12 efficacy_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
L-Histidine_ddi|P|l-histidine|h2 blocker|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 although_LE1 not_LE1 report_LE1 BIOENTITY via_BE12 its_BE12 metabolism_BE12 to_BE12 histamine_BE12 may_BE12 decrease_BE12 the_BE12 efficacy_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
L-Lysine_ddi|P|calcium|l-lysine|concomitant_LE1 use_LE1 of_LE1 BIOENTITY supplement_BE12 and_BE12 BIOENTITY may_RE2 increase_RE2 BIOGENERAL_RE2 absorption_RE2 
L-Methionine_ddi|P|l-methionine|acetaminophen|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 decrease_BE12 hepatic_BE12 toxicity_BE12 in_BE12 those_BE12 with_BE12 BIOENTITY overdosage_RE2 or_RE2 in_RE2 those_RE2 take_RE2 BIOGENERAL_RE2 
L-Methionine_ddi|P|l-methionine|methotrexate|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 decrease_BE12 hepatic_BE12 toxicity_BE12 in_BE12 those_BE12 with_BE12 BIOGENERAL_BE12 overdosage_BE12 or_BE12 in_BE12 those_BE12 take_BE12 BIOENTITY 
L-Methionine_ddi|P|methionine|gentamicin|BIOGENERAL_LE1 BIOENTITY may_BE12 protect_BE12 against_BE12 the_BE12 ototoxic_BE12 effect_BE12 of_BE12 BIOENTITY 
L-Phenylalanine_ddi|P|l-phenylalanine|non-selective mao inhibitor|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 cause_RE2 hypertension_RE2 
L-Phenylalanine_ddi|P|l-phenylalanine|selegiline|BIOGENERAL_LE1 BIOENTITY and_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY may_RE2 have_RE2 synergistic_RE2 antidepressant_RE2 activity_RE2 if_RE2 use_RE2 concomitant_RE2 
L-Phenylalanine_ddi|P|neuroleptic drug|l-phenylalanine|BIOENTITY BIOENTITY may_RE2 potentiate_RE2 the_RE2 tardive_RE2 dyskinesia_RE2 side_RE2 reaction_RE2 of_RE2 BIOGENERAL_RE2 if_RE2 use_RE2 concomitant_RE2 with_RE2 they_RE2 
L-Tyrosine_ddi|P|l-tyrosine|mao inhibitor|BIOGENERAL_LE1 including_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 hc1_LE1 :_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 non-selective_BE12 BIOENTITY may_RE2 cause_RE2 hypertension_RE2 
Labetalol_ddi|P|labetalol hcl|tricyclic antidepressant|In_LE1 one_LE1 survey_LE1 NUM_LE1 of_LE1 patient_LE1 take_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY experience_RE2 tremor_RE2 as_RE2 compare_RE2 to_RE2 NUM_RE2 report_RE2 to_RE2 occur_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Labetalol_ddi|P|cimetidine|labetalol hcl|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 increase_BE12 the_BE12 bioavailability_BE12 of_BE12 BIOENTITY 
Labetalol_ddi|P|halothane|labetalol hcl|synergism_LE1 have_LE1 be_LE1 show_LE1 between_LE1 BIOENTITY anesthesia_BE12 and_BE12 intravenous_BE12 administer_BE12 BIOENTITY 
Labetalol_ddi|P|labetalol hcl|halothane|During_LE1 controlled_LE1 hypotensive_LE1 anesthesia_LE1 use_LE1 BIOENTITY in_BE12 association_BE12 with_BE12 BIOENTITY high_RE2 concentration_RE2 -LRB-_RE2 NUM_RE2 or_RE2 above_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 not_RE2 be_RE2 use_RE2 because_RE2 the_RE2 degree_RE2 of_RE2 hypotension_RE2 will_RE2 be_RE2 increase_RE2 and_RE2 because_RE2 of_RE2 the_RE2 possibility_RE2 of_RE2 large_RE2 reduction_RE2 in_RE2 cardiac_RE2 output_RE2 and_RE2 increase_RE2 in_RE2 central_RE2 venous_RE2 pressure_RE2 
Labetalol_ddi|P|labetalol hcl|nitroglycerin|BIOENTITY blunt_BE12 the_BE12 reflex_BE12 tachycardia_BE12 produce_BE12 by_BE12 BIOENTITY without_RE2 prevent_RE2 its_RE2 hypotensive_RE2 effect_RE2 
Labetalol_ddi|P|labetalol hcl|nitroglycerin|if_LE1 BIOENTITY be_BE12 use_BE12 with_BE12 BIOENTITY in_RE2 patient_RE2 with_RE2 angina_RE2 pectoris_RE2 additional_RE2 antihypertensive_RE2 effect_RE2 may_RE2 occur_RE2 
Labetalol_ddi|P|labetalol|calcium antagonist|care_LE1 shall_LE1 be_LE1 take_LE1 if_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 BIOENTITY of_RE2 the_RE2 BIOGENERAL_RE2 type_RE2 
Lactulose_ddi|P|antacid|lactulose|result_LE1 of_LE1 preliminary_LE1 study_LE1 in_LE1 human_LE1 and_LE1 rat_LE1 suggest_LE1 that_LE1 nonabsorbable_LE1 BIOENTITY give_BE12 concurrent_BE12 with_BE12 BIOENTITY may_RE2 inhibit_RE2 the_RE2 desired_RE2 BIOGENERAL_RE2 drop_RE2 in_RE2 colonic_RE2 ph_RE2 
Lamivudine_ddi|P|lamivudine|zalcitabine|BIOENTITY and_BE12 BIOENTITY may_RE2 inhibit_RE2 the_RE2 intracellular_RE2 phosphorylation_RE2 of_RE2 one_RE2 another_RE2 
Lamivudine_ddi|P|lamivudine|zalcitabine|therefore_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 combination_BE12 with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Lansoprazole_ddi|P|lansoprazole|theophylline|when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY -LRB-_RE2 cyp1a2_RE2 cyp3a_RE2 -RRB-_RE2 minor_RE2 increase_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 in_RE2 the_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 see_RE2 
Lansoprazole_ddi|P|theophylline|lansoprazole|nonetheless_LE1 individual_LE1 patient_LE1 may_LE1 require_LE1 additional_LE1 titration_LE1 of_LE1 their_LE1 BIOENTITY dosage_BE12 when_BE12 BIOENTITY be_RE2 start_RE2 or_RE2 stop_RE2 to_RE2 ensure_RE2 clinical_RE2 effective_RE2 blood_RE2 level_RE2 
Lansoprazole_ddi|P|proton pump inhibitor|sucralfate|In_LE1 single-dose_LE1 crossover_LE1 study_LE1 examine_LE1 BIOGENERAL_LE1 NUM_LE1 mg_LE1 and_LE1 BIOGENERAL_LE1 NUM_LE1 mg_LE1 each_LE1 administer_LE1 alone_LE1 and_LE1 concomitant_LE1 with_LE1 BIOGENERAL_LE1 NUM_LE1 gram_LE1 absorption_LE1 of_LE1 the_LE1 BIOENTITY be_BE12 delay_BE12 and_BE12 their_BE12 bioavailability_BE12 be_BE12 reduce_BE12 by_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Lansoprazole_ddi|P|proton pump inhibitor|sucralfate|therefore_LE1 BIOENTITY shall_BE12 be_BE12 take_BE12 at_BE12 little_BE12 NUM_BE12 minute_BE12 prior_BE12 to_BE12 BIOENTITY 
Lansoprazole_ddi|P|lansoprazole|digoxin|therefore_LE1 it_LE1 be_LE1 theoretical_LE1 possible_LE1 that_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 ester_BE12 BIOGENERAL_BE12 salt_BE12 BIOENTITY -rrb-._RE2 
Lansoprazole_ddi|P|lansoprazole|iron|therefore_LE1 it_LE1 be_LE1 theoretical_LE1 possible_LE1 that_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 ester_BE12 BIOENTITY salt_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Lansoprazole_ddi|P|lansoprazole|ampicillin|therefore_LE1 it_LE1 be_LE1 theoretical_LE1 possible_LE1 that_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY ester_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Lansoprazole_ddi|P|lansoprazole|ketoconazole|therefore_LE1 it_LE1 be_LE1 theoretical_LE1 possible_LE1 that_LE1 BIOENTITY may_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 drug_BE12 where_BE12 gastric_BE12 ph_BE12 be_BE12 important_BE12 determinant_BE12 of_BE12 bioavailability_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 ester_RE2 BIOGENERAL_RE2 salt_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Lapatinib_ddi|P|ketoconazole|lapatinib|BIOGENERAL_LE1 :_LE1 In_LE1 healthy_LE1 subject_LE1 receive_LE1 BIOENTITY cyp3a4_BE12 inhibitor_BE12 at_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 systemic_BE12 exposure_BE12 -LRB-_BE12 auc_BE12 -RRB-_BE12 to_BE12 BIOENTITY be_RE2 increase_RE2 to_RE2 approximate_RE2 NUM_RE2 of_RE2 control_RE2 and_RE2 half-life_RE2 increase_RE2 to_RE2 NUM_RE2 of_RE2 control_RE2 
Lapatinib_ddi|P|carbamazepine|lapatinib|BIOGENERAL_LE1 :_LE1 In_LE1 healthy_LE1 subject_LE1 receive_LE1 the_LE1 cyp3a4_LE1 inducer_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 and_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 systemic_BE12 exposure_BE12 -LRB-_BE12 auc_BE12 -RRB-_BE12 to_BE12 BIOENTITY be_RE2 decrease_RE2 approximate_RE2 NUM_RE2 %._RE2 
Leflunomide_ddi|P|cholestyramine|leflunomide|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 in_BE12 patient_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 volunteer_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 result_BE12 in_BE12 rapid_BE12 and_BE12 significant_BE12 decrease_BE12 in_BE12 plasma_BE12 m1_BE12 -LRB-_BE12 the_BE12 active_BE12 metabolite_BE12 of_BE12 BIOENTITY -RRB-_RE2 concentration_RE2 
Leflunomide_ddi|P|activated charcoal|leflunomide|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY in_BE12 patient_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 and_BE12 volunteer_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 result_BE12 in_BE12 rapid_BE12 and_BE12 significant_BE12 decrease_BE12 in_BE12 plasma_BE12 m1_BE12 -LRB-_BE12 the_BE12 active_BE12 metabolite_BE12 of_BE12 BIOENTITY -RRB-_RE2 concentration_RE2 
Leflunomide_ddi|P|arava|methotrexate|In_LE1 small_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 combination_LE1 study_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY NUM_RE2 to_RE2 NUM_RE2 elevation_RE2 in_RE2 liver_RE2 enzyme_RE2 be_RE2 see_RE2 in_RE2 NUM_RE2 of_RE2 NUM_RE2 patient_RE2 
Leflunomide_ddi|P|arava|rifampin|BIOGENERAL_LE1 :_LE1 Following_LE1 concomitant_LE1 administration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY to_BE12 subject_BE12 receive_BE12 multiple_BE12 dose_BE12 of_BE12 BIOENTITY m1_RE2 peak_RE2 level_RE2 be_RE2 increase_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 over_RE2 those_RE2 see_RE2 when_RE2 BIOGENERAL_RE2 be_RE2 give_RE2 alone_RE2 
Leflunomide_ddi|P|arava|rifampin|Because_LE1 of_LE1 the_LE1 potential_LE1 for_LE1 BIOGENERAL_LE1 level_LE1 to_LE1 continue_LE1 to_LE1 increase_LE1 with_LE1 multiple_LE1 dosing_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 patient_LE1 be_LE1 to_LE1 be_LE1 receive_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY 
Leflunomide_ddi|P|arava|warfarin|BIOGENERAL_LE1 :_LE1 increase_LE1 inr_LE1 -LRB-_LE1 international_LE1 normalize_LE1 ratio_LE1 -RRB-_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 co-administer_RE2 have_RE2 be_RE2 rare_RE2 report_RE2 
Letrozole_ddi|P|femara|tamoxifen|-LRB-_LE1 see_LE1 clinical_LE1 pharmacology_LE1 -RRB-_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY NUM_RE2 mg_RE2 daily_RE2 result_RE2 in_RE2 reduction_RE2 of_RE2 BIOGENERAL_RE2 plasma_RE2 level_RE2 by_RE2 NUM_RE2 on_RE2 average_RE2 
Leucovorin_ddi|P|folic acid|primidone|BIOENTITY in_BE12 large_BE12 amount_BE12 may_BE12 counteract_BE12 the_BE12 antiepileptic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 increase_RE2 the_RE2 frequency_RE2 of_RE2 seizure_RE2 in_RE2 susceptible_RE2 pediatric_RE2 patient_RE2 
Leucovorin_ddi|P|folic acid|phenytoin|BIOENTITY in_BE12 large_BE12 amount_BE12 may_BE12 counteract_BE12 the_BE12 antiepileptic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 the_RE2 frequency_RE2 of_RE2 seizure_RE2 in_RE2 susceptible_RE2 pediatric_RE2 patient_RE2 
Leucovorin_ddi|P|folic acid|phenobarbital|BIOENTITY in_BE12 large_BE12 amount_BE12 may_BE12 counteract_BE12 the_BE12 antiepileptic_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 increase_RE2 the_RE2 frequency_RE2 of_RE2 seizure_RE2 in_RE2 susceptible_RE2 pediatric_RE2 patient_RE2 
Leucovorin_ddi|P|leucovorin|methotrexate|however_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 efficacy_BE12 of_BE12 intrathecal_BE12 administer_BE12 BIOENTITY 
Leucovorin_ddi|P|leucovorin|5-fluorouracil|BIOENTITY may_BE12 enhance_BE12 the_BE12 toxicity_BE12 of_BE12 BIOENTITY 
Levamisole_ddi|P|ergamisol|alcohol|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 have_BE12 be_BE12 report_BE12 to_BE12 produce_BE12 antabuse-like_BE12 side_BE12 effect_BE12 when_BE12 give_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Levamisole_ddi|P|levamisole hydrochloride|alcohol|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 have_BE12 be_BE12 report_BE12 to_BE12 produce_BE12 antabuse-like_BE12 side_BE12 effect_BE12 when_BE12 give_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Levamisole_ddi|P|levamisole|warfarin sodium|Because_LE1 of_LE1 report_LE1 of_LE1 prolongation_LE1 of_LE1 the_LE1 prothrombin_LE1 time_LE1 beyond_LE1 the_LE1 therapeutic_LE1 range_LE1 in_LE1 patient_LE1 take_LE1 concurrent_LE1 BIOENTITY and_BE12 BIOENTITY it_RE2 be_RE2 suggest_RE2 that_RE2 the_RE2 prothrombin_RE2 time_RE2 be_RE2 monitor_RE2 careful_RE2 and_RE2 the_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 or_RE2 other_RE2 BIOGENERAL_RE2 drug_RE2 shall_RE2 be_RE2 adjust_RE2 according_RE2 in_RE2 patient_RE2 take_RE2 both_RE2 drug_RE2 
Levetiracetam_ddi|P|levetiracetam|aed|effect_LE1 of_LE1 BIOGENERAL_LE1 in_LE1 pediatric_LE1 patient_LE1 there_LE1 be_LE1 about_LE1 NUM_LE1 increase_LE1 of_LE1 apparent_LE1 total_LE1 body_LE1 clearance_LE1 of_LE1 BIOENTITY when_BE12 it_BE12 be_BE12 co-administer_BE12 with_BE12 enzyme-inducing_BE12 BIOENTITY 
Levobunolol_ddi|P|betagan|epinephrine|although_LE1 BIOGENERAL_LE1 use_LE1 alone_LE1 have_LE1 little_LE1 or_LE1 no_LE1 effect_LE1 on_LE1 pupil_LE1 size_LE1 mydriasi_LE1 result_LE1 from_LE1 concomitant_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 occur_RE2 
Levobunolol_ddi|P|beta-blocker|reserpine|close_LE1 observation_LE1 of_LE1 the_LE1 patient_LE1 be_LE1 recommend_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 to_BE12 patient_BE12 receive_BE12 catecholamine-depleting_BE12 drug_BE12 such_BE12 as_BE12 BIOENTITY because_RE2 of_RE2 possible_RE2 additive_RE2 effect_RE2 and_RE2 the_RE2 production_RE2 of_RE2 hypotension_RE2 and_RE2 marked_RE2 bradycardia_RE2 which_RE2 may_RE2 produce_RE2 vertigo_RE2 syncope_RE2 or_RE2 postural_RE2 hypotension_RE2 
Levobunolol_ddi|P|beta-adrenergic blocking agent|calcium antagonist|patient_LE1 receive_LE1 BIOENTITY along_BE12 with_BE12 either_BE12 oral_BE12 or_BE12 intravenous_BE12 BIOENTITY shall_RE2 be_RE2 monitor_RE2 for_RE2 possible_RE2 atrioventricular_RE2 conduction_RE2 disturbance_RE2 left_RE2 ventricular_RE2 failure_RE2 and_RE2 hypotension_RE2 
Levobunolol_ddi|P|beta-adrenergic blocking agent|calcium antagonist|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY may_RE2 have_RE2 additive_RE2 effect_RE2 on_RE2 prolong_RE2 atrioventricular_RE2 conduction_RE2 time_RE2 
Levobunolol_ddi|P|beta-adrenergic blocking agent|digitali|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 may_RE2 have_RE2 additive_RE2 effect_RE2 on_RE2 prolong_RE2 atrioventricular_RE2 conduction_RE2 time_RE2 
Levobunolol_ddi|P|phenothiazine-related compound|beta-adrenergic blocking agent|BIOENTITY and_BE12 BIOENTITY may_RE2 have_RE2 additive_RE2 hypotensite_RE2 effect_RE2 due_RE2 to_RE2 the_RE2 inhibition_RE2 of_RE2 each_RE2 other_RE2 metabolism_RE2 
Levobupivacaine_ddi|P|chirocaine|anesthetic|BIOENTITY shall_BE12 be_BE12 use_BE12 with_BE12 caution_BE12 in_BE12 patient_BE12 receive_BE12 other_BE12 local_BE12 BIOENTITY or_RE2 agent_RE2 structural_RE2 related_RE2 to_RE2 amide-type_RE2 local_RE2 anesthetic_RE2 since_RE2 the_RE2 toxic_RE2 effect_RE2 of_RE2 these_RE2 drug_RE2 can_RE2 be_RE2 additive_RE2 
Levobupivacaine_ddi|P|levobupivacaine|phenytoin|although_LE1 no_LE1 clinical_LE1 study_LE1 have_LE1 be_LE1 conduct_LE1 it_LE1 be_LE1 likely_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 known_BE12 cyp3a4_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 -RRB-_RE2 cyp3a4_RE2 inhibitor_RE2 -LRB-_RE2 azole_RE2 antimycotic_RE2 e.g._RE2 BIOGENERAL_RE2 
Levobupivacaine_ddi|P|levobupivacaine|ketoconazole|although_LE1 no_LE1 clinical_LE1 study_LE1 have_LE1 be_LE1 conduct_LE1 it_LE1 be_LE1 likely_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 known_BE12 cyp3a4_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 cyp3a4_BE12 inhibitor_BE12 -LRB-_BE12 azole_BE12 antimycotic_BE12 e.g._BE12 BIOENTITY 
Levobupivacaine_ddi|P|levobupivacaine|phenobarbital|although_LE1 no_LE1 clinical_LE1 study_LE1 have_LE1 be_LE1 conduct_LE1 it_LE1 be_LE1 likely_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 known_BE12 cyp3a4_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 -RRB-_RE2 cyp3a4_RE2 inhibitor_RE2 -LRB-_RE2 azole_RE2 antimycotic_RE2 e.g._RE2 BIOGENERAL_RE2 
Levobupivacaine_ddi|P|levobupivacaine|rifampin|although_LE1 no_LE1 clinical_LE1 study_LE1 have_LE1 be_LE1 conduct_LE1 it_LE1 be_LE1 likely_LE1 that_LE1 the_LE1 metabolism_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 known_BE12 cyp3a4_BE12 inducer_BE12 -LRB-_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY -RRB-_RE2 cyp3a4_RE2 inhibitor_RE2 -LRB-_RE2 azole_RE2 antimycotic_RE2 e.g._RE2 BIOGENERAL_RE2 
Levofloxacin_ddi|P|quinolone|cyclosporine|however_LE1 the_LE1 systemic_LE1 administration_LE1 of_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 elevate_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 its_BE12 derivative_BE12 and_BE12 have_BE12 be_BE12 associate_BE12 with_BE12 transient_BE12 elevation_BE12 in_BE12 serum_BE12 creatinine_BE12 in_BE12 patient_BE12 receive_BE12 systemic_BE12 BIOENTITY concomitant_RE2 
Levofloxacin_ddi|P|quinolone|warfarin|however_LE1 the_LE1 systemic_LE1 administration_LE1 of_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 elevate_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 its_RE2 derivative_RE2 and_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 transient_RE2 elevation_RE2 in_RE2 serum_RE2 creatinine_RE2 in_RE2 patient_RE2 receive_RE2 systemic_RE2 BIOGENERAL_RE2 concomitant_RE2 
Levofloxacin_ddi|P|quinolone|caffeine|however_LE1 the_LE1 systemic_LE1 administration_LE1 of_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 elevate_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOGENERAL_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY and_RE2 enhance_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 derivative_RE2 and_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 transient_RE2 elevation_RE2 in_RE2 serum_RE2 creatinine_RE2 in_RE2 patient_RE2 receive_RE2 systemic_RE2 BIOGENERAL_RE2 concomitant_RE2 
Levofloxacin_ddi|P|quinolone|theophylline|however_LE1 the_LE1 systemic_LE1 administration_LE1 of_LE1 some_LE1 BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 elevate_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY interfere_RE2 with_RE2 the_RE2 metabolism_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 enhance_RE2 the_RE2 effect_RE2 of_RE2 the_RE2 oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 its_RE2 derivative_RE2 and_RE2 have_RE2 be_RE2 associate_RE2 with_RE2 transient_RE2 elevation_RE2 in_RE2 serum_RE2 creatinine_RE2 in_RE2 patient_RE2 receive_RE2 systemic_RE2 BIOGENERAL_RE2 concomitant_RE2 
Levorphanol_ddi|P|levo-dromoran|phenothiazine|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|tricyclic antidepressant|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|antihistamine|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|skeletal muscle relaxant|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|tranquilizer|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|opioid|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOENTITY general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|hypnotic|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY other_RE2 BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|barbiturate|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|anesthetic|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 other_BE12 BIOGENERAL_BE12 general_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|central nervous system depressant|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|alcohol|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|sedative|interaction_LE1 with_LE1 other_LE1 cns_LE1 agent_LE1 :_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 all_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 other_RE2 BIOGENERAL_RE2 general_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 result_RE2 in_RE2 additive_RE2 central_RE2 nervous_RE2 system_RE2 depressant_RE2 effect_RE2 
Levorphanol_ddi|P|levo-dromoran|mao inhibitor|although_LE1 no_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY have_BE12 be_BE12 observe_BE12 it_BE12 be_BE12 not_BE12 recommend_BE12 for_BE12 use_BE12 with_BE12 BIOENTITY 
Levorphanol_ddi|P|agonist/antagonist analgesic|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|pure agonist opioid analgesic|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 -RRB-_LE1 shall_LE1 not_LE1 be_LE1 administer_LE1 to_LE1 patient_LE1 who_LE1 have_LE1 receive_LE1 or_LE1 be_LE1 receive_LE1 course_LE1 of_LE1 therapy_LE1 with_LE1 BIOENTITY such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|buprenorphine|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|nalbuphine|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|pentazocine|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|dezocine|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levorphanol_ddi|P|butorphanol|levo-dromoran|interaction_LE1 with_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 to_BE12 patient_BE12 who_BE12 have_BE12 receive_BE12 or_BE12 be_BE12 receive_BE12 course_BE12 of_BE12 therapy_BE12 with_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY 
Levothyroxine_ddi|P|levothyroxine sodium|sucralfate|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 resin_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 soybean_BE12 flour_BE12 -LRB-_BE12 e.g._BE12 infant_BE12 formula_BE12 -RRB-_BE12 BIOENTITY 
Levothyroxine_ddi|P|levothyroxine sodium|sodium polystyrene sulfonate|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 resin_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY soybean_RE2 flour_RE2 -LRB-_RE2 e.g._RE2 infant_RE2 formula_RE2 -RRB-_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|ferrous sulfate|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 resin_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 soybean_RE2 flour_RE2 -LRB-_RE2 e.g._RE2 infant_RE2 formula_RE2 -RRB-_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|colestipol hydrochloride|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 resin_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 soybean_RE2 flour_RE2 -LRB-_RE2 e.g._RE2 infant_RE2 formula_RE2 -RRB-_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|cholestyramine|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY resin_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 soybean_RE2 flour_RE2 -LRB-_RE2 e.g._RE2 infant_RE2 formula_RE2 -RRB-_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|aluminum hydoxide|BIOGENERAL_LE1 absorption_LE1 :_LE1 the_LE1 following_LE1 agent_LE1 may_LE1 bind_LE1 and_LE1 decrease_LE1 absorption_LE1 of_LE1 BIOENTITY from_BE12 the_BE12 gastrointestinal_BE12 tract_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 resin_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 soybean_RE2 flour_RE2 -LRB-_RE2 e.g._RE2 infant_RE2 formula_RE2 -RRB-_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|perphenazine|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|methadone|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|mefenamic acid|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|estrogen-containing compound|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|estrogen|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|clofibrate|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|asparaginase|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|tamoxifen|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY 
Levothyroxine_ddi|P|levothyroxine sodium|anabolic hormone|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|salicylate|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|androgen|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOENTITY and_RE2 related_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|phenytoin|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|phenylbutazone|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|glucocorticoid|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|meclofenamic acid|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|5-fluorouracil|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|furosemide|bind_LE1 to_LE1 serum_LE1 protein_LE1 :_LE1 the_LE1 follow_LE1 agent_LE1 may_LE1 either_LE1 inhibit_LE1 BIOENTITY binding_BE12 to_BE12 serum_BE12 protein_BE12 or_BE12 alter_BE12 the_BE12 concentration_BE12 of_BE12 serum_BE12 binding_BE12 protein_BE12 :_BE12 BIOGENERAL_BE12 and_BE12 related_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Levothyroxine_ddi|P|levothyroxine sodium|ketamine|BIOGENERAL_LE1 :_LE1 marked_LE1 hypertension_LE1 and_LE1 tachycardia_LE1 have_LE1 be_LE1 report_LE1 in_LE1 association_LE1 with_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Lidocaine_ddi|P|norepinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Lidocaine_ddi|P|norepinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Lidocaine_ddi|P|epinephrine|monoamine oxidase inhibitor|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Lidocaine_ddi|P|epinephrine|tricyclic antidepressant|the_LE1 administration_LE1 of_LE1 local_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 to_BE12 patient_BE12 receive_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY may_RE2 produce_RE2 severe_RE2 prolonged_RE2 hypertension_RE2 
Lidocaine_ddi|P|butyrophenone|epinephrine|BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 reduce_BE12 or_BE12 reverse_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY 
Lidocaine_ddi|P|phenothiazine|epinephrine|BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 or_BE12 reverse_BE12 the_BE12 pressor_BE12 effect_BE12 of_BE12 BIOENTITY 
Lincomycin_ddi|P|lincomycin|neuromuscular blocking agent|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 neuromuscular_BE12 blocking_BE12 property_BE12 that_BE12 may_BE12 enhance_BE12 the_BE12 action_BE12 of_BE12 other_BE12 BIOENTITY 
Lincomycin_ddi|P|lincomycin|erythromycin|antagonism_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 vitro_RE2 have_RE2 be_RE2 demonstrate_RE2 
Linezolid_ddi|P|linezolid|serotonergic agent|therefore_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Linezolid_ddi|P|linezolid|adrenergic|therefore_LE1 BIOENTITY have_BE12 the_BE12 potential_BE12 for_BE12 interaction_BE12 with_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Linezolid_ddi|P|zyvox|sympathomimetic agent|BIOGENERAL_LE1 :_LE1 some_LE1 individual_LE1 receive_LE1 BIOENTITY may_BE12 experience_BE12 reversible_BE12 enhancement_BE12 of_BE12 the_BE12 pressor_BE12 response_BE12 to_BE12 indirect-acting_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Linezolid_ddi|P|zyvox|vasopressor|BIOGENERAL_LE1 :_LE1 some_LE1 individual_LE1 receive_LE1 BIOENTITY may_BE12 experience_BE12 reversible_BE12 enhancement_BE12 of_BE12 the_BE12 pressor_BE12 response_BE12 to_BE12 indirect-acting_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Linezolid_ddi|P|zyvox|dopaminergic agent|BIOGENERAL_LE1 :_LE1 some_LE1 individual_LE1 receive_LE1 BIOENTITY may_BE12 experience_BE12 reversible_BE12 enhancement_BE12 of_BE12 the_BE12 pressor_BE12 response_BE12 to_BE12 indirect-acting_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Linezolid_ddi|P|zyvox|ssri|spontaneous_LE1 report_LE1 of_LE1 serotonin_LE1 syndrome_LE1 associate_LE1 with_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 have_RE2 be_RE2 report_RE2 
Linezolid_ddi|P|zyvox|selective serotonin reuptake inhibitor|spontaneous_LE1 report_LE1 of_LE1 serotonin_LE1 syndrome_LE1 associate_LE1 with_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 report_RE2 
Linezolid_ddi|P|zyvox|antidepressant|spontaneous_LE1 report_LE1 of_LE1 serotonin_LE1 syndrome_LE1 associate_LE1 with_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 report_RE2 
Linezolid_ddi|P|zyvox|serotonergic agent|spontaneous_LE1 report_LE1 of_LE1 serotonin_LE1 syndrome_LE1 associate_LE1 with_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 such_RE2 as_RE2 BIOGENERAL_RE2 -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 be_RE2 report_RE2 
Linezolid_ddi|P|zyvox|serotonergic agent|patient_LE1 who_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 concomitant_BE12 BIOENTITY shall_RE2 be_RE2 close_RE2 observe_RE2 for_RE2 sign_RE2 and_RE2 symptom_RE2 of_RE2 serotonin_RE2 syndrome_RE2 -LRB-_RE2 e.g._RE2 cognitive_RE2 dysfunction_RE2 hyperpyrexia_RE2 hyperreflexia_RE2 incoordination_RE2 -rrb-._RE2 
Linezolid_ddi|P|zyvox|serotonergic agent|if_LE1 any_LE1 sign_LE1 or_LE1 symptom_LE1 occur_LE1 physician_LE1 shall_LE1 consider_LE1 discontinuation_LE1 of_LE1 either_LE1 one_LE1 or_LE1 both_LE1 agent_LE1 -LRB-_LE1 BIOENTITY or_BE12 concomitant_BE12 BIOENTITY -rrb-._RE2 
Liothyronine_ddi|P|anticoagulant|thyroid|patient_LE1 stabilise_LE1 on_LE1 oral_LE1 BIOENTITY who_BE12 be_BE12 find_BE12 to_BE12 require_BE12 BIOENTITY replacement_RE2 therapy_RE2 shall_RE2 be_RE2 watch_RE2 very_RE2 close_RE2 when_RE2 thyroid_RE2 be_RE2 start_RE2 
Liothyronine_ddi|P|cholestyramine|t4|BIOGENERAL_LE1 :_LE1 BIOENTITY bind_BE12 both_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 intestine_RE2 thus_RE2 impair_RE2 absorption_RE2 of_RE2 these_RE2 BIOGENERAL_RE2 
Liothyronine_ddi|P|cholestyramine|t3|BIOGENERAL_LE1 :_LE1 BIOENTITY bind_BE12 both_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 the_RE2 intestine_RE2 thus_RE2 impair_RE2 absorption_RE2 of_RE2 these_RE2 BIOGENERAL_RE2 
Liothyronine_ddi|P|cholestyramine|thyroid hormone|therefore_LE1 NUM_LE1 to_LE1 NUM_LE1 hour_LE1 shall_LE1 elapse_LE1 between_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Liothyronine_ddi|P|levothyroxine|estrogen|In_LE1 patient_LE1 with_LE1 nonfunctioning_LE1 thyroid_LE1 gland_LE1 who_LE1 be_LE1 receive_LE1 thyroid_LE1 replacement_LE1 therapy_LE1 free_LE1 BIOENTITY may_BE12 be_BE12 decrease_BE12 when_BE12 BIOENTITY be_RE2 start_RE2 thus_RE2 increase_RE2 BIOGENERAL_RE2 requirement_RE2 
Liothyronine_ddi|P|thyroid|contraceptive|therefore_LE1 patient_LE1 without_LE1 function_LE1 BIOENTITY gland_BE12 who_BE12 be_BE12 on_BE12 thyroid_BE12 replacement_BE12 therapy_BE12 may_BE12 need_BE12 to_BE12 increase_BE12 their_BE12 thyroid_BE12 dose_BE12 if_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY be_RE2 give_RE2 
Liothyronine_ddi|P|thyroid|estrogen|therefore_LE1 patient_LE1 without_LE1 function_LE1 BIOENTITY gland_BE12 who_BE12 be_BE12 on_BE12 thyroid_BE12 replacement_BE12 therapy_BE12 may_BE12 need_BE12 to_BE12 increase_BE12 their_BE12 thyroid_BE12 dose_BE12 if_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 oral_RE2 BIOGENERAL_RE2 be_RE2 give_RE2 
Liothyronine_ddi|P|thyroid product|tricyclic antidepressant|BIOGENERAL_LE1 :_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY may_RE2 increase_RE2 receptor_RE2 sensitivity_RE2 and_RE2 enhance_RE2 antidepressant_RE2 activity_RE2 transient_RE2 cardiac_RE2 arrhythmia_RE2 have_RE2 be_RE2 observe_RE2 
Liothyronine_ddi|P|thyroid product|imipramine|BIOGENERAL_LE1 :_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 may_RE2 increase_RE2 receptor_RE2 sensitivity_RE2 and_RE2 enhance_RE2 antidepressant_RE2 activity_RE2 transient_RE2 cardiac_RE2 arrhythmia_RE2 have_RE2 be_RE2 observe_RE2 
Liothyronine_ddi|P|thyroid preparation|digitali|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 toxic_BE12 effect_BE12 of_BE12 BIOENTITY 
Liothyronine_ddi|P|thyroid preparation|anesthetic|BIOGENERAL_LE1 :_LE1 when_LE1 administer_LE1 to_LE1 patient_LE1 on_LE1 BIOENTITY this_BE12 parenteral_BE12 BIOENTITY may_RE2 cause_RE2 hypertension_RE2 and_RE2 tachycardia_RE2 
Liothyronine_ddi|P|thyroxine|epinephrine|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 adrenergic_BE12 effect_BE12 of_BE12 catecholamine_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Liothyronine_ddi|P|thyroxine|norepinephrine|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 the_BE12 adrenergic_BE12 effect_BE12 of_BE12 catecholamine_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|sodium acid phosphate|amphetamine|urinary_LE1 acidifying_LE1 agent_LE1 these_LE1 agent_LE1 -LRB-_LE1 BIOGENERAL_LE1 BIOENTITY etc._BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 ionize_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 increase_RE2 urinary_RE2 excretion_RE2 
Lisdexamfetamine_ddi|P|ammonium chloride|amphetamine|urinary_LE1 acidifying_LE1 agent_LE1 these_LE1 agent_LE1 -LRB-_LE1 BIOENTITY BIOGENERAL_BE12 etc._BE12 -RRB-_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 the_BE12 ionize_BE12 specie_BE12 of_BE12 the_BE12 BIOENTITY molecule_RE2 thereby_RE2 increase_RE2 urinary_RE2 excretion_RE2 
Lisdexamfetamine_ddi|P|adrenergic blocker|amphetamine|BIOGENERAL_LE1 BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|tricyclic antidepressant|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 activity_BE12 of_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Lisdexamfetamine_ddi|P|amphetamine|sympathomimetic agent|BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 activity_BE12 of_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|d-amphetamine|protriptyline|BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY and_RE2 possible_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Lisdexamfetamine_ddi|P|d-amphetamine|tricyclic|BIOENTITY with_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 and_BE12 possible_BE12 other_BE12 BIOENTITY cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Lisdexamfetamine_ddi|P|d-amphetamine|desipramine|BIOENTITY with_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 and_RE2 possible_RE2 other_RE2 BIOGENERAL_RE2 cause_RE2 striking_RE2 and_RE2 sustained_RE2 increase_RE2 in_RE2 the_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 the_RE2 brain_RE2 
Lisdexamfetamine_ddi|P|maoi antidepressant|amphetamine|BIOGENERAL_LE1 BIOENTITY as_BE12 well_BE12 as_BE12 metabolite_BE12 of_BE12 BIOGENERAL_BE12 slow_BE12 BIOENTITY metabolism_RE2 
Lisdexamfetamine_ddi|P|furazolidone|amphetamine|BIOGENERAL_LE1 BIOGENERAL_LE1 as_LE1 well_LE1 as_LE1 metabolite_LE1 of_LE1 BIOENTITY slow_BE12 BIOENTITY metabolism_RE2 
Lisdexamfetamine_ddi|P|amphetamine|antihistamine|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 counteract_BE12 the_BE12 sedative_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|antihypertensive|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 antagonize_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|chlorpromazine|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY block_BE12 dopamine_BE12 and_BE12 norepinephrine_BE12 receptor_BE12 thus_BE12 inhibit_BE12 the_BE12 central_BE12 stimulant_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 can_RE2 be_RE2 use_RE2 to_RE2 treat_RE2 BIOGENERAL_RE2 poisoning_RE2 
Lisdexamfetamine_ddi|P|amphetamine|ethosuximide|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|haloperidol|amphetamine|BIOGENERAL_LE1 :_LE1 BIOENTITY block_BE12 dopamine_BE12 receptor_BE12 thus_BE12 inhibit_BE12 the_BE12 central_BE12 stimulant_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|lithium carbonate|BIOGENERAL_LE1 :_LE1 the_LE1 anorectic_LE1 and_LE1 stimulatory_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|meperidine|BIOGENERAL_LE1 :_LE1 BIOENTITY potentiate_BE12 the_BE12 analgesic_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|methenamine|BIOGENERAL_LE1 therapy_LE1 urinary_LE1 excretion_LE1 of_LE1 BIOENTITY be_BE12 increase_BE12 and_BE12 efficacy_BE12 be_BE12 reduce_BE12 by_BE12 acidify_BE12 agent_BE12 use_BE12 in_BE12 BIOENTITY therapy_RE2 
Lisdexamfetamine_ddi|P|amphetamine|norepinephrine|BIOGENERAL_LE1 :_LE1 BIOENTITY enhance_BE12 the_BE12 adrenergic_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|phenobarbital|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|amphetamine|phenytoin|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 delay_BE12 intestinal_BE12 absorption_BE12 of_BE12 BIOENTITY 
Lisdexamfetamine_ddi|P|propoxyphene|amphetamine|BIOGENERAL_LE1 :_LE1 In_LE1 case_LE1 of_LE1 BIOENTITY overdosage_BE12 BIOENTITY cns_RE2 stimulation_RE2 be_RE2 potentiate_RE2 and_RE2 fatal_RE2 convulsion_RE2 can_RE2 occur_RE2 
Lisdexamfetamine_ddi|P|amphetamine|veratrum alkaloid|BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 the_BE12 hypotensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Lisinopril_ddi|P|diuretic|prinivil|hypotension_LE1 patient_LE1 on_LE1 diuretic_LE1 therapy_LE1 :_LE1 patient_LE1 on_LE1 BIOENTITY and_BE12 especial_BE12 those_BE12 in_BE12 who_BE12 diuretic_BE12 therapy_BE12 be_BE12 recent_BE12 institute_BE12 may_BE12 occasional_BE12 experience_BE12 excessive_BE12 reduction_BE12 of_BE12 blood_BE12 pressure_BE12 after_BE12 initiation_BE12 of_BE12 therapy_BE12 with_BE12 BIOENTITY 
Lisinopril_ddi|P|diuretic|prinivil|the_LE1 possibility_LE1 of_LE1 hypotensive_LE1 effect_LE1 with_LE1 BIOGENERAL_LE1 can_LE1 be_LE1 minimize_LE1 by_LE1 either_LE1 discontinue_LE1 the_LE1 BIOENTITY or_BE12 increase_BE12 the_BE12 salt_BE12 intake_BE12 prior_BE12 to_BE12 initiation_BE12 of_BE12 treatment_BE12 with_BE12 BIOENTITY 
Lisinopril_ddi|P|diuretic|prinivil|if_LE1 it_LE1 be_LE1 necessary_LE1 to_LE1 continue_LE1 the_LE1 BIOENTITY initiate_BE12 therapy_BE12 with_BE12 BIOENTITY at_RE2 dose_RE2 of_RE2 NUM_RE2 mg_RE2 daily_RE2 and_RE2 provide_RE2 close_RE2 medical_RE2 supervision_RE2 after_RE2 the_RE2 initial_RE2 dose_RE2 until_RE2 blood_RE2 pressure_RE2 have_RE2 stabilise_RE2 
Lisinopril_ddi|P|diuretic|prinivil|when_LE1 BIOENTITY be_BE12 add_BE12 to_BE12 the_BE12 therapy_BE12 of_BE12 patient_BE12 receive_BE12 BIOENTITY additional_RE2 antihypertensive_RE2 effect_RE2 be_RE2 usual_RE2 observe_RE2 
Lisinopril_ddi|P|ace inhibitor|diuretic|study_LE1 with_LE1 BIOGENERAL_LE1 in_LE1 combination_LE1 with_LE1 BIOGENERAL_LE1 indicate_LE1 that_LE1 the_LE1 dose_LE1 of_LE1 the_LE1 BIOENTITY can_BE12 be_BE12 reduce_BE12 when_BE12 it_BE12 be_BE12 give_BE12 with_BE12 BIOENTITY 
Lisinopril_ddi|P|non-steroidal anti-inflammatory drug|lisinopril|BIOGENERAL_LE1 :_LE1 In_LE1 some_LE1 patient_LE1 with_LE1 compromise_LE1 renal_LE1 function_LE1 who_LE1 be_LE1 be_LE1 treat_LE1 with_LE1 BIOENTITY the_BE12 co-administration_BE12 of_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 further_RE2 deterioration_RE2 of_RE2 renal_RE2 function_RE2 
Lisinopril_ddi|P|nsaid|lisinopril|report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY 
Lisinopril_ddi|P|nsaid|ace inhibitor|report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 
Lisinopril_ddi|P|nsaid|ace inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Lisinopril_ddi|P|prinivil|thiazide-type diuretic|agent_LE1 increase_LE1 serum_LE1 potassium_LE1 :_LE1 BIOENTITY attenuate_BE12 potassium_BE12 loss_BE12 cause_BE12 by_BE12 BIOENTITY 
Lisinopril_ddi|P|prinivil|spironolactone|use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 supplement_RE2 or_RE2 potassium-containing_RE2 salt_RE2 substitute_RE2 may_RE2 lead_RE2 to_RE2 significant_RE2 increase_RE2 in_RE2 serum_RE2 potassium_RE2 
Lisinopril_ddi|P|prinivil|triamterene|use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 supplement_RE2 or_RE2 potassium-containing_RE2 salt_RE2 substitute_RE2 may_RE2 lead_RE2 to_RE2 significant_RE2 increase_RE2 in_RE2 serum_RE2 potassium_RE2 
Lisinopril_ddi|P|prinivil|amiloride|use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY -RRB-_RE2 BIOGENERAL_RE2 supplement_RE2 or_RE2 potassium-containing_RE2 salt_RE2 substitute_RE2 may_RE2 lead_RE2 to_RE2 significant_RE2 increase_RE2 in_RE2 serum_RE2 potassium_RE2 
Lisinopril_ddi|P|prinivil|potassium|use_LE1 of_LE1 BIOENTITY with_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOENTITY supplement_RE2 or_RE2 potassium-containing_RE2 salt_RE2 substitute_RE2 may_RE2 lead_RE2 to_RE2 significant_RE2 increase_RE2 in_RE2 serum_RE2 potassium_RE2 
Lisinopril_ddi|P|prinivil|potassium-sparing diuretic|use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 -RRB-_RE2 BIOGENERAL_RE2 supplement_RE2 or_RE2 potassium-containing_RE2 salt_RE2 substitute_RE2 may_RE2 lead_RE2 to_RE2 significant_RE2 increase_RE2 in_RE2 serum_RE2 potassium_RE2 
Lisinopril_ddi|P|lithium|ace inhibitor|BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 toxicity_LE1 have_LE1 be_LE1 report_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concomitant_BE12 with_BE12 drug_BE12 which_BE12 cause_BE12 elimination_BE12 of_BE12 sodium_BE12 including_BE12 BIOENTITY 
Lisinopril_ddi|P|lithium|ace inhibitor|BIOGENERAL_LE1 toxicity_LE1 be_LE1 usual_LE1 reversible_LE1 upon_LE1 discontinuation_LE1 of_LE1 BIOENTITY and_BE12 the_BE12 BIOENTITY 
Lisinopril_ddi|P|prinivil|lithium|it_LE1 be_LE1 recommend_LE1 that_LE1 serum_LE1 BIOGENERAL_LE1 level_LE1 be_LE1 monitor_LE1 frequent_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Lofexidine_ddi|P|lofexidine|alcohol|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns_BE12 depressive_BE12 effect_BE12 of_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 
Lofexidine_ddi|P|lofexidine|barbiturate|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns_BE12 depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Lofexidine_ddi|P|lofexidine|sedative|BIOENTITY may_BE12 enhance_BE12 the_BE12 cns_BE12 depressive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Lofexidine_ddi|P|lofexidine|anti-hypertensive drug|BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY therapy_RE2 
Lofexidine_ddi|P|tricyclic antidepressant|lofexidine|concomitant_LE1 use_LE1 of_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 efficacy_BE12 of_BE12 BIOENTITY 
Lomefloxacin_ddi|P|didanosine|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 as_LE1 well_LE1 as_LE1 formulation_LE1 contain_LE1 divalent_LE1 and_LE1 trivalent_LE1 cation_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 can_BE12 form_BE12 chelation_BE12 complex_BE12 with_BE12 BIOENTITY and_RE2 interfere_RE2 with_RE2 its_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|sucralfate|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 as_BE12 well_BE12 as_BE12 formulation_BE12 contain_BE12 divalent_BE12 and_BE12 trivalent_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 can_BE12 form_BE12 chelation_BE12 complex_BE12 with_BE12 BIOENTITY and_RE2 interfere_RE2 with_RE2 its_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|magnesium|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 as_BE12 well_BE12 as_BE12 formulation_BE12 contain_BE12 divalent_BE12 and_BE12 trivalent_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 can_BE12 form_BE12 chelation_BE12 complex_BE12 with_BE12 BIOENTITY and_RE2 interfere_RE2 with_RE2 its_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|aluminum|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY as_BE12 well_BE12 as_BE12 formulation_BE12 contain_BE12 divalent_BE12 and_BE12 trivalent_BE12 cation_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 can_BE12 form_BE12 chelation_BE12 complex_BE12 with_BE12 BIOENTITY and_RE2 interfere_RE2 with_RE2 its_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|videx|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 as_LE1 well_LE1 as_LE1 formulation_LE1 contain_LE1 divalent_LE1 and_LE1 trivalent_LE1 cation_LE1 such_LE1 as_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 can_BE12 form_BE12 chelation_BE12 complex_BE12 with_BE12 BIOENTITY and_RE2 interfere_RE2 with_RE2 its_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|sucralfate|lomefloxacin|BIOENTITY administer_BE12 NUM_BE12 hour_BE12 before_BE12 BIOENTITY result_RE2 in_RE2 slow_RE2 absorption_RE2 -LRB-_RE2 mean_RE2 max_RE2 decrease_RE2 by_RE2 NUM_RE2 and_RE2 mean_RE2 max_RE2 increase_RE2 by_RE2 NUM_RE2 hour_RE2 -RRB-_RE2 and_RE2 less_RE2 extent_RE2 of_RE2 absorption_RE2 -LRB-_RE2 mean_RE2 auc_RE2 decrease_RE2 by_RE2 approximate_RE2 NUM_RE2 %-rrb-._RE2 
Lomefloxacin_ddi|P|aluminum|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOENTITY BIOGENERAL_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY significant_RE2 decrease_RE2 the_RE2 bioavailability_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Lomefloxacin_ddi|P|magnesium|lomefloxacin|BIOENTITY and_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY significant_RE2 decrease_RE2 the_RE2 bioavailability_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Lomefloxacin_ddi|P|antacid|lomefloxacin|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOENTITY administer_BE12 concomitant_BE12 with_BE12 BIOENTITY significant_RE2 decrease_RE2 the_RE2 bioavailability_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Lomefloxacin_ddi|P|antacid|lomefloxacin|separate_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY minimize_RE2 this_RE2 decrease_RE2 in_RE2 bioavailability_RE2 
Lomefloxacin_ddi|P|quinolone|caffeine|other_LE1 BIOENTITY have_BE12 demonstrate_BE12 moderate_BE12 to_BE12 marked_BE12 interference_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 reduce_RE2 clearance_RE2 prolongation_RE2 of_RE2 plasma_RE2 half-life_RE2 and_RE2 increase_RE2 in_RE2 symptom_RE2 that_RE2 accompany_RE2 high_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Lomefloxacin_ddi|P|cimetidine|quinolone|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 demonstrate_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 elimination_BE12 of_BE12 other_BE12 BIOENTITY 
Lomefloxacin_ddi|P|cyclosporine|quinolone clas|BIOGENERAL_LE1 :_LE1 elevated_LE1 serum_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 member_BE12 of_BE12 the_BE12 BIOENTITY 
Lomefloxacin_ddi|P|quinolone|anticoagulant|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 
Lomefloxacin_ddi|P|quinolone|warfarin|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Loracarbef_ddi|P|loracarbef|probenecid|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 renal_LE1 excretion_LE1 of_LE1 BIOENTITY be_BE12 inhibit_BE12 by_BE12 BIOENTITY and_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 auc_RE2 for_RE2 BIOGENERAL_RE2 
Loracarbef_ddi|P|b-lactam antibiotic|probenecid|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY renal_BE12 excretion_BE12 of_BE12 BIOGENERAL_BE12 be_BE12 inhibit_BE12 by_BE12 BIOENTITY and_RE2 result_RE2 in_RE2 approximate_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 auc_RE2 for_RE2 BIOGENERAL_RE2 
Loratadine_ddi|P|erythromycin|loratadine|plasma_LE1 concentration_LE1 -LRB-_LE1 auc_LE1 NUM_LE1 hr_LE1 -RRB-_LE1 of_LE1 BIOENTITY decrease_BE12 NUM_BE12 with_BE12 coadministration_BE12 of_BE12 BIOENTITY relative_RE2 to_RE2 that_RE2 observe_RE2 with_RE2 BIOGENERAL_RE2 alone_RE2 
Lorazepam_ddi|P|lorazepam|barbiturate|tablet_LE1 :_LE1 the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 cns-depressant_BE12 effect_BE12 when_BE12 administer_BE12 with_BE12 such_BE12 medication_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Lorazepam_ddi|P|lorazepam|alcohol|tablet_LE1 :_LE1 the_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY produce_BE12 cns-depressant_BE12 effect_BE12 when_BE12 administer_BE12 with_BE12 such_BE12 medication_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Lorazepam_ddi|P|benzodiazepine|barbiturate|tablet_LE1 :_LE1 the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 cns-depressant_BE12 effect_BE12 when_BE12 administer_BE12 with_BE12 such_BE12 medication_BE12 as_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Lorazepam_ddi|P|benzodiazepine|alcohol|tablet_LE1 :_LE1 the_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 produce_BE12 cns-depressant_BE12 effect_BE12 when_BE12 administer_BE12 with_BE12 such_BE12 medication_BE12 as_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Lorazepam_ddi|P|benzodiazepine|antidepressant|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOENTITY produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|benzodiazepine|ethyl alcohol|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOENTITY produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|benzodiazepine|phenothiazine|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOENTITY produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|benzodiazepine|barbiturate|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOENTITY produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|benzodiazepine|mao inhibitor|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOENTITY produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|lorazepam|barbiturate|injection_LE1 :_LE1 BIOENTITY injection_BE12 like_BE12 other_BE12 injectable_BE12 BIOGENERAL_BE12 produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|lorazepam|phenothiazine|injection_LE1 :_LE1 BIOENTITY injection_BE12 like_BE12 other_BE12 injectable_BE12 BIOGENERAL_BE12 produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|lorazepam|antidepressant|injection_LE1 :_LE1 BIOENTITY injection_BE12 like_BE12 other_BE12 injectable_BE12 BIOGENERAL_BE12 produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|lorazepam|mao inhibitor|injection_LE1 :_LE1 BIOENTITY injection_BE12 like_BE12 other_BE12 injectable_BE12 BIOGENERAL_BE12 produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|scopolamine|lorazepam|injection_LE1 :_LE1 BIOGENERAL_LE1 injection_LE1 like_LE1 other_LE1 injectable_LE1 BIOGENERAL_LE1 produce_LE1 depression_LE1 of_LE1 the_LE1 central_LE1 nervous_LE1 system_LE1 when_LE1 administer_LE1 with_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOGENERAL_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 injectable_BE12 BIOENTITY increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Lorazepam_ddi|P|lorazepam|ethyl alcohol|injection_LE1 :_LE1 BIOENTITY injection_BE12 like_BE12 other_BE12 injectable_BE12 BIOGENERAL_BE12 produce_BE12 depression_BE12 of_BE12 the_BE12 central_BE12 nervous_BE12 system_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 other_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 be_RE2 use_RE2 concomitant_RE2 with_RE2 injectable_RE2 BIOGENERAL_RE2 increase_RE2 incidence_RE2 of_RE2 sedation_RE2 hallucination_RE2 and_RE2 irrational_RE2 behavior_RE2 have_RE2 be_RE2 observe_RE2 
Losartan_ddi|P|rifampin|losartan|BIOENTITY inducer_BE12 of_BE12 drug_BE12 metabolism_BE12 decrease_BE12 the_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 its_RE2 active_RE2 metabolite_RE2 
Losartan_ddi|P|fluconazole|losartan|BIOENTITY inhibitor_BE12 of_BE12 p450_BE12 2c9_BE12 decrease_BE12 active_BE12 metabolite_BE12 concentration_BE12 and_BE12 increase_BE12 BIOENTITY concentration_RE2 
Losartan_ddi|P|losartan|indomethacin|as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 the_LE1 antihypertensive_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 blunt_BE12 by_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Lovastatin_ddi|P|danazol|lovastatin|BIOGENERAL_LE1 :_LE1 the_LE1 risk_LE1 of_LE1 myopathy_LE1 be_LE1 increase_LE1 by_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY particular_BE12 with_BE12 high_BE12 dose_BE12 of_BE12 BIOENTITY -LRB-_RE2 see_RE2 warn_RE2 myopathy_RE2 -rrb-._RE2 
Lovastatin_ddi|P|amiodarone|hmg-coa reductase inhibitor clas|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 risk_LE1 of_LE1 myopathy_LE1 be_LE1 increase_LE1 when_LE1 either_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 be_BE12 use_BE12 concomitant_BE12 with_BE12 close_BE12 related_BE12 member_BE12 of_BE12 the_BE12 BIOENTITY -LRB-_RE2 see_RE2 warn_RE2 myopathy_RE2 -rrb-._RE2 
Lovastatin_ddi|P|verapamil|hmg-coa reductase inhibitor clas|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 risk_LE1 of_LE1 myopathy_LE1 be_LE1 increase_LE1 when_LE1 either_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY be_BE12 use_BE12 concomitant_BE12 with_BE12 close_BE12 related_BE12 member_BE12 of_BE12 the_BE12 BIOENTITY -LRB-_RE2 see_RE2 warn_RE2 myopathy_RE2 -rrb-._RE2 
Lovastatin_ddi|P|hmg-coa reductase inhibitor|warfarin|however_LE1 another_LE1 BIOENTITY have_BE12 be_BE12 find_BE12 to_BE12 produce_BE12 little_BE12 than_BE12 two-second_BE12 increase_BE12 in_BE12 prothrombin_BE12 time_BE12 in_BE12 healthy_BE12 volunteer_BE12 receive_BE12 low_BE12 dose_BE12 of_BE12 BIOENTITY 
Lovastatin_ddi|P|coumarin anticoagulant|lovastatin|also_LE1 bleeding_LE1 and_LE1 increase_LE1 prothrombin_LE1 time_LE1 have_LE1 be_LE1 report_LE1 in_LE1 few_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Lovastatin_ddi|P|anticoagulant|lovastatin|it_LE1 be_LE1 recommend_LE1 that_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY prothrombin_BE12 time_BE12 be_BE12 determine_BE12 before_BE12 start_BE12 BIOENTITY and_RE2 frequent_RE2 enough_RE2 during_RE2 early_RE2 therapy_RE2 to_RE2 insure_RE2 that_RE2 no_RE2 significant_RE2 alteration_RE2 of_RE2 prothrombin_RE2 time_RE2 occur_RE2 
Loxapine_ddi|P|loxapine|lorazepam|there_LE1 have_LE1 be_LE1 rare_LE1 report_LE1 of_LE1 significant_LE1 respiratory_LE1 depression_LE1 stupor_LE1 and_LE1 hypotension_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Lymecycline_ddi|P|lymecycline|zinc|the_LE1 absorption_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 simultaneous_BE12 administration_BE12 of_BE12 indigestion_BE12 remedy_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY supplement_RE2 
Lymecycline_ddi|P|lymecycline|iron|the_LE1 absorption_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 affect_BE12 by_BE12 the_BE12 simultaneous_BE12 administration_BE12 of_BE12 indigestion_BE12 remedy_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 supplement_RE2 
Lymecycline_ddi|P|contraceptive|lymecycline|oral_LE1 BIOENTITY may_BE12 be_BE12 little_BE12 effective_BE12 while_BE12 you_BE12 be_BE12 take_BE12 BIOENTITY 
Meclofenamic acid_ddi|P|warfarin|meclofenamate sodium|BIOENTITY :_BE12 BIOENTITY enhance_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Meclofenamic acid_ddi|P|meclofenamate sodium|warfarin|therefore_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 to_BE12 patient_BE12 receive_BE12 BIOENTITY the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 reduce_RE2 to_RE2 prevent_RE2 excessive_RE2 prolongation_RE2 of_RE2 the_RE2 prothrombin_RE2 time_RE2 
Meclofenamic acid_ddi|P|aspirin|meclofenamate sodium|BIOGENERAL_LE1 :_LE1 concurrent_LE1 administration_LE1 of_LE1 BIOENTITY may_BE12 low_BE12 BIOENTITY plasma_RE2 level_RE2 possible_RE2 by_RE2 compete_RE2 for_RE2 protein-binding_RE2 site_RE2 
Mefenamic acid_ddi|P|ponstel|aspirin|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOGENERAL_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 general_RE2 recommend_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 of_RE2 increase_RE2 adverse_RE2 effect_RE2 
Mefenamic acid_ddi|P|nsaid|aspirin|BIOGENERAL_LE1 :_LE1 as_LE1 with_LE1 other_LE1 BIOENTITY concomitant_BE12 administration_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY be_RE2 not_RE2 general_RE2 recommend_RE2 because_RE2 of_RE2 the_RE2 potential_RE2 of_RE2 increase_RE2 adverse_RE2 effect_RE2 
Mefenamic acid_ddi|P|nsaid|methotrexate|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 competitive_BE12 inhibit_BE12 BIOENTITY accumulation_RE2 in_RE2 rabbit_RE2 kidney_RE2 slice_RE2 
Mefenamic acid_ddi|P|nsaid|methotrexate|caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Mefenamic acid_ddi|P|nsaid|ace inhibitor|BIOGENERAL_LE1 :_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Mefenamic acid_ddi|P|nsaid|ace inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Mefenamic acid_ddi|P|nsaid|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Mefenamic acid_ddi|P|nsaid|thiazide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Mefenamic acid_ddi|P|ponstel|furosemide|During_LE1 concomitant_LE1 therapy_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY the_RE2 patient_RE2 shall_RE2 be_RE2 observe_RE2 close_RE2 for_RE2 sign_RE2 of_RE2 renal_RE2 failure_RE2 as_RE2 well_RE2 as_RE2 to_RE2 assure_RE2 diuretic_RE2 efficacy_RE2 
Mefenamic acid_ddi|P|nsaid|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOGENERAL_BE12 level_BE12 and_BE12 reduction_BE12 in_BE12 renal_BE12 BIOENTITY clearance_RE2 
Mefenamic acid_ddi|P|nsaid|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY level_RE2 and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 
Mefenamic acid_ddi|P|nsaid|lithium|thus_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concurrent_RE2 subject_RE2 shall_RE2 be_RE2 observe_RE2 careful_RE2 for_RE2 sign_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Mefenamic acid_ddi|P|warfarin|nsaid|BIOGENERAL_LE1 :_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY on_RE2 gi_RE2 bleeding_RE2 be_RE2 synergistic_RE2 such_RE2 that_RE2 user_RE2 of_RE2 both_RE2 drug_RE2 together_RE2 have_RE2 risk_RE2 of_RE2 serious_RE2 gi_RE2 bleeding_RE2 high_RE2 than_RE2 user_RE2 of_RE2 either_RE2 drug_RE2 alone_RE2 
Mefenamic acid_ddi|P|magnesium hydroxide|mefenamic acid|BIOGENERAL_LE1 :_LE1 In_LE1 single_LE1 dose_LE1 study_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 ingestion_LE1 of_LE1 BIOGENERAL_LE1 containing_LE1 NUM_LE1 of_LE1 BIOENTITY with_BE12 NUM_BE12 of_BE12 BIOENTITY increase_RE2 the_RE2 cmax_RE2 and_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respectively._RE2 number_RE2 of_RE2 compound_RE2 be_RE2 inhibitor_RE2 of_RE2 cyp2c9_RE2 including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|halofantrine|mefloquine|Because_LE1 of_LE1 the_LE1 danger_LE1 of_LE1 potential_LE1 fatal_LE1 prolongation_LE1 of_LE1 the_LE1 qtc_LE1 interval_LE1 BIOENTITY must_BE12 not_BE12 be_BE12 give_BE12 simultaneous_BE12 with_BE12 or_BE12 subsequent_BE12 to_BE12 BIOENTITY 
Mefloquine_ddi|P|mefloquine|quinine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 related_BE12 compound_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 produce_RE2 electrocardiographic_RE2 abnormality_RE2 and_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 convulsion_RE2 
Mefloquine_ddi|P|mefloquine|quinidine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 related_BE12 compound_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 produce_RE2 electrocardiographic_RE2 abnormality_RE2 and_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 convulsion_RE2 
Mefloquine_ddi|P|mefloquine|chloroquine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 related_BE12 compound_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 may_RE2 produce_RE2 electrocardiographic_RE2 abnormality_RE2 and_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 convulsion_RE2 
Mefloquine_ddi|P|mefloquine|anti-arrhythmic|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|beta-adrenergic blocking agent|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|calcium channel blocker|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|antihistamine|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|h1-blocking agent|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|tricyclic antidepressant|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|mefloquine|phenothiazine|this_LE1 appear_LE1 to_LE1 be_LE1 the_LE1 only_LE1 clinical_LE1 relevant_LE1 interaction_LE1 of_LE1 this_LE1 kind_LE1 with_LE1 BIOENTITY although_BE12 theoretical_BE12 coadministration_BE12 of_BE12 other_BE12 drug_BE12 know_BE12 to_BE12 alter_BE12 cardiac_BE12 conduction_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 may_RE2 also_RE2 contribute_RE2 to_RE2 prolongation_RE2 of_RE2 the_RE2 qtc_RE2 interval_RE2 
Mefloquine_ddi|P|phenobarbital|mefloquine|In_LE1 patient_LE1 take_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY may_RE2 reduce_RE2 seizure_RE2 control_RE2 by_RE2 lower_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|phenytoin|mefloquine|In_LE1 patient_LE1 take_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 the_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY may_RE2 reduce_RE2 seizure_RE2 control_RE2 by_RE2 lower_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|valproic acid|mefloquine|In_LE1 patient_LE1 take_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY may_RE2 reduce_RE2 seizure_RE2 control_RE2 by_RE2 lower_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|carbamazepine|mefloquine|In_LE1 patient_LE1 take_LE1 BIOGENERAL_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY may_RE2 reduce_RE2 seizure_RE2 control_RE2 by_RE2 lower_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|anticonvulsant|mefloquine|In_LE1 patient_LE1 take_LE1 BIOENTITY -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 the_BE12 concomitant_BE12 use_BE12 of_BE12 BIOENTITY may_RE2 reduce_RE2 seizure_RE2 control_RE2 by_RE2 lower_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Mefloquine_ddi|P|mefloquine|live typhoid vaccine|when_LE1 BIOENTITY be_BE12 take_BE12 concurrent_BE12 with_BE12 oral_BE12 BIOENTITY attenuation_RE2 of_RE2 immunization_RE2 can_RE2 be_RE2 exclude_RE2 
Mefloquine_ddi|P|mefloquine|anticoagulant|nevertheless_LE1 the_LE1 effect_LE1 of_LE1 BIOENTITY on_BE12 traveler_BE12 receive_BE12 comedication_BE12 particular_BE12 diabetic_BE12 or_BE12 patient_BE12 use_BE12 BIOENTITY shall_RE2 be_RE2 check_RE2 before_RE2 departure_RE2 
Menadione_ddi|P|cholestyramine|vitamin k|BIOGENERAL_LE1 intake_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 reduce_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Menadione_ddi|P|colestipol|vitamin k|BIOGENERAL_LE1 intake_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 reduce_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Menadione_ddi|P|mineral oil|vitamin k|BIOGENERAL_LE1 intake_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY may_RE2 reduce_RE2 the_RE2 absorption_RE2 of_RE2 BIOGENERAL_RE2 
Menadione_ddi|P|orlistat|vitamin k|BIOENTITY may_BE12 decrease_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY 
Menadione_ddi|P|vitamin k|warfarin|BIOGENERAL_LE1 BIOENTITY can_BE12 antagonize_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY 
Nabilone_ddi|P|nabilone|alcohol|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 who_BE12 be_BE12 take_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 or_RE2 to_RE2 those_RE2 with_RE2 history_RE2 of_RE2 psychiatric_RE2 disorder_RE2 -LRB-_RE2 include_RE2 manic-depressive_RE2 illness_RE2 and_RE2 schizophrenia_RE2 -rrb-._RE2 
Nabilone_ddi|P|nabilone|cns depressant|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 who_BE12 be_BE12 take_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 or_RE2 to_RE2 those_RE2 with_RE2 history_RE2 of_RE2 psychiatric_RE2 disorder_RE2 -LRB-_RE2 include_RE2 manic-depressive_RE2 illness_RE2 and_RE2 schizophrenia_RE2 -rrb-._RE2 
Nabilone_ddi|P|nabilone|narcotic analgesic|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 who_BE12 be_BE12 take_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY or_RE2 to_RE2 those_RE2 with_RE2 history_RE2 of_RE2 psychiatric_RE2 disorder_RE2 -LRB-_RE2 include_RE2 manic-depressive_RE2 illness_RE2 and_RE2 schizophrenia_RE2 -rrb-._RE2 
Nabilone_ddi|P|nabilone|barbiturate|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 who_BE12 be_BE12 take_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 or_RE2 to_RE2 those_RE2 with_RE2 history_RE2 of_RE2 psychiatric_RE2 disorder_RE2 -LRB-_RE2 include_RE2 manic-depressive_RE2 illness_RE2 and_RE2 schizophrenia_RE2 -rrb-._RE2 
Nabilone_ddi|P|nabilone|psychoactive drug|BIOENTITY shall_BE12 be_BE12 administer_BE12 with_BE12 caution_BE12 to_BE12 patient_BE12 who_BE12 be_BE12 take_BE12 other_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 including_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 or_RE2 to_RE2 those_RE2 with_RE2 history_RE2 of_RE2 psychiatric_RE2 disorder_RE2 -LRB-_RE2 include_RE2 manic-depressive_RE2 illness_RE2 and_RE2 schizophrenia_RE2 -rrb-._RE2 
Nabilone_ddi|P|nabilone|secobarbitone sodium|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Nabilone_ddi|P|nabilone|diazepam|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 either_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 or_RE2 BIOGENERAL_RE2 
Nabilone_ddi|P|nabilone|codeine|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Nabilone_ddi|P|nabilone|alcohol|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 have_BE12 additive_BE12 cns_BE12 depressant_BE12 effect_BE12 when_BE12 give_BE12 with_BE12 either_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Nabumetone_ddi|P|nabumetone|warfarin|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOENTITY with_BE12 BIOENTITY since_RE2 interaction_RE2 have_RE2 be_RE2 see_RE2 with_RE2 other_RE2 BIOGENERAL_RE2 
Nabumetone_ddi|P|warfarin|nsaid|caution_LE1 shall_LE1 be_LE1 exercise_LE1 when_LE1 administer_LE1 BIOGENERAL_LE1 with_LE1 BIOENTITY since_BE12 interaction_BE12 have_BE12 be_BE12 see_BE12 with_BE12 other_BE12 BIOENTITY 
Nadolol_ddi|P|beta-adrenergic receptor blocking agent|anesthetic|when_LE1 administer_LE1 concurrent_LE1 the_LE1 follow_LE1 drug_LE1 may_LE1 interact_LE1 with_LE1 BIOENTITY :_BE12 BIOENTITY general_RE2 :_RE2 exaggeration_RE2 of_RE2 the_RE2 hypotension_RE2 induce_RE2 by_RE2 general_RE2 BIOGENERAL_RE2 
Nafcillin_ddi|P|tetracycline|penicillin|BIOENTITY BIOGENERAL_BE12 may_BE12 antagonize_BE12 the_BE12 bactericidal_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 concurrent_RE2 use_RE2 of_RE2 these_RE2 drug_RE2 shall_RE2 be_RE2 avoid_RE2 
Nalidixic Acid_ddi|P|theophylline|quinolone|elevated_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 with_BE12 concomitant_BE12 BIOENTITY use_RE2 
Nalidixic Acid_ddi|P|quinolone|theophylline|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 BIOGENERAL_LE1 side_LE1 effect_LE1 in_LE1 patient_LE1 on_LE1 concomitant_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY 
Nalidixic Acid_ddi|P|quinolone|caffeine|BIOENTITY have_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Nalidixic Acid_ddi|P|quinolone|warfarin|BIOENTITY including_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Nalidixic Acid_ddi|P|nalidixic acid|warfarin|BIOGENERAL_LE1 including_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 the_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 
Nalidixic Acid_ddi|P|nitrofurantoin|nalidixic acid|BIOENTITY interfere_BE12 with_BE12 the_BE12 therapeutic_BE12 action_BE12 of_BE12 BIOENTITY 
Nalidixic Acid_ddi|P|didanosine|quinolone|and_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 may_BE12 substantial_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 systemic_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desire_RE2 
Nalidixic Acid_ddi|P|videx|quinolone|and_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 may_BE12 substantial_BE12 interfere_BE12 with_BE12 the_BE12 absorption_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 systemic_RE2 level_RE2 considerable_RE2 low_RE2 than_RE2 desire_RE2 
Nalidixic Acid_ddi|P|quinolone|cyclosporine|elevated_LE1 serum_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 with_LE1 the_LE1 concomitant_LE1 use_LE1 of_LE1 some_LE1 BIOENTITY and_BE12 BIOENTITY 
Naltrexone_ddi|P|revia|disulfiram|the_LE1 safety_LE1 and_LE1 efficacy_LE1 of_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 unknown_RE2 and_RE2 the_RE2 concomitant_RE2 use_RE2 of_RE2 two_RE2 potential_RE2 hepatotoxic_RE2 medication_RE2 be_RE2 not_RE2 ordinary_RE2 recommend_RE2 unless_RE2 the_RE2 probable_RE2 benefit_RE2 outweigh_RE2 the_RE2 known_RE2 risk_RE2 
Naltrexone_ddi|P|revia|thioridazine|lethargy_LE1 and_LE1 somnolence_LE1 have_LE1 be_LE1 report_LE1 following_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Naltrexone_ddi|P|revia|opioid|patient_LE1 take_LE1 BIOENTITY may_BE12 not_BE12 benefit_BE12 from_BE12 BIOENTITY containing_RE2 medicine_RE2 such_RE2 as_RE2 cough_RE2 and_RE2 cold_RE2 preparation_RE2 antidiarrheal_RE2 preparation_RE2 and_RE2 BIOGENERAL_RE2 
Naltrexone_ddi|P|revia|opioid analgesic|patient_LE1 take_LE1 BIOENTITY may_BE12 not_BE12 benefit_BE12 from_BE12 BIOGENERAL_BE12 containing_BE12 medicine_BE12 such_BE12 as_BE12 cough_BE12 and_BE12 cold_BE12 preparation_BE12 antidiarrheal_BE12 preparation_BE12 and_BE12 BIOENTITY 
Naltrexone_ddi|P|revia|opioid|In_LE1 emergency_LE1 situation_LE1 when_LE1 opioid_LE1 analgesia_LE1 must_LE1 be_LE1 administer_LE1 to_LE1 patient_LE1 receive_LE1 BIOENTITY the_BE12 amount_BE12 of_BE12 BIOENTITY require_RE2 may_RE2 be_RE2 great_RE2 than_RE2 usual_RE2 and_RE2 the_RE2 result_RE2 respiratory_RE2 depression_RE2 may_RE2 be_RE2 deep_RE2 and_RE2 much_RE2 prolonged_RE2 
Naproxen_ddi|P|nsaid|ace inhibitor|the_LE1 use_LE1 of_LE1 BIOENTITY in_BE12 patient_BE12 who_BE12 be_BE12 receive_BE12 BIOENTITY may_RE2 potentiate_RE2 renal_RE2 disease_RE2 state_RE2 
Naproxen_ddi|P|naproxen|aspirin|concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 because_LE1 BIOENTITY be_BE12 displace_BE12 from_BE12 its_BE12 binding_BE12 site_BE12 during_BE12 the_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY result_RE2 in_RE2 low_RE2 plasma_RE2 concentration_RE2 and_RE2 peak_RE2 plasma_RE2 level_RE2 
Naproxen_ddi|P|naproxen|aspirin|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 because_RE2 BIOGENERAL_RE2 be_RE2 displace_RE2 from_RE2 its_RE2 binding_RE2 site_RE2 during_RE2 the_RE2 concomitant_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 result_RE2 in_RE2 low_RE2 plasma_RE2 concentration_RE2 and_RE2 peak_RE2 plasma_RE2 level_RE2 
Naproxen_ddi|P|nsaid|beta-blocker|BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Naproxen_ddi|P|nsaid|propranolol|BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Naproxen_ddi|P|naproxen|beta-blocker|BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 BIOENTITY 
Naproxen_ddi|P|naproxen|propranolol|BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 can_BE12 reduce_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 BIOGENERAL_RE2 
Naproxen_ddi|P|probenecid|naproxen|BIOENTITY give_BE12 concurrent_BE12 increase_BE12 BIOENTITY anion_RE2 plasma_RE2 level_RE2 and_RE2 extend_RE2 its_RE2 plasma_RE2 half-life_RE2 significant_RE2 
Naproxen_ddi|P|naproxen|methotrexate|caution_LE1 shall_LE1 be_LE1 use_LE1 if_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY 
Naproxen_ddi|P|naproxen|methotrexate|BIOENTITY BIOGENERAL_BE12 and_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY in_RE2 animal_RE2 model_RE2 possible_RE2 increase_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Naproxen_ddi|P|nsaid|methotrexate|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 other_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY in_RE2 animal_RE2 model_RE2 possible_RE2 increase_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Naproxen_ddi|P|naproxen sodium|methotrexate|BIOGENERAL_LE1 BIOENTITY and_BE12 other_BE12 BIOGENERAL_BE12 have_BE12 be_BE12 report_BE12 to_BE12 reduce_BE12 the_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY in_RE2 animal_RE2 model_RE2 possible_RE2 increase_RE2 the_RE2 toxicity_RE2 of_RE2 BIOGENERAL_RE2 
Naratriptan_ddi|P|ergot-type medication|naratriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 be_RE2 contraindicate_RE2 
Naratriptan_ddi|P|dihydroergotamine|naratriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 be_RE2 contraindicate_RE2 
Naratriptan_ddi|P|ergotamine|naratriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 -LRB-_BE12 like_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 be_RE2 contraindicate_RE2 
Naratriptan_ddi|P|methysergide|naratriptan|because_LE1 there_LE1 be_LE1 theoretical_LE1 basis_LE1 that_LE1 these_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 -LRB-_LE1 like_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY -RRB-_BE12 and_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 be_RE2 contraindicate_RE2 
Naratriptan_ddi|P|naratriptan|5-ht1 agonist|because_LE1 their_LE1 vasospastic_LE1 effect_LE1 may_LE1 be_LE1 additive_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 other_BE12 BIOENTITY within_RE2 NUM_RE2 hour_RE2 of_RE2 each_RE2 other_RE2 be_RE2 not_RE2 recommend_RE2 
Naratriptan_ddi|P|naratriptan|ssri|if_LE1 concomitant_LE1 treatment_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 clinical_RE2 warrant_RE2 appropriate_RE2 observation_RE2 of_RE2 the_RE2 patient_RE2 be_RE2 advise_RE2 
Natalizumab_ddi|P|avonex|tysabri|After_LE1 multiple_LE1 dosing_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY NUM_BE12 mcg_BE12 im_BE12 once_BE12 weekly_BE12 -RRB-_BE12 reduce_BE12 BIOENTITY clearance_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Natalizumab_ddi|P|interferon beta-1a|tysabri|After_LE1 multiple_LE1 dosing_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 NUM_BE12 mcg_BE12 im_BE12 once_BE12 weekly_BE12 -RRB-_BE12 reduce_BE12 BIOENTITY clearance_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Nateglinide_ddi|P|starlix|tolbutamide|BIOENTITY be_BE12 potential_BE12 inhibitor_BE12 of_BE12 the_BE12 cyp2c9_BE12 isoenzyme_BE12 in_BE12 vivo_BE12 as_BE12 indicate_BE12 by_BE12 its_BE12 ability_BE12 to_BE12 inhibit_BE12 the_BE12 in_BE12 vitro_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Nateglinide_ddi|P|non-selective beta-adrenergic-blocking agent|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|monoamine oxidase inhibitor|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|monoamine oxidase inhibitor|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|salicylate|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|salicylate|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|nonsteroidal anti-inflammatory agent|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|nsaid|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|non-selective beta-adrenergic-blocking agent|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|nsaid|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|nonsteroidal anti-inflammatory agent|starlix|certain_LE1 drug_LE1 including_LE1 BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 potentiate_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|sympathomimetic|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|thiazide|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|sympathomimetic|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|thyroid product|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|corticosteroid|antidiabetic drug|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 other_BE12 oral_BE12 BIOENTITY 
Nateglinide_ddi|P|thiazide|starlix|certain_LE1 drug_LE1 including_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|thyroid product|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nateglinide_ddi|P|corticosteroid|starlix|certain_LE1 drug_LE1 including_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 reduce_BE12 the_BE12 hypoglycemic_BE12 action_BE12 of_BE12 BIOENTITY and_RE2 other_RE2 oral_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|antimycobacterial agent|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|cisapride|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 gi_BE12 motility_BE12 agent_BE12 :_BE12 BIOENTITY 
Nelfinavir_ddi|P|viracept|ergot derivative|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|triazolam|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|benzodiazepine|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|midazolam|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|rifampin|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 antimigraine_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|amiodarone|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|antiarrhythmic|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOENTITY :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|antihistamine|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|quinidine|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|terfenadine|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOENTITY antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|astemizole|drug_LE1 That_LE1 shall_LE1 not_LE1 be_LE1 coadminister_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 :_BE12 BIOENTITY BIOGENERAL_RE2 antimigraine_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 :_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 gi_RE2 motility_RE2 agent_RE2 :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|rifabutin|drug_LE1 Which_LE1 require_LE1 dose_LE1 reduction_LE1 when_LE1 coadminster_LE1 With_LE1 BIOENTITY BIOGENERAL_BE12 :_BE12 BIOENTITY 
Nelfinavir_ddi|P|viracept|antimycobacterial agent|drug_LE1 Which_LE1 require_LE1 dose_LE1 reduction_LE1 when_LE1 coadminster_LE1 With_LE1 BIOENTITY BIOENTITY :_RE2 BIOGENERAL_RE2 
Nelfinavir_ddi|P|viracept|terfenadine|therefore_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY because_RE2 of_RE2 the_RE2 potential_RE2 for_RE2 serious_RE2 and_RE2 life-threatening_RE2 cardiac_RE2 arrhythmia_RE2 
Nelfinavir_ddi|P|viracept|astemizole|because_LE1 similar_LE1 interaction_LE1 be_LE1 likely_LE1 BIOENTITY shall_BE12 also_BE12 not_BE12 be_BE12 administer_BE12 concurrent_BE12 with_BE12 BIOENTITY 
Nelfinavir_ddi|P|indinavir|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|ritonavir|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 auc_RE2 and_RE2 very_RE2 little_RE2 change_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|saquinavir|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 use_BE12 experimental_BE12 soft-gelatin_BE12 capsule_BE12 formulation_BE12 of_BE12 BIOGENERAL_BE12 1200mg_BE12 -RRB-_BE12 with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|ketoconazole|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|nelfinavir|didanosine|therefore_LE1 BIOENTITY shall_BE12 be_BE12 administer_BE12 -LRB-_BE12 with_BE12 food_BE12 -RRB-_BE12 one_BE12 hour_BE12 after_BE12 or_BE12 many_BE12 than_BE12 two_BE12 hour_BE12 before_BE12 BIOENTITY 
Nelfinavir_ddi|P|zidovudine|viracept|dose_LE1 adjustment_LE1 be_LE1 not_LE1 need_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 with_BE12 BIOENTITY 
Nelfinavir_ddi|P|rifabutin|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|rifabutin|viracept|it_LE1 be_LE1 recommend_LE1 that_LE1 the_LE1 dose_LE1 of_LE1 BIOENTITY be_BE12 reduce_BE12 to_BE12 one-half_BE12 the_BE12 usual_BE12 dose_BE12 when_BE12 administer_BE12 with_BE12 BIOENTITY 
Nelfinavir_ddi|P|rifampin|viracept|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 a.c._RE2 
Nelfinavir_ddi|P|viracept|rifampin|BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 be_RE2 coadminister_RE2 
Nelfinavir_ddi|P|viracept|ovcon-35|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY result_RE2 in_RE2 NUM_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 and_RE2 NUM_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Neomycin_ddi|P|neomycin|penicillin v|oral_LE1 BIOENTITY inhibit_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 BIOENTITY oral_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Neomycin_ddi|P|neomycin|5-fluorouracil|oral_LE1 BIOENTITY inhibit_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY 
Neomycin_ddi|P|neomycin|methotrexate|oral_LE1 BIOENTITY inhibit_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 BIOGENERAL_BE12 oral_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Neomycin_ddi|P|neomycin|vitamin b-12|oral_LE1 BIOENTITY inhibit_BE12 the_BE12 gastrointestinal_BE12 absorption_BE12 of_BE12 BIOGENERAL_BE12 oral_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 
Neomycin_ddi|P|neomycin sulfate|coumarin|oral_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY in_RE2 BIOGENERAL_RE2 by_RE2 decrease_RE2 vitamin_RE2 availability_RE2 
Neomycin_ddi|P|neomycin sulfate|anticoagulant|oral_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 in_BE12 BIOENTITY by_RE2 decrease_RE2 vitamin_RE2 availability_RE2 
Neostigmine_ddi|P|antibiotic|anticholinesterase|these_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 in_BE12 the_BE12 myasthenic_BE12 patient_BE12 only_BE12 where_BE12 definite_BE12 indicate_BE12 and_BE12 then_BE12 careful_BE12 adjustment_BE12 shall_BE12 be_BE12 make_BE12 of_BE12 adjunctive_BE12 BIOENTITY dosage_RE2 
Netilmicin_ddi|P|netilmicin|ethacrynic acid|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 potent_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY as_RE2 the_RE2 potential_RE2 for_RE2 ototoxicity_RE2 be_RE2 enhance_RE2 by_RE2 the_RE2 combination_RE2 
Netilmicin_ddi|P|netilmicin|furosemide|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 potent_BE12 BIOGENERAL_BE12 such_BE12 as_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 as_RE2 the_RE2 potential_RE2 for_RE2 ototoxicity_RE2 be_RE2 enhance_RE2 by_RE2 the_RE2 combination_RE2 
Netilmicin_ddi|P|netilmicin|loop diuretic|BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 potent_BE12 BIOENTITY such_RE2 as_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 as_RE2 the_RE2 potential_RE2 for_RE2 ototoxicity_RE2 be_RE2 enhance_RE2 by_RE2 the_RE2 combination_RE2 
Nevirapine_ddi|P|nevirapine|warfarin|the_LE1 in_LE1 vitro_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY be_RE2 complex_RE2 
Nevirapine_ddi|P|warfarin|nevirapine|when_LE1 BIOENTITY be_BE12 co-administer_BE12 with_BE12 BIOENTITY anticoagulation_RE2 level_RE2 shall_RE2 be_RE2 monitor_RE2 frequent_RE2 
Nevirapine_ddi|P|clarithromycin|nevirapine|BIOENTITY exposure_BE12 be_BE12 significant_BE12 decrease_BE12 by_BE12 BIOENTITY 
Nevirapine_ddi|P|contraceptive|nevirapine|oral_LE1 BIOENTITY and_BE12 other_BE12 hormonalmethod_BE12 of_BE12 birth_BE12 control_BE12 shall_BE12 not_BE12 be_BE12 usedas_BE12 the_BE12 sole_BE12 method_BE12 of_BE12 contraception_BE12 inwomen_BE12 take_BE12 BIOENTITY since_RE2 nevirapinemay_RE2 low_RE2 the_RE2 plasma_RE2 level_RE2 of_RE2 thesemedication_RE2 
Nevirapine_ddi|P|nevirapine|ketoconazole|BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 beadminister_RE2 concomitant_RE2 becausedecrease_RE2 in_RE2 BIOGENERAL_RE2 plasmaconcentration_RE2 may_RE2 reduce_RE2 the_RE2 efficacy_RE2 of_RE2 the_RE2 drug_RE2 
Nevirapine_ddi|P|ritonavir|nevirapine|dose_LE1 increase_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 with_BE12 food_BE12 isrecommend_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Nevirapine_ddi|P|ritonavir|nevirapine|dose_LE1 increase_LE1 of_LE1 BIOENTITY to_BE12 NUM_BE12 mg_BE12 twice_BE12 daily_BE12 with_BE12 food_BE12 isrecommend_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Nevirapine_ddi|P|methadone|nevirapine|BIOGENERAL_LE1 level_LE1 may_LE1 be_LE1 decrease_LE1 increase_LE1 dosage_LE1 may_LE1 be_LE1 require_LE1 to_LE1 prevent_LE1 symptom_LE1 of_LE1 BIOGENERAL_LE1 withdrawal._LE1 BIOENTITY maintained_BE12 patient_BE12 begin_BE12 BIOENTITY therapy_RE2 shall_RE2 be_RE2 monitor_RE2 forevidence_RE2 of_RE2 withdrawal_RE2 and_RE2 BIOGENERAL_RE2 dose_RE2 shall_RE2 be_RE2 adjust_RE2 according_RE2 
Nevirapine_ddi|P|nevirapine|rifampin|BIOENTITY and_BE12 BIOENTITY shall_RE2 not_RE2 beadminister_RE2 concomitant_RE2 becausedecrease_RE2 in_RE2 BIOGENERAL_RE2 plasmaconcentration_RE2 may_RE2 reduce_RE2 the_RE2 efficacy_RE2 ofthe_RE2 drug_RE2 
Nevirapine_ddi|P|nevirapine|methadone|abase_LE1 on_LE1 report_LE1 of_LE1 narcotic_LE1 withdrawal_LE1 syndrome_LE1 in_LE1 patient_LE1 treat_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY concurrent_RE2 and_RE2 evidence_RE2 of_RE2 decrease_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 
Niacin_ddi|P|nicotinic acid|ganglionic blocking agent|interaction_LE1 for_LE1 BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 BIOGENERAL_LE1 therapy_LE1 :_LE1 BIOENTITY may_BE12 potentiate_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 vasoactive_RE2 drug_RE2 result_RE2 in_RE2 postural_RE2 hypotension_RE2 
Niacin_ddi|P|aspirin|nicotinic acid|BIOGENERAL_LE1 :_LE1 concomitant_LE1 BIOENTITY may_BE12 decrease_BE12 the_BE12 metabolic_BE12 clearance_BE12 of_BE12 BIOENTITY 
Nicardipine_ddi|P|cimetidine|nicardipine hcl|BIOGENERAL_LE1 :_LE1 BIOENTITY increase_BE12 BIOENTITY plasma_RE2 level_RE2 
Nicardipine_ddi|P|calcium blocker|digitalis preparation|BIOGENERAL_LE1 :_LE1 some_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 concentration_BE12 of_BE12 BIOENTITY in_RE2 the_RE2 blood_RE2 
Nicardipine_ddi|P|digoxin|nicardipine hcl|BIOGENERAL_LE1 usual_LE1 do_LE1 not_LE1 alter_LE1 the_LE1 plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 however_LE1 serum_LE1 BIOENTITY level_BE12 shall_BE12 be_BE12 evaluate_BE12 after_BE12 concomitant_BE12 therapy_BE12 with_BE12 BIOENTITY be_RE2 initiate_RE2 
Nicardipine_ddi|P|cyclosporine|nicardipine|plasma_LE1 concentration_LE1 of_LE1 BIOENTITY shall_BE12 therefore_BE12 be_BE12 close_BE12 monitor_BE12 and_BE12 its_BE12 dosage_BE12 reduce_BE12 according_BE12 in_BE12 patient_BE12 treat_BE12 with_BE12 BIOENTITY 
Nifedipine_ddi|P|nifedipine|beta-blocking agent|BIOGENERAL_LE1 :_LE1 experience_LE1 in_LE1 over_LE1 NUM_LE1 patient_LE1 in_LE1 non-comparative_LE1 clinical_LE1 trial_LE1 have_LE1 show_LE1 that_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 usual_RE2 well_RE2 tolerate_RE2 but_RE2 there_RE2 have_RE2 be_RE2 occasional_RE2 literature_RE2 report_RE2 suggest_RE2 that_RE2 the_RE2 combination_RE2 may_RE2 increase_RE2 the_RE2 likelihood_RE2 of_RE2 congestive_RE2 heart_RE2 failure_RE2 severe_RE2 hypotension_RE2 or_RE2 exacerbation_RE2 of_RE2 angina_RE2 
Nifedipine_ddi|P|digoxin|nifedipine|BIOGENERAL_LE1 :_LE1 immediate_LE1 release_LE1 capsule_LE1 :_LE1 since_LE1 there_LE1 have_LE1 be_LE1 isolate_LE1 report_LE1 of_LE1 patient_LE1 with_LE1 elevated_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 there_LE1 be_LE1 possible_LE1 interaction_LE1 between_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY level_BE12 be_BE12 monitor_BE12 when_BE12 initiate_BE12 adjust_BE12 and_BE12 discontinue_BE12 BIOENTITY to_RE2 avoid_RE2 possible_RE2 over-_RE2 or_RE2 under-digitalization_RE2 
Nifedipine_ddi|P|digoxin|nifedipine|BIOGENERAL_LE1 :_LE1 immediate_LE1 release_LE1 capsule_LE1 :_LE1 since_LE1 there_LE1 have_LE1 be_LE1 isolate_LE1 report_LE1 of_LE1 patient_LE1 with_LE1 elevated_LE1 BIOGENERAL_LE1 level_LE1 and_LE1 there_LE1 be_LE1 possible_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY it_RE2 be_RE2 recommend_RE2 that_RE2 BIOGENERAL_RE2 level_RE2 be_RE2 monitor_RE2 when_RE2 initiate_RE2 adjust_RE2 and_RE2 discontinue_RE2 BIOGENERAL_RE2 to_RE2 avoid_RE2 possible_RE2 over-_RE2 or_RE2 under-digitalization_RE2 
Nifedipine_ddi|P|digoxin|digoxin|extended_LE1 release_LE1 tablet_LE1 :_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 with_LE1 BIOENTITY increase_BE12 BIOENTITY level_RE2 in_RE2 NUM_RE2 of_RE2 NUM_RE2 normal_RE2 volunteer_RE2 
Nifedipine_ddi|P|digoxin|nifedipine|since_LE1 there_LE1 have_LE1 be_LE1 isolate_LE1 report_LE1 of_LE1 patient_LE1 with_LE1 elevated_LE1 BIOGENERAL_LE1 level_LE1 it_LE1 be_LE1 recommend_LE1 that_LE1 BIOENTITY level_BE12 be_BE12 monitor_BE12 when_BE12 initiate_BE12 adjust_BE12 and_BE12 discontinue_BE12 BIOENTITY to_RE2 avoid_RE2 possible_RE2 over-_RE2 or_RE2 under-digitalization_RE2 
Nifedipine_ddi|P|quinidine|nifedipine|BIOGENERAL_LE1 :_LE1 immediate_LE1 release_LE1 capsule_LE1 :_LE1 there_LE1 have_LE1 be_LE1 rare_LE1 report_LE1 of_LE1 interaction_LE1 between_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 with_RE2 decrease_RE2 plasma_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Nifedipine_ddi|P|coumarin anticoagulant|nifedipine|BIOGENERAL_LE1 :_LE1 there_LE1 have_LE1 be_LE1 rare_LE1 report_LE1 of_LE1 increase_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY to_BE12 who_BE12 BIOENTITY be_RE2 administer_RE2 
Nifedipine_ddi|P|cimetidine|nifedipine|BIOGENERAL_LE1 :_LE1 study_LE1 in_LE1 NUM_LE1 healthy_LE1 volunteer_LE1 have_LE1 show_LE1 significant_LE1 increase_LE1 in_LE1 peak_LE1 BIOGENERAL_LE1 plasma_LE1 level_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 and_LE1 area-under-the-curve_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 after_LE1 NUM_LE1 week_LE1 course_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 per_BE12 day_BE12 and_BE12 BIOENTITY at_RE2 NUM_RE2 mg_RE2 per_RE2 day_RE2 
Nifedipine_ddi|P|nifedipine|cimetidine|if_LE1 BIOENTITY therapy_BE12 be_BE12 initiate_BE12 in_BE12 patient_BE12 current_BE12 receive_BE12 BIOENTITY cautious_RE2 titration_RE2 be_RE2 advise_RE2 
Nilutamide_ddi|P|vitamin k antagonist|nilutamide|For_LE1 example_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY prothrombin_RE2 time_RE2 shall_RE2 be_RE2 careful_RE2 monitor_RE2 and_RE2 if_RE2 necessary_RE2 the_RE2 dosage_RE2 of_RE2 BIOGENERAL_RE2 shall_RE2 be_RE2 reduce_RE2 
Nimodipine_ddi|P|calcium channel blocker|nimotop|it_LE1 be_LE1 possible_LE1 that_LE1 the_LE1 cardiovascular_LE1 action_LE1 of_LE1 other_LE1 BIOENTITY can_BE12 be_BE12 enhance_BE12 by_BE12 the_BE12 addition_BE12 of_BE12 BIOENTITY 
Nimodipine_ddi|P|nimotop|antihypertensive compound|In_LE1 europe_LE1 BIOENTITY be_BE12 observe_BE12 to_BE12 occasional_BE12 intensify_BE12 the_BE12 effect_BE12 of_BE12 BIOENTITY take_RE2 concomitant_RE2 by_RE2 patient_RE2 suffer_RE2 from_RE2 hypertension_RE2 
Nimodipine_ddi|P|cimetidine|nimodipine|study_LE1 in_LE1 eight_LE1 healthy_LE1 volunteer_LE1 have_LE1 show_LE1 NUM_LE1 increase_LE1 in_LE1 mean_LE1 peak_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 and_LE1 NUM_LE1 increase_LE1 in_LE1 mean_LE1 area_LE1 under_LE1 the_LE1 curve_LE1 after_LE1 one_LE1 week_LE1 course_LE1 of_LE1 BIOENTITY at_BE12 NUM_BE12 mg_BE12 and_BE12 BIOENTITY at_RE2 NUM_RE2 mg_RE2 
Nimodipine_ddi|P|cimetidine|nimodipine|this_LE1 effect_LE1 may_LE1 be_LE1 mediate_LE1 by_LE1 the_LE1 known_LE1 inhibition_LE1 of_LE1 hepatic_LE1 cytochrome_LE1 p-_LE1 NUM_LE1 by_LE1 BIOENTITY which_BE12 can_BE12 decrease_BE12 first_BE12 pass_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Nisoldipine_ddi|P|nisoldipine|cimetidine 400 mg|NUM_LE1 to_LE1 NUM_LE1 increase_LE1 in_LE1 auc_LE1 and_LE1 cmax_LE1 of_LE1 BIOENTITY be_BE12 observe_BE12 with_BE12 concomitant_BE12 administration_BE12 of_BE12 BIOENTITY twice_RE2 daily_RE2 
Nisoldipine_ddi|P|phenytoin|sular|coadministration_LE1 of_LE1 BIOENTITY with_BE12 NUM_BE12 mg_BE12 BIOENTITY tablet_RE2 in_RE2 epileptic_RE2 patient_RE2 lower_RE2 the_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 to_RE2 undetectable_RE2 level_RE2 
Nisoldipine_ddi|P|sular|phenytoin|coadministration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY or_RE2 any_RE2 known_RE2 cyp3a4_RE2 inducer_RE2 shall_RE2 be_RE2 avoid_RE2 and_RE2 alternative_RE2 BIOGENERAL_RE2 therapy_RE2 shall_RE2 be_RE2 consider_RE2 
Nisoldipine_ddi|P|propranolol|nisoldipine|BIOENTITY attenuate_BE12 the_BE12 heart_BE12 rate_BE12 increase_BE12 following_BE12 administration_BE12 of_BE12 immediate_BE12 release_BE12 BIOENTITY 
Nisoldipine_ddi|P|sular|atenolol|the_LE1 blood_LE1 pressure_LE1 effect_LE1 of_LE1 BIOENTITY tend_BE12 to_BE12 be_BE12 great_BE12 in_BE12 patient_BE12 on_BE12 BIOENTITY than_RE2 in_RE2 patient_RE2 on_RE2 no_RE2 other_RE2 BIOGENERAL_RE2 therapy_RE2 
Nisoldipine_ddi|P|quinidine|nisoldipine|BIOENTITY at_BE12 NUM_BE12 mg_BE12 bid_BE12 decrease_BE12 the_BE12 bioavailability_BE12 -LRB-_BE12 auc_BE12 -RRB-_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 but_RE2 not_RE2 the_RE2 peak_RE2 concentration_RE2 
Nisoldipine_ddi|P|nisoldipine|quinidine|the_LE1 immediate_LE1 release_LE1 but_LE1 not_LE1 the_LE1 coat-core_LE1 formulation_LE1 of_LE1 BIOENTITY increase_BE12 plasma_BE12 BIOENTITY concentration_RE2 by_RE2 about_RE2 NUM_RE2 %._RE2 
Nitazoxanide_ddi|P|nitazoxanide|warfarin|therefore_LE1 caution_LE1 shall_LE1 be_LE1 use_LE1 when_LE1 administer_LE1 BIOENTITY concurrent_BE12 with_BE12 other_BE12 high_BE12 plasma_BE12 protein-bound_BE12 drug_BE12 with_BE12 narrow_BE12 therapeutic_BE12 index_BE12 as_BE12 competition_BE12 for_BE12 binding_BE12 site_BE12 may_BE12 occur_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -rrb-._RE2 
Nitric Oxide_ddi|P|nitroglycerin|inomax|although_LE1 there_LE1 be_LE1 no_LE1 study_LE1 data_LE1 to_LE1 evaluate_LE1 the_LE1 possibility_LE1 BIOGENERAL_LE1 including_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY on_RE2 the_RE2 risk_RE2 of_RE2 develop_RE2 methemoglobinemia_RE2 
Nitric Oxide_ddi|P|sodium nitroprusside|inomax|although_LE1 there_LE1 be_LE1 no_LE1 study_LE1 data_LE1 to_LE1 evaluate_LE1 the_LE1 possibility_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY on_RE2 the_RE2 risk_RE2 of_RE2 develop_RE2 methemoglobinemia_RE2 
Nitric Oxide_ddi|P|nitric oxide donor compound|inomax|although_LE1 there_LE1 be_LE1 no_LE1 study_LE1 data_LE1 to_LE1 evaluate_LE1 the_LE1 possibility_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 have_BE12 additive_BE12 effect_BE12 with_BE12 BIOENTITY on_RE2 the_RE2 risk_RE2 of_RE2 develop_RE2 methemoglobinemia_RE2 
Nitrofurantoin_ddi|P|magnesium trisilicate|nitrofurantoin|BIOGENERAL_LE1 contain_LE1 BIOENTITY when_BE12 administer_BE12 concomitant_BE12 with_BE12 BIOENTITY reduce_RE2 both_RE2 the_RE2 rate_RE2 and_RE2 extent_RE2 of_RE2 absorption_RE2 
Nitrofurantoin_ddi|P|nitrofurantoin|magnesium trisilicate|the_LE1 mechanism_LE1 for_LE1 this_LE1 interaction_LE1 probable_LE1 be_LE1 adsorption_LE1 of_LE1 BIOENTITY onto_BE12 the_BE12 surface_BE12 of_BE12 BIOENTITY 
Nitrofurantoin_ddi|P|probenecid|nitrofurantoin|BIOGENERAL_LE1 such_LE1 as_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY 
Nitrofurantoin_ddi|P|uricosuric drug|nitrofurantoin|BIOENTITY such_BE12 as_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 can_BE12 inhibit_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY 
Nitrofurantoin_ddi|P|sulfinpyrazone|nitrofurantoin|BIOGENERAL_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY can_BE12 inhibit_BE12 renal_BE12 tubular_BE12 secretion_BE12 of_BE12 BIOENTITY 
Nitroglycerin_ddi|P|nitroglycerin|vasodilator|the_LE1 vasodilating_LE1 effect_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 additive_BE12 with_BE12 those_BE12 of_BE12 other_BE12 BIOENTITY 
Nitroglycerin_ddi|P|calcium channel blocker|nitrate|marked_LE1 symptomatic_LE1 orthostatic_LE1 hypotension_LE1 have_LE1 be_LE1 report_LE1 when_LE1 BIOENTITY and_BE12 organic_BE12 BIOENTITY be_RE2 use_RE2 in_RE2 combination_RE2 
Nitroprusside_ddi|P|sodium nitroprusside|ganglionic blocking agent|the_LE1 hypotensive_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 augment_BE12 by_BE12 that_BE12 of_BE12 many_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY negative_RE2 inotropic_RE2 agent_RE2 and_RE2 inhaled_RE2 BIOGENERAL_RE2 
Nitroprusside_ddi|P|sodium nitroprusside|anesthetic|the_LE1 hypotensive_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 augment_BE12 by_BE12 that_BE12 of_BE12 many_BE12 other_BE12 BIOGENERAL_BE12 including_BE12 BIOGENERAL_BE12 negative_BE12 inotropic_BE12 agent_BE12 and_BE12 inhaled_BE12 BIOENTITY 
Nitroprusside_ddi|P|sodium nitroprusside|hypotensive drug|the_LE1 hypotensive_LE1 effect_LE1 of_LE1 BIOENTITY be_BE12 augment_BE12 by_BE12 that_BE12 of_BE12 many_BE12 other_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 negative_RE2 inotropic_RE2 agent_RE2 and_RE2 inhaled_RE2 BIOGENERAL_RE2 
Nizatidine_ddi|P|aspirin|nizatidine|In_LE1 patient_LE1 given_LE1 very_LE1 high_LE1 dose_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 -RRB-_LE1 of_LE1 BIOENTITY daily_BE12 increase_BE12 in_BE12 serum_BE12 BIOGENERAL_BE12 level_BE12 be_BE12 see_BE12 when_BE12 BIOENTITY NUM_RE2 mg_RE2 b.i.d._RE2 be_RE2 administer_RE2 concurrent_RE2 
Norethindrone_ddi|P|progestin|carbamazepine|the_LE1 effectiveness_LE1 of_LE1 BIOENTITY pill_BE12 be_BE12 reduce_BE12 by_BE12 hepatic_BE12 enzyme-inducing_BE12 drug_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Norethindrone_ddi|P|progestin|phenytoin|the_LE1 effectiveness_LE1 of_LE1 BIOENTITY pill_BE12 be_BE12 reduce_BE12 by_BE12 hepatic_BE12 enzyme-inducing_BE12 drug_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 and_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Norethindrone_ddi|P|progestin|rifampin|the_LE1 effectiveness_LE1 of_LE1 BIOENTITY pill_BE12 be_BE12 reduce_BE12 by_BE12 hepatic_BE12 enzyme-inducing_BE12 drug_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 and_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY 
Norethindrone_ddi|P|progestin|barbiturate|the_LE1 effectiveness_LE1 of_LE1 BIOENTITY pill_BE12 be_BE12 reduce_BE12 by_BE12 hepatic_BE12 enzyme-inducing_BE12 drug_BE12 such_BE12 as_BE12 the_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY and_RE2 the_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|theophylline|quinolone|elevated_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 report_BE12 with_BE12 concomitant_BE12 BIOENTITY use_RE2 
Norfloxacin_ddi|P|norfloxacin|theophylline|there_LE1 have_LE1 be_LE1 report_LE1 of_LE1 BIOGENERAL_LE1 side_LE1 effect_LE1 in_LE1 patient_LE1 on_LE1 concomitant_LE1 therapy_LE1 with_LE1 BIOENTITY and_BE12 BIOENTITY 
Norfloxacin_ddi|P|cyclosporine|norfloxacin|elevated_LE1 serum_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 with_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY 
Norfloxacin_ddi|P|norfloxacin|anticoagulant|BIOGENERAL_LE1 including_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 or_RE2 similar_RE2 agent_RE2 
Norfloxacin_ddi|P|norfloxacin|warfarin|BIOGENERAL_LE1 including_LE1 BIOENTITY may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 or_RE2 similar_RE2 agent_RE2 
Norfloxacin_ddi|P|quinolone|anticoagulant|BIOENTITY including_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOENTITY including_RE2 BIOGENERAL_RE2 or_RE2 its_RE2 derivative_RE2 or_RE2 similar_RE2 agent_RE2 
Norfloxacin_ddi|P|quinolone|warfarin|BIOENTITY including_BE12 BIOGENERAL_BE12 may_BE12 enhance_BE12 the_BE12 effect_BE12 of_BE12 oral_BE12 BIOGENERAL_BE12 including_BE12 BIOENTITY or_RE2 its_RE2 derivative_RE2 or_RE2 similar_RE2 agent_RE2 
Norfloxacin_ddi|P|norfloxacin|glyburide|the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 on_RE2 rare_RE2 occasion_RE2 result_RE2 in_RE2 severe_RE2 hypoglycemia_RE2 
Norfloxacin_ddi|P|quinolone|glyburide|the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 with_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 have_RE2 on_RE2 rare_RE2 occasion_RE2 result_RE2 in_RE2 severe_RE2 hypoglycemia_RE2 
Norfloxacin_ddi|P|probenecid|norfloxacin|diminish_LE1 urinary_LE1 excretion_LE1 of_LE1 BIOGENERAL_LE1 have_LE1 be_LE1 report_LE1 during_LE1 the_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY 
Norfloxacin_ddi|P|nitrofurantoin|norfloxacin|the_LE1 concomitant_LE1 use_LE1 of_LE1 BIOGENERAL_LE1 be_LE1 not_LE1 recommend_LE1 since_LE1 BIOENTITY may_BE12 antagonize_BE12 the_BE12 antibacterial_BE12 effect_BE12 of_BE12 BIOENTITY in_RE2 the_RE2 urinary_RE2 tract_RE2 
Norfloxacin_ddi|P|multivitamin|norfloxacin|BIOENTITY or_BE12 other_BE12 product_BE12 contain_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|zinc|norfloxacin|BIOGENERAL_LE1 or_LE1 other_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|iron|norfloxacin|BIOGENERAL_LE1 or_LE1 other_LE1 product_LE1 contain_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 or_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|sucralfate|norfloxacin|BIOGENERAL_LE1 or_LE1 other_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|antacid|norfloxacin|BIOGENERAL_LE1 or_LE1 other_LE1 product_LE1 contain_LE1 BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 they_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|videx|norfloxacin|BIOENTITY -LRB-_BE12 BIOGENERAL_BE12 -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 these_RE2 product_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|didanosine|norfloxacin|BIOGENERAL_LE1 -LRB-_LE1 BIOENTITY -RRB-_BE12 chewable_BE12 tablet_BE12 or_BE12 the_BE12 pediatric_BE12 powder_BE12 for_BE12 oral_BE12 solution_BE12 shall_BE12 not_BE12 be_BE12 administer_BE12 concomitant_BE12 with_BE12 or_BE12 within_BE12 NUM_BE12 hour_BE12 of_BE12 the_BE12 administration_BE12 of_BE12 BIOENTITY because_RE2 these_RE2 product_RE2 may_RE2 interfere_RE2 with_RE2 absorption_RE2 result_RE2 in_RE2 low_RE2 serum_RE2 and_RE2 urine_RE2 level_RE2 of_RE2 BIOGENERAL_RE2 
Norfloxacin_ddi|P|quinolone|caffeine|some_LE1 BIOENTITY have_BE12 also_BE12 be_BE12 show_BE12 to_BE12 interfere_BE12 with_BE12 the_BE12 metabolism_BE12 of_BE12 BIOENTITY 
Nortriptyline_ddi|P|tricyclic antidepressant|cimetidine|steady-state_LE1 serum_LE1 concentration_LE1 of_LE1 BIOENTITY be_BE12 report_BE12 to_BE12 fluctuate_BE12 significant_BE12 when_BE12 BIOENTITY be_RE2 either_RE2 add_RE2 or_RE2 delete_RE2 from_RE2 the_RE2 drug_RE2 regimen_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|cimetidine|serious_LE1 anticholinergic_LE1 symptom_LE1 -LRB-_LE1 severe_LE1 dry_LE1 mouth_LE1 urinary_LE1 retention_LE1 blurred_LE1 vision_LE1 -RRB-_LE1 have_LE1 be_LE1 associate_LE1 with_LE1 elevation_LE1 in_LE1 the_LE1 serum_LE1 level_LE1 of_LE1 BIOENTITY when_BE12 BIOENTITY be_RE2 add_RE2 to_RE2 the_RE2 drug_RE2 regimen_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|cimetidine|In_LE1 addition_LE1 higher-than_LE1 expect_LE1 steady-state_LE1 serum_LE1 concentration_LE1 of_LE1 BIOENTITY have_BE12 be_BE12 observe_BE12 when_BE12 therapy_BE12 be_BE12 initiate_BE12 in_BE12 patient_BE12 already_BE12 take_BE12 BIOENTITY 
Nortriptyline_ddi|P|cimetidine|tricyclic antidepressant|In_LE1 well-controlled_LE1 patient_LE1 undergo_LE1 concurrent_LE1 therapy_LE1 with_LE1 BIOENTITY decrease_BE12 in_BE12 the_BE12 steady-state_BE12 serum_BE12 concentration_BE12 of_BE12 BIOENTITY may_RE2 occur_RE2 when_RE2 cime-tidine_RE2 therapy_RE2 be_RE2 discontinue_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|cimetidine|the_LE1 therapeutic_LE1 efficacy_LE1 of_LE1 BIOENTITY may_BE12 be_BE12 compromise_BE12 in_BE12 these_BE12 patient_BE12 when_BE12 BIOENTITY be_RE2 discontinue_RE2 
Nortriptyline_ddi|P|antidepressant|fluoxetine hydrochloride|there_LE1 have_LE1 be_LE1 great_LE1 than_LE1 NUM_LE1 increase_LE1 in_LE1 previous_LE1 stable_LE1 plasma_LE1 level_LE1 of_LE1 other_LE1 BIOENTITY including_BE12 BIOGENERAL_BE12 when_BE12 BIOENTITY have_RE2 be_RE2 administer_RE2 in_RE2 combination_RE2 with_RE2 these_RE2 agent_RE2 
Nortriptyline_ddi|P|nortriptyline|fluoxetine hydrochloride|there_LE1 have_LE1 be_LE1 great_LE1 than_LE1 NUM_LE1 increase_LE1 in_LE1 previous_LE1 stable_LE1 plasma_LE1 level_LE1 of_LE1 other_LE1 BIOGENERAL_LE1 including_LE1 BIOENTITY when_BE12 BIOENTITY have_RE2 be_RE2 administer_RE2 in_RE2 combination_RE2 with_RE2 these_RE2 agent_RE2 
Nortriptyline_ddi|P|reserpine|tricyclic antidepressant|administration_LE1 of_LE1 BIOENTITY during_BE12 therapy_BE12 with_BE12 BIOENTITY have_RE2 be_RE2 show_RE2 to_RE2 produce_RE2 stimulating_RE2 effect_RE2 in_RE2 some_RE2 depressed_RE2 patient_RE2 
Nortriptyline_ddi|P|nortriptyline hydrochloride|anticholinergic drug|close_LE1 supervision_LE1 and_LE1 careful_LE1 adjustment_LE1 of_LE1 the_LE1 dosage_LE1 be_LE1 require_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 with_BE12 other_BE12 BIOENTITY or_RE2 BIOGENERAL_RE2 
Nortriptyline_ddi|P|nortriptyline hydrochloride|sympathomimetic drug|close_LE1 supervision_LE1 and_LE1 careful_LE1 adjustment_LE1 of_LE1 the_LE1 dosage_LE1 be_LE1 require_LE1 when_LE1 BIOENTITY be_BE12 use_BE12 with_BE12 other_BE12 BIOGENERAL_BE12 or_BE12 BIOENTITY 
Nortriptyline_ddi|P|tricyclic antidepressant|quinidine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 or_BE12 that_BE12 inhibit_BE12 this_BE12 enzyme_BE12 -LRB-_BE12 eg_BE12 BIOENTITY -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|encainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|phenothiazine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|antidepressant|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOENTITY BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|type 1c antiarrhythmic|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|carbamazepine|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|flecainide|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOGENERAL_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Nortriptyline_ddi|P|tricyclic antidepressant|propafenone|therefore_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 other_BE12 drug_BE12 that_BE12 be_BE12 metabolize_BE12 by_BE12 this_BE12 isoenzyme_BE12 including_BE12 other_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 eg_BE12 BIOENTITY BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 -RRB-_RE2 or_RE2 that_RE2 inhibit_RE2 this_RE2 enzyme_RE2 -LRB-_RE2 eg_RE2 BIOGENERAL_RE2 -RRB-_RE2 shall_RE2 be_RE2 approach_RE2 with_RE2 caution_RE2 
Oxcarbazepine_ddi|P|aed|oxcarbazepine|In_LE1 addition_LE1 several_LE1 BIOENTITY that_BE12 be_BE12 cytochrome_BE12 p450_BE12 inducer_BE12 can_BE12 decrease_BE12 plasma_BE12 concentration_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 
Oxcarbazepine_ddi|P|phenytoin|trileptal|NUM_LE1 nc_LE1 denote_LE1 mean_LE1 change_LE1 of_LE1 little_LE1 than_LE1 NUM_LE1 NUM_LE1 pediatrics_LE1 NUM_LE1 mean_LE1 increase_LE1 in_LE1 adult_LE1 at_LE1 high_LE1 BIOGENERAL_LE1 dose_LE1 in_LE1 vivo_LE1 the_LE1 plasma_LE1 level_LE1 of_LE1 BIOENTITY increase_BE12 by_BE12 up_BE12 to_BE12 NUM_BE12 when_BE12 BIOENTITY be_RE2 give_RE2 at_RE2 dose_RE2 above_RE2 NUM_RE2 mg_RE2 
Oxcarbazepine_ddi|P|trileptal|phenytoin|therefore_LE1 when_LE1 use_LE1 dose_LE1 of_LE1 BIOENTITY great_BE12 than_BE12 NUM_BE12 mg_BE12 during_BE12 adjunctive_BE12 therapy_BE12 decrease_BE12 in_BE12 the_BE12 dose_BE12 of_BE12 BIOENTITY may_RE2 be_RE2 require_RE2 
Oxcarbazepine_ddi|P|phenobarbital|trileptal|the_LE1 increase_LE1 of_LE1 BIOENTITY level_BE12 however_BE12 be_BE12 small_BE12 -LRB-_BE12 NUM_BE12 -RRB-_BE12 when_BE12 give_BE12 with_BE12 BIOENTITY 
Oxcarbazepine_ddi|P|trileptal|contraceptive|hormonal_LE1 BIOGENERAL_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 oral_BE12 BIOENTITY have_RE2 be_RE2 show_RE2 to_RE2 influence_RE2 the_RE2 plasma_RE2 concentration_RE2 of_RE2 the_RE2 two_RE2 hormonal_RE2 component_RE2 BIOGENERAL_RE2 -LRB-_RE2 ee_RE2 -RRB-_RE2 and_RE2 BIOGENERAL_RE2 -LRB-_RE2 lng-rrb-._RE2 
Oxcarbazepine_ddi|P|trileptal|hormonal contraceptive|therefore_LE1 concurrent_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 render_RE2 these_RE2 BIOGENERAL_RE2 little_RE2 effective_RE2 
Oxcarbazepine_ddi|P|trileptal|felodipine|BIOGENERAL_LE1 :_LE1 After_LE1 repeated_LE1 co-administration_LE1 of_LE1 BIOENTITY the_BE12 auc_BE12 of_BE12 BIOENTITY be_RE2 lower_RE2 by_RE2 NUM_RE2 NUM_RE2 ci_RE2 :_RE2 NUM_RE2 -rsb-._RE2 
Paclitaxel_ddi|P|taxol|cisplatin|In_LE1 phase_LE1 trial_LE1 use_LE1 escalating_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 -RRB-_LE1 and_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 or_LE1 NUM_LE1 mg_LE1 -RRB-_LE1 give_LE1 as_LE1 sequential_LE1 infusion_LE1 myelosuppression_LE1 be_LE1 much_LE1 profound_LE1 when_LE1 BIOENTITY be_BE12 give_BE12 after_BE12 BIOENTITY than_RE2 with_RE2 the_RE2 alternate_RE2 sequence_RE2 -LRB-_RE2 ie_RE2 BIOGENERAL_RE2 before_RE2 BIOGENERAL_RE2 -rrb-._RE2 
Paclitaxel_ddi|P|taxol|cisplatin|pharmacokinetic_LE1 datum_LE1 from_LE1 these_LE1 patient_LE1 demonstrate_LE1 decrease_LE1 in_LE1 BIOGENERAL_LE1 clearance_LE1 of_LE1 approximate_LE1 NUM_LE1 when_LE1 BIOENTITY be_BE12 administer_BE12 following_BE12 BIOENTITY 
Paclitaxel_ddi|P|paclitaxel|doxorubicin|report_LE1 in_LE1 the_LE1 literature_LE1 suggest_LE1 that_LE1 plasma_LE1 level_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 and_LE1 its_LE1 active_LE1 metabolite_LE1 BIOGENERAL_LE1 -RRB-_LE1 may_LE1 be_LE1 increase_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 use_RE2 in_RE2 combination_RE2 
Paclitaxel_ddi|P|cyclosporin|taxol|hypersensitivity_LE1 reaction_LE1 :_LE1 patient_LE1 with_LE1 history_LE1 of_LE1 severe_LE1 hypersensitivity_LE1 reaction_LE1 to_LE1 product_LE1 contain_LE1 cremophor_LE1 el_LE1 -LRB-_LE1 eg_LE1 BIOENTITY for_BE12 injection_BE12 concentrate_BE12 and_BE12 BIOGENERAL_BE12 for_BE12 injection_BE12 concentrate_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY 
Paclitaxel_ddi|P|teniposide|taxol|hypersensitivity_LE1 reaction_LE1 :_LE1 patient_LE1 with_LE1 history_LE1 of_LE1 severe_LE1 hypersensitivity_LE1 reaction_LE1 to_LE1 product_LE1 contain_LE1 cremophor_LE1 el_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 for_LE1 injection_LE1 concentrate_LE1 and_LE1 BIOENTITY for_BE12 injection_BE12 concentrate_BE12 -RRB-_BE12 shall_BE12 not_BE12 be_BE12 treat_BE12 with_BE12 BIOENTITY 
Peginterferon alfa-2a_ddi|P|pegasy|theophylline|treatment_LE1 with_LE1 BIOENTITY once_BE12 weekly_BE12 for_BE12 NUM_BE12 week_BE12 in_BE12 healthy_BE12 subject_BE12 be_BE12 associate_BE12 with_BE12 inhibition_BE12 of_BE12 p450_BE12 1a2_BE12 and_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY auc_RE2 
Peginterferon alfa-2a_ddi|P|theophylline|pegasy|BIOGENERAL_LE1 serum_LE1 level_LE1 shall_LE1 be_LE1 monitor_LE1 and_LE1 appropriate_LE1 dose_LE1 adjustment_LE1 consider_LE1 for_LE1 patient_LE1 given_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY 
Peginterferon alfa-2a_ddi|P|copegu|didanosine|nucleoside_LE1 analogue_LE1 BIOGENERAL_LE1 co-administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Peginterferon alfa-2a_ddi|P|ribavirin|zidovudine|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOENTITY can_BE12 antagonize_BE12 the_BE12 in_BE12 vitro_BE12 antiviral_BE12 activity_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY against_RE2 hiv_RE2 
Peginterferon alfa-2a_ddi|P|ribavirin|stavudine|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 BIOENTITY can_BE12 antagonize_BE12 the_BE12 in_BE12 vitro_BE12 antiviral_BE12 activity_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 against_RE2 hiv_RE2 
Piperacillin_ddi|P|piperacillin|aminoglycoside|BIOGENERAL_LE1 :_LE1 the_LE1 mixing_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY in_RE2 vitro_RE2 can_RE2 result_RE2 in_RE2 substantial_RE2 inactivation_RE2 of_RE2 the_RE2 BIOGENERAL_RE2 
Piperacillin_ddi|P|piperacillin|vecuronium|BIOGENERAL_LE1 :_LE1 when_LE1 use_LE1 in_LE1 the_LE1 perioperative_LE1 period_LE1 BIOENTITY have_BE12 be_BE12 implicate_BE12 in_BE12 the_BE12 prolongation_BE12 of_BE12 the_BE12 neuromuscular_BE12 blockade_BE12 of_BE12 BIOENTITY 
Piperacillin_ddi|P|piperacillin|vecuronium|In_LE1 one_LE1 controlled_LE1 clinical_LE1 study_LE1 the_LE1 ureidopenicillin_LE1 including_LE1 BIOENTITY be_BE12 report_BE12 to_BE12 prolong_BE12 the_BE12 action_BE12 of_BE12 BIOENTITY 
Piperacillin_ddi|P|non-depolarizing muscle relaxant|piperacillin|Due_LE1 to_LE1 their_LE1 similar_LE1 mechanism_LE1 of_LE1 action_LE1 it_LE1 be_LE1 expect_LE1 that_LE1 the_LE1 neuromuscular_LE1 blockade_LE1 produce_LE1 by_LE1 any_LE1 of_LE1 the_LE1 BIOENTITY can_BE12 be_BE12 prolong_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 BIOENTITY 
Piperacillin_ddi|P|probenecid|pipracil|BIOGENERAL_LE1 :_LE1 the_LE1 oral_LE1 combination_LE1 of_LE1 BIOENTITY before_BE12 intramuscular_BE12 injection_BE12 of_BE12 BIOENTITY produce_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 peak_RE2 serum_RE2 level_RE2 of_RE2 about_RE2 NUM_RE2 %._RE2 
Piperacillin_ddi|P|piperacillin sodium|methotrexate|BIOGENERAL_LE1 :_LE1 BIOENTITY may_BE12 reduce_BE12 the_BE12 excretion_BE12 of_BE12 BIOENTITY 
Piperazine_ddi|P|piperazine|phenothiazine|BIOGENERAL_LE1 take_LE1 BIOENTITY and_BE12 BIOENTITY together_RE2 may_RE2 increase_RE2 the_RE2 risk_RE2 of_RE2 convulsion_RE2 -LRB-_RE2 seizures-rrb-._RE2 
Piperazine_ddi|P|piperazine|pyrantel|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 take_LE1 BIOENTITY and_BE12 BIOENTITY together_RE2 may_RE2 decrease_RE2 the_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Rofecoxib_ddi|P|nsaid|angiotensin converting enzyme (ace) inhibitor|BIOGENERAL_LE1 :_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 -LRB-_BE12 ace_BE12 -RRB-_BE12 BIOENTITY 
Rofecoxib_ddi|P|vioxx|benazepril|In_LE1 patient_LE1 with_LE1 mild_LE1 to_LE1 moderate_LE1 hypertension_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 daily_LE1 of_LE1 BIOENTITY with_BE12 the_BE12 BIOGENERAL_BE12 BIOENTITY NUM_RE2 to_RE2 NUM_RE2 mg_RE2 for_RE2 NUM_RE2 week_RE2 be_RE2 associate_RE2 with_RE2 average_RE2 increase_RE2 in_RE2 mean_RE2 arterial_RE2 pressure_RE2 of_RE2 about_RE2 NUM_RE2 mm_RE2 hg_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 alone_RE2 
Rofecoxib_ddi|P|vioxx|ace inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Rofecoxib_ddi|P|aspirin|vioxx|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 low-dose_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 rate_RE2 of_RE2 gi_RE2 ulceration_RE2 or_RE2 other_RE2 complication_RE2 compared_RE2 to_RE2 use_RE2 of_RE2 BIOGENERAL_RE2 alone_RE2 
Rofecoxib_ddi|P|cimetidine|rofecoxib|BIOGENERAL_LE1 :_LE1 co-administration_LE1 with_LE1 high_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 twice_BE12 daily_BE12 -rsb-_BE12 increase_BE12 the_BE12 cmax_BE12 of_BE12 BIOENTITY by_RE2 NUM_RE2 the_RE2 auc0-120hr_RE2 by_RE2 NUM_RE2 and_RE2 the_RE2 t1_RE2 by_RE2 NUM_RE2 %._RE2 
Rofecoxib_ddi|P|nsaid|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Rofecoxib_ddi|P|nsaid|thiazide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Rofecoxib_ddi|P|nsaid|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY have_BE12 produce_BE12 elevation_BE12 of_BE12 plasma_BE12 BIOENTITY level_RE2 and_RE2 reduction_RE2 in_RE2 renal_RE2 BIOGENERAL_RE2 clearance_RE2 
Rofecoxib_ddi|P|vioxx|lithium|thus_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concurrent_RE2 subject_RE2 shall_RE2 be_RE2 observe_RE2 careful_RE2 for_RE2 sign_RE2 of_RE2 BIOGENERAL_RE2 toxicity_RE2 
Rofecoxib_ddi|P|vioxx|methotrexate|At_LE1 high_LE1 than_LE1 recommend_LE1 dose_LE1 BIOENTITY NUM_BE12 mg_BE12 administer_BE12 once_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 increase_BE12 plasma_BE12 concentration_BE12 by_BE12 NUM_BE12 as_BE12 measure_BE12 by_BE12 auc0-24hr_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY NUM_RE2 to_RE2 NUM_RE2 mg_RE2 for_RE2 rheumatoid_RE2 arthritis_RE2 
Rofecoxib_ddi|P|methotrexate|rofecoxib|At_LE1 NUM_LE1 hour_LE1 postdose_LE1 similar_LE1 proportion_LE1 of_LE1 patient_LE1 treat_LE1 with_LE1 BIOGENERAL_LE1 alone_LE1 -LRB-_LE1 NUM_LE1 -RRB-_LE1 and_LE1 subsequent_LE1 treat_LE1 with_LE1 BIOENTITY co-administer_BE12 with_BE12 NUM_BE12 mg_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 -RRB-_RE2 have_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 below_RE2 the_RE2 measurable_RE2 limit_RE2 -LRB-_RE2 NUM_RE2 ng_RE2 -rrb-._RE2 
Rofecoxib_ddi|P|vioxx|methotrexate|standard_LE1 monitoring_LE1 of_LE1 BIOGENERAL_LE1 toxicity_LE1 shall_LE1 be_LE1 continue_LE1 if_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 administer_RE2 concomitant_RE2 
Rofecoxib_ddi|P|vioxx|rifampin|BIOGENERAL_LE1 :_LE1 co-administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY NUM_RE2 mg_RE2 daily_RE2 potent_RE2 inducer_RE2 of_RE2 hepatic_RE2 metabolism_RE2 produce_RE2 approximate_RE2 NUM_RE2 decrease_RE2 in_RE2 BIOGENERAL_RE2 plasma_RE2 concentration_RE2 
Rofecoxib_ddi|P|vioxx|theophylline|BIOGENERAL_LE1 BIOENTITY NUM_BE12 NUM_BE12 and_BE12 NUM_BE12 mg_BE12 administer_BE12 once_BE12 daily_BE12 for_BE12 NUM_BE12 day_BE12 increase_BE12 plasma_BE12 BIOENTITY concentration_RE2 -LRB-_RE2 auc_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 -RRB-_RE2 by_RE2 NUM_RE2 to_RE2 NUM_RE2 in_RE2 healthy_RE2 subject_RE2 administer_RE2 single_RE2 NUM_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 
Rofecoxib_ddi|P|vioxx|theophylline|adequate_LE1 monitoring_LE1 of_LE1 BIOGENERAL_LE1 plasma_LE1 concentration_LE1 shall_LE1 be_LE1 consider_LE1 when_LE1 therapy_LE1 with_LE1 BIOENTITY be_BE12 initiate_BE12 or_BE12 change_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Rofecoxib_ddi|P|vioxx|warfarin|BIOGENERAL_LE1 :_LE1 anticoagulant_LE1 activity_LE1 shall_LE1 be_LE1 monitor_LE1 particular_LE1 in_LE1 the_LE1 first_LE1 few_LE1 day_LE1 after_LE1 initiate_LE1 or_LE1 change_LE1 BIOENTITY therapy_BE12 in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 similar_RE2 agent_RE2 since_RE2 these_RE2 patient_RE2 be_RE2 at_RE2 increase_RE2 risk_RE2 of_RE2 bleeding_RE2 complication_RE2 
Rofecoxib_ddi|P|warfarin|rofecoxib|In_LE1 single_LE1 and_LE1 multiple_LE1 dose_LE1 study_LE1 in_LE1 healthy_LE1 subject_LE1 receive_LE1 both_LE1 BIOENTITY and_BE12 BIOENTITY prothrombin_RE2 time_RE2 -LRB-_RE2 measure_RE2 as_RE2 inr_RE2 -RRB-_RE2 be_RE2 increase_RE2 by_RE2 approximate_RE2 NUM_RE2 to_RE2 NUM_RE2 %._RE2 
Rofecoxib_ddi|P|vioxx|warfarin|In_LE1 post-marketing_LE1 experience_LE1 bleeding_LE1 event_LE1 have_LE1 be_LE1 report_LE1 predominant_LE1 in_LE1 the_LE1 elderly_LE1 in_LE1 association_LE1 with_LE1 increase_LE1 in_LE1 prothrombin_LE1 time_LE1 in_LE1 patient_LE1 receive_LE1 BIOENTITY concurrent_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|fentanyl|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|triazolam|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|carbamazepine|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|alprazolam|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|alfentanyl|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|pimozide|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|amiodarone|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|quinidine|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|warfarin|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|tacrolimu|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|cyclosporine|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|ergot derivative|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|calcium channel blocker|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|dapsone|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|disopyramide|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|quinine|saquinavir|although_LE1 specific_LE1 study_LE1 have_LE1 not_LE1 be_LE1 perform_LE1 coadministration_LE1 with_LE1 drug_LE1 that_LE1 be_LE1 main_LE1 metabolize_LE1 by_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 have_BE12 elevated_BE12 plasma_BE12 concentration_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Saquinavir_ddi|P|invirase|ritonavir|since_LE1 BIOENTITY be_BE12 coadminister_BE12 with_BE12 BIOENTITY the_RE2 BIOGENERAL_RE2 label_RE2 shall_RE2 be_RE2 review_RE2 for_RE2 additional_RE2 drug_RE2 that_RE2 shall_RE2 not_RE2 be_RE2 coadminister_RE2 
Saquinavir_ddi|P|phenobarbital|saquinavir|coadministration_LE1 with_LE1 compound_LE1 that_LE1 be_LE1 potent_LE1 inducer_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 result_BE12 in_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Saquinavir_ddi|P|phenytoin|saquinavir|coadministration_LE1 with_LE1 compound_LE1 that_LE1 be_LE1 potent_LE1 inducer_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 BIOGENERAL_BE12 -RRB-_BE12 may_BE12 result_BE12 in_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Saquinavir_ddi|P|dexamethasone|saquinavir|coadministration_LE1 with_LE1 compound_LE1 that_LE1 be_LE1 potent_LE1 inducer_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY BIOGENERAL_BE12 -RRB-_BE12 may_BE12 result_BE12 in_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Saquinavir_ddi|P|carbamazepine|saquinavir|coadministration_LE1 with_LE1 compound_LE1 that_LE1 be_LE1 potent_LE1 inducer_LE1 of_LE1 cyp3a4_LE1 -LRB-_LE1 eg_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 BIOENTITY -RRB-_BE12 may_BE12 result_BE12 in_BE12 decrease_BE12 plasma_BE12 level_BE12 of_BE12 BIOENTITY 
Sulfacetamide_ddi|P|sulfacetamide|silver|BIOENTITY preparation_BE12 be_BE12 incompatible_BE12 with_BE12 BIOENTITY preparation_RE2 
Sulfapyridine_ddi|P|sulfapyridine|tylenol|BIOENTITY may_BE12 interact_BE12 with_BE12 any_BE12 of_BE12 the_BE12 following_BE12 :_BE12 BIOGENERAL_BE12 -LRB-_BE12 e.g._BE12 BIOENTITY -RRB-_RE2 -LRB-_RE2 with_RE2 long-term_RE2 high-dose_RE2 use_RE2 -RRB-_RE2 or_RE2 
Sulfapyridine_ddi|P|sulfapyridine|acetaminophen|BIOENTITY may_BE12 interact_BE12 with_BE12 any_BE12 of_BE12 the_BE12 following_BE12 :_BE12 BIOENTITY -LRB-_RE2 e.g._RE2 BIOGENERAL_RE2 -RRB-_RE2 -LRB-_RE2 with_RE2 long-term_RE2 high-dose_RE2 use_RE2 -RRB-_RE2 or_RE2 
Sulfapyridine_ddi|P|antidiabetic|sulfapyridine|BIOGENERAL_LE1 oral_LE1 -LRB-_LE1 diabetes_LE1 medicine_LE1 you_LE1 take_LE1 by_LE1 mouth_LE1 -RRB-_LE1 use_LE1 of_LE1 oral_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 chance_RE2 of_RE2 side_RE2 effect_RE2 affect_RE2 the_RE2 blood_RE2 and_RE2 the_RE2 side_RE2 effect_RE2 or_RE2 oral_RE2 BIOGENERAL_RE2 
Sulfapyridine_ddi|P|methotrexate|sulfapyridine|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 chance_RE2 of_RE2 side_RE2 effect_RE2 affect_RE2 the_RE2 liver_RE2 and_RE2 the_RE2 side_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Sulfapyridine_ddi|P|methyldopa|sulfapyridine|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 chance_RE2 of_RE2 side_RE2 effect_RE2 affecting_RE2 the_RE2 liver_RE2 and_RE2 the_RE2 blood_RE2 
Sulfapyridine_ddi|P|phenytoin|sulfapyridine|BIOGENERAL_LE1 -LRB-_LE1 e.g._LE1 BIOGENERAL_LE1 -RRB-_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 increase_RE2 the_RE2 chance_RE2 of_RE2 side_RE2 effect_RE2 affect_RE2 the_RE2 liver_RE2 and_RE2 the_RE2 side_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Tiagabine_ddi|P|tiagabine|valproate|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 slight_BE12 decrease_BE12 -LRB-_BE12 about_BE12 NUM_BE12 -RRB-_BE12 in_BE12 steady-state_BE12 BIOENTITY concentration_RE2 
Tiagabine_ddi|P|tiagabine|carbamazepine|effect_LE1 of_LE1 other_LE1 antiepilepsy_LE1 drug_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 on_LE1 BIOGENERAL_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 indicate_LE1 that_LE1 BIOENTITY clearance_BE12 be_BE12 NUM_BE12 great_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY with_RE2 or_RE2 without_RE2 other_RE2 enzyme-_RE2 inducing_RE2 BIOGENERAL_RE2 
Tiagabine_ddi|P|tiagabine|phenytoin|BIOGENERAL_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 indicate_LE1 that_LE1 BIOENTITY clearance_BE12 be_BE12 NUM_BE12 great_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY with_RE2 or_RE2 without_RE2 other_RE2 enzyme-_RE2 induce_RE2 BIOGENERAL_RE2 
Tiagabine_ddi|P|tiagabine|primidone|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 indicate_LE1 that_LE1 BIOENTITY clearance_BE12 be_BE12 NUM_BE12 great_BE12 in_BE12 patient_BE12 take_BE12 BIOGENERAL_BE12 -LRB-_BE12 BIOENTITY -RRB-_RE2 with_RE2 or_RE2 without_RE2 other_RE2 enzyme-inducing_RE2 BIOGENERAL_RE2 
Tiagabine_ddi|P|tiagabine|phenobarbital|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 population_LE1 pharmacokinetic_LE1 analysis_LE1 indicate_LE1 that_LE1 BIOENTITY clearance_BE12 be_BE12 NUM_BE12 great_BE12 in_BE12 patient_BE12 take_BE12 BIOENTITY -LRB-_RE2 BIOGENERAL_RE2 -RRB-_RE2 with_RE2 or_RE2 without_RE2 other_RE2 enzyme-inducing_RE2 BIOGENERAL_RE2 
Tiagabine_ddi|P|valproate|tiagabine|BIOGENERAL_LE1 :_LE1 the_LE1 addition_LE1 of_LE1 BIOGENERAL_LE1 to_LE1 patient_LE1 take_LE1 BIOGENERAL_LE1 chronic_LE1 have_LE1 no_LE1 effect_LE1 on_LE1 BIOGENERAL_LE1 pharmacokinetic_LE1 but_LE1 BIOENTITY significant_BE12 decrease_BE12 BIOENTITY binding_RE2 in_RE2 vitro_RE2 from_RE2 NUM_RE2 to_RE2 NUM_RE2 which_RE2 result_RE2 in_RE2 increase_RE2 of_RE2 approximate_RE2 NUM_RE2 in_RE2 the_RE2 free_RE2 tiagabine_RE2 concentration_RE2 
Tiagabine_ddi|P|triazolam|tiagabine|Because_LE1 of_LE1 the_LE1 possible_LE1 additive_LE1 effect_LE1 of_LE1 drug_LE1 that_LE1 may_LE1 depress_LE1 the_LE1 nervous_LE1 system_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Tiagabine_ddi|P|ethanol|tiagabine|Because_LE1 of_LE1 the_LE1 possible_LE1 additive_LE1 effect_LE1 of_LE1 drug_LE1 that_LE1 may_LE1 depress_LE1 the_LE1 nervous_LE1 system_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 shall_BE12 be_BE12 use_BE12 cautious_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Valdecoxib_ddi|P|aspirin|valdecoxib|BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY may_RE2 result_RE2 in_RE2 increase_RE2 risk_RE2 of_RE2 gi_RE2 ulceration_RE2 and_RE2 complication_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 alone_RE2 
Valdecoxib_ddi|P|nsaid|ace-inhibitor|BIOGENERAL_LE1 :_LE1 report_LE1 suggest_LE1 that_LE1 BIOENTITY may_BE12 diminish_BE12 the_BE12 antihypertensive_BE12 effect_BE12 of_BE12 BIOENTITY 
Valdecoxib_ddi|P|bextra|ace-inhibitor|this_LE1 interaction_LE1 shall_LE1 be_LE1 give_LE1 consideration_LE1 in_LE1 patient_LE1 take_LE1 BIOENTITY concomitant_BE12 with_BE12 BIOENTITY 
Valdecoxib_ddi|P|nsaid|furosemide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 in_RE2 some_RE2 patient_RE2 
Valdecoxib_ddi|P|nsaid|thiazide|BIOGENERAL_LE1 :_LE1 clinical_LE1 study_LE1 as_LE1 well_LE1 as_LE1 post-marketing_LE1 observation_LE1 have_LE1 show_LE1 that_LE1 BIOENTITY can_BE12 reduce_BE12 the_BE12 natriuretic_BE12 effect_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY in_RE2 some_RE2 patient_RE2 
Valdecoxib_ddi|P|valdecoxib|phenytoin|BIOGENERAL_LE1 -LRB-_LE1 BIOGENERAL_LE1 -RRB-_LE1 :_LE1 steady_LE1 state_LE1 plasma_LE1 exposure_LE1 -LRB-_LE1 auc_LE1 -RRB-_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 be_BE12 decrease_BE12 by_BE12 NUM_BE12 when_BE12 co-administer_BE12 with_BE12 multiple_BE12 dose_BE12 -LRB-_BE12 NUM_BE12 mg_BE12 qd_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 of_BE12 BIOENTITY -LRB-_RE2 cyp_RE2 3a4_RE2 inducer_RE2 -rrb-._RE2 
Valdecoxib_ddi|P|valdecoxib|phenytoin|patient_LE1 already_LE1 stabilise_LE1 on_LE1 BIOENTITY shall_BE12 be_BE12 close_BE12 monitor_BE12 for_BE12 loss_BE12 of_BE12 symptom_BE12 control_BE12 with_BE12 BIOENTITY coadministration_RE2 
Valdecoxib_ddi|P|valdecoxib|dextromethorphan|coadministration_LE1 with_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 result_BE12 in_BE12 significant_BE12 increase_BE12 in_BE12 BIOENTITY plasma_RE2 level_RE2 suggest_RE2 that_RE2 at_RE2 these_RE2 dose_RE2 BIOGENERAL_RE2 be_RE2 weak_RE2 inhibitor_RE2 of_RE2 2d6_RE2 
Valdecoxib_ddi|P|dextromethorphan|valdecoxib|even_LE1 so_LE1 BIOENTITY plasma_BE12 concentration_BE12 in_BE12 the_BE12 presence_BE12 of_BE12 high_BE12 dose_BE12 of_BE12 BIOENTITY be_RE2 almost_RE2 NUM_RE2 low_RE2 than_RE2 those_RE2 see_RE2 in_RE2 cyp_RE2 2d6_RE2 poor_RE2 metabolizer_RE2 suggest_RE2 that_RE2 dose_RE2 adjustment_RE2 be_RE2 not_RE2 necessary_RE2 
Valdecoxib_ddi|P|valdecoxib|lithium|BIOGENERAL_LE1 :_LE1 BIOENTITY NUM_BE12 mg_BE12 bid_BE12 for_BE12 NUM_BE12 day_BE12 produce_BE12 significant_BE12 decrease_BE12 in_BE12 BIOENTITY serum_RE2 clearance_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 and_RE2 renal_RE2 clearance_RE2 -LRB-_RE2 NUM_RE2 -RRB-_RE2 with_RE2 NUM_RE2 high_RE2 serum_RE2 exposure_RE2 compared_RE2 to_RE2 BIOGENERAL_RE2 alone_RE2 
Valdecoxib_ddi|P|bextra|lithium|BIOGENERAL_LE1 serum_LE1 concentration_LE1 shall_LE1 be_LE1 monitor_LE1 close_LE1 when_LE1 initiate_LE1 or_LE1 change_LE1 therapy_LE1 with_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY 
Valdecoxib_ddi|P|valdecoxib|r-warfarin|BIOENTITY cause_BE12 statistical_BE12 significant_BE12 increase_BE12 in_BE12 plasma_BE12 exposure_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 -RRB-_RE2 and_RE2 in_RE2 the_RE2 pharmacodynamic_RE2 effect_RE2 -LRB-_RE2 prothrombin_RE2 time_RE2 measure_RE2 as_RE2 inr_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Valdecoxib_ddi|P|valdecoxib|s-warfarin|BIOENTITY cause_BE12 statistical_BE12 significant_BE12 increase_BE12 in_BE12 plasma_BE12 exposure_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 -RRB-_RE2 and_RE2 in_RE2 the_RE2 pharmacodynamic_RE2 effect_RE2 -LRB-_RE2 prothrombin_RE2 time_RE2 measure_RE2 as_RE2 inr_RE2 -RRB-_RE2 of_RE2 BIOGENERAL_RE2 
Valdecoxib_ddi|P|valdecoxib|warfarin|BIOENTITY cause_BE12 statistical_BE12 significant_BE12 increase_BE12 in_BE12 plasma_BE12 exposure_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 -LRB-_BE12 NUM_BE12 and_BE12 NUM_BE12 respective_BE12 -RRB-_BE12 and_BE12 in_BE12 the_BE12 pharmacodynamic_BE12 effect_BE12 -LRB-_BE12 prothrombin_BE12 time_BE12 measure_BE12 as_BE12 inr_BE12 -RRB-_BE12 of_BE12 BIOENTITY 
Valdecoxib_ddi|P|bextra|warfarin|BIOGENERAL_LE1 therapy_LE1 shall_LE1 be_LE1 monitor_LE1 particular_LE1 during_LE1 the_LE1 first_LE1 few_LE1 week_LE1 after_LE1 initiate_LE1 therapy_LE1 with_LE1 BIOENTITY in_BE12 patient_BE12 receive_BE12 BIOENTITY or_RE2 similar_RE2 agent_RE2 
Valdecoxib_ddi|P|valdecoxib|fluconazole|concomitant_LE1 single_LE1 dose_LE1 administration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 with_BE12 multiple_BE12 dose_BE12 of_BE12 BIOGENERAL_BE12 and_BE12 BIOENTITY produce_RE2 significant_RE2 increase_RE2 in_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 
Valdecoxib_ddi|P|valdecoxib|ketoconazole|concomitant_LE1 single_LE1 dose_LE1 administration_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 with_BE12 multiple_BE12 dose_BE12 of_BE12 BIOENTITY and_RE2 BIOGENERAL_RE2 produce_RE2 significant_RE2 increase_RE2 in_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 
Valdecoxib_ddi|P|valdecoxib|fluconazole|plasma_LE1 exposure_LE1 -LRB-_LE1 auc_LE1 -RRB-_LE1 to_LE1 BIOENTITY be_BE12 increase_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY and_RE2 NUM_RE2 when_RE2 coadminister_RE2 with_RE2 BIOGENERAL_RE2 
Valdecoxib_ddi|P|valdecoxib|ketoconazole|plasma_LE1 exposure_LE1 -LRB-_LE1 auc_LE1 -RRB-_LE1 to_LE1 BIOENTITY be_BE12 increase_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOGENERAL_BE12 and_BE12 NUM_BE12 when_BE12 coadminister_BE12 with_BE12 BIOENTITY 
Valdecoxib_ddi|P|valdecoxib|glyburide|coadministration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 -LRB-_BE12 day_BE12 NUM_BE12 -RRB-_BE12 and_BE12 NUM_BE12 mg_BE12 qd_BE12 -LRB-_BE12 day_BE12 NUM_BE12 -RRB-_BE12 -RRB-_BE12 with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 BIOGENERAL_RE2 bid_RE2 -RRB-_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 NUM_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 cmax_RE2 lead_RE2 to_RE2 NUM_RE2 decrease_RE2 in_RE2 glucose_RE2 NUM_RE2 
Valdecoxib_ddi|P|glyburide|valdecoxib|because_LE1 change_LE1 in_LE1 glucose_LE1 concentration_LE1 with_LE1 BIOGENERAL_LE1 coadministration_LE1 be_LE1 within_LE1 the_LE1 normal_LE1 variability_LE1 and_LE1 individual_LE1 glucose_LE1 concentration_LE1 be_LE1 above_LE1 or_LE1 near_LE1 NUM_LE1 mg_LE1 dose_LE1 adjustment_LE1 for_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 qd_BE12 and_BE12 NUM_BE12 mg_BE12 bid_BE12 -RRB-_BE12 with_BE12 BIOENTITY coadministration_RE2 -LRB-_RE2 up_RE2 to_RE2 NUM_RE2 mg_RE2 qd_RE2 -RRB-_RE2 be_RE2 not_RE2 indicate_RE2 
Valdecoxib_ddi|P|valdecoxib|omeprazole|coadministration_LE1 with_LE1 BIOENTITY increase_BE12 exposure_BE12 of_BE12 BIOENTITY -LRB-_RE2 auc_RE2 -RRB-_RE2 by_RE2 NUM_RE2 %._RE2 
Valdecoxib_ddi|P|valdecoxib|ortho-novum|coadministration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY NUM_RE2 increase_RE2 the_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 and_RE2 BIOGENERAL_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Valdecoxib_ddi|P|contraceptive|valdecoxib|these_LE1 increase_LE1 exposure_LE1 of_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 shall_LE1 be_LE1 take_LE1 into_LE1 consideration_LE1 when_LE1 select_LE1 oral_LE1 BIOENTITY for_BE12 woman_BE12 take_BE12 BIOENTITY 
Valdecoxib_ddi|P|diazepam|valdecoxib|plasma_LE1 exposure_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 bid_BE12 -RRB-_BE12 be_BE12 increase_BE12 by_BE12 NUM_BE12 following_BE12 administration_BE12 of_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 bid_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 while_RE2 plasma_RE2 exposure_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 bid_RE2 -RRB-_RE2 be_RE2 not_RE2 substantial_RE2 increase_RE2 following_RE2 administration_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 bid_RE2 -RRB-_RE2 for_RE2 NUM_RE2 day_RE2 
Valdecoxib_ddi|P|valdecoxib|diazepam|although_LE1 the_LE1 magnitude_LE1 of_LE1 change_LE1 in_LE1 BIOGENERAL_LE1 plasma_LE1 exposure_LE1 when_LE1 coadminister_LE1 with_LE1 BIOENTITY be_BE12 not_BE12 sufficient_BE12 to_BE12 warrant_BE12 dosage_BE12 adjustment_BE12 patient_BE12 may_BE12 experience_BE12 enhance_BE12 sedative_BE12 side_BE12 effect_BE12 cause_BE12 by_BE12 increase_BE12 exposure_BE12 of_BE12 BIOENTITY under_RE2 this_RE2 circumstance_RE2 
Vardenafil_ddi|P|erythromycin|vardenafil|BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 t.i.d_BE12 -RRB-_BE12 produce_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 cmax_RE2 when_RE2 co-administer_RE2 with_RE2 BIOGENERAL_RE2 NUM_RE2 mg_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Vardenafil_ddi|P|vardenafil|erythromycin|it_LE1 be_LE1 recommend_LE1 not_LE1 to_LE1 exceed_LE1 single_LE1 NUM_LE1 mg_LE1 dose_LE1 of_LE1 BIOENTITY in_BE12 NUM_BE12 period_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Vardenafil_ddi|P|ketoconazole|vardenafil|BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 once_BE12 daily_BE12 -RRB-_BE12 produce_BE12 NUM_BE12 increase_BE12 in_BE12 BIOENTITY auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 cmax_RE2 when_RE2 co-administer_RE2 with_RE2 BIOGENERAL_RE2 -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 in_RE2 healthy_RE2 volunteer_RE2 
Vardenafil_ddi|P|vardenafil|ketoconazole|NUM_LE1 BIOENTITY dose_BE12 shall_BE12 not_BE12 be_BE12 exceed_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 NUM_BE12 mg_BE12 once_BE12 daily_BE12 BIOENTITY 
Vardenafil_ddi|P|vardenafil|ketoconazole|since_LE1 high_LE1 dose_LE1 of_LE1 BIOGENERAL_LE1 -LRB-_LE1 NUM_LE1 mg_LE1 daily_LE1 -RRB-_LE1 may_LE1 result_LE1 in_LE1 high_LE1 increase_LE1 in_LE1 cmax_LE1 and_LE1 auc_LE1 single_LE1 NUM_LE1 mg_LE1 dose_LE1 of_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 exceed_BE12 in_BE12 NUM_BE12 period_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 daily_RE2 
Vardenafil_ddi|P|indinavir|vardenafil|BIOGENERAL_LE1 :_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 t.i.d._BE12 -RRB-_BE12 co-administer_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 cmax_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 half-life_RE2 
Vardenafil_ddi|P|vardenafil|indinavir|it_LE1 be_LE1 recommend_LE1 not_LE1 to_LE1 exceed_LE1 single_LE1 NUM_LE1 mg_LE1 BIOENTITY dose_BE12 in_BE12 NUM_BE12 period_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Vardenafil_ddi|P|ritonavir|vardenafil|BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 b.i.d._BE12 -RRB-_BE12 co-administer_BE12 with_BE12 BIOENTITY NUM_RE2 mg_RE2 result_RE2 in_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 auc_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 cmax_RE2 
Vardenafil_ddi|P|vardenafil|ritonavir|the_LE1 interaction_LE1 be_LE1 consequence_LE1 of_LE1 block_LE1 hepatic_LE1 metabolism_LE1 of_LE1 BIOENTITY by_BE12 BIOENTITY high_RE2 potent_RE2 cyp3a4_RE2 inhibitor_RE2 which_RE2 also_RE2 inhibit_RE2 cyp2c9_RE2 
Vardenafil_ddi|P|ritonavir|vardenafil|BIOENTITY significant_BE12 prolong_BE12 the_BE12 half-life_BE12 of_BE12 BIOENTITY to_RE2 NUM_RE2 hour_RE2 
Vardenafil_ddi|P|vardenafil|ritonavir|consequent_LE1 it_LE1 be_LE1 recommend_LE1 not_LE1 to_LE1 exceed_LE1 single_LE1 NUM_LE1 mg_LE1 BIOENTITY dose_BE12 in_BE12 NUM_BE12 period_BE12 when_BE12 use_BE12 in_BE12 combination_BE12 with_BE12 BIOENTITY 
Vardenafil_ddi|P|nitrate|vardenafil|in_LE1 vivo_LE1 study_LE1 :_LE1 BIOGENERAL_LE1 :_LE1 the_LE1 blood_LE1 pressure_LE1 lowering_LE1 effect_LE1 of_LE1 sublingual_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 take_BE12 NUM_BE12 and_BE12 NUM_BE12 hour_BE12 after_BE12 BIOENTITY and_RE2 increase_RE2 in_RE2 heart_RE2 rate_RE2 when_RE2 take_RE2 at_RE2 NUM_RE2 NUM_RE2 and_RE2 NUM_RE2 hour_RE2 be_RE2 potentiate_RE2 by_RE2 NUM_RE2 mg_RE2 dose_RE2 of_RE2 BIOGENERAL_RE2 in_RE2 healthy_RE2 middle-aged_RE2 subject_RE2 
Vardenafil_ddi|P|vardenafil|nitrate|potentiation_LE1 of_LE1 the_LE1 hypotensive_LE1 effect_LE1 of_LE1 BIOGENERAL_LE1 for_LE1 patient_LE1 with_LE1 ischemic_LE1 heart_LE1 disease_LE1 have_LE1 not_LE1 be_LE1 evaluate_LE1 and_LE1 concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 contraindicate_RE2 
Vardenafil_ddi|P|nifedipine|vardenafil|In_LE1 these_LE1 patient_LE1 whose_LE1 hypertension_LE1 be_LE1 control_LE1 with_LE1 BIOENTITY BIOENTITY NUM_RE2 mg_RE2 produce_RE2 mean_RE2 additional_RE2 supine_RE2 systolic_RE2 blood_RE2 pressure_RE2 reduction_RE2 of_RE2 NUM_RE2 mm_RE2 hg_RE2 compared_RE2 to_RE2 placebo_RE2 
Vardenafil_ddi|P|vardenafil|terazosin|BIOGENERAL_LE1 :_LE1 when_LE1 BIOENTITY NUM_BE12 or_BE12 NUM_BE12 mg_BE12 be_BE12 give_BE12 to_BE12 healthy_BE12 volunteer_BE12 either_BE12 simultaneous_BE12 or_BE12 NUM_BE12 hour_BE12 after_BE12 NUM_BE12 mg_BE12 dose_BE12 of_BE12 BIOENTITY significant_RE2 hypotension_RE2 develop_RE2 in_RE2 substantial_RE2 number_RE2 of_RE2 subject_RE2 
Vardenafil_ddi|P|vardenafil|terazosin|With_LE1 simultaneous_LE1 dosing_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 NUM_RE2 of_RE2 NUM_RE2 subject_RE2 experience_RE2 standing_RE2 systolic_RE2 blood_RE2 pressure_RE2 of_RE2 little_RE2 than_RE2 NUM_RE2 mm_RE2 hg_RE2 
Vardenafil_ddi|P|vardenafil|terazosin|With_LE1 simultaneous_LE1 dosing_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 NUM_RE2 of_RE2 NUM_RE2 subject_RE2 experience_RE2 standing_RE2 systolic_RE2 blood_RE2 pressure_RE2 of_RE2 little_RE2 than_RE2 NUM_RE2 mm_RE2 hg_RE2 
Vardenafil_ddi|P|vardenafil|terazosin|when_LE1 BIOENTITY dosing_BE12 be_BE12 separate_BE12 from_BE12 BIOENTITY NUM_RE2 mg_RE2 by_RE2 NUM_RE2 hour_RE2 NUM_RE2 of_RE2 NUM_RE2 subject_RE2 who_RE2 receive_RE2 NUM_RE2 mg_RE2 of_RE2 BIOGENERAL_RE2 experience_RE2 decrease_RE2 in_RE2 standing_RE2 systolic_RE2 blood_RE2 pressure_RE2 below_RE2 NUM_RE2 mm_RE2 hg_RE2 
Vardenafil_ddi|P|vardenafil|tamsulosin|In_LE1 similar_LE1 study_LE1 with_LE1 BIOGENERAL_LE1 in_LE1 healthy_LE1 volunteer_LE1 NUM_LE1 of_LE1 NUM_LE1 subject_LE1 dose_LE1 with_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 separate_RE2 by_RE2 NUM_RE2 hour_RE2 experience_RE2 standing_RE2 systolic_RE2 blood_RE2 pressure_RE2 below_RE2 NUM_RE2 mm_RE2 hg_RE2 
Vardenafil_ddi|P|vardenafil|tamsulosin|two_LE1 of_LE1 NUM_LE1 subject_LE1 dose_LE1 simultaneous_LE1 with_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 experience_RE2 standing_RE2 systolic_RE2 blood_RE2 pressure_RE2 below_RE2 NUM_RE2 mm_RE2 hg_RE2 
Vardenafil_ddi|P|vardenafil|alpha-blocker|Based_LE1 on_LE1 these_LE1 datum_LE1 BIOENTITY shall_BE12 not_BE12 be_BE12 use_BE12 in_BE12 patient_BE12 on_BE12 BIOENTITY therapy_RE2 
Vardenafil_ddi|P|vardenafil|ritonavir|BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 Upon_LE1 concomitant_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY with_BE12 NUM_BE12 mg_BE12 bid_BE12 BIOENTITY the_RE2 cmax_RE2 and_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 reduce_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Vardenafil_ddi|P|vardenafil|indinavir|Upon_LE1 administration_LE1 of_LE1 NUM_LE1 mg_LE1 of_LE1 BIOENTITY with_BE12 NUM_BE12 mg_BE12 tid_BE12 BIOENTITY the_RE2 cmax_RE2 and_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 be_RE2 reduce_RE2 by_RE2 NUM_RE2 and_RE2 NUM_RE2 respective_RE2 
Zalcitabine_ddi|P|zalcitabine|zdv|BIOENTITY also_BE12 have_BE12 no_BE12 significant_BE12 effect_BE12 on_BE12 the_BE12 intracellular_BE12 phosphorylation_BE12 of_BE12 BIOENTITY as_RE2 show_RE2 in_RE2 vitro_RE2 in_RE2 peripheral_RE2 blood_RE2 mononuclear_RE2 cell_RE2 or_RE2 in_RE2 two_RE2 other_RE2 cell_RE2 line_RE2 -LRB-_RE2 u937_RE2 and_RE2 NUM_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|lamivudine|zalcitabine|BIOGENERAL_LE1 :_LE1 in_LE1 vitro_LE1 study_LE1 in_LE1 peripheral_LE1 blood_LE1 mononuclear_LE1 cell_LE1 u937_LE1 and_LE1 NUM_LE1 cell_LE1 reveal_LE1 that_LE1 BIOENTITY significant_BE12 inhibit_BE12 BIOENTITY phosphorylation_RE2 in_RE2 dose_RE2 dependent_RE2 manner_RE2 
Zalcitabine_ddi|P|zalcitabine|lamivudine|BIOENTITY inhibit_BE12 BIOENTITY phosphorylation_RE2 at_RE2 high_RE2 concentration_RE2 ratio_RE2 -LRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 -rrb-;_RE2 
Zalcitabine_ddi|P|zalcitabine|lamivudine|these_LE1 in_LE1 vitro_LE1 study_LE1 suggest_LE1 that_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY in_RE2 human_RE2 may_RE2 result_RE2 in_RE2 sub-therapeutic_RE2 concentration_RE2 of_RE2 active_RE2 phosphorylated_RE2 BIOGENERAL_RE2 which_RE2 may_RE2 lead_RE2 to_RE2 decrease_RE2 BIOGENERAL_RE2 effect_RE2 of_RE2 BIOGENERAL_RE2 
Zalcitabine_ddi|P|zalcitabine|lamivudine|concomitant_LE1 use_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Zalcitabine_ddi|P|hivid|didanosine|concomitant_LE1 use_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY be_RE2 not_RE2 recommend_RE2 
Zalcitabine_ddi|P|pentamidine|hivid|death_LE1 due_LE1 to_LE1 fulminant_LE1 pancreatitis_LE1 possible_LE1 related_LE1 to_LE1 intravenous_LE1 BIOENTITY and_BE12 BIOENTITY have_RE2 be_RE2 report_RE2 
Zalcitabine_ddi|P|pentamidine|hivid|if_LE1 intravenous_LE1 BIOENTITY be_BE12 require_BE12 to_BE12 treat_BE12 pneumocystis_BE12 carinii_BE12 pneumonia_BE12 treatment_BE12 with_BE12 BIOENTITY shall_RE2 be_RE2 interrupt_RE2 
Zalcitabine_ddi|P|aminoglycoside|zalcitabine|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 adverse_BE12 event_BE12 by_BE12 interfere_BE12 with_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|foscarnet|zalcitabine|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 adverse_BE12 event_BE12 by_BE12 interfere_BE12 with_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|amphotericin|zalcitabine|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOGENERAL_BE12 adverse_BE12 event_BE12 by_BE12 interfere_BE12 with_BE12 the_BE12 renal_BE12 clearance_BE12 of_BE12 BIOENTITY -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|aminoglycoside|hivid|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOENTITY may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOENTITY adverse_RE2 event_RE2 by_RE2 interfere_RE2 with_RE2 the_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|foscarnet|hivid|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOGENERAL_LE1 BIOENTITY and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOENTITY adverse_RE2 event_RE2 by_RE2 interfere_RE2 with_RE2 the_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|amphotericin|hivid|BIOGENERAL_LE1 BIOGENERAL_LE1 and_LE1 BIOGENERAL_LE1 :_LE1 drug_LE1 such_LE1 as_LE1 BIOENTITY BIOGENERAL_BE12 and_BE12 BIOGENERAL_BE12 may_BE12 increase_BE12 the_BE12 risk_BE12 of_BE12 develop_BE12 peripheral_BE12 neuropathy_BE12 or_BE12 other_BE12 BIOENTITY adverse_RE2 event_RE2 by_RE2 interfere_RE2 with_RE2 the_RE2 renal_RE2 clearance_RE2 of_RE2 BIOGENERAL_RE2 -LRB-_RE2 thereby_RE2 raise_RE2 systemic_RE2 exposure_RE2 -rrb-._RE2 
Zalcitabine_ddi|P|probenecid|zalcitabine|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOENTITY or_BE12 BIOGENERAL_BE12 decrease_BE12 the_BE12 elimination_BE12 of_BE12 BIOENTITY much_RE2 likely_RE2 by_RE2 inhibition_RE2 of_RE2 renal_RE2 tubular_RE2 secretion_RE2 of_RE2 BIOGENERAL_RE2 
Zalcitabine_ddi|P|cimetidine|zalcitabine|BIOGENERAL_LE1 or_LE1 BIOGENERAL_LE1 :_LE1 concomitant_LE1 administration_LE1 of_LE1 BIOGENERAL_LE1 or_LE1 BIOENTITY decrease_BE12 the_BE12 elimination_BE12 of_BE12 BIOENTITY much_RE2 likely_RE2 by_RE2 inhibition_RE2 of_RE2 renal_RE2 tubular_RE2 secretion_RE2 of_RE2 BIOGENERAL_RE2 
Zalcitabine_ddi|P|zalcitabine|antacid|the_LE1 clinical_LE1 significance_LE1 of_LE1 this_LE1 reduction_LE1 be_LE1 not_LE1 know_LE1 hence_LE1 BIOENTITY be_BE12 not_BE12 recommend_BE12 to_BE12 be_BE12 ingest_BE12 simultaneous_BE12 with_BE12 BIOGENERAL_BE12 BIOENTITY 
Zalcitabine_ddi|P|zalcitabine|aluminum|the_LE1 clinical_LE1 significance_LE1 of_LE1 this_LE1 reduction_LE1 be_LE1 not_LE1 know_LE1 hence_LE1 BIOENTITY be_BE12 not_BE12 recommend_BE12 to_BE12 be_BE12 ingest_BE12 simultaneous_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 
Zalcitabine_ddi|P|zalcitabine|aluminum|the_LE1 clinical_LE1 significance_LE1 of_LE1 this_LE1 reduction_LE1 be_LE1 not_LE1 know_LE1 hence_LE1 BIOENTITY be_BE12 not_BE12 recommend_BE12 to_BE12 be_BE12 ingest_BE12 simultaneous_BE12 with_BE12 BIOENTITY BIOGENERAL_RE2 
Zalcitabine_ddi|P|zalcitabine|metoclopramide|BIOGENERAL_LE1 :_LE1 bioavailability_LE1 be_LE1 mild_LE1 reduce_LE1 -LRB-_LE1 approximate_LE1 NUM_LE1 -RRB-_LE1 when_LE1 BIOENTITY and_BE12 BIOENTITY be_RE2 coadminister_RE2 
Zalcitabine_ddi|P|doxorubicin|zalcitabine|BIOGENERAL_LE1 :_LE1 BIOENTITY cause_BE12 decrease_BE12 in_BE12 BIOENTITY phosphorylation_RE2 -LRB-_RE2 NUM_RE2 inhibition_RE2 of_RE2 total_RE2 phosphate_RE2 formation_RE2 -RRB-_RE2 in_RE2 u937_RE2 NUM_RE2 cell_RE2 
Zaleplon_ddi|P|sonata|ethanol|cns-active_LE1 drug_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY NUM_BE12 mg_BE12 potentiate_BE12 the_BE12 cns-impairing_BE12 effect_BE12 of_BE12 BIOENTITY NUM_RE2 on_RE2 balance_RE2 testing_RE2 and_RE2 reaction_RE2 time_RE2 for_RE2 NUM_RE2 hour_RE2 after_RE2 BIOGENERAL_RE2 administration_RE2 and_RE2 on_RE2 the_RE2 digit_RE2 symbol_RE2 substitution_RE2 test_RE2 -LRB-_RE2 dsst_RE2 -RRB-_RE2 symbol_RE2 copying_RE2 test_RE2 and_RE2 the_RE2 variability_RE2 component_RE2 of_RE2 the_RE2 divided_RE2 attention_RE2 test_RE2 for_RE2 NUM_RE2 hour_RE2 after_RE2 BIOGENERAL_RE2 administration_RE2 
Zaleplon_ddi|P|sonata|imipramine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 produce_RE2 additive_RE2 effect_RE2 on_RE2 decrease_RE2 alertness_RE2 and_RE2 impaired_RE2 psychomotor_RE2 performance_RE2 for_RE2 NUM_RE2 to_RE2 NUM_RE2 hour_RE2 after_RE2 administration_RE2 
Zaleplon_ddi|P|sonata|thioridazine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY NUM_BE12 mg_BE12 and_BE12 BIOENTITY NUM_RE2 mg_RE2 produce_RE2 additive_RE2 effect_RE2 on_RE2 decrease_RE2 alertness_RE2 and_RE2 impaired_RE2 psychomotor_RE2 performance_RE2 for_RE2 NUM_RE2 to_RE2 NUM_RE2 hour_RE2 after_RE2 administration_RE2 
Zaleplon_ddi|P|zaleplon|promethazine|BIOGENERAL_LE1 :_LE1 coadministration_LE1 of_LE1 single_LE1 dose_LE1 of_LE1 BIOENTITY and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 and_RE2 NUM_RE2 mg_RE2 respective_RE2 -RRB-_RE2 result_RE2 in_RE2 NUM_RE2 decrease_RE2 in_RE2 maximal_RE2 plasma_RE2 concentration_RE2 of_RE2 BIOGENERAL_RE2 but_RE2 no_RE2 change_RE2 in_RE2 the_RE2 area_RE2 under_RE2 the_RE2 plasma_RE2 concentration-time_RE2 curve_RE2 
Zaleplon_ddi|P|rifampin|zaleplon|multiple-dose_LE1 administration_LE1 of_LE1 the_LE1 potent_LE1 cyp3a4_LE1 inducer_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 every_BE12 NUM_BE12 hour_BE12 q24h_BE12 for_BE12 NUM_BE12 day_BE12 -RRB-_BE12 however_BE12 reduce_BE12 BIOENTITY cmax_RE2 and_RE2 auc_RE2 by_RE2 approximate_RE2 NUM_RE2 %._RE2 
Zaleplon_ddi|P|zaleplon|erythromycin|coadministration_LE1 of_LE1 single_LE1 oral_LE1 dose_LE1 of_LE1 BIOENTITY with_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 and_RE2 NUM_RE2 mg_RE2 respective_RE2 -RRB-_RE2 strong_RE2 selective_RE2 cyp3a4_RE2 inhibitor_RE2 produce_RE2 NUM_RE2 increase_RE2 in_RE2 BIOGENERAL_RE2 maximal_RE2 plasma_RE2 concentration_RE2 and_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 area_RE2 under_RE2 the_RE2 plasma_RE2 concentration-time_RE2 curve_RE2 
Zaleplon_ddi|P|ketoconazole|zaleplon|other_LE1 strong_LE1 selective_LE1 cyp3a4_LE1 inhibitor_LE1 such_LE1 as_LE1 BIOENTITY can_BE12 also_BE12 be_BE12 expect_BE12 to_BE12 increase_BE12 the_BE12 exposure_BE12 of_BE12 BIOENTITY 
Zaleplon_ddi|P|cimetidine|zaleplon|drug_LE1 that_LE1 inhibit_LE1 both_LE1 aldehyde_LE1 oxidase_LE1 and_LE1 cyp3a4_LE1 BIOGENERAL_LE1 :_LE1 BIOENTITY inhibit_BE12 both_BE12 aldehyde_BE12 oxidase_BE12 -LRB-_BE12 in_BE12 vitro_BE12 -RRB-_BE12 and_BE12 cyp3a4_BE12 -LRB-_BE12 in_BE12 vitro_BE12 and_BE12 in_BE12 vivo_BE12 -RRB-_BE12 the_BE12 primary_BE12 and_BE12 secondary_BE12 enzyme_BE12 respective_BE12 responsible_BE12 for_BE12 BIOENTITY metabolism_RE2 
Zaleplon_ddi|P|sonata|cimetidine|concomitant_LE1 administration_LE1 of_LE1 BIOENTITY -LRB-_BE12 NUM_BE12 mg_BE12 -RRB-_BE12 and_BE12 BIOENTITY -LRB-_RE2 NUM_RE2 mg_RE2 -RRB-_RE2 produce_RE2 NUM_RE2 increase_RE2 in_RE2 the_RE2 mean_RE2 cmax_RE2 and_RE2 auc_RE2 of_RE2 BIOGENERAL_RE2 
